<SEC-DOCUMENT>0000950123-24-006482.txt : 20240823
<SEC-HEADER>0000950123-24-006482.hdr.sgml : 20240823
<ACCEPTANCE-DATETIME>20240711170723
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-24-006482
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20240711
<PUBLIC-REL-DATE>20240823
DATE AS OF CHANGE:		20240711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MBX Biosciences, Inc.
		CENTRAL INDEX KEY:			0001776111
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07147
		FILM NUMBER:		241112644

	BUSINESS ADDRESS:	
		STREET 1:		12406 HORESHAM STREET
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		3179893100

	MAIL ADDRESS:	
		STREET 1:		12406 HORESHAM STREET
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on July&nbsp;11, 2024 as
Amendment No. 2 to the draft registration statement submitted on March 22, 2024. This Amendment No. 2 has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Registration No.&nbsp;333&#150;&#8195;&#8195;&#8195; </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:arial" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:20pt; font-family:arial" ALIGN="center"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center">(Exact name of
registrant as specified in its charter) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">84-1882872</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>MBX Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>11711 N. Meridian Street, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Carmel, Indiana 46032 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(317) <FONT
STYLE="white-space:nowrap">659-0200</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>P. Kent Hawryluk </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>President and Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>MBX Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>11711 N. Meridian Street, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Carmel, Indiana 46032 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(317) <FONT
STYLE="white-space:nowrap">659-0200</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for
service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Mitchell S. Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Edwin O&#146;Connor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Daniel Hughes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>100 Northern
Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Boston, Massachusetts 02210</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Richard D. Truesdell, Jr.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Yasin Keshvargar</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Davis Polk&nbsp;&amp;
Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>450 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>New York, New York 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">450-4000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after the effective date of this registration statement.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as
amended, check the following box.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Exchange Act.&#8194;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant files a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such
date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the Securities and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><FONT COLOR="#8b3f4e"><B>Subject to completion, dated &#8195;&#8195;&#8195;&#8195;, 2024 </B></FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B><I>&#8195;&#8195;&#8195;Shares
</I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g00m01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This is
an initial public offering of shares of common stock of MBX Biosciences, Inc. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering &#8195;&#8195;&#8195;&#8195; shares of our common stock. We expect
that the initial public offering price will be between $&#8195;&#8195;&#8195;&#8195; and $&#8195;&#8195;&#8195;&#8195; per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has
been no public market for our common stock. We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; We believe that upon the completion of this offering, we will meet the standards for listing on
the Nasdaq Global Select Market, and the closing of this offering is contingent upon such listing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; and a &#147;smaller
reporting company&#148; under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and for future filings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should read carefully the discussion of the material risks of investing in
our common stock under the heading &#147;<A HREF="#toc790774_4">Risk factors</A>&#148; starting on page 16 of this prospectus. </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds, before expenses, to MBX Biosciences, Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page&nbsp;210 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the underwriters an option for a period of 30 days to purchase an additional &#8195;&#8195;&#8195;&#8195; shares of our common stock from us at the
initial public offering price, less underwriting discounts and commissions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At our request, the underwriters have reserved up to&#8195;&#8195;&#8195;&#8195;% of the
shares offered by this prospectus for sale, at the initial public offering price, to our directors, officers, certain employees and certain other persons associated with us. See &#147;Underwriting&#151;Directed share program.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares against payment in New York, New York on &#8195;&#8195;&#8195;&#8195;, 2024. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Prospectus dated&#8195;&#8195;&#8195;&#8195;, 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>Table of contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_1">Prospectus summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_2">The offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_3">Summary financial data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_4">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_5">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_6">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_7">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_10">Management&#146;s discussion and analysis of financial condition and results of operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_13">Executive compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_14">Certain relationships and related person transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_15">Principal stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_16">Description of capital stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_17">Shares eligible for future sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_18">Material U.S. federal income tax considerations for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_20">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_22">Where you can find more information</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc790774_23">Index to financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than
those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.
The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our
business, financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For investors outside the United States: We have not, and the
underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States
who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Market data and certain other statistical information used throughout this prospectus are based on independent
industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that
their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe that
these sources are reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates,
in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#147;Risk factors&#148; and
elsewhere in this prospectus. Some data are also based on our good faith estimates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to apply for various trademarks that we use in connection with the
operation of our business. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#146; trademarks, service marks, trade
names or products in this prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear
without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or
the right of the applicable owner of these trademarks, service marks and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_1"></A>Prospectus summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto included elsewhere in this prospectus. You should also
consider, among other things, the information set forth under the sections entitled &#147;Risk factors,&#148; &#147;Special note regarding forward-looking statements,&#148; and &#147;Management&#146;s discussion and analysis of financial condition
and results of operations,&#148; in each case included elsewhere in this prospectus. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and
metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or PEP<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and
simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically
validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 2109:</B> Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a
potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous,
infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the
concentration of active drug observed immediately prior to the next dose, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an
extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2
clinical trial in patients with HP and anticipate topline data in the third quarter of 2025. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 1416:</B> We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide-1, or <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin
secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase&nbsp;1 clinical trial, preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or
pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional
single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Obesity portfolio:</B> Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT
STYLE="white-space:nowrap">GLP-1</FONT> and glucose-dependent insulinotropic polypeptide, or GIP, receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> prodrug with the goal of reducing dosing frequency and improving efficacy and tolerability
relative to existing standards of </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX 4291, supporting the potential for once-monthly administration. During our preclinical
studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent
dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting
potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an anticipated investigational new drug, or IND, submission in
the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the lead optimization stage of development. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain homeostasis, which impact metabolism,
growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to using peptides as hormone replacement therapies, peptide-based
drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic peptides often have significant drawbacks. Unmodified peptides
often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours<B> </B>by<B><I> </I></B>the liver and kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide
fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies
could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential
efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved
efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target
selectivity, 3) half-lives that allow for dosing at weekly or less frequent intervals, and 4) low or flat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios to improve tolerability, thereby
facilitating higher dosing and greater potential efficacy. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our platform </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have built our proprietary PEP platform to develop innovative precision peptide therapies that are designed to overcome key limitations of current peptide therapies.
We were founded by leaders in the field of peptide discovery and development with the goal of transforming the treatment landscape for endocrine and metabolic diseases with novel, efficacious, safe and convenient treatments. Our PEP platform builds
upon the expertise and chemical technologies originally discovered at the Indiana University laboratory of our scientific <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Richard DiMarchi, who is globally recognized for translational
breakthroughs in endocrine pharmacology, including the discovery of the first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> as well as other dual and triple incretin agonists. Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> proprietary PEP platform has enabled us to engineer novel product candidates that are designed to have optimized
pharmaceutical properties, including a longer duration of action, consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, and less frequent dosing, which support
our goals of improved tolerability, efficacy </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and potency. We currently rely on the discovery capabilities of Dr. DiMarchi through the Indiana University laboratory, but are continuing to grow and develop our internal discovery and
development capacity, including having hired an experienced <FONT STYLE="white-space:nowrap">cross-functional</FONT> discovery team and building a peptide synthesis laboratory that will fully launch in the third quarter of 2024. We have developed a
proprietary platform of tools that we believe will allow us to continually design transformative therapies. These proprietary tools and <FONT STYLE="white-space:nowrap">know-how</FONT> include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advanced chemical modifications</B> with a goal to provide enhanced physical properties including stability and
solubility, increased potency, and multiple mechanisms of action in a single peptide </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Programmable prodrug technologies</B> that are designed to precisely time the chemical conversion of the prodrug into an
active form to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and improve clinical outcomes </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Fatty acylation</B> that aims to provide increased duration of action for more convenient dosing regimens and
compatibility with <FONT STYLE="white-space:nowrap">non-injectable</FONT> formulations </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PEP platform is designed to improve clinical outcomes
and simplify disease management for patients. Our PEPs are engineered to potentially optimize pharmaceutical properties yielding peptides with extended time-action profiles, convenient dosing regimens and the potential to enhance compliance and
improve treatment effectiveness in a real-world setting. PEPs may improve efficacy and reduce adverse events by providing a more continuous, infusion-like exposure to the peptide. We believe that our PEP technology, along with our significant <FONT
STYLE="white-space:nowrap">know-how</FONT> in the synergistic application of these tools, provides the opportunity to discover novel, highly selective and efficacious peptides with extended time-action profiles and low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios that may improve on the shortcomings of existing peptide therapies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our pipeline </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are leveraging our PEP platform to advance a
pipeline of programs to treat both endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet needs and large potential market opportunities. Developing product candidates,
including conducting preclinical studies and clinical trials, is a time consuming, expensive and uncertain process. We have not yet demonstrated an ability to obtain regulatory approvals. We retain exclusive, worldwide development and
commercialization rights to all of our product candidates and discovery programs. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g02s97.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond MBX 4291, we have a robust discovery pipeline including multiple obesity programs in the lead optimization stage of
development. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MBX 2109: Potential treatment for chronic hypoparathyroidism </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment
of HP. HP is a rare endocrine disease where parathyroid glands fail to produce sufficient amounts of PTH, which is a hormone that regulates calcium levels in the blood through its effects on bone, kidneys and intestines. We estimate that HP affects
approximately 120,000 people in the United States and more than 250,000 in the United States and Europe. HP is caused by damage to or removal of the parathyroid glands during neck surgery in approximately 75% of cases or, less commonly, from an
autoimmune disease or a genetic disorder. A deficiency of PTH results in lower blood calcium levels, or hypocalcemia, which can result in a variety of acute symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as
depression, confusion and cognitive impairment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To avoid hypocalcemia and its symptoms, patients are treated with high dose calcium supplements and prescription
strength active vitamin D therapy, which can require the daily ingestion of approximately seven or more pills taken at multiple times throughout the day. This treatment does not address PTH deficiency and symptom relief can be suboptimal. Once-daily
injectable PTH therapies have been shown in clinical studies to reduce the need for high doses of calcium and active vitamin D supplements, decrease urinary calcium excretion and, by patient-reported-outcome assessments, result in improvements in
patients&#146; quality of life. However, these therapies can have significant fluctuations in drug concentrations that require daily subcutaneous injections, which impacts the potential outcomes for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP. MBX 2109 is a prodrug, which is a compound engineered to be
biologically inactive at the time of subcutaneous injection that then converts to an active peptide in an intrinsically controlled, time-dependent fashion. The prodrug design is supplemented by fatty acylation, the addition of fatty acids to the
compound, which facilitates binding to proteins and extends the time of the compound in circulation. This combination is meant to provide an extended time-action profile that allows a once-weekly administration and provides a continuous,
infusion-like PTH exposure with lower daily <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios than observed with daily PTH dosing regimens. This continuous, infusion-like exposure to MBX 2109 may
reduce the frequency and severity of excessive blood calcium, or hypercalcemic, events and insufficient blood calcium, or hypocalcemic, symptoms. The once-weekly MBX 2109 dosing regimen may improve compliance relative to daily PTH dosing regimens,
which we believe improves effectiveness in a real-world setting. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In a Phase 1 clinical trial in 76 healthy adults, weekly subcutaneous injections of MBX 2109
led to sustained and dose-dependent elevations of serum calcium and the suppression of endogenous PTH. The half-life of the MBX 2109 active drug across all doses was approximately 7.7 to 8.9 days, supporting a once-weekly dosing regimen. MBX 2109
was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating the safety, tolerability and efficacy of three fixed doses of MBX 2109 in a randomized, double-blind, placebo-controlled Phase 2
clinical trial in approximately 48 patients with HP. The primary endpoint of the Phase 2 clinical trial is the proportion of patients who can discontinue active vitamin D and reduce calcium supplements after 12 weeks of treatment while maintaining
normal serum calcium levels. We expect to report topline data from our Phase 2 clinical trial in the third quarter of 2025. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MBX 1416: Potential treatment for
post-bariatric hypoglycemia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416, our potential treatment for PBH, is designed to be a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT>
receptor antagonist, which is a molecule that binds to the applicable receptor to prevent the native molecule that would otherwise activate the receptor from binding. PBH is a rare, serious and chronic complication of bariatric surgery typically
occurring </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
six months or later after surgery. We estimate PBH affects more than 90,000 people in the United States. In PBH, pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> are released
following a meal leading to hyperinsulinemia, or excessive levels of insulin, that may result in hypoglycemia, or low blood glucose. Hypoglycemic symptoms may include confusion, weakness, dizziness, blurred vision, loss of consciousness and
seizures. While <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT><B> </B>therapies have been recently approved to treat obesity and its <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> people with
severe obesity, defined as a BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, often can require a greater degree of weight loss than these current therapies can achieve.
According to the CDC, the prevalence of severe obesity in the United States in adults over 20 years increased from 4.7% in 2000 to 9.2% in 2018. Bariatric surgery still remains the most efficacious means of treating severe obesity, with bariatric
surgeries increasing by approximately 23% since 2017 to approximately 280,000 in the United States in 2022, according to the American Society for Metabolic and Bariatric Surgery. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are currently no U.S. Food and Drug Administration, or FDA, approved pharmacologic therapies for PBH. The current treatment options to reduce the frequency and
severity of hypoglycemic episodes focus on dietary interventions and, secondarily, on the use of <FONT STYLE="white-space:nowrap">off-label</FONT> medications with significant side effect profiles and unproven effectiveness in patients with PBH.
While glucagon is used as a rescue therapy to treat severe hypoglycemic events, it does not prevent hypoglycemia from occurring. In certain patients with severe, intractable hypoglycemia, surgical reversal of the bariatric procedure may be
considered. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416 is designed as a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist to prevent
<FONT STYLE="white-space:nowrap">GLP-1</FONT> from augmenting insulin release to cause hyperinsulinemia following a meal and thereby prevent the occurrence of severe hypoglycemia in patients with PBH. Leveraging our PEP platform, we aim to improve
the pharmaceutical properties of the <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence required to inhibit <FONT STYLE="white-space:nowrap">GLP-1</FONT> action by chemically modifying the amino acid backbone to achieve enhanced potency,
stability and solubility, relative to the corresponding, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence. We are evaluating the safety, tolerability, pharmacokinetics and the effects that the drug has on the body, or
pharmacodynamics, of MBX 1416 in an ongoing randomized double-blind, placebo-controlled single- and multiple- ascending dose, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial in
healthy adults. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a
half-life supporting once-weekly dosing. We anticipate topline results from our Phase 1 clinical trial in the fourth quarter of 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our obesity portfolio
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP platform, we are discovering and developing candidates with optimized pharmacokinetic profiles and pharmacologic attributes to
potentially improve on the current treatments for obesity and related <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We are engineering our candidates to extend the time-action profile and to potentially improve tolerability, thereby
providing the potential for higher doses leading to greater weight loss than can be achieved with existing therapies. We are prioritizing candidates targeting clinically validated mechanisms for weight loss and are focusing on discovering peptides
that target multiple unique receptors. Our obesity portfolio currently includes one product candidate, MBX 4291, in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and a robust discovery pipeline with multiple development programs in
lead optimization. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>MBX 4291: Long-acting and highly potent potential treatment for obesity </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> prodrug. Obesity is a common and costly chronic condition leading to significant morbidity and mortality. According to the CDC, an estimated 42% of U.S. adults aged 20 and over have obesity, or BMI<FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>30 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, as of 2018, including 9% of adults with severe obesity, and another 31% of adults who are overweight, or
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
BMI between 25.0 and 29.9 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. Based on the CDC&#146;s 2018 prevalence rates, we estimate that at least 190 million adults in the United
States are obese or overweight. While the current, approved GLP-1-based agonists represent significant and clinically meaningful advances in the treatment of obesity, they require weekly injections and can be associated with significant
gastrointestinal, or GI, side effects. These side effects often lead to reduced adherence and increased discontinuation, thereby limiting a patient&#146;s ability to lose weight. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe MBX 4291 has the potential to be a safe and efficacious therapy that will help people achieve their weight loss goals and improve their overall health. MBX
4291 is designed to achieve the extended time-action profile using two of our proprietary technologies, programmable prodrug and fatty acylation. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile
and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX&nbsp;4291
supporting the potential for once-monthly administration. We believe that our proprietary PEP platform and <FONT STYLE="white-space:nowrap">know-how</FONT> also provide significant optionality in devising dosing regimens that could lead to
clinically meaningful improvements in tolerability and increase the maximally attained weight loss, relative to existing, approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. MBX 4291 is
currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an IND submission in the second quarter of 2025. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our company and team
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX was founded by pioneers in the endocrine drug development field and is led by a team of seasoned industry veterans with a common goal to transform the
treatment of endocrine and metabolic disorders and improve patients&#146; lives. Members of our leadership team have collaborated successfully over several decades on the discovery, development and commercialization of endocrine therapeutics
including Forteo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Humalog<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Byetta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Our
<FONT STYLE="white-space:nowrap">co-founders,</FONT> Dr.&nbsp;DiMarchi and Kent Hawryluk, were central to the success of MB2 and Marcadia Biotech in advancing multiple
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-</FONT></FONT> and glucagon-based product candidates in clinical development through strategic transactions with Eli Lilly, Merck, Novo Nordisk, and Roche. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our team is led by executives who have deep experience in drug development and company-building in the biopharmaceutical industry. Key members of our executive and
leadership team include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Kent Hawryluk, President, Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> has spent more
than 20 years as a life sciences entrepreneur, leader and investor, and prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> MBX held biopharma executive leadership roles at Avidity Biosciences, MB2, and Marcadia Biotech.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Salomon (Sam) Azoulay, M.D., Chief Medical Officer, has over 35 years of experience in drug development and operations,
including as the Chief Medical Officer at Sumitovant Biopharma and Pfizer Essential Health. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Richard Bartram, Chief Financial Officer, has over 15 years of financial leadership experience spanning strategic and
operational finance roles, including serving as the Chief Financial Officer of Esperion Therapeutics and as a public accountant at PricewaterhouseCoopers LLP. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Michelle Graham, Chief Human Resources Officer, has over 25 years of experience in human resources, talent management, and
organizational development across various sectors of the healthcare industry, including as the Chief Human Resources Officer at Albireo Pharma, Tesaro, and Parexel. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Steven J. Prestrelski, Ph.D., Chief Scientific Officer, is a seasoned biopharmaceutical executive with over 30 years of
scientific and operational expertise who has led successful endocrine and metabolism product development programs from discovery through regulatory approval, including Byetta, Bydureon<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
Gvoke<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our platform technology includes patent rights and proprietary technology
exclusively licensed from Indiana University and developed in the Indiana University laboratory of our scientific founder, Dr.&nbsp;DiMarchi. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Dr.&nbsp;DiMarchi developed the original PEP technology, and is the inventor of the first dual and triple incretin agonists. Dr.&nbsp;DiMarchi is known as a world class innovator and inventor, a
member of the National Inventor Hall of Fame and the National Academy of Medicine, and one of the world&#146;s leading peptide chemists. He is a former decade-long chairman of the Peptide Therapeutics Foundation and is widely recognized as an
international spokesperson for macromolecular medicines. He has an extensive track record of drug development in big pharma, early-stage biotech, and academia, and is a successful repeat entrepreneur. In particular, he is recognized for his
contributions to the discovery and development of rDNA-derived Humalog, rGlucagon, and Forteo, which he shepherded through development and commercialization. His research has broadened the understanding of glucagon physiology and the discovery of
single molecule multimode agonists for the treatment of diabetes and obesity. A former officer and director, Dr. DiMarchi is not currently an employee of the Company, but acts as the principal investigator under our research agreement with the
Trustees of Indiana University, pursuant to which we have the option to license intellectual property developed on our behalf by Dr. DiMarchi. Dr. DiMarchi is not required to devote any specified number of hours to the Company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $150&nbsp;million in funding from leading healthcare investors, including Frazier Life Sciences, New Enterprise
Associates, Norwest Venture Partners, OrbiMed, RA Capital Management, and Wellington Management. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and
in certain cases received their shares in prior offerings at prices lower than the price offered to the public in this offering. See the sections titled &#147;Certain relationships and related person transactions&#148; and &#147;Principal
stockholders&#148; for more information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are building a
leading biopharmaceutical company with a focus on endocrine and metabolic disorders. Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative precision peptide
therapies. We are leveraging our propriety PEP platform to significantly improve clinical outcomes by discovering novel treatments that overcome key limitations of current peptide therapies. The key pillars of our business strategy to achieve this
mission include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance MBX 2109, a potential PTH peptide prodrug therapy, through clinical development to improve outcomes for patients
with HP. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance MBX 1416, a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, through clinical
development to potentially address the unmet medical need in patients with PBH. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Advance our obesity portfolio, including our lead obesity candidate, MBX 4291, with a focus on improving efficacy,
tolerability and dosing frequency compared to existing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Leverage our proprietary PEP technology platform and the capabilities of our experienced discovery team to expand our
pipeline in endocrine, metabolic and other disease areas. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Build a fully-integrated biopharmaceutical company and selectively evaluate strategic opportunities to maximize the value
of our pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Maintain an entrepreneurial, scientifically rigorous, and inclusive corporate culture where employees are fully engaged and
strive to bring improved therapeutic options to patients. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks associated with our business </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never
achieve or maintain profitability. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The results observed from preclinical studies or early-stage clinical trials of our product candidates, including, but not
limited to, our preclinical studies of MBX 4291, may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. Similarly, positive results from such preclinical studies or early-stage clinical trials may not be
replicated in our subsequent preclinical studies or clinical trials. </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have never generated revenue from product sales and may never become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will need substantial additional funding in addition to the net proceeds we receive from this offering. If we are unable
to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other operations.
</P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our business is highly dependent on the success of our product candidates. If we are unable to successfully complete
clinical development, obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we fail to discover, develop and commercialize other product candidates, or successfully build out our own internal
discovery capacities, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of our product candidates. </P></TD></TR></TABLE>   <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may find it difficult to enroll patients in our future clinical trials given the limited number of patients who have the
diseases some of our product candidates are intended to target. Additionally, we also compete for trial participants with other clinical trials for product candidates that are in the same areas as our product candidates. If we experience delays or
difficulties in the enrollment of patients in clinical trials, our clinical development activities and our receipt of necessary regulatory approvals could be delayed or prevented. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or
all of those indications, or any other indication that we elect to pursue, may be significantly smaller than our estimates. The actual number of patients with these disease indications may, however, be significantly lower than we believe, which may
delay enrollment in our clinical trials and delay or prevent development of our product candidates. </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if any of our product candidates receives regulatory approval, it may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with Orphan Drug Designation,
including the potential for market exclusivity. Furthermore, Orphan Drug Designation does not shorten the development time or regulatory review time of a product candidate and does not provide any guarantee of approval in the regulatory review or
approval process. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We face significant competition in an environment of rapid change, and there is a possibility that our competitors may
achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, or that we are unable to compete with existing entities that have made substantial investment into novel treatments for disease, which
may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We have not yet demonstrated an ability to obtain regulatory approvals. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Unless we can demonstrate that MBX 2109 is either not a similar medicinal product to Yorvipath<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a once-daily PTH replacement therapy that is approved in the European Union, or EU, for the treatment of HP, or, if it is, that MBX 2109 is safer, more effective or otherwise clinically
superior, we may not be able to gain approval for MBX 2109 in the European Union until expiry of the market exclusivity period for Yorvipath. The exclusivity period could run until 2035 at the latest. Yorvipath has a new drug application, or NDA,
currently under review by the FDA for the same indication. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may in the future conduct clinical trials for drug candidates outside the United States, and the FDA and comparable
foreign regulatory authorities may not accept data from such trials. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may
have to alter our development and commercialization plans.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be
able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our use of third parties to manufacture our product candidates may increase the risk that we will not have sufficient
quantities of our product candidates, raw materials, active pharmaceutical ingredients, or APIs, or drug products when needed or at an acceptable cost. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to
retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property
and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates similar to ours and our
ability to successfully develop and commercialize our product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third
parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose license rights that are important to our business. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will need to continue to significantly increase the size of our organization and we may have difficulties in managing
our growth and expanding our operations successfully. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We do not know whether a market will develop for our common stock or what the market price of our common stock will be,
and, as a result, it may be difficult for you to sell your shares of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were founded as MBX Biosciences LLC, an Indiana limited liability company, in August 2018. We converted to a Delaware corporation in April 2019 and incorporated under
the name MBX Biosciences, Inc. Our principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032, and our telephone number is (317) <FONT STYLE="white-space:nowrap">659-0200.</FONT> Our website address is
https://www.mbxbio.com. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as
an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Implications of being an emerging growth company and a smaller reporting company </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth
company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to the Sarbanes-Oxley Act of 2002; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of these exemptions for up
to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but not
all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold
stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised
accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of other public companies that
comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted for private companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by nonaffiliates plus the proposed aggregate amount of gross
proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering
if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal
year and the market value of our shares held by nonaffiliates is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to
present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure
obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_2"></A>The offering </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Shares of common stock offered by us </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">&#8195;&#8195;&#8195;&#8195; shares. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Underwriters&#146; option to purchase additional shares </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to &#8195;&#8195;&#8195;&#8195;additional
shares of our common stock at the initial public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Shares of our common stock to be outstanding after this offering </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">&#8195;&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares in
full). </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Use of proceeds </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">We estimate that the net proceeds to us from the sale of &#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering will be
approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million, or $&#8195;&#8195;&#8195;&#8195; million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of
$&#8195;&#8195;&#8195;&#8195;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We
intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and short-term investments, to fund the continued development of MBX 2109 and MBX 1416, our two clinical stage programs, and MBX 4291, our
preclinical stage program, fund our discovery research and development activities and additional clinical development and for general corporate purposes and working capital. See &#147;Use of proceeds.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Directed share program </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">At our request, the underwriters have reserved up to &#8195;% of the shares of common stock being offered by this prospectus for sale at the initial
public offering price to our directors, officers, certain employees and certain other persons associated with us. The sales will be made by J.P. Morgan Securities LLC, an underwriter of this offering, through a directed share program. We do not know
if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Any reserved shares not so purchased will be
offered by the underwriters to the general public on the same terms as the other shares of </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="47%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
common stock. Except for reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT>
restrictions described elsewhere in this prospectus.&#148; See &#147;Underwriting&#151;Directed share program&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Proposed Nasdaq Global Select Market symbol </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; The closing of this offering is
contingent upon such listing. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="47%"> <P STYLE="margin-top:8pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B><I>Risk factors </I></B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:arial">Investment in our common stock involves substantial risks. You should read this prospectus carefully, including the section entitled &#147;Risk
factors&#148; and the financial statements and the related notes to those statements included in this prospectus, before investing in our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common outstanding after this offering is based on 198,383,608 shares of our common stock (which includes 695,990 shares underlying unvested
restricted stock awards subject to a repurchase option by us) outstanding as of March 31, 2024, after giving effect to the conversion of all outstanding shares of our convertible Series A preferred stock and Series B preferred stock, or the
preferred stock, into an aggregate of 182,838,619 shares of our common stock, which will occur immediately upon the closing of this offering, or the Preferred Stock Conversion, and excludes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">32,761,221 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2024, with a
weighted-average exercise price of $0.53 per share under our 2019 Stock Option and Grant Plan, or the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,205,455 shares of common stock issuable upon the exercise of stock options granted after March 31, 2024, with a
weighted-average exercise price of $0.87 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">5,014,218 shares of common stock reserved for issuance under the 2019 Plan as of March 31, 2024, which shares will cease to
be available for issuance at the time our 2024 Stock Option and Incentive Plan, or the 2024 Plan, becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under our 2024 Plan, which will become
effective upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under our 2024 Employee Stock Purchase
Plan, or the 2024 ESPP, which will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise noted, all information in this prospectus assumes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the underwriters&#146; option to purchase up to &#8195;&#8195;&#8195;&#8195; additional shares of common
stock in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no vesting of the restricted common stock described above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no purchases by existing stockholders or their affiliates pursuant to the directed share program; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#8195;&#8195;&#8195;&#8195; -for- &#8195;&#8195;&#8195;&#8195;reverse stock split of our common stock effected on
&#8195;&#8195;&#8195;&#8195;, 2024; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the filing and effectiveness of our third amended and restated certificate of incorporation immediately prior to the
closing of this offering and the adoption of our amended and restated bylaws upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><A NAME="toc790774_3"></A>Summary financial data </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>You should read the
following summary financial data together with our financial statements and the related notes appearing at the end of this prospectus and the &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148;
section of this prospectus. We have derived the statement of operations and comprehensive loss data for the years ended December 31, 2022 and 2023 from our audited financial statements appearing at the end of this prospectus. We have derived the
statement of operations and comprehensive loss data for the three months ended March 31, 2023 and 2024 and the summary balance sheet data as of March 31, 2024, except for pro forma amounts, from our unaudited condensed interim financial statements
and related notes as of and for the three months ended March 31, 2023 and 2024 appearing at the end of this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period. </I></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years Ended December 31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Three Months Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except per share and per share data)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Statement of operations:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reclassification of net (gains) losses included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in computation of net loss per common share, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,018,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,247,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,299,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,455,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>As of March&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma,&nbsp;as<BR>adjusted(3)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See notes 2 and 15 to our audited financial statements and note 14 to our unaudited condensed interim financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the
net loss per share attributable to common stockholders, basic and diluted, and the weighted average number of shares used in the computation of the per share amounts. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column above gives effect to (i)&nbsp;the filing and effectiveness of our third amended and restated certificate of incorporation in Delaware immediately prior to the closing of this offering and the
adoption of our amended and restated bylaws upon the effectiveness of the registration statement of which this prospectus forms a part and (ii)&nbsp;the automatic conversion of all of our convertible preferred stock into an equal number of shares of
common stock. </TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gives further effect to the sale of&#8195;&#8195;&#8195;&#8195;shares of common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the
price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and commissions and estimated offering expenses payable by us. This pro forma as adjusted information is illustrative only and will depend on the
actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by
$&#8195;&#8195;&#8195;&#8195;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us. Each increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and
stockholders&#146; equity by $&#8195;&#8195;&#8195;&#8195;, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included elsewhere in this prospectus for further details regarding our
current assets and current liabilities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_4"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other
information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any of the events or developments described below were to
occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described below are
not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to financial position and need for capital </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have
incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since
inception, we have incurred significant operating losses. Our net loss was $26.1&nbsp;million and $32.6&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. Our net loss was $12.3 million for the three months ended March
31, 2024. As of December&nbsp;31, 2023, we had an accumulated deficit of $75.6&nbsp;million. As of March 31, 2024, we had an accumulated deficit of $87.9&nbsp;million. We have financed our operations primarily through issuing convertible preferred
stock and convertible promissory notes. Substantially all of our losses have resulted from expenses incurred in connection with our research and development and from general and administrative costs associated with our operations. We expect to
continue to incur significant expenses and increasing operating losses for the foreseeable future. Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization
of our current product candidates and potential future product candidates. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially for the foreseeable future if and as
we: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance our current research activities and further develop our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue preclinical development and progress clinical trials for our product candidates and any future product candidates
we may identify; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approval for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish our manufacturing capacity capabilities to supply our clinical trials in our pipeline and eventually for
commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">commercialize our product candidates, if approved, which will require significant marketing, sales, and distribution
infrastructure expenses; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">hire additional research and development, clinical, commercial, and general and administration personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect, and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">confirm, maintain or obtain freedom to operate for any of our owned or licensed technologies and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add operational, financial and management information systems and personnel; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, audit, accounting, compliance, insurance, investor relations and other expenses to operate as a
public company that we did not incur as a private company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result, we will need substantial additional funding to support our continuing
operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may
include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or
enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of our platform, product candidates or delay our pursuit of potential
<FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have not yet demonstrated an ability to successfully complete any pivotal clinical trials,
advance any product candidate beyond Phase 2, obtain regulatory approvals, manufacture our product candidates at commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for
successful product commercialization. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a therapy or therapies with market potential. This will require us to be successful in a
range of challenging activities, including completing preclinical studies and clinical trials of product candidates, obtaining regulatory approval for these product candidates, manufacturing, marketing and selling those therapies for which we may
obtain regulatory approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because of the numerous risks and uncertainties associated with developing our technology, platform and our product candidates, we are unable to predict the extent of
any future losses or when we will become profitable, if at all. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the
value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your
investment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have never generated revenue from product sales and may never become profitable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the
development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We may not generate revenues from product sales for many years, if ever. Our ability to generate future revenues from product sales depends
heavily on our or our collaborators&#146; ability to successfully: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">complete research and development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identify new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek and obtain regulatory approvals for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">launch and commercialize any product candidates for which we may obtain regulatory approval by establishing a sales force,
marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which
we may obtain regulatory approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount
and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">address competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our
obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary rights,
including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defend against third-party intellectual property claims of infringement, misappropriation or other violation; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration, or the FDA, or other regulatory authorities to perform
preclinical studies or clinical trials in addition to those that we currently anticipate. Even if one or more of our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any
approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues from the sale of any
approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will need substantial
additional funding in addition to the net proceeds we receive from this offering. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and
product development programs, future commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Developing product candidates, including conducting preclinical studies
and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our
ongoing activities, particularly as we continue the research and development of, continue, initiate and conduct clinical trials of, and seek regulatory approval for, our product candidates. In addition, if we obtain regulatory approval for our
product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility
of a collaborator. Other unanticipated costs may also arise. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce, or eliminate our research and product development programs, future
commercialization efforts or other operations. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March 31, 2024, our cash, cash equivalents and marketable securities were $70.3&nbsp;million. We expect
that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
securities, will enable us to fund our operating expenses and capital expenditure requirements into&#8195;&#8195;&#8195;&#8195;. However, our operating plan may change as a result of factors
currently unknown to us, and we may need to seek funding sooner than planned. Our future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents and other
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any product liability or other lawsuits related to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of economic uncertainty, global health crises and geopolitical tensions, which may exacerbate the magnitude of
the factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming,
expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not
achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing
to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we
believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly other restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. We have no committed sources of additional capital and, if we are unable to raise additional
capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our future product candidates or other research and development initiatives. Without
sufficient funding, our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product
development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Additionally, if we raise funds through additional collaborations, strategic
alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or we may have to grant licenses on terms that may not be
favorable to us and/or that may reduce the value of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our short operating history may make it difficult for you to evaluate the success of our
business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an early-stage company. We commenced our operations in August 2018. Our operations to date have
been limited to organizing and staffing our company, business planning, raising capital, and research and development activities such as developing our platform and technology and identifying and beginning to advance preclinical and clinical testing
of our product candidates. Two of our product candidates, MBX 2109 and MBX 1416 are in clinical development, while MBX 4291 is in the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> phase and our other development programs in our obesity
portfolio remain in the research or lead optimization stage of development. We have not yet demonstrated an ability to complete any large-scale, pivotal clinical trials, advance any product candidate beyond Phase 2, obtain regulatory approvals,
manufacture our product candidates at commercial scale, arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful commercialization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our limited operating history, particularly in light of the evolving field of peptide therapies, may make it difficult to evaluate our platform, technology and industry
and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by very early
stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a new business that is rapidly
growing, we may encounter other unforeseen expenses, difficulties, complications, and delays in our product development. We will need to transition from a company with a focus on research and conducting clinical trials to a company capable of
supporting commercial activities if any of our product candidates are approved. We may not be successful in such a transition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our future ability to utilize
our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred losses and we may never achieve
profitability. As of December&nbsp;31, 2023, we had U.S. federal net operating loss carryforwards of $30.1&nbsp;million which are not subject to expiration and state net operating loss carryforwards of $71.3&nbsp;million which begin to expire in
various amounts in 2039, and $4.7&nbsp;million of U.S. federal research and development carryforwards which begin to expire in various amounts in 2039, and $1.2&nbsp;million of research credit carryforwards for state income tax purposes which begin
to expire in various amounts in 2029. To the extent that we continue to generate taxable losses, under current law, our unused U.S. federal net operating losses, or NOLs, may be carried forward to offset a portion of future taxable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
income, if any. Additionally, we continue to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a portion of future
taxable income, if any, subject to expiration of such credit carryforwards. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change,&#148; generally defined as
one or more shareholders or groups of shareholders who own at least 5&nbsp;percent of the corporation&#146;s equity increasing their equity ownership in the aggregate by more than 50 percentage points (by value) over a three-year period, the
corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its post-change income
or taxes may be limited. Similar rules may apply under state tax laws. To date, we have not completed an analysis under Section&nbsp;382 of the Code. It is possible that our prior equity offerings and other changes in our stock ownership could have
resulted in such ownership changes in the past. In addition, we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we
earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs or other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset U.S. federal taxable income may be subject to limitations,
which could potentially result in increased future tax liability to us. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be
unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes
owed. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in tax
laws or in their implementation or interpretation may adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The rules dealing with U.S. federal, state and
local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could
adversely affect our business and our financial condition. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, under Section&nbsp;174 of the Code, currently, in taxable years
beginning after December&nbsp;31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. More recently, however, there have been proposals to
retroactively reinstate deductibility under Section&nbsp;174 of the Code. In addition, it is unclear how changes in U.S. federal income tax laws will affect state and local taxation. We cannot predict whether, when, in what form or with what
effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided or whether they could increase our or our shareholders&#146; tax liability or require changes in the manner in which we operate in order to minimize any
adverse effects of changes in tax laws or in the interpretation thereof. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our business and industry </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our business is highly dependent on the success of our product candidates. If we are unable to successfully complete clinical development, obtain regulatory
approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
in the early stages of our development efforts and have only two product candidates, MBX 2109 and MBX 1416, in clinical development. All of our other development programs are still in the preclinical or drug discovery stage. To date, as an
organization, we have not completed the development of any product candidates. Our future success and ability to generate revenue from our product candidates is dependent on our ability to successfully develop, obtain regulatory approval for and
commercialize one or more of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
product candidates. All of our product candidates will require substantial additional investment for clinical development, regulatory review and approval in one or more jurisdictions. If any of
our product candidates encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be materially harmed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have the financial resources to continue development of our product candidates if we experience any issues that delay or prevent regulatory approval of, or
our ability to commercialize, our product candidates, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product
candidates are safe and effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insufficiency of our financial and other resources to complete the necessary clinical trials and preclinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negative or inconclusive results from our clinical trials, preclinical studies or the clinical trials of others for product
candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product-related adverse events experienced by subjects in our clinical trials, including unexpected toxicity results or
drug-drug interactions, or by individuals using drugs or therapeutic biologics similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in submitting an Investigational New Drug, or IND, application or comparable foreign applications or delays or
failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension or termination, or hold, of a clinical trial once commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conditions imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">poor effectiveness of our product candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive
results from our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in enrolling or inability to enroll subjects in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of subjects from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">higher than anticipated clinical trial or manufacturing costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to timely or adequately finalize the design or formulation of any product candidate or demonstrate that a
formulation of any product candidate will be stable for commercially reasonable time periods; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unfavorable FDA or comparable regulatory authority inspection and review of our clinical trial sites;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or the clinical trial
protocol or otherwise meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure to acquire patent rights over our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory
oversight around clinical testing generally or with respect to our therapies in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">varying interpretations of data by the FDA and comparable foreign regulatory authorities.<B><I><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to discover, develop and commercialize other product candidates, or
successfully build out our own internal discovery capacities, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although the development and commercialization of MBX 2109, MBX 1416 and MBX 4291 and the other development candidates in our obesity portfolio are our initial focus, as
part of our longer-term growth strategy, we plan to continue to develop our additional assets in earlier stages of development and to build fully functional internal discovery capabilities to develop other product candidates. We intend to evaluate
internal opportunities from our existing product candidates or other potential product candidates. We have historically relied on the discovery capabilities of our <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Richard DiMarchi, but we
are currently continuing to build fully functional internal discovery capabilities, including laboratory space, and internalizing our ability to develop other product candidates. Dr. DiMarchi is a current consultant to the Company, as well as the
principal investigator under our research agreement with the Trustees of Indiana University, under which we retain intellectual property developed on our behalf by Dr. DiMarchi, but the consulting agreement and research agreement are both terminable
by either party. We have leased laboratory and office space at a research facility suitable for peptide chemistry, <I>in vitro</I> pharmacology and bioanalytical chemistry. We have built a team devoted to peptide chemistry and <I>in vitro</I>
pharmacology, and are continuing to expand that team. The peptide chemistry lab will be based around a state-of-the-art peptide synthesizer capable of synthesizing up to 106 peptides of variable scales and chemistries simultaneously. We are
equipping the laboratories currently and expect to have our internal discovery efforts established in the third quarter of 2024. If we are unable to complete this expansion and internalization, we may not be able to add internally-developed product
candidates to our pipeline and will have to rely on our existing product candidates, additional product candidates we may in-license, or additional candidates we may develop through third-party research partners. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates to treat patients suffering from other disorders with
significant unmet medical needs and limited treatment options. These <FONT STYLE="white-space:nowrap">in-licensed</FONT> or internally developed potential product candidates will require additional, time-consuming development efforts prior to
commercial sale, including preclinical studies, clinical trials and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development,
including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or
produced economically, successfully commercialized or widely accepted in the marketplace or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These
research programs to discover and identify additional product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified, and all efforts are as of now completed
externally as we continue our efforts to internalize certain of our discovery capabilities. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development
for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competitors may develop alternatives that render our product candidates obsolete; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects, interactions with other drugs, or other
characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may not be sufficiently differentiated or offer substantial improvement over the currently available
treatment options or standard of care in a given therapeutic category; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the future, we may also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire product candidates or the underlying technology.
The process of proposing, negotiating and implementing a license or acquisition is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or
acquisition of product candidates. We have limited resources to identify and execute the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of third-party products, businesses and technologies and integrate them into our current
infrastructure. Moreover, we may devote resources to potential acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may
not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, future acquisitions may entail numerous
operational and financial risks, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exposure to unknown liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disruption of our business and diversion of management&#146;s time and attention to develop acquired products or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">higher than expected acquisition and integration costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issues maintaining uniform standards, procedures, controls and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent
liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased amortization expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential losses related to investments in other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and
ownership; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inability to motivate key employees of any acquired businesses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unsuccessful in identifying and developing additional product candidates, either through internal
development or licensing or acquisition from third parties, our potential for growth and achieving our strategic objectives may be impaired and we may not be able to increase our revenues in future periods, which could harm our business, results of
operations and prospects, and the value of our shares.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The successful development of
pharmaceutical products is highly uncertain. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Successful development of pharmaceutical products is highly uncertain and is dependent on numerous factors,
many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical trial results may show the product candidates to be less effective than expected (for example, a clinical trial
could fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things,
may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to <FONT STYLE="white-space:nowrap">follow-up,</FONT> length of time to achieve trial endpoints,
additional time requirements for data analysis or New Drug Application, or NDA, preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data (such as long-term toxicology studies) or unexpected safety or
manufacturing issues; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful side effects;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">post-marketing approval requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the proprietary rights of others and their competing products and technologies that may prevent our product candidates from
being commercialized. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The length of time necessary to complete clinical trials and submit an application for marketing approval for a final
decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and
adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may
be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a
product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial
success would be reduced. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations
regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with current Good Manufacturing Practices, or cGMPs, and Good
Clinical Practices, or GCPs, for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third-party might identify previously unknown problems with a product post-approval, such
as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and
results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we
must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing
additional clinical trials or preclinical studies, including as a result of regulators not allowing or delay in allowing clinical trials to proceed under an IND, or not approving or delaying approval for any clinical trial grant or similar approval
we need to initiate a clinical trial. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators, institutional review boards, or IRBs, or other reviewing bodies may not authorize us or our investigators to
commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of subjects or patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be insufficient or slower than we anticipate, including because of the small number of patients for certain of our rare disease indications, and the number of clinical trials being conducted at any given time
may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our
behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect
changes to incorporate adjustments in our planned analysis or in regulatory requirements or guidance, which may be required to resubmit to an IRB and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulators or other reviewing bodies may find deficiencies with, fail to approve or subsequently find fault with the
manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies, or the supply or quality of any product candidate or other materials necessary to conduct clinical trials of
our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulators or IRBs of the institutions in which clinical
trials are being conducted may suspend, limit or terminate a clinical trial, or data monitoring committees may recommend that we suspend or terminate a clinical trial, due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side
effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Negative or inconclusive results
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct clinical trials in other indications, could result in
changes to or delays in clinical trials of our product candidates in such other indications. We do not know whether any clinical trials that we conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our
product candidates for the indications that we are pursuing. If later-stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market our
product candidates would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete clinical
trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure or otherwise modify our trials after they have begun. For instance, we have adjusted our
protocol for MBX 2109 to take into account feedback from our CRO. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring
products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials
may ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we complete the necessary preclinical studies and clinical trials,
the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidate we develop and the activities associated with its development and commercialization, including its design, testing, manufacture, safety, efficacy,
recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries.
Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any
jurisdiction and it is possible that none of the product candidates we are developing or may seek to develop in the future will ever obtain regulatory approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
have no experience in submitting and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the
submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing regulatory approval also
requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately
effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude its obtaining marketing approval or prevent or limit commercial use. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if
approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in
or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries
have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval that
we may ultimately obtain could be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we
experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial
profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Undesirable side effects caused by
any of our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory
authorities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain side effects and potential drug-drug interactions have been observed in our product candidates to date. For example, in our Phase 1 clinical
trial of MBX 1416, injection site adverse events were the most common treatment-related adverse event, and hypercalcemic events were observed at the top doses in three subjects each in the single and multiple ascending dose cohort. Although these
events were not serious adverse events and resolved without intervention, if we were unable to identify a dose with a tolerable side-effect profile, or were limited in our ability for our product candidates to be used with certain other drugs, the
commercial success of our product candidates, if approved, could be limited. We have added a drug interaction cohort to our Phase 1 clinical trial of MBX 1416 to evaluate interactions between MBX 1416 and certain other common drugs, which could be
costly and time-consuming. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also observe additional safety or tolerability issues with our product candidates in ongoing or future clinical trials. Many
compounds that initially showed promise in clinical or earlier-stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Results of future clinical trials of our product
candidates could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics, despite a favorable tolerability profile observed in earlier-stage testing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory authorities, the IRBs, or independent
ethics committees at the institutions in which our trials are conducted, could suspend, limit or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit or terminate our trials, or the FDA
or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-emergent side effects that are deemed to be drug-related could delay
recruitment of clinical trial subjects or may cause subjects that enroll in our clinical trials to discontinue participation in our clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating
medical staff. We may need to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or
managing the potential side effects of our product candidates could result in harm to patients that are administered our product candidates. Any of these occurrences may adversely affect our business, financial condition and prospects significantly.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently,
it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials
conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
results observed from preclinical studies or early-stage clinical trials of our product candidates may not necessarily be predictive of the results of later-stage clinical trials that we conduct. Similarly, positive results from such preclinical
studies or early-stage clinical trials may not be replicated in our subsequent preclinical studies or clinical trials. Furthermore, our product candidates may not be able to demonstrate similar activity or adverse event profiles as other product
candidates that we believe may have similar profiles. For example, our future preclinical or clinical trials for our existing and future product candidates may not continue to demonstrate the extended half lives and low <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios that we have seen so far in our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in
our planned future clinical trials, we may utilize clinical trial designs or dosing regimens that have not been tested in prior clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There can be no
assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks
have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we may utilize an &#147;open-label&#148; clinical trial design. An &#147;open-label&#148; clinical trial is one where both the patient and investigator
know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose
levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a
&#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where
those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an
open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a controlled environment with a placebo or active control. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed
satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the
final data.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may publish interim, topline or preliminary data from our clinical
trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline
data also remain subject to audit and verification procedures that may result in the final data being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse
differences between preliminary or interim data and final data could significantly harm our reputation and business prospects.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may find it difficult to enroll patients in our future clinical trials given the limited number of patients who have the diseases some of our product candidates
are intended to target. Additionally, we also compete for trial participants with other clinical trials for product candidates that are in the same areas as our product candidates. If we experience delays or difficulties in the enrollment of
patients in clinical trials, our clinical development activities and our receipt of necessary regulatory approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As we
progress our programs, we may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or
other comparable regulatory authorities outside the United States, or as needed to provide appropriate statistical power for a given trial. Enrollment may be particularly challenging for some of the rare diseases we are targeting in our programs
such as MBX 2109 and MBX 1416. For instance, in our Phase 1 trial of MBX 2109, we added one new site to the trial following slow enrollment at the originally selected sites, in order to meet our enrollment requirements. Enrollment may also be
challenging for product candidates targeting prevalent diseases, such as MBX 4291 or other product candidates in our obesity portfolio, due to the intense competition in the field. In addition, if patients are unwilling to participate in our trials
because of negative publicity from adverse events, competitive clinical trials for similar patient populations, clinical trials in competing product candidates or for other reasons, the timeline for recruiting patients, conducting studies and
obtaining regulatory approval of our product candidates may be delayed. Moreover, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as our product candidates, and patients who would
otherwise be eligible for our future clinical trials may instead enroll in clinical trials of our competitors&#146; product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patient enrollment is also
affected by other factors, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">size of the patient population and process for identifying patients, including proximity and availability of clinical trial
sites for prospective patients with conditions that have small patient pools; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">effects of global health crises, such as those related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> on enrollment
and/or completion of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">design of the trial protocol, including efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ability to obtain and maintain patient informed consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risk that enrolled patients will drop out before completion of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">eligibility and exclusion criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">perceived risks and benefits of the product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patient referral practices of physicians. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if we are unable to enroll a sufficient number of eligible patients in these trials in the United States,
we may look to enroll in sites outside of the United States. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, some of
which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in establishing or managing relationships with CROs and physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">different <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for patients
with a particular disease; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulty in locating qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the
regulation of pharmaceutical and biotechnology products. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Enrollment delays in our clinical trials may result in increased development costs for
our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct our clinical trials,
we may need to delay, limit or terminate ongoing or planned clinical trials or entire clinical programs, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The number of patients with the diseases and disorders for which we are developing our product candidates has not been established with precision. If the actual
number of patients with the diseases or disorders we elect to pursue with our product candidates is smaller than we anticipate, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our
product candidates. Even if such product candidates are successfully developed and approved, the markets for our products may be smaller than we expect and our revenue potential and ability to achieve profitability may be materially adversely
affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pipeline includes product candidates for both endocrine and metabolic diseases, with our lead product candidates targeting chronic
hypoparathyroidism, or HP, post-bariatric hypoglycemia, or PBH, and obesity. There is no precise method of establishing the actual number of patients with any of these disorders in any geography over any time period. With respect to many of the
indications in which we have developed, are developing, or plan to develop our product candidates, we have estimates of the prevalence of the disease or disorder. The process we have used in developing an estimated incidence and prevalence for the
indications we are targeting has involved collating limited data from multiple sources. Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or all of those indications, or any
other indication that we elect to pursue, may be significantly smaller than our estimates. For example, the estimated patient population for HP, a rare endocrine disease, already tends to be small, and may be even smaller than our current estimates.
Moreover, the patient population for PBH may decrease due to the development of novel treatments for obesity, reducing the potential need for bariatric surgery, and the patient population for obesity may decrease as novel treatments for obesity are
introduced. In estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our estimates as to the prevalence of HP, PBH and obesity, we apply assumptions to available information that may not prove to
be accurate. In each case, there is a range of estimates in the published literature and in marketing studies, which include estimates within the range that are lower than our estimates. The actual number of patients with these disease indications
may, however, be significantly lower than we believe. Even if our prevalence estimates are correct, our product candidates may be developed for only a subset of patients with the relevant disease or </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disorder or our products, if approved, may be indicated for or used by only a subset. In the event the number of patients with the diseases and disorders we are studying is significantly lower
than we expect, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. If any of our product candidates are approved and our prevalence estimates with respect to any
indication or our other market assumptions are not accurate, the markets for our product candidates for these indications may be smaller than we anticipate, which could limit our revenues and our ability to achieve profitability or to meet our
expectations with respect to revenues or profits.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if any of our product candidates
receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant
revenues or become profitable. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never commercialized a product, and even if any of our product candidates is approved by the appropriate regulatory
authorities for marketing and sale, it may nonetheless fail to achieve sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Many of the indications for our product candidates have
well-established standards of care that physicians, patients and payors are familiar with. Even if our product candidates are successful in registrational clinical trials, they may not be successful in displacing these current standards of care if
we are unable to demonstrate superior efficacy, safety, ease of administration and/or cost-effectiveness. For example, physicians may be reluctant to take their patients off their current medications and switch their treatment regimen to our product
candidates. Further, patients often acclimate to the treatment regimen that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch due to lack of coverage and adequate
reimbursement. Even if we are able to demonstrate our product candidates&#146; safety and efficacy to the FDA and other regulators, safety or efficacy concerns in the medical community may hinder market acceptance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, including management time
and financial resources, and may not be successful. If any product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market
acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efficacy and safety of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential advantages of the product compared to competitive therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the product&#146;s convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations or warnings, including interactions with other drugs or distribution or use restrictions contained in the
product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the strength of sales, marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the standard of care for the targeted indications for the product; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or commercial success
would adversely affect our business prospects.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face significant competition in an
environment of rapid change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, or that we are unable to compete with existing
entities that have made substantial investment into novel treatments for disease, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The development and commercialization of new drug products is highly competitive. We will face competition with respect to our product candidates and any product
candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government
agencies and other public and private research organizations that conduct research, seek patent or other intellectual property protection and establish collaborative arrangements for research, development, manufacturing and commercialization. There
are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these
competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, while others are based on entirely different approaches. For more information, see &#147;Business&#150;Competition.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that
are approved to treat the same diseases for which we may obtain approval for any product candidates we may develop. This may include other types of therapies, such as small molecule, antibody and/or protein therapies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in
research and development, manufacturing, conducting preclinical studies and clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may
result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are
more convenient, or are less expensive than any product candidates that we may develop or that would render any product candidates that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may
obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally,
technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a result of the expiration or successful challenge of our patent or other intellectual property rights, we could face risks relating to our ability to
successfully prevent or delay launch of competitors&#146; products. The availability of our competitors&#146; products could limit the demand and the price we are able to charge for any product candidates that we may develop and commercialize. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Due to the significant resources required for the development of our pipeline, and depending on our ability to
access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a
greater likelihood of success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently have three product candidates as well as several other programs at various stages of discovery and development.
We seek to advance discovery and development for product candidates with an initial focus on both endocrine and metabolic disorders with high unmet need. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to the
significant resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of
research, development, collaboration, management and financial resources toward particular product candidates, therapeutic areas or indications may not lead to the development of viable commercial products and may divert resources away from better
opportunities. For instance, we have elected to evaluate MBX 1416 as a treatment for PBH, but there may be better indications for which to evaluate MBX 1416, and this decision may divert resources away from better opportunities for MBX 1416. If we
make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the pharmaceutical industry, in particular for the rare diseases we are pursuing, our business, financial condition and
results of operations could be materially and adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product
candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or royalty
arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We currently have no commercial marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest
significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately
receives regulatory approval, we expect to establish a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time
consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and
incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our
internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either
to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing
and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any
products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in
commercializing our products, either on our own or through arrangements with one or more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our
product candidates may be delayed, and our business and results of operations may be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For planning purposes, we sometimes estimate the timing of the
accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of
regulatory filings or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt
of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the
timing of achievement of the milestones to vary considerably from our estimates, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including the
extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our receipt of approvals by the FDA and other regulatory authorities and the timing thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we fail to achieve announced milestones in the timeframes we expect, the development and commercialization of our product
candidates may be delayed, and our business and results of operations may be harmed.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks
related to regulatory, legal, and clinical trials </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy,
time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining regulatory approval from the FDA. Foreign
regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and comparable foreign authorities is inherently unpredictable, but typically takes many years following the commencement of clinical trials and
depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product
candidate&#146;s clinical development and may vary among jurisdictions. Jurisdictions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
outside of the United States, such as the European Union or Japan, may have different requirements for regulatory approval, which may require us to conduct additional clinical, nonclinical or
chemistry, manufacturing and control studies. To date, we have not submitted an NDA to the FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidate. We must complete additional preclinical
studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition, a product known as Yorvipath has received orphan medicine designation for hypoparathyroidism in the EU and was granted a marketing authorization in November 2023. In the EU, orphan medicines benefit from 10 years of market exclusivity once
they receive a marketing authorization in the EU (which may be extended by two additional years when the results of specific studies are reflected in the summary of product characteristics, or SmPC, addressing the paediatric population and completed
in accordance with a fully compliant paediatric investigation plan). This market exclusivity prevents the EMA and all EU Member States from accepting an application or granting a marketing authorization for a &#147;similar medicinal product&#148;
for the same therapeutic indication as the authorized orphan medicine, subject to certain specific derogations. Regulation (EC) 847/2000 defines a &#147;similar medicinal product&#148; as one which contains a similar active substance or substances
as contained in an authorized orphan medicinal product and which is intended for the same therapeutic indication. A &#147;similar active substance&#148; is defined in the same Regulation as an identical active substance, or an active substance with
the same principal molecular structural features (but not necessarily all of the same molecular structural features) and which acts via the same mechanism. There are some limited derogations to the market exclusivity granted to orphan medicinal
products in the EU. Specifically, a company may be able to market a similar medicinal product to an authorized orphan product if: (i)&nbsp;the marketing authorization holder for the authorized orphan product consents to the grant of a marketing
authorization for the similar product; (ii)&nbsp;the marketing authorization holder for the authorized orphan product is unable to supply sufficient quantities of its product; or (iii)&nbsp;the later applicant can establish that its product,
although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior. Regulation (EC) 847/2000 provides details on what would constitute clinical superiority in this context, including that direct comparative
clinical trials may be required to demonstrate greater efficacy or safety to the authorized orphan product. As a result, we may not be able to gain approval for MBX 2109 in the EU until expiry of the market exclusivity period for Yorvipath (which
could run until 2035 at the latest), unless we can demonstrate that MBX 2109 is either not a similar medicinal product to Yorvipath (i.e. the active substance in MBX 2109, if not identical to Yorvipath, does not have the same principal molecular
structural features and act via the same mechanism as Yorvipath) or, if it is, that MBX 2109 is safer, more effective or otherwise clinically superior. Any comparative studies required to demonstrate clinical superiority could be costly and
time-consuming, and there is no certainty that we would succeed in adequately demonstrating that our product is clinically superior to Yorvipath. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current and
future product candidates could fail to receive regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product
candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign
regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or
preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA
to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing
processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">another company may benefit from market exclusivity for their product which prevents us from obtaining marketing
authorization for our product in the same indication during such exclusivity period (as described above). </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This lengthy approval process as well as
the unpredictability of clinical trial results and market exclusivity issues described above may result in our failing to obtain regulatory approval to market any product candidate we develop, which would substantially harm our business, results of
operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we
believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request,
may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our product candidates require specific shipping, storage, handling and administration, which in some cases, may require cold-chain logistics and subject our
product candidates to risk of loss or damage if failures occur. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our product candidates are sensitive to temperature, storage and handling conditions. They
must be stored at very low temperatures in specialized freezers or specialized shipping containers until immediately prior to use. The handling and administration of the therapy product, if approved, may need to be performed according to specific
instructions and in some steps within specific time periods. Failure to correctly handle our product could negatively impact the efficacy and or safety of our product, or cause a loss of product. In addition, if approved, certain of our products may
need to be frozen using specialized equipment and maintained following specific procedures in order to be stored without damage in a cost-efficient manner and without degradation. We will need to <FONT STYLE="white-space:nowrap">scale-up</FONT> a
cost-effective and reliable cold-chain distribution and logistics network, which we may be unable to accomplish. Failure to effectively <FONT STYLE="white-space:nowrap">scale-up</FONT> our cold-chain supply logistics, by us or third parties, could
in the future lead to additional manufacturing costs and delays in our ability to supply required quantities for commercial supply. For these and other reasons, we may not be able to manufacture our current or future product candidates at commercial
scale or in a cost-effective manner. Even if we are able to manufacture and distribute the product candidates, if our products require specific procedures to maintain and use them, we may be limited in commercial opportunity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Any drug delivery device that we potentially use to deliver our product candidates may have its own regulatory,
development, supply and other risks. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system.
There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Our product candidates may not be approved
or may be substantially delayed in receiving approval if the devices that we choose to utilize or develop do not gain and/or maintain their own regulatory approvals or clearances, if required. Where approval of the drug product and device is sought
under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation
and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent on those
third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or
maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for
expanded labels for new indications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The FDA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product candidates.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The general approach for FDA approval of a new drug is dispositive data from two or more adequate and well-controlled clinical trials of the product
candidate in the relevant patient population. Adequate and well-controlled clinical trials typically involve a large number of patients, have significant costs and take years to complete. The FDA or other regulatory authorities may disagree with us
about whether a clinical trial is adequate and well-controlled or may request that we conduct additional clinical trials prior to regulatory approval. In addition, there is no assurance that the doses, endpoints and trial designs that we intend to
use for our planned clinical trials, including those that we have developed based on feedback from regulatory agencies or those that have been used for the approval of similar drugs, will be acceptable for future approvals. For instance, if our
ongoing Phase 1 trial of MBX 1416 is successful, we plan to run a combined Phase 2/3 to evaluate MBX 1416 in PBH. If the FDA disagrees with our approach, we may have to evaluate MBX 1416 in two separate trials, which would be costly and
time-consuming. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our clinical trial results may not support approval of our product candidates. In addition, our product candidates could fail to receive regulatory
approval, or regulatory approval could be delayed, for many reasons, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may not file or accept our NDA or marketing application for
substantive review; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the dosing regimen, design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our
product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of our clinical trials may not meet the level of statistical significance required by the FDA or comparable
foreign regulatory authorities for approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate that our product candidates&#146; clinical and other benefits outweigh their safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from our preclinical
studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or
comparable foreign regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing
processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may in the future conduct clinical trials for drug candidates outside the
United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may in the future choose to conduct one or
more additional clinical trials outside the United States, including, among other places, in the EU, South America, Australia and/or Asia. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction
by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for regulatory approval in the United
States, the FDA will generally not approve the application based on foreign data alone unless: (i)&nbsp;the data is applicable to the U.S. population and U.S. medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of
recognized competence and pursuant to GCP regulations. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar
approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority
will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could
be costly and time-consuming, and which may result in drug candidates that we may develop not receiving approval for commercialization in such jurisdiction.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory
approval of our product candidates in other jurisdictions.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining and maintaining regulatory
approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may
have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing and marketing of the
product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies
or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before
it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the
United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in
significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>While we may in the future
seek designations for our product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can
be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates
that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory
authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the
development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, we may seek a Fast Track Designation for future product candidates we develop. If a product is intended for the treatment of a serious or life-threatening
condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this
designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development
process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in
combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial
can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval
and priority review. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets
the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product candidate may not result in a faster
development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we develop qualifies as a breakthrough
therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even in the absence of obtaining Fast
Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at the time of submitting a marketing application. The FDA may designate a product for priority </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies.
Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may
lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the
FDA&#146;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market
exclusivity.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug
intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the U.S. In the U.S., Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax
advantages and user fee waivers. In July 2022, the FDA granted MBX 2109 Orphan Drug Designation for the treatment of hypoparathyroidism. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, in the EU, the
EC grants orphan medicinal product designation after receiving the opinion of the EMA&#146;s Committee for Orphan Medicinal Products on an orphan medicinal product designation application. Orphan medicinal product designation is intended to promote
the development of medicinal products that are intended for the diagnosis, prevention or treatment of life threatening or chronically debilitating conditions affecting not more than five (5)&nbsp;in ten thousand (10,000) persons in the EU or for
products intended for the diagnosis, prevention, or treatment of a life threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the product in the EU would generate sufficient
return to justify the necessary investment in developing the product. In each case, there must be no satisfactory method of diagnosis, prevention, or treatment authorized for marketing in the EU (or, if such a method exists, the product would be of
significant benefit to those affected by the condition). In the EU, orphan medicinal product designation entitles a party to financial incentives such as reduction of fees or fee waivers. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is
entitled to a period of marketing exclusivity, which precludes the EC or the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven
years in the U.S. and ten years in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan medicinal product designation or if the drug is sufficiently profitable so that market exclusivity is
no longer justified. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the designated drug from competition because
different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown
to be safer, more effective or makes a major contribution to patient care.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Where appropriate, we plan to secure approval from the FDA or comparable foreign regulatory authorities through
the use of expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase
the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not
comply with rigorous post-marketing requirements, the FDA or such other regulatory authorities may seek to withdraw the accelerated approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where
possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for one or more of our therapeutic candidates from the FDA or comparable foreign regulatory authorities. Under
the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#146;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or life-threatening condition
that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.
The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is
a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint
that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases
in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on
the sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#146;s clinical benefit. Under the Food and Drug Omnibus Reform Act, or FDORA, the FDA is permitted to
require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased
authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly
posted by the agency, or if such post-approval studies fail to verify the drug&#146;s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval
confirmatory study or submit timely reports to the agency on their progress. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to seeking accelerated approval, we would seek feedback from the FDA or
comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or
submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, or comparable foreign regulatory authorities, we will
continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no
assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our
application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of
expedited development, review or approval for our therapeutic candidate would result in a longer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or
case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of
pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we conduct research and would sell, market and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to
Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations that may affect our ability to operate may apply. See the section titled, &#147;Business&#150;Government regulation&#150;Other healthcare laws.&#148;
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the
lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations,
prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare and privacy laws, as well as responding to possible investigations by government authorities, can be time and
resource-consuming and can divert a company&#146;s attention from the business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that our internal operations and future business arrangements with third
parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency
guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be
subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm and the
curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful
in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws,
they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could
be adversely affected.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Coverage and reimbursement may be limited or unavailable in certain
market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The success of our
product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. See the section
titled, &#147;Business&#150;Government regulation&#150;Coverage and reimbursement.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients who are provided medical treatment for their conditions generally
rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new
product acceptance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining
coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the
use of our products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. In the United States, the principal decisions
about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to
follow CMS to a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require
<FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations
required following the use of product candidates, once approved. Patients are unlikely to use our product candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is
significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product
candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future
relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts
from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and
timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, increasing efforts by governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the
United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward
pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether
the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our product candidates, if any, may be. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of
medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available
therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no
assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the
European Union do not follow price structures of the United States and generally prices tend to be significantly lower.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, (1)&nbsp;changes to our
manufacturing arrangements, (2)&nbsp;additions or modifications to product labeling, (3)&nbsp;the recall or discontinuation of our products or (4)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could
adversely affect the operation of our business. See the sections titled, &#147;Business&#150;Government regulation&#150;Current and future U.S. healthcare reform.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. There
have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other
changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenue generated from the sale of any approved products.
Even if we do receive a favorable coverage determination for our products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery
models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and
proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated
that it will continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict the initiatives that may be adopted in the future. The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to set a price that we believe is fair for our approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other
healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Off-label</FONT> use or misuse of our product candidates may harm our reputation in the marketplace or result in injuries that
lead to costly product liability suits. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our product candidates are approved by the FDA, we may only promote or market our product candidates in a manner
consistent with their <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. We will train our marketing and sales force against promoting our product candidates for uses outside of the approved indications for use, known as <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; We cannot, however, prevent a physician from using our product candidates <FONT STYLE="white-space:nowrap">off-label,</FONT> when in the physician&#146;s independent professional medical
judgment he or she deems it appropriate. Furthermore, the use of our product candidates for indications other than those approved by the FDA may not effectively treat such conditions. Any such <FONT STYLE="white-space:nowrap">off-label</FONT> use of
our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our product candidates for these uses for which they are not
approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Inadequate funding for the FDA or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products
and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability
to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government
agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA or other government agencies may also
slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, including as a result of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
reaching the debt ceiling, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our
business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.<B><I><SUP STYLE="font-size:75%; vertical-align:top">
</SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Failure to access or a significant delay in accessing animal research models may materially adversely affect our ability to advance our
preclinical programs and successfully develop any product candidates, which could result in significant harm to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Consistent with various rules,
regulations and cGMP, our ability to advance our preclinical and clinical programs for our product candidates requires access to animal research models sufficient to assess safety and in some cases to establish the rationale for therapeutic use.
Failure to access or a significant delay in accessing animal research models that meet our needs or that fulfill regulatory requirements may materially adversely affect our ability to advance our preclinical programs and successfully develop any
product candidates and this could result in significant harm to our business. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, researchers and CROs (including those engaged by us) experienced significant limitations in their
access to animal research models, specifically including a sharp reduction in the availability of <FONT STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs, originating from breeding farms in Southeast Asia and limited access to the
generation of genetically-modified rodent models used in efficacy evaluations. Prior to the pandemic, China was the leading exporter of NHPs employed in basic and applied research; however, early in 2020, China ceased exportation of cynomolgus
monkeys, the species most commonly involved in pharmaceutical product development. This change in the world supply of a critical research model has resulted in increased demand from breeding farms principally located in Cambodia, Vietnam, and
Mauritius Island, with a resultant marked increase in unit pricing. Consequently, this has further exacerbated an already constrained NHP supply for research purposes. If we are unable to obtain NHPs in sufficient quantities and in a timely manner
to meet the needs of our preclinical research programs, if the price of NHPs that are available increases significantly, or if our suppliers are unable to ship the NHPs in their possession that are reserved for us, our ability to advance our
preclinical programs and successfully develop any additional preclinical candidates we may identify may be materially adversely affected or significantly delayed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may
result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising,
promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign
regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring
that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess
compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all
areas of regulatory compliance, including manufacturing, production and quality control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved
indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of
the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also
require a risk evaluation and mitigation strategies, or REMS, program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide,
physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our
product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product
candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add
new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, under FDORA, sponsors of approved drugs and biologics must provide 6 months&#146; notice to the FDA of any changes in marketing status, such as the
withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#146;s ability to be marketed. The FDA strictly regulates marketing, labeling, advertising and
promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The policies of the FDA and comparable foreign regulatory authorities may
change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are and will continue to be subject to U.S. and certain foreign export and import controls, sanctions,
embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious
consequences for violations, which can harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to export control and import laws and regulations, including the U.S. Export
Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control, the U.S. Foreign Corrupt Practices Act of 1977, as amended,
or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.
Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of
value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory
approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of
our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal
fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and any contract manufacturers and suppliers
we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and
disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. We cannot eliminate the risk of contamination or injury from hazardous
materials, including chemical and biological materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under
certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and
penalties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting
requirements. These current or future laws, regulations, and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in
substantial fines, penalties, or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations.
Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
exposed to the risk of fraud or other misconduct by our employees, consultants and commercial partners, and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with
FDA regulations and other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data
accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could
involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We are also exposed
to risks in connection with any insider trading violations by employees or others affiliated with us. Upon the effectiveness of this registration statement, we will adopt a code of conduct and an insider trading policy applicable to all of our
employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may
develop. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face
an even greater risk if we commercially sell such product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual
outcome, liability claims may result in: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">decreased demand for any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">loss of revenue; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inability to commercialize any of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that we will need to increase our insurance coverage when we begin clinical trials and if we successfully commercialize any product candidate. Insurance
coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our internal computer and information technology systems, or those of our third-party vendors, collaborators,
contractors, consultants or other third parties, may fail, become unavailable, or suffer security incidents, compromises, or data breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our product
development programs, compromise confidential, sensitive or personal information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our internal computer and information technology systems and those of our current and any future
third-party vendors, collaborators, contractors, consultants or other third parties, are vulnerable to damage or interruption from, among other things, computer viruses, computer hackers, phishing attacks, ransomware, malware, social engineering,
service interruptions, system malfunction, malicious code, employee theft, fraud, misconduct or misuse, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, sophisticated nation-state and
nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we seek to protect our information technology systems from system failure, accident and security breach, we
have in the past and may in the future experience phishing and other security incidents which could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary,
personal or confidential information or other disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we have implemented cybersecurity measures designed to protect our information technology systems as well as the confidential and
sensitive data in our possession, there can be no assurance that these measures will be adequate to detect, prevent, or adequately address any cybersecurity incident or data breach that we may face. Controls employed by our information technology
department and other third parties could prove inadequate, and our ability to monitor such third parties&#146; data security practices is limited. Due to applicable laws, rules, regulations and standards or contractual obligations, we may be held
responsible for any information security failure or cybersecurity incident or compromise attributed to our third-party vendors as they relate to the information we share with them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we were to experience a cybersecurity incident, breach, compromise or other security event relating to our information systems or data, the costs, time and effort
associated with the investigation, remediation and potential notification of the breach to counterparties, regulators and data subjects could be material. We may incur significant costs in an effort to detect and prevent security incidents or
compromises, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident or compromise. In addition, techniques used to sabotage or to obtain unauthorized access to
networks in which data is stored or through which data is transmitted change frequently, become more complex over time and generally are not recognized until launched against a target. The risk of a cybersecurity breach, incident, compromise or
disruption, particularly through cyberattacks including supply chain attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of
attempted attacks and intrusions from around the world have increased. As a result, we and our third-party vendors may be unable to anticipate these techniques or implement adequate preventative measures quickly enough to prevent either an
electronic intrusion into our systems or services or a compromise of critical information. We cannot guarantee that we will be able to detect or prevent any such incidents, and, our remediation efforts may not be successful or timely. Our efforts to
improve our cybersecurity and protect data from compromise may also identify previously undiscovered instances of data breaches, compromises or other cybersecurity incidents. If we do not allocate and effectively manage the resources necessary to
build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of
or damage to intellectual property or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
proprietary, personal or confidential information. Although we currently maintain cybersecurity insurance, the insurance we maintain against the risk of this type of loss may not be sufficient to
cover actual losses, or may not apply to the circumstances relating to any particular loss. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that any disruption or security breach were to result in a
loss of, or damage to, our or our third-party vendors&#146;, collaborators&#146;, contractors&#146;, employees&#146;, consultants&#146; or other third parties&#146; data, including personal data, or applications or inappropriate disclosure, loss,
destruction or alteration of, or access to, confidential, personal or proprietary information, we could incur significant liability including litigation exposure, substantial penalties and fines, we could become the subject of regulatory action,
inquiry or investigation, our competitive position could be harmed, we could incur significant reputational damage and the further development and commercialization of any product candidates we may develop could be delayed. Any of the above could
have a material adverse effect on our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Laws and regulations governing any international
operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates we may identify outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will be subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate in the future. The creation, implementation and
maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign
official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are
listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise
and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records
provisions of the FCPA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, the U.K. Bribery Act 2010 has extra-territorial effect for companies and individuals having a connection with the United Kingdom.
The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a
recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.
Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and
will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain drugs and drug candidates outside of the United States, which could limit our
growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA
can result in significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a
violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international
business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the
FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to stringent and often unsettled laws, rules, regulations, policies, standards and contractual obligations
related to data privacy and security and changes in such laws, rules, regulations, policies, standards and contractual obligations could adversely affect our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to data privacy and protection laws, rules, regulations, policies, standards and contractual obligations that apply to the collection, transmission,
storage, use, disclosure, transfer, maintenance and other processing of sensitive, personal and personally-identifying information, which, among other things, impose certain requirements relating to the privacy, security, transmission and other
processing of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the
potential to affect our business. However, our data privacy program is in its early stages and we have not yet assessed the applicability of and our compliance with data privacy-related laws, rules and regulations. As a result, we cannot guarantee
that we are and have been in compliance with all applicable data privacy and protection laws, rules, regulations, policies and standards, and we may need to expend significant resources to implement privacy compliance measures. Additionally, we rely
on certain third-party vendors to process certain confidential, sensitive or personal information on our behalf. Failure by us or our third-party vendors to comply with any of these laws, rules, regulations, contractual obligations or standards
could result in notification obligations, enforcement actions, regulatory investigations or inquiries, significant fines, imprisonment of company officials and public censure, litigation and claims for damages by affected individuals, customers or
business partners, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are numerous U.S. federal and state laws, rules and regulations related to the privacy and security of personal information. In particular, regulations promulgated
pursuant to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and
require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. The
Genetic Information Nondiscrimination Act of 2008, or GINA, which clarified that genetic information is protected under HIPAA and restricts the use and disclosure of genetic information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a
cybersecurity incident or data breach. These laws are not consistent, and compliance in the event of a widespread cybersecurity incident or data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws,
requiring attention to changing regulatory requirements. We also may be contractually required to notify patients or other counterparties of a cybersecurity breach, incident, or compromise. Although we may have contractual protections with our
service providers, any actual or perceived security breach, cybersecurity incident, or other information system compromise could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data
security and in responding to any such actual or perceived breach, incident, or compromise. Any contractual protections we may have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and
we may be unable to enforce any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory information technology system
standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards. Determining whether personal information has been handled in compliance with applicable privacy
standards and our contractual obligations can be complex and may be subject to changing interpretation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to properly protect the privacy and
security of personal information, we could be alleged or actually found to have breached our contracts. Furthermore, if we fail to comply with applicable privacy laws, we could face significant administrative, civil and criminal penalties. We cannot
be sure how these laws, rules and regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with
evolving laws, rules and regulations at the international, federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We make public statements about our use, collection, disclosure and other processing of personal information through our privacy policies and information provided on our
website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policies and other statements that provide promises and
assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Data privacy remains an evolving landscape at both the domestic and international level, with new laws, rules and regulations coming into effect and continued legal
challenges. At the state level, numerous states have enacted or are in the process of enacting or considering comprehensive data privacy and security laws, rules and regulations while other states have focused on more narrow aspects of privacy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, Washington state passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of
action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or
security of certain specific types of information. For example, a number of states have passed laws that regulate biometric data specifically. These various privacy and security laws may impact our business activities, including our identification
of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to
which we may likely become subject, if enacted. The existence of different privacy laws in various jurisdictions in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to
enforcement actions or otherwise incur liability for noncompliance. Although many of the existing state privacy laws exempt clinical trial information and health information governed by HIPAA, future privacy and data protection laws may be broader
in scope. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that these laws are or become applicable, all of these evolving compliance and operational requirements may impose significant costs, such
as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. In addition, such requirements may require us to
modify our data processing practices and policies, utilize management&#146;s time and/or divert resources from other initiatives and projects. Our efforts to comply with these evolving data protection laws, rules and regulations may be unsuccessful.
It is possible that these laws, rules and regulations may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
laws are not consistent, and compliance in the event of a widespread cybersecurity incident or data breach is costly and time-consuming. States are also frequently amending existing laws,
requiring attention to frequently changing regulatory requirements. We must devote significant resources to understanding and complying with this changing landscape. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any failure or perceived failure by us or our third-party vendors to comply with laws, rules and regulations regarding data privacy and protection could result in damage
to our reputation or expose us to risk of enforcement actions taken by data protection authorities and/or other third parties, including class action privacy litigation in certain jurisdictions, which carry the potential for significant penalties if
we are found to be <FONT STYLE="white-space:nowrap">non-compliant.</FONT> Similarly, failure to comply with federal and state laws, rules and regulations in the United States regarding privacy and security of personal information could expose us to
penalties under such laws, rules and regulations. Any such failure, or perceived failure, by us or our third-party vendors to comply with data protection and privacy laws, rules and regulations could result in significant government-imposed fines or
orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we
are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial
condition, results of operations or prospects. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The use of new and evolving technologies, such as artificial intelligence, or AI, in our operations may require us to expend material resources and may present
risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and liability, or
otherwise adversely affect our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may choose to integrate AI into our operations, and this innovation presents risks and challenges that could
affect its adoption, and therefore our business. There are significant risks involved in utilizing AI and no assurance can be provided that the usage of AI will enhance our business or assist our business in becoming more efficient or profitable.
The use of certain AI technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement and misappropriation. Other known risks of AI currently include
inaccuracy, bias, toxicity, data privacy and cybersecurity issues, and data provenance disputes. In addition, AI may have errors or inadequacies that are not easily detectable. AI may also be subject to data herding and interconnectedness (i.e.,
multiple market participants utilizing the same data), which may adversely impact our business. If the data used to train AI or the content, analyses, or recommendations that AI applications assist in producing are or are alleged to be deficient,
inaccurate, incomplete, overbroad or biased, our business, financial condition, and results of operations may be adversely affected. Additionally, we expect to see increasing government and supranational regulation and ethical concerns related to AI
use which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#146;s Artificial Intelligence Act, or AI Act &#151; the world&#146;s first comprehensive AI law &#151; is
anticipated to enter into force in 2024 and, with some exceptions, become effective 24 months thereafter. This legislation imposes significant obligations on providers and deployers of high risk AI systems, and encourages providers and deployers of
AI systems to account for certain ethical principles in their design, development and use of these systems. The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our technology and
products to help ensure that AI is implemented in accordance with applicable laws and regulations and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. The legal landscape and subsequent legal
protection for the use of AI remains uncertain, and development of the law in this area </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
could impact our ability to enforce our proprietary rights or protect against infringing uses. If we do not have sufficient rights to use the data on which AI relies or to the outputs produced by
AI applications, we may incur liability through the violation of certain laws, third-party privacy or other rights or contracts to which we are a party. Our use of AI applications may also, in the future, result in cybersecurity incidents that
implicate the personal data of customers or patients. Any such cybersecurity incidents related to our use of AI applications could adversely affect our reputation and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our vendors may also incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry
standards, including with respect to intellectual property, privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and
misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and
adversely impact our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to third-party relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are reliant on a license agreement with Indiana University Research and Technology Corporation. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are reliant on a License Agreement, or the IURTC License Agreement, with Indiana University Research and Technology Corporation, or IURTC, pursuant to which we have
been granted an exclusive, royalty-bearing license to certain IURTC patent rights, or the Licensed Intellectual Property, developed by Dr.&nbsp;DiMarchi and other collaborators to further scientific research, for new product development, and for
other applications in public interest. In particular, we have been granted an exclusive, royalty-bearing license to make, have made, use, have used, offer to sell, have offered for sale, sell, have sold, import and have imported products that are
covered by the Licensed Intellectual Property. Termination of our IURTC License Agreement or reduction or elimination of our licensed rights may require us to negotiate new or reinstated licenses with less favorable terms or to cease all development
and commercialization of our current product candidates. In addition, delay in appointing or finding a suitable replacement provider, if one exists, could make it difficult for us to operate our business for that period. If any such events were to
occur, they could have a material adverse effect on our business prospects, financial condition and results of operations. For more information, see &#147;Business&#151;License agreement&#148;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that
were previously conducted for our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have relied on third parties, including Indiana University, to conduct certain preclinical studies
and clinical trials. Therefore, we are dependent on these third parties having conducted their research and development in accordance with the applicable protocols, legal and regulatory requirements, and scientific standards; having accurately
reported the results of all preclinical studies and clinical trials conducted with respect to such product candidates and having correctly collected and interpreted the data from these studies and trials. These risks also apply to any additional
product candidates that we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. If these activities were not compliant, accurate or correct, the clinical development, regulatory approval or commercialization of our
product candidates will be adversely affected.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If conflicts arise between us and our
collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If conflicts
arise between our collaborators and corporate or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our collaborators
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may
develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or
strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for any product candidates we may develop. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop
competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, prevent us from obtaining timely regulatory approvals, terminate their agreements with us prematurely or fail to
devote sufficient resources to the collaboration efforts, including development, delivery, manufacturing and commercialization of products. Any of these developments could harm our company and product development efforts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and
commercialization plans.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The advancement of our product candidates and development programs and the
potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with other pharmaceutical and biotechnology companies with
respect to development and potential commercialization. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.
In addition, if we are able to obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into collaborations with international biotechnology or pharmaceutical companies for the commercialization of such
product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend,
among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the
potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such
approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates
or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or
bring them to market and generate product revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant
number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration agreements that we enter into in the future may contain restrictions on our
ability to enter into potential collaborations or to otherwise develop specified product candidates. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail
the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we
may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have relied upon and plan to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators,
to conduct our clinical trials and expect to rely on these third parties to conduct clinical trials of any other product candidate that we develop. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These
factors include protocol design, regulatory and IRB approval, patient enrollment rates and compliance with GCPs. We have opened clinical trial sites and may in the future enroll patients in a number of countries where our experience is limited. In
most cases, we use the services of third parties, including CROs, to carry out our clinical trial-related activities and rely on such parties to accurately report their results. Our reliance on third parties for clinical development activities may
impact or limit our control over the timing, conduct, expense and quality of our clinical trials. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal investigators, clinical
trial sites and IRBs. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking
and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific
standards. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical trial data or other sanctions. If we or our third-party
clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful. Additionally, if we or our
third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which
would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We are also required to register certain clinical trials and post the results of
completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such
contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. Moreover, many CROs, including some of those that we have engaged to conduct our clinical trials, are experiencing
enrollment challenges as a result of, among other things, high employee turnover driven by the post-COVID macroeconomic environment and the inexperience of new employees. Furthermore, at clinical trial sites, the availability of staff and trial
participants has been limited due to a decrease in the number of clinical investigative sites across the globe. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be
conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not successfully carry out their
contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the
commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay
clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any of the third-party organizations we utilize may terminate their engagements with us under certain circumstances. The replacement of an existing CRO or other third
party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates. For example, although we believe there are a number of other CROs we could
engage, we may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, while we believe there may be suitable replacements for one or more of these service providers, there is a natural transition
period when a new service provider begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.<B><I><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs
or delay. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is
common that various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the
risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials
manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. Moreover, if the formulation of our product candidates requires the use of delivery methods such as cold-chain distribution
provided by third parties, whereby the product must be maintained between specified temperatures, we will be subject to reliance on our distribution partners to maintain the temperature of the formulation or else risk it being adulterated and
rendered unusable. Any of the above could delay or prevent completion of clinical trials, require conducting bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of our
product candidates and jeopardize our ability to commence sales and generate revenue.<I> </I> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our use of third parties to manufacture our product candidates
may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, active pharmaceutical ingredients, or APIs, or drug products when needed or at an acceptable cost.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities
of our product candidates, and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of our product candidates to third parties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently rely on and engage third-party manufacturers to provide all of the API and the final drug product formulation of all of our product candidates that are
being used in our clinical trials and preclinical studies. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying
any such replacement. In addition, we typically order raw materials, API and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
manufacturer. We may not be able to timely secure needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse
effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable
terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and the costs of manufacturing could be prohibitive. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our manufacturers have difficulty or suffer delays in successfully manufacturing material that meets our specifications, it may limit supply of our product candidates
and could delay our clinical trials. Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third parties
for manufacturing process development, regulatory compliance and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our
product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible breach of manufacturing agreements by third parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by the
third party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we do not maintain our key manufacturing relationships, we may fail to find replacement
manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our product candidates. If we do find replacement manufacturers, we may not be able to enter into agreements with
them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign regulatory authorities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, if any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which
we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the
technical skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <FONT
STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be required to verify that the new
manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will
produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of
additional clinical trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget.
Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third party owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a
license from such third-party manufacturer in order to have another third party manufacture our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our product candidates is approved by any regulatory agency, we intend to utilize arrangements with
third-party contract manufacturers for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract
manufacturers operating under cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some of our manufacturers may be located outside of the United States. There is currently significant uncertainty about the future relationship between the United States
and various other countries, including China, with respect to trade policies, treaties, government regulations and tariffs. Increased tariffs could potentially disrupt our existing supply chains and impose additional costs on our business.
Additionally, it is possible further tariffs may be imposed that could affect imports of APIs used in our product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including
restricted access to such raw materials used in our product candidates. Given the unpredictable regulatory environment in China and the United States and uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs,
international trade agreements and policies, further governmental action related to tariffs, additional taxes, regulatory changes or other retaliatory trade measures in the future could occur with a corresponding detrimental impact on our business
and financial condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions and criminal prosecutions, any of which could
significantly affect supplies of our product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA. We do not control the manufacturing process of, and are completely
dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we
may not be able to secure and/or maintain regulatory approval for our product candidates manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality
assurance and qualified personnel. If the FDA finds deficiencies or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may
need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Contract manufacturers may face manufacturing or quality
control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and
comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products, if approved. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding foreign regulators also inspect
these facilities to confirm compliance with cGMPs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Contract manufacturers may face manufacturing or quality control problems causing drug substance production and
shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and comparable foreign regulatory requirements could
adversely affect our clinical research activities and our ability to develop our product candidates and market our products following approval, if obtained.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If any third-party manufacturer of our product candidates is unable to increase the scale of its production of
our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates, our
third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove difficult. In addition,
if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the same
quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operations.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may need to maintain licenses for APIs from third parties to develop and commercialize some of our
product candidates, which could increase our development costs and delay our ability to commercialize those product candidates.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should we decide to use any APIs in any of our product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those APIs
from those third parties. If we are unable to gain or continue to access rights to these APIs prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these
programs by either accessing or developing alternate APIs, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired APIs on
commercially reasonable terms or develop suitable alternate APIs, we may not be able to commercialize product candidates from these programs.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to personnel, operations, and growth </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are dependent on
the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly
dependent upon our senior management, including our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the
successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our
senior management team, these agreements are terminable at will with notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or
any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will need
to continue to significantly increase the size of our organization and we may have difficulties in managing our growth and expanding our operations successfully. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March 31, 2024, we had 28 full-time employees. As we advance our products and product candidates through the development and commercialization process, we will
need to expand managerial, operational, financial, sales and marketing and other resources to manage our operations, preclinical and clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities or contract with other organizations to provide
these capabilities for us. As operations expand, we expect that we will need to manage additional relationships with various suppliers and other organizations. Our ability to manage our operations and growth requires us to continue to improve our
operational, financial and management controls, reporting systems and procedures across a global organization. Such growth could place a strain on our administrative and operational infrastructure. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, we may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical
personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we may not be able to make improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in
existing systems and controls. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we either internally, together
with collaboration partners or through third-party contractors, as applicable: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expand our general and administrative functions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identify, recruit, screen, retain, incentivize and integrate additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manage our internal development efforts effectively while carrying out our contractual obligations to third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and build a marketing and commercial organization; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue to improve our operational, legal, financial, compliance and management controls, reporting systems and
procedures. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience
constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our commercial success
depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other
third parties could develop and commercialize products and product candidates similar to ours and our ability to successfully develop and commercialize our product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends, in large part, on our ability to obtain and maintain intellectual property rights protection through patents, trademarks, and trade
secrets in the United States and other countries with respect to our technology and product candidates. If we do not adequately protect our intellectual property rights, competitors or other third parties may be able to erode, negate or preempt any
competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed patent applications and may file other patent applications in the United States or abroad
related to our product candidates that are important to our business; we also license and may purchase patents or patent applications filed by others. In particular, we are heavily reliant on patent rights we have exclusively <FONT
STYLE="white-space:nowrap">in-licensed</FONT> from IURTC pursuant to the IURTC License Agreement. The patent application process is expensive, time-consuming and complex. We may not be able to file, prosecute, maintain, enforce or license all
necessary or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
desirable patent applications at a reasonable cost or in a timely manner. Our owned and in-licensed patent portfolio is generally at a very early stage. In particular, we do not currently own or <FONT
STYLE="white-space:nowrap">in-license</FONT> any issued patents relating to any of our product candidates and we also do not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued U.S. patents relating to our PEP technology or
otherwise. Further, the only pending patent applications we currently own are two U.S. provisional patent applications relating to one of our product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not be able to obtain patents on certain inventions if those inventions are publicly disclosed prior to our filing a patent application covering them. We enter
into nondisclosure and confidentiality agreements with parties who have access to confidential information, including confidential information regarding inventions not yet disclosed in patent applications. We cannot guarantee that any of these
parties will not breach these confidentiality agreements and publicly disclose any of our inventions before a patent application is filed covering such inventions. If such confidential information is publicly disclosed, we may not be able to
successfully patent it and consequently, we may not be able to prevent third parties from using such inventions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Composition of matter patents for pharmaceutical
and biological product candidates can provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our or our
licensors&#146; pending patent applications directed to the composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries, or that
the claims in any of the issued patents we may own or license will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of
patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our
targeted indications, physicians may prescribe such products <FONT STYLE="white-space:nowrap">&#147;off-label.&#148;</FONT> Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of
method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the scope of the patent protection we obtain is not
sufficiently broad, we may not be able to prevent others from developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be
unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents have, or that any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications that mature into issued patents will include claims with a scope sufficient to protect our product candidates or otherwise
provide any competitive advantage. Other parties have developed or may develop technologies that may be related or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents
with claims that overlap or conflict with our patent portfolio, either by claiming the same compounds, formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not
protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be
available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such product candidates might expire
before or shortly after such product candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical
to ours. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if they are unchallenged, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and pending patent applications, if issued, may
not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patent portfolio by developing similar or alternative product candidates in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a product candidate that provides benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
similar to one of our product candidates but falls outside the scope of our patent protection or license rights. If the patent protection provided by the patent and patent applications we hold or
pursue with respect to such product candidate is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidate could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is
possible that defects of form in the preparation or filing of our patent portfolio may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we
or our partners, collaborators, or licensees whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or
licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or
enforcement of our patent portfolio, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on
patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and patent applications. We rely on our outside counsel or our
licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several
procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules,
there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT
STYLE="white-space:nowrap">Non-compliant</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our
business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent position of biotechnology and pharmaceutical companies carries uncertainty. As a result, the issuance, scope, validity, enforceability and
commercial value of our patent rights are characterized by uncertainty. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending patent applications cannot be enforced against third parties practicing the
technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent.
However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United
States and other jurisdictions are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patent portfolio, or that we were the first to
file for patent protection of such inventions. If third parties have filed prior patent applications on inventions claimed in our patent portfolio that were filed on or before March&nbsp;15, 2013, an interference proceeding in the United States can
be initiated by such third parties to determine who was the first to invent any of the subject matter covered by our patent portfolio. If third parties have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the
United States can be initiated by such third parties to determine whether our invention was derived from theirs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or
enforceability, any patents we may own or license may be challenged in the courts or patent offices in the United States and abroad. There is no assurance that all the potentially relevant prior art relating to our patent portfolio has been found.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at
all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patent portfolio, or that we were the first to file for patent protection of such inventions. If such prior art exists, it may be used to
invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior art to the USPTO, or to other patent offices around the world.
Alternately or additionally, we may become involved in post-grant review procedures, oppositions, derivation proceedings, ex parte reexaminations, inter partes review, supplemental examinations, or interference proceedings or challenges before the
USPTO or in district court in the United States, or similar proceedings in various foreign jurisdictions, including both national and regional, challenging patents or patent applications in which we have rights, including patents on which we rely to
protect our business. An adverse determination in any such challenges may result in loss of the patent or claims in the patent portfolio being narrowed, invalidated or held unenforceable, in whole or in part, or in denial of the patent application
or loss or reduction in the scope of one or more claims of the patent portfolio, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent
protection of our technology and products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our or our licensors&#146; pending and future patent applications may not result in patents being issued that protect our
business, in whole or in part, or which effectively prevent others from commercializing competitive products. For example, our or our licensors&#146; provisional applications may never result in issued patents. A provisional patent application is
not eligible to become an issued patent until, among other things, we or our licensors file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of filing the related provisional patent application. If we or
our licensors do not timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we or our licensors may lose the priority dates with respect to such provisional patent applications and any patent protection on the
inventions disclosed in such provisional patent applications. While we intend to timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our current and future provisional patent applications, we cannot
predict whether any of our or our licensors&#146; patent applications for our technology and product candidates will result in the issuance of patents that effectively protect our technology and product candidates. Further, competitors may be able
to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries also may diminish the value of our patents or narrow the scope of our patent protection. In addition, the
laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including jurisdiction covering significant commercial markets, such
as the European Patent Office, China, and Japan, restrict the patentability of methods of treatment of the human body more than United States law does. If these developments were to occur, they could have a material adverse effect on our ability to
generate revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future
development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">company-owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that have been issued or may be issued in the
future may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing products; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the U.S. may, under certain circumstances, force us to grant a license under our patents to a
competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Issued patents that we may own or license may not provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any
competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our competitors may also seek approval to
market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of
proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors do not infringe our patents. Thus, even if we have valid and enforceable patents, these patents still may not provide
protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain certain information as company trade secrets. This
information may relate to inventions that are not patentable or not optimally protected with patents. We use commercially acceptable practices to protect this information, including, for example, limiting access to the information and requiring
passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scientific advisors, collaborators, vendors, contractors,
and advisors. We cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant
to our business will be independently developed by a person who is not a party to such a confidentiality or invention assignment agreement. If any of our trade secrets were to be independently developed by a competitor or other third party, we would
have no right to prevent such competitor or third party, or those to whom they communicate such independently developed information, from using that information to compete with us. We may not be able to prevent the unauthorized disclosure or use of
our technical knowledge or trade secrets by contract manufacturers, consultants, collaborators, vendors, advisors, former employees and current employees. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps
we have taken to protect our proprietary technologies will be effective. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or
violation, and we could lose our trade secrets as a consequence of such breaches or violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose
protection for our trade secrets, our business, financial condition, results of operation and prospects may be materially and adversely harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to
comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose license
rights that are important to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are heavily reliant upon the IURTC License Agreement pursuant to which we have been granted an exclusive,
royalty-bearing license to certain patent rights that are important or necessary to the development of our proprietary technology and product candidates. Termination of the IURTC License Agreement or reduction or elimination of our licensed rights
could lead to the loss of our ability to develop and commercialize our proprietary technology and product candidates. Further development of our proprietary technology and product candidates may require us to enter into additional license or
collaboration agreements. Our future licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in all
relevant fields of use and in all territories in which we may wish to develop or commercialize our product candidates and proprietary technology in the future. Additionally, the IURTC License Agreement imposes, and future agreements may impose,
various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the
licenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may arise between us and our current or future licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual
property of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our current or future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we
believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual
property that we have licensed, or license in the future, prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite our best efforts, our current or future licensors might conclude that we materially breached our license
agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products, if approved, and technology covered by these license agreements. As a result, we may be required to cease our
development and commercialization of our product candidates and use of our proprietary technologies covered by the patent rights owned by the licensors. Furthermore, if the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights fail to
provide the intended exclusivity, competitors will have the freedom to seek regulatory approval of, and to market, products identical to ours. These events could have a material adverse effect on our competitive position, business, financial
condition, results of operations, and prospects.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>It is difficult and costly to protect our
intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success will depend in part on
obtaining and maintaining patent protection and trade secret protection for our product candidates, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our product candidates from
unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which
important legal principles remain unresolved and have in recent years been the subject of much litigation. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our
intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing interpretations of patent law. Further, the determination that a patent
application or patent claim meets all the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO or by a court or other trier of fact in the United
States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications, patents and other information that
may affect the patentability of claims in our patent portfolio, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our own patent portfolio.
</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> pending patent applications relating to our MBX 2109, MBX 1416, and MBX 4291 product
candidates and we own two pending provisional patent applications relating to our MBX 2109 product candidate, we cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior art
publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent applications nor to the outcome of any proceedings by any potential third
parties that could challenge the patentability, validity or enforceability of our patent portfolio in the United States or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our product candidates and/or
materially harm our business. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to challenges during litigation, third parties can challenge the validity of our patents in the United States using
post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent filed March&nbsp;16, 2013 or later, a petition for
post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to
March&nbsp;16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review
proceedings can be brought on any ground of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims
without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third
party to have a U.S. patent invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there
is no guarantee that we will be successful in defending the patent, which may result in a loss of the challenged patent right to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection
for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of
developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent claims will not have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under
United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not successfully commercialize our product candidates, if approved, before our relevant patents expire;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be the first to file patent applications for the inventions covered by our patent portfolio; or
</P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies that are separately patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, to the extent that we are unable to obtain and maintain patent protection for our product candidates, or in the event that such patent protection expires,
it may no longer be cost-effective to extend our portfolio by pursuing additional development of any of our product candidates for <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its
earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and
Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent having an earlier expiration date. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Various
extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such product candidates
might expire before or shortly after such product candidates are commercialized. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the Drug Price Competition and Patent Term Restoration Act of
1984 permits a Patent Term Extension, or PTE, of up to five years beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot extend
the remaining term of a patent beyond a total of 14 years from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication&#151;in other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
words, only one patent (for example, covering the product itself, an approved use of said product, or a method of manufacturing said product) can be extended by PTE. Moreover, the scope of
protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. We anticipate applying for PTE in the United States. Similar extensions may be available in other
countries where we are prosecuting patents and we likewise anticipate applying for such extensions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The granting of such patent term extensions is not guaranteed
and is subject to numerous requirements. We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents, failure to exercise due diligence during
the testing phase or regulatory review process or any other failure to satisfy any of the numerous applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a patent that we
<FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory
authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be
able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse
effect on our ability to generate revenue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value
of patents in general, thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The United States Congress is responsible for passing laws establishing
patentability standards. As with any laws, implementation is left to federal agencies and the federal courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the USPTO, and across the
various federal courts, including the U.S. Supreme Court. Recently, the Supreme Court has ruled on several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of
patentability standards that the Supreme Court has yet to decisively address. Absent clear guidance from the Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the U.S. has created uncertainty with respect to
the value of patents. Depending on any actions by Congress, and future decisions by the lower federal courts and the U.S. Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could change in
unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patent
reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our future issued patents. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted,
redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional
procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant
proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even
though the same evidence would be insufficient to invalidate the claim if first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged
by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
future issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After
March&nbsp;16, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to
the patent on an invention regardless of whether this inventor was the first to invent the claimed invention. As a result, a third party that files a patent application in the USPTO on or after March&nbsp;16 2013, but before we file an application
covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to
filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing until publication or issuance, we cannot be certain that we or our licensors were the first to
file any patent application related to our product candidates and other proprietary technologies we may develop. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the
other party can show that they used the invention in commerce before our filing date. Accordingly, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our future issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other
countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. The U.S. Supreme Court
has ruled on several patent cases in recent years; these cases often narrow the scope of patent protection available to inventions in the biotechnology and pharmaceutical spaces. For example, in <I>Amgen Inc. v. Sanofi</I>, or <I>Amgen</I>, the U.S.
Supreme Court held that certain of Amgen&#146;s patent claims defined a class of antibodies by their function of binding to a particular antigen. The U.S. Supreme Court further wrote that because the patent claims defined the claimed class of
antibodies only by their function of binding to a particular antigen, a skilled artisan would have to use significant trial and error to identify and make all of the molecules in that class. The U.S. Supreme Court ultimately held that Amgen failed
to properly enable its patent claims. In the 2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents
owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. In 2023, the Federal Circuit issued a decision in <I>In
re Cellect, LLC</I> involving the interaction of patent term adjustment, or PTA, terminal disclaimers, and obviousness-type double patenting which may affect the patent term of any issued patents that rely on any PTA. In 2022, Congress passed the
Inflation Reduction Act, or IRA, which authorizes the Secretary of the Department of Health and Human Services, or HHS, to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines
are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we
cannot be certain that it will not affect our patent strategy in the long run. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, a new court system recently became operational in the European Union. The Unified Patent Court, or UPC,
began accepting patent cases on June&nbsp;1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The broad geographic reach of the
UPC could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is
validated. Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial
or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and,
resultantly, on our business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and we cannot predict what the outcomes of cases tried before the UPC will be.
The case law of the UPC may adversely affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to <FONT STYLE="white-space:nowrap">opt-out</FONT> their European Patents from the jurisdiction of the
UPC, defaulting to <FONT STYLE="white-space:nowrap">pre-UPC</FONT> enforcement mechanisms. We have decided to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our
European patents could be subject to the jurisdiction of the UPC. We cannot be certain that our European patents will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Filing, prosecuting, enforcing, and defending patents protecting our product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in
countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, our ability to
protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual
property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it
difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third
parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe or from selling or importing products made from our inventions in and into the United States
or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products to territories where we have
patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Proceedings to enforce our patent rights, whether successful or not, could result in substantial costs and divert our efforts and resources
from other aspects of our business. Further, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications at risk of not issuing; and provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all
jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent
applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, further to the United States and foreign government actions related
to Russia&#146;s invasion of Ukraine, the Kremlin issued Decree 299 stating that Russian companies and individuals can use patented inventions without the owner&#146;s permission or compensation, if the patent is held by owners from &#147;unfriendly
countries,&#148; which include the United States. As a result, we would not be able to enforce our otherwise valid patent rights against an infringer in Russia. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the
degree of future protection that we will have on our technologies, products and product candidates. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents, as
appropriate, the process of obtaining patents is time consuming, expensive and unpredictable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>In order to protect our competitive position around our product
candidates, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Competitors may seek to commercialize competitive products to our product candidates. In order to protect our competitive position, we may become involved in lawsuits
asserting infringement of our patents, or misappropriation or other violations of other of our intellectual property rights. Litigation is expensive and time consuming and would likely divert the time and attention of our management and scientific
personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the
monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we file a patent infringement lawsuit against a perceived infringer, such a lawsuit could provoke the defendant to counterclaim that we infringe their patents and/or
that our patents are invalid and/or unenforceable. In patent litigation in the United States, it is commonplace for a defendant to counterclaim alleging invalidity and/or unenforceability. In any patent litigation there is a risk that a court will
decide that the asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the defendant from using the invention at issue. With respect to a counterclaim of invalidity, we cannot be certain that
there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent claims narrowly or decide that we
do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. If any of our patents are found invalid or unenforceable, or construed narrowly, our ability to stop
the other party from launching a competitive product would be materially impaired. Further, such adverse outcomes could limit our ability to assert those patents against future competitors. Loss of patent protection would have a material adverse
impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an
injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should
instead pay us a &#147;reasonable royalty&#148; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related
product would have a material adverse impact on our business. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation often involves significant amounts of public disclosures. Such disclosures could have a
materially adverse impact on our competitive position or our stock prices. During U.S. litigation we would be required to produce voluminous records related to our patents and our research and development activities in a process called discovery.
The discovery process may result in the disclosure of some of our confidential information. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could adversely affect the price of our common shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation is inherently expensive, and the outcome is
often uncertain. Any litigation likely would substantially increase our operating costs and reduce our resources available for development activities. Further, we may not have sufficient financial or other resources to adequately conduct such
litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. As a result, we may conclude that even if
a competitor is infringing any of our patents, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent
course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If
in the future, we <FONT STYLE="white-space:nowrap">in-license</FONT> any patent rights, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly
assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business,
and our commercialization efforts may suffer as a result. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with an infringement litigation, third parties may also be able to challenge the validity of
our patents before administrative bodies in the United States or abroad. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition
proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our products, potentially negatively impacting any concurrent litigation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from
developing or commercializing our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our
product candidates without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that
we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Third parties may have U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent
applications relating to compounds, methods of manufacturing compounds and/or methods of use for the treatment of the disease indications for which we are developing our product candidates. If any third-party patents or patent applications are found
to cover our product candidates, or their methods of use or manufacture, we may not be free to manufacture or market such product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at
all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries,
and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates, including patent infringement lawsuits in the U.S. or abroad. There may be
third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our product candidates. Third parties may assert infringement claims
against us based on existing patents that they own or <FONT STYLE="white-space:nowrap">in-license</FONT> or patents that may grant to them (or which they may <FONT STYLE="white-space:nowrap">in-license)</FONT> in the future, regardless of the merit
of such patents or infringement claims. If our defenses to such assertions of infringement were unsuccessful, we could be liable for a court-determined reasonable royalty on our existing sales and further damages to the patent owner (or licensee),
such as lost profits. Such royalties and damages could be significant. If we are found to have willfully infringed the claims of a third party&#146;s patent, the third party could be awarded treble damages and attorney&#146;s fees. Further, unless
we obtain a license to such patent, we may be precluded from commercializing the infringing product candidate. Any of the aforementioned could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we perform periodic searches for relevant patents and patent applications with respect to our product candidates, including MBX 2109, MBX 1416, and MBX 4291,
we cannot guarantee the completeness or thoroughness of any of our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, nor can we be
certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of any of our product candidates in any jurisdiction. Patent applications in the
United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will
not be filed outside the U.S. can remain confidential until patents issue. As a result, we may be unable to identify such patents or patent applications despite our best efforts. In addition, patent applications can take many years to issue, there
may be currently pending patent applications which may later result in issued patents that any of our product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation is subject to
uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover
various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need
to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is
difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur
substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, parties making claims against us
may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are found to infringe, misappropriate or otherwise violate a third party&#146;s intellectual property rights, we could be forced, including by court order, to
cease developing, manufacturing or commercializing the infringing product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the
infringing product. If we were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. Even if we were
able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We cannot assure you that any such license will be available on acceptable terms, if at all.
Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights, Further, the outcome of
intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property
cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to
obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our
ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding
of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our
confidential information could be compromised by disclosure. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to
be negative, it could adversely affect the price of our common shares. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or
otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Others may challenge inventorship or claim
an ownership interest in our intellectual property which could expose it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be
subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper
inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors or the effects of foreign
laws where foreign nationals are involved in the development of the subject matter of the patent. Furthermore, ownership disputes may arise from alleged contributions of third parties involved in developing our product candidates and may result in
joint ownership of our inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Any disagreement over inventorship could result in our being forced to defend our determination of
inventorship in a legal action which could result in substantial costs and be a distraction to our senior management and scientific personnel. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such
intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an
outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements assigning such intellectual
property to us, we may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment
agreements may be breached. In either case, we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals
executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. If we
are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops intellectual property on our behalf, the employee, consultant or contractor may later claim ownership of the invention. Any disagreement over
ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the contested intellectual property, paying monetary damages and/or being enjoined from clinical testing, manufacturing and marketing of the affected
product candidate(s). Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or by third parties asserting that our employees or we have misappropriated
their intellectual property or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our current and former employees and our
licensors&#146; current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors. Although
we take commercially reasonable steps to ensure that our employees do not use the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, including incorporating such intellectual
property into our product candidates, we may be subject to claims that we or these employees have misappropriated the intellectual property of a third party. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we
or any of our employees are accused of misappropriating the proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of a third party, we may be forced to defend such claims in litigation. If we are found to have
misappropriated the intellectual property rights of a third party, we may be forced to pay monetary damages, sustain reputational damage, lose key personnel, or lose valuable intellectual property rights. Further, it may become necessary for us to
obtain a license from such third party to commercialize any of our product candidates. Such a license may not be available on commercially reasonable terms or at all. Any of the aforementioned could materially affect the commercialization of any of
our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may rely on trade secrets and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> which can be difficult to trace and enforce and, if we are unable to
protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We consider proprietary trade secrets or
confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> to be important to our business. We may rely on trade secrets or confidential
<FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection is believed by us to be of limited value. We expect to rely on third parties for future manufacturing of our product candidates. We also
expect to collaborate with third parties on the development of our product candidates and as a result must, at times, share trade secrets with our collaborators. We also conduct joint research and development programs that may require us to share
trade secrets under the terms of our research and development partnerships or similar agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Trade secrets or confidential
<FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to
beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees,
consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential
information. The need to share trade secrets and other confidential information, including with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, increases the risk
that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results
of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time consuming and unpredictable. In addition, some courts inside and
outside the United States are less willing or unwilling to protect trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to
our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties,
independent development or publication of information by any of our third-party collaborators and we would have no right to prevent them from using that technology or information to compete with us. A competitor&#146;s discovery of our trade secrets
would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may need to acquire or license additional intellectual property from
third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A third party may hold intellectual
property, including patent rights that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and
future product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established
companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater
clinical development. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize our product
candidates, if approved, would likely be delayed or we may have to abandon development of that product candidate and our business and financial condition could suffer. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates in the future, we might become dependent on proprietary rights from third parties with
respect to those product candidates. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any product candidates subject to such licenses.
Even if we are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on nonexclusive terms, including with respect to the use, field or territory of the licensed intellectual property,
thereby giving our competitors and other third parties access to the same intellectual property licensed to us. <FONT STYLE="white-space:nowrap">In-licensing</FONT> IP rights could require us to make substantial licensing and royalty payments.
Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
filed by or against our licensors or another licensee or in administrative proceedings. If any <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents are invalidated or held unenforceable,
we may not be able to prevent competitors or other third parties from developing and commercializing competitive products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not have the right to control the
prosecution, maintenance, enforcement or defense of patents and patent applications that we license from third parties. In such cases, we would be reliant on the licensor to take any necessary actions. We cannot be certain that such licensor would
act with our best interests in mind, or in compliance with applicable laws and regulations, or that their actions would result in valid and enforceable patents. For example, it is possible that a licensor&#146;s actions in enforcing and/or defending
a patent licensed by us may be less vigorous than had we conducted them ourselves. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our present or future licensors may have relied upon or may rely upon third-party consultants or collaborators or on funds from third parties such that our present or
future licensors may not be the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership rights to our present or future <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results
of operations, and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations with respect to the use of licensed technology in relation to our development and
commercialization of our product candidates and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The risks described elsewhere pertaining to our intellectual property rights also
apply to the intellectual property rights that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse
effect on our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense
process with respect to such patents, and potential future licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our trademarks of interest and our business may be adversely affected. </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not currently own any registered trademarks and we have not
filed any trademark applications to date. While we may have common law protection for certain of our trademarks and trade names, it may be harder for us to rely on any such common law protection to prevent third parties from copying or using our
trademarks or trade names without our permission. Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark
rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to
protect our rights to our trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or
trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered
trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to
compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such
rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation
proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered
it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an
equivalent administrative body in a foreign jurisdiction) objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under
applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent
infringement claim asserted by the owner of a senior trademark. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property rights do not necessarily address all potential threats to our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may be able to make products that are competitive to our product candidates or any of our future product candidates
that are not covered by the claims of our patent rights; </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies
without infringing our patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we or any of our collaborators might not have been the first to invent the inventions covered by our patent portfolio;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or
patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that our owned and in-licensed pending patent applications or those that we or our collaborators may file in
the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may have access to the same intellectual property rights licensed to us on a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents that we may own or in-license may not provide us with any competitive advantage, or may be held invalid or
unenforceable, including as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we cannot predict the scope of protection of any patent issuing based on our owned or in-licensed patent applications,
including whether the patent applications that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued patents with claims that are directed to our product candidates or uses thereof in the United States or in other
foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the claims of any patent issuing based on our owned or in-licensed patent applications may not provide protection against
competitors or any competitive advantages, or may be challenged by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if enforced, a court may not hold that our owned or in-licensed patents are valid, enforceable and infringed;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be
costly whether we win or lose; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">ownership of our patent portfolio may be challenged by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent enforcement is expensive and time-consuming and difficult to predict; thus, we may not be able to enforce any of our
patents against a competitor; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject
matter similar to or improving that covered by our patents and patent applications; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may choose not to file a patent application for certain inventions, instead choosing to rely on trade secret protection,
and a third party may subsequently file a patent application covering such intellectual property. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should any of these or similar events
occur, they could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to the offering, our common stock, and operating as a
public company </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you purchase common stock in this offering, you will incur immediate and substantial dilution of $&#8195;&#8195;&#8195;&#8195; per share, representing the difference
between the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
share, the estimated midpoint of the price range set forth on the cover page of this prospectus, and our pro forma as adjusted net tangible book value per share as of March 31, 2024 after giving
effect to this offering. To the extent the underwriters exercise their option to purchase additional shares, you will incur further dilution. For a further description of the dilution you will experience immediately after this offering, see
&#147;Dilution.&#148; </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in
this offering. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The initial public offering price for our common stock was determined through negotiations with the underwriters. This initial public
offering price may vary from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. The market price for our common stock may be influenced
by those factors discussed in this &#147;Risk factors&#148; section and many others, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and results of preclinical studies and clinical trials for our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">failure or discontinuation of any of our development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">commencement or termination of collaborations for our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary
rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of efforts and level of expenses related to any of our research programs, clinical development programs or
current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts, if any, that cover our stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic, industry and market conditions, including the ongoing geopolitical conflict in Ukraine and the
Israel-Hamas war, tensions in U.S.-China relations, rising interest rates and inflation; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the other factors described in this &#147;Risk factors&#148; section. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In recent years, the stock market in general and the market for pharmaceutical and biotechnology companies in
particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. In
particular, in relation to uncertainty around inflation and the U.S. Federal Reserve&#146;s measures to slow inflation, the stock market has been exceptionally volatile. Market and industry factors may seriously affect the market price of our common
stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such volatility in the market price of a company&#146;s
securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result
in substantial costs and divert management&#146;s attention and resources from our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have wide discretion in the use of the net proceeds from this
offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our
management will have wide discretion in the application of the net proceeds, including for any of the purposes described in &#147;Use of proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use
of the proceeds, with only limited information concerning management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a
favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that
does not produce income or that loses value. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required
to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, and particularly after we are no longer an
&#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act,
the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls
and corporate governance practices. We expect that we will need to hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company. Our management
and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming
and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us
to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and
regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could
result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to
SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC
after we become a public company. However, while we remain an emerging growth company, we will not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404
within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources,
potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls
are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or
at all, that our internal control over financial reporting is effective as required by SOX Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not know whether a market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may
be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before this offering, there was no public trading market for our common stock. Although we
have applied to list our common stock on the Nasdaq Global Select Market, an active trading market for our shares may never develop or be sustained following this offering. If a market for our common stock does not develop or is not sustained, it
may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be
below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may
not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our common stock is listed on
Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&#146;s listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq&#146;s listing standards, our common stock
may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair
our stockholders&#146; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our
ability to raise capital and the value of your investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If securities analysts do not publish research or reports about our business or if they publish
negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading market for our common stock will rely in part on the research and
reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our
stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover
our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future sales of our common stock in the
public market could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our stock price could decline as a result of sales of a large number of shares of our common stock after
this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem
appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, &#8195;&#8195;&#8195;&#8195;shares of our common stock will be outstanding (or
&#8195;&#8195;&#8195;&#8195; shares of common stock will be outstanding assuming exercise in full of the underwriters&#146; option to purchase additional shares), based on our shares outstanding as of&#8195;&#8195;&#8195;&#8195;. All shares of
common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, unless held by our &#147;affiliates,&#148; as that term is
defined in Rule 144 under the Securities Act. The resale of &#8195;&#8195;&#8195;&#8195;, or approximately 100% of our outstanding shares of common stock, after giving effect to the conversion of convertible preferred stock into shares of common
stock, but before giving effect to this offering, is currently prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by our stockholders with us, stock option agreements entered into by
our employees with us, or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our directors, officers and stockholders with the underwriters. However, subject to applicable securities law restrictions and excluding shares of
restricted common stock that will remain unvested, these shares will be able to be sold in the public market beginning 180 days after the date of this prospectus. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters
are subject to certain exceptions and the representatives of the underwriters may, in their sole discretion, release all or some portion of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and for any
reason. See &#147;Underwriting&#148; for more information on <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters. Shares of unvested restricted common stock that were issued and outstanding as of the date of this
prospectus will become available for sale immediately upon the vesting of such shares, as applicable, and the expiration of any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. Shares issued upon the exercise of stock options pursuant to future awards that may be granted under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to
the extent permitted by the provisions of applicable vesting schedules, any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the
Securities Act. For more information see the section entitled &#147;Shares eligible for future sale&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of
this offering, the holders of approximately &#8195;&#8195;&#8195;&#8195; shares, or approximately &#8195;&#8195;&#8195;&#8195;%, of our common stock, will have rights, subject to some conditions, to require us to file registration statements
covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our
equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights and shares to be issued under our equity incentive plans, they can be freely sold in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section entitled &#147;Underwriting&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition,
in the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance
could result in substantial dilution to our existing stockholders and could cause our stock price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are an &#147;emerging growth company&#148;
and a &#147;smaller reporting company,&#148; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We could be an emerging growth company for
up to five years following the completion of this offering, although circumstances could cause us to lose that status earlier, including if we are deemed to be a &#147;large accelerated filer,&#148; which occurs when the market value of our common
stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June&nbsp;30, or if we have total annual gross revenue of $1.235&nbsp;billion or more during any fiscal year before that time, in
which cases we would no longer be an emerging growth company as of the following December&nbsp;31, or if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any
three-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
year period before that time, in which case we would no longer be an emerging growth company immediately. For so long as we remain an emerging growth company, we are permitted and plan to rely on
exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of SOX
Section&nbsp;404, not being required to comply with any requirement for a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive
compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders
will be different than the information that is available with respect to other public companies. In this prospectus, we have not included all of the executive compensation related information that would be required if we were not an emerging growth
company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption, and,
therefore, while we are an emerging growth company we will not be subject to the new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this
election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting
standards whenever such early adoption is permitted for private companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue is less than $100&nbsp;million during
the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth
companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict whether investors will find our
common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions,
including a change of control. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After this offering, our directors and executive officers and their affiliates will beneficially own shares representing
approximately &#8195;&#8195;&#8195;&#8195;% percent of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval. For
example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This concentration of ownership may have the effect
of delaying or preventing a change in control of our company and might affect the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not expect to pay any dividends for the foreseeable future. Investors in this offering may never obtain a
return on their investment. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any
dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount
of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result,
investors seeking cash dividends should not purchase our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to establish and maintain proper and effective internal control over
financial reporting, our operating results and our ability to operate our business could be harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ensuring that we have adequate internal financial and
accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In
connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures for compliance with SOX Section&nbsp;404, which will require annual management assessment of the effectiveness
of our internal control over financial reporting starting with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take
significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy or consequent inability to produce accurate financial statements on a timely
basis could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis cause investors to
lose confidence in the accuracy and completeness of our financial reports and could cause the market price of our common stock to decline significantly. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the closing of this offering, we will become subject to the
periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to
management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how
well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These inherent limitations
include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people
or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and restated bylaws that will become effective upon the effectiveness of our registration statement
designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to our amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, unless
we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf;
(ii)&nbsp;any action asserting a claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (iii)&nbsp;any action asserting a claim pursuant to any provision of the Delaware
General Corporation Law, or DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&nbsp;any action
asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended, or
the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any
complaint asserting a cause of action arising under the Securities Act, the Exchange Act, the respective rules and regulations promulgated thereunder or the Federal Forum Provision. In addition, our amended and restated bylaws will provide that any
person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and
will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We recognize that the Delaware Forum
Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware.
Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which
may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the
validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum
Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or
invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be
located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provisions in our third
amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which
this prospectus forms a part and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to
replace or remove our current management. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our third amended and restated certificate of incorporation that will become effective immediately prior to the
closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which this prospectus forms a part and Delaware law contain provisions that may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might
otherwise receive a premium for your shares. Our third amended and restated certificate of incorporation and our amended and restated bylaws will include provisions that: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders,
including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated bylaws; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated
certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These provisions, alone or together, could delay or prevent hostile takeovers and
changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&nbsp;203 of the DGCL, which prohibits a person who owns
in excess of 15&nbsp;percent of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15&nbsp;percent of our outstanding voting stock,
unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any provision of our third amended and restated certificate of incorporation, amended and
restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some
investors are willing to pay for our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Adverse developments affecting the financial services industry could adversely affect our current and
projected business operations and our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Adverse developments that affect financial institutions, such as events
involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&nbsp;10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection
and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts
adequate to finance or capitalize our current and projected future business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
operations could be significantly impaired by factors that us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or
economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or
instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other general risks </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may become involved in securities class action
litigation that could divert management&#146;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other
strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or investigation even
if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#146;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic
transaction or the ultimate value our stockholders receive in any such transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unfavorable global economic conditions could adversely affect our
business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our results of operations could be adversely affected by general conditions in the global economy,
geopolitical tensions and in the global financial markets. A severe or prolonged economic downturn or additional global financial and political crises could result in a variety of risks to our business, including weakened demand for any product
candidates we develop or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers or other third parties and create import and export issues, possibly resulting
in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious diseases, which could significantly disrupt our operations,
impact our financial results or otherwise adversely impact our business.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant outbreaks of
contagious diseases and other adverse public health developments could have a material impact on our business operations and operating results. For example, the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> affected segments of the
global economy and our operations. As a result of similar public health crises that may arise, we may experience disruptions that could adversely impact our operations, research and development, and as we continue developing, any preclinical
studies, clinical trials and manufacturing activities we may conduct, some of which may include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays or disruptions in research programs, preclinical studies, clinical trials or
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies that we or our collaborators may conduct; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of, or delays in receiving and distributing, supplies of drug substance and drug product from our contract
development manufacturing organizations, or CDMOs, to preclinical or clinical research sites or delays or disruptions in any preclinical studies or clinical trials performed by CROs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations imposed on our business operations by local, state or federal authorities to address a pandemic or similar
public health crises; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees
working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, and cybersecurity and data accessibility or security issues. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the trading prices for biopharmaceutical companies have been highly volatile and we may face similar volatility in our stock price after we complete this
public offering. We cannot predict the scope and severity of any economic recovery of health epidemics, pandemics and other widespread outbreaks of contagious diseases, including following any additional &#147;waves&#148; or other intensifying of a
pandemic. If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively
affected, which could have a material adverse impact on our business, financial condition, our results of operations and prospects. Furthermore, such pandemics could exacerbate the other risks described in this section. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We or the third parties upon whom we depend may be adversely affected by climate change, earthquakes, outbreak of disease, or other natural disasters and our
business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Climate change, earthquakes, outbreak of disease, or
other natural disasters, including extreme weather events and changing weather patterns such as storms, flooding, droughts, fires and temperature changes, which have become more common, could severely disrupt our operations, and have a material
adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, extreme weather risk, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant
portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party CDMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our
business for a substantial period of time. For example, we may experience delays in the supply of drug product for our clinical trials as a result of disruptions to the operations of the manufacturing facilities of some of our third-party CDMOs. The
disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. In addition, cybersecurity liability insurance is difficult to obtain and
may not cover any damages we would sustain based on any breach or compromise of our computer security protocols or other cybersecurity attack. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business
continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.<B><I><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance matters,
including related social expectations and concerns, may impose unexpected costs on us or result in reputational or other harm to us that could have a material adverse effect on our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is an increasing focus and rapid and ongoing developments and changing expectations from certain investors, customers, consumers, employees and other
stakeholders concerning environmental, social and corporate governance, or ESG matters. Additionally, public interest and legislative pressure related to public companies&#146; ESG practices continue to grow, which may result in increased
regulatory, social or other scrutiny on us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are
widely publicized. In addition, investment in funds that specialize in companies that perform </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. Topics taken into
account in such assessments include, among others, the company&#146;s efforts and impacts on climate change and human rights, ethics and compliance with law, and the role of the company&#146;s board of directors in supervising various sustainability
issues. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be required to make investments in matters related to ESG, which could be significant. Our failure or perceived failure to meet the standards set by
various constituencies could damage our reputation and our relationships with investors, governments, customers, employees, third parties and the communities in which we operate and expose us to increased regulatory risk, put us at a commercial
disadvantage relative to our peers and materially adversely affect our business, financial condition, results of operations, ability to participate in debt and equity markets and the value of our shares.<B><I><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_5"></A>Special note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus, including the sections entitled &#147;Prospectus summary,&#148; &#147;Risk factors,&#148; &#147;Management&#146;s discussion and analysis of financial
condition and results of operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in
this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the initiation, timing, progress and results of our current and future research and development programs, preclinical
studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to successfully complete our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to finalize the design or formulation of any product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability of our platform to optimize pharmacokinetic and/or pharmacologic properties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to advance any product candidates that we may identify and successfully complete any clinical studies,
including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to quickly leverage programs within our initial target indications and to progress additional programs to
further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to internalize certain of our discovery capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prevalence of certain diseases and conditions we intend to treat and the size of the market opportunity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">estimates of the number of patients with certain diseases and conditions we intend to treat and the number of patients that
we will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of our investigational new drug applications submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of announcement of interim and final results from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our projected operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the implementation of our strategic plans for our business, programs and technology; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology and
platform; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to leverage the clinical, regulatory, and manufacturing advancements to accelerate our clinical trials and
approval of product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to meet future regulatory standards with respect to our product candidates, if approved; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to identify and enter into future license agreements and collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our reliance on third parties to conduct clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our reliance on third parties for the manufacture of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments related to our technology and platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our commercialization, marketing and manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act or a
smaller reporting company; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our use of proceeds from this offering, our financial performance, estimates of our expenses, capital requirements, and
needs for additional financing. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148;
&#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms
or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases,
beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk factors&#148; and
elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking
statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement, of which
this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause
our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus also contains estimates, projections
and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties
and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal
estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not
aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to
change based on various factors, including those discussed under the section entitled &#147;Risk factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><A NAME="toc790774_6"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the net proceeds to us from the sale of &#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering will be approximately
$&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195; million if the underwriters exercise in full their option to purchase additional shares, assuming an initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the
cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $&#8195;&#8195;&#8195;&#8195;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the
same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this
prospectus, would increase (decrease) net proceeds to us from this offering by $&#8195;&#8195;&#8195;&#8195; million, assuming no change in the assumed initial public offering price per share, the midpoint of the price range set forth on the cover
page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the offering price or the number of shares by these amounts would have a
material effect on our intended uses of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March 31, 2024, we had cash, cash equivalents and marketable securities of $70.3&nbsp;million. We currently intend to use the net proceeds from this offering,
together with our existing cash and cash equivalents and marketable securities, as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to advance development of our two clinical-stage programs, MBX 2109
through Phase 2 topline data and into Phase 3 development, and MBX 1416 through Phase 1 topline data and into Phase 2 development; </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;million to advance development of MBX 4291 through preclinical development and
into clinical development; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the remainder to fund our discovery research and development activities and additional clinical development, and for
general corporate purposes, working capital and capital expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also use a portion of the remaining net proceeds and our existing
cash, cash equivalents and marketable securities to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do
so. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our current plans, we believe our existing cash and cash equivalents and marketable securities, together with the net proceeds from this offering, will
be sufficient to fund our operations and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195; . </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have multiple programs in preclinical and clinical
development, including one product candidate in a Phase 2 trial and one product candidate in a Phase 1 trial. The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions,
which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the
amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development, the status of and
results from preclinical studies or clinical trials, as well as any collaborations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our management will retain
broad discretion over the allocation of the net proceeds from this offering. We expect the net proceeds from this offering, together with our existing cash and cash equivalents, and short-term investments, will not be sufficient for us to advance
any of our programs through regulatory approval, and we will need to raise additional capital to complete the development and potential commercialization of any of our programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending our use of proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term,
investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_7"></A>Dividend policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to fund the development and expansion of our
business, and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our results of
operations, financial condition, capital requirements and other factors deemed relevant by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_8"></A>Capitalization </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our cash and cash equivalents and our capitalization as of March&nbsp;31, 2024: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the filing and effectiveness of our third amended and restated certificate
of incorporation immediately prior to the closing of this offering in each case as if such events had occurred on March&nbsp;31, 2024 and (ii)&nbsp;the conversion of all outstanding shares of our convertible preferred stock into an aggregate of
182,838,619 shares of common stock immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of
our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The pro forma as adjusted information below is illustrative only, and our
capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with our
financial statements and the related notes included elsewhere in this prospectus and &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; section of this prospectus. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of March&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro forma</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;forma<BR>as&nbsp;adjusted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">70,316</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">70,316</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock (Series A and B), $0.0001 par value; 182,838,619 shares authorized; 182,838,619
shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding, actual; shares authorized
and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.0001 par value; 237,000,000 shares authorized, 15,544,989 shares issued and outstanding,
and treasury stock shares, actual; shares authorized, shares issued and outstanding, pro forma; shares authorized, shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">69,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">69,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is
the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; equity and total
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase
(decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; equity and total capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming no change in the assumed initial public offering price per
share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our common stock
in the table above is based on 198,383,608 shares of our common stock (which includes 695,990 shares underlying unvested restricted stock awards subject to a repurchase option by us) outstanding as of March&nbsp;31, 2024, after giving effect to the
Preferred Stock Conversion, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">32,761,221 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2024, with a
weighted-average exercise price of $0.53 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,205,455 shares of common stock issuable upon the exercise of stock options granted after March&nbsp;31, 2024, with a
weighted-average exercise price of $0.87 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">5,014,218 shares of common stock reserved for issuance under the 2019 Plan as of March&nbsp;31, 2024, which shares will
cease to be available for issuance at the time our 2024 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;shares of common stock reserved for future issuance under our 2024 Plan, which will become effective
upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of common stock reserved for future issuance under our 2024 ESPP, which will become
effective upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_9"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our historical net tangible book value (deficit) as of March 31, 2024 was $(83.0)&nbsp;million, or $(5.34) per share of our common stock. Our historical net tangible
book deficit per share is the amount of our total tangible assets less our total liabilities and the carrying values of our convertible preferred stock, which is not included within stockholders&#146; deficit. Our historical net tangible book value
(deficit) per share represents historical net tangible book value (deficit) divided by the 15,544,989 shares of our common stock outstanding as of March 31, 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pro forma net tangible book value as of March&nbsp;31, 2024 was $69.3&nbsp;million, or $0.35&nbsp;per share of our common stock. Pro forma net tangible book value
represents the amount of our total tangible assets less our total liabilities, after giving effect to the Preferred Stock Conversion. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total
number of shares outstanding as of March 31, 2024, after giving effect to the pro forma adjustment described above. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After giving further effect to our issuance and
sale of&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2024 would have been $&#8195;&#8195;&#8195;&#8195;million, or
$&#8195;&#8195;&#8195;&#8195;per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to our existing stockholders and immediate dilution of
$&#8195;&#8195;&#8195;&#8195;in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dilution per
share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on
a per share basis (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Historical net tangible book value (deficit) per share as of March 31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase per share attributable to the pro forma adjustment described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net tangible book value per share as of March 31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and
other terms of this offering determined at pricing.&nbsp;Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;and dilution per share to new investors purchasing common stock in this offering by
$&#8195;&#8195;&#8195;&#8195;, assuming that the number of shares offered by us, as set forth on the cover </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase of 1,000,000 shares in
the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;and decrease dilution per share to
new investors purchasing common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this
offering by $&#8195;&#8195;&#8195;&#8195;and increase dilution per share to new investors purchasing common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming no change in the assumed initial public offering price and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option to purchase additional
shares in full, our pro forma as adjusted net tangible book value per share after this offering would be $&#8195;&#8195;&#8195;&#8195;, representing an immediate increase in pro forma as adjusted net tangible book value per share of
$&#8195;&#8195;&#8195;&#8195;to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195;to new investors purchasing common stock in this offering, based on the assumed
initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes on the pro forma as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to
common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors in this offering at an assumed initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As
the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Average<BR>price per<BR>share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the
underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to &#8195; percent of the total number of shares of our common stock outstanding
after this offering, and the number of shares of common stock held by new investors purchasing common stock in this offering would be increased to &#8195; percent of the total number of shares of our common stock outstanding after this offering.
</P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The discussion and tables above are based on 198,383,608 shares of our common stock (which includes 695,990 shares underlying unvested restricted stock awards
subject to a repurchase option by us) outstanding as of March 31, 2024, after giving effect to the Preferred Stock Conversion, and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">32,761,221 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2024, with a
weighted-average exercise price of $0.53 per share under the 2019 Plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,205,455 shares of common stock issuable upon the exercise of stock options granted after March 31, 2024, with a
weighted-average exercise price of $0.87 per share under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">5,014,218 shares of common stock reserved for issuance under the 2019 Plan as of March 31, 2024, which shares will cease to
be available for issuance at the time our 2024 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under our 2024 Plan, which will become effective
upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under our 2024 ESPP, which will become effective
upon the date immediately preceding the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that new stock options are issued or any outstanding options are exercised, or we issue additional shares of common stock in the future, there will be
further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we
raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_10"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial
statements and the related notes appearing elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives,
expectations, intentions and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those
discussed in the &#147;Risk factors&#148; section of this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. </I></B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company focused on
the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging
this expertise, we designed our proprietary Precision Endocrine Peptide<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or PEP<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, platform to overcome the key limitations of
unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and
consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically
validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our
inception, we have devoted substantially all of our resources to drug discovery and development of our product candidates, MBX 2109, MBX 1416 and MBX 4291, and other preclinical programs, building our intellectual property portfolio, organizing and
staffing our company, business planning, raising capital and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. We have historically
funded our operations primarily through sales of our convertible preferred stock and convertible notes, which generated approximately $150.6&nbsp;million in aggregate gross proceeds. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred significant operating losses since inception and we expect to continue to incur substantial losses for the foreseeable future. Our ability to generate
revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $5.9 million and $12.3 million for the three months ended
March 31, 2023 and 2024, respectively. Our net losses were $26.1 million and $32.6 million for the years ended December 31, 2022 and 2023, respectively. We had an accumulated deficit of $75.6 million and $87.9 million as of December 31, 2023 and
March 31, 2024, respectively. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that our expenses and operating losses will increase substantially for the foreseeable future as we: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance the development of our lead product candidates, MBX 2109, MBX 1416 and MBX 4291, and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">advance our&nbsp;current research activities and further develop our platform; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue preclinical development and discover and develop future product candidates we may identify; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approval for any product candidates for which we successfully complete clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish either internally or through contract manufacturing organizations manufacturing capacity capabilities to supply
our clinical trials in our pipeline and eventually for commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">transition from a company with a research focus to a company capable of supporting commercial activities, including
establishing sales, marketing, and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain additional research and development, clinical, commercial, general and administrative personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defend against any claims by third parties that we have infringed, misappropriated or otherwise violated any intellectual
property of any such third party; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">confirm, maintain or obtain freedom to operate for any of our owned or licensed technologies and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add operational, financial and management information systems and personnel; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, audit, accounting, compliance, insurance, investor relations and other expenses to operate as a
public company that we did not incur as a private company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will not generate revenue from product sales unless and until we successfully
complete clinical development and obtain regulatory approval for one or more product candidates. If we obtain regulatory approval for any product candidate and do not enter into a commercialization partnership, we expect to incur significant
expenses related to developing our commercialization capability to support product sales, manufacturing, marketing, and distribution. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth
strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing,
distribution or licensing arrangements with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such
agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of our platform or delay our pursuit of potential <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P>
 <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We had cash, cash equivalents and marketable securities of $80.7 million and $70.3 million as of December 31, 2023 and March 31, 2024, respectively. We believe that
the anticipated net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through&#8195;&#8195;&#8195;&#8195;.
We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;Liquidity and capital resources&#148; and &#147;Risk factors&#151;Risks related to financial
position and need for capital.&#148; </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>License agreement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Below is a
summary of the key terms for our license agreement. For a more detailed description of this agreement, see the section titled &#147;Business&#151;License agreement.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Indiana University Research And Technology Corporation Exclusive License Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2020, we entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation, or IURTC, a non-profit corporation organized
under the laws of the State of Indiana, represented by The Trustees of Indiana University, or IU, pursuant to which we have been granted an exclusive, royalty-bearing license to certain IURTC patent rights, or the Licensed Intellectual Property,
developed by Dr.&nbsp;DiMarchi and other collaborators to further scientific research, for new product development, and for other applications in public interest, such license, the IURTC License Agreement. In particular, we have been granted an
exclusive, royalty-bearing license to make, have made, use, have used, offer to sell, have offered for sale, sell, have sold, import and have imported products that are covered by the Licensed Intellectual Property, or Licensed Products, with the
right to sublicense to third parties. IURTC and IU have retained the right to (i)&nbsp;practice and use the Licensed Intellectual Property for <FONT STYLE="white-space:nowrap">non-commercial</FONT> educational, research, and patient care and
treatment purposes, and (ii)&nbsp;permit other <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic entities to practice and use the Licensed Intellectual Property for the same <FONT STYLE="white-space:nowrap">non-commercial</FONT>
purposes. Under the IURTC License Agreement, we agreed to use commercially reasonable efforts to develop, promote and sell Licensed Products in accordance with the IURTC License Agreement and any applicable laws. The IURTC License Agreement
leverages IURTC&#146;s expertise in peptide therapies as well as our scientific, clinical, and regulatory capabilities to accelerate the development of peptide treatments for people with endocrine and metabolic disorders. MBX 2109, MBX 1416 and MBX
4291 are Licensed Products under the IURTC License Agreement. Any future product candidates developed pursuant to our sponsored research agreement with IU or otherwise covered by the Licensed Intellectual Property may be subject to the IURTC License
Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As initial consideration for the license, we paid IURTC an immaterial issue fee. As additional consideration for the license, we are required to pay
IURTC: (i)&nbsp;royalties with a rate based on net sales per calendar year; (ii)&nbsp;an annual maintenance fee of up to $0.1&nbsp;million beginning in the first year in which the first commercial sale occurs; (iii)&nbsp;a mid-single digits
percentage of any sublicensing revenue; and (iv)&nbsp;milestone payments in the event of successful achievement of specified development milestones up to an aggregate of $0.4&nbsp;million. IURTC is also entitled to receive reimbursement for all
patent prosecution and maintenance related expenses. Our tiered royalties are in the low single-digits on annual net sales of the Licensed Products. In the event that we are required to pay a <FONT STYLE="white-space:nowrap">non-affiliate</FONT>
third party consideration for intellectual property owned or controlled by such <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third party that we or a sublicensee licensed for the development of Licensed Products, we can deduct such amounts
from the royalty payments up to a certain amount of the running royalties owed that year. The royalty term will terminate on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each
Licensed Product, until the expiration or termination of the last valid claim within the patent rights covering such Licensed Product in that country. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
January&nbsp;5, 2024, we and IURTC entered into a fourth amendment to the IURTC License Agreement, or the Fourth Amendment. The Fourth Amendment specifies IURTC is entitled to the receipt of additional clinical and regulatory milestones, as defined
in the Fourth Amendment, up to an aggregate of $9.0&nbsp;million. Following the execution of the Fourth Amendment, future remaining clinical and regulatory milestone payments in the IURTC License Agreement and all amendments total up to
$9.3&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IURTC License Agreement will expire at the expiration of the last of the patent rights covered in the IURTC License Agreement, unless
terminated earlier by mutual agreement or by one of the parties. We may terminate the IURTC License Agreement with or without cause upon ninety (90)&nbsp;days prior written notice to IURTC. IURTC may terminate the IURTC License Agreement if we
commit a material breach of the IURTC License Agreement and fail to cure the breach within the respective cure period after receipt of the notice of material breach or upon our failure to undertake certain activities in furtherance of commercial
development goals. Upon termination of the IURTC License Agreement, all rights granted by IURTC will terminate and automatically revert to IURTC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Components of results of operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our operating expenses consist of (i)&nbsp;research
and development expenses and (ii)&nbsp;general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and development </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The largest component of our total operating expenses since our inception has been research and development activities. Research and development expenses are expensed as
incurred and consist primarily of: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external research and development expenses incurred under agreements with contract research organizations, or CROs,
consultants and other third parties to conduct our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs related to manufacturing our product candidates for preclinical studies and clinical trials, including agreements
with contract development and manufacturing organizations, or CDMOs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">license fees, including any milestone-based payments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compensation and benefits, including stock-based compensation expense, for research and development personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of acquiring research and development supplies and services; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing process development costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs associated with regulatory activities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">costs incurred in development of intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other outside services and consulting costs; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an allocated portion of facilities and other infrastructure costs associated with our research and development activities.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and
development activities to advance our programs and conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product
candidates is highly uncertain. As a result, expenses may vary significantly based on factors such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our existing or future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our existing or future product candidates by the FDA and
comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or for such authorities to change their requirements
on studies that had previously been agreed to; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our existing or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">per subject clinical trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of sites included in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the countries in which our clinical trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">length of time required to enroll subjects and initiate our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number of subjects that participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> and discontinuation rate of subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the duration of subject participation in our clinical trials and <FONT STYLE="white-space:nowrap">follow-up,</FONT>
including the duration of open label extensions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of license agreement milestone payments related to development, regulatory and commercial events;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing success with patient materials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">mitigation/responses to potential health authority questions and/or inspections; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the degree to which we obtain, maintain, defend and enforce our intellectual property rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we establish collaboration, licensing or similar arrangements and the performance of any related third
parties. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A change in the outcome of any of these variables with respect to the development of any of our existing or future product candidates
could significantly change the costs and timing associated with the development of that product candidate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>General and administrative </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses consist primarily of compensation and benefits, including stock-based compensation expense, for general and administrative personnel;
other expenses for outside professional services, including legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, consulting and tax services; insurance costs; administrative travel expenses;
website development costs; marketing and public relations costs; and facilities, information technology and other allocated overhead costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that our
general and administrative expenses will increase in the future as we increase our headcount to support continued growth of our research and development activities. We also anticipate that we will incur increased accounting, audit, legal,
regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company. We also expect our intellectual property expenses to increase as we expand our intellectual
property portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Other income (expense) </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest expense </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest expense related to the issuance of our 2022
convertible notes and subsequent conversion to Series B Convertible Preferred Stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Interest and other income, net </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Total other income, net, is comprised of interest income earned on our cash and cash equivalents and marketable securities and amortization expense and accretion income
on our marketable securities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in derivative liability and loss on extinguishment debt </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Change in derivative liability and loss on extinguishment of debt related to the issuance of our 2022 convertible notes and subsequent conversion to Series B Convertible
Preferred Stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Results of operations </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Comparison of the
three months ended March 31, 2023 and 2024 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the three months ended March 31, 2023 and 2024 (in
thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">(6,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>The following table summarizes our research and development expenses for the periods indicated (in thousands): </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development program expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 2109</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 1416</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preclinical and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indirect research and development costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel related costs (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facility-related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">5,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $5.8 million from $5.3 million for the three months ended March 31,
2023 to $11.1 million for the three months ended March 31, 2024, as detailed below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Direct research and development program expenses related to MBX 2109 increased
by $1.6 million, primarily due to the initiation of the Phase 2 clinical trial and costs associated with conducting preclinical studies. Direct program expenses related to MBX 1416 increased by $1.3 million, primarily due to the ongoing Phase 1
clinical trial. Direct program expenses for preclinical and other programs increased by $0.2 million primarily due to pipeline candidate development activities. Personnel-related costs (including stock-based compensation), increased by $1.5 million,
primarily due to increased headcount and stock-based compensation expense. Facility-related and other, which include allocated overhead, including rent, repairs and maintenance costs, common facilities and information technology-related expenses
allocated to research and development increased by $1.2 million, primarily due to a one-time cash gift to Indiana University to support research in macromolecular chemistry and peptide therapeutics and related areas in the Department of Chemistry,
and other infrastructure costs to support organizational growth. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses increased by $1.2 million, from $1.1 million for the three months ended March 31, 2023 to $2.3 million for the three months ended
March 31, 2024. The increase was primarily due to higher professional fees related to legal and accounting services and higher personnel-related costs, including compensation, benefits and stock-based compensation, as we expanded our infrastructure
to support growth in our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest and other income, net </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net, which includes interest income and amortization of premiums and discounts on our investments in marketable securities, increased by $0.6
million from $0.4 million for the three months ended March 31, 2023 to $1.0 million for the three months ended March 31, 2024, due to increased interest on our cash, cash equivalents and marketable securities, which increased primarily due to the
closing for the Series B Convertible Preferred Stock financing in August 2023. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Comparison of the years ended December&nbsp;31, 2022 and 2023
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the years ended December&nbsp;31, 2022 and 2023 (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our research and development expenses for the periods indicated (in thousands): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development program expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 2109</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">MBX 1416</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preclinical and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indirect research and development costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Personnel related costs (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facility-related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $7.1&nbsp;million from $21.4&nbsp;million for the year ended December&nbsp;31, 2022
to $28.5&nbsp;million for the year ended December&nbsp;31, 2023, as detailed below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Direct research and development program expenses related to MBX 2109 decreased
by $2.8&nbsp;million, primarily due to the completion of the Phase 1 clinical trial in 2023. Direct program expenses related to MBX 1416 increased by $6.2&nbsp;million, primarily due to the initiation of a Phase 1 clinical trial, costs associated
with conducting preclinical trials and costs associated with manufacturing drug supply. Direct program expenses for preclinical and other programs increased by $0.9&nbsp;million primarily due to pipeline candidate development activities.
Personnel-related costs (including stock-based compensation), increased by $2.5&nbsp;million, primarily due to increased headcount and stock-based compensation expense. Facility-related and other, which include allocated overhead, including rent,
repairs and maintenance costs, common facilities and information technology-related expenses allocated to research and development increased by $0.4&nbsp;million, primarily due to increases in rent expense and other infrastructure costs to support
organizational growth. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses increased by $3.0&nbsp;million, from $3.8&nbsp;million for the year ended December&nbsp;31, 2022 to $6.8&nbsp;million for the year
ended December&nbsp;31, 2023. The increase was primarily due to higher professional fees related to legal and accounting services and higher personnel-related costs, including compensation, benefits and stock-based compensation, as we expanded our
infrastructure to support growth in our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest expense decreased by $0.4&nbsp;million, from $0.4&nbsp;million for the year ended December&nbsp;31, 2022 to $0 for the year ended December&nbsp;31, 2023 due to
our convertible notes issuance and subsequent conversion to Series B Convertible Preferred Stock in 2022. There were no similar activities for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest and other income, net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Interest and other income, net, which
includes interest income and amortization of premiums and discounts on our investments in marketable securities, increased by $2.4&nbsp;million from $0.4&nbsp;million for the year ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
December&nbsp;31, 2022 to $2.8&nbsp;million for the year ended December&nbsp;31, 2023, due to increased interest on our cash, cash equivalents and marketable securities, which increased primarily
due to the closing for the Series B Convertible Preferred Stock financing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Change in derivative liability and loss on extinguishment debt </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Change in derivative liability and loss on extinguishment of debt decreased by $1.0&nbsp;million, from $1.0&nbsp;million for the year ended December&nbsp;31, 2022 to $0
for the year ended December&nbsp;31, 2023 due to our convertible notes issuance and subsequent conversion to Series B Convertible Preferred Stock in 2022. There were no similar activities for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Liquidity and capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sources of liquidity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have incurred significant operating losses. We have historically funded our operations primarily through sales of our convertible preferred stock
and convertible notes, which generated approximately $150.6&nbsp;million in aggregate gross proceeds. As of December&nbsp;31, 2023 and March 31, 2024, we had $80.7&nbsp;million and $70.3 million in cash, cash equivalents and marketable securities,
respectively. We have not yet generated any revenue from product sales and do not expect to in the foreseeable future as our product candidates are in various phases of clinical and preclinical development. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future funding requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our expenses to increase
substantially in connection with our ongoing activities, particularly as we advance the development of our product candidates. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a
public company. The timing and amount of our operating expenditures will depend largely on: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and progress of research and development, preclinical&nbsp;and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our existing or future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our existing or future product candidates by the FDA and
comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or for such authorities to change their requirements
on studies that had previously been agreed to; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our existing or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our existing or future product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of filing and prosecuting our patent applications, and maintaining and enforcing our patents and other
intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any product liability or other lawsuits related to our existing or future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of other factors, including inflation, economic uncertainty and geopolitical tensions, which may exacerbate the
magnitude of the factors discussed above. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We had $80.7 million and $70.3 million in cash, cash equivalents and marketable securities as of
December 31, 2023 and March 31, 2024, respectively. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our current operating plan for at least the next 12 months from the date of this prospectus.
Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities, together with the estimated net proceeds from this offering, will be sufficient to fund our projected operating expenses and capital
expenditure requirements into&#8195;&#8195;&#8195;&#8195;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings,
collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interest for existing
investors may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect existing investors&#146; rights as a stockholder. Debt financing and preferred equity financing, if available,
may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic
alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not
be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or
grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
following table summarizes our sources and uses of cash for the periods presented (in thousands): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Three months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows from operating activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the three months ended March 31, 2024 was $10.7 million. This was primarily due to our net loss of $12.3 million, partially
offset by non-cash charges of $1.2 million and net cash provided by changes in our operating assets and liabilities of $0.4 million. The changes in our net operating assets and liabilities primarily consisted of $0.4 million decrease in our prepaid
expenses and other current assets related to prepaid balances with CROs and CDMOs. Non-cash charges primarily consisted of $1.6 million of stock-based compensation expense and $0.1 million of depreciation expense, partially offset by $0.5 million of
net amortization and accretion of marketable securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the three months ended March 31, 2023 was $5.7 million. This was
primarily due to our net loss of $5.9 million, partially offset by net cash provided by changes in our operating assets and liabilities of $0.2 million. The changes in our net operating assets and liabilities primarily consisted of a $0.3 million
decrease in our prepaid expenses and other current assets, partially offset by decreases in accounts payable, accrued expenses and operating lease liability of $0.1 million total. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the year ended December&nbsp;31, 2023 was $32.0&nbsp;million. This was primarily due to our net loss of $32.6&nbsp;million and
net cash used by changes in our operating assets and liabilities of $0.7&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.3&nbsp;million. The changes in our net operating assets and liabilities
primarily consisted of a $1.1&nbsp;million increase in our prepaid expenses and other current assets and other assets related to prepaid balances with CROs and CDMOs and a $0.1&nbsp;million increase in our operating lease liability, offset by a
$0.5&nbsp;million increase in accounts payable and accrued expenses related to timing. <FONT STYLE="white-space:nowrap">Non-cash</FONT> charges primarily consisted of $2.0&nbsp;million of stock-based compensation expense, $0.2&nbsp;million of
depreciation expense on fixed assets, and $0.1&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense, offset by $1.0&nbsp;million of net amortization and accretion of marketable securities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in operating activities for the year ended December&nbsp;31, 2022 was $23.1&nbsp;million. This is primarily due to our net loss for the period of
$26.1&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.7&nbsp;million and net cash provided by changes in our operating assets and liabilities of $1.3&nbsp;million.
<FONT STYLE="white-space:nowrap">Non-cash</FONT> charges primarily consisted of $0.9&nbsp;million in loss on extinguishment of convertible notes, $0.4&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense,
$0.3&nbsp;million of stock-based compensation expense, and $0.1&nbsp;million of change in derivative liability. The changes in our net operating assets and liabilities primarily consisted of a $2.1&nbsp;million increase in accounts payable and
accrued expenses related to timing, offset by a $0.8&nbsp;million increase in prepaid expenses and other current assets driven by an increase in our prepaid balances with CROs and CDMOs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows from investing activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by investing activities for the three months ended March 31, 2024 was $15.4 million, which consisted of maturities of marketable securities of $24.3
million, partially offset by purchases of marketable securities of $8.5 million and purchases of property and equipment of $0.3 million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing
activities for the three months ended March 31, 2023 was $3.3 million, which consisted of purchases of marketable securities of $9.3 million, partially offset by maturities of marketable securities of $6.0 million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash used in investing activities for the year ended December&nbsp;31, 2023 was $30.9&nbsp;million, which consisted of purchases of marketable securities of
$63.8&nbsp;million and purchases of property and equipment of $0.1&nbsp;million, partially offset by maturities of marketable securities of $33.0&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net
cash used in investing activities for the year ended December&nbsp;31, 2022 was $11.4&nbsp;million, which consisted of purchases of marketable securities of $20.2&nbsp;million and purchases of property and equipment of $0.4&nbsp;million, partially
offset by maturities of marketable securities of $9.2&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash flows from financing activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the three months ended March 31, 2024 was $0.2 million, which primarily consisted of proceeds from the exercise of common
stock options of $0.2 million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the three months ended March 31, 2023 was $0.1 million, which consisted of proceeds
from the exercise of common stock options of $0.1 million. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the year ended December&nbsp;31, 2023 was
$69.2&nbsp;million, which primarily consisted of proceeds from the issuance of Series B Convertible Preferred Stock of $68.5&nbsp;million and proceeds from the exercise of common stock options of $0.7&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net cash provided by financing activities for the year ended December&nbsp;31, 2022 was $46.1&nbsp;million, which primarily consisted of proceeds from the issuance of
Series B Convertible Preferred Stock of $36.5&nbsp;million and proceeds from issuance of convertible notes of $10.0&nbsp;million, partially offset by preferred stock issuance costs of $0.4&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Contractual obligations and commitments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Leases </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into two separate lease agreements for corporate office space and laboratory space, with terms extending through December 2025 and December 2024,
respectively. As of December&nbsp;31, 2023, our future remaining operating lease payments were $0.4&nbsp;million, with $0.2 million payable within the next twelve months, with respect to leases already commenced as of such date. As of March 31,
2024, our future remaining operating lease payments were $0.3 million, with $0.2&nbsp;million payable within the next twelve months, with respect to leases already commenced as of such date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Refer to Note 8 in our audited financial statements and Note 9 in our unaudited financial statements included elsewhere in this prospectus for more information on our
lease obligations. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>License agreement and other agreements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the IURTC License Agreement, we have payment obligations that are contingent upon future events, such as the achievement of specified development, regulatory and
commercial milestones, and in some cases, we are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to make royalty payments in connection with the sales of products developed under those agreements. Although we could be required to make milestone payments under the IURTC License
Agreement, we are unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional details regarding the IURTC License Agreement, see the section titled &#147;Business&#151;License
Agreement.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for
preclinical studies and clinical trials, research supplies and other services and drugs for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts. In addition, certain
of our supply agreements contain minimum purchase commitments in certain situations, the timing and likelihood of which we cannot estimate at this time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recently issued accounting pronouncements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A description of recently issued
accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Critical accounting policies and significant judgments and estimates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of
these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the
reported expenses incurred during the reporting periods. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On an ongoing basis, we evaluate our estimates and judgments, including but not limited to those related to
accrued research and development costs, the fair value of common stock and stock-based compensation expense and other fair value measurements. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances,
and material changes in these estimates and assumptions could occur in the future. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may
differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While our significant accounting policies are described in more detail in Note&nbsp;2 to our
audited financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Accrued research and development expenses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development
expenses are recognized as services are performed and as costs occur. As part of our process of preparing our financial statements, we are required to estimate our research and development expenses as of each balance sheet date. Research and
development expense accruals are estimated based on the level of services performed, progress of the work orders, including the phase or completion of events, and contracted costs. This process involves reviewing open contracts and purchase orders
and communicating with our personnel to identify the level of services that have been performed. We then make estimates of levels of service performed when we have not yet been invoiced or otherwise notified of actual costs incurred as of the
balance sheet date. We make significant judgments and estimates in determining the accrual balance at each reporting period based on the facts and circumstances known to us at that time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There may be instances in which vendors will require nonrefundable advance payments for goods or services to be
received in the future. Such advance payments for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are
performed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the level of services and timing
of services performed differ from actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular reporting period. To date, there have been no material differences between
estimates of such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Stock-based compensation expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (usually
the vesting period) on a straight-line basis. We estimate the fair value of all stock option grants using the Black-Scholes option pricing model and recognize forfeitures as they occur. Estimating the fair value of equity awards as of the grant date
using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the
expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are
subjective and generally require significant analysis and judgment to develop. See Note 12 to our audited financial statements and unaudited condensed interim financial statements included elsewhere in this prospectus for information concerning
certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted for the years ended December 31, 2022 and 2023, respectively, and the three months
ended March 31, 2023 and 2024, respectively. The majority of our stock option program allows for early exercise of granted options, before vesting requirements have been satisfied. Shares acquired through the early exercise of options which have not
vested at the time of any employee&#146;s termination may be purchased by us at the lower of the original exercise price or the then current fair market value. As of March 31, 2024, the unrecognized stock-based compensation expense related to stock
options was $10.6 million and is expected to be recognized as expense over a weighted-average period of approximately 3.3 years. The intrinsic value of all outstanding stock options as of March 31, 2024 was approximately
$&#8195;&#8195;&#8195;&#8195;million, based on the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share (the midpoint of the price range set forth on the cover page of this prospectus), of which approximately
$&#8195;&#8195;&#8195;&#8195;million related to vested options and approximately $&#8195;&#8195;&#8195;&#8195;million related to unvested options. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Determination of the fair value of common stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are required to
estimate the fair value of the common stock underlying our stock-based awards when performing fair value calculations. As there has been no public market for our common stock to date, we develop an estimate of the fair value of our common stock on
each grant date of options to purchase common stock. The fair value of our common stock has been determined by our board of directors on each grant date of options to purchase common stock, taking into account input from management, results from
independent third-party valuations and our board of directors&#146; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date our most recent valuation through the date of the
grant. These objective and subjective factors include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development programs, including the status of preclinical studies and clinical trials for
our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a
sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">trends and developments in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the economy in general. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our determinations of the fair value of our common stock were made using methodologies, approaches and assumptions consistent with the American Institute of Certified
Public Accountants Accounting and Valuation Guide: Valuation of Privately Held Company Equity Securities Issued as Compensation, or the Practice Aid. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Practice
Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach
establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present
value of future cash flows that are reasonably reflective of our future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the
value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology was considered in our valuations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock in accordance with the Practice Aid include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Current value method.</I> Under the current value method, once the fair value of the enterprise is established, the
value is allocated to the various series of preferred and common stock based on their respective seniority, liquidation preferences or conversion values, whichever is greatest. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Option pricing method, or OPM</I>. Under the OPM, shares are valued by creating a series of call options with exercise
prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Probability-weighted expected return method, or PWERM</I>. The PWERM is a scenario-based analysis that estimates the
value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our early stage of development, the complexity of our capital structure, the difficulty in predicting the likelihood and range of specific outcomes, including
uncertainty related to the timing and type of an exit event, and other relevant factors, the OPM was considered most appropriate for valuations prior to August 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For options granted after April&nbsp;19, 2023, a hybrid method between the PWERM and OPM was used, where the equity
value was probability-weighted across multiple scenarios. The value of the shares under an initial public offering event scenario was determined according to the PWERM and the OPM scenario, using an appropriate time to a liquidity event, was used to
estimate the fair value of the share class assuming the initial public offering event does not occur. The resulting share values under each scenario are weighted by their respective probabilities. This method was determined to be the most
appropriate valuation methodology based on our stage of development and other relevant factors. In determining the estimated fair value of our common stock, our board of directors also considered the fact that our stockholders could not freely trade
our common stock in the public markets. Accordingly, discounts were applied to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions
regarding our future operating performance, the time to complete an initial public offering or other liquidity event, and the determination of the appropriate valuation methods. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board
of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options or for any other such awards we may grant, as the fair value of our common stock will be determined based on the closing price of
our common stock as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes information
related to stock options we granted from January&nbsp;1, 2023 through July&nbsp;11, 2024: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Grant date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>shares&nbsp;subject<BR>options&nbsp;granted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share<BR>exercise&nbsp;price<BR>of&nbsp;options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fair&nbsp;value&nbsp;per<BR>common&nbsp;share<BR>on grant date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Per share<BR>estimated&nbsp;fair<BR>value&nbsp;of&nbsp;options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">January&nbsp;18, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April&nbsp;19, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,404,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">August&nbsp;15, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,057,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">November&nbsp;2, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,571,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">January&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">April 24, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,205,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We utilize a third-party valuation firm to assist in determining the grant date fair market value of our common stock. On
November&nbsp;7, 2022, our board of directors, with the assistance of a third-party valuation firm, determined the fair market value of our common stock to be $0.27, or the Initial Valuation. The fair market value of our common stock was
subsequently reassessed as of November&nbsp;7, 2022, solely for financial reporting purposes, to appropriately bifurcate upside and downside scenarios in accordance with the Practice Aid. As a result, the fair value of common stock as of
November&nbsp;7, 2022 was determined to be $0.34, as compared to the $0.27 determined by the Initial Valuation for tax reporting purposes. This revaluation resulted in recognition of additional stock-based compensation expense. The exercise price
for stock options granted from November&nbsp;7, 2022 through April&nbsp;19, 2023 was derived from the Initial Valuation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined in the
rules and regulations of the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Quantitative and qualitative disclosures about market risks </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Interest rate risk </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary objectives of our investment activities
are to ensure liquidity and to preserve capital. We are exposed to market risks related to changes in interest rates of our cash equivalents and marketable securities. However, due to the nature of these cash equivalents and marketable securities,
we do not believe that a hypothetical 10% increase or decrease in interest rates during any of the periods presented would have had a material effect on our business, results of operations, or financial condition, or on our audited financial
statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Effects of inflation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Inflation generally affects us by increasing our cost of labor and research and development costs. We do not believe that inflation had a material effect on our
business, results of operations, or financial condition, or on our audited financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Emerging growth company
and smaller reporting company status </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We qualify as an &#147;emerging growth company,&#148; as defined in the JOBS Act. As an emerging growth company, we may
take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: (i)&nbsp;being permitted to present only two years of audited financial statements, in
addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure in this prospectus; (ii)&nbsp;reduced
disclosure about our executive compensation arrangements; (iii)&nbsp;not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements not previously approved; (iv)&nbsp;an
exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and (v)&nbsp;an exemption from compliance with the requirements of the Public Company
Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#146;s report on the financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may take advantage of
these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we
have total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these
exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock.
Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting
standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our audited financial statements and unaudited condensed financial statements may not be
comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by nonaffiliates plus the proposed aggregate amount of gross
proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering
if either (i)&nbsp;the market value of our shares held by nonaffiliates is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares
held by nonaffiliates is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to
smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and,
similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_11"></A>Business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage biopharmaceutical company focused on the
discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this
expertise, we designed our proprietary Precision Endocrine Peptide<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or PEP<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, platform to overcome the key limitations of unmodified
and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent
drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel
candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include:
</P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 2109:</B>&#8195;Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a
potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous,
infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the
concentration of active drug observed immediately prior to the next dose, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an
extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2
clinical trial in patients with HP and anticipate topline data in the third quarter of 2025. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>MBX 1416:</B>&#8195;We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide 1, or <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin
secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase&nbsp;1 clinical trial preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or
pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional
single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Obesity portfolio:</B>&#8195;Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly
potent <FONT STYLE="white-space:nowrap">GLP-1</FONT> and glucose-dependent insulinotropic polypeptide, or GIP, receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> prodrug with the goal of reducing dosing frequency of and improving efficacy
and tolerability relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX 4291 supporting the potential for once-monthly administration. During our preclinical
studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent
dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting
potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
studies with an anticipated investigational new drug, or IND, submission in the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the
lead optimization stage of development. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate
their function and maintain homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to
using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic
peptides often have significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours<B> </B>by<B><I> </I></B>the liver and kidney. This often necessitates
frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies
could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential
efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved
efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target
selectivity, 3) half-lives that allow a dosing at weekly or less frequent intervals, and 4) low or flat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios to improve tolerability, thereby
facilitating higher dosing and greater potential efficacy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our platform </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have built our proprietary PEP platform to develop innovative precision peptide therapies that are designed to overcome key limitations of current peptide therapies.
We were founded by leaders in the field of peptide discovery and development with the goal of transforming the treatment landscape for endocrine and metabolic diseases with novel, efficacious, safe and convenient treatments. Our PEP platform builds
upon the expertise and chemical technologies originally discovered at the Indiana University laboratory of our scientific <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Richard DiMarchi, who is globally recognized for translational
breakthroughs in endocrine pharmacology, including the discovery of the first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> as well as other dual and triple incretin agonists. Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> proprietary PEP platform has enabled us to engineer novel product candidates that are designed to have optimized
pharmaceutical properties, including a longer duration of action, consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, and less frequent dosing, which support
our goals of improved tolerability, efficacy and potency. We currently rely on the discovery capabilities of Dr. DiMarchi and the Indiana University laboratory, but are continuing to grow and develop our internal discovery and development capacity,
including having hired an experienced cross-functional discovery team and building a peptide synthesis laboratory that will fully launch in the third quarter of 2024. We have developed a proprietary platform of tools that we believe will allow us to
continually design transformative therapies. These proprietary tools and <FONT STYLE="white-space:nowrap">know-how</FONT> include: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advanced chemical modifications</B> with a goal to provide enhanced physical properties including stability and
solubility, increased potency, and multiple mechanisms of action in a single peptide </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Programmable prodrug technologies</B> that are designed to precisely time the chemical conversion of the prodrug into an
active form to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and improve clinical outcomes </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Fatty acylation</B> aims to increase duration of action for more convenient dosing regimens and compatibility with <FONT
STYLE="white-space:nowrap">non-injectable</FONT> formulations </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PEP platform is designed to improve clinical outcomes and simplify disease
management for patients. Our PEPs are engineered to potentially optimize pharmaceutical properties yielding peptides with extended time-action profiles, convenient dosing regimens and the potential to enhance compliance and improve treatment
effectiveness in a real-world setting. PEPs may improve efficacy and reduce adverse events by providing a more continuous, infusion-like exposure to the peptide. We believe that our PEP technology, along with our significant <FONT
STYLE="white-space:nowrap">know-how</FONT> in the synergistic application of these tools, provides the opportunity to discover novel, highly selective and efficacious peptides with extended time-action profiles and low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios that may improve on the shortcomings of existing peptide therapies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our pipeline </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are leveraging our PEP platform to advance a
pipeline of programs to treat both endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet needs and large potential market opportunities. Developing product candidates,
including conducting preclinical studies and clinical trials, is a time consuming, expensive and uncertain process. We have not yet demonstrated an ability to obtain regulatory approvals. We retain exclusive, worldwide development and
commercialization rights to all of our product candidates and discovery programs. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g02s97.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyond MBX 4291, we have a robust discovery pipeline including multiple obesity programs in the lead optimization stage of
development. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>MBX 2109: Potential treatment for chronic hypoparathyroidism </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment
of HP. HP is a rare endocrine disease where parathyroid glands fail to produce sufficient amounts of PTH, which is a hormone that regulates calcium levels in the blood through its effects on bone, kidneys and intestines. We estimate that HP affects
approximately 120,000 people in the United States and more than 250,000 in the United States and Europe. HP is caused by damage to or removal of the parathyroid glands during neck surgery in approximately 75% of cases, or, less commonly, from an
autoimmune disease or a genetic disorder. A deficiency of PTH results in lower blood calcium levels, or hypocalcemia, which can result in a variety of acute symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as
depression, confusion and cognitive impairment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To avoid hypocalcemia and its symptoms, patients are treated with high dose calcium supplements and prescription
strength active vitamin D therapy, which can require the daily ingestion of approximately seven or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
more pills taken at multiple times throughout the day. This treatment does not address PTH deficiency and symptom relief can be suboptimal. Once-daily injectable PTH therapies have been shown in
clinical studies to reduce the need for high doses of calcium and active vitamin D supplements, decrease urinary calcium excretion and, by patient-reported-outcome assessments, result in improvements in patients&#146; quality of life. However, these
therapies can have significant fluctuations in drug concentrations that require daily subcutaneous injections, which impacts the potential outcomes for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP. MBX 2109 is a prodrug, which is a compound engineered to be
biologically inactive at the time of subcutaneous injection that then converts to an active peptide in an intrinsically controlled, time-dependent fashion. The prodrug design is supplemented by fatty acylation, the addition of fatty acids to the
compound, which facilitates binding to proteins and extends the time of the compound in circulation. This combination is meant to provide an extended time-action profile that allows a once-weekly administration and provides a continuous,
infusion-like PTH exposure with lower daily <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios than observed with daily PTH dosing regimens. This continuous, infusion-like exposure to MBX 2109 may
reduce the frequency and severity of excessive blood calcium, or hypercalcemic, events and insufficient blood calcium, or hypocalcemic, symptoms. The once-weekly MBX 2109 dosing regimen may improve compliance relative to daily PTH dosing regimens,
which we believe improves effectiveness in a real-world setting. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In a Phase 1 clinical trial in 76 healthy adults, weekly subcutaneous injections of MBX 2109
led to sustained and dose-dependent elevations of serum calcium and the suppression of endogenous PTH. The half-life of the MBX 2109 active drug across all doses was approximately 7.7 to 8.9 days, supporting a once-weekly dosing regimen. MBX 2109
was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating the safety, tolerability and efficacy of three fixed doses of MBX 2109 in a randomized, double-blind, placebo-controlled Phase 2
clinical trial in approximately 48 patients with HP. The primary endpoint of the Phase 2 clinical trial is the proportion of patients who can discontinue active vitamin D and reduce calcium supplements after 12 weeks of treatment while maintaining
normal serum calcium levels. We expect to report topline data from our Phase 2 clinical trial in the third quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>MBX 1416: Potential treatment for
post-bariatric hypoglycemia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416, our potential treatment for PBH, is designed to be a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT>
receptor antagonist, which is a molecule that binds to the applicable receptor to prevent the native molecule that would otherwise activate the receptor from binding. PBH is a rare, serious and chronic complication of bariatric surgery typically
occurring six months or later after surgery. We estimate PBH affects more than 90,000 people in the United States. In PBH, pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> are released following a meal leading to
hyperinsulinemia, or excessive levels of insulin, that may result in hypoglycemia, or low blood glucose. Hypoglycemic symptoms may include confusion, weakness, dizziness, blurred vision, loss of consciousness and seizures. While <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT><B> </B>therapies have been recently approved to treat obesity and its <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> people with severe obesity, defined
as a BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, often can require a greater degree of weight loss than these current therapies can achieve. According to the CDC, the
prevalence of severe obesity in the United States in adults over 20 years increased from 4.7% in 2000 to 9.2% in 2018. Bariatric surgery still remains the most efficacious means of treating severe obesity, with bariatric surgeries increasing by
approximately 23% since 2017 to approximately 280,000 in the United States in 2022, according to the American Society for Metabolic and Bariatric Surgery. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There
are currently no U.S. Food and Drug Administration, or FDA, approved pharmacologic therapies for PBH. The current treatment options to reduce the frequency and severity of hypoglycemic episodes focus on dietary interventions and, secondarily, on the
use of <FONT STYLE="white-space:nowrap">off-label</FONT> medications with significant side effect profiles and unproven effectiveness in patients with PBH. While glucagon is used as a rescue therapy to treat severe hypoglycemic events, it does not
prevent hypoglycemia from occurring. In certain patients with severe, intractable hypoglycemia, surgical reversal of the bariatric procedure may be considered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416 is designed as a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist to prevent <FONT
STYLE="white-space:nowrap">GLP-1</FONT> from augmenting insulin release to cause hyperinsulinemia following a meal and thereby prevent the occurrence of severe hypoglycemia in patients with PBH. Leveraging our PEP platform, we aim to improve the
pharmaceutical properties of the <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence required to inhibit <FONT STYLE="white-space:nowrap">GLP-1</FONT> action by chemically modifying the amino acid backbone to achieve enhanced potency, stability
and solubility, relative to the corresponding, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence. We are evaluating the safety, tolerability, pharmacokinetics and the effects that the drug has on the body, or pharmacodynamics, of MBX
1416 in an ongoing randomized double-blind, placebo-controlled single-and multiple-ascending dose, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial in healthy adults. Preliminary
pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting once-weekly
dosing. We anticipate topline results from our Phase 1 clinical trial in the fourth quarter of 2024. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our obesity portfolio </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP platform, we are discovering and developing candidates with optimized pharmacokinetic profiles and pharmacologic attributes to potentially improve on
the current treatments for obesity and related <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We are engineering our candidates to extend the time-action profile and to potentially improve tolerability, thereby providing the potential for
higher doses leading to greater weight loss than can be achieved with existing therapies. We are prioritizing candidates targeting clinically validated mechanisms for weight loss and are focusing on discovering peptides that target multiple unique
receptors. Our obesity portfolio currently includes one product candidate, MBX 4291, in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and a robust discovery pipeline with multiple development programs in lead optimization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MBX 4291: Long-acting and highly potent potential treatment for obesity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> prodrug. Obesity is a common and costly chronic condition leading to significant morbidity and mortality. According to the CDC, an estimated 42% of U.S. adults aged 20 and over have obesity, or BMI<FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>30&nbsp;kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, as of 2018, including 9% of adults with severe obesity, and another 31% of adults who are overweight, or BMI between 25.0 and 29.9
kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. Based on the CDC&#146;s 2018 prevalence rates, we estimate that at least 190&nbsp;million adults in the United States are obese or overweight. While the current, approved <FONT
STYLE="white-space:nowrap">GLP-1-based</FONT> agonists represent significant and clinically meaningful advances in the treatment of obesity, they require weekly injections and can be associated with significant gastrointestinal, or GI, side effects.
These side effects often lead to reduced adherence and increased discontinuation, thereby limiting a patient&#146;s ability to lose weight. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe MBX 4291 has
the potential to be a safe and efficacious therapy that will help people achieve their weight loss goals and improve their overall health. MBX 4291 is designed to achieve the extended time-action profile using two of our proprietary technologies,
programmable prodrug and fatty acylation. In our preclinical studies, MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT
STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component of MBX 4291 supporting the potential for once-monthly administration. We believe that our proprietary PEP platform and <FONT
STYLE="white-space:nowrap">know-how</FONT> also provide significant optionality in devising dosing regimens that could lead to clinically meaningful improvements in tolerability and increase the maximally attained weight loss, relative to existing,
approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an anticipated IND submission in the second
quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our company and team </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX was founded by pioneers
in the endocrine drug development field and is led by a team of seasoned industry veterans with a common goal to transform the treatment of endocrine and metabolic disorders and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
improve patients&#146; lives. Members of our leadership team have collaborated successfully over several decades on the discovery, development and commercialization of endocrine therapeutics
including Forteo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Humalog<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Byetta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. Our
<FONT STYLE="white-space:nowrap">co-founders,</FONT> Dr.&nbsp;DiMarchi and Kent Hawryluk, were central to the success of MB2 and Marcadia Biotech in advancing multiple
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-and</FONT></FONT> glucagon-based product candidates in clinical development through strategic transactions with Eli Lilly, Merck, Novo Nordisk, and Roche. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our team is led by executives who have deep experience in drug development and company-building in the biopharmaceutical industry. Key members of our executive and
leadership team include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Kent Hawryluk, President, Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> has spent more
than 20 years as a life sciences entrepreneur, leader and investor, and prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> MBX held biopharma executive leadership roles at Avidity Biosciences, MB2, and Marcadia Biotech.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Salomon (Sam) Azoulay, M.D., Chief Medical Officer, has over 35 years of experience in drug development and operations,
including as the Chief Medical Officer at Sumitovant Biopharma and Pfizer Essential Health. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Richard Bartram, Chief Financial Officer, has over 15 years of financial leadership experience spanning strategic and
operational finance roles, including serving as the Chief Financial Officer of Esperion Therapeutics and as a public accountant at PricewaterhouseCoopers LLP. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Michelle Graham, Chief Human Resources Officer, has over 25 years of experience in human resources, talent management, and
organizational development across various sectors of the healthcare industry, including as the Chief Human Resources Officer at Albireo Pharma, Tesaro, and Parexel. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Steven J. Prestrelski, Ph.D., Chief Scientific Officer, is a seasoned biopharmaceutical executive with over 30 years of
scientific and operational expertise who has led successful endocrine and metabolism product development programs from discovery through regulatory approval, including Byetta, Bydureon<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
Gvoke<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our platform technology includes patent rights and proprietary technology
exclusively licensed from Indiana University and developed in the Indiana University laboratory of our scientific founder, Dr.&nbsp;DiMarchi. Dr.&nbsp;DiMarchi developed the original PEP technology, and is the inventor of the first dual and triple
incretin agonists. Dr.&nbsp;DiMarchi is known as a world class innovator and inventor, a member of the National Inventor Hall of Fame and the National Academy of Medicine, and one of the world&#146;s leading peptide chemists. He is a former
decade-long chairman of the Peptide Therapeutics Foundation and is widely recognized as an international spokesperson for macromolecular medicines. He has an extensive track record of drug development in big pharma, early-stage biotech, and
academia, and is a successful repeat entrepreneur. In particular, he is recognized for his contributions to the discovery and development of rDNA-derived Humalog, rGlucagon, and Forteo, which he shepherded through development and commercialization.
His research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. A former officer and director, Dr.&nbsp;DiMarchi is not currently an employee of
the Company, but acts as the principal investigator under our research agreement with the Trustees of Indiana University, pursuant to which we have the option to license intellectual property developed on our behalf by Dr.&nbsp;DiMarchi. Dr.
DiMarchi is not required to devote any specified number of hours to the Company. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have raised approximately $150&nbsp;million in funding
from leading healthcare investors, including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management, and Wellington Management. Prospective investors should not rely on the investment decisions of
our existing investors, as these investors may have different risk tolerances and in certain cases received their shares in prior offerings at prices lower than the price offered to the public in this offering. See the sections titled &#147;Certain
relationships and related person transactions&#148; and &#147;Principal stockholders&#148; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
building a leading biopharmaceutical company with a focus on endocrine and metabolic disorders. Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative
precision peptide therapies. We are leveraging our propriety PEP platform to significantly improve clinical outcomes by discovering novel treatments that overcome key limitations of current peptide therapies. The key pillars of our business strategy
to achieve this mission include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance MBX 2109, a potential PTH peptide prodrug therapy, through clinical development to improve outcomes for patients
with HP.</B>&#8195;MBX 2109 leverages our PEP platform and is designed as a long-acting PTH replacement therapy for HP, a rare endocrine disorder that we estimate affects more than 250,000 people throughout the United States and Europe. MBX 2109 is
precisely engineered to treat the underlying pathophysiology of HP by achieving a continuous, infusion-like exposure to PTH with a convenient once-weekly dosing regimen. We believe MBX 2109 has the potential to transform the HP treatment paradigm by
providing dependable control to normalize serum and urinary calcium levels and simplifying treatment through once-weekly dosing that could significantly improve patient outcomes and quality of life. In a Phase 1 clinical trial, MBX 2109 demonstrated
a low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life, potentially enabling the first once-weekly PTH
dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and anticipate reporting topline
data in the third quarter of 2025. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance MBX 1416, a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, through clinical
development to potentially address the unmet medical need in patients with PBH.</B>&#8195;There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies for patients who suffer from hypoglycemia after bariatric surgery. We
estimate PBH affects more than 90,000 people in the United States, representing a large unmet medical need and significant commercial opportunity. We are developing MBX 1416 to be a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor
antagonist, a clinically validated mechanism, which is designed to reduce the frequency and severity of hypoglycemic events. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated
that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional single ascending dose and multiple ascending dose data from our
ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advance our obesity portfolio, including our lead obesity candidate, MBX 4291, with a focus on improving efficacy,
tolerability and dosing frequency compared to existing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies.&#8195;</B>While there have been significant advances in the treatment of obesity, there is
a need for better tolerated, more convenient and efficacious treatment options. Our lead obesity product candidate, MBX 4291, is designed as a long-acting <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor
<FONT STYLE="white-space:nowrap">co-agonist</FONT> prodrug. We also have a robust discovery pipeline with multiple development candidates in lead optimization. In our preclinical studies, the active component of MBX 4291 demonstrated a similar
activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active
component of MBX 4291, supporting the potential for once-monthly administration. In addition to providing a less frequent and more convenient dosing regimen, the extended time-action profile and lower <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio provide the opportunity to identify an optimal dosing regimen to improve tolerability and potentially increase the maximally attained weight loss, relative to existing, approved <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an anticipated IND submission in the second quarter of 2025.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Leverage our proprietary PEP technology platform and the capabilities of our experienced discovery team to expand our
pipeline in endocrine, metabolic and other disease areas.&#8195;</B>Our focus is on diseases with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
unmet medical need and clinically validated targets with established endpoints for regulatory approval and large potential market opportunities to allow us to minimize our risk profile and
efficiently advance our programs through development and regulatory approval. We are continuing to build upon our discovery capabilities to complement the scientific foundation of our <FONT STYLE="white-space:nowrap">co-founder</FONT>
Dr.&nbsp;DiMarchi. Our initial focus is building out a robust pipeline in endocrine and metabolic disorders. Our PEP platform is also widely applicable in discovering and developing peptides in other therapeutic areas. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Build a fully-integrated biopharmaceutical company</B> <B>and selectively evaluate strategic opportunities to maximize
the value of our pipeline.&#8195;</B>We aim to discover, develop, manufacture, and commercialize our endocrine product candidates.&nbsp;We may seek strategic collaborations where we believe the resources and expertise of third-party pharmaceutical
or biotechnology companies could accelerate the clinical development or maximize the market potential of our product candidates, or where such collaborations could expand our internal capabilities and PEP platform. In particular, assets within our
obesity portfolio may also benefit from a partnership to expand the indications under development, such as type 2 diabetes. We may seek additional partnership opportunities which complement our technologies, with the objective of accelerating our
development programs and potentially supplementing our future commercial capabilities. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Maintain an entrepreneurial, scientifically rigorous, and inclusive corporate culture where employees are fully engaged
and strive to bring improved therapeutic options to patients.&#8195;</B>We are driven to make a positive impact for patients worldwide and are guided by our core values of transparency, integrity, teamwork, and innovation to help us achieve our
mission rapidly, responsibly, and efficiently. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our platform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Peptide background.&#8195;</I>Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain
homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. Diseases characterized by hormonal
deficiencies are optimally treated by replacing the deficient hormone. The development of peptides as endocrine replacement therapies has led to significant advances in the treatment of human disease such as in the treatment of diabetes with
insulin. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and
other diseases. Due to the selective and highly specific nature of the peptide binding to its cognate receptor, peptide drugs typically carry a lower risk of <FONT STYLE="white-space:nowrap">off-target</FONT> side effects relative to small
molecules. Further, peptide therapeutics are typically associated with lower production complexity compared with protein-based biopharmaceuticals and, therefore, the production costs are also lower, generally closer to those of small molecules. More
than 80 peptide therapies have been approved, and there are currently more than 150 peptides candidates in clinical trials, and another 400 to 600 in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. Global sales of peptide-based
therapies exceeded $50&nbsp;billion in 2019, according to the Global Peptide Therapeutics Sales Market Report<I>. </I> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, whether as replacement therapies or
novel pharmacological actions, these therapeutic peptides often have some significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours by the liver and
kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high
levels of the peptide. Alternatively, the unmodified peptide can be delivered by a subcutaneous pump infusion to maintain optimal blood levels of the hormone, such as insulin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens.
Although these convenient, patient-friendly therapies could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios,
which can lead to side effects and limit potential efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent
injections and have the potential to provide improved efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we believe we are designing and developing novel peptide therapeutics with the goal of
achieving four key, distinct attributes: 1) high potency, 2) high target selectivity, 3) half-lives that allow a dosing at weekly or less frequent intervals, and 4) low or flat
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios to improve tolerability, thereby facilitating higher dosing and greater potential efficacy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Our PEP Platform</I>.&#8195;We have built our proprietary PEP platform to develop innovative precision peptide therapies that are designed to overcome key limitations
of current peptide therapies by extending the half-life and providing a more continuous, infusion-like exposure to the peptide. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>PEPs are designed
to overcome limitations of existing peptide therapeutics by </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>demonstrating infusion-like exposure </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g790774g14v41.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have developed a deep understanding of the relationship between the chemical structure and the biologic activity and
pharmacokinetic properties to address the current limitations of peptide therapies. We were founded by leaders in the field of peptide discovery and development with the goal of transforming the treatment landscape for endocrine and metabolic
diseases with novel, efficacious, safe and convenient treatments. Dr.&nbsp;DiMarchi and his research team at Indiana University are recognized as global leaders in the peptide field through their groundbreaking approach to peptide drug design and
development, including the discovery of the first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> as well as other dual and triple incretin agonists. Leveraging this expertise and <FONT
STYLE="white-space:nowrap">know-how,</FONT> we have built our PEP platform with chemical technology and tools that we are utilizing in developing PEPs with clinically validated targets, established endpoints for regulatory approval, significant
unmet medical needs and large potential market opportunities. We believe our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> proprietary PEP platform has
enabled us to engineer novel product candidates that are designed to have optimized pharmaceutical properties, including a longer duration of action, consistent drug concentrations with low <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, and less frequent dosing, which support our goals of improved tolerability, efficacy and potency. We are continuing to grow and develop our internal discovery and development capacity,
including having hired an experienced cross-functional discovery team and building a peptide synthesis laboratory that will fully launch in the third quarter of 2024. We have developed a proprietary platform of tools that we believe will allow us to
continually design transformative therapies. These proprietary tools and <FONT STYLE="white-space:nowrap">know-how</FONT> include: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Advanced chemical modifications</B> with a goal to provide enhanced physical properties including stability and
solubility, increased potency, and multiple mechanisms of action in a single peptide. Advanced chemical modifications, or ACM, of peptides as part of the PEP platform employs the use of native amino acid substitutions,
<FONT STYLE="white-space:nowrap">non-native</FONT> amino acid substitutions, alternative amino acid linkers, and other chemical modifications. The goal of these modifications is to create peptides with enhanced physical properties relative to the
existing peptide therapies, improving their utility as drugs. Some typical properties enhanced with ACM are the solubility and stability of the peptide, the potency at the applicable receptor, and importantly, the ability to design more than one
mechanism of action into a single peptide sequence such as MBX 4291. ACM is utilized in the design of each of MBX 2109, MBX 1416 and MBX 4291. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Programmable prodrug technologies</B> that are designed to precisely time the chemical conversion of prodrug into an
active form to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and improve clinical outcomes. This transformative proprietary programmable prodrug technology allows for the insertion of
two amino acids that locks the peptide in an inactive form and is transformed to an active drug at an intrinsically controlled <FONT STYLE="white-space:nowrap">(non-enzymatic)</FONT> rate under physiologic conditions. We can precisely program this
rate of activation from minutes to weeks with established design rules. By using modifications intrinsic to the peptide structure, the programmable prodrug approach can avoid the potential toxicity of other means to achieve an extended time-action
profile. The prodrug approach enables the design of peptides with more convenient weekly or monthly dosing as well as the potential for greater efficacy and tolerability, relative to shorter acting peptide therapies. This programmable prodrug
technology was utilized in designing the MBX 2109 and MBX 4291 peptides. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Fatty acylation</B> that aims to provide increased duration of action for more convenient dosing regimens and
compatibility with <FONT STYLE="white-space:nowrap">non-injectable</FONT> formulations. Fatty acids can improve the pharmacokinetic profiles and biological activities of peptides by increasing their stability, solubility, and interactions. Fatty
acylation of peptides leads to serum albumin binding of the acylated peptide, thereby extending serum half-lives. Fatty acylation has also been utilized to extend the half-life of peptides such as semaglutide and tirzepatide. We apply this fatty
acylation to increase the duration of action of our designed peptides, including in the design of MBX 2109, MBX 1416 and MBX 4291. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our PEP
platform is designed to improve clinical outcomes and simplify disease management for patients. Our PEPs are engineered to optimize pharmaceutical properties yielding peptides with extended time-action profiles, convenient dosing regimens and the
potential to enhance compliance and improve treatment effectiveness in a real-world setting. PEPs may improve efficacy and reduce adverse events by providing a more continuous, infusion-like exposure to the peptide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have developed significant <FONT STYLE="white-space:nowrap">know-how</FONT> in the synergistic application of these tools to create proprietary PEPs with novel
mechanisms of action and enhanced pharmacokinetic profiles. To date, we have designed and tested numerous novel peptides with the PEP technology in <I>in vitro</I> and <I>in vivo</I> trials. This gives us the ability to uniquely and synergistically
combine these three aspects of PEP technology to meet our designed target product profile of a new peptide to program a longer duration of action and blood levels with low
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios, consistent with an infusion-like profile. Given that MBX 2109 and MBX 1416 displayed extended time-action profiles in Phase 1 trials as those
predicted based on their chemical modifications, we believe we have validated the reproducible nature of the three components of our PEP platform in their ability to yield long-acting peptides. We believe our expertise and nonclinical and clinical
experience with our PEP platform will allow us to develop our future programs efficiently. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our Programs </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
leveraging our proprietary PEP platform to advance a pipeline of programs to treat both endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet needs and large potential
market opportunities. We retain exclusive worldwide development and commercialization rights to all of our product candidates and discovery programs. Our lead product candidates and programs include two clinical-stage programs targeting rare
endocrine disorders, MBX 2109 for the treatment of HP and MBX 1416 for the treatment of PBH, and an advancing obesity portfolio with MBX 4291 in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and multiple development programs in lead
optimization. We believe these programs have significant benefits over current treatment options and these include: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Potential benefits of our
programs over current treatment options </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g00s44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MBX 2109 for the treatment of chronic hypoparathyroidism </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment
of HP. HP is a rare endocrine disease where parathyroid glands fail to produce sufficient amounts of PTH, which is a hormone that regulates calcium levels in the blood through its effects on bone, kidneys and intestines. Leveraging our proprietary
PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to PTH with a convenient once-weekly injection. In a Phase 1 clinical trial in healthy adults, MBX 2109 demonstrated a
low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life potentially enabling the first once-weekly PTH dosing
regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. The FDA has granted Orphan Drug Designation to MBX 2109 for the treatment of HP. Orphan Drug Designation does not shorten the
development time or regulatory review time of a product candidate and does not provide any guarantee of approval in the regulatory review or approval process. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and
anticipate topline data in the third quarter of 2025. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Overview of chronic hypoparathyroidism </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">HP is a rare endocrine disease caused by a deficiency of PTH released by parathyroid glands that results in decreased calcium levels in the blood leading to
hypocalcemia. Hypocalcemia can result in a variety of acute </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as depression, confusion and cognitive impairment. More serious complications can occur, including seizures
and cardiac arrhythmias. As a result, HP can interfere with daily activities, negatively impacting the quality of life for patients. We estimate that HP affects approximately 120,000 people in the United States and more than 250,000 in the United
States and Europe. The most common cause for HP, in approximately 75% of cases, is inadvertent removal or damage to the parathyroid glands during neck surgery. It can also be caused by certain autoimmune processes and genetic conditions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Current treatments and limitations </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The current standard of care for HP
does not address the PTH deficiency, which is the underlying cause of the disease. To avoid hypocalcemia and its symptoms due to PTH deficiency, the current standard of care consists primarily of high doses of oral calcium supplements and active
vitamin&nbsp;D. Patients are treated with high dose calcium supplements (approximately 1.8 grams per day, compared to 250 to 500 mg in a multivitamin) and prescription strength active vitamin D therapy, which can require the daily ingestion of
approximately seven or more pills taken at multiple times throughout the day. Despite this therapy, symptom relief can be suboptimal and does not address PTH deficiency. In addition, treatment with large doses of calcium and active vitamin D are
associated with long-term complications such as cardiovascular disease, vascular calcification and increased urinary calcium excretion, which can result in chronic kidney disease and kidney stones. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As the underlying pathophysiology of HP is a deficiency in PTH, clinicians have used Natpara<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a once-daily,
unmodified PTH peptide replacement therapy to treat HP. However, Natpara has a short half-life and does not provide PTH exposure over a full <FONT STYLE="white-space:nowrap">24-hour</FONT> period. The inability to provide continuous blood exposure
to PTH leads to suboptimal efficacy as patients are unable to stop active vitamin D and calcium supplements. After the recall of Natpara in 2019, Takeda announced in 2022 that it decided to discontinue manufacturing of Natpara on a voluntary basis
at the end of 2024 due to unresolved supply issues that are specific to the product and has indicated that it will not <FONT STYLE="white-space:nowrap">re-commercialize</FONT> the product. Palopegteriparatide, manufactured by Ascendis Pharma, is a
once-daily PTH replacement therapy that is approved in the European Union (Yorvipath<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) for the treatment of HP and is under review by the FDA for the same indication. In Phase 3 trials,
palopegteriparatide treatment rendered the majority of patients independent of active vitamin D and calcium supplements (which reduced pill burden), reduced urinary calcium excretion and, by patient-reported-outcome assessments, improved quality of
life. We believe there is a need for a more effective therapy, which can ultimately normalize serum and urine calcium levels with a sustained PTH pharmacology, with a more convenient, once-weekly dosing regimen for patients with HP. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our solution: MBX 2109 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 is designed to treat the underlying
pathophysiology of HP by providing a continuous, infusion-like exposure to PTH with a convenient once-weekly injection. Utilizing our PEP platform, we designed MBX 2109 to address the narrow therapeutic window of PTH by delivering a consistent
exposure to the hormone, thereby maintaining normal serum and urinary calcium levels and reducing the need for vitamin D and calcium supplements. The FDA granted Orphan Drug Designation to MBX 2109 for the treatment of HP in July 2022. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 is a fatty acylated prodrug engineered to be biologically inactive at the time of subcutaneous injection and convert to an active PTH peptide in an
intrinsically controlled, time-dependent fashion to enable once-weekly administration with reduced fluctuations in peptide concentration. As shown in &#147;A&#148; in the graphic below, MBX 2109 features fatty acids at both termini which facilitate
binding to plasma proteins like albumin, extending time in circulation. Under physiologic conditions, as depicted in &#147;B&#148;, the prodrug is converted at a precisely controlled rate to the active peptide and an inactive fatty acylated two
amino acid metabolite. This conversion step is essential for achieving the desired pharmacokinetic profile. Finally, in &#147;C,&#148; the fatty acylated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
active drug slowly diffuses from albumin and engages the PTH receptor, increasing calcium levels in the blood. MBX 2109 incorporates two independent mechanisms utilizing our PEP technologies
&#151; programmable prodrug and fatty acylation &#151; to provide sustained, predictable PTH peptide levels and convenient, once-weekly dosing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 2109: Prodrug chemically converts to active drug at a precisely controlled rate </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g84m86.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The once-weekly MBX 2109 dosing regimen may improve compliance relative to daily PTH dosing regimens, which we believe has the
potential to improve effectiveness in a real-world setting. The prodrug design and the fatty acylation are meant to provide an extended time-action profile that allows a once-weekly administration and provides a continuous, infusion-like PTH
exposure with a lower daily <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios than observed with daily PTH dosing regimens. This continuous, infusion-like exposure to MBX 2109 may reduce the
frequency and severity of hypercalcemic events and hypocalcemic symptoms. Our goal is to simplify and improve the treatment of HP by providing a convenient, once-weekly therapy that addresses the underlying pathophysiology of HP and thereby
eliminating the need for complicated treatment regimens with oral calcium supplements and active vitamin D and their long-term complications. By maintaining normal serum calcium levels, MBX 2109 aims to reduce episodes of hypercalcemia and
hypocalcemia and thereby potentially improve the quality of life of patients living with HP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 normalized serum calcium levels in a preclinical study of rats with surgically removed parathyroid glands, or PTX rats, that induced a PTH deficiency and
hypocalcemia. In this study, we administered daily subcutaneous injections of MBX 2109 at 7.5 or 15 nmol/kg, for 28 days.&nbsp;As shown in the figure below, MBX 2109 normalized serum calcium levels in PTX rats. The results of this study provided
proof of concept for MBX 2109 to treat HP and served as key data in support of the Orphan Drug Designation for MBX 2109 in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 2109 demonstrated normalized serum calcium level in PTX rats </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g72d51.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Phase 1 clinical development and results </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of MBX 2109 in our completed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> randomized double-blind, placebo-controlled, single and multiple ascending dose Phase 1 clinical trial in healthy adults. The primary endpoint of the
Phase 1 clinical trial was safety and tolerability and secondary endpoints were pharmacokinetics and pharmacodynamic activity of MBX 2109. The key pharmacokinetic endpoints for the active drug were half-life, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios and time to reach steady-state. The key pharmacodynamic endpoints for the active drug were changes in albumin-adjusted serum calcium levels and suppression of endogenous PTH secreted by
the parathyroid gland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Five single ascending dose cohorts of healthy adults received subcutaneous placebo or MBX 2109 doses ranging between 50 &micro;g and 600
&micro;g, while subjects in the four multiple ascending dose cohorts received four weekly subcutaneous placebo or MBX 2109 doses of 200 &micro;g, 400 &micro;g, 600 &micro;g and 900 &micro;g. 36 and 40 adults were randomized into the single- and
multiple-dose portions, respectively, of the Phase 1 clinical trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects
being observed. No dose-limiting toxicities or <FONT STYLE="white-space:nowrap">off-target</FONT> adverse effects were noted. Adverse events were generally mild in nature. Injection site adverse events were the most common treatment-related adverse
event, with the most common reaction being a <FONT STYLE="white-space:nowrap">non-raised,</FONT> painless and <FONT STYLE="white-space:nowrap">non-pruritic</FONT> red area generally less than 50 mm in diameter, which resolved without intervention.
Similar injection site reactions have been observed in trials with daily PTH agents. As expected for a trial investigating the dose range for PTH replacement, hypercalcemia was observed in three subjects each in the single and multiple ascending
parts of the trial. These events occurred at the higher dose levels, resolved without intervention and were asymptomatic laboratory findings.<B> </B> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Single and
multiple weekly doses of MBX 2109 had dose-proportional and time-dependent increases in exposure to the active drug, with low to moderate intersubject variability. We believe these findings support use of a reliable titration regimen across
subjects. The half-life of the MBX 2109 active drug across all doses was approximately 7.7 to 8.9 days, which we believe supports a once-weekly dosing regimen. Mean
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peak-to-trough</FONT></FONT> ratios of the active drug following the last dose ranged from 1.47 to 1.79, indicating a continuous, infusion-like profile over a <FONT
STYLE="white-space:nowrap">seven-day</FONT> period. The graphic below shows the mean concentration of active drug for each dose at each measured time post dose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Plasma concentration-time profile for active drug demonstrated infusion-like profile </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>and supported once-weekly dosing </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g70y95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We observed similar mean serum calcium concentrations in our Phase&nbsp;1 trial as were observed in the TransCon PTH Phase&nbsp;1
trial when both agents were estimated to be at steady state, which was after the fourth weekly dose of MBX 2109 and day 11 for daily dosing of TransCon PTH, according to the Journal of Bone and Mineral Research. The active component of MBX 2109 is
highly bound to albumin and the free, unbound fraction is thought to be the biologically-active form able to bind to and activate the PTH receptor, which increases calcium levels in the blood. Using the total serum concentrations of the active
component of MBX 2109, which measures both albumin bound and unbound peptide, observed in our Phase&nbsp;1 trial, we calculated the peak and trough concentrations of the unbound active component of MBX 2109 using different assumptions (0.01 to 10%)
for the unbound percentage. Based on these calculations, a free, unbound fraction of MBX 2109 active of 0.1% yields PTH exposures comparable to the PTH exposure estimates seen in response to TransCon PTH in their Phase 1 study. The cross-study
comparison is provided for illustrative purposes only as there is no head-to-head comparison available. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once-weekly MBX 2109 increased serum calcium levels
assessed by either the maximal increase in serum calcium (E<SUB STYLE="font-size:75%; vertical-align:bottom">max,adj</SUB>) or the total serum calcium levels between injections (AUEC0-<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#116;</FONT></FONT> adj) in a dose- and time-dependent fashion. Maximal increases in albumin-adjusted serum calcium, or <FONT STYLE="white-space:nowrap">adj-Ca,</FONT> were seen approximately 48 hours after injection. At
the higher doses, increases in serum calcium were apparent after the first injection, with the effect being nearly maximal after the third weekly injection. These results have demonstrated a dose- and time-dependent effect of MBX 2109 in increasing
serum calcium levels with an initial effect within days after the first dose and nearly maximal after the third dose. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Maximal serum calcium levels
(E<SUB STYLE="font-size:75%; vertical-align:bottom">max,adj</SUB>) after MBX 2109 weekly injections increased in a </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">dose-and</FONT> time-dependent fashion </B></P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g80i17.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once-weekly MBX 2109 increased serum calcium levels assessed by the total serum calcium levels between injections
(AUEC0-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#116;</FONT></FONT> adj) in a dose- and time-dependent fashion, as shown below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Total serum calcium levels between MBX 2109 weekly injections (AUEC0-<FONT STYLE="FONT-FAMILY:SYMBOL">&#116;</FONT>, adj) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>increased in a dose- and time- dependent fashion </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g77b51.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Increases in serum calcium create a negative feedback response that reduces the endogenous secretion of PTH from the parathyroid
glands in these normal adults, which is another pharmacodynamic marker of MBX 2109 action. The figure below shows the endogenous PTH at days after the first injection. We observed a dose-dependent reduction in PTH to levels at or below the lower
limit of normal for PTH with the maximal effect seen between one and four days after the initial injection of MBX 2109. Suppression of endogenous PTH secretion further substantiated the PTH agonist activity of MBX 2109 at the doses evaluated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Endogenous PTH in healthy subjects decreased after MBX 2109 weekly injections in a </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>dose- and time-dependent fashion </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g75h77.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Ongoing Avail<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Phase 2 clinical trial </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are conducting a randomized double-blind, placebo controlled Phase 2 clinical trial in adult patients with HP, or the Avail trial. The Avail trial evaluates the
safety, tolerability and efficacy of MBX 2109 over a <FONT STYLE="white-space:nowrap">12-week</FONT> period in approximately 48 patients. The primary endpoint of the Phase 2 clinical trial is the proportion of patients who can discontinue active
vitamin D and reduce calcium supplements to less than or equal to 600 mg per day after 12 weeks of treatment while maintaining normal serum calcium levels. Secondary endpoints include safety and tolerability of MBX 2109 and characterization of the
pharmacokinetics and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
pharmacodynamic activity (including urine calcium, serum phosphorus, 1,25 dihydroxyvitamin D and bone biomarkers) and the impact on quality of life using patient-reported outcome tools. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the Avail trial, patients are randomized (1:1:1:1) to weekly subcutaneous injections of placebo and 400 &micro;g, 600 &micro;g, and 800 &micro;g of MBX 2109. The <FONT
STYLE="white-space:nowrap">12-week</FONT> treatment period is comprised of a 4-week fixed dose period and a 8-week titration period. During the titration period, patients who have not been able to discontinue active vitamin D and/or reduce calcium
supplements may <FONT STYLE="white-space:nowrap">up-titrate</FONT> the study drug using a protocol-specified algorithm. Patients completing the <FONT STYLE="white-space:nowrap">12-week</FONT> treatment period will be eligible to participate in a <FONT
STYLE="white-space:nowrap">104-week</FONT> long-term extension study in which all patients will receive MBX 2109. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g43a01.jpg" ALT="LOGO">
 </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Avail trial began in 2024 and we anticipate reporting
topline results in the third quarter of 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe there is a regulatory pathway for approval of PTH replacement therapy in HP. The general design and the
primary endpoint analysis used in the Phase 3 trial is anticipated to be similar to that used for the Phase 3 trial supporting EU approval of palopegteriparatide, a daily PTH replacement therapy, for the treatment of HP. The New Drug Application for
palopegteriparatide is under review by the FDA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MBX 1416 for the treatment of post-bariatric surgery hypoglycemia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are developing MBX 1416, a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist, that is designed to be a potential treatment for PBH. MBX
1416 is designed to block pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> released following a meal, which leads to hyperinsulinemia and may result in hypoglycemia. By inhibiting <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">GLP-1-induced</FONT></FONT> hyperinsulinemia in patients with PBH, MBX 1416 is designed to reduce insulin secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events with convenient
once-weekly administration. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure
and a half-life supporting a once-weekly dosing regimen. We anticipate topline results from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Post-bariatric surgery hypoglycemia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">PBH is a rare, serious and chronic
complication of bariatric surgery typically occurring six months or later after surgery. We estimate PBH affects more than 90,000 people in the United States. In PBH, pathologic increases in <FONT STYLE="white-space:nowrap">GLP-1</FONT> are released
following a meal leading to hyperinsulinemia, or excessive levels of insulin, that may result in hypoglycemia, or low blood glucose. Hypoglycemic symptoms may include confusion, weakness, dizziness, blurred vision, loss of consciousness and
seizures. The unpredictable onset of hypoglycemia and anxiety due to fear of hypoglycemia significantly negatively impact the quality of life in patients with PBH. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies have been recently approved to treat obesity and its <FONT
STYLE="white-space:nowrap">co-morbidities,</FONT> people with severe obesity, defined as a BMI <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, often can require a greater degree
of weight loss than these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
current therapies can achieve. According to the CDC, the prevalence of severe obesity in the United States in adults over 20 years increased from 4.7% in 2000 to 9.2% in 2018. Bariatric surgery
still remains the most efficacious means of treating severe obesity. Bariatric surgeries have increased by approximately 23% since 2017 to approximately 280,000 in the United States in 2022, according to the American Society for Metabolic and
Bariatric Surgery. Further, the use of bariatric surgery to address severe obesity and related comorbidities has increased by more than 50% over the past decade from 2011 to 2022, according to the Journal of the American Heart Association, with
further increases expected due to the use of bariatric surgery to treat severe obesity and its <FONT STYLE="white-space:nowrap">co-morbidity</FONT> of type 2 diabetes. The most commonly employed bariatric procedures are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Roux-en-Y</FONT></FONT> gastric bypass, or RYGB, and sleeve gastrectomy, or SG, which represent approximately 75% of bariatric surgeries performed annually. We estimate that PBH impacts up
to approximately 13% and approximately 2% of patients who undergo RYGB and SG, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following a meal, nutrients are absorbed from the upper small intestine
causing blood glucose levels to increase. In response to increasing glucose levels, <FONT STYLE="white-space:nowrap">GLP-1</FONT> is released from intestinal <FONT STYLE="white-space:nowrap">L-cells</FONT> which augments insulin release from the
pancreas to maintain euglycemia, or normalized blood glucose levels. Following RYGB and SG, the transit of nutrients from the stomach to the upper small intestine is markedly increased, which requires more rapid
<FONT STYLE="white-space:nowrap">GLP-1</FONT> and insulin secretion to maintain euglycemia. In PBH, <FONT STYLE="white-space:nowrap">GLP-1</FONT> release following a meal is excessive which results in a pathologic increase in insulin release from
the pancreas leading to hyperinsulinemia and hypoglycemia. The figures below show concentrations of blood glucose, insulin, and <FONT STYLE="white-space:nowrap">GLP-1</FONT> after a meal in patients with hypoglycemia resulting from RYGB,
asymptomatic patients following a RYGB, and <FONT STYLE="white-space:nowrap">non-surgical</FONT> controls. Both peak <FONT STYLE="white-space:nowrap">GLP-1</FONT> and peak insulin levels are higher and the lowest blood glucose levels are lower in
patients with PBH than in patients without hypoglycemia following bariatric surgery. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Patients with PBH have higher
<FONT STYLE="white-space:nowrap">GLP-1</FONT> and insulin levels and lower blood glucose </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>relative to normal subjects or post-bariatric surgery
patients without PBH </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g40a82.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><I>Source: J Clin Endocrinol Metab 103: 2815-2826, 2018 </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients with PBH can experience symptomatic hypoglycemia sometimes multiple times a day. Hypoglycemia also causes a shortage of glucose in the brain, or
neuroglycopenia. Neuroglycopenic symptoms, such as confusion, weakness, dizziness, blurred vision, loss of consciousness and/or seizures may develop, which can result in emotional and physical trauma to the individual. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The unpredictable nature and severity of hypoglycemic episodes can meaningfully hinder daily activities. As a result, the patient burden is substantial with some
patients unable to drive, work, or live alone, leading to a significant negative impact on a patient&#146;s quality of life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Current treatments and limitations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> pharmacologic therapies for PBH. The current treatment options to reduce the frequency and
severity of hypoglycemic episodes focus on dietary interventions and secondarily on the use of <FONT STYLE="white-space:nowrap">off-label</FONT> medications with unproven effectiveness for patients with PBH and significant effect profiles. While
glucagon is used as a rescue therapy to treat severe hypoglycemic events, it does not prevent hypoglycemia from occurring. In certain patients with severe, intractable hypoglycemia, surgical reversal of the bariatric procedure may be considered.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">GLP-1</FONT> antagonism as a clinically validated solution for PBH </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Use of a <FONT STYLE="white-space:nowrap">GLP-1</FONT> inhibition-based mechanism has been clinically validated as a potential therapy to reduce the frequency and
severity of hypoglycemic episodes in patients with PBH. When administered to patients with PBH, exendin <FONT STYLE="white-space:nowrap">(9-39),</FONT> a short-acting, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist,
prevents hyperinsulinemia and blood glucose levels from decreasing into the hypoglycemic range. In a study in patients with PBH, patients who received treatment with exendin <FONT STYLE="white-space:nowrap">(9-39)</FONT> did not experience
hyperinsulinemia and blood glucose levels remained in the euglycemic range after a meal. On the other hand, without treatment with exendin <FONT STYLE="white-space:nowrap">(9-39),</FONT> blood glucose levels in patients can decrease into the
hypoglycemic range and rescue therapy was needed to avert symptomatic hypoglycemia after a meal. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our solution: MBX 1416 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX 1416 is a long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor antagonist that is designed to prevent <FONT STYLE="white-space:nowrap">GLP-1</FONT>
from augmenting insulin release to cause hyperinsulinemia following a meal and thereby prevent the occurrence of severe hypoglycemia in patients with PBH. Unlike exendin (9-39), which is derived from a non-human sequence, we have engineered the
amino acid sequence derived from a segment of human GLP-1 to improve immunogenicity. MBX&nbsp;1416 binds to the GLP-1 receptor but lacks the ability to activate the receptor, acting as a competitive antagonist of GLP-1. Leveraging our PEP platform,
we aim to improve the pharmaceutical properties of the <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence required to inhibit <FONT STYLE="white-space:nowrap">GLP-1</FONT> action by chemically modifying the amino acid backbone to achieve
enhanced potency, stability and solubility, relative to the corresponding, unmodified <FONT STYLE="white-space:nowrap">GLP-1</FONT> sequence. To achieve sustained exposures able to support once-weekly dosing, fatty acylation has been incorporated to
enhance binding to albumin from which the peptide is slowly released. Leveraging the clinically validated <FONT STYLE="white-space:nowrap">GLP-1</FONT> antagonist approach, MBX 1416 has the potential to be the first pharmacologic therapy to prevent
and reduce the severity of hypoglycemia in patients with PBH with convenient once-weekly administration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal is for MBX 1416 to improve the quality of life in
patients with PBH by reducing the burden of living with the unpredictable nature of hypoglycemia and anxiety from fear of suffering the potentially severe adverse clinical outcomes from hypoglycemia. We aim to do this by reducing the frequency and
decreasing the severity of hypoglycemic episodes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In <I>in vitro</I> studies, MBX 1416 inhibited <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor activation and was approximately a six to nine times more potent
inhibitor than exendin <FONT STYLE="white-space:nowrap">(9-39).</FONT> By blocking <FONT STYLE="white-space:nowrap">GLP-1</FONT> action, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-induced</FONT></FONT> augmentation of
insulin release is blocked. The ability of MBX 1416 and exendin <FONT STYLE="white-space:nowrap">(9-39)</FONT> to block <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor activation were evaluated in an <I>in vitro</I> <FONT
STYLE="white-space:nowrap">GLP-1</FONT> receptor assay. In <I>in vitro</I> receptor assays, the concentration required to inhibit 50% of <FONT STYLE="white-space:nowrap">GLP-1</FONT> action was 54 nM and 503 nM for MBX 1416 and exendin <FONT
STYLE="white-space:nowrap">(9-39),</FONT> respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We established the proof of mechanism for MBX 1416 inhibition of
<FONT STYLE="white-space:nowrap">GLP-1</FONT> action in an <I>in vivo</I> model. In a diet-induced obesity mouse model, we evaluated whether MBX 1416 could block the ability of semaglutide, a <FONT STYLE="white-space:nowrap">GLP-1</FONT> agonist, to
reduce food intake. In this study, on days 0, 1 and 2, rodents were administered semaglutide alone, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
MBX 1416 alone or semaglutide in combination with MBX 1416. In the graph below, semaglutide is shown to inhibit food intake. However, this inhibition was blocked by the administration of MBX 1416
with semaglutide. MBX 1416 administered alone did not affect food intake. These data provide <I>in vivo</I> evidence for the clinical potential of MBX 1416-induced inhibition of <FONT STYLE="white-space:nowrap">GLP-1</FONT> action. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 1416 induces inhibition of <FONT STYLE="white-space:nowrap">GLP-1</FONT> action when administered in combination with </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>semaglutide in an </B><B><I>in vivo</I></B><B> model </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g75q33.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In rodent and <FONT STYLE="white-space:nowrap">non-human</FONT> primate toxicology studies of up to four weeks in duration, no
clinical signs of toxicity were observed. In <I>in vitro</I> assessments of interactions with drug transporters, MBX 1416 inhibited hepatic organic anion transporting polypeptide transporters, OATP1B1 and OATP1B3. Inhibition of these transporters
could result in a potential drug-drug interaction by reducing elimination of drugs transported by these transporters that could require an adjustment in dose or avoidance in using the drug when treated with MBX 1416.<B><I> </I></B>The clinical
relevance of this preclinical finding is being evaluated in our Phase 1 clinical trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Phase 1 clinical development and results </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of MBX 1416 in an ongoing randomized, double-blind, placebo-controlled, single- and
multiple- ascending dose, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 clinical trial in healthy adults. The primary endpoint of the Phase 1 clinical trial is to evaluate the safety and
tolerability of MBX 1416. Secondary endpoints are to evaluate the pharmacokinetic profile of MBX 1416 to establish the time-action profile to support a once-weekly dosing regimen and to utilize pharmacodynamic parameters (e.g., blood glucose,
insulin, <FONT STYLE="white-space:nowrap">c-peptide</FONT> levels) obtained during a mixed meal tolerance test to select a range of MBX 1416 doses to advance into the next phase of development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The single ascending dose portion of this Phase 1 trial evaluates subcutaneous MBX 1416 doses of 10 mg, 30 mg, 100 mg and 200 mg, in up to eight healthy adults per
cohort randomized 3:1 (six MBX 1416; two placebo in each cohort). The multiple ascending dose portion of the trial evaluates four weekly subcutaneous doses of placebo and 10 mg, 30 mg and 100 mg MBX 1416 in four cohorts in up to eight healthy adults
per cohort (six MBX 1416; two placebo in each cohort). An additional cohort will assess the clinical relevance of preclinical transporter findings. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The single
ascending dose portion of this Phase 1 clinical trial is clinically complete, and the multiple ascending dose portion is ongoing. Preliminary pharmacokinetic data from the single ascending dose portion of our ongoing Phase 1 clinical trial
demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and showed a half-life supporting a once-weekly dosing regimen. In the graph below, preliminary pharmacokinetic data from the single
ascending dose portion of the Phase 1 trial demonstrate dose-proportional increases in MBX 1416 concentration levels. The observed mean half-life of MBX 1416 was approximately 90 hours supporting a once-weekly dosing regimen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Preliminary data demonstrate dose-proportional increases in mean MBX 1416 concentrations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>with increasing doses </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g83a26.jpg" ALT="LOGO">
 </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate topline results from our ongoing Phase 1 trial in the fourth quarter of 2024. Following completion of the Phase
1 clinical trial and using the pharmacodynamic results from the mixed meal tolerance test, we plan to select MBX 1416 doses to be administered once-weekly and advance MBX 1416 into a Phase 2 clinical trial in which the primary endpoint will be the
rate of severe hypoglycemic episodes that require the assistance of another person, or Level&nbsp;3 hypoglycemia. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Obesity portfolio </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obesity is widely recognized as a global epidemic which imposes a substantial health care burden and is associated with significant
<FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We believe that we are well positioned to deliver an array of differentiated obesity candidates offering treatment flexibility to improve patient outcomes. Based on the significant unmet need,
we see a potentially large commercial opportunity for our obesity portfolio. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP platform, we are discovering and developing candidates with
optimized pharmacokinetic profiles and pharmacologic attributes to potentially improve on the current treatments for obesity and related <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We are engineering our candidates to extend the
time-action profile and to potentially improve tolerability, thereby providing the potential for higher doses leading to greater weight loss than can be achieved with existing therapies. We are prioritizing candidates targeting clinically validated
mechanisms for weight loss and are focusing on discovering peptides that target multiple unique receptors. Our obesity portfolio currently includes one product candidate, MBX 4291, in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and
a robust discovery pipeline with multiple development programs in lead optimization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>MBX 4291 for the treatment of obesity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> prodrug that reduces dosing frequency with a goal of improving tolerability and efficacy relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a
similar activity profile and body weight loss in mice as tirzepatide, an approved weekly <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist,</FONT> and an extended duration of action of the active component
of MBX 4291, supporting the potential for once-monthly administration. MBX 4291 is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with an IND submission anticipated in the second quarter of 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Obesity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obesity is
a common and costly chronic condition leading to significant morbidity and mortality. According to the CDC, an estimated 42% of U.S. adults aged 20 and over have obesity (BMI<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>30 kg/m<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP>) as of 2018, including 9% of adults with severe obesity (BMI<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>40 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>), and another 31% of
adults who are overweight (BMI between 25.0 and 29.9 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>). Based on the CDC&#146;s 2018 prevalence rates, we estimate that at least 190 million adults in the United States are obese or
overweight. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obesity leads to <FONT STYLE="white-space:nowrap">co-morbidities</FONT> that have a significant impact on the health. Obesity associated <FONT
STYLE="white-space:nowrap">co-morbidities</FONT> include illnesses such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, osteoarthritis, metabolic dysfunction associated steatohepatitis, infertility, heart failure, stroke, coronary
artery disease, venous thromboembolic disease, gall stones, disease, depression and certain types of cancer. These <FONT STYLE="white-space:nowrap">co-morbidities</FONT> have a negative impact on the quality and quantity of life, reduce productivity
and impose a substantial economic cost to society. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Current treatments and limitations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Initial treatment options for people with obesity focus on a combination of diet, exercise and lifestyle modifications. The American College of Cardiology, or the ACC,
and American Association of Clinical Endocrinologists, or the AACE, recommend people with obesity should initially be prescribed aerobic exercise and resistance training, a reduced calorie diet, and behavioral intervention. Behavioral modification
therapy typically results in only modest weight loss that is often not sustained. Therefore, surgery and pharmacological treatment are often required. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The AACE
guidelines recommend that pharmacotherapy combined with lifestyle modifications be considered in individuals with a BMI of at least 27 kg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor
mono-agonists have been approved by the FDA and EMA for obesity, such as Wegovy<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (semaglutide) and Saxenda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (liraglutide). Recently the
first <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist,</FONT> Zepbound<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (tirzepatide), has been approved for obesity. In a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study in overweight and obese subjects with type 2 diabetes, tirzepatide, the <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist,</FONT> provided statistically and clinically meaningful greater weight loss, relative to semaglutide, the <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor mono- agonist. Based on demonstrating reductions
in the risk of heart attack, stroke, or cardiovascular disease-related death, a weight loss drug (Wegovy) has been approved by the FDA to reduce the risk of major cardiovascular events in overweight or obese individuals with cardiovascular disease
and no prior history of type 2 diabetes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While the current GLP-1-based agonists represent significant and clinically meaningful advances in the treatment of
obesity, they require weekly injections and can be associated with significant GI side effects such as nausea, diarrhea, constipation, and vomiting. These side effects often lead to reduced adherence and increased discontinuation, thereby limiting a
patient&#146;s ability to lose weight. The availability of better tolerated agents with weight loss equal to or exceeding the approved <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor mono-agonist therapies or more efficacious <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> therapies would be a clinically meaningful therapeutic advance for people with obesity and its
<FONT STYLE="white-space:nowrap">co-morbidities.</FONT> We believe that our PEP technology can improve on the shortcomings of existing pharmacologic weight loss therapies through the discovery of novel, highly selective and efficacious peptides with
extended time-action profiles and the flexibility to utilize dosing regimens that may improve efficacy and tolerability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Our solution: MBX 4291 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leveraging our PEP technology, we have engineered MBX 4291, a highly selective and potent <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT
STYLE="white-space:nowrap">co-agonist</FONT> with an extended time-action profile, and have advanced this product candidate into <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for the treatment of obesity. MBX 4291&#146;s <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> <FONT STYLE="white-space:nowrap">co-agonist</FONT> approach has been clinically validated in providing a similar activity profile and body weight loss in mice relative to dual agonist
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approaches in existing therapies, such as tirzepatide. MBX 4291 was designed to achieve an extended time-action profile to reduce dosing frequency and improve GI tolerability. MBX 4291 has
demonstrated the desired pharmacokinetic profile by utilizing two independent mechanisms &#150; programmable prodrug and fatty acylation. When injected subcutaneously, MBX 4291 is an inactive prodrug that at physiological conditions will slowly and
precisely convert in an intrinsically controlled, time-dependent fashion to the active drug. Additionally, we incorporated fatty acylation into the peptide to enhance binding to albumin from which the active peptide is slowly released to interact
with its cognate receptors. The combination of the prodrug and fatty acylation approaches to MBX 4291 provides the potential for a once-monthly dosing regimen. We believe that our proprietary PEP platform and
<FONT STYLE="white-space:nowrap">know-how</FONT> provide significant optionality in devising dosing regimens that could lead to clinically meaningful improvements in tolerability and increase the maximally attained weight loss, relative to existing,
approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1-based</FONT></FONT> therapies.</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While the design of MBX 4291 utilized similar,
clinically validated mechanisms to prolong half-life as those used in designing MBX 2109, including prodrug and fatty acylation, with its extended half-life, additional prodrug modifications were made to extend the time-action profile beyond that
seen with MBX 2109 potentially allowing for a once-monthly dosing regimen. We believe MBX 4291 has the potential to be a safe and efficacious therapy that will help people achieve their weight loss goals and improve their overall health. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The active component of MBX 4291 has demonstrated
a similar activity profile and body weight loss in mice as the clinically-validated and approved weight-loss drug, tirzepatide, in <I>in vitro </I>studies. In the <I>in vitro </I>study in cells expressing the human
<FONT STYLE="white-space:nowrap">GLP-1</FONT> or GIP receptors, MBX 4291 active drug binds to <FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP receptors with the same activity as tirzepatide, as shown in the graphs below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B></B><B><I>In vitro</I></B><B> receptor binding of MBX 4291 active drug has similar activity in binding to the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP receptors as tirzepatide </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774g59i17.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The MBX 4291 active drug was compared to tirzepatide in diet-induced obesity, or DIO, rodent models, which are
commonly used to assess weight loss of agents being evaluated as clinical development candidates. In this study, eight mice were subcutaneously dosed daily with the MBX 4291 active drug and eight with tirzepatide for ten days and weight and food
intake were assessed each day. As shown in the graphs below, MBX 4291 active drug produced similar reductions in body weight and food intake as tirzepatide. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 4291 active drug produced similar reductions in body weight and food intake as </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>tirzepatide in DIO mouse model </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g80w10.jpg" ALT="LOGO">
 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As metabolism and albumin turnover rates in <FONT STYLE="white-space:nowrap">non-human</FONT> primates more closely resemble
humans than rodents, <FONT STYLE="white-space:nowrap">non-human</FONT> primates were used to assess the conversion of MBX 4291 to the active drug and overall pharmacokinetic profile. The figure below shows the pharmacokinetic profile observed in a
preclinical study of two non-human primates dosed with MBX 4291, and two dosed with tirzepatide. After a single, subcutaneous MBX 4291 injection, peak exposure to the biologically active component of MBX 4291 occurred
<FONT STYLE="white-space:nowrap">4-5</FONT> days later. This reflects the prodrug design, in which the biologically inactive prodrug converts into the active peptide in a time-dependent fashion, allowing an extended duration of action for the
biologically active component of the compound. In contrast, peak exposure to tirzepatide, which is itself the active compound, occurred within 24 hours of injection as shown in the below figure. In addition, the decline in exposure to the active
component of MBX 4291 was flatter than the more rapid reduction in tirzepatide exposures, which requires weekly dosing because of its loss in efficacy after one week. Based on this observed pharmacokinetic profile, which illustrates the prodrug and
fatty acylation mechanisms, we believe MBX 4291 has the potential to be dosed less frequently than the once weekly dosing required for tirzepatide in humans. The mean concentration of tirzepatide ranged from a maximum of 387 nM at 12 hours to 50.0
nM at 168 hours, whereas the mean concentration of the active component of MBX 4291 ranged from a maximum of 5.05 nM at 96 hours to 3.96 nM at 168 hours and 0.615 nM at the final measurable concentration at 456 hours. Based on the findings in the
figure below, it appears that less frequent dosing would necessarily require a higher dose, and possibly an adjustment based on the prodrug conversion and fatty acylation mechanisms. We believe the observed slower flatter decline in mean active drug
concentration may allow us to find a dosage for MBX 4291 that can maintain an appropriate active concentration of MBX 4291 within the therapeutic window for longer, without dosing once a week. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>MBX 4291 active drug demonstrated extended time-action profile compared to tirzepatide that </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>may support once-monthly dosing </B></P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g48m48.jpg" ALT="LOGO">
 </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently in the process of conducting
IND-enabling studies of MBX&nbsp;4291. IND submission is anticipated in the second quarter of 2025, with the goal of moving to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials in healthy obese
adults as soon as possible. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Manufacturing </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third
parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing if our product candidates receive marketing approval. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">As a key part of our product development approach, we aim to complete formulation work at an early stage of development,
such that our clinical studies are conducted with a formulation that has the potential for eventual <FONT STYLE="white-space:nowrap">scale-up.</FONT> We expect to continue to develop product candidates that can be produced cost-effectively at
contract manufacturing facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Commercial strategy </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We
intend to build a commercial infrastructure to support sales of any of our approved future drugs if and when we believe a regulatory approval of the first of such product candidates in a particular geographic market appears imminent. We expect to
manage sales, marketing and distribution through a combination of internal resources and third-party relationships. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In addition, we will opportunistically explore commercialization partnerships, particularly with entities that have strong
capabilities in geographies outside the United States and depending on the specific development path pursued. For more specialized indications, we would consider commercializing our product candidates independently. For example, we believe the
patient and prescriber populations for HP and PBH are relatively concentrated, with significant overlap, and can be addressed with a focused sales team. We also do not believe any existing pharmaceutical companies have significant expertise in the
commercialization of therapies in the PBH specific area. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will, however, continuously review our partnering strategy in the light of new clinical data and market understanding.
As our current and future drug candidates progress through clinical development, our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
commercial plans may change. Clinical data, the size of the development programs, the size of our target markets, the size of the requisite commercial infrastructure and manufacturing needs may
all influence our commercialization strategies. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Competition </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding
of disease etiology, intense competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
research institutions and governmental agencies and public and private research institutions. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new
therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates. This may include other peptide companies using similar approaches or other types of
therapies, such as small molecule, antibody, and/or protein therapies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In addition, many of our current or potential competitors, either alone or with their collaboration partners, have
significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and approved products than we do today. Mergers and acquisitions in the pharmaceutical and
biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. We also compete with these companies in recruiting, hiring, and retaining qualified scientific and management talent, establishing clinical trial sites and patient registration for clinical trials, obtaining
manufacturing slots at contract manufacturing organizations. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, particularly if they represent cures, have
fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for
ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their potential efficacy, safety,
convenience, and availability of reimbursement. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our most direct competitors with respect to HP include: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Ascendis Pharma currently has TransCon PTH (palopegteriparatide), an investigational once-daily injectable, in development
for HP in adults. Palopegteriparatide is approved in the EU for the treatment of HP (Yorvipath). TransCon PTH is approved in the EU and marketed in Germany and Austria as Yorvipath. TransCon PTH&#146;s NDA is under review by the FDA and has a PDUFA
date of August&nbsp;14, 2024. </P></TD></TR></TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Amolyt is developing <FONT STYLE="white-space:nowrap">AZP-3601</FONT> (eneboparatide), an investigational once-daily
injectable PTH receptor 1 agonist, for the treatment of HP in adults. Eneboparatide is currently in Phase 3 clinical development. On March&nbsp;14, 2024, Amolyt announced it had entered into a definitive agreement for AstraZeneca to acquire Amolyt.
The transaction is expected to close in the third quarter of 2024. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Extend Biosciences has underway a Phase 1 clinical trial investigating injectable EXT608, a long-acting <FONT
STYLE="white-space:nowrap">PTH(1-34)</FONT> using <FONT STYLE="white-space:nowrap">D-VITylation</FONT> technology. Extend announced positive interim results and that they intend to move directly into a Phase 2a clinical trial. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In 2015, Natpara was approved for once-daily subcutaneous injection as an adjunct to vitamin D and calcium in patients with
hypoparathyroidism. Natpara has not demonstrated an ability to reduce </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
incidences of hypercalcemia, hypocalcemia, or hypercalciuria relative to conventional therapy in treated patients, and was recalled in 2019 and will ultimately be discontinued by Takeda at the
end of 2024. Natpara is currently only available via a compassionate use program. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our most direct competitors with respect to PBH include: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In May 2020, Xeris Pharmaceuticals announced results from a Phase 2 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> glucagon injector but has not announced any updates on its PBH program since then.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Vogenx is developing mizagliflozin for treatment of PBH, and in June 2023 announced results from a Phase 2 single ascending
dose trial evaluating mizagliflozin in patients with PBH. In February, Vogenx they completed enrollment for its their second Phase 2 clinical trial. Mizagliflozin is designed to inhibit sodium dependent glucose cotransporter 1.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">In July 2024, Amylyx Pharmaceuticals Inc., or Amylyx, announced its acquisition of avexitide (exendin <FONT
STYLE="white-space:nowrap">9-39)</FONT> from Eiger BioPharmaceuticals, Inc., or Eiger, as a once or twice daily subcutaneous injection of a&nbsp;selective GLP-1 antagonist, which has received Breakthrough Therapy and Orphan Drug Designation from the
FDA. Eiger previously completed Phase 2 clinical trials for avexitide in 2021. Amylyx announced its plans to initiate a Phase&nbsp;3 trial in PBH in 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our most direct competitors with respect to obesity include: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Eli Lilly and Company has several obesity compounds approved and under development, including: tirzepatide&#151;expanding
indications and labeling of Zepbound (tirzepatide) via the potential addition of long-term usage data, as well as data showing long-term reductions in cardiovascular-related mortality. Orforglipron, an oral
<FONT STYLE="white-space:nowrap">(non-peptide)</FONT> <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist currently in phase 3 trials. Retatrutide, a <FONT STYLE="white-space:nowrap">tri-agnoist</FONT> targeting <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP and glucagon currently in Phase 3 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Novo Nordisk has several obesity compounds approved and under development, including: semaglutide &#150; expanding
indications and labeling of Wegovy (semaglutide). Novo received FDA approval on March&nbsp;8, 2024 for reducing the risk of heart attacks, strokes and cardiovascular-related death in patients with heart disease and who are overweight or obese.
Amycretin, a fusion peptide, that acts on <FONT STYLE="white-space:nowrap">GLP-1</FONT> as well as amylin receptors expected to enter Phase 2 clinical trials in H2 2024 with both injectable and oral formulations being evaluated. CagriSema, a
combination of semaglutide and cagrilinitide, a dual amylin and calcitonin receptor agonist, administered as a single, once-weekly injection currently in Phase 3 clinical development. NN9541 a potential once-weekly oral <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> has completed Phase 1 clinical development and will be moving into Phase 2 clinical development as an injectable. NNC0480-0389, a potential
once-weekly injectable GIP receptor agonist to be <FONT STYLE="white-space:nowrap">co-administered</FONT> with semaglutide has completed Phase 1 clinical development. <FONT STYLE="white-space:nowrap">INV-202</FONT> (NN9441) and <FONT
STYLE="white-space:nowrap">INV-347</FONT> are two potential once-daily, oral cannabinoid <FONT STYLE="white-space:nowrap">receptor-1</FONT> (CB1R) inverse agonists currently in Phase 2 clinical development. INV 202 (NN9441) and <FONT
STYLE="white-space:nowrap">INV-347</FONT> were acquired by Novo in late 2023 through their acquisition of Inversago Pharma. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Amgen is developing <FONT STYLE="white-space:nowrap">AMG-133</FONT> (maridebart cagraglutide), a fused/conjugated molecule
combining a <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist with a GIP receptor antagonist, as a potential once-monthly injectable currently in Phase 2 clinical development. <FONT STYLE="white-space:nowrap">AMG-786</FONT> is an oral
candidate with an undisclosed target currently in Phase 1 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Carmot Therapeutics, recently acquired by Roche, is developing <FONT STYLE="white-space:nowrap">CT-868,</FONT> <FONT
STYLE="white-space:nowrap">CT-388,</FONT> and <FONT STYLE="white-space:nowrap">CT-996</FONT> for obesity (with or without type 1 or type 2 diabetes). <FONT STYLE="white-space:nowrap">CT-388</FONT> is a potential weekly, injectable <FONT
STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist.</FONT> <FONT STYLE="white-space:nowrap">CT-868</FONT> is being targeted for obesity with type 1 diabetes and is a once-daily injectable and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
<FONT STYLE="white-space:nowrap">CT-996</FONT> is a potential once-daily oral for type 2 diabetes and obesity. Both <FONT STYLE="white-space:nowrap">CT-388</FONT> and <FONT
STYLE="white-space:nowrap">CT-868</FONT> are in Phase 2 clinical development and CT996 is in Phase 1 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Pfizer is developing danuglipron, a potential twice-daily oral <FONT STYLE="white-space:nowrap">(non-peptide)</FONT> <FONT
STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist currently in Phase 3 clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Viking Therapeutics is developing <FONT STYLE="white-space:nowrap">VK-2735,</FONT> a potential once-weekly subcutaneous
injectable <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> currently in Phase 2 clinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Zealand Pharma is developing 3 obesity compounds: petrenlintide, a long-acting, once-weekly amylin analog currently in
Phase 1b clinical development; dapiglutide a long-acting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GLP-1/GLP-2R</FONT></FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> in Phase 2 clinical development; and
survodutide, a long-acting once-weekly injectable <FONT STYLE="white-space:nowrap">GLP-1/glucagon</FONT> receptor <FONT STYLE="white-space:nowrap">co-agonist</FONT> currently in Phase 2 clinical development. Survodutide was <FONT
STYLE="white-space:nowrap">co-invented</FONT> by Boehringer Ingelheim who is leading development of the candidate. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>License agreement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Indiana University Research and Technology Corporation Exclusive License Agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2020, we entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation, or IURTC, a
<FONT STYLE="white-space:nowrap">non-profit</FONT> corporation organized under the laws of the State of Indiana, represented by The Trustees of Indiana University, or IU, pursuant to which we have been granted an exclusive, royalty-bearing license
to certain IURTC patent rights, or the Licensed Intellectual Property, developed by Dr.&nbsp;DiMarchi and other collaborators, to further scientific research, for new product development, and for other applications in public interest, such license,
the IURTC License Agreement. In particular, we have been granted an exclusive, royalty-bearing license to make, have made, use, have used, offer to sell, have offered for sale, sell, have sold, import and have imported products that are covered by
the Licensed Intellectual Property, or Licensed Products, with the right to sublicense to third parties. IURTC and IU have retained the right to (i)&nbsp;practice and use the Licensed Intellectual Property for
<FONT STYLE="white-space:nowrap">non-commercial</FONT> educational, research, and patient care and treatment purposes, and (ii)&nbsp;permit other <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic entities to practice and use the
Licensed Intellectual Property for the same <FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes. Under the IURTC License Agreement, we agreed to&nbsp;use commercially reasonable efforts to develop, promote and sell Licensed Products in
accordance with the IURTC License Agreement and any applicable laws. The IURTC License Agreement leverages IURTC&#146;s expertise in peptide therapies as well as our scientific, clinical, and regulatory capabilities to accelerate the development of
peptide treatments for people with endocrine and metabolic disorders. MBX 2109, MBX 1416 and MBX 4291 are Licensed Products under the IURTC License Agreement. Any future product candidates developed pursuant to our sponsored research agreement with
IU or otherwise covered by the Licensed Intellectual Property may be subject to the IURTC License Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As initial consideration for the license, we paid IURTC
an immaterial issue fee. As additional consideration for the license, we are required to pay IURTC: (i)&nbsp;royalties with a rate based on net sales per calendar year; (ii)&nbsp;an annual maintenance fee of up to $0.1&nbsp;million beginning in the
first year in which the first commercial sale occurs; (iii)&nbsp;a mid-single digits percentage of any sublicensing revenue; and (iv)&nbsp;milestone payments in the event of successful achievement of specified development milestones up to an
aggregate of $0.4&nbsp;million. IURTC is also entitled to receive reimbursement for all patent prosecution and maintenance related expenses. Our tiered royalties are in the low single-digits on annual net sales of the Licensed Products. In the event
that we are required to pay a <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third party consideration for intellectual property owned or controlled by such <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third party that we or a
sublicensee licensed for the development of Licensed Products, we can deduct such amounts from the royalty payments up to a certain amount of the running royalties owed that year. The royalty term will terminate on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis as to each Licensed Product, until the expiration or termination of the last valid claim within the patent rights covering such Licensed Product
in that country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;5, 2024, we and IURTC entered into a fourth amendment to the IURTC License Agreement, or the Fourth
Amendment. The Fourth Amendment specifies IURTC is entitled to the receipt of additional clinical and regulatory milestones, as defined in the Fourth Amendment, up to an aggregate of $9.0&nbsp;million. Following the execution of the Fourth
Amendment, future remaining clinical and regulatory milestone payments in the IURTC License Agreement and all amendments total up to $9.3&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IURTC
License Agreement will expire at the expiration of the last of the patent rights covered in the IURTC License Agreement, unless terminated earlier by mutual agreement or by one of the parties. We may terminate the IURTC License Agreement with or
without cause upon ninety (90)&nbsp;days prior written notice to IURTC. IURTC may terminate the IURTC License Agreement if we commit a material breach of the IURTC License Agreement and fail to cure the breach within the respective cure period after
receipt of the notice of material breach or upon our failure to undertake certain activities in furtherance of commercial development goals. Upon termination of the IURTC License Agreement, all rights granted by IURTC will terminate and
automatically revert to IURTC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We strive to
protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from
third parties. We also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary and intellectual property position. We additionally may rely on regulatory and other protections afforded through data
exclusivity, market exclusivity and patent term extensions, where available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends in part upon our ability to obtain and maintain patent
and other proprietary protection for commercially important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our
trade secrets and operate without infringing valid and enforceable intellectual property rights of others. A discussion of risks relating to intellectual property is provided under the section titled &#147;Risk factors&#151;Risks related to our
intellectual property&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal,
scientific, and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee
that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims
of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our patent portfolio includes issued patents and pending patent applications exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> from IURTC relating to our
PEP technology and product candidates, and two pending U.S. provisional patent applications that are owned by us relating to MBX 2109. We do not currently own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued patents relating to any
of our product candidates and we also do not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued U.S. patents relating to our PEP technology or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to our PEP technology, as of July&nbsp;1, 2024, we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> from IURTC two issued patents, in Japan
and Mexico, with claims directed to composition of matter relating to peptide prodrugs with fatty acylation linked via a <FONT STYLE="white-space:nowrap">non-enzymatic</FONT> self-cleaving dipeptide, each with an expected expiration date of 2029,
not including any patent term adjustments or patent term extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to our MBX 2109 product candidate, as of July&nbsp;1, 2024, we exclusively <FONT
STYLE="white-space:nowrap">in-license</FONT> from IURTC a pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application and 12 foreign patent applications pending in Australia, Brazil, Canada, China, Europe, Israel, Japan,
South Korea, Mexico, New Zealand, Russia, and Singapore, with claims directed to composition of matter, pharmaceutical composition, and method of treatment relating to MBX 2109. Any patents that issue from these applications are expected to expire
in 2041, not including any patent term adjustment or patent term extensions that may be available. We also own two pending U.S. provisional patent applications with claims directed to dosage regimen relating to MBX 2109. Patent applications claiming
priority to these provisional applications, if issued, are expected to expire in 2044, not including any patent term adjustment or patent term extensions that may be available. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With regard to our MBX 1416 product candidate, as of July&nbsp;1, 2024, we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> from IURTC two pending U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, 13 foreign patent applications pending in Australia, Brazil, Canada, China, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Saudi Arabia, and Singapore, and an
international patent application with claims directed to composition of matter, pharmaceutical composition, and method of treatment relating to MBX 1416. Any patents that issue from these patent applications or claim priority to the international
patent application are expected to expire between 2042 and 2043, not including any patent term adjustment or patent term extensions that may be available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With
regard to our obesity portfolio including our MBX 4291 product candidate, as of July&nbsp;1, 2024, we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> from IURTC three pending U.S. provisional applications, including one with claims
directed to composition of matter, pharmaceutical composition, and method of treatment relating to MBX 4291. Patent applications claiming priority to this provisional application, if issued, are expected to expire in 2045, not including any patent
term adjustment or patent term extensions that may be available. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of individual patents depends upon the legal term of the patents in the countries in
which they are obtained. In most countries in which we file, the patent term is 20&nbsp;years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent term extension under the
Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the
expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval. Only one patent among those eligible for an extension may be extended, and only those claims covering an
approved product, a method for using it or a method of manufacturing it may be extended. Moreover, a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent
that covers an approved drug. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term
extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length
of such extensions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to patent protection, we also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret protection for our
proprietary information to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and our
confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to
our proprietary information. As a result, we may be unable to meaningfully protect our <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, and other proprietary information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and
market exclusivities. See &#147;&#151;Government regulation&#148; for additional information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Government regulation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and
import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the
expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Review and approval of drugs in the united states </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The failure to comply with
applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve
pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the U.S. Department of Justice or other governmental entities. In addition, an applicant may need to recall a
product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in compliance with the
FDA&#146;s good laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the FDA of an investigational new drug application, or IND, which must take effect before human clinical
trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approval by an institutional review board, or IRB, representing each clinical site before each clinical trial may be
initiated at that site; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCPs, to
establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparation and submission to the FDA of a new drug application, or NDA, and payment of user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or
components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">FDA review and approval of the NDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compliance with any post-approval requirements, including risk evaluation and mitigation strategies, or REMS, and
post-approval studies required by the FDA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before an applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of
the purity and stability of the manufactured drug substance or active pharmaceutical ingredient, or API, and the formulated drug or drug product, as well as <I>in vitro</I> and animal studies to assess the safety and activity of the drug for initial
testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term preclinical testing, such as animal tests of
reproductive adverse events, or AEs, and carcinogenicity, may continue after the IND is submitted. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>The IND and IRB processes </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for
FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND, applicants must submit a protocol for each clinical trial
and any subsequent protocol amendments. In addition, the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the
FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. The
FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing
investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold) may only resume after the FDA has notified the sponsor that the
investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND
requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with GCP, including review and approval by an independent ethics committee, or
IEC, and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials, as well as the quality and integrity of
the resulting data. FDA must also be able to validate the data from the study through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if necessary. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing
review of the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can
suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with
unexpected serious harm to patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a
data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. The FDA or the
sponsor may suspend or terminate a clinical trial at any time on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving
business objectives and/or competitive climate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of
Health, or NIH, for public dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Human clinical trials in support of an NDA </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP
requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted
under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Phase 1</I>. The drug is initially introduced into healthy human subjects or, in certain indications such as cancer,
patients with the target disease or<I> </I>condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine maximal dosage.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Phase 2</I>. The drug is administered to a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate<I> </I>the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><I>Phase 3</I>. The drug is administered to an expanded patient population, generally at geographically dispersed clinical
trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the
labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Post-approval studies, often referred to as Phase 4 studies, may be conducted after initial regulatory approval. These
studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Progress reports detailing the results of the
clinical trials must be submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be submitted to the FDA for any of the following:
serious and unexpected suspected adverse reactions; findings from other studies or animal or <I>in vitro</I> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious
suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s
initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and
the integrity of the clinical data submitted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional
information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the drug candidate and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Review of
an NDA by the FDA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical
trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one
or more indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain
exceptions and waivers are available for some of these fees. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA conducts a preliminary review of an NDA within 60 days of its receipt, before accepting the NDA
for filing, to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the
additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review.
The FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10 months from the date of filing, and applications for &#147;priority
review&#148; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the
applicant to address an outstanding deficiency identified by the FDA following the original submission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During its review of an NDA, the FDA typically will inspect
the facility or facilities where the product is or will be manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs),
finished drug product manufacturing, and control testing laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk
minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product,
seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans
for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and
the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a
panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fast track, breakthrough therapy, and priority review </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended to address an unmet medical need in the
treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment
of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may
initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a
Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#146;s time period goal for
reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data
emerging in the clinical trial process. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or
more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process;
providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical
trials in an efficient manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Third, the FDA may designate an NDA review for a priority review if it is for a product that treats a serious or life-threatening
disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the
proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial
reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to
direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from 10 months to six months. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accelerated approval pathway </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA may grant accelerated approval
to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely
to predict clinical benefit or on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit,
taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those
granted traditional approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement,
radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An
intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on
intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is
a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accelerated approval pathway is
most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs
rapidly. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory
studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical
trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period
after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post
this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely
manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>The FDA&#146;s decision on an NDA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On the basis of the FDA&#146;s evaluation
of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes
commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in
order for the FDA to reconsider the application. If a complete response letter is issued, the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the
applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have been addressed to the FDA&#146;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the
product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#146;s safety or effectiveness after approval, require testing and surveillance programs to monitor the product after
commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or
surveillance programs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Post-approval requirements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Drugs manufactured or
distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and
promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to
prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain marketed products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, drug
manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these
state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any
deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the
area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or
imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning or untitled letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved
indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be
subject to significant liability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA,
which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription
pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Hatch-Waxman amendments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the
information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.
This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section&nbsp;505(j) establishes an abbreviated
approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form,
strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug, or RLD. ANDAs are termed &#147;abbreviated&#148; because they are
generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as,
the innovator drug through <I>in vitro</I>, <I>in vivo</I>, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same amount of time as the innovator drug and can often be
substituted by pharmacists under prescriptions written for the reference listed drug. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-patent</FONT> exclusivity </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any applicable period of <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a new chemical entity, or
NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological
action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, which states the
proposed generic drug will not infringe one or more of the already approved product&#146;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the original
product approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDCA also provides for a period of three years of exclusivity for <FONT STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a
supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application or supplement.
This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication, but it generally would not protect the original, unmodified product from
generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; it only
prevents FDA from approving such ANDAs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A drug product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six
months to existing exclusivity periods&nbsp;for all formulations, dosage forms, and indications of the active moiety and to patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other
exclusivity protection&nbsp;and patent term,&nbsp;may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a
study,&nbsp;provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Hatch-Waxman patent certification and the <FONT STYLE="white-space:nowrap">30-month</FONT> stay </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#146;s product or
an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Upon submission
of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no patent information on the drug product that is the subject of the application has been submitted to the FDA;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such patent has expired; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the date on which such patent expires; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the drug product
for which the application is submitted. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except
where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking
approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV
certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in
response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application
until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#146;s favor or settled, or
such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV
certification, the NDA holder or patent owner(s) regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of
an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent litigation. If the drug has NCE exclusivity and
the ANDA is submitted four years after approval, the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires seven and a half years after approval of the innovator drug, unless the patent expires or there is a decision
in the infringement case that is favorable to the ANDA applicant before then. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Patent term restoration and extension </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent term restoration of up
to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the
submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of
14 years from the product&#146;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
within 60 days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark
Office, or USPTO, reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rest of the world regulation
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For other countries outside of the United States, such as those in Europe, Latin America or Asia, the requirements governing product development, the conduct of
clinical trials, product marketing, product licensing, pricing and reimbursement can vary from country to country. Failure to comply with applicable foreign regulatory requirements may subject sponsors, manufacturers or marketers of pharmaceutical
products to, among other things, fines, suspension or withdrawal of regulatory authorizations and approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other healthcare laws </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business operations and current and future
arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect
our ability to operate include, but are not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting,
receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease,
order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment,
and exclusion from government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, or FCA, which can be enforced through civil
&#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims
for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal
government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to
&#147;cause&#148; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the FCA. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal
statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any
materially false </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or
entity can be found guilty of violating these statutes without actual knowledge of the statutes or specific intent to violate them in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, imposes
requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health
information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal
penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs
associated with pursuing federal civil actions. Even when HIPAA does not apply, according to the Federal Trade Commission, or FTC, failing to take appropriate steps to keep consumers&#146; personal information secure constitutes unfair acts or
practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, 15 U.S.C. &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity
and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that
merits stronger safeguards; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which requires
manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to
payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals, and teaching hospitals, as well as ownership and investment
interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate
and timely manner to government programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales
representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be
subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Coverage and reimbursement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States and markets in other
countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product
candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care
organizations, provide coverage, and establish adequate reimbursement levels for, the product. Factors payors consider in determining coverage and reimbursement are based on whether the product is: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug
products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay
for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage
costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order
to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private
health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product
is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be
approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly
from payor to payor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a
focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products,
government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for
substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from
countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the
level of reimbursement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average
sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare
programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved
products. Even if we do receive a favorable coverage determination for approved products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the U.S. Centers for Medicare&nbsp;&amp;
Medicaid Services, or CMS, may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial
products, which has resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to
government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to
other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the European Union, pricing and
reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the
cost-effectiveness of a particular product candidate to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU
Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for
a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control
prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to
manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement
has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no
assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Current and future U.S. healthcare reform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the U.S., there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. For
example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including
those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the
average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
70&nbsp;percent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers
who sell &#147;branded prescription drugs&#148; to specified federal government programs. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There has been increasing legislative and enforcement
interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to
drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. President Biden has issued multiple
executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will
test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#146;s accelerated approval pathway. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, on December&nbsp;2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan
sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The Inflation Reduction Act of 2022, or IRA, delayed implementation of this rule
to January&nbsp;1, 2032. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of
2% per fiscal year, and, due to subsequent legislative amendments to the statute, will remain in effect until 2031. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">On May&nbsp;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework
for certain patients to access certain investigational new drug products that have completed a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without
obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. Due to the Statutory
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Pay-As-You-Go</FONT></FONT></FONT> Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent
legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices
we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our
product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IRA includes
several provisions that may impact our business to varying degrees, including provisions that create a $2,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D beneficiaries, impose
new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, and require
companies to pay rebates to Medicare for drug prices that increase faster than inflation. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which
the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The drug price negotiation provisions of the
IRA are subject to ongoing constitutional challenges. The outcome of these challenges and the effect of IRA on our business and the healthcare industry in general is not yet known. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Individual states have also been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other
health care programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although a number of these and other proposed measures may require authorization through additional
legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Human capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March&nbsp;1, 2024, we had 29 full-time
employees, of which eight have M.D. or Ph.D. degrees. Within our workforce, 17 employees are engaged in research and development and 12 are engaged in general and administrative. We have never had a work stoppage, and none of our employees is
represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and
integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase
shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Facilities
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We lease our office space, which consists of 6,493 square feet located in Carmel, Indiana. Our lease expires on December&nbsp;31, 2025, with the option to renew
for an additional three-year period. We also lease 1,580 square feet of laboratory space in Indianapolis, Indiana, under a lease that expires on December&nbsp;1, 2024, with the option to renew for an additional
<FONT STYLE="white-space:nowrap">six-month</FONT> period. We believe our current facilities are sufficient to meet our needs until the expiration of our leases. To meet the future needs of our business, we may lease additional or alternate space. We
believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Legal proceedings </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may become involved in litigation or
other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.
Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_12"></A>Management </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth information about our executive officers and directors as of the date of this prospectus. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Position(s)</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Salomon Azoulay, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl Gordon, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Corporate Governance Committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a biographical summary of the experience of our executive officers and
directors. There are no family relationships among any of our executive officers or directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Kent Hawryluk</I> is one of our <FONT STYLE="white-space:nowrap">co-founders</FONT> and has served as our President and Chief Executive Officer since January 2020 and
as a member of our board of directors since April 2019. Mr.&nbsp;Hawryluk has also served as a partner of Twilight Venture Partners, LLC, a private seed- and early-stage life science venture capital fund, since January 2003. Prior to joining MBX,
Mr.&nbsp;Hawryluk was <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Business Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), an RNA therapeutics company, from January 2013 to December 2019. Previously, he served as <FONT
STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer of MB2 LLC (subsequently acquired by Novo Nordisk Inc.), a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. Mr.&nbsp;Hawryluk <FONT
STYLE="white-space:nowrap">co-founded</FONT> Marcadia Biotech Inc. (subsequently acquired by F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG) and served as its Chief Business Officer and Vice President, Business Development from
January 2006 to April 2011. Mr.&nbsp;Hawryluk served as a director of Gemphire Therapeutics Inc. (Nasdaq: GEMP), a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. Mr.&nbsp;Hawryluk holds a B.A. from Princeton
University, an MBA from Kellogg School of Management at Northwestern University, and an M.S. in Biology from Purdue University. Our board of directors believes that Mr. Hawryluk is qualified to serve as a director because of his experience founding
and developing biopharmaceutical companies and his extensive management experience in the biopharmaceutical industry. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Salomon (Sam) Azoulay, M.D.</I>, has
served as our Chief Medical Officer since June 2024. Prior to joining MBX, Dr.&nbsp;Azoulay served as Consulting Chief Executive Officer of Nervosave Therapeutics from September 2023 to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
June 2024. Prior to that, Dr. Azoulay served as Chief Medical Officer at Sumitovant Biopharma Ltd., following Roivant Sciences Ltd.&#146;s, or Roivant, strategic spin-out of multiple portfolio
companies to create an independent subsidiary of Sumitomo Pharma Co. Ltd., from January&nbsp;2021 to July&nbsp;2023. Dr. Azoulay also previously served as Chief Medical Officer of Roivant from May&nbsp;2018 to December&nbsp;2020. Prior to Roivant,
he served at Pfizer for nearly 20 years in positions of increasing responsibility, culminating in his position as Chief Medical Officer of Pfizer Essential Health from September&nbsp;2013 to May&nbsp;2018. Dr. Azoulay serves as an advisor to the
board of directors of PharmStars. Dr.&nbsp;Azoulay earned his M.D., with a specialty in cardiology, from the University of Paris VI. He also holds a D.E.S.S. in Business Administration and Management from Sorbonne University. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Richard Bartram</I> has served as our Chief Financial Officer since April 2022. Prior to joining MBX, Mr.&nbsp;Bartram served as Chief Financial Officer at Esperion
Therapeutics, Inc., or Esperion, (Nasdaq: ESPR), a publicly-traded pharmaceutical company focused on the development and commercialization of therapies for patients with elevated <FONT STYLE="white-space:nowrap">LDL-C</FONT> cholesterol, from
January 2018 to April 2022. Mr.&nbsp;Bartram also served as Esperion&#146;s Vice President, Finance, from January 2015 to January 2018, and as Esperion&#146;s Controller from February 2013 to January 2015. Previously, Mr.&nbsp;Bartram served as a
public accountant at PricewaterhouseCoopers, LLP in its assurance practice. Mr.&nbsp;Bartram earned both a M.S. in Accounting and a B.A. in Accounting from Michigan State University and is a licensed Certified Public Accountant in the state of
Michigan. </P>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Tiba Aynechi, Ph.D.,</I> has served on our board of directors since November 2022. She has served as a General Partner of Norwest Venture Partners&#146; healthcare
team since December 2021 and previously, Dr.&nbsp;Aynechi served in various roles at Novo Holdings A/S, one of the top life sciences investment firms, from March 2010 to December 2021, most recently as senior partner. Dr.&nbsp;Aynechi currently
serves on the boards of directors of Spruce Biosciences Inc. (Nasdaq: SPRB), Rezo Therapeutics Inc., Avalyn Pharma Inc., Engrail Therapeutics, Inc. and Ray Therapeutics, Inc. She previously served on various public and private boards of directors
including iRhythm Technologies, Inc. (Nasdaq: IRTC) from May 2014 to April 2017, Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from October 2018 to August 2021, Nkarta, Inc. (Nasdaq: NKTX) from August 2015 to June 2022, Aristea Therapeutics, Inc. from
August 2018 to December 2021, Arcellx Inc., from July 2015 to November 2021, and MDLive Inc. from July 2018 to May 2021. Dr.&nbsp;Aynechi attended the University of California Irvine where she received a B.S. in Physics with a biomedical
concentration. She also holds a Ph.D. in Biophysics from the University of California San Francisco, where she also did her Postdoctoral Fellowship. Dr.&nbsp;Aynechi is also a published author of scientific articles and book chapters in rational
drug design. Our board of directors believes Dr. Aynechi is qualified to serve as a director because of her extensive experience in the biotechnology and pharmaceutical industries, including her expertise in handling a wide range of financing
transactions. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>James M.</I> <I>Cornelius</I> has served on our board of directors since September 2020. Mr.&nbsp;Cornelius is an accomplished global
biopharmaceutical leader as well as a recognized venture investor and philanthropist. Previously, he served as Chairman of the Board of Bristol Myers Squibb Co., or BMY, (NYSE: BMY) from February 2008 to May 2015, and as Chief Executive Officer from
September 2006 to March 2010. Mr.&nbsp;Cornelius served as Chairman of the Board of Mead Johnson Nutrition (subsequently acquired by Reckitt Benckiser) from December 2009 to June 2017. Mr.&nbsp;Cornelius served as Board Chairman and Chief Executive
Officer of Guidant Corporation (subsequently acquired by Boston Scientific Corporation (NYSE: BSX)), from November 2005 to April 2006. Previously, he was executive Chairman of the Board of Guidant Corporation and its senior executive starting from
September 1994 when the Company was formed within Eli Lilly and Co., or Eli Lilly, (NYSE: LLY). Mr.&nbsp;Cornelius was a member of Eli Lilly&#146;s Board of Directors and its Chief Financial Officer from 1983 until 1995. In addition, he has served
on the Board of Directors of a dozen private and public companies, including The Chubb Corporation, The DIRECTV Group and Given Imaging. Mr.&nbsp;Cornelius is currently Chairman of Cornelius Family Foundation and Cornelius Private Investments. He
earned a B.A. magna cum laude and M.B.A. from Michigan State University. Our board of directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
believes that Mr.&nbsp;Cornelius is qualified to serve as a director because of his extensive experience as a venture capitalist and his experience serving on multiple public boards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Carl L. Gordon, Ph.D.,</I> <I>CFA</I>, has served on our board of directors since July 2020. He has served as a founding member, Managing Partner, and <FONT
STYLE="white-space:nowrap">Co-Head</FONT> of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr.&nbsp;Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc.
(Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr.&nbsp;Gordon previously served on the boards of Alector,
Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics
Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc.
(formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr.&nbsp;Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The
Rockefeller University. Our board of directors believes that Dr.&nbsp;Gordon is qualified to serve as a director because of his venture capital experience, expertise in the scientific field of molecular biology and financial credentials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Patrick Heron</I> has served on our board of directors since July 2020. He has been a Managing Partner of Frazier&#146;s Life Sciences team since August 1999. Prior
to that, Mr.&nbsp;Heron helped develop McKinsey&nbsp;&amp; Company&#146;s west coast biotechnology consulting practice. He currently serves on the boards of directors of HilleVax, Inc. (Nasdaq: HLVX) since September 2021 and Mirum Pharmaceuticals,
Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr.&nbsp;Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December
2023, and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck&nbsp;&amp; Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021,
Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to March 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage
drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and
Morehead Scholar. Our board of directors believes that Mr.&nbsp;Heron is qualified to serve as a director because of his investment experience in the biopharmaceutical industry as well as his experience on numerous public and private company boards
of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Edward T. Mathers</I> has served on our board of directors since July 2020. He has been a Partner at New Enterprise Associates, a venture capital
firm, since August 2008. Mr.&nbsp;Mathers currently serves on the boards of directors of Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), Inozyme Pharma, Inc. (Nasdaq: INZY), Synlogic, Inc. (Nasdaq: SYBX), Trevi Therapeutics, Inc. (Nasdaq: TRVI), Reneo
Pharmaceuticals, Inc. (Nasdaq: PHM), and Senti Biosciences, Inc. (Nasdaq: XBIO), as well as a number of private life sciences companies. Mr.&nbsp;Mathers previously served on the board of directors of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from
November 2019 to September 2022, Akouos, Inc. (Nasdaq: Formerly AKUS, acquired by Eli Lilly) from October 2017 to December 2022, Ra Pharmaceuticals, Inc. until its acquisition by UCB S.A. in April 2020 and Liquidia Corporation (Nasdaq: LQDA) until
May 2019. Prior to joining New Enterprise Associates, Mr.&nbsp;Mathers served in various corporate development roles at MedImmune, Inc., a biotechnology company that was acquired by AstraZeneca PLC in 2007, culminating in the position of Executive
Vice President, Corporate Development and Venture. In this role, he also led the company&#146;s venture capital subsidiary, MedImmune Ventures, Inc. Prior to that, Mr.&nbsp;Mathers was Vice President, Marketing and Corporate Licensing and
Acquisitions at Inhale Therapeutic Systems, Inc., a biopharmaceutical company, which is now known as Nektar Therapeutics, Inc. (Nasdaq: NKTR). Previously, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
15 years, Mr.&nbsp;Mathers was at Glaxo Wellcome, Inc., where he held sales and marketing positions of increasing responsibility. Mr.&nbsp;Mathers received a B.S. in chemistry from North Carolina
State University. Our board of directors believes that Mr.&nbsp;Mathers is qualified to serve as a director because of his senior executive roles in publicly traded life sciences companies, his extensive experience as a venture capitalist, and his
service on the boards of directors of numerous biotechnology companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Ora Pescovitz, M.D.</I><B>,</B><I></I> has served on our board of directors since April
2022. She has served as President of Oakland University since July 2017 and currently serves on the board of directors of Priority Health and Transformative AI Limited. Previously, Dr.&nbsp;Pescovitz served as Senior Vice President and U.S. Medical
Leader for Lilly Biomedicines at Eli Lilly from October 2014 to June 2017. From April 2012 to February 2014, she served on the board of directors of Life Technologies Corporation (Nasdaq: Formerly LIFE, acquired by Thermo Fisher Scientific Inc.
(NYSE: TMO)). From May 2009 to October 2014, she was the University of Michigan&#146;s first female Executive Vice President for Medical Affairs and Health System Chief Executive Officer. Dr.&nbsp;Pescovitz is a nationally recognized pediatric
endocrinologist and researcher who has published 180 papers and books, and received numerous awards for her research and teaching. Dr Pescovitz received her B.M.Sc. in the Honors Program in Medical Education at Northwestern University and earned her
M.D. from the Northwestern University Feinberg School of Medicine, where she earned Distinguished Alumni Awards from both the Feinberg School of Medicine and Northwestern University. Dr.&nbsp;Pescovitz was elected to the National Academy of
Medicine.&nbsp;Our board of directors believes that Dr.&nbsp;Pescovitz is qualified to serve as a director because of her extensive academic, business and medical experience in the health care fields and her service on
<FONT STYLE="white-space:nowrap">non-profit</FONT> boards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Steven Ryder, M.D.,</I><B> </B>has served on our board of directors since January 2024. Dr.&nbsp;Ryder
has served as the Chief Medical Officer of Rallybio Corporation (Nasdaq: RLYB) since January 2019. Previously, Dr.&nbsp;Ryder was the Chief Development Officer at Alexion Pharmaceuticals, Inc. (Nasdaq: Formerly ALXN, acquired by AstraZeneca PLC)
from July 2013 to December 2018 and was the founding President of Astellas Pharma Global Development, Inc. from April 2008 to April 2013. Dr.&nbsp;Ryder also worked at Pfizer Inc. (Nasdaq: PFE) for 21 years where he held positions of increasing
responsibility, including senior vice president of Global Research and Development. He has also held board positions at Reata Pharmaceuticals, Inc. (Nasdaq: Formerly RETA, acquired by Biogen Inc. (Nasdaq: BIIB)) and Levo Therapeutics, Inc.
Dr.&nbsp;Ryder earned his Doctor of Medicine from the Icahn School of Medicine at Mount Sinai. Our board of directors believes that Dr.&nbsp;Ryder is qualified to serve as a director because of his extensive drug development experience at
biopharmaceutical companies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board composition </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors
currently consists of eight directors, each of whom is a member pursuant to the board composition provisions of our current second amended and restated certificate of incorporation and agreements with our stockholders, which agreements are described
in the section of this prospectus entitled &#147;Certain relationships and related person transactions.&#148; These board composition provisions will terminate upon the closing of this offering. Upon the termination of these provisions, there will
be no further contractual obligations regarding the election of our directors. Our nomination and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background
of nominees. Our nomination and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who will further the interests of our stockholders through their established
record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences and expertise
relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until their earlier resignation or removal. Our third amended and restated certificate of incorporation and amended and restated
bylaws that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
will become effective immediately prior to the closing of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part, respectively, also provide
that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our stockholders would be entitled to cast in an annual election of
directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Staggered board </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In accordance with the terms of our third amended and
restated certificate of incorporation and our amended and restated bylaws that will become effective immediately prior to the closing of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part,
respectively, our board of directors will be divided into three staggered classes of directors and each director will be assigned to one of the three classes. At each annual meeting of the stockholders, one class of directors will be elected for a
three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the
years 2025 for Class&nbsp;I directors, 2026 for Class&nbsp;II directors and 2027 for Class&nbsp;III directors. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;I directors will be&#8195;&#8195;&#8195;&#8195;; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;II directors will be&#8195;&#8195;&#8195;&#8195;; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our Class&nbsp;III directors will be&#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our third amended and restated certificate of incorporation and amended and restated bylaws will provide that the number of our directors shall be fixed from time to
time by a resolution of the majority of our board of directors. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The division of our board of directors into three classes with staggered three-year terms may
delay or prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Director independence </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; Under the Nasdaq listing rules, independent directors must
comprise a majority of a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit,
compensation and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule
<FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not
have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (i)&nbsp;accept, directly or indirectly, any
consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be
considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining
whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the
director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In&#8195;&#8195;&#8195;&#8195;2024, our board of
directors undertook a review of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and
affiliations, including family relationships, our board of directors has determined that all members of our board of directors, except P. Kent Hawryluk, are independent directors, including for purposes of Nasdaq and the SEC rules. In making that
determination, our board of directors considered the relationships that each director has with us and all other facts and circumstances the board of directors deemed relevant in determining independence, including the potential deemed beneficial
ownership of our capital stock by each director, including <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that are affiliated with certain of our major stockholders. Upon the completion of this offering, we expect that the
composition and functioning of our board of directors and each of our committees will comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC. There are no family relationships among any of our executive officers
and directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to adopt a policy, subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part,
that outlines a process for our securityholders to send communications to the board of directors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Board committees </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors will establish an audit committee, a compensation committee and a nomination and corporate governance committee, each of which will operate
pursuant to a charter to be adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which this prospectus forms a part. We believe that the composition and functioning of all of our committees
will comply with the applicable requirements of Nasdaq, the Sarbanes-Oxley Act of 2002 and SEC rules and regulations that will be applicable to us. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following the consummation of this offering, the full text of our audit committee charter, compensation committee charter and nomination and corporate governance
committee charter will be posted on the investor relations portion of our website at https://www.mbxbio.com. We do not incorporate the information contained on, or accessible through, our corporate website into this prospectus, and you should not
consider it a part of this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Audit committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the
effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist of &#8195;&#8195;&#8195;&#8195; and will be chaired by&#8195;&#8195;&#8195;&#8195;. The functions of the audit committee will
include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq listing rules.
Our board of directors has determined that &#8195;&#8195;&#8195;&#8195; qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC regulations. In making this determination, our board of directors considered
the nature and scope of experience that &#8195;&#8195;&#8195;&#8195; has previously had with public reporting companies, including service as &#8195;&#8195;&#8195;&#8195;. Our board of directors has determined that all of the directors that will
become members of our audit committee upon the effectiveness of the registration statement of which this prospectus forms a part satisfy the relevant independence requirements for service on the audit committee set forth in the rules of the SEC and
the Nasdaq listing rules. Both our independent registered public accounting firm and management will periodically meet privately with our audit committee. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compensation committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness of the registration
statement of which this prospectus forms a part, our compensation committee will consist of &#8195;&#8195;&#8195;&#8195;, and will be chaired by&#8195;&#8195;&#8195;&#8195;. The functions of the compensation committee will include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such
evaluation (i)&nbsp;reviewing and determining the cash compensation of our Chief Executive Officer and (ii)&nbsp;reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and when
required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each member of our compensation committee will be a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as
defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Nominating and corporate governance committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the effectiveness
of the registration statement of which this prospectus forms a part, our nominating and corporate governance committee will consist of &#8195;&#8195;&#8195;&#8195;and will be chaired by &#8195;&#8195;&#8195;&#8195;. The functions of the nominating
and corporate governance committee will include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate
skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation committee interlocks and insider participation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the
members of our compensation committee is, or has at any time during the prior three years been, one of our officers or employees. None of our executive officers currently serve, or have in the past fiscal year served, as a member of the board of
directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Code of business conduct and ethics </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors intends to adopt,
subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, a Code of Business Conduct and Ethics in connection with this offering. The Code of Business Conduct and Ethics will apply to all of
our employees, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics and our Code
of Ethics on our website identified below. Upon the completion of this offering, the full text of our Code of Business Conduct and Ethics and our Code of Ethics will be posted on our website at https://www.mbxbio.com. The inclusion of our website
address in this prospectus does not include or incorporate by reference the information on our website into this prospectus, and you should not consider that information a part of this prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and indemnification agreements </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by
Delaware law, provisions in our third amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the closing of this offering and upon the effectiveness of the registration
statement of which this prospectus forms a part, respectively, limit or eliminate the personal liability of directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when
acting on behalf of the corporation, a director and or officer exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director or officer will not be personally liable to us or
our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director or officer&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief,
such as injunctive relief or rescission. These provisions will not alter a director or officer&#146;s liability under other laws, such as the federal securities laws or other state or federal laws. Our third amended and restated certificate of
incorporation that will become effective upon the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As permitted by Delaware law, our amended and restated bylaws to be effective upon the effectiveness of the registration statement will provide that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability of our
directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other
agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained such insurance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the indemnification that will be provided for in our third amended and restated certificate of
incorporation and amended and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware
General Corporation Law. These indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts
incurred by a director or executive officer in any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that
these provisions and agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This description of the
indemnification provisions of our third amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as
an exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act may be
permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act,
and is, therefore, unenforceable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought,
nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_13"></A>Executive compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding our future
compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As an emerging growth company, we have opted to comply with the executive compensation disclosure </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">rules applicable to &#147;smaller reporting companies,&#148; as such term is defined in the rules promulgated under the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities Act. The compensation provided to our named executive officers for the fiscal year ended December&nbsp;31, 2023 is detailed in the 2023 Summary Compensation
Table, and accompanying footnotes and narrative that follow. Our named executive officers, or NEOs, for the fiscal year ended December&nbsp;31, 2023 are: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Peter Kent Hawryluk, our President and Chief Executive Officer and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Richard Bartram, our Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, the compensation of our named executive officers has consisted of a combination of base salary, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">cash bonuses, and equity interests in the form of stock awards and option awards. Our named executive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">officers, like all of our full-time employees, are eligible to participate in our health and welfare benefit plans </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">and 401(k) plan. As we transition from a private company to a publicly traded company, we intend to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">evaluate our compensation values and philosophy and compensation plans and arrangements as </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">circumstances require. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 Summary compensation table </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during the fiscal year
ended December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name and principal position</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>awards(1)&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>incentive plan<BR>compensation(2)&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peter Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,290,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,862,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value of stock options granted to the named executive officers during 2023, as calculated in accordance with Financial Accounting Standards
Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. Such grant date value does not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date fair value of the
awards in this column are described in Note 12&#151;Stock-Based Compensation to our financial statements included elsewhere in this prospectus. These awards are described in more detail under &#147;Narrative Disclosure to Summary Compensation
Table&#151;Equity-Based Compensation&#148; below. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported represent annual bonuses under our annual cash bonus program based on achievement of company performance and individual performance during the year ended December&nbsp;31, 2023. For more information
on these bonuses, see description of the annual performance bonuses under the section titled &#147;Narrative disclosure to summary compensation table&#151;Annual cash bonuses&#148; below. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Narrative disclosure to summary compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2023 base salaries
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named executive officers each receive a base salary to compensate them for services rendered to our Company. The base salary payable to each named
executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role, and responsibilities. Base salaries may be adjusted from time to time to realign salaries with market levels
after taking into account individual responsibilities, performance, and experience. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, the annual base salary for Mr.&nbsp;Hawryluk and Mr.&nbsp;Bartram were $420,000 and
$425,000, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2023 cash bonuses </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the fiscal year
ended December&nbsp;31, 2023, each of the named executive officers was eligible to earn an annual cash bonus determined by our board of directors in its reasonable and sole discretion, based on the individual performance and achievement of certain
corporate performance milestones, including clinical milestones, research and development goals, and business development and organizational goals.. The target annual bonus for each of our named executive officers for the fiscal year ended
December&nbsp;31, 2023 was equal to the percentage of the executive&#146;s respective annual base salary specified below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Target&nbsp;bonus<BR>percentage</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peter Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Equity-based compensation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we
do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and
help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. During
the fiscal year ended December&nbsp;31, 2023, we granted stock options to our named executed officers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For additional information regarding outstanding equity
awards held by our named executive officers as of December&nbsp;31, 2023, see the &#147;Outstanding equity awards at 2023 fiscal year end&#148; table below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Perquisites or personal benefits </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not provide perquisites or
personal benefits to our employees with an aggregate equal to or greater than $10,000. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>401(k) plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain a retirement savings plan for our employees, or 401(k) plan, that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code,
and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. U.S. employees are generally eligible to participate in the 401(k) plan, subject to certain criteria. Participants may make <FONT
STYLE="white-space:nowrap">pre-tax</FONT> and certain <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code.
Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up</FONT> contributions. Participant contributions are held in trust as required by law. We do
not provide matching or discretionary contributions under the 401(k) Plan at this time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Outstanding equity awards at fiscal 2023&nbsp;year end </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2023 </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option&nbsp;awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock&nbsp;awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Vesting<BR>commencement<BR>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>exercise<BR>price&nbsp;($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Option<BR>expiration<BR>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Number&nbsp;of<BR>shares or<BR>units of<BR>stock that<BR>have not<BR>vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Market<BR>value of<BR>shares or<BR>units of<BR>stock&nbsp;that<BR>have not<BR>vested<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="28" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peter Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/15/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,636,580</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/14/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,757,720</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,618</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/12/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,688</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/8/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,326</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/15/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">952,260</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/14/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634,840</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/19/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="28" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each stock option award is subject to the terms of our 2019 Stock Option and Grant Plan, as amended, or the 2019 Plan. Each stock option is subject to acceleration in the event of a sale event (as defined in the 2019
Plan), subject to the named executive officer&#146;s service relationship with the Company at the time of the sale event, as described below under &#147;Executive compensation arrangements&#151;Employment arrangements in place prior to the offering
for named executive officers.&#148; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the fair market value of a share of our common stock as of December&nbsp;31, 2023. The fair market value is based on the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;, per share,
which is the midpoint of the price range set forth on the cover page of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. All the shares subject to this option vest in 48 equal monthly installments following the
vesting commencement date, in each case, subject to Mr.&nbsp;Hawryluk&#146;s continuous service relationship with the Company through each applicable vesting date. As of December&nbsp;31, 2023, 719,715 shares of common stock underlying this option
had vested, with an unvested balance of 7,916,865 shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the 5,757,720 shares originally subject to this option were exercisable as of the date of grant, subject to a right of repurchase that lapses as the shares vest, and Mr.&nbsp;Hawryluk exercised 2,000,000 shares.
All the shares subject to this option vest in 48 equal monthly installments following the vesting commencement date, in each case, subject to Mr.&nbsp;Hawryluk&#146;s continuous service relationship with the Company through each applicable vesting
date. As of December&nbsp;31, 2023, (i) Mr.&nbsp;Hawryluk has exercised 2,000,000 shares subject to the option, of which 440,618 shares remain unvested and (ii)&nbsp;all 3,757,720 unexercised were unvested. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents shares of restricted stock acquired upon the early exercise of a stock option, subject to a right of repurchase that lapses as the shares vest. Such shares vest in 48 equal monthly installments following the
vesting commencement date, in each case, subject to Mr.&nbsp;Hawryluk&#146;s continuous service relationship with the Company through each applicable vesting date. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. All the shares subject to this option vest in 48 equal monthly installments following the
vesting commencement date, in each case, subject to Mr.&nbsp;Bartram&#146;s continuous service relationship with the Company through each applicable vesting date. As of December&nbsp;31, 2023, 79,355 shares of common stock underlying this option had
vested, with an unvested balance of 872,905 shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. 25% of the shares subject to the stock option vested on the first anniversary following the
vesting commencement date, and the remaining 75% of the shares subject to the stock option vest in 36 equal monthly installments thereafter, subject to Mr.&nbsp;Bartram&#146;s continuous service relationship with the Company through each applicable
vesting date. As of December&nbsp;31, 2023, 171,935 shares of common stock underlying this option had vested, with an unvested balance of 462,905 shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares subject to this stock option are early exercisable, subject to a right of repurchase that lapses as the shares vest. 25% of the shares subject to the stock option vested on the first anniversary following the
vesting commencement date, and the remaining 75% of the shares subject to the stock option vest in 36 equal monthly installments thereafter, subject to Mr.&nbsp;Bartram&#146;s continuous service relationship with the Company through each applicable
vesting date. As of December&nbsp;31, 2023, 468,750 shares of common stock underlying this option had vested, with an unvested balance of 656,250 shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive compensation arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into executive employment agreements with each of our named executive officers. Each employment agreement provides for
<FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and the compensation and benefits described below. In connection with this offering, we intend to enter into a new employment agreement with our named executive officers that
will be effective as of the closing of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Employment arrangements in place prior to the offering for named executive officers </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Peter Kent Hawryluk </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On July&nbsp;8, 2020, we entered into an executive
employment agreement with Mr.&nbsp;Hawryluk, or the Hawryluk Employment Agreement, for the position of President and Chief Executive Officer. The Hawryluk Employment Agreement provides for Mr.&nbsp;Hawryluk&#146;s
<FONT STYLE="white-space:nowrap">at-will</FONT> employment. Mr.&nbsp;Hawryluk&#146;s current annual base salary is $460,000, and he is eligible to receive an annual discretionary bonus with an annual target amount of 40% of his current annual base
salary. Mr.&nbsp;Hawryluk is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a
termination of Mr.&nbsp;Hawryluk&#146;s employment by us without Cause (other than due to death or in connection with a bankruptcy, assignment for the benefit of creditors or winding up of the Company) or by Mr.&nbsp;Hawryluk for Good Reason, each,
as such terms are defined in the Hawryluk Employment Agreement and collectively, a Qualifying Termination, at any time, subject to (i)&nbsp;signing a general release of claims in favor of the Company and (ii)&nbsp;not breaching any of the
post-employment covenants and contractual obligations to the Company, collectively, the Severance Conditions, Mr.&nbsp;Hawryluk shall be entitled to receive (A)&nbsp;continued payment of his then-current base salary for a period of twelve
(12)&nbsp;months following termination, (B)&nbsp;accelerated vesting of the unvested portion of any outstanding time-based equity award in an amount equal to the amount that would have vested had Mr.&nbsp;Hawryluk remained employed with us through
the twelve (12)&nbsp;month anniversary following the date of termination, and (C)&nbsp;if Mr.&nbsp;Hawryluk was participating in the Company&#146;s group health plan immediately prior to the termination date and timely elects continuation coverage
under COBRA, a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Mr.&nbsp;Hawryluk had Mr.&nbsp;Hawryluk remained employed by us, or the Hawryluk COBRA Premium, until the
earliest of (a)&nbsp;the twelve (12)&nbsp;month anniversary following the date of termination; (b)&nbsp;Mr.&nbsp;Hawryluk&#146;s eligibility for group health plan benefits under any other employer&#146;s group health plan; or (c)&nbsp;the cessation
of Mr.&nbsp;Hawryluk&#146;s continuation rights under COBRA; provided, however, if the Company determines that the Hawryluk COBRA Premium would result in a violation of applicable law, then the Hawryluk COBRA Premium shall be converted into a
taxable cash payment and will be paid on a monthly basis to Mr.&nbsp;Hawryluk during the same period set forth in (a)-(b), provided that such cash payment will be grossed up by the Company in an amount that results in Mr.&nbsp;Hawryluk receiving,
after reductions for tax withholdings, the full Hawryluk COBRA Premium for such period before any reductions for tax withholding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Hawryluk Employment Agreement
also provides that, upon a sale event (as defined in the 2019 Plan), provided Mr.&nbsp;Hawryluk remains employed by the Company as of the closing date of the sale event, 100% of all outstanding equity awards held by Mr.&nbsp;Hawryluk will be fully
accelerated and vested on such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Hawryluk Employment Agreement further provides that, in the event the amount of any compensation by the Company to or for
the benefit of Mr.&nbsp;Hawryluk under the Hawryluk Employment Agreement would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such compensation shall be reduced (but not below zero) so that the sum of the compensation
shall be $1.00 less than the amount at which the NEO becomes subject to the excise tax imposed under Section&nbsp;4999 of the Code; provided that such reduction shall only occur if such reduction would result in a higher net <FONT
STYLE="white-space:nowrap">after-tax</FONT> benefit to Mr.&nbsp;Hawryluk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Mr.&nbsp;Hawryluk has entered into an Employee Confidentiality, Assignment, and Noncompetition Agreement that contains
various restrictive covenants, including confidentiality and nonsolicitation. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Richard Bartram </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On March&nbsp;16, 2022, we entered into an executive employment agreement with Mr.&nbsp;Bartram, or the Bartram Employment Agreement, for the position of Chief Financial
Officer. The Bartram Employment Agreement provides for Mr.&nbsp;Bartram&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Mr.&nbsp;Bartram&#146;s current annual base salary is $442,000, and he is eligible to receive an annual
discretionary bonus with an annual target amount of 40% of his current annual base salary. Mr.&nbsp;Bartram is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon a Qualifying Termination (which, in the case of Mr.&nbsp;Bartram, shall not include a termination due to disability) not in connection with a sale event, and
subject to the Severance Conditions, Mr.&nbsp;Bartram shall be entitled to receive the following severance benefits, collectively, the Bartram Severance Benefits: (A) continued payment of his then-current base salary for a period of twelve
(12)&nbsp;months following termination, (B)&nbsp;accelerated vesting of the unvested portion of any outstanding time-based equity award in an amount equal to the amount that would have vested had Mr.&nbsp;Bartram remained employed with us through
the twelve (12)&nbsp;month anniversary following the date of termination, and (C)&nbsp;if Mr.&nbsp;Bartram was participating in the Company&#146;s group health plan immediately prior to the termination date and timely elects continuation coverage
under COBRA, a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to Mr.&nbsp;Bartram had Mr.&nbsp;Bartram remained employed by us, or the Bartram COBRA Premium, until the earliest
of (i)&nbsp;the twelve (12)&nbsp;month anniversary following the date of termination; (ii)&nbsp;Mr.&nbsp;Bartram&#146;s eligibility for group health plan benefits under any other employer&#146;s group health plan; or (iii)&nbsp;the cessation of
Mr.&nbsp;Bartram&#146;s continuation rights under COBRA; provided, however, if the Company determines that the Bartram COBRA Premium would result in a violation of applicable law, then the Bartram COBRA Premium shall be converted into a taxable cash
payment and will be paid on a monthly basis to Mr.&nbsp;Bartram during the same period set forth in (i)-(ii), provided that such cash payment will be grossed up by the Company in an amount that results in Mr.&nbsp;Bartram receiving, after reductions
for tax withholdings, the full Bartram COBRA Premium for such period before any reductions for tax withholding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the Bartram Severance Benefits, upon
a Qualifying Termination (which, in the case of Mr.&nbsp;Bartram, shall not include a termination due to disability) on, or within six (6)&nbsp;months following, a sale event, subject to the Severance Conditions, Mr.&nbsp;Bartram shall be entitled
to receive a payment equal to 100% of the annual performance bonus for the year in which the termination occurs, payable in twelve (12)&nbsp;monthly installments following the date of termination. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Notwithstanding anything to the contrary set forth above, the Bartram Employment Agreement also provides that, upon a sale event, provided Mr.&nbsp;Bartram remains
employed by the Company as of the closing date of the sale event, 100% of all outstanding equity awards held by Mr.&nbsp;Bartram will be fully accelerated and vested on such date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Bartram Employment Agreement further provides that, in the event the amount of any compensation by the Company to or for the benefit of Mr.&nbsp;Bartram under the
Bartram Employment Agreement would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such compensation shall be reduced (but not below zero) so that the sum of the compensation shall be $1.00 less than the amount at which
the NEO becomes subject to the excise tax imposed under Section&nbsp;4999 of the Code; provided that such reduction shall only occur if such reduction would result in a higher net <FONT STYLE="white-space:nowrap">after-tax</FONT> benefit to
Mr.&nbsp;Bartram. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Mr.&nbsp;Bartram has entered into an Employee Confidentiality, Assignment, and Noncompetition Agreement that contains various restrictive
covenants, including confidentiality and nonsolicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employee benefit and equity compensation plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019 Stock option and grant plan </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan was adopted by our
board of directors and approved by our stockholders on April&nbsp;9, 2019. The 2019 Plan will continue to govern outstanding equity awards granted thereunder. As of March&nbsp;31, 2024, options to purchase 32,761,221&nbsp;shares of our common stock
at a weighted-average exercise price of $0.53 per share and 5,014,218&nbsp;shares of our common stock remained available for future issuance under the 2019 Plan. Following this offering, we will not grant any further awards under our 2019 Plan, but
all outstanding awards under the 2019 Plan will continue to be governed by their existing terms. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock underlying any awards under the
2019 Plan that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise) and shares withheld upon exercise of an option or settlement of an award to
cover the exercise price or tax withholding, are currently added back to the shares of common stock available for issuance under the 2019 Plan. Following this offering, such shares will be added to the shares of common stock available for issuance
under the 2024 Plan. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors and our compensation committee have acted as administrators of the 2019 Plan. The administrator has the full power
to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to determine the time or times of grant, and the amount, any award, to accelerate at any time
the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2019 Plan. Persons eligible to participate in the 2019 Plan are officers, employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and key persons as selected from time to time by the administrator in its discretion. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
2019 Plan permits the granting of nonqualified stock options and options intended to qualify as incentive stock options under Section&nbsp;422 of the Code. The per share exercise price of each option is determined by our board of directors but may
not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option is fixed by the administrator but may not exceed 10 years from the date of grant. The administrator determines at what time or times
each option may be exercised. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the 2019 Plan permits the granting of restricted shares of common stock, unrestricted stock awards and restricted stock
units. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2019 Plan provides that in the case of and subject to the consummation of a sale event, the 2019 Plan and all outstanding stock options issued thereunder
shall terminate upon the effective time of any such sale event unless assumed, substituted, or continued by the successor entity. In the event of a termination of the 2019 Plan and all stock options issued thereunder, each holder of stock options
shall be permitted, within a period of time prior to the consummation of the sale event, to exercise all such stock options which are then exercisable or will become exercisable as of the effective time of the sale event. In addition, the
administrator may provide for a cash payment to the holders of stock options for each stock option award canceled in the sale event. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to restricted
stock awards or restricted stock units, in the case of and subject to the consummation of a sale event, all such awards shall be forfeited immediately prior to the effective time of the sale event unless assumed, substituted, or continued by the
successor entity. In the event of a forfeiture of restricted stock awards, all such awards shall be repurchased from the holder at a price per share equal to the original purchase price paid by the holder. Notwithstanding anything to the contrary,
the Company may provide for a cash payment to the holders of restricted stock or restricted stock units, without the consent of such holders, in exchange for the cancellation of such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the occurrence of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse
stock split or other similar change in common stock, the administrator will equitably adjust the outstanding awards, which may include adjustments to the number and type of securities subject to such outstanding award and/or the exercise price or
grant price, thereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise determined by the administrator, awards may generally not be sold, assigned, transferred, pledged or otherwise encumbered by
the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The board of directors may
amend, suspend or terminate the 2019 Plan at any time, subject to stockholder approval where such approval is required by applicable law. The administrator of the 2019 Plan may also amend, modify or cancel any outstanding award, provided that no
amendment to an award may materially and adversely affect a participant&#146;s rights without his or her consent. In addition, the administrator may exercise its discretion to reduce the exercise price of outstanding stock options or effect
repricing through cancellation of outstanding stock options and by granting such holders new awards in replacement of the cancelled Stock Options. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No awards may be
granted under the 2019 Plan upon the earlier of 10 years from the date on which the 2019 Plan was initially adopted by our board of directors or 10 years from the date the 2019 Plan was initially approved by our stockholders. Our board of directors
has determined not to make any further awards under the 2019 Plan following the closing of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Stock option and incentive plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our 2024 Plan was adopted by our board of directors on,&#8195;&#8195;&#8195;&#8195;, 2024, approved by our stockholders on&#8195;&#8195;&#8195;&#8195;, 2024 and will
become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2024 Plan will replace the 2019 Plan as our board of directors has determined
not to make additional awards under the 2019 Plan following the closing of our initial public offering. However, the 2019 Plan will continue to govern outstanding equity awards granted thereunder. The 2024 Plan allows us to make equity-based and
cash-based incentive awards to our officers, employees, directors and consultants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have initially reserved&#8195;&#8195;&#8195;&#8195;shares of our common stock
for the issuance of awards under the 2024 Plan, or the Initial Limit. The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January&nbsp;1, 2025 and each
January&nbsp;1 thereafter, by&#8195;&#8195;&#8195;&#8195; percent of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee, or
the Annual Increase. The number of shares reserved under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares we issue under the 2024 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards under the
2024 Plan and the 2019 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are
otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2024 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The maximum number of
shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2025 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such
year or&#8195;&#8195;&#8195;&#8195;shares of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The grant date fair value of all awards made under our 2024 Plan and all other cash compensation paid by
us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
$&#8195;&#8195;&#8195;&#8195;; provided, however, that such amount shall be $&#8195;&#8195;&#8195;&#8195; for the calendar year in which the applicable
<FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan will be administered by our
compensation committee. Our compensation committee has the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination
of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2024 Plan. Persons eligible to participate in the 2024
Plan will be those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options
that do not so qualify. The option exercise price of each option will be determined by our compensation committee but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the option
(i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of
the Code. The term of each option will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award stock appreciation rights under the 2024 Plan subject to such conditions and restrictions as it may determine. Stock appreciation
rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right will be determined by our compensation committee
but generally may not be less than 100&nbsp;percent of the fair market value of our common stock on the date of grant unless the stock appreciation right (i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with
Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax or (iii)&nbsp;complies with Section&nbsp;409A of the Code. The term of each stock appreciation right will be fixed by our compensation
committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may
determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our compensation committee may also grant shares of common stock that are
free from any restrictions under the 2024 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the
recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may grant cash bonuses under the 2024 Plan to participants, subject to
the achievement of certain performance goals. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2024 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2024 Plan, an
acquirer or successor entity may assume, continue or substitute outstanding awards under the 2024 Plan. To the extent that awards granted under the 2024 Plan are not assumed or continued or substituted by the successor entity, upon the effective
time of the sale event, such awards shall terminate. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise such options and stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants
holding vested and exercisable options and stock appreciation rights equal&nbsp;(A) the difference between the per share cash consideration payable to stockholders in the sale event and the per share exercise price of the options or stock
appreciation rights, multiplied by (B)&nbsp;the number of shares subject to such outstanding vested and exercisable options and stock appreciation rights (to the extent exercisable at prices not in excess of the per share cash consideration), and we
may make or provide for a payment, in cash or in kind, to participants holding other vested awards equal to the per share cash consideration multiplied by the number of vested shares underlying such awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may amend or discontinue the 2024 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in
law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2024 Plan require the approval of our stockholders. The administrator of the 2024 Plan is
specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and
<FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2024 Plan after the date that is 10 years from the effective date of the 2024 Plan. No awards under the 2024 Plan have been made prior
to the date of this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2024 Employee stock purchase plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ESPP was adopted by our board of directors on&#8195;&#8195;&#8195;&#8195;, 2024, approved by our stockholders on&#8195;&#8195;&#8195;&#8195;, 2024 and will become
effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within
the meaning of Section&nbsp;423 of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of&#8195;&#8195;&#8195;&#8195;shares of our common stock to participating employees. The ESPP provides that the number of shares
reserved and available for issuance will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter through January&nbsp;1, 2034, by the least of (i)&#8195;&#8195;&#8195;&#8195;shares of common stock, (ii)&#8195;&#8195;percent
of the outstanding number of shares of common stock on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the
ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All employees employed by us or any designated
subsidiary as of the first day of an offering are eligible to participate; provided that the administrator of the ESPP may determine that employees must satisfy one or more of the following service requirements before participating in the ESPP:
(1)&nbsp;customary employment with us for more than 20 hours per week and 5 or more months per calendar year, (2)&nbsp;continuous employment with us for a minimum period of time, not to exceed two years, prior to the first date of an offering or
(3)&nbsp;such other criteria as the administrator of the ESPP may determine consistent with the requirements of section 423 of the Code.&nbsp;However, any employee who owns&nbsp;5&nbsp;percent or more of the total combined voting power or value of
all classes of our stock will not be eligible to purchase shares of common stock under the ESPP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may make one or more offerings each year to our employees to
purchase shares under the ESPP, consisting of one or more purchase periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering date </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to&#8195;&#8195;percent of his or her
eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of
the offering period at a price equal to&nbsp;85&nbsp;percent of the fair market value of the shares of our common stock on the first business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
day of the offering period or the last business day of the purchase period, whichever is lower, provided that no more than a number of shares of common stock determined by dividing $25,000 by the
fair market value of our common stock on the offering date of the offering (or such other number as established by the administrator in advance of the offering period) may be purchased by any one employee during each offering period. Under
applicable tax rules, an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee&#146;s rights under the
ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ESPP may be terminated or amended by our
board of directors at any time. An amendment that increases the number of shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Senior executive cash incentive bonus plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On&#8195;&#8195;&#8195;&#8195;, 2024 our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan. The Bonus Plan provides for annual
cash bonus payments based upon the attainment of Company and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our
Company, or the Corporate Performance Goals, as well as individual performance objectives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee may select Corporate Performance Goals from
among the following: research, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> <FONT STYLE="white-space:nowrap">non-clinical,</FONT> developmental, publication, clinical or regulatory milestones; scientific or technological advances; R&amp;D
capabilities; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation, and amortization; net income (loss) (either before or after interest, taxes,
depreciation, and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions or strategic transactions, including collaborations, joint ventures, or promotion arrangements; operating income (loss); return
on capital assets, equity, or investment; stockholder returns; sales; net sales; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss)
per share of our common stock; bookings, new bookings, or renewals; sales or market shares; number of customers, number of new customers, or customer references; operating income and/or net annual recurring revenue; or any other performance goal as
selected by the compensation committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, as compared to results of a peer group, against the market as a whole, compared to applicable market
indices, and/or measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each executive officer who
is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The
Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and
individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period, but no later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the
rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to
approve additional bonuses to executive officers in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Director compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2023 director compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the total
compensation paid by the Company to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors during the fiscal year ended December&nbsp;31, 2023. We did not pay any compensation or issue any equity awards or <FONT
STYLE="white-space:nowrap">non-equity</FONT> awards to any of the members of our board of directors in 2023 for their services as members of the board of directors. In addition, Mr.&nbsp;Hawryluk, our President and Chief Executive Officer, does not
receive any compensation from the Company for his service on our board of directors. See the section titled &#147;Executive compensation&#148;, above, for more information on the compensation paid to or earned by Mr.&nbsp;Hawryluk as an employee for
year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name (1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>Awards($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ed Mathers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No grants of equity awards or any other compensation were made to any directors in 2023. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, Mr.&nbsp;Cornelius held outstanding options to purchase an aggregate of 200,000 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, Mr.&nbsp;DiMarchi held (i)&nbsp;outstanding options to purchase 1,706,860 shares of our common stock, and (ii) 115,994 shares of restricted stock. Effective January&nbsp;1, 2023, we entered
into a consulting agreement with Mr.&nbsp;DiMarchi, or the DiMarchi Consulting Agreement, pursuant to which Mr.&nbsp;DiMarchi is entitled to continue to vest in the outstanding equity awards held by him as of January&nbsp;1, 2023, subject to the
terms and conditions of the existing equity award agreements (including the condition the Mr.&nbsp;DiMarchi continues to be in a service relationship with us on each vesting date). In addition, the DiMarchi Consulting Agreement provides that, upon
the achievement of specified milestones, subject to and contingent upon approval by our board of directors, Mr.&nbsp;DiMarchi will be granted an option to purchase 900,000 shares of our common stock. The DiMarchi Consulting Agreement was
subsequently amended on January&nbsp;17, 2024 to provide that such milestones were successfully achieved, and on January&nbsp;31, 2024 our board of directors approved an option to Mr.&nbsp;DiMarchi to purchase 900,000 shares of our common stock,
which was fully vested as of the grant date. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2023, Ms.&nbsp;Pescovitz held 58,334 shares of restricted stock. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we have reimbursed
and will continue to reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in
attending board of directors and committee meetings. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> director compensation policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to adopt a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become effective
as of the completion of this offering and will be designed to enable us to attract and retain, on a long term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the policy, <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> will be eligible to receive cash retainers (which will be payable
quarterly in arrears and prorated for partial years of service) and equity awards as set forth below: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Annual Retainer for Board Membership</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$ &#8195;&#8195;&#8195;&#8195;for general availability and participation in meetings and conference calls of
our Board of Directors</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional Annual Retainer for Committee Membership</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Audit Committee Chairperson: $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Audit Committee member (other than Chairperson): $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation Committee Chairperson: $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation Committee member (other than Chairperson): $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nominating and Corporate Governance Committee Chairperson: $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nominating and Corporate Governance Committee member (other than Chairperson): $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Science&nbsp;&amp; Technology Committee Chairperson: $</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Science&nbsp;&amp; Technology Committee member (other than Chairperson): $</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our policy will provide that, upon initial election or appointment to our board of directors, each <FONT
STYLE="white-space:nowrap">new&nbsp;non-employee&nbsp;director</FONT> will be granted <FONT STYLE="white-space:nowrap">a&nbsp;one-time&nbsp;grant</FONT> of <FONT STYLE="white-space:nowrap">a&nbsp;non-statutory&nbsp;stock</FONT> option to purchase
&#8195;&#8195;&#8195;&#8195;on the date of such director&#146;s election or appointment to the board of directors, or the Director Initial Grant. The Director Initial Grant will vest&#8195;&#8195;&#8195;&#8195;, subject to <FONT
STYLE="white-space:nowrap">the&nbsp;non-employee&nbsp;director&#146;s</FONT> continued services to the us. On the date of each annual meeting of stockholders of our company following the completion of this offering,
<FONT STYLE="white-space:nowrap">each&nbsp;non-employee&nbsp;director</FONT> who will continue as <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> following such meeting will be granted an annual award of <FONT
STYLE="white-space:nowrap">a&nbsp;non-statutory&nbsp;stock</FONT> option to purchase &#8195;&#8195;&#8195;&#8195; . The Director Annual Grant will vest in full on the earlier of
<FONT STYLE="white-space:nowrap">the&nbsp;one-year&nbsp;anniversary</FONT> of the grant date or on the date of our next annual meeting of stockholders, subject to <FONT STYLE="white-space:nowrap">the&nbsp;non-employee&nbsp;director&#146;s</FONT>
continued services to the us. If a <FONT STYLE="white-space:nowrap">new&nbsp;non-employee&nbsp;director</FONT> joins our Board on a date other than the date of the Company&#146;s annual meeting of stockholders, then
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director</FONT> will be granted <FONT STYLE="white-space:nowrap">a&nbsp;pro-rata&nbsp;portion</FONT> of the Director Annual Grant based on the time between
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director&#146;s</FONT> appointment and such next annual meeting of stockholders on the first eligible grant date following such <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s appointment to our board of directors. Such awards are subject to full acceleration vesting upon the sale of our company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate amount of
compensation, including both equity compensation and cash compensation, paid to <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director</FONT> for service as <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> in a
calendar year period will not exceed $&#8195;&#8195;&#8195;&#8195;in the first calendar year such individual becomes <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> and $&#8195;&#8195;&#8195;&#8195;in any other calendar
year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will reimburse all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reasonable&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> incurred by
directors for their attendance at meetings of our board of directors or any committee thereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Employee directors will receive no additional compensation for their
service as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_14"></A>Certain relationships and related person transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a description of transactions or series of transactions since January&nbsp;1, 2021, to which we were or will be a party, in which: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amount involved in the transaction exceeds, or will exceed, the lesser of (i) $120,000 or (ii)&nbsp;one percent of the
average of our total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">in which any of our executive officers, directors or holder of five percent or more of any class of our capital stock,
including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Compensation
arrangements for our named executive officers and our directors are described elsewhere in this prospectus under &#147;Executive compensation&#148; and &#147;Director compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series A convertible preferred stock milestone financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021,
we issued an aggregate of 16,011,641 shares of our Series A convertible preferred stock in connection with the achievement of a certain development milestone for gross proceeds of $11.0 million. The following table summarizes purchases of our Series
A convertible preferred stock by related persons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;purchase&nbsp;and/or<BR>conversion price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,307,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,333,332.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237,499.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New Enterprise Associates 17, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,124,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,833,332.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,124,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,833,332.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">345,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">237,499.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr. Heron is a Managing Partner of Frazier and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Cornelius is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. DiMarchi was a former member of our board of directors until January 2024. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with NEA are holders of five percent or more of our capital stock. Mr. Mathers is a General Partner of NEA and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed Private Investments VII, LP, or OrbiMed, is a holder of five percent or more of our capital stock. Dr. Gordon is founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed and a member of
our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr. Hawryluk is our President and Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Convertible promissory notes </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, we entered into certain convertible promissory notes with certain shareholders, or the 2022 Notes. In connection with the Series B convertible preferred
stock financing, the 2022 Notes were converted into 12,573,381 shares of Series B convertible preferred stock. The following table summarizes purchases of the original 2022 Notes by related persons: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Stockholder</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Original&nbsp;Note&nbsp;Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,552,606.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,465.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">440,300.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New Enterprise Associates 17, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,322,857.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,322,857.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">440,568.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr.&nbsp;Heron is a Managing Partner of Frazier and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Cornelius is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Richard DiMarchi was a former member of our board of directors until January 2024. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with NEA are holders of five percent or more of our capital stock. Mr.&nbsp;Mathers is a General Partner of NEA and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed is a holder of five percent or more of our capital stock. Dr.&nbsp;Gordon is founding member, Managing Partner, and <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Global Private Equity at OrbiMed and a
member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hawryluk is our President and Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series B
convertible preferred stock financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2022 and August 2023, we issued an aggregate of 129,240,032 shares of our Series B convertible preferred stock
as follows: (a) 40,545,552 shares of Series B convertible preferred stock sold at a purchase price of $0.90 per share at the initial closing for gross proceeds of $36.5&nbsp;million, (b) 12,573,381 shares of Series B convertible preferred stock
which were converted pursuant to the conversion of the 2022 Notes and (c) 76,121,099 shares of Series B convertible preferred stock sold at a purchase price of $0.90 per share pursuant to the achievement of certain development milestones for gross
proceeds of $68.5&nbsp;million. The following table summarizes purchases of our Series B convertible preferred stock by related persons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;purchase&nbsp;and/or<BR>conversion price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,297,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065,524.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Cornelius (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">188,886.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard DiMarchi (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448,421.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New Enterprise Associates 17, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,142,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,365,700.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Norwest Venture Partners XVI, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,587,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,365,700.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,207,230.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliates with RA Capital (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wellington Biomedical Innovation Master Investors (Cayman) II L.P.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frazier is a holder of five percent or more of our capital stock. Mr.&nbsp;Heron is a Managing Partner of Frazier and a member of our board of directors. 4,466,829 shares were issued pursuant to conversion of a
convertible note in the amount of $3,618,132.07 of principal and interest then outstanding. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Cornelius is a member of our board of directors. All shares were issued pursuant to conversion of a convertible note in the amount of $188,886.33 of principal and interest then outstanding. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;DiMarchi was a former member of our board of directors until January 2024. All of the shares were issued pursuant to conversion of a convertible note. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with NEA are holders of five percent or more of our capital stock. Mr.&nbsp;Mathers is a General Partner of NEA and a member of our board of directors. 2,920,619 shares were issued pursuant to
conversion of a convertible note in the amount of $2,365,701.74 of principal and interest then outstanding. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Norwest Venture Partners XVI, LP, or Norwest, is a holder of five percent or more of our capital stock. Dr.&nbsp;Aynechi is a General Partner at Norwest and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">OrbiMed is a holder of five percent or more of our capital stock. Dr.&nbsp;Gordon is founding member, Managing Partner, and <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Global Private Equity at OrbiMed and a
member of our board of directors. 2,920,619 shares were issued pursuant to conversion of a convertible note in the amount of $2,365,701.73 of principal and interest then outstanding. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hawryluk is our President and Chief Executive Officer and a member of our board of directors. 553,944 shares were issued pursuant to conversion of a convertible note in the amount of $448,694.74 of principal
and interest then outstanding. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliates with RA Capital, or RA Capital, are holders of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Wellington Biomedical Innovation Master Investors (Cayman) II L.P., or Wellington, is a holder of five percent or more of our capital stock. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Agreements with stockholders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our Series A and Series B
convertible preferred stock financings, we entered into investors&#146; rights, voting and right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, voting rights and
rights of first refusal, among other things, with certain holders of our preferred stock and certain holders of our common stock. These agreements will terminate upon the closing of this offering, except for the registration rights granted under our
amended and restated investors&#146; rights agreement, as more fully described in &#147;Description of Capital stock&#151;Registration rights.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Management&nbsp;rights&nbsp;and side letters </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the initial
issuance and sale of our convertible preferred stock, we entered into management rights and side letters with certain purchasers of our convertible preferred stock, including holders of more than 5% of our capital stock and entities with which
certain of our directors or officers are affiliated, pursuant to which such entities were granted certain&nbsp;management&nbsp;rights, among other things, including the right to consult with and advise our management on significant business issues,
review our operating plans, examine our books and records and inspect our facilities. These management rights letters will terminate upon completion of this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Research and consulting agreements </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2019, we entered into the IU
Research Agreement, pursuant to which we agreed to fund certain research of Dr.&nbsp;DiMarchi. The term of the agreement was originally June&nbsp;1, 2019 through May&nbsp;30, 2022 with a total contract cost of $2.8&nbsp;million, and was subsequently
extended through April&nbsp;1, 2026 and amended to increase the total contract costs by $3.3&nbsp;million. We paid $0.7&nbsp;million, $1.2&nbsp;million and $1.1&nbsp;million pursuant to this agreement during the years ended December&nbsp;31, 2023,
2022 and 2021, respectively. We paid $0.3 million pursuant to this agreement during the three months ended March 31, 2024. The IU Research Agreement also provided us an option to license the technology arising under the agreement, which option was
exercised and pursuant to which we <FONT STYLE="white-space:nowrap">in-license</FONT> technology pursuant to our IURTC License Agreement. For additional information on our IURTC License Agreement, please see &#147;Business &#150; Indiana University
Research and Technology Corporation Exclusive License Agreement.&#148; Dr.&nbsp;DiMarchi was our former Chief Scientific Officer and a former member of our board of directors until January 2024 and currently serves as a consultant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;1, 2023, we entered into a consulting agreement with Dr.&nbsp;DiMarchi, or the Consulting Agreement. Pursuant to the Consulting Agreement,
Dr.&nbsp;DiMarchi&#146;s outstanding equity continued to vest, and we granted him an additional 900,000 in options in January 2024. All of Dr. DiMarchi&#146;s outstanding options were accelerated to vest on January 31, 2024. We did not pay any
consulting fees during the year ended December&nbsp;31, 2023 nor during the quarter ended March 31, 2024. This agreement can be terminated by either party at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock option grants to directors and executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted stock options to our directors and named executive officers as more fully described in the section entitled &#147;Executive compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we intend to
enter into new agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement
amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of
directors to the maximum extent allowed under Delaware law. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Certain relationships </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Timothy Knickerbocker, son-in-law of our co-founder and former director and chief scientific officer, Richard DiMarchi, served as the Company&#146;s Chief Operating
Officer from August 1, 2020 to December 31, 2022. In fiscal 2021, Mr. Knickerbocker received cash compensation of $209,615, and a cash bonus in the amount of $44,000. In fiscal 2022, Mr. Knickerbocker received cash compensation of $210,000, a cash
bonus in the amount of $60,000 and the option to purchase up to 200,000 shares of common stock under our 2019 Plan, with an aggregate grant date fair value of $34,468. As part of his Separation Agreement, Mr. Knickerbocker&#146;s 2019, 2020 and 2022
stock option grants fully accelerated. In fiscal 2023, Mr. Knickerbocker received cash compensation of $178,412 as part of his severance package. While at the Company, Mr. Knickerbocker was also eligible to participate in our employee benefit plans.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Directed share program </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At our request, the underwriters have reserved
for sale, at the initial public offering price, up to approximately&#8195;&#8195;&#8195;&#8195;shares of our common stock being offered hereby (approximately&#8195;&#8195;&#8195;&#8195;%) for directors, executive officers, employees and business
associates. The directed share program will not limit the ability of our directors, officers and their family members, or holders of more than 5% of our capital stock, to purchase more than $120,000 in value of our common stock. We do not currently
know the extent to which these related persons will participate in our directed share program, if at all, or the extent to which they will purchase more than $120,000 in value of our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Policies for approval of related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors
reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the relationship or interest in the
transaction were disclosed to our board of directors prior to their consideration of such transaction, and the transaction was not considered approved by our board of directors unless a majority of the directors who are not interested in the
transaction approved the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the transaction were disclosed to the
stockholders, who must approve the transaction in good faith. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, we expect to adopt a written related party transactions policy that
will provide that such transactions must be approved by our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. Pursuant to this
policy, the audit committee has the primary responsibility for reviewing and approving or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and
in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director, or greater than 5&nbsp;percent beneficial owner
of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><A NAME="toc790774_15"></A>Principal stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth, as of July&nbsp;1, 2024, information regarding the beneficial ownership of our common stock by: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each person, or group of affiliated persons, who is known by us to be the beneficial owner of five percent or more of our
outstanding common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The information in the following table is calculated based on 198,673,437 shares of common stock deemed to be outstanding before this offering
and&#8195;&#8195;&#8195;&#8195;shares of common stock outstanding after this offering, assuming no exercise by the underwriters of their option to purchase additional shares of common stock. The number of shares outstanding is based on the number of
shares of common stock outstanding as of July&nbsp;1, 2024 as adjusted to give effect to: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 182,838,619 shares of
common stock upon the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the sale of&#8195;&#8195;&#8195;&#8195;shares of common stock in this offering (assuming no exercise of the
underwriters&#146; option to purchase additional shares). </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each individual or entity shown on the table has furnished information with respect to
beneficial ownership. Except as otherwise indicated below, the address of each officer, director and five percent stockholder listed below is c/o MBX Biosciences, Inc., 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other
purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities as well as any shares of common stock that the person has the right
to acquire within 60&nbsp;days of July&nbsp;1, 2024 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the
percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and
investment power with respect to all shares shown as beneficially owned by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table does not reflect any shares of common stock that may be purchased pursuant to our directed
share program described under &#147;Underwriting&#151;Directed share program.&#148; If any shares are purchased by our existing principal stockholders, directors or their affiliated entities, the number and percentage of shares of our common stock
beneficially owned by them after this offering will differ from those set forth in the following table. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Shares of</B><br><B>common&nbsp;stock</B><br><B>beneficially<BR>owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage&nbsp;of&nbsp;shares<BR>beneficially&nbsp;owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of Beneficial Owner</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Before&nbsp;offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>After<BR>offering</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Frazier Life Sciences X, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,220,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.77%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with New Enterprise Associates(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,515,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.88%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Norwest Venture Partners XVI, LP(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.39%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">OrbiMed Private Investments VII, LP(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,959,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.09%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliates with RA Capital(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.39%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wellington Biomedical Innovation Master Investors (Cayman) II L.P.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.39%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors, Named Executive Officers and Other Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">P. Kent Hawryluk(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,999,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.54%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Richard Bartram(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,712,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi, Ph.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.39%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,699,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl Gordon, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,959,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.09%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron(12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,220,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.77%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers(13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,442,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.85%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz, M.D.(14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Steven Ryder, M.D.(15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">All executive officers and directors as a group (10&nbsp;persons)(16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,644,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.72%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 18,922,852 shares of common stock issuable upon conversion of Series A preferred stock and 28,297,265 shares of common stock issuable upon conversion of Series B preferred stock held directly by Frazier Life
Sciences X, L.P., or FLS X. FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and
investment power of the securities held by FLS X. Mr. Heron is a member of our board of directors. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. The address for
FLS X is 1001 Page Mill Rd., Building 4, Ste. B, Palo Alto, CA 94304. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 12,299,854 shares of common stock issuable upon conversion of Series A preferred stock and 25,142,840 shares of common stock issuable upon conversion of Series B preferred stock held by New Enterprise
Associates 17, L.P., or NEA 17, and (ii) 72,780 shares of common stock issuable upon conversion of Series A preferred stock held by NEA Ventures 2020, L.P., or NEA Ven 2020. NEA Partners 17, L.P., or NEA Partners 17, is the sole general partner of
NEA 17. NEA 17 GP, LLC, or NEA 17 LLC, is the sole general partner of NEA Partners 17. The securities directly held by NEA Ven 2020 are indirectly held by Karen Welsh, the general partner of NEA Ven 2020. Forest Baskett, Ali Behbahani, Carmen Chang,
Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott D. Sandell, Paul Walker, and Rick Yang are the managers of NEA 17 LLC. NEA 17, NEA Partners 17, NEA 17 LLC and the managers of NEA 17 LLC share voting and dispositive power with regard
to the securities held by NEA 17. Mr. Mathers is a partner at New Enterprise Associates and member of our board of directors. Each of NEA 17, NEA Partners 17 and NEA 17 LLC as well as each of the managers of NEA 17 LLC disclaims beneficial ownership
of all shares held by NEA 17 except to the extent of their actual pecuniary interest therein. NEA 17&#146;s and NEA Ventures 2020, L.P.&#146;s mailing address is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093-4135. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 16,666,666 shares of common stock issuable upon conversion of Series B preferred stock held by Norwest Venture Partners XVI, LP (&#147;NVP XVI&#148;). Genesis VC Partners XVI, LLC (&#147;Genesis XVI&#148;)
is the general partner of NVP XVI and NVP Associates, LLC (&#147;NVP Associates&#148;) is the managing member of Genesis XVI. Genesis XVI, NVP Associates and Promod Haque, Jeffrey Crowe, and Jon E. Kossow, as co-chief executive officers of NVP
Associates, LLC, may be deemed to share voting and dispositive power over the shares held by NVP XVI. Each of Genesis XVI, NVP Associates and Messrs. Haque, Crowe and Kossow disclaims beneficial ownership of the securities held by NVP XVI, except to
the extent of its or his pecuniary interest therein. The address for each of these entities and individuals is c/o 1300 El Camino Real, Suite 200, Menlo Park CA 94025. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">Consists of 12,372,634 shares of common stock issuable upon conversion of Series A preferred stock and 19,587,284 shares
of common stock issuable upon conversion of Series B preferred stock held by OrbiMed Private Investments VII, LP, or OPI VII. OrbiMed Capital GP VII LLC, or OrbiMed GP VII, is the general partner of OPI VII. OrbiMed Advisors LLC, or OrbiMed
Advisors, is the managing member of OrbiMed GP VII. By </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">
virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to
have beneficial ownership of such shares. Dr. Gordon is a member of OrbiMed Advisors and a member of our board of directors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Dr. Gordon, Sven H. Borho
and W. Carter Neild. Each of OrbiMed GP VII, OrbiMed Advisors, Mr. Borho, Mr. Neild and Dr. Gordon disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein if any. The address for
each of the entities and individuals identified in this footnote is c/o OrbiMed Advisors LLC, 601 Lexington Avenue 54th Floor, New York, NY 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 5,000,000 shares of common stock issuable upon conversion of Series B preferred stock held by RA Capital Healthcare Fund, L.P., or RA Healthcare, and (ii) 11,666,666 shares of common stock issuable upon
conversion of Series B preferred stock held by RA Capital Nexus Fund III, L.P., or Nexus III. RA Capital Management, L.P. is the investment manager for RA Healthcare and Nexus III. The general partner of RA Capital Management, L.P. is RA Capital
Management GP, LLC, of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky, Ph.D. and Rajeev Shah may be deemed to have voting and investment power over
the shares held of record by RA Healthcare and Nexus III. RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky, Ph.D. and Rajeev Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. The address of the entities listed above is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 16,666,666 shares of common stock issuable upon conversion of Series B preferred stock held by Wellington Biomedical Innovation Master Investors (Cayman) II L.P., or Wellington Biomedical Fund. Wellington
Management Company LLP, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment adviser to Wellington Biomedical Fund, and Wellington Alternative Investments LLC is its general partner. Wellington
Management Investment, Inc. is the managing member of Wellington Alternative Investments LLC. Wellington Management Company LLP is an indirect subsidiary of Wellington Management Group LLP. Wellington Management Group LLP and Wellington Management
Company LLP may be deemed beneficial owners with shared voting and investment power over the shares held by Wellington Biomedical Fund. Additional information about Wellington Management Company LLP is available in its Form ADV filed with the SEC.
The address of all entities referenced in this footnote is 280 Congress Street, Boston, MA 02210. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,466,667 shares of common stock outstanding held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011 (the &#147;Hawryluk Trust&#148;), 2,242,187 and 908,612&nbsp;shares of common stock
outstanding issued pursuant to early exercise of stock options held by Mr. Hawryluk and the Hawryluk Trust, respectively, 132,813 and 19,333&nbsp;shares of restricted stock outstanding issued pursuant to early exercise of stock options subject to
continued vesting for Mr. Hawryluk and the Hawryluk Trust, respectively, 2,015,681 and 345,705 shares of common stock issuable upon conversion of Series A preferred stock held by Mr. Hawryluk and the Hawryluk Trust, respectively, 1,396,762 and
76,969 shares of common stock issuable upon conversion of Series B preferred stock held by Mr. Hawryluk and the Hawryluk Trust, respectively, and 12,394,300 shares of common stock underlying outstanding early exercise stock options that are
immediately exercisable within 60 days of July&nbsp;1, 2024. Mr. Hawryluk exercises voting and dispositive power over the shares beneficially owned by the Hawryluk Trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,712,100 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of July&nbsp;1, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in footnote (3) above. Dr. Aynechi disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 994,069 shares of common stock issuable upon conversion of Series A preferred stock held by Mr. Cornelius, 233,192 shares of common stock issuable upon conversion of Series B preferred stock held by Mr.
Cornelius and 472,202 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of July&nbsp;1, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in footnote (4) above. Dr. Gordon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in footnote (1) above. Mr. Heron disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares held by NEA 17 described under footnote (2) above, over which Mr. Mathers shares voting and dispositive power. Mr. Mathers, a member of our board of directors and a General Partner at New Enterprise
Associates, Inc. has no voting or dispositive power with regard to any shares held by NEA Ventures. In addition, Mr. Mathers disclaims beneficial ownership of above-referenced shares held by entities affiliated with New Enterprise Associates, Inc.
described in footnote (2) except to the extent of his actual pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 95,021&nbsp;shares of common stock outstanding issued pursuant to early exercise of stock options, 104,979&nbsp;shares of restricted stock outstanding issued pursuant to early exercise of stock options
subject to continued vesting, and 272,202 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of July&nbsp;1, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(15)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 472,202 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of July&nbsp;1, 2024. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(16)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 5,969,612 shares of common stock, of which a certain number are restricted stock subject to vesting as noted above, (ii) 46,950,795 shares of common stock issuable upon conversion of Series A preferred
stock, (iii) 91,400,978 shares of common stock issuable upon conversion of Series B preferred stock and (iv) 16,323,006 shares of common stock underlying outstanding early exercise stock options that are immediately exercisable within 60 days of
July&nbsp;1, 2024, including &#8195;&#8195;&#8195;&#8195;&#8195;held by Dr. Salomon Azoulay. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_16"></A>Description of capital stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following descriptions are summaries of the material terms of our third amended and restated certificate of incorporation and amended and restated bylaws, which
will be effective immediately prior to the closing of this offering and upon the effectiveness of the registration statement of which this prospectus forms a part, respectively. The descriptions of the common stock and preferred stock give effect to
changes to our capital structure, that will occur immediately upon the closing of this offering. We refer in this section to our third amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended
and restated bylaws as our bylaws. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of
this offering, our authorized capital stock will consist of &#8195;&#8195;&#8195;&#8195;&#8195; shares of common stock, par value $&#8195;&#8195;&#8195;&#8195;per share, and&#8195;&#8195;&#8195;&#8195;shares of preferred stock, par value
$&#8195;&#8195;&#8195;&#8195;per share, all of which shares of preferred stock will be undesignated. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March&nbsp;31, 2024, 15,544,989 shares of our common
stock were outstanding and held of record by 36 stockholders, and 53,598,587 shares of Series A preferred stock and 129,240,032 shares of Series&nbsp;B preferred stock were outstanding and held of record by 28 stockholders. This amount does not take
into account the conversion of all outstanding shares of our preferred stock into common stock upon the closing of this offering. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the common stockholders. The holders of our common
stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights
of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all
debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preferred stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon the closing of this offering,
our board of directors will have the authority, without further action by our stockholders, to issue up to &#8195;&#8195;&#8195;&#8195;&#8195; shares of preferred stock in one or more series and to fix the rights, preferences, privileges and
restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the
designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive
dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after consummation
of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Options </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March
31, 2024, options to purchase 32,761,221 shares of common stock at a weighted-average exercise price of $0.53 per share were outstanding under the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of this offering, the holders
of&#8195;&#8195;&#8195;&#8195;shares of our common stock, including those issuable upon the conversion of preferred stock upon closing of this offering, will be entitled to rights with respect to the registration of these securities under the
Securities Act. These rights are provided under the terms of an amended and restated investors&#146; rights agreement between us, certain holders of our common stock and holders of our preferred stock. The amended and restated investors&#146; rights
agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including
underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Demand registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beginning 180 days after the effective date of this registration statement, the holders of&#8195;&#8195;&#8195;&#8195;shares of our common stock, including those
issuable upon the conversion of shares of our preferred stock upon closing of this offering, are entitled to demand registration rights. Under the terms of the amended and restated investors&#146; rights agreement, upon the written request of
holders of at least 40% of the securities eligible for registration then outstanding to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> with respect to the securities eligible for registration having an anticipated
aggregate offering price of not less than $10&nbsp;million, net of selling expenses, we will be required to file a registration statement within 60 days of such request covering all securities eligible for registration that our holders request to be
included in such registration. We are required to effect only one registration pursuant to this provision of the amended and restated investors&#146; rights agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Short-form registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the amended and restated
investors&#146; rights agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of holders of at least 20% of the securities eligible for registration then
outstanding to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to securities eligible for registration having an aggregate offering price of at least $5&nbsp;million, net of selling expenses, we will be
required to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within 45 days of such request covering all outstanding securities eligible for registration that our holders request to be included in such registration.
We are required to effect only two registrations in any twelve month period pursuant to the amended and restated investors&#146; rights agreement. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is
further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Piggyback registration rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the amended and restated investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, certain holders of our common stock, including those issuable upon the conversion of our preferred stock, are entitled to include their shares in the registration. Subject to certain exceptions contained in the amended and restated
investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of
the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
amended and restated investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of securities eligible for registration in the event of material misstatements or omissions
in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Expiration of registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The demand registration rights,
short form registration rights and piggyback registration rights granted under the amended and restated investors&#146; rights agreement will terminate on the earliest to occur of (a)&nbsp;the closing of certain liquidation events, (b)&nbsp;the
fifth anniversary of the completion of this offering or (c)&nbsp;at such time after this offering when the holder&#146;s shares may be sold without limitation pursuant to Rule 144 or another similar exemption under the Securities Act during a
three-month period without registration and such holder holds less than one percent of the outstanding capital stock of the company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ordinarily, other than underwriting discounts and commissions, we are generally required to pay all expenses incurred by us related to any registration effected pursuant
to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling security holders and <FONT
STYLE="white-space:nowrap">blue-sky</FONT> fees and expenses. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Anti-takeover effects of delaware law and certain provisions of our certificate of
incorporation and bylaws </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some provisions of Delaware law include, and our third amended and restated certificate of incorporation and amended and restated
bylaws will include, a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals
to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Board composition and filling vacancies </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of
incorporation will provide for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also will provide that directors may be removed
only for cause and then only by the affirmative vote of the holders of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of the outstanding shares of capital stock of the voting power of the outstanding shares of
capital stock then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative
vote a majority of the remaining directors then in office even if less than a quorum or by sole remaining director. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of
making it more difficult for stockholders to change the composition of our board of directors. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>No written consent of stockholders </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation will provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and
that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our
stockholders without holding a meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Meetings of stockholders </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation and bylaws will provide that only our board of directors may call special meetings of stockholders and only those matters set forth in
the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws will limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the
meeting. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Advance notice requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will
establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures will provide that notice
of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days
nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws will specify the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders
from bringing matters before the stockholders at an annual or special meeting. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Amendment to certificate of incorporation and bylaws </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of
incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the
provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote
of our board of directors, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the
amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Preferred stock </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our certificate of incorporation will
provide for&#8195;&#8195;&#8195;&#8195;authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger,
tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors
could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder
group. In this regard, our certificate of incorporation will grant our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could
decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying,
deterring or preventing a change in control of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Delaware anti-takeover statute </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203
prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless
the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85&nbsp;percent of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of
10&nbsp;percent or more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15&nbsp;percent or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Choice of forum </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our bylaws will provide that, unless we consent in writing
to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (3)&nbsp;any action asserting a claim arising pursuant to the Delaware General Corporation Law, our certificate of
incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (4)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine; provided, however, that the this provision shall not apply to
any causes of action arising under the Securities Act or Exchange Act. In addition, our bylaws will provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the
sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit our stockholders&#146; ability to bring a
claim in a forum they find favorable, and the designated courts may reach different judgments or results than other courts.&nbsp;In addition, there is uncertainty as to whether the federal forum provision for Securities Act claims will be enforced,
which may impose additional costs on us and our stockholders. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Stock exchange listing </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; The closing of this offering is contingent upon such
listing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfer agent and registrar </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Transfer Agent and
Registrar for our common stock will be Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_17"></A>Shares eligible for future sale </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of such shares for
sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on
resale. Nevertheless, sales of shares of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise
equity capital in the future. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on the number of shares outstanding as of March 31, 2024, upon the completion of this offering,
&#8195;&#8195;&#8195;&#8195;shares of our common stock will be outstanding, assuming the issuance of&#8195;&#8195;&#8195;&#8195;shares offered by us in this offering, no exercise of the underwriters&#146; option to purchase additional shares and no
exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only
be sold in compliance with the limitations described below, and&nbsp;restricted shares of common stock are subject to time-based vesting terms. All remaining shares of common stock held by existing stockholders immediately prior to the completion of
this offering will be &#147;restricted securities&#148; as such term is defined in Rule 144 under the Securities Act. These restricted securities were issued and sold by us in private transactions and are eligible for public sale only if registered
under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In general, a person who has beneficially owned restricted
stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are
subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the
90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1&nbsp;percent of the number of shares then outstanding, which will equal approximately&#8195;&#8195;&#8195;&#8195;shares
immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares outstanding as of March 31, 2024; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Select Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided, in each case, that we are subject to the periodic
reporting requirements of the Exchange Act for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information
and notice provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rule&nbsp;701
under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our
employees, executive officers or directors who purchased shares under a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the date
of this prospectus before selling their shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We, all of our
directors and officers and substantially all of our stockholders have agreed not to sell or otherwise transfer or dispose of any of our securities for a period of 180 days from the date of this prospectus, subject to certain exceptions. The
representatives of the underwriters may, in their sole discretion, permit early release of shares subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. See the section entitled &#147;Underwriting,&#148; included elsewhere in
this prospectus for more information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon
completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these
shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section entitled &#147;Description of capital stock&#151;Registration rights&#148; included elsewhere in
this prospectus for more information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity incentive plans </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend
to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration
statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open
market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. As of the date of this prospectus, we estimate that such registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> will cover approximately&#8195;&#8195;&#8195;&#8195;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><A NAME="toc790774_18"></A>Material U.S. federal income tax considerations for
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion is a summary of certain material U.S. federal income tax considerations
applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, referred to below as &#147;our common
stock&#148;. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign corporation or other foreign organization taxable as a corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a foreign trust or estate the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are treated as pass-through entities for
U.S. federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax
advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and
judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax
consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences
described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for
investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any aspects of U.S. state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, the Medicare contribution tax on net investment income, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code, or
any other aspect of any U.S. federal tax other than income taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special
tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;regulated investment companies&#148; and &#147;real estate investment trusts&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and partners
and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who have elected to mark securities to market for U.S. federal income tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that hold our common stock as part of a straddle, conversion transaction, synthetic security or other integrated
investment; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our
common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions on our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash
distributions on our capital stock and we do not anticipate paying cash distributions on our common stock for the foreseeable future. Distributions, if any, on our common stock will generally constitute dividends for U.S. federal income tax purposes
to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject
to the tax treatment described below in &#147;Gain on sale and other taxable disposition of our common stock.&#148; Any such distributions will also be subject to the discussions below under the sections entitled &#147;Backup withholding and
information reporting&#148; and &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion in the following two paragraphs
in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30&nbsp;percent rate or a reduced rate specified by an applicable income tax treaty
between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30&nbsp;percent withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected
income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30&nbsp;percent rate or a reduced rate
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a
properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable or successor form) to the applicable withholding agent and
satisfy applicable certification and other requirements. Any documentation provided to an applicable withholding agent may need to be updated in certain circumstances. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult
their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S.
withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Gain
on sale or other taxable disposition of our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below under &#147;Backup withholding and information reporting&#148; and
&#147;Withholding and information reporting requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income or withholding tax on any gain realized upon such
holder&#146;s sale or other taxable disposition of shares of our common stock unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S.
trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30&nbsp;percent
tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed
U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; as described below, unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5&nbsp;percent of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period
ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation if the fair market value of its U.S.
real property interests, as defined in the Code and applicable Treasury regulations, equals or exceeds 50&nbsp;percent of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade
or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be
regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Backup withholding and information reporting
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We (or the applicable paying agent) must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the
distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may have to comply with specific certification procedures to establish
that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders subject to withholding of U.S. federal income tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock
by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies
certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the
transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding
rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or
agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Withholding and information reporting requirements&#151;FATCA </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Provisions of
the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a rate of 30&nbsp;percent on payments of dividends on, or, subject to the discussion of certain proposed U.S.
Treasury regulations below, gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain
due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign
entity is otherwise exempt under FATCA. However, the U.S. Treasury released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30&nbsp;percent applicable to the gross proceeds of a sale or
other disposition of our common stock. In the preamble to such proposed regulations, the U.S. Treasury stated that taxpayers (including withholding agents) may generally rely on the proposed regulations until final regulations are issued. Under
certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United&nbsp;States and an applicable foreign country may
modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the
entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30&nbsp;percent withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_19"></A>Underwriting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC and Jefferies LLC are acting as
joint book-running managers of the offering, and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell
to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next
to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to offer the shares of common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus
and to certain dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195; per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $&#8195;&#8195;&#8195;&#8195; per share
from the initial public offering price. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other
selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up to
&#8195;&#8195;&#8195;&#8195; additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus
to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any
additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The
underwriting fee is $&#8195;&#8195;&#8195;&#8195; per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the
underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Without<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>With full<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees
and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&#8195;&#8195;&#8195;&#8195;. We have agreed to reimburse the underwriters for expenses relating to the clearance of this offering
with the Financial Industry Regulatory Authority. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">At our request, the underwriters have reserved up to&#8195;% of the shares of common stock being offered by this
prospectus for sale at the initial public offering price to our directors, officers, certain employees and certain other persons associated with us. The sales will be made by J.P. Morgan Securities LLC, an underwriter of this offering, through a
directed share program. We do not know if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public. Except for
reserved shares purchased by our executive officers and directors, these reserved shares will not be subject to the lock-up restrictions described below. Any reserved shares not so purchased will be offered by the underwriters to the general public
on the same terms as the other shares of common stock. We have agreed to indemnify J.P. Morgan Securities LLC against certain liabilities and expenses, including liabilities under the Securities Act of 1933, as amended, or the Securities Act, in
connection with the sales of the directed shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters,
or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be
allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We<I>
</I>have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose
of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or
exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic
consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or
otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions on our actions, as described above, do not apply to certain transactions, including (i)&nbsp;the issuance of shares of common stock or securities
convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net
settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of our
common stock or securities convertible into or exercisable or exchangeable for shares of our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms
of an equity compensation plan in effect as of the closing of this offering and described in this prospectus; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of our common stock, or securities convertible into, exercisable for, or
which are otherwise exchangeable for, our common stock, immediately following the closing of this offering, in connection with any bona fide licensing, commercialization, joint venture, technology transfer, acquisition, development collaboration or
other strategic transaction, provided that for (i)-(iii) such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; or (iv)&nbsp;our filing of any registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
on the date of the underwriting agreement and described in this prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and executive officers, and substantially all of our shareholders, or such persons, the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties, have
entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a
period of 180&nbsp;days after the date of this prospectus or such period, the restricted period, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Jefferies
LLC, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly,
any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such <FONT
STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant, or collectively with the common
stock, the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, (2)&nbsp;enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise,
(3)&nbsp;make any demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. Such persons or entities
have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or
combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (by any person
or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction or
arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the
underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities: (i) as bona fide gifts, as a charitable contribution, or for bona fide estate planning purposes, (ii)&nbsp;by will or intestacy or any other testamentary document, (iii)&nbsp;to any trust for the direct or indirect benefit of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or its immediate family, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee (or co-trustee) or beneficiary of the trust or to the estate of a beneficiary
of such trust (for purposes hereof, &#147;immediate family&#148; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin), (iv) to a corporation, partnership, limited
liability company, investment fund or other entity (A)&nbsp;of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or its immediate family are the legal and beneficial owner of all of the outstanding equity securities or similar
interests or (B)&nbsp;controlled by, or under common control with, the lock-up party or the immediate family of the lock-up party, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under
clauses (i)&nbsp;through (iv), (vi) if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited
liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling,
controlled by, managing or managed by or under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates (including, for the avoidance of doubt, where the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is
a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution to limited partners, members or shareholders of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, (vii)&nbsp;by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement, (viii)&nbsp;to us from an employee upon death,
disability or termination of employment, in each case, of such employee, (ix)&nbsp;as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
part of a transaction related to <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in this offering (if not a director or officer) or in open market transactions following this
offering, (x)&nbsp;to us in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of our common stock (including, in each case, by way of &#147;net&#148; or
&#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such
shares of our common stock received upon such exercise, vesting or settlement shall be subject to the restrictions similar to those in the immediately preceding paragraph, and provided further that any such restricted stock units, options, warrants
or rights are held by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in this
prospectus, (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by our board of directors and made to all shareholders involving a change in control, provided that if such
transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph (xii)&nbsp;to an immediate family member of the lock-up party, or
(xiii)&nbsp;to us in connection with the transfer of shares pursuant to option agreements relating to the early exercise by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party of unvested options issued pursuant to our equity incentive plans,
which plans are in each case described in this Registration Statement, under which we have the right to repurchase such shares and only to the extent we elect to exercise such right.; provided that (A)&nbsp;in the case of any transfer or
distribution pursuant to clauses&nbsp;(i), (ii), (iii), (iv), (v), (vi), (vii) and (xii)&nbsp;of this paragraph, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to
the representatives of the underwriters a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (B)&nbsp;in the case of any transfer or distribution pursuant to
clauses&nbsp;(iii), (iv), (v), (vi), (ix) and (xii)&nbsp;of this paragraph, no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or
shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 or a filing required pursuant to Section 13 of the Exchange Act and the rules and regulations promulgated thereunder made after the
expiration of the restricted period) and (C)&nbsp;in the case of any transfer or distribution pursuant to clauses (i), (ii), (vii), (viii), (x) and (xiii)&nbsp;of this paragraph it shall be a condition to such transfer that no public filing, report
or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of our common stock in connection with
such transfer or distribution shall be legally required during the restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (b)&nbsp;exercise of the options,
settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to plans described in in this prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or
settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common
stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; (d)&nbsp;the establishment or
modification by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities,
provided that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement
shall be required or made voluntarily in connection with such trading plan; and (e)&nbsp;the sale of our common stock pursuant to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC and Jefferies LLC, in their sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with the underwriters described above, in whole or in part at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the Nasdaq Global Select Market under the symbol &#147;MBX.&#148; The
closing of this offering is contingent upon such listing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves
making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may
include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to
cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148;
shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market.
In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase
additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in
this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids.
This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering
to repay the underwriting discount received by them. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These activities may have the effect of raising or maintaining the market price of the common stock or
preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities,
they may discontinue them at any time. The underwriters may carry out these transactions on the &#8195;&#8195;&#8195;&#8195;&#8195;, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or
otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations
between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters can assure investors that an active trading market will develop for our shares of
common stock, or that the shares will trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the United States, no action has been
taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold,
directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will
result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the
distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial
banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Selling restrictions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to
prospective investors in the european economic area </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to each Member State of the European Economic Area, or each, a Relevant State, no shares of our
common stock have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of our common stock which has been approved by the competent authority
in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of shares of common stock may be
made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of
shares of common stock shall require the Issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each person in a Relevant State who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and
agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the case of any shares of
common stock being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock
acquired by it in the offer have not been acquired </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give
rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of common stock in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock, and the
expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the united kingdom </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to the United Kingdom, or the UK, no shares of our common stock have been offered or will be offered pursuant to the offering to the public in the UK prior
to the publication of a prospectus in relation to the shares of common stock which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of shares of common
stock may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at any time in other circumstances falling within section 86 of the FSMA, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of shares of
common stock shall require the Issuer or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each person in the UK who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to
and with the Company and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the case of any shares of common
stock being offered to a financial intermediary as that term is used in Article 5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock
acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise
to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of our common stock in the UK means the communication in
any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
purchase or subscribe for any shares of our common stock, the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018, and the expression &#147;FSMA&#148; means the Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document is for distribution only
to persons who (i)&nbsp;have professional experience in matters relating to investments and who qualify as investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,
or as amended, the Financial Promotion Order, (ii) are persons falling within Article 49(2)(a) to (d) (&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the United
Kingdom, or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated
or caused to be communicated (all such persons together being referred to as &#147;relevant persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice
to prospective investors in Canada </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are
accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal
advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts, or NI 33-105, the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Switzerland </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock
may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or six or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of,
and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules
or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares of common stock, or the offering may be publicly distributed or
otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this document nor any other offering or marketing material relating to the offering, the Company, the
shares of common stock have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be supervised
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of shares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective
Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares of common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Hong Kong </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have
not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or
SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong
Kong), or CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any
person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong)
other than with respect to shares of common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Singapore </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each joint book-running manager
has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any shares of common
stock or caused the shares of common stock to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares of common stock or cause the shares of common stock to be made the subject of an invitation for
subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares
of common stock, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA,) pursuant to Section&nbsp;274 of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where the
shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of
the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever
described) in that trust shall not be transferred within six </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
months after that corporation or that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of
shares of common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of common stock are &#145;&#145;prescribed capital markets products&#146;&#146; (as defined in the
CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on
Recommendations on Investment Products). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Japan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none
of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including
any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to
an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the United Arab Emirates </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of
common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and
the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial
Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Israel </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the State of Israel this
prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it
complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the
Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&#151;1968, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
subject to certain conditions, or the Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase
securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#151;1968. We have not and will not
distribute this prospectus or make, distribute or direct an offer to subscribe for our shares of common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#151;1968. In
particular, we may request, as a condition to be offered shares of common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the
categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968 regarding Qualified Investors is applicable to it;
(iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued shares of common stock; (iv)&nbsp;that the shares of common
stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of
Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence
in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number.</P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Australia </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, a as a disclosure document for the purposes of the Corporations Act and does not purport to include the
information required of a disclosure document for the purposes of the Corporations Act; and </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act, or Exempt
Investors. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the shares of common stock may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure to
investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us that
you are an Exempt Investor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter 6D.2 of the
Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that
resale. By applying for the shares of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
transfer, assign or otherwise alienate those shares of common stock to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the
Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in China </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus will not be circulated or distributed in the PRC and the shares of common stock will not be offered or sold, and will not be offered or sold to any
person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other
offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Korea </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have not
been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder, or FSCMA, and the shares of common stock have been and will be offered in Korea as a private
placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in
Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or FETL. Furthermore, the purchaser
of the shares of common stock shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares of common stock. By the purchase of the shares of common
stock, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares of common stock pursuant to the applicable laws and regulations of Korea. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Saudi Arabia </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document may not be
distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended, or
the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document.
Prospective purchasers of the shares of common stock offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an
authorized financial adviser. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the Dubai International Financial Centre, or DIFC </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or DFSA. This document is intended for
distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt
Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The shares of common stock to which this document relates may be illiquid and/or
subject to restrictions on their resale. Prospective purchasers of the shares of common stock offered should conduct their own due diligence on the securities. If you do not understand the contents of this document, you should consult an authorized
financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a
limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the
public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Bermuda </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares
of common stock may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally,
<FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in the British Virgin Islands </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of
common stock are not being and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of us. The shares of common stock may be offered to companies incorporated under the BVI
Business Companies Act, 2004 (British Virgin Islands) (BVI Companies), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Taiwan </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock have
not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which
constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give
advice regarding or otherwise intermediate the offering and sale of the shares of common stock in Taiwan.</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in South Africa
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to restrictions under the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in the South African Companies Act,
No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the South African Companies Act), is being made in connection with the issue of the shares of common stock in South Africa. Accordingly, this document does not,
nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the
South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares of common stock are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a
person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (a) the offer,
transfer, sale, renunciation or delivery is to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the South African Public Investment Corporation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons or entities regulated by the Reserve Bank of South Africa; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorized financial service providers under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions recognized as such under South African law; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a wholly-owned subsidiary of any person or entity contemplated in (iii), (iv) or (v), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment
scheme (in each case duly registered as such under South African law); or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the person in (i)&nbsp;to (vi); or </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (b) the total contemplated acquisition cost of
the shares of common stock, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the
South African Companies Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information made available in this prospectus should not be considered as &#147;advice&#148; as defined in the South African Financial
Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Malaysia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No prospectus or other offering material or document in connection with the offer and sale of the shares of common stock has been or will be registered with the
Securities Commission of Malaysia, or the Commission, for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or
invitation for subscription or purchase, of the shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether
directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the shares of common stock, as principal, if
the offer is on terms that the shares of common stock may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total
net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or
its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with&nbsp;his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the
preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding
RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan
Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares of common stock is made by a
holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose
of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Notice to prospective investors in Qatar </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of common stock
described in this prospectus have not been, and will not be, offered, sold or delivered, at any time, directly or indirectly in the State of Qatar in a manner that would constitute a public offering. This prospectus has not been, and will not be,
registered with or approved by the Qatar Financial Markets Authority or Qatar Central Bank and may not be publicly distributed. This prospectus is intended for the original recipient only and must not be provided to any other person. It is not for
general circulation in the State of Qatar and may not be reproduced or used for any other purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_20"></A>Legal matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal matters
relating to this offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_21"></A>Experts
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements as of December&nbsp;31, 2023 and December&nbsp;31, 2022, and for the years then ended, included in this Prospectus have been audited
by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting
and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_22"></A>Where you can find more information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File Number <FONT STYLE="white-space:nowrap">333-</FONT>
&#8195;&#8195;&#8195;&#8195;) under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information included in
the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other
documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy
statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at https://www.mbxbio.com and upon completion of the offering,
you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and
any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not
incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc790774_23"></A>Index to financial statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt"><B>Index to Annual Financial Statements</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_4">Statements of Stockholders&#146; Deficit (Equity) and Convertible PreferredStock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt"><B>Index to Unaudited Interim Condensed Financial Statements</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_7">Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-27</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_8">Condensed Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_9">Condensed Statements of Stockholders&#146; Deficit (Equity) and Convertible Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_10">Condensed Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-30</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin790774_11">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-31</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_1"></A>Report of independent registered public accounting firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the Stockholders and the Board of Directors of MBX Biosciences, Inc. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Opinion
on the financial statements </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have audited the accompanying balance sheets of MBX Biosciences, Inc. (the Company) as of December&nbsp;31, 2023 and 2022,
the related statements of operations and comprehensive loss, stockholders&#146; equity (deficit) and convertible preferred stock, and cash flows for the years then ended, and the related notes (collectively referred to as the &#147;financial
statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2023 and 2022, and the results of its operations and its cash flows for the years then
ended, in conformity with U.S. generally accepted accounting principles. </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Basis for opinion </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an
opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">/s/ Ernst&nbsp;&amp; Young LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">We have served as the Company&#146;s auditor since 2023.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indianapolis, Indiana</P></TD></TR>
</TABLE>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">March&nbsp;22, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_2"></A>Balance sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share repurchase liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock, $0.0001 par value, 53,598,587 shares authorized, issued and
outstanding (liquidation preference of $36,822,229) as of December&nbsp;31, 2023 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock, $0.0001 par value, 129,240,032 shares authorized and 129,240,032
issued and outstanding (liquidation preference of $116,316,029) as of December&nbsp;31, 2023 and 129,240,032 shares authorized and 53,118,933 issued and outstanding (liquidation preference of $47,807,040) as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.0001 par value, 237,000,000 shares authorized and 15,113,124 issued and outstanding as of
December&nbsp;31, 2023 and 237,000,000 shares authorized and 12,118,446 issued and outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_3"></A>Statements of operations and comprehensive loss </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Years ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reclassification of net (gains) losses included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in computation of net loss per common share, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,018,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,247,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:220pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_4"></A>Statements of stockholders&#146; equity (deficit) and convertible preferred stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(in thousands, except share amounts) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series A<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series B<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income (Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,708,268</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,885</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of Series B Convertible Preferred Stock, net of $429 issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,118,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="37" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance&nbsp;at&nbsp;December&nbsp;31,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,118,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,118,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>411</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(43,020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,605</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of Series B Convertible Preferred Stock, net of $30 issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,121,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="37" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>129,240,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>115,856</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,113,124</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(75,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(72,468</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:8pt">
<TD COLSPAN="40" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_5"></A>Statements of cash flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Years ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Non cash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion and amortization of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Non cash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from the issuance of Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible notes issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vesting of early exercised stock options and founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> property and equipment disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_6"></A>Notes to financial statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>for the years ended December&nbsp;31, 2023 and 2022 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Nature of business and liquidity </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX Biosciences, Inc. (&#147;MBX&#148;
or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of
novel candidates for endocrine and metabolic disorders. The Company was organized in August 2018 in Indiana as a Limited Liability Company and converted to a C corporation in the state of Delaware in April 2019. The Company maintains its corporate
offices in Carmel, Indiana. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since inception, the Company has devoted substantially all of its resources to drug discovery and development of its product candidates
MBX 2109, MBX 1416 and MBX 4291, and other preclinical programs, building an intellectual property portfolio, organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these
operations. The Company does not have any products approved for sale and have not generated any revenue from product sales. The Company has historically funded its operations primarily through sales of convertible preferred stock and convertible
notes, which generated approximately $150.6 million in aggregate gross proceeds. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From inception and through December&nbsp;31, 2023, the Company has devoted substantially all of its efforts to drug discovery and development. The Company has a limited
operating history, has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December&nbsp;31, 2023, the Company has an accumulated deficit of $75.6&nbsp;million and
cash, cash equivalents and marketable securities of $80.7&nbsp;million. Based on the Company&#146;s current business plan, management believes that existing cash and cash equivalents and marketable securities will be sufficient to fund the
Company&#146;s obligations for at least 12 months from the date of issuance of these financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Summary of significant accounting policies
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements have been
prepared in accordance with generally accepted accounting principles in the United States of America (US GAAP). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Use of estimates </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of financial statements in conformity with US&nbsp;GAAP requires management to make judgments, assumptions, and estimates that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the
determination of the fair value of stock option grants and estimates related to the amount of prepaid and accrued research and development expenses as of the balance sheet date. Management evaluates its estimates and assumptions on an ongoing basis
using historical experience and other factors, including the current economic environment, and makes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
adjustments when the facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from
those estimates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Cash and cash equivalents </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considers
all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&nbsp;31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and savings deposits,
money market fund holdings, and commercial paper. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Concentration of credit risk </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company&#146;s
investment policy includes guidelines regarding the quality of the financial institutions and financial instruments and defines allowable marketable securities that it believes minimizes the exposure to concentration of credit risk. The Company may
invest in money market funds (minimum of $1&nbsp;billion in assets), U.S. Treasury securities, corporate debt, bank debt, U.S. government-related agency securities, other sovereign debt, municipal debt and commercial paper. These deposits may exceed
federally insured limits. The Company has not experienced any losses historically in these accounts. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Property and equipment </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life
of each asset, generally three to seven years. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Upon retirement or sale, the cost of assets disposed of, and the related accumulated
depreciation, are removed from the accounts and any resulting gain or loss is included in loss from operations in the period realized. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating
expenses as incurred. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment losses have been recognized during the years ended December&nbsp;31, 2023 and 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Fair value of financial instruments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value is defined as the
price that the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most
advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 investments) and the lowest priority to unobservable inputs (Level 3 investments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The three levels of the fair value hierarchy are as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level&nbsp;1 inputs: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level&nbsp;2 inputs: Quoted prices in markets that are not considered to be active or financial instrument valuations for
which all significant inputs are observable, either directly or indirectly; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Level&nbsp;3 inputs: Prices or valuations that require inputs that are both significant to the fair value measurement and
unobservable. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value
measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s money market funds and marketable securities are carried at fair value determined according to the fair value hierarchy described above (Level 1 and
Level&nbsp;2, respectively). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses include employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; external research and
development expenses incurred under arrangements with third parties, such as contract research organization agreements, contract manufacturing organization agreements, clinical sites and consultants; costs associated with preclinical and clinical
activities; costs associated with required regulatory filings, licenses and fees; costs incurred in development of intellectual property; and an allocated portion of facilities and other infrastructure costs associated with our research and
development activities. Costs incurred in connection with research and development activities, both internal and external, are expensed as incurred. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Costs are
considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to the Company by its clinical sites and vendors. These costs consist of direct and indirect costs
associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued
expenses related to these costs. These accrued or prepaid expenses are based on management&#146;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of
these factors and adjusts estimates accordingly. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Deferred financing costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Direct costs incurred in connection with the issuance of the convertible notes are capitalized as incurred, presented as a direct reduction of the carrying amount of the
notes, and amortized over the period of indebtedness using the effective interest method. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Patent costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in
general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company measures all stock options and other stock-based awards granted to employees, nonemployees, and directors based on the fair value on the date of the grant
and recognizes compensation expense of those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
awards over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues stock option awards with only service-based vesting
conditions and records the expense for these awards using the straight-line method. The Company&#146;s policy is to account for forfeitures when they occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&#146;s payroll costs are classified or in which the award recipients&#146; service payments are classified. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical
and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until it has adequate historical data regarding
the volatility of its own traded stock price. The expected term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The expected term of
stock options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the US Treasury yield curve in effect at the time of grant
of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero because the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable
future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In determining the exercise prices for options granted, the Company has considered the estimated fair value of the common stock as of the measurement date.
The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> sales of the
Company&#146;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Among other factors are the Company&#146;s financial position and
historical financial performance, forecasted future operations of the Company, an evaluation or benchmark of the Company&#146;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying
the factors used could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a
determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies,
and results of recent operations. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on
deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded
amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records
uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical
merits of the position and (2)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent
likely to be realized upon ultimate settlement with the related tax authority. The Company&#146;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. Any accrued interest and penalties are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
included within the related tax liability. The Company had no significant uncertain tax positions as of December&nbsp;31, 2023 and December&nbsp;31, 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) asset and lease liability for substantially all leases for which it is a lessee, in accordance with ASC 842. Leases with an initial term of 12 months or less are not recorded on
the balance sheet. The Company recognizes lease expense for leases on a straight-line basis over the lease term. At inception of a contract, the Company considers all relevant facts and circumstances to assess whether or not the contract represents
a lease by determining whether or not the contract conveys the right to control the use of an identified asset, either explicit or implicit, for a period of time in exchange for consideration. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basic and diluted net loss per share </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company calculates basic and
diluted net loss per share using the <FONT STYLE="white-space:nowrap">two-class</FONT> method. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between
common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#146;s Series A Convertible Preferred Stock and Series B Convertible Preferred Stock
are participating securities. These participating securities do not contractually require the holders of such shares to participate in the Company&#146;s losses. As such, net losses for the years presented were not allocated to the Company&#146;s
participating securities. Accordingly, basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net
loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially
dilutive securities include vested and unexercised stock options, restricted stock issued upon early exercise of stock options, restricted stock related to unvested founder shares and convertible preferred shares. The dilutive effect of stock
options are computed using the treasury stock method and the dilutive effect of convertible preferred shares is calculated using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company has generated a net loss for all periods
presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Segments </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Operating segments are defined as components of an entity
for which separate financial information is made available and is regularly evaluated by the chief operating decision maker (&#147;CODM&#148;) in making decisions regarding resource allocation and assessing performance. The Company&#146;s CODM is
the chief executive officer and operations are managed as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#146;s assets are located in the United States. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive income (loss) </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Comprehensive income (loss) represents
net income (loss) for the period plus the results of certain other changes in stockholders&#146; equity (deficit). The Company&#146;s comprehensive loss included unrealized gains related to marketable securities for the years ended December&nbsp;31,
2023 and 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency, decision usefulness and effectiveness of income tax
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
disclosures. The amendments in this ASU require an entity to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. An entity is also required
to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes
and also disaggregated by individual jurisdictions. The amendments also remove certain disclosures that are no longer considered cost beneficial. The amendments are effective prospectively for public entities for annual periods beginning after
December&nbsp;15, 2024 and for entities other than public entities for annual periods beginning after December&nbsp;15, 2025. Early adoption and retrospective application are permitted. Although the ASU only modifies the Company&#146;s required
income tax disclosures, the Company is currently evaluating the impact of adopting this guidance on its financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2023, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2023-07,</FONT> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional and more detailed
information about a reportable segment&#146;s expenses. The amendments expand a public entity&#146;s segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker
(&#147;CODM&#148;), clarifying when an entity may report one or more additional measures to assess segment performance, requiring enhanced interim disclosures, providing new disclosure requirements for entities with a single reportable segment, and
requiring other new disclosures. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods within fiscal years beginning after December&nbsp;15, 2024, with early
adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company does not anticipate the adoption to have a material impact on the Company&#146;s financial disclosures. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Fair value measurements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents information about
the Company&#146;s financial instruments as of December&nbsp;31, 2023 and 2022, that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value (<I>in
thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. Marketable securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of
the Company&#146;s marketable securities as of December&nbsp;31, 2023 and 2022 is based on Level&nbsp;1 and Level&nbsp;2 inputs. The Company&#146;s investments consist mainly of U.S. government and agency securities, government-sponsored bond
obligations and certain other corporate debt securities. Fair value is determined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs
are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
There were no transfers between levels within the fair value hierarchy during the years ended December&nbsp;31, 2023 and 2022. The Company has assessed U.S. government treasuries as Level&nbsp;1 and all other marketable securities as Level&nbsp;2
within the fair value hierarchy of ASC 820. The Company classifies its entire investment portfolio as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> as defined in ASC 320, Debt Securities, and
views all investments as available for use in its current operations. We have therefore classified all securities as current, even if we do not necessarily intend to dispose of the securities in the following year. Securities are carried at fair
value with the unrealized gains (losses) reported in other comprehensive income (loss). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023 and 2022, none of the Company&#146;s
investments were determined to be other than temporarily impaired. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the Company&#146;s investments (<I>in thousands</I>): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair values of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities as
of December&nbsp;31, 2023, by contractual maturity, are summarized as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due in one year or less</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due after one year through two years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Prepaid expenses and other current assets </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid and other current assets consisted of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Property and equipment, net </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net consisted of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation expense was $0.2&nbsp;million for the year ended December&nbsp;31, 2023 and $0.1&nbsp;million for the year ended
December&nbsp;31, 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Accrued expenses </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses consisted
of the following (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>2022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>2023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Commitments and contingencies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2022, the Company entered into an operating lease
agreement for principal executive office in Carmel, Indiana (the &#147;Carmel Lease&#148;). The Carmel Lease commenced in October 2022 and has an initial term of 39 months, terminating in December 2025, with an option to extend for 36 additional
months at the Company&#146;s discretion. The option to extend is not considered reasonably certain as of the lease inception. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, The Company entered
into an operating lease agreement for laboratory space in Indianapolis, Indiana (the &#147;Laboratory Lease&#148;). The Laboratory Lease commenced in December 2023 and has a term of 12 months, terminating in December 2024. The lease does not contain
an option to extend the term. Due to the lease term being only one year, we have elected to account for it as a short-term lease with no corresponding lease liability or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset recorded, and lease payments recognized as expense on a straight-line basis over the lease term. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has no other operating or finance leases as of December&nbsp;31, 2023 or 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The future minimum rent payments relating to the Carmel Lease under the terms and conditions existing as of
December&nbsp;31, 2023, are summarized as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>Years ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company incurred rent expense of $0.2&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2023 and 2022,
respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the operating lease term and discount rate for the Carmel Lease as of December&nbsp;31, 2023 and 2022: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash paid for amounts included in the measurement of the Company&#146;s operating lease liability was $0.2&nbsp;million for the year
ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the amount of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities included on the Company&#146;s balance sheet as of December&nbsp;31, 2023 and 2022 (<I>in thousands</I>): </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Right-of</FONT> use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>License agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2020, the
Company entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation (&#147;IURTC&#148;) (the &#147;License Agreement&#148;), to license certain intellectual property arising under the Research Agreement.
Pursuant to the License Agreement, IURTC is also entitled to receive reimbursement for all patent prosecution and maintenance related expenses and an annual maintenance fee of up to $0.1&nbsp;million beginning in the first year in which the first
commercial sale occurs. In addition, IURTC is entitled to the receipt of specified clinical and regulatory milestones, as defined in the License Agreement, up to an aggregate of $0.4&nbsp;million, plus certain royalties on net sales. The parties may
terminate the License Agreement at any time by mutual agreement. In addition, the Company may terminate the License Agreement by giving 90 days&#146; notice to IURTC and IURTC may terminate the License Agreement immediately in the event of certain
breaches of the agreement by the Company or upon the Company&#146;s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the License Agreement will
continue until the final expiration of all patent rights under the License Agreement. In consideration for the license, during the years ended December&nbsp;31, 2023 and 2022, the Company paid immaterial licensing fees to IURTC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential
range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Convertible notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, the Company received gross cash
proceeds of $10.0&nbsp;million from the issuance of convertible notes (the &#147;2022 Notes&#148;). The Company incurred immaterial issuance costs in relation to the issuance of the 2022 Notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2022 Notes accrued interest at a rate of 8% per annum and were not payable until converted or paid in connection with repayment in full of the principal amount of
the 2022 Notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The 2022 Notes a) automatically convert into shares of convertible preferred stock from the next qualified financing, as defined in the 2022 Notes
agreement, at 90% of the per share price of the convertible preferred stock sold in the qualified financing consummated on or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in the qualified
financing consummated after March&nbsp;31, 2023; b) note holders had the right, but not the obligation to convert into shares of convertible preferred stock from the next <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing at 90% of the
per share price of the convertible preferred stock sold in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated on or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in
the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated after March&nbsp;31, 2023; or c) redeem in the event of a change in control. The number of shares of convertible preferred stock to be issued upon such conversion would
be equal to the quotient obtained by dividing the amount due on the date of conversion by 90% of the per share price of the convertible preferred stock sold in the qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing, if
consummated prior to March&nbsp;31, 2023, or 80% of the per share price, if consummated after March&nbsp;31, 2023. In the event of a change in control, the holders would receive an amount equal to 2.5 times the principal then outstanding plus the
amount of accrued interest outstanding immediately prior to the closing of such change in control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company evaluated the provisions of the Notes and determined
an embedded derivative liability existed which was recorded upon issuance and remeasured periodically through the conversion date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with the Series B
Convertible Preferred Stock issuance (&#147;Series B Issuance&#148;), the 2022 Notes were converted into 12,573,381 shares of Series B Convertible Preferred Stock at a price of $0.90, on November&nbsp;7, 2022. As the Series B Issuance was a
qualified financing event and was consummated prior to March&nbsp;31, 2023, the shares were converted using a 90% discount rate as follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Principal balance of convertible notes</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total converted to Series B convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Convertible preferred stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
November&nbsp;7, 2022, the Company amended and restated its certificate of incorporation increasing the total number of shares authorized to issue 237,000,000 shares of common stock, $0.0001 par value per share, and 182,838,619 shares of convertible
preferred stock, $0.0001 par value per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Issuances of convertible preferred stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July 2020, the Company entered into a Series A convertible preferred stock purchase agreement (&#147;Series A SPA&#148;) under which it issued 29,112,081 shares of
Series A convertible preferred stock, for cash, at a price of $0.687 per share, for gross proceeds of $20.0&nbsp;million (the &#147;Initial Series A Closing&#148;). The Company incurred issuance costs of $0.3&nbsp;million in relation to the issuance
of Series A Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series A Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. The Series A SPA contained provisions that potentially
obligated the Company to sell an additional 14,556,039 shares of Series A Convertible Preferred Stock at $0.687 per share in an additional closing contingent upon either the achievement of a regulatory milestone defined in the Series A SPA or upon
the agreement of the Company&#146;s board of directors and lead investor to waive the requirement to achieve the milestone. In the event that an Initial Series A Closing purchaser failed to purchase all of their required shares in the subsequent
Series A closing, each of the Series A Convertible Preferred Stock held by such purchaser automatically converted into <FONT STYLE="white-space:nowrap">one-half</FONT> of a share of common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with the Initial Series A Closing, convertible notes issued by the Company in 2019 and 2020, including accrued interest and accrued deferred compensation,
plus interest, were converted into 8,474,865 shares of Series A convertible preferred stock at a conversion price equal to 90% of the Series A financing, or $0.6183, representing a total of $5.4&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;12, 2021, the Company sold 16,011,641 additional shares of Series A convertible preferred stock at the same terms and conditions as those contained in
the initial Agreement. The gross proceeds from the sale of Series A Convertible Preferred Stock upon achieving the milestone event was $11.0&nbsp;million at $0.687 per share. The Company incurred immaterial issuance costs in relation to the issuance
of Series A Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series A Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;7, 2022 (the &#147;Initial Series B Closing&#148;), the Company entered into a Series B Preferred Stock Purchase Agreement (the &#147;Series B
SPA&#148;) to issue certain investors Series B Convertible Preferred Stock at a purchase price of $0.90 per share ($0.0001 par value). The Company amended the Certificate of Incorporation (&#147;Charter&#148;) on November&nbsp;7, 2022, which
authorized the issuance of 129,240,032 shares of Series B Convertible Preferred Stock, in addition to 53,598,587 shares of Series A Convertible Preferred Stock issued and outstanding. The Company also executed the Amended and Restated Right of First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement (the &#147;ROFR and CS&#148;) and the Amended and Restated Investors&#146; Rights Agreement (the &#147;A&amp;R Investors&#146; Rights&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Initial Series B Closing resulted in the issuance of 40,545,552 shares of Series B Convertible Preferred Stock, at a price of $0.90 per share, for gross cash
proceeds of $36.5&nbsp;million. The Company incurred issuance costs of $0.4&nbsp;million in relation to the issuance of Series B Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series B Convertible Preferred
Stock in mezzanine equity in the accompanying balance sheets. Concurrently with the Initial Series B Closing, the 2022 Notes, including accrued interest, were converted into 12,573,381 shares of Series B Convertible Preferred Stock at a conversion
price equal to 90% of the Series B financing. After the Initial Closing, the Company agreed to sell on the same terms and conditions as the first sale, an additional 76,121,099 shares of Series B Preferred Stock (the &#147;Series B Milestone
Issuance&#148;) upon achieving certain development milestones. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;15, 2023, the Company issued 76,121,099 shares of Series B Convertible Preferred
Stock, at a price of $0.90 per share, for gross cash proceeds of $68.5&nbsp;million in the Series B Milestone Issuance. The Company incurred immaterial issuance costs in relation to this issuance of Series B Convertible Preferred Stock, which have
been recorded as a reduction to the value of the Series B Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the Series A and Series B Convertible Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Series A and Series B Convertible Preferred Stock are
entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A and Series B Convertible Preferred Stock held by such holder are convertible as of the record date for determining
stockholders entitled to vote on such matter. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Election of directors </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of record of shares of Series A Convertible Preferred Stock, exclusively and as a separate class, shall be entitled to elect three directors of the Company.
The holders of record of shares of Series B Convertible Preferred Stock, exclusively and as a separate class, shall be entitled to elect one director of the Company. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-cumulative</FONT> dividend </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders of Series A and Series B Convertible Preferred Stock, in preference to the holders of common stock, are entitled to receive, when, as and if declared by the
board of directors of the Company, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the Series A and Series B original issue price per annum on each outstanding share of Series A and
Series B Convertible Preferred Stock (the &#147;Preferred Dividends&#148;). All such Preferred Dividends shall be payable only when, as and if declared by the board of directors of the Company and shall be
<FONT STYLE="white-space:nowrap">non-cumulative.</FONT> No dividends have been declared <FONT STYLE="white-space:nowrap">to-date</FONT> as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion right </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of Series A and Series B Convertible
Preferred Stock is automatically converted into common stock upon either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $2.061 or $2.25, respectively, per share (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act
of 1933, as amended, resulting in at least $50,000,000 of gross proceeds to the Corporation and in connection with such offering the common stock is listed for trading on the Nasdaq Stock Market&#146;s National Market, the New York Stock Exchange or
another exchange or marketplace approved the Board of Directors or (b)&nbsp;the affirmative vote or written consent of the majority preferred stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation, the holders of shares of Series A and Series B Convertible Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its
stockholders, and in the event of a Deemed Liquidation Event (as defined in the Company&#146;s amended and restated certificate of incorporation), the holders of shares of Series A and Series B Convertible Preferred Stock then outstanding shall be
entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the available proceeds, as applicable, before any payment shall be made to the holders of common stock by reason of their ownership
thereof, an amount per share equal to the greater of (i)&nbsp;the Series A and Series B Convertible Preferred Stock original issue prices, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable
had all shares of Series A and Series B Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s certificate of incorporation, as amended and restated, authorized the Company to issue 237,000,000 shares of common stock, $0.0001 par value. As of December&nbsp;31, 2023 and 2022, there were 15,113,124 and 12,118,446 shares of common
stock issued and outstanding, respectively. Shares of common stock issued and outstanding as of December&nbsp;31, 2023, include 1,085,978 shares of restricted stock related to the unvested portion of early exercised common stock options. Shares of
common stock issued and outstanding as of December&nbsp;31, 2022, include 1,171,406 shares of restricted stock related to the unvested portion of early exercised common stock options and 1,079,167 shares of restricted stock related to unvested
founder shares. These are included in shares of common stock as they are considered to be legally outstanding as of December&nbsp;31, 2023 and 2022, respectively. These shares are subject to the Company&#146;s option to repurchase and are not
transferrable until such time as they are fully vested. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock reserved </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of common stock that have been reserved for the potential conversion of Preferred Stock, and outstanding stock options granted and stock options
available for grant under the Company&#146;s 2019 Stock Option and Grant Plan (the &#147;2019 Plan&#148;) as of December&nbsp;31, 2023 and 2022, are as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,118,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,465,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,980,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock options available for grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,536,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,226,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,719,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,045,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Stock-based compensation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2019
Stock option and grant plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s 2019 Plan, as amended, provides for the Company to sell or issue common stock or restricted common stock or
to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors, and consultants of the Company. The 2019 Plan is administered by the board of directors or at the
discretion of the board of directors by a committee of the board. The exercise prices, vesting periods, and other restrictions are determined at the discretion of the board of directors or a committee of the board, except that the exercise price per
share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the contractual term of stock option may not be greater than 10 years. Stock options granted to date typically vest and
become exercisable over four years from the date of grant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of shares of common stock that may be authorized under the 2019 Plan is 44,820,428
shares, of which 8,226,538 remained available for future grant as of December&nbsp;31, 2023. The shares available for issuance under the 2019 Plan may be authorized but unissued shares or shares reacquired by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock option valuation </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25&#151;$0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34&#151;$0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80%&#151;90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.62%&#151;4.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.42%&#151;4.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.02&#151;6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.02&#151;6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The determination of the grant date fair value of stock-based awards granted to employees, directors and nonemployees during the years
ended December&nbsp;31, 2023 and 2022, is estimated using the Black-Scholes option-pricing model, which is affected by a number of assumptions, presented as follows: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value of common stock: </I></B>As there has been no public market for the Company&#146;s common stock to date, the Company develops an estimate of the fair
value of our common stock on each grant date of options to purchase common stock. The fair value of the common stock underlying stock option awards was determined on each grant date by the Company&#146;s board of directors, taking into account input
from management and independent third-party valuation specialists, as well as other objective and subjective factors. These objective and subjective factors include, but are not limited to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development programs, including the status of preclinical studies and clinical trials for
our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a
sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">trends and developments in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the economy in general. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividends: </I></B>Expected dividend yield is zero because the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
in the foreseeable future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected volatility: </I></B>The Company lacks company-specific historical and implied volatility information. Therefore, it
estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. To
identify these peer companies, the Company considered the industry, stage of development, size, and financial leverage of potential comparable companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Risk-free interest rate: </I></B>The risk-free interest rate is determined by reference to the US Treasury yield
curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expected term: </I></B>The expected
term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The expected term of stock options granted to
<FONT STYLE="white-space:nowrap">non-employees</FONT> is equal to the contractual term of the option award. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Summary of option activity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s stock option activity regarding employees, directors, and nonemployees for the years ended December&nbsp;31, 2023 and 2022, is summarized as follows
(<I>in thousands except share and per share amounts</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>average<BR>remaining<BR>contractual<BR>life (years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>intrinsic<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding&#151;January 1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,827,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,516,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(568,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(289,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding&#151;December 31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,465,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,067,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,009,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,557,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding and exercisable&#151;December 31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,980,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additional information with regard to stock option activity involving employees and directors for the years ended December&nbsp;31, 2023
and 2022, is as follows (<I>in thousands except per share amounts</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8195;As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average grant date fair value per option of total options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aggregate intrinsic value of stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, total unrecognized compensation cost related to the unvested awards to employees, directors, and
nonemployees is $10.2&nbsp;million, which is expected to be recognized over a weighted-average period of 3.4 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2023 and 2022, the Company recorded stock-based compensation expense regarding its employees, directors, and nonemployees as
follows (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8195;For&nbsp;the&nbsp;year&nbsp;ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recorded no
income tax benefit for the net loss incurred for the years ended December&nbsp;31, 2023 and 2022, due to the uncertainty of realizing a benefit from such losses. All of the Company&#146;s operating losses since inception have been generated in the
United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s effective tax rate is as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>&#8195;As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State tax rate, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Debt financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Permanent differences and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Significant components of the Company&#146;s deferred tax assets as of December&nbsp;31, 2023 and 2022, are included
in the table below (<I>in thousands</I>): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Capitalized research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets,
which are composed primarily of net operating loss (&#147;NOL&#148;) carryforwards, capitalized research and development costs and research and development credit carryforwards. Management has considered the Company&#146;s history of net losses
incurred since inception and probability of future losses to conclude it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. As a result, the Company has established a valuation
allowance for the full amount of the net deferred tax assets as of December&nbsp;31, 2023 and 2022. At such time as it is determined that it is more likely than not that the deferred tax assets will be realizable, the valuation allowance will be
reduced. The valuation allowance increased by $9.2&nbsp;million during the year ended December&nbsp;31, 2023, due to the increase in the deferred tax assets by the same amounts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2023, the Company had $30.1&nbsp;million and $71.3&nbsp;million of US federal NOLs and state NOL carryforwards, respectively. The federal NOLs
have no expiration and the state NOLs begin to expire in 2039. In addition, the Company had US federal research and development tax credit carryforwards of $4.7&nbsp;million, which may be available to reduce future tax liabilities which start to
expire in 2039. The Company had Indiana state research and development tax credits of $1.2&nbsp;million as of December&nbsp;31, 2023, which begin to expire in 2029. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Effective January&nbsp;1, 2022, the 2017 Tax Cuts and Jobs Act (&#147;TCJA&#148;) requires research and experimental (&#147;R&amp;E&#148;) expenses under Internal
Revenue Code Section&nbsp;174 to be capitalized. R&amp;E expenses are required to be amortized over a five-year period for domestic expenses and over a fifteen-year period for foreign expenses. Prior to the TCJA being effective, businesses had the
option of deducting Section&nbsp;174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The Company has reflected this change in treatment of R&amp;E expenses in the current tax provision and resulted in the
capitalization of $27.3&nbsp;million and $21.0&nbsp;million of R&amp;E expenses for tax years ended December&nbsp;31, 2023 and 2022, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Realization of
the future tax benefits is dependent on many factors, including the Company&#146;s ability to generate taxable income within the NOL carryforward period. Under the provisions of Sections 382 and 383 of the Internal Revenue Code, and corresponding
provisions of state law, certain substantial changes in the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of NOL carryforwards, which could
be used annually to offset future taxable income. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits will
not impact the Company&#146;s effective tax rate. The Company is subject to taxation in the U.S and various state jurisdictions. All tax years since incorporation remain open to examination by the major taxing jurisdictions (state and federal) to
which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (IRS) or other authorities if they have or will be used in a future period. The Company is not
currently under examination by the IRS or any other jurisdictions for any tax year. The Company&#146;s practice is to recognize interest and penalties related to income tax matters in income tax expense. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company had no accrued interest or penalties related to income tax matters in the Company&#146;s balance sheets as of December&nbsp;31, 2023, and 2022. Further, the
Company is not currently under examination by any federal, state or local tax authority. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Inflation Reduction Act 2022 (&#147;IRA 2022&#148;) which incorporates
a Corporate Alternative Minimum Tax (CAMT) was signed on August&nbsp;16, 2022 and became applicable to the Company on January&nbsp;1, 2023. The new tax will require companies to compute two separate calculations for federal income tax purposes and
pay the greater of the new minimum tax or their regular tax liability. As of December&nbsp;31, 2023, IRA 2022 has not had a material impact to the Company&#146;s financial results. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the changes to the Company&#146;s gross unrecognized tax benefits for the years ended December&nbsp;31, 2023 and 2022, respectively (in
thousands): </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decrease related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The unrecognized tax benefit amounts are reflected in the determination of the Company&#146;s deferred tax assets. If recognized, none of
these amounts would affect the Company&#146;s effective tax rate, since it would be offset by an equal corresponding adjustment in the valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits
within the next twelve months. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is subject to taxation in the U.S. federal and various state jurisdictions. All tax years since incorporation remain open
to examination by the major taxing jurisdictions (state and federal) to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (IRS) or other
authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax year. The Company&#146;s practice is to recognize interest and penalties related to income
tax matters in income tax expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company had no accrued interest or penalties related to income tax matters in the Company&#146;s balance sheets as of
December&nbsp;31, 2023, and 2022. Further, the Company is not currently under examination by any federal, state or local tax authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Defined contribution plan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company established a defined contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet
minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. As of December&nbsp;31, 2023 and 2022, the Company did not make any contributions to the plan on behalf of our employees.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. Net loss per share attributable to common stockholders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net
loss per share </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company.
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in computation of net loss per common share, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,018,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,247,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s potential dilutive securities, which include convertible preferred stock, restricted stock related to early exercise
of common stock options, restricted stock related to unvested founder shares and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted
average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The potential dilutive securities included in the table below, presented on an as converted
basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,118,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,465,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,980,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to early exercise of options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,171,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to unvested founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,079,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,433,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,905,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. Related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April
2019, the Company executed a Master Research Agreement with The Trustees of Indiana University (the &#147;Research Agreement&#148;) pursuant to which the Company agreed to fund certain research of a director and former officer of the Company. The
period of performance for this agreement is June&nbsp;1, 2019 through April&nbsp;30, 2022 and the contract totals approximately $2.8&nbsp;million. On February&nbsp;14, 2022, the Research Agreement was amended to extend the period of performance from
April&nbsp;30, 2022 to April&nbsp;30, 2025 and increase the total contract costs by $3.0&nbsp;million. The Company paid $0.7&nbsp;million and $1.2&nbsp;million pursuant to this agreement during the years ended December&nbsp;31, 2023 and 2022,
respectively. The Research Agreement also provides the Company an option to license the technology arising under the agreement (see Note 8 and 16). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, two of the officers of the Company, who are also directors, participated in the 2022 Notes financing
totaling $0.9&nbsp;million. The 2022 Notes were converted to Series B Convertible Preferred Stock (see Note 9 and 10) in November 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2023, one of the
officers of the Company, who is also a director, participated in the Series B Milestone Issuance financing totaling $0.7&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>17. Subsequent events
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has evaluated subsequent events through March&nbsp;22, 2024, the date the financial statements were available to be issued, to ensure these
financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has concluded no subsequent events have occurred
that require disclosure, except for those referenced below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>License agreement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;5, 2024, The Company and IURTC entered into a fourth amendment to The License Agreement (the &#147;Amendment&#148;). The Amendment specifies IURTC is
entitled to the receipt of additional clinical and regulatory milestones, as defined in the Amendment, up to an aggregate of $9.0&nbsp;million. Following the execution of the Amendment, future remaining clinical and regulatory milestone payments in
the License Agreement and all amendments total up to $9.3&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">****** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_7"></A>CONDENSED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(in thousands, except
share and per share amounts) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Share repurchase liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock, $0.0001 par value, 53,598,587 shares authorized, issued and
outstanding (liquidation preference of $36,822,229) as of March&nbsp;31, 2024 and December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock, $0.0001 par value, 129,240,032 shares authorized and 129,240,032
issued and outstanding (liquidation preference of $116,316,029) as of March&nbsp;31, 2024 and December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.0001 par value, 237,000,000 shares authorized and 15,544,989 issued and outstanding as of
March&nbsp;31, 2024 and 237,000,000 shares authorized and 15,113,124 issued and outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_8"></A>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(Unaudited - in thousands, except share and per share amounts) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Three Months Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reclassification of net (gains) losses included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in computation of net loss per common share, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,299,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,455,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:220pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_9"></A>CONDENSED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) AND CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(Unaudited - in thousands, except share amounts) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series A<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series B<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,118,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,118,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>411</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(43,020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,605</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at March&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,118,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,447,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>692</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,969</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series A<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Series B<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:6.5pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at January&nbsp;1, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>129,240,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>115,856</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,113,124</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(75,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(72,468</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">431,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:arial">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:arial"><B>Balance at March&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,598,587</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>129,240,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>115,856</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,544,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,875</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,920</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83,047</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_10"></A>CONDENSED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>(Unaudited -
in thousands) </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2.00pt solid #000000;border-bottom:1.00px solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Non cash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion and amortization of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payments related to offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vesting of early exercised stock options and founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred initial public offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>See notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>MBX BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin790774_11"></A>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. NATURE OF BUSINESS AND LIQUIDITY </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MBX Biosciences, Inc. (&#147;MBX&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel
precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders. The Company was organized in August 2018 in Indiana as a Limited
Liability Company and converted to a C corporation in the state of Delaware in April 2019. The Company maintains its corporate offices in Carmel, Indiana. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since
inception, the Company has devoted substantially all of its resources to drug discovery and development of its product candidates MBX 2109, MBX 1416 and MBX 4291, and other preclinical programs, building an intellectual property portfolio,
organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company does not have any products approved for sale and have not generated any revenue from product
sales. The Company has historically funded its operations primarily through sales of convertible preferred stock and convertible notes, which generated approximately $150.6&nbsp;million in aggregate gross proceeds. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From inception and through March&nbsp;31, 2024, the Company
has devoted substantially all of its efforts to drug discovery and development. The Company has a limited operating history, has incurred operating losses since inception and expects to continue to incur significant operating losses for the
foreseeable future. As of March&nbsp;31, 2024, the Company has an accumulated deficit of $87.9&nbsp;million and cash, cash equivalents and marketable securities of $70.3&nbsp;million. Based on the Company&#146;s current business plan, management
believes that existing cash and cash equivalents and marketable securities will be sufficient to fund the Company&#146;s obligations for at least 12 months from the date of issuance of these financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying unaudited condensed financial
statements as of March&nbsp;31, 2024 and for the three months ended March&nbsp;31, 2023 and 2024 have been prepared in accordance with U.S. generally accepted accounting principle (U.S. GAAP) for interim financial information and pursuant to Article
10 of Regulation of the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal
and recurring adjustments that the Company believes are necessary to fairly state the Company&#146;s financial position and the results of its operations and cash flows. The results for the three months ended March&nbsp;31, 2024 are not necessarily
indicative of the results expected for the full fiscal year or any subsequent interim period. The condensed balance sheet at December&nbsp;31, 2023 has been derived from the audited financial statements at that date but does not include all
disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed financial statements and the notes
accompanying them should be read in conjunction with the Company&#146;s audited consolidated financial statements for the year ended December&nbsp;31, 2023 included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s significant accounting policies are disclosed in the audited financial statements appearing elsewhere in this prospectus. Since the date of such
audited financial statements, there have been no changes to the Company&#146;s significant accounting policies, except as noted below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Deferred offering
costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company capitalizes as deferred offering costs all direct and incremental legal, professional, accounting and other third-party fees incurred in
connection with the Company&#146;s initial public offering (&#147;IPO&#148;). The deferred offering costs will be offset against the IPO proceeds upon the consummation of an offering. As of March&nbsp;31, 2024, $1.3&nbsp;million of deferred offering
costs were included in accounts payable and $0.4&nbsp;million deferred offering costs were included in accrued expenses in the accompanying balance sheets. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, new
accounting pronouncements are issued by the FASB or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are
not yet effective will not have a material impact on the accompanying financial statements and disclosures. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents information about the Company&#146;s financial instruments as of March&nbsp;31, 2024 and December&nbsp;31, 2023, that are measured at fair
value on a recurring basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities (cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">68,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">66,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. MARKETABLE SECURITIES </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair
value of the Company&#146;s marketable securities as of March&nbsp;31, 2024 and December&nbsp;31, 2023 is based on Level&nbsp;1 and Level&nbsp;2 inputs. The Company&#146;s investments consist mainly of U.S. government and agency securities,
government-sponsored bond obligations and certain other corporate debt securities. Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry
standard valuation models, for which all significant inputs are observable, either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities;
and other observable inputs. There were no transfers between levels within the fair value hierarchy during the three months ended March&nbsp;31, 2024 and year ended December&nbsp;31, 2023. The Company has assessed U.S. government treasuries as
Level&nbsp;1 and all other marketable securities as Level&nbsp;2 within the fair value hierarchy of ASC 820. The Company classifies its entire investment portfolio as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> as defined in ASC 320, Debt Securities, and views all investments as available for use in its current operations. We have therefore classified all
securities as current, even if we do not necessarily intend to dispose of the securities in the following year. Securities are carried at fair value with the unrealized gains (losses) reported in other comprehensive income (loss). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March&nbsp;31, 2024 and December&nbsp;31, 2023, none of the Company&#146;s investments were determined to be other than temporarily impaired. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the Company&#146;s investments (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unrealized<BR>(Loss)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Fair<BR>Value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Government and agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair values of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt
securities as of March&nbsp;31, 2024, by contractual maturity, are summarized as follows (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due in one year or less</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due after one year through two years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">36,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. PREPAID EXPENSES AND OTHER CURRENT ASSETS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid and other current assets consisted of the following (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">2,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment, net consisted of the following (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation expense was immaterial for the three months ended March&nbsp;31, 2024 and 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. ACCRUED EXPENSES </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses consisted of the following (<I>in
thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">2,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">2,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. OTHER ASSETS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other assets
consisted of the following (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Security deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">1,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2022, the Company entered into an operating lease
agreement for principal executive office in Carmel, Indiana (the &#147;Carmel Lease&#148;). The Carmel Lease commenced in October 2022 and has an initial term of 39 months, terminating in December 2025, with an option to extend for 36 additional
months at the Company&#146;s discretion. The option to extend is not considered reasonably certain as of the lease inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2023, The Company entered into an operating lease agreement for laboratory space in Indianapolis,
Indiana (the &#147;Laboratory Lease&#148;). The Laboratory Lease commenced in December 2023 and has a term of 12 months, terminating in December 2024. The lease does not contain an option to extend the term. Due to the lease term being only one
year, we have elected to account for it as a short-term lease with no corresponding lease liability or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset recorded, and lease payments recognized as
expense on a straight-line basis over the lease term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has no other operating or finance leases as of March&nbsp;31, 2024 or December&nbsp;31, 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The future minimum rent payments relating to the Carmel Lease under the terms and conditions existing as of March&nbsp;31, 2024, are summarized as follows (<I>in
thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024 (remaining nine months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company incurred immaterial rent expense for the three months ended March&nbsp;31, 2024 and 2023. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the operating lease term and discount rate for the Carmel Lease as of March&nbsp;31, 2024 and December&nbsp;31, 2023: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">8.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cash paid for amounts included in the measurement of the Company&#146;s operating lease liability was immaterial for the three
months ended March&nbsp;31, 2024. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the amount of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities included on the Company&#146;s balance sheet as of March&nbsp;31, 2024 and December&nbsp;31, 2023 (<I>in thousands</I>): </P>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Right-of</FONT> use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>License agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In January
2024, the Company entered into an amendment (the &#147;Amendment&#148;) for the Exclusive License Agreement with Indiana University Research and Technology Corporation (&#147;IURTC&#148;) (the &#147;License Agreement&#148;), to license certain
intellectual property arising under the Research Agreement. The Amendment specifies IURTC is entitled to the receipt of additional clinical and regulatory milestones, as defined in the Amendment, up to an aggregate of $9.0&nbsp;million. Following
the execution of the Amendment, future remaining clinical and regulatory milestone payments in the License Agreement and all amendments total up to $9.3&nbsp;million. In consideration for the license, during the three months ended March&nbsp;31,
2024 and year ended December&nbsp;31, 2023, the Company paid immaterial licensing fees to IURTC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Legal proceedings </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential
range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;7, 2022, the Company
amended and restated its certificate of incorporation increasing the total number of shares authorized to issue 237,000,000 shares of common stock, $0.0001 par value per share, and 182,838,619 shares of convertible preferred stock, $0.0001 par value
per share. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Issuances of convertible preferred stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July
2020, the Company entered into a Series A convertible preferred stock purchase agreement (&#147;Series A SPA&#148;) under which it issued 29,112,081 shares of Series A convertible preferred stock, for cash, at a price of $0.687 per share, for gross
proceeds of $20.0&nbsp;million (the &#147;Initial Series A Closing&#148;). The Company incurred issuance costs of $0.3&nbsp;million in relation to the issuance of Series A Convertible Preferred Stock, which have been recorded as a reduction to the
value of the Series A Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. The Series A SPA contained provisions that potentially obligated the Company to sell an additional 14,556,039 shares of Series A Convertible
Preferred Stock at $0.687 per share in an additional closing contingent upon either the achievement of a regulatory milestone defined in the Series A SPA or upon the agreement of the Company&#146;s board of directors and lead investor to waive the
requirement to achieve the milestone. In the event that an Initial Series A Closing purchaser failed to purchase all of their required shares in the subsequent Series A closing, each of the Series A Convertible Preferred Stock held by such purchaser
automatically converted into <FONT STYLE="white-space:nowrap">one-half</FONT> of a share of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrently with the Initial Series A Closing,
convertible notes issued by the Company in 2019 and 2020, including accrued interest and accrued deferred compensation, plus interest, were converted into 8,474,865 shares of Series A convertible preferred stock at a conversion price equal to 90% of
the Series A financing, or $0.6183, representing a total of $5.4&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;12, 2021, the Company sold 16,011,641 additional shares of Series A
convertible preferred stock at the same terms and conditions as those contained in the initial Agreement. The gross proceeds from the sale of Series A Convertible Preferred Stock upon achieving the milestone event was $11.0&nbsp;million at $0.687
per share. The Company incurred immaterial issuance costs in relation to the issuance of Series A Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series A Convertible Preferred Stock in mezzanine equity in
the accompanying balance sheets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On November&nbsp;7, 2022 (the &#147;Initial Series B Closing&#148;), the Company entered into a Series B Preferred Stock Purchase
Agreement (the &#147;Series B SPA&#148;) to issue certain investors Series B Convertible Preferred Stock at a purchase price of $0.90 per share ($0.0001 par value). The Company amended the Certificate of Incorporation (&#147;Charter&#148;) on
November&nbsp;7, 2022, which authorized the issuance of 129,240,032 shares of Series B Convertible Preferred Stock, in addition to 53,598,587 shares of Series A Convertible Preferred Stock issued and outstanding. The Company also executed the
Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement (the &#147;ROFR and CS&#148;) and the Amended and Restated Investors&#146; Rights Agreement (the &#147;A&amp;R Investors&#146; Rights&#148;).
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Initial Series B Closing resulted in the issuance of 40,545,552 shares of Series B Convertible Preferred Stock, at a price of $0.90 per share, for gross cash
proceeds of $36.5&nbsp;million. The Company incurred issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
costs of $0.4&nbsp;million in relation to the issuance of Series B Convertible Preferred Stock, which have been recorded as a reduction to the value of the Series B Convertible Preferred Stock in
mezzanine equity in the accompanying balance sheets. Concurrently with the Initial Series B Closing, the 2022 Notes, including accrued interest, were converted into 12,573,381 shares of Series B Convertible Preferred Stock at a conversion price
equal to 90% of the Series B financing. After the Initial Closing, the Company agreed to sell on the same terms and conditions as the first sale, an additional 76,121,099 shares of Series B Preferred Stock (the &#147;Series B Milestone
Issuance&#148;) upon achieving certain development milestones. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On August&nbsp;15, 2023, the Company issued 76,121,099 shares of Series B Convertible Preferred
Stock, at a price of $0.90 per share, for gross cash proceeds of $68.5&nbsp;million in the Series B Milestone Issuance. The Company incurred immaterial issuance costs in relation to this issuance of Series B Convertible Preferred Stock, which have
been recorded as a reduction to the value of the Series B Convertible Preferred Stock in mezzanine equity in the accompanying balance sheets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the
Series A and Series B Convertible Preferred Stock have the following rights and preferences: </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Voting rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Series A and Series B Convertible Preferred Stock are entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of
Series A and Series B Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Election of directors </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of record of shares of Series A
Convertible Preferred Stock, exclusively and as a separate class, shall be entitled to elect three directors of the Company. The holders of record of shares of Series B Convertible Preferred Stock, exclusively and as a separate class, shall be
entitled to elect one director of the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Non-cumulative</FONT> dividend </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Holders of Series A and Series B Convertible Preferred Stock, in preference to the holders of common stock, are entitled to receive, when, as and if declared by the
board of directors of the Company, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the Series A and Series B original issue price per annum on each outstanding share of Series A and
Series B Convertible Preferred Stock (the &#147;Preferred Dividends&#148;). All such Preferred Dividends shall be payable only when, as and if declared by the board of directors of the Company and shall be
<FONT STYLE="white-space:nowrap">non-cumulative.</FONT> No dividends have been declared <FONT STYLE="white-space:nowrap">to-date</FONT> as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Conversion right </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of Series A and Series B Convertible
Preferred Stock is automatically converted into common stock upon either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $2.061 or $2.25, respectively, per share (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act
of 1933, as amended, resulting in at least $50,000,000 of gross proceeds to the Corporation and in connection with such offering the common stock is listed for trading on the Nasdaq Stock Market&#146;s National Market, the New York Stock Exchange or
another exchange or marketplace approved the Board of Directors or (b)&nbsp;the affirmative vote or written consent of the majority preferred stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Liquidation preference </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series A and Series B Convertible
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, and in the event of a Deemed Liquidation Event (as defined in the Company&#146;s amended and restated
certificate of incorporation), the holders of shares of Series A and Series B Convertible Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the
available proceeds, as applicable, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the Series A and Series B Convertible Preferred Stock
original issue prices, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of Series A and Series B Convertible Preferred Stock been converted into common stock immediately
prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. COMMON STOCK </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s certificate of incorporation, as amended and restated, authorized the Company to issue 237,000,000 shares of common stock, $0.0001 par value. As of
March&nbsp;31, 2024 and December&nbsp;31, 2023, there were 15,544,989 and 15,113,124 shares of common stock issued and outstanding, respectively. Shares of common stock issued and outstanding as of March&nbsp;31, 2024, include 695,990 shares of
restricted stock related to the unvested portion of early exercised common stock options. Shares of common stock issued and outstanding as of December&nbsp;31, 2023, include 1,085,978 shares of restricted stock related to the unvested portion of
early exercised common stock options. These are included in shares of common stock as they are considered to be legally outstanding as of March&nbsp;31, 2024 and December&nbsp;31, 2023, respectively. These shares are subject to the Company&#146;s
option to repurchase and are not transferrable until such time as they are fully vested. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Common stock reserved </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of common stock that have been reserved for the potential conversion of Preferred Stock, and outstanding stock options granted and stock options
available for grant under the Company&#146;s 2019 Stock Option and Grant Plan (the &#147;2019 Plan&#148;) as of March&nbsp;31, 2024 and December&nbsp;31, 2023, are as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,980,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,761,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock options available for grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,226,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,014,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">221,045,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">220,614,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. STOCK-BASED COMPENSATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2019 Stock Option and Grant Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s 2019 Plan, as
amended, provides for the Company to sell or issue common stock or restricted common stock or to grant incentive stock options or nonqualified stock options for the purchase of common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stock, to employees, members of the board of directors, and consultants of the Company. The 2019 Plan is administered by the board of directors or at the discretion of the board of directors by a
committee of the board. The exercise prices, vesting periods, and other restrictions are determined at the discretion of the board of directors or a committee of the board, except that the exercise price per share of stock options may not be less
than 100% of the fair market value of the share of common stock on the date of grant and the contractual term of stock option may not be greater than 10 years. Stock options granted to date typically vest and become exercisable over four years from
the date of grant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of shares of common stock that may be authorized under the 2019 Plan is 44,820,428 shares, of which 5,014,218 remained available
for future grant as of March&nbsp;31, 2024. The shares available for issuance under the 2019 Plan may be authorized but unissued shares or shares reacquired by the Company. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Stock option valuation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The determination of the grant date fair value
of stock-based awards granted to employees, directors and nonemployees during the three months ended March&nbsp;31, 2024 and 2023, is estimated using the Black-Scholes option-pricing model and was calculated based on the following assumptions. </P>
 <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.93%&#8201;-&#8201;5.18</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50&#8201;-&#8201;6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Summary of option activity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s stock option activity regarding employees, directors, and nonemployees for the three months ended March&nbsp;31, 2024, is summarized as follows (<I>in
thousands except share and per share amounts</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life (years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>intrinsic<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding&#151;December 31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,980,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(462,797</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(462,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options outstanding and exercisable&#151;March 31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">32,761,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">0.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">9.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">11,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additional information with regard to stock option activity involving employees and directors for the three months ended
March&nbsp;31, 2024 and 2023, is as follows (<I>in thousands except per share amounts</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average grant date fair value per option of total options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Aggregate intrinsic value of stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of March&nbsp;31, 2024, total unrecognized compensation cost related to the unvested awards to employees,
directors, and nonemployees is $10.6&nbsp;million, which is expected to be recognized over a weighted-average period of 3.3 years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Stock-based compensation
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the three months ended March&nbsp;31, 2024 and 2023, the Company recorded stock-based compensation expense regarding its employees, directors, and
nonemployees as follows (<I>in thousands</I>): </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the three<BR>months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. DEFINED CONTRIBUTION PLAN </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company established a defined contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of
their annual compensation on a pretax basis. As of March&nbsp;31, 2024, the Company did not make any contributions to the plan on behalf of our employees. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss
per share </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in
thousands except share and per share amounts). </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the three months ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average number of common shares outstanding used in computation of net loss per common share, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,299,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,455,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s potential dilutive securities, which include convertible preferred stock, restricted stock
related to early exercise of common stock options, restricted stock related to unvested founder shares and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive.
Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The potential dilutive securities included in the table below, presented
on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>For the three months ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,598,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Convertible Preferred Stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,118,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,240,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,150,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,761,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to early exercise of options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">968,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">695,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock related to unvested founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">616,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,453,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,295,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. RELATED PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
April 2019, the Company executed a Master Research Agreement with The Trustees of Indiana University (the &#147;Research Agreement&#148;) pursuant to which the Company agreed to fund certain research of a director and former officer of the Company.
The period of performance for this agreement is June&nbsp;1, 2019 through April&nbsp;30, 2022 and the contract totals approximately $2.8&nbsp;million. On February&nbsp;14, 2022, the Research Agreement was amended to extend the period of performance
from April&nbsp;30, 2022 to April&nbsp;30, 2025 and increase the total contract costs by $3.0&nbsp;million. The Company paid $0.3&nbsp;million and $0 pursuant to this agreement during the three months ended March&nbsp;31, 2024 and 2023,
respectively. The Research Agreement also provides the Company an option to license the technology arising under the agreement (see Note 9). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. SUBSEQUENT
EVENTS </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has evaluated subsequent events through July 11, 2024, the date the unaudited condensed financial statements were available to be issued, to
ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has concluded no subsequent events have
occurred that require disclosure, except for those referenced below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">****** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B>&#8195;&#8195;&#8195;</B><B><I>Shares</I></B><B> </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g790774g00a06.jpg" ALT="LOGO" STYLE="width:2.27777in;height:0.664165in;">
 </B></P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:110pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&#8195;&#8195;&#8195;&#8195;, 2024 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Through and including
&#8195;&#8195;&#8195;&#8195;, 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in
addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Part II </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Information not
required in prospectus </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;13. Other expenses of issuance and distribution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, to be paid by us in connection with the sale of the shares of
common stock being registered hereby. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and the Nasdaq Global Select Market initial listing fee. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.50pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SEC registration fee</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.50pt solid #000000" ALIGN="right">$&#8195;&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;14. Indemnification of directors and officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Section&nbsp;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out
of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including
attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay expenses
(including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on
behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to
indemnify the director or officer against such liability under Section&nbsp;145. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will adopt provisions in our third amended and restated certificate of
incorporation and our amended and restated bylaws, which will be effective immediately prior to the closing of this offering and upon the effectiveness of this registration statement, respectively, that limit or eliminate the personal liability of
our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of
fiduciary duty as a director or officer, except for liability for: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director or officer&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These limitations of liability do not alter director and officer liability under the federal securities laws and do
not affect the availability of equitable remedies such as an injunction or rescission. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our bylaws, which will be effective upon the effectiveness
of this registration statement will provide that: </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our
directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding judgments, fines and settlement amounts), to each
indemnified director or executive officer in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person&#146;s services as a director
or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third
parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our
obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers, including liabilities under the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting agreement filed as Exhibit 1.1 to this registration
statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;15. Recent sales of unregistered securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the three years
preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Convertible
note issuances </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2022, we issued the 2022 Notes to certain accredited investors for gross in the aggregate principle amount of $10.0&nbsp;million
which included two options for conversion: (1)&nbsp;automatic conversion into shares of convertible preferred stock from the next qualified financing at 90% of the per share price of the convertible preferred stock sold in the qualified financing
consummated on or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in the qualified financing consummated after March&nbsp;31, 2023 and (2)&nbsp;optional conversion into shares of convertible
preferred stock from the next <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing at 90% of the per share price of the convertible preferred stock sold in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated on
or prior to March&nbsp;31, 2023, or 80% of the per share price of the convertible preferred stock sold in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing consummated after March&nbsp;31, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preferred stock issuances </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021, we issued an aggregate of 16,011,641 shares of our Series A preferred stock at a purchase price of $0.687 per share in connection with the achievement
of a certain development milestone for gross proceeds of $11.0 million. In November 2022 and August 2023, we issued an aggregate of 129,240,032 shares of our Series B preferred stock as follows: (a) 40,545,552 shares of Series B preferred stock sold
at a purchase price of $0.90 per share at the initial closing for gross proceeds of $36.5&nbsp;million, (b) 12,573,381 shares of Series B preferred stock which were converted pursuant to the conversion of the 2022 Notes and (c) 76,121,099 shares of
Series B preferred stock sold at a purchase price of $0.90 per share pursuant to the achievement of certain development milestones for gross proceeds of $68.5&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Option issuances </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January&nbsp;1, 2021, we have granted to our
directors, officers, employees, consultants, and other key persons options to purchase an aggregate of 41,871,866 shares of common stock pursuant to the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock issuances </I></B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January 1, 2021, we have sold to our
directors, officers, employees, consultants, and other key persons an aggregate of 4,962,027&nbsp;shares of common stock at a weighted-average exercise price of $0.21 per share pursuant to the 2019 Plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common stock repurchases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since January 1, 2021, we have repurchased
217,238 shares of our common stock from former employees at a weighted-average cash purchase price of $0.07 per share for an immaterial total fair value. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of
the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, the Registrant believes these transactions were exempt from registration under the Securities Act
in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering
or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view
to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with the Registrant, to
information about the Registrant. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;16. Exhibits and financial statement schedules </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(a) Exhibits. </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" COLSPAN="3" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Exhibit<BR>number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Exhibit table</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.1*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.1**&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Second Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.2*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Third Amended and Restated Certificate of Incorporation of the Registrant (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.3**&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bylaws of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.4*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Amended and Restated Bylaws (to be effective upon the effectiveness of this registration statement)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.1**&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amended and Restated Investors&#146; Rights Agreement among the Registrant and certain of its stockholders, dated November&nbsp;7, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.2&#8196;&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Common Stock Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.1*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Opinion of Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.1**#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2019 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.2*#&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2024 Stock Option and Incentive Plan and forms of award agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3*#&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2024 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4*#&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Officer Indemnification Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5*#&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Director Indemnification Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.6*#&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Cash Incentive Bonus Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.7*#&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Non-Employee Director Compensation Policy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.8**&#134;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exclusive License Agreement, dated as of June&nbsp;10, 2020, between Indiana University Research and Technology Corporation and MBX Biosciences, Inc., as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.9**&#134;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Office Lease between Zeller-Carmel Property, L.L.C. and MBX Biosciences, Inc., dated April&nbsp;28, 2022.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.10*#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement between the Registrant and P. Kent Hawryluk, President and Chief Executive Officer, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.11*#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement between the Registrant and Richard Bartram, Chief Financial Officer, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.12*#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement between the Registrant and Salomon Azoulay, Chief Medical Officer, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21.1**&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subsidiaries of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.1*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.2*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24.1*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Power of Attorney (included on signature page to this registration statement)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">107*&#8199;&#8199;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Filing Fees Exhibit</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">**</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">#</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or any compensatory plan, contract or arrangement. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the SEC because the Registrant has determined that information is both not material and is the type that the registrant
treats as private or confidential. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>(b) Financial statement schedules. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Item&#8201;17. Undertakings </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the Underwriting Agreement certificates in such denominations and
registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Signatures </B></P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to
the requirements of the Securities Act, MBX Biosciences, Inc. has duly caused this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Carmel, Indiana, on the &#8195; day of &#8195;&#8195;&#8195;, 2024. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MBX Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">P. Kent Hawryluk</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="ii790774_sig"></A>Signatures and power of attorney </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints P. Kent Hawryluk and Richard Bartram, and each of them,
either of whom may act without the joinder of the other, as his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents with full power of substitution and <FONT
STYLE="white-space:nowrap">re-substitution,</FONT> for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign
any registration statement for the same offering covered by the registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same,
with all exhibits thereto and all documents in connection therewith, with the SEC, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities indicated on the &#8195; day
of &#8195;&#8195;&#8195;, 2024. </P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Signature</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Title</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">P. Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">Richard Bartram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial" ALIGN="center">(Principal Financial Officer and Principal Accounting Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tiba Aynechi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James M. Cornelius</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Carl Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Edward T. Mathers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ora Pescovitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:arial">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">Steven Ryder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774page015.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD ADD ADD 4 3 2 1 A Box
DESIGNATION SAMPLE 43004, Certificate Shares (IF Number * * 000000 ****************** * * * 000000 ***************** ANY) ZQ00000000 **** 000000 **************** Providence ***** 000000 *************** RI MBX BIOSCIENCES, INC. ****** 000000
************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 02940 ** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David
Sample SEE REVERSE FOR CERTAIN DEFINITIONS&#151;**** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David THIS CERTIFIES THAT
Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;MR. Alexander David SAMPLE Sample ****
Mr.&nbsp;Alexander David&nbsp;&amp;Sample MRS. **** Mr.&nbsp;Alexander SAMPLE David Sample **** Mr.&nbsp;Alexander&nbsp;&amp; David Sample **** Mr.&nbsp;3004 Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David
Sample **** Mr Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** CUSIP XXXXXX XX X Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample ****
Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander MR.
David Sample SAMPLE **** Mr.&nbsp;Alexander David Sample **** &amp;Mr.&nbsp;Alexander MRS. David Sample SAMPLE **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander
David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample ****
Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Alexander David Sample **** Mr.&nbsp;Sample **** Mr.&nbsp;Sample is the owner of
**000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares***
*000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****
000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0 THIS CERTIFICATE IS TRANSFERABLE IN 00000**Shares****000000**Shares****000000**Shares****000000**
Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00 ***ZERO HUNDRED THOUSAND 0000**Shares****000000**Shares****000000**Shares****000000**Shares****
000000**Shares****000000**Shares****000000**Shares****000000**Shares****000 CITIES DESIGNATED BY THE TRANSFER 000**Shares****000000**Shares****000000**Shares****000000**Shares****
000000**Shares****000000**Shares****000000**Shares****000000**Shares****0000 AGENT, AVAILABLE ONLINE AT 00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00000
0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000 ZERO HUNDRED AND ZERO*** www.computershare.com
**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000*
*Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**
Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S FULLY-PAID AND <FONT STYLE="white-space:nowrap">NON-ASSESSABLE</FONT> SHARES OF COMMON STOCK OF MBX
Biosciences, Inc. (hereinafter called the &#147;Company&#148;), transferable on the books of the Company in Total DTC person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and Holder the shares
represented hereby, are issued and shall be held subject to all of the provisions of the Certificate of Number Certificateof Insurance ID Incorporation, as amended, and the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> as amended, of the Company
(copies of which are on file with the Value Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Transaction Shares CUSIP/IDENTIFIER Certificate is not valid unless countersigned and registered by
the Transfer Agent and Registrar. Numbers 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 Witness the facsimile seal of the Company and the facsimile signatures of
its duly authorized officers. DATED <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DD-MMM-YYYY</FONT></FONT> oscienc i e COUNTERSIGNED AND REGISTERED: FACSIMILE SIGNATURE TO COME B s, X POR I R A COMPUTERSHARE TRUST COMPANY, N.A.
Num/No 12345678901234512345678 B CO TE nc M . TRANSFER AGENT AND REGISTRAR, 666 555 444 333 222 111 Denom. President XXXXXX April&nbsp;9, 2019 Total. DEL RE FACSIMILE SIGNATURE TO COME AWA 7 00.1,000,000 XX 123456 XXXXXXXXXX X By Secretary
AUTHORIZED SIGNATURE </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g790774page016.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">MBX BIOSCIENCES, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,
PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO
DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL
REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM&#151;as tenants in common UNIF GIFT MIN ACT - Custodian (Cust) (Minor) TEN
ENT &#151;as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN &#151;as joint tenants with right of survivorship UNIF TRF MIN ACT - Custodian (until age ) and not as tenants in common (Cust) .under Uniform Transfers to
Minors Act (Minor) (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and transfer unto (PLEASE PRINT OR
TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock on the books of the
within-named Company with full power of substitution in the premises. Dated: 20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan
Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.</FONT> Signature: Signature: Notice: The signature to this assignment must
correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever. The IRS requires that the named transfer agent (&#147;we&#148;) report the cost basis of certain
shares or units acquired after January&nbsp;1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you
requested. If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. If you do not keep in contact
with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state. </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g790774g00a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g00a06.jpg
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M ?<  /IQ^?Y1CG9_6OW?_KU+_P#&Z/Y-= _T1P7\!#_PX/QZUC_23+_QDO\
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MI<'\';37H\+D]46(]ILO/Z"BS#R*%!SZB1&_9L7BT3C]J@I_>M'.S.^IRE#
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MRTI8;\=8R16)V@E@EK58:I4;QNDD;I CJP<,&9D9 %5WH-_(,<\__+:=Q_\
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=LXE-31?%+BIF1C46-:9O*HF:$1Q]+LQ*(25'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g790774g00m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g00m01.jpg
M_]C_X1$ 17AI9@  34T *@    @ # $   ,    ! WH   $!  ,    ! 2H
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-#HQ.2 P,#HS-CHQ-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   %:H , !     $   !G          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M4L<&,;D5%SG$ #]5:-7.4F*(AGS"@>&,I1!']V45DY<6+%J?5*(E^U@[H?\
MC!J&\7Y+RW6&YA<=/Y%KVL<MCZH?6O*S<EW2>JZY8#C3<6['.+#^FQ\BKV[,
MFK^2QGT+/T==E7Z7H+>M]&I87VYV.UK1))M9_P"27#]'M_:WU\^WX;"RCU++
MR8B*VT_9/4>#&S[386NV?3_2I"1S8\GN8Q'@B91F!P^K]U1 QRAP3,N(\)B3
MQ:.Y]?'=:HQL;.Z?D648^,YQRO1=M<"[9Z%U@^C;CU[7LMK?^C_2_I*_3_FM
M#ZK_ %BKZWADV 5YV/#<JH<2?H753[O1NV_];_FO\&MA[&6,=78T/8\%KV.$
M@@Z.:YI^DUR\VZOT[-^J'6:L[ITC$>2,9Q)+2T^ZWIN2[7V[6;J7/_,9ZO\
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M!8W]'>S^Q<Q[%7Y['K&8Z^D_]RS\I/0P[:AR_KYD"KZMW5]\FRJD?-[;'_\
M@5=BP^E]&=E_4'+<UNZZRZS,HTD[J"*FM;_QK,9]7_75:_QEY.S%P,?\UUEE
M[OA4ST__ '971?5O%^R= Z?1$.;0PO'\MP]2S_P1[DP2./EH$;RR<?\ B?\
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M _\ *S$_[8K_ /(*Y113CU-IQZVTU,$,K8 UK1X-8WVM1$DC*1W)/F5"(&P
M:/4^B]+ZL*AU'';D"AQ=7ND1/TF^TMW5OC])4[]'8KO&@3I)$D@ DT-AV50L
MFMW'ZS3T6C,Q.IYF&[)SFN]+%-3'662&ON_FV>U_I-;997O_ )G_  :MX_5L
M7*IKNQVV6!]OH/:*W!]5@G>W*K< ^CT]OOWJE]8V6%_3GM.16VO(<;+L6LVV
M,!IO8'-K;5D?2>[T_P"9_/67BXV8'U"JO(MQ!U6NYF1=6YE[PZJS[3;DLV5.
M]%ENRNNVRJO_ $?YE:-D@6=MF">249D :$]!KM\ST%_1>EY'4*NIWXS'YE B
MJXS(B=OMG8_9O=Z>]OZ/_!H.?]6>A=1R3EYF&RV]P#762YI<&_1W^FYF]S?H
M[G+%P\2YM^*[T,H=>&2#G9;@\5.JW?K.Z]P^R6X=F.W9AXU7OI?Z/Z.OT[$/
M'Q>IULZLS$IRA:\;G9#MU-S_ -.\W4-]2RW$OROL>[[+GX?L]/T/YM$2F*J9
M%"AKT0<@(UQW=G][8?W?YQT<CZH?5:BHVGIIL +1MK-KW>XAGT&V?F[MS_Y"
MT^G=$Z3TO<<#%KH<X0ZQHEY'[KK7;K'-_M+GKL2C[#ELZ/B9U-!^RS4]MC6.
ML%];K'4X]_ZUZ[*F_K-S/T+T'-P.J6]7R#:ZRO,?DC[%EMQ[[C73+?0]')IM
MKPL>BMKG?;*;J_?^E]7U_41,YR%&<B.Q)1[@B;&(;#6.WZ>T^'^J]1U'HW2^
MJ&D]0QF9)QW;JMXF"8W-_EUOVMWU/_16*ZN9S>EOS6=9SKZ[SG8[GMZ8]IL:
MY@KIKLI=AM;'\YD^I]#^?_FT#.I??D6W=7QLS(>_'J=TTX@L_1V;!Z[:_1]N
M)F_:??Z^5_@O3_2?HK$W4@ DT.G;R7G*03Z-]C?3^OZ?2]:J9Z1TP]1'5#C5
MG.:W8,B/=$;?\_9^C]3^<]/]']!<QUG#ZC9G/=EMMLK&/4,)WHW9+V/#?T_I
MNZ=913CY_KC?]HL]C_9Z=OIU[%;?B9E7UAP76MOS+FUTLLO+7LK;M9;]HR:<
MBFST&5O?_2L'+JWW/?5Z*0L;&K'1'O$FCCVD!K_TN'_HO__9_^T8F%!H;W1O
M<VAO<" S+C  .$))300$       :' %:  ,;)4<< @   B2H' (%  9G,#!M
M,#$X0DE-!"4      ! BK:EPRE^=C2MMG9\S?IYQ.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  @$L     0 ".$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -!    !@              9P   5H    &
M &< ,  P &T ,  Q     0                         !
M  %:    9P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    9P    !29VAT;&]N9P   5H    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &<     4F=H
M=&QO;F<   %:     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M      0    !.$))300,      ^6     0   *     P   !X   6@    ]Z
M !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1
M# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P * #
M 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<(
M"0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(
M!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U
M 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5<)];OK5U3'Z
MP["Z9DG'JQ6-%Q:QCBZUX]0C=:RWVU5.J^C^>]Z[3.S*L'"OS;M*L>MUC_&&
MC=M'\IR\<MNNR+;,B\S=>]UMI'[[R;'_ /2<KG)8A*4I2 (CH+U]1:W-9#$"
M(-$]NSJ?\[_K,-3U%\=_T=/_ *07>?5[JEUO06Y75+0;Z&%^580&PR/78][6
M -_H[F^IM;_.;UYIT_%^UYM..?H.=NM_XMGOL_SF_H_[:Z#KN?91TV[&88/4
M2*W@:>QA]6W_ *KT/^O*?/AA+AA&,8DF[B -&+#EE'BE(DBJU-ZM&SZY?62V
MQ]K,UU++'%S*1740QI,LJE]+G_HV>WW(N#]:OK/;G8]8SG6@V-+JW5U;7,;[
M[FNV5,?_ #37_1<L%;7U;QI?=F.'T1Z-?Q,/N=_F>FS^VI9X\48D\$?\4,<9
MY#(>N7VOJ%=C+:VV,,L> YI\01(4EC?5KJ-&13?@M?NNP'AEC8.@?[Z]?HN_
MPE7M_P!$ME9,XF,C$]'1C+B *EYU]6?K1G6?60.R\E]F)U%[V-J>XEE9<2_#
M]%GT:OHMQ_9_.>K^D7;]<RCB=&SLD':ZG'M<T_R@QVS_ *:\C91DUXK<JF6M
MIM;37:.U[6_::O\ HU^HK?)XHSADXJ]50!:_,9#&4*Z>HOM2XWZ_]:R<9V+T
MW#O?COL!OR'U.+'[ ?3I8+&;7-;99ZC_ /K"ZCI>?7U+IV-G5Z-R*VOV\[21
M[Z_^MO\ 8O,.IWW==ZUU#,H]U;&6W,.L#&Q6[6N'_'?39_PN2F<IBO*3(:8]
M[_>7<QDJ $=Y[5V?1?JQGV]0Z#A95SM]SJ]EKCR7UDT6//\ 7?7N7'?6/,ZY
MD_6R_IN#F7UDNKJQZ:[74L$TLR';O3+?SG6NWO6Q_BXR@_I63BETG'R"YH\&
M6M;8/_!?663FO97_ (R/4L<&,;D5%SG$ #]5:-7.4F*(AGS"@>&,I1!']V45
MDY<6+%J?5*(E^U@[H?\ C!J&\7Y+RW6&YA<=/Y%KVL<MCZH?6O*S<EW2>JZY
M8#C3<6['.+#^FQ\BKV[,FK^2QGT+/T==E7Z7H+>M]&I87VYV.UK1))M9_P"2
M7#]'M_:WU\^WX;"RCU++R8B*VT_9/4>#&S[386NV?3_2I"1S8\GN8Q'@B91F
M!P^K]U1 QRAP3,N(\)B3Q:.Y]?'=:HQL;.Z?D648^,YQRO1=M<"[9Z%U@^C;
MCU[7LMK?^C_2_I*_3_FM#ZK_ %BKZWADV 5YV/#<JH<2?H753[O1NV_];_FO
M\&MA[&6,=78T/8\%KV.$@@Z.:YI^DUR\VZOT[-^J'6:L[ITC$>2,9Q)+2T^Z
MWIN2[7V[6;J7/_,9ZO\ /XJCQ"&7'[1J.2-G'+][^K)?D,L<N/4P.DQ^[_6?
M1,W,QL#%MS,NP544MW/>?#P'[SW.]K&?GO7$=#ZMU_KWUI;DU764X5'NNQP?
MT3*"'MJIL8/T=N7>_P!_J?\ &>G^AI5/KG6\SZU]0QNG=/J+*)!IJ?H76Q^E
MR,G9NV4XK=W_ )]_G+<==WT3H^/T;I[,*@[R/?=:1!LL/T[7?=[/]'7LK1,1
M@QGB .7(*$3^A!0D<LQPFL<#O^_)_]#IO\8O4O2P<?IC#[LM_J6C3^:I+70?
M^,R#3_VW:N"6G]9^I?M'KV7?/Z.IWV:D'LRDNK=_GW^O8LOW.(;6-]CB&UL'
M+G..VM@_KO.U;'+X^#%$=3ZI><G-SSX\A/;TCZ.]]6\;;7=F.&MA]*K^JT[K
M7#^M;MK_ .M*EUS)]?J#V@RS&'HM^(]USO\ MWV?];79=6Z?7T+ZN8UC(<>G
M5['GL]]A_G/^N9K]W_75YZ#XF3W/B3R4W#(9)2R#:^$?R_NIRQX (?4J)@$\
MQV764,;TKI@%@UQ:R^T>-A]SV?\ ;SO165]4^G?M'K^-4=:L<_:KOA41Z3?[
M>2ZG^QZBT_KTX8N5]B:=,IWVEW]4'Z/]K)W6)9)"62.+PXBJ$:@<G^"&A]3N
MIOPOK!2ZUTMSIQ[SKJ^P^I2__P!B?T?_ *$+U%>)&8]KMKN6N!U#AJUP_JN7
MK_1.I-ZITG%SQ -S ; .!8W]'>S^Q<Q[%7Y['K&8Z^D_]RS\I/0P[:AR_KYD
M"KZMW5]\FRJD?-[;'_\ @5=BP^E]&=E_4'+<UNZZRZS,HTD[J"*FM;_QK,9]
M7_75:_QEY.S%P,?\UUEE[OA4ST__ '971?5O%^R= Z?1$.;0PO'\MP]2S_P1
M[DP2./EH$;RR<?\ B?\ HJXQ$\T@=A#A_P 9XCHWUB.)]4NI8;7Q>QP;AF8.
MW+EI-?\ Q%@R<A:?^+WH];L',S;F>S)_5*@?]$P;;MI_X2YWI_\ H.N4ZQTU
M_3^KY73J6;G5V[<5@U);<0_$8/\ MVNE>K=)Z?7TWIN-@5ZC'K:PN&FYT?I+
M/^N6;K%+S4HPQG@_RY$_\%CP"4I^K_)#A^KP_P#BZMLQ>L9?3[='.IAP/._&
ML]%P_P#!WJM]8,(=0^N^1@%_I_:K:J]Y;NV_J]3IV2W=]!&$=+_QB'G99E1\
M1F5S_P"W5JAUK+JPOK[;FW!QJQ[Z7O#!+H^S5-]K=/WD\6<QR1WGAXA_>]-+
M37MB!VAEX3_=;X_Q8P9'4@#Y8X'_ *.67U+IG6?J?G49>+D"UKS%=K06LL+1
MN?B9=&Y[?>WZ'O\ ^%J]&VM=+_XXO0_]#E?]MC_THN?^LOUCL^LEV+T[IN-9
MM%A=56_:++;2UU;/8TN]*FEC[/4L?9_PEGI>BFXI<R95E'ZNCQ<0C$4F8P"-
MXSZ_T>$R+Z#@9E>=A8^;4"*\FMEK0>0'@/VG^K*X[Z^?6&NZ>A8@]5P>PY;V
MC<=X+7T8E$?2R'6>GZFW^13_ #EOZ*]UOJSOJMT#"Z7C/#NH&@55V$2U@K:U
ME^6YKOY3OT+'_P"$_P"#KM53ZC?5J=G7,\.<]TNPJWZGW?2SK=WN?==N_0[O
MS/TW\Y=^BAQ0ACO/+Y03[4?WY=&:<I2K$-R/UA_=#B]+S,SZI==V]0I#6V5M
M&2V-SA4_WMOQ[&_2]&SVW,K_ )S997^9CKTZNRNVMMM3A978 YCVD%KFD;FN
M:YOTFN63]9OJ_7UO ]-I;7F42_%N=P''Z55D>[T;HVV?V+?\$N9^I'7;L'+_
M .;^>TL8ZQS* [FFX2^W$?\ \'9#GT_\)_P5U.Q9*SP]R.F2 _61[Q_>"(?J
MI<!^27R'Q_=?_]'T>WH71+K'6V]/Q;++"7/>ZFMSG$\N<YS-SG)5=#Z)38VV
MKI^+7;60YCV4UM<TCAS7-9N:Y7DD[CEMQ'[4<,>P^QA=33?4ZF]C;:K!M?6\
M!S7 _FN8[VN5+_F]T#_RLQ/^V*__ ""T$D!*0V)'DHQ!W +6Q.G=/PB\X6+3
MC&R-_HUMKW;9V[_3:W=MW)\OIW3\W9]MQ:<GTYV>M6VS;NC=L]1KMN[:K"27
M$;NS??JJA55IV<__ )O= _\ *S$_[8K_ /(*Y113CU-IQZVTU,$,K8 UK1X-
M8WVM1$DC*1W)/F5"(&P :/4^B]+ZL*AU'';D"AQ=7ND1/TF^TMW5OC])4[]'
M8KO&@3I)$D@ DT-AV50LFMW'ZS3T6C,Q.IYF&[)SFN]+%-3'662&ON_FV>U_
MI-;997O_ )G_  :MX_5L7*IKNQVV6!]OH/:*W!]5@G>W*K< ^CT]OOWJE]8V
M6%_3GM.16VO(<;+L6LVV,!IO8'-K;5D?2>[T_P"9_/67BXV8'U"JO(MQ!U6N
MYF1=6YE[PZJS[3;DLV5.]%ENRNNVRJO_ $?YE:-D@6=MF">249D :$]!KM\S
MT%_1>EY'4*NIWXS'YE BJXS(B=OMG8_9O=Z>]OZ/_!H.?]6>A=1R3EYF&RV]
MP#762YI<&_1W^FYF]S?H[G+%P\2YM^*[T,H=>&2#G9;@\5.JW?K.Z]P^R6X=
MF.W9AXU7OI?Z/Z.OT[$/'Q>IULZLS$IRA:\;G9#MU-S_ -.\W4-]2RW$OROL
M>[[+GX?L]/T/YM$2F*J9%"AKT0<@(UQW=G][8?W?YQT<CZH?5:BHVGIIL +1
MMK-KW>XAGT&V?F[MS_Y"T^G=$Z3TO<<#%KH<X0ZQHEY'[KK7;K'-_M+GKL2C
M[#ELZ/B9U-!^RS4]MC6.L%];K'4X]_ZUZ[*F_K-S/T+T'-P.J6]7R#:ZRO,?
MDC[%EMQ[[C73+?0]')IMKPL>BMKG?;*;J_?^E]7U_41,YR%&<B.Q)1[@B;&(
M;#6.WZ>T^'^J]1U'HW2^J&D]0QF9)QW;JMXF"8W-_EUOVMWU/_16*ZN9S>EO
MS6=9SKZ[SG8[GMZ8]IL:Y@KIKLI=AM;'\YD^I]#^?_FT#.I??D6W=7QLS(>_
M'J=TTX@L_1V;!Z[:_1]N)F_:??Z^5_@O3_2?HK$W4@ DT.G;R7G*03Z-]C?3
M^OZ?2]:J9Z1TP]1'5#C5G.:W8,B/=$;?\_9^C]3^<]/]']!<QUG#ZC9G/=EM
MMLK&/4,)WHW9+V/#?T_INZ=913CY_KC?]HL]C_9Z=OIU[%;?B9E7UAP76MOS
M+FUTLLO+7LK;M9;]HR:<BFST&5O?_2L'+JWW/?5Z*0L;&K'1'O$FCCVD!K_T
MN'_HO__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
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M?+I!N^Z6>R;7?[ON#Z;.VB:1R,FBBM /,G@!YD@=:U=5_P *2<Q+55$F+^'
MBQCS.V.CS/=,,&76C)_8_BD%!U_6T-/7LEC+'#--'&Q*K(X&HY6)]U6!443<
M]5FIW:;6JU\]),P)'H2 3QH.'6/;_>"E+L8N4QX5<5N,T\J@1$ ^H!-/4]8/
M^@D7<_\ WAYC/_1W2?\ VMO=_P#@5K/_ *;A_P#LD'_6_JG_  05S_TR:_\
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MD%QE8(V\X822 <>))JDI32!@U[@<[W7.^]&[&I-G@)6VC.**>,KC_?D@H3_
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MGQ=^7/0G=\E5)28';>^J' ;\:-0YDZWWV/[H[TUHS*C1X['Y1<CZN ]"I%B
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M9&V9'7U+@=NS)6;@JXK@%/O\_)'#J'#I2$>X=]SMT\6\V_9(SV0IXLG^G?"
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M0AV/E]1%2.;Y L/#D^9<GK+3V,W_ />'*\^QS25N=NETKZ^#)5X_]Y.M/D%
MZO>]XY]39U[W[KW6K%_PI'W\DN3^(W4\,KAX6[4[1R,(8A'6FI=M[,PKNH-C
MI;,5]KCD\CZ'WF-]U/;2(N=]Z88/T]NI^TR2O_QU.L9_O"WX\3E7:P<_KS'\
M@D:_\>;JJ+^4EUT.S/YC7QEQLB:J79F<W5VO6L02B1]?[0R]5CF?2&M_OXLC
M0A218.5Y!(/N9_>S=3M'M9S;*#WW$<=L/^;TJAO^,*_Y5ZB_VKVX;E[@<N1G
MX87><_\ -I&(_P"-E>M_KWS2ZSHZ #Y5='8OY*_'#NGHC+Z%@[.Z]W#MJCG=
M@BT&>FHVJ=LY77I;2V(W'34M4#]08?\ 8^Q+R;S%-RGS5L',<'Q6=TDA'J@-
M)%_VR%E_/HBYGV6+F+E_>-DE^&Y@9!\FI5&_VKA3^77S<9J+*XNIK<1GJ1J#
M/X3(9#!;@H'5D:@S^#KJC$YNA9& 931Y6CFCY_U/OJRLD,R1SVSZK:15=&]4
M<!D/YJ0>N>K)+$[Q3KIG1BK#T9258?DP(Z%/H?IC-?(SN_J3H3 "1:_MO?N"
MV=4U4:2.,7MVJF:MWCFY3$KR11879]#7U6L V:)1]2/9/S)O\'*O+V]\R7-/
M"L;9Y0,=S@4B05XEY2B_GT9['L\W,&\[7LD']I=3K&3_  J<R-_M8PQ_+KZ3
MNU]MX;9NVMN[0VY11XW;VU<'B=MX''0\0T&&P=!3XO%T40_$=+0TL:+_ (+[
MY0W=W/?W=U?74A>ZFD:1V/%F=BS$_:23UT.MK>&TMX+2W0+!$BHH]%4 */R
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M);C_ ,X'_P W7O\ 9%_G#_WAO\E__12[F_\ J;W[_7$]O?\ IN]I_P"RF/\
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M@=%OZI^??PV[NW=3["ZP^0O7VYMXUKM%C-N_?5N%R69G0F]-@H=PT.)&=J[
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MZUZB7[K/)</)7+'.%G#S;M.[^/O,DFNPN$N(T'A1J%D9"0DK4+&,Y52I)JQ
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M)B*>>GB*@D8(B+F/VL]]>;HK"U]^O=[:=N]O;6>,R/#)%!XT@8:*DP6T3.Y
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>&,1^)' \]7%OXDC>+,]%33602#8S]@>ORZS]Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g790774g00s44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g00s44.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-  !:@  !I-P  ALQ  *1[__; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!E0,4 P$1
M  (1 0,1 ?_$ 5$  0 " @,! 0$            '" 4& P0) @$* 0$  04!
M 0              ! (#!08' 0@0  $$ 0(!"04' P,% 0$!  4" P0& 0 '
M%B P$A,4%387&!! $28W4& R-#5'"#%",W!$1H A(B,XD"5($0 !! $"! ,!
M!@X.!@@#! L# 0($!081$@ A$Q0B%0<Q05$R(Q8V$" P84+3))2UY::G"$CP
M<5(SLS2T-76%I59VAD!0<R7%%X&1H6)R0R:VL5-W@E25M\&2HK)T948G-\=X
M$@ ! @($" D'"@4#!0$  P ! @, $2$Q$@1!46&A(C(3,S!Q@9'AHN(4!2"Q
MP4)RDC004&#P4L+2(Z/CT6*"LH- )!5P@/%#!I!3<W03 0$  @(! 08& P$!
M 0$   $1 "$Q05%A$#! \'&!(%"1H<'Q8+'AT7" D/_:  P# 0 "$0,1   !
M]--\U"KVX:N               + \^T_7;NN@              ?-SK\,9OM
MP               ]2N<Z]Y?]CY+YO=7YD      !]>>_?E7%51S4U_IP54
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MY65&.0D6[UC%Z%-O[W"L;9%M17DY5<\[/XO0 _I0X%H/G#USD?F]U?F0
MS\69BK\;JUT  #+6+^2M7]7F00    !>/AO)H^D\_  &WQ=BU"5KH  _3[\K
MX_: !L%C+Z_?Q'+Y<[-%_(T3,!?Q   'W=^L:D[=]G@  <GC*6Z,/=K  &3M
MT]&NKB]#:(]O5Y%SD., &P6:-?O5@ ?TH<"T'SAZYR/S>ZOS(   #/Q9GH9R
M_I$>Y3'[%$D19F<7@Y-F2,3D\/?L=>NW]>48B^VR%*@?9->AS/:^    +Q\-
MY-'TGGX  MYK/T+U_;./KCPEE>:>B>F_5]0MAX7(</:]*DZ]B;^'F3%](U*_
MA?GVG5[^&X?;>P6<GW:9.MWL5N4?/5FSW$]1E:\  /N[]8U)V[[/M7K>,FS$
M1(PR,GKU>[-'MXJY[MD6WU*_8XGWXYGR=NBV9?Q<6NF=R%@\) SMFC0IM[Z\
M=FGS,VJ.K5[!V8F[I$LR9CX^CS+VYQ+6P6+<1Y23VJ6>L6]$FWZP;#D?Z4.!
M:#YP]<Y'YO=7YD   !V:+EQ]#WC2\AC]M@Y"+,SB-CBR;(:GM58MPU"5,+F8
M0V+7.Y;O27B<K5G<M/UV5%    %X^&\FCZ3S\  2QC=]D['[SJ4G7X9RG.)/
M@[GD+60S%K(]VF3&.0T?=8VPYNQEMACYN&LKS638&[="JSU*H^F2]7E/'[S
MF8Y5J4K7P !]W?K&I.W?9\U8F),.*B:E*NY&W3D[=//YYB[E>U1K4%9F;A+U
M>^0K$J8V-4_9<G;K6,7.^&A5EV#(]*NK"7JNC7[(T"Q N:G3]A8'1JJC+(29
M6QL;7[]<:9"1,F*B23CX\39.54':,I_2AP+0?.'KG(_-[J_,@      .U1=R
MMF[AK]CAJH'8HKR]F]V:+G6KMX"3&   %X^&\FCZ3S\      9*W-ZU5GK56
M !V*;V1HEX:[C@   /N[]8U)V[[/  ^S\/D WF'9T:9> Y_/-PBVM(EW@-MC
M6M2DW1R^.+T  .]1YQ^NK5[_ $H<"T'SAZYR/S>ZOS( #T]X_P!<UV7 B3-X
MWL4^YJ/>P4BUA),;98<G R;4A8O)823#D#%Y2)<YAMBB3-6FP_OQML&5GHTO
M'W8^I3;'<H1'G,' ^R:X !>/AO)H^D\_   %UM4^E=JCYRN.:Y)+6/WK#W,=
MB[D/>X>TQS.T_8K&7Q-W'_CS=8NR1_+U?O4WM3E:_!&8Y6   /N[]8U)V[[/
M    %]-+PN8MTQ1DI&FRKUI==QV@S;W7]]^/0F'%Q:M[%D=4E78.R\P    ?
MTH<"T'SAZYR/S>ZOS( "Q^J;5G8UV8,%GXYRN,[E%6PQ9F DP]>E6HZRN)LW
MJ&V0AL. ^E&ZX_(XZ[1%6:PF^8S*9V/=PM^C#2(DO8/.0#LVL=>I"VP8  "\
M?#>31])Y^   )?QG0=YA[2\NR+#VK2)6N;/'S?WY7A+V+CN=J&QV,QJ=_#;E
M8S6FR,#)<'<H[FZC"&7Y>   /N[]8U)V[[/    $[8:'8#"0:^9R=HTR]:/7
M,;%63DR!!LQ_.O;Y"LY.W3K<BY$F3E1/DI(    _I0X%H/G#USD?F]U?F0
M^_*OOSWC]I^??.6FOBJH  '-37PU4      "\?#>31])Y^   !R>7!^G%[;[
MM$KX4_'M/!59       ^[OUC4G;OL\         <OCB]     ?TH<"T&L6S:
M=$6UZR               -^T;4LG=U\              #3:NLZOF.T
M          "X.@:_W8]-@                5_+                %?RP
M                //\ + %@ :'DH&Y0)G:HKJV28<ILYDC'D-$Q&B&P$,&I
M%C02>      5_+  U*5@=MBY[%E/2V)^&;, 9HUTPYGCF,V8P^C%F>,D
M 5_+  $;3Y$DP(^+(0)6-(-X-H*GECS].N<QL1T")B23\,X:Z=@^#90  #S_
M "P!8 K9MFM=&Y1:'3]H'G>:N1H2Z:@3T5"+SE32V!@SMD4$FES@     "OY
M8 JOLO#;"8+K6R1\QIAYQD\%3S?#MG6)#);(D*]EA"'3[).)L+5@    %?RP
M!^'G5OF?O7IF$VN-;TP\C25C=3G+-GG*6Z*JD]FBET3R7)Z-U.<N 4F,&3<7
MI   //\ + %@#$WK.5LWOT&F&/-7.F9 WHB<SAUB0S:S4 #<P     "OY8 Z
M%<3OT2QTC#' 16;X8DYS8C &K' ;X?)KYL!W#>P    "OY8 &'NU9BU2.D1N
M8(V\K671(")6(E.Z=PEHCLY38B+25"("4S5B9   #S_+ %@  #6C\.8B\D,[
MAU3-&H&S'R8DPYT34B93F->-L,$;$=H  %?RP  -=(^)1,*9@&OFB$N&/. X
MC5S:C:35CO'.0^3P   "OY8   &MD0$QG$<AWR+20#KG,9L^3'&F&TD6F?)#
M,4?9D2*R;0 >?Y8 L   4H*GEGRO1W"QQ$Y@B52IA()+Y+9'I6PFDT,L@58)
MH-;/28  %?RP  -#//<Q!8,K&=TF<AXZ!8XCTT0QQ;\%3RRQ5HM$7.   !7\
ML   0T5".X082B:Z6O(2.J9D@$]'SR\-E-H-N.F1^>J!YE%BBM1:4N. #S_+
M %@  #4B*S5"3#0#=C'&S&RD='=-U, <1QGX<YBB'R<S2RQ0  *_E@  8\T4
MC\T@F(BLC,L<=(S1CS:#'G2-F(C)D-9/LEX   %?RP  !QD '5-K,6?9O!V"
M+SLG 6 ('-L,&5M);)--C(0)D-&-I)+ !Y_E@"P ,1?L]BBKOV[D#$O&;-<,
M^:>;H 1H8DTXXB4S-FT@     K^6  !^&J '8.$PYEC4S<B(R?B)S;S23>#/
M'=    !7\L   8LT@S9S&5.@<YDC"FK&EDUD?&ZF<,$9(Q!VC%FG F0  \_R
MP!8 AO/8:)\UB;>:/MXI\:R:B1$69*UE@BKIGBQ!\F[F-*U%PSSE+)F\D$$E
M$)%WB,RG9[8 %?RP  -**$&P'T0.6C,<:&:L9,CL]2CSM)[*SDZEEB8
M5_+   &F'G01V6X*Q%FR%",2U!W 5,,J6L)B*E&FF4.R;8<1+I;,  \_RP!8
M T;(P=FAR<G:NB!C!'9,0<QBR<"(3.&1-G),(S,8;,1 ;"1"2(=XU(V,DLBD
MLP 5_+   Q97LS9RG0,N;"1L;X:\8HL$:&80V<CLE@VP    %?RP  !TB/3I
M$-$\',?A@3Y-G.L80P9*!M) !OYJIMIH1L!MYMX !Y_E@"P      ,09<
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MAJAC3C,(;22T0@2L142J0:84D8VLZ)K9P'?-H)*  !7\L
M #S_ "P!8 KKM.N8&38M1INU"GIQE62R1!)I!9(AHU(LD5D/2<J,8<V,[)LI
M$IAB.R8B(BSA$9ZLGT"OY8   TDT8F0UX_#[/PS9IP,H=XYR'R63G.8Q!B#I
MFQD:DY@ K^6 !P>^P_E94SXF)KQ4<VXPI*1BSO'3,:;"8<X"#"+2[9FC"F2-
MW-V   !Y_E@"P!CKMK(6KOZ"&CI'Z2(8@T(E,U$UHE,C,FT@DWXU0[)MAQGX
M1Z90VTUPUDL4 5_+   C4\[ 6M-*(&-=+%D EKSM$:FM$<%HC92'B-27S!D?
M%J2E)Z_@ K^6 /P\V.@;#Z-:%K_>H\TP\UCL%JBM!"!Z $;E5RVY(11XMR5I
M)Y.P52+J&0+6@   \_RP!8   UTB\E@CHW$RAPFP          K^6  !H!0\
MO :N<1IY7XLN;N9$RI'1L1Q'V=\UDXC#$5$U'9,<6& !7\L   #H';/HZYP'
M?.@#F.T8\[Y\G2/T&KF;,Z   #S_ "P!8   I"5J)$, 3N5(+G%P
M  5_+   QQC09\Y  #1C+&Q@       K^6                !Y_E@"P  !
M"Q\'R8TE,J8;,6Z         !7\L  #3SSV(Q)3-'+'%<"3S53)GP:Z3L7D
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MF*KEMS$%82]YYNF,)^,N0@30;>7K!7\L                #S_+ %@
M           5_+ 'X\_7H$'F;-].N"/#?#F-%-L,<;.:(;X1T<1,)@SK&E'7
M-V.R: 3&"OY8                'G^6 +                 K^6  !^%*
MR;3N&-/@[IN1N0        !7\L                #S_+ %@
M     5_+   @\K@8P^S"'=-8+MDT@        %?RP                //\
ML 6                !7\L   1(<QPF['R5\)-)=         *_E@
M          >?Y8 L                "OY8                K^6
M           !Y_F;,(               #6C90              #5S:
M            ;J?_V@ ( 0$  04"W/W/F4&9ZCB^O4<7UZCB^O4<7UZCB^O4
M<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB
M^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7UZCB^O4<7T
M5W=FC9WG7.UYUSM>=<[7G7.UYUSM>=<[7G7.UYUSM>=<[7G7.UYUSM>=<[7G
M7.UYUSM>=<[7G7.UYUSM>=<[7G7.UYUSM>=<[7G7.UYUSM>=<[7G7.UYUSM>
M=<[7G7.UYUSM>=<[7G7.U.WJ(107J2,:]21C7J2,:]21C7J2,:]21C7J2,:]
M21C7J2,:]21C7J2,:]21C7J2,:]21C7J2,:]21C7J2,:]21C7J2,:]21C7J2
M,:]21C7J2,:]21C7J2,:]21C7J2,:]21C7J2,:]21C7J2,:]21C7>"NY?Y'?
MJ_/XQE65H6VK2FW$I;:<=SSEH_6_?R_@GW'#3F4)0MQ6<93GG/\ A_\ ([]7
MYJE1DEMI1D;(O9J!,ML6CD;)'J^\NY$%J@AZX;-@B-_.R1P6RA8)O?JL6$I?
MK"+78!NU]UJH0U=G$X0YS5H_6^:O8Y1JOWOJT0Y;QG-IHSZ2K=\E=60VOE_^
M=0@QVM;B$'(ECN(7!W<VSP'C4,J&'P!7-%_!/-;*=0]7ML1KP&I[42#,6@7F
MQ$0+M_8BT\6+&3#)$F^,:VOVGLUND/U94ENC;@/OP1^Z0J"5W=,0HXTKS7_#
M_P"1WZOS56W A5V)-W'"/0,VK;LQ5Y&Y @E?9-S@&J-MU8@56-%GMN)DFS[B
MAY-ZQ<:4"=IY6OAY4*TA3EP<RC+G-6C];YJ%N&'9)S;;%G!7;K2DV2/9H\03
M;[ -LNJ2> 5[,:WEPK=IM\"U33-W$NVWB>KB$%I%;=$\T7\$\U7;>R  2-V:
MYD_3+35!]5DWJDN)QN-$-"01XK6B,;> JJH2;5MJ4KX&57(9P]:8UPL5LMU"
MM-X,.#'2O-?\/_D=^K\PT+(/#QHL@7D<U#%D"#7,=!?0]EH_6^94A:?;A"U8
M6*(-C=*'340,(6K"ATU$#G2_@GG$H6O+(4K)%^U#;CN?Z<F$,GDM(;<=S_3E
M_P##_P"1WZOK9";U-]KP0/9#EU%B01,11@9<8?HH<+&\IQ6"->HT!%69H,IH
M;1D 6-R!U;'F*'?@HRN'^]+\/HDJP.US>,A:CQ3>.HU"7 W:'LHD3[%6:I'L
MAC;@/B)&!485!%@DUF30ZK6;0V%K%=%UFK54'9GINWXK%@8KE"?"+V^!GSI2
MAB7PG ](>--YKS&S/LM'ZWR@DRR0MN#5<'FCA(6 F5NWP!DV>3I0O$:/5:AB
MP@6@\*GSH3.*(+K  V.G?3*KY#MT9A\*QM\YM^/XV,U>"D;:(52"3I=8#2ZV
MR'J0^*NH#4.V8/""Q>47\$\B9]"JY7P,6GRZ("3=%U2GD*UG;^GQCRZ1990.
M@U2LVE 2L5T76-O%5.1)BCX,RACZ/0\VP#5@46K;D@Q%<+S9=@IX:@-6=O>C
M;/Q^]+LY8@W1;4]6[S-P1VKC_+VVDV78*>&J[5G;LE7(W$9L_O*S&;(\C_A_
M\COU?6V]@K]5L,*RUL'.O%A%VF=5;[%!4ZV7N,>K)VZ5.T*$W #-JD6\PPX5
M&X%91=]F7^K/%B+Q<H<O7:ZI5BK 2R\7C?,VLWH2&W*@OIC3;!;FYE_M5CIQ
MS1&35X=<3N!%DSHFX53Q,C6NJOC*];:R"?C6"M!K9%N(Q@5"W'C"GC)BF]*-
MN*$9NXZQUUZ@^RT?K?*3:\1Z95+)@&3+G0[%=*VD1+58#M9*X3=A6+D(L(7L
M$D] 55E7:KN'IIR [5*V;#QPDTY =J<C<(>JX$R !MTC9(<F[/VFJJ<G/@(H
M2MEY1_<:VDTE[#RB_@GD!+31G:)'L](R(E;A#';F,N0MD>4$),F9"$-/Q-PZ
MGB9%ME4?%UFRU*O&46()!J<?<8(SN%2GG&ZCN<"AA2R;53[+7(.YP1G<B$8V
MRKYFU6.5836CMBIA6E[B$8+YA-JI]EKGF>$6=1>$Q=NEK6XOD?\ #_Y'?J_-
M0H1*5+?9=C/<J# F$Y9886#2N<M'ZWRH $R4C\M25(5R)8HA!C:4A:=(Q(DK
MF1" :;RR_@GEJ0M.,D)ZH_*C39D+*UK<7["H4J#>TI*D*Y$841F0^3_P_P#D
M=^K\R+[)WB=[I:WS*@JF>$B-M133 ZI5X<,KL:KE9SFW0)&Y+ 6A%Z\3H(T$
M_L6N,F_@0]=.-II-:*R[6FKQ%<U:/UOE(FCH^US%=K S356!BXK;D-VP/R;)
M)O, * C!HU%!OEX,02BZG!#]EM]-BG0]:OZDKBRZP&EUN2-JH8&2'P(\(]6Q
M+-;N[07M1\?5Q)>36!*#9E\/(E<HOX)T*#4^!31NVH9"85.K]="U6J [,].V
M]%8L/#=+)"[^+"DB3U.I1*<*#4^!3:36VKC;YT:GV J]3J42G2:+8Q(J=30$
MZG#*)54J;KE6@")=$!)NCM5I\ZLOTP43W%C"0$6];D/#GKH,#U,?3)6W=7AE
MPX.H&$Q=N 5HF0WZL[09@>F *U*I85I^%2*ZR3OH4$'&:_X?_([]7YEESJG2
M]VJ<J_P+H+BC,W.KGQ$:S#V*@#LM>X'KMB"6C<F?9:[$I^XYA[@S;JS0:C:Z
M9:!PF%B_@A\XO+;GEN:M'ZWRG#L1=*C6RN3$RK<S/#PGDQYEPM#E@,@SPK-?
M(6,&7*E+I"=-6F2&G%JT?K\2O2[F&90_::JIPZ<B%! V[BX4F6=K?#INP@2R
M3QR(4MF;L(EEC& B9/*+^"=2K'!?H.;G5CX@':@#M=KUMK )^LR ;VXA>S5H
M$D[=@L_,J_5*')E6."_0:;97:C92!2F"B$J_5*')KY)L,<EW6DN/1(;ZARBM
M8$Q)6X0QVYP+J+BB[#9*]9;'-W%$QM7:: *'XW<&=I9VY0N=+I=H'"8+.YH\
M!.<M--%A++8X)@ Q>*H\-J9%LO-W."QV(>O^'_R._5^?1UR,2A9"#'6XMSVL
MM.R'2@L@%GL!"TF"4%D L_F+1^M\]$B29\EYIR.[R&FG'W9X^8+E\R7\$\E*
ME(SG.<Y]K59L#X?VY;<PB,BP9$>TD",!Y/LZ:^CRH\J3$<>>>D+U_P /_D=^
MK\FZ5"6<,V<"+L^[X.E!G(RZU3R8>-4Z<'RBF 0D"R5ZKCI]LIXAFEW /3*N
MR%IM9L8=O->8V9ZFL31.:0&R^-H%?=)5\#4+<9E5^MEJZJDC2&Y;CH$AM<U2
M1)+<P=509NX]V;>KINXM?&5ZP<FT?K?,%:](/4^Q!!YBSN (,,)FK5-\TQ7:
MP,T-J Z-(B"Q T^1!PR@U%,"*M(4/6;84,U>"D;BK4]10@( /B9XT4S<[U7X
M0-_F"_@GFKG,%9VR30Z4U:8("IB*IMJ%@6._U*ZE[=N#64AQ="7MP(.6*PT8
M6JL;@U$%5(E9#"H6ZP<+6[2-N  ?787-?\/_ )'?J_)N-O&V$V1M.;#NS.(1
MY6]Q>S5H$F'>*G.2.+PC]+B[D X%HFV2H\)W:RP;&5<W%I;]HAV*L/4;-T%Y
M56"_$>\#5\'1-R:):6:J5G6VO#@#6XHMN_N6NL#ZN5L%;L%YSN>$;L#=F@HV
MZO-CA68ER;1^M\P?/PRH&79<&K=<IS4F\V \"KMNC6RN3$U2>^3R7[ "*4*>
MB1:0=O[#811^KU@D3( &W4W,7BT-V*$FMYN8.;,M)L,7&\P7\$\U8+1"*53&
MY554?(6B+.H]9/2:P>B7*@U\T LP9NM+W*ABC]H(TZ5%XQK(>KQMR@\:_P"W
M[<'S(O)E!^U\U_P_^1WZORDJ4C/6+PO.<YSKIKPGE(<6WGGK1^M\RE2D*Z2L
MJ4M2U:8D2(JW7GI"TN.(QSY?P3[HA:V\\W_P^\TF/N?8_39KTV:]-FO39KTV
M:]-FO39KTV:]-FO39KTV:]-FO39KTV:]-FO39KTV:]-FO39KTV:]-FO39KTV
M:]-FO39KTV:]-FO39KTV:]-FO39KTV:A[=Q[K%\D=>2.O)'7DCKR1UY(Z\D=
M>2.O)'7DCKR1UY(Z\D=>2.O)'7DCKR1UY(Z\D=>2.O)'7DCKR1UY(Z\D=>2.
MO)'7DCKR1UY(Z\D=%MK8_P ?31KTT:]-&O31KTT:]-&O31KTT:]-&O31KTT:
M]-&O31KTT:]-&O31KTT:]-&O31KTT:]-&O31KTT:]-&O31KTT:]-&O31KTT:
M]-&O31KTT:XE'^6]=\=_8&UO@3W\S]1_L#]B:[X[]AVQ0 #;*G%LZ,;DRH-K
M W0">KYZX@@%4P=#9&L$1\J'&.!)KK=^9/U<@<$!FCMJ<%V.X6:)3:Q%W0>Q
M*8W<.OGZ]:8=CF5"TP[B&YW:WP)[&R[,@EJ=*1 A"-YFY@Z:9#C=2#0:).:?
M8?U+.!!\+M<7JH]BK\N'4K2+N5?FG@8V7(-!HDY+["W7R@R+%9)C9,5%A .#
MHDR(0C<V9^H_M@V:(5,:G2D0(4C<47'VTF'@HU-@L[X:S2#P.&^M:6TE-UA?
M D,R'(R.^1'>4T\#&RR!H,(RM:6T]MAXQ<+;PVT-,"#+<8R(F3776V&QYP(6
M88+B94L<9#F.8_8FN^.];@74E1U4$3/(+]G6W)K>IBFY#77<08/B![R.>AVN
MQUZQ@ML3%> AMRHP@3!_C/:ID4E;:0I_,3?;Z/8K-ZM\P=]>:8.N,RT[!I>3
MMSSNUO@31"TV%XD)%Q0\'5C\/4VLWJ][2"P(,QN[%!VVXC;!.,T:41#DAVYI
M&JE!-",@PL2_[)#1T#:NUC5TDY#"VNZ"[(6>VULTT"?!R"]3-08.X@UR%=]L
MZ]8P4KFS/U']D^]7.PE@@4?7A>K'X>(C+OC^,+48\;W B"3@&6%K57+Q-MWY
M9C;2"&$0_P"-Y8('KNYF!X]7\;K4-<I)QQ@X>W*H(,N)H3\F=D.1@Q#U7N*>
M$[.7 @:]5[Z7#A*MB.4'WLV)A!/XXUVKVQJ^<O\ 8FN^.]38$(DQ[8U?$Q#E
MCJXBTQHVWU6C5^1MU7989%" 9KLL&,G%4[7U'$"PT(%9"(C;FI@M'P0NSAD)
M2A+=?$M'Q5?$A) &OB:R/YW:WP)KLL;M/LD1V9<<*''U\1%!C(9<EMI6B9,O
M4P!TE9*4%L[^*8![K6 $N&:I4!%,'&=N*]8)Y+;2M$R=DJ8"W0[)5 UKCQJ$
M 9@62J!K7'K]>AUR)S9GZC^Q ^"W-]DB.S+CNTJMO4XUM[7S9#-6"9<&[0!I
MQ%"$-(1MA4D0Y8,9.*^5U0[R,[<5ZP3SM  GB<&&P.AHH]7;6FEUML*H *6:
M$;8U,(0/ A=F$P=K:O"G\- \UNO4<56I7+_8FN^.^3-,AQNI!H-$G3BPL6W;
M;?W"-6?!-$2184&8EG0D"#F7$PSQ95NPR2(^'#9)C9,6/8J_+AU*TB[E7V+H
M!?M=)OPZS"2186&CND1[##]HK,6(J5&;;BG@<Z*X\RUGE;6^!.07FJ&B:C<A
M=G$XF1%1IQX&,1*G0H,6+.A3HL2R5TAJBV[BRO.S8<?0XP(,,03@0HA-@ KD
ME; IZL$#@@,TA:7$K/@FB,XJ+%MI(0%PAMVC&+KS!GZC\J,9$3)H"^CR$XD6
M%AH\TR'&PG"PID?$F1"$859WR%VC&1$R:H\#03D&@T2<^^Q&:5(CI?D%!D2*
M5-3%#B!L,)6<N\42>-W:NAJG!GPR499\$T1(' @E$LB/@1*U;L6(_P C]B:[
MX[Y(L"#,;NQ0=MN(U89DENQ(0W$B;ESD&:C)@0CF]]@@D$;ND*L4$4*+4ZOY
MVB.]WHA>IFH,$R#"Q+_LD-'0-JZZ#"9WU;!!8^PMM[]G;SPJ=-@E#W=*K)"8
M3/V8/U,),W'H!>;?;#RMK? G(M/AF(""B*26;7%EB@ (ONS3,(,2KE%:&,5^
MLQ[!N! :5#V:*MHLQK>4=% ;8/5>V-%556LXI^X,.(,&6J9%)6W8]3^=L-RY
MR#-1,"19?>Q,5G,,.'$A][N8,_4?D[BSR(O;\N! UZK@ZM5C$:O3+;8#XW;>
M[#8IDUQ.7VSKUC!2K!/(B[ 7 @:]5V!ZMNCD4';;B-/5R59MOXMP=,&FX)YO
M!.O6,%%+.1$;E1Z#" :W!%#&*Z$&CA(O<N<@S418$&9W;I#""R=NQ@T1>^1^
MQ-=\=\F*#&0RY+;2M$R=BV\:L]^:H548#E-H:68=-4(&<U/VWK<^/BF >ZT
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M,*R'IUTCT>1L]8 ]"$"1Y$BS4^&!%RW-;L!0J QBPQDUBM!ZMO)NW,FC[;6
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M>CSG[$UWQW[#E@@ &8RWW(^K!>E##4 ZEP&P1'RH<8X$FNYEQ4L2#0:).('
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M ANB_P"DU8? *UV+4JN\5J4&#8+5-A0EP;.%#)W$,UMR3-G6-ZV1:U4[:XC
M$++_ (\;DLRY&W9NVF:MLZ%^N6Z(8.4OU?#!['N-37Y#[,4';;B-JU>@E-RM
MRYR#-1,!Q1?>V0TB%%LWTS-@PD[?TLVN++QC"<>S]B:[X[U;+K!ISM8[5?R?
ML)V4M5-U"7> &BE7['5Q:Z97JENSVZ=Z?HM?%[A;@WA]$W<G:ENPQZM2:R'O
MDF&"B7D.+PC<>Q/@8<3;*RAH-FW9F..1AI@X9@U(C4MN*#7J3&CP-R!(6"!_
MCHP$&[B7X3)G7 <NOETL[9NU!OE;6^!/?S/U']B8D5N1['FFWVH%)K0QENL!
M6GY^U0Z?;&:)58PFQU<1:8U<JP>JQJY4*[4A(+;>NUR:YM-277M2MF:3*;9K
MXF.>LU1$6QLUMU7#DE-0KC626VE:)DX@,9"+%-H:68=*T$"7=CT"JQ@TJBU>
M8+.4P+8"BZC(E[I^W]B:[X[U8  RSC(L6/!C>R'58$*THVL",U?@1XB%%T!<
M4V[L_$=BEZ$]).FZ,HC.#0)(P<K;V1%+E=KV9S[%2%Q;"]ML&?JMDJ!<YN:W
MMB!:"N;<U^2,D;<32P@/M_,@6C&TL+APU0US3,/;X".T_3,=KK%/[@G\G:WP
M)[()E9:;J7*CP8M>M>X=F07W$I($L?NM6J[@^XU<JP]8 D:2$W"IMCP,W)HI
MDJ%,*3JN7JIVUY&Z.W[A&+NG69.X10J-!CQVX-,*C 5_IUF(%-QZ2&,$]Q:2
M&,:=N=68#R#X6))KM[J5L="[BTFQ$Z_=<=36;SA]]PJ.:)^PS]1_L#]B:[X[
M^P-K? FB#MMG&XD2/!C:W!&S#-"V_-C"E"KKPYBB4-F:W<)$5QNFVO$HUM@6
MK%TESUH2G;NU)EJH(VL727=>@G'\<*[C.-Z]V<]6[OAT73MI2E.Z.T3B&800
M!>;(%&@+?")6&NR+)8IY.===J+O5-Q2,"MUFWV$<ER:-N,.N.6RO;4F,[@G/
M89^H_P!@?L37?'?V!M;X$Y*]M-OG#1.C4XT5R/@YGM"1;#,82+A#0VWM&KKF
M0HC,9H2+92 H=+JLKA\%W7+JE:GFR ^ 6A0*/3A8QX?!D2RE!I)PL9V]HUA(
M_P!-)&#4$H84..' *'2ZK*&[>T4.76!".1(0H>*;H-4X*JGL,_4?[ _8FN^.
M_L#:WP)R/Z:+[O5^67+[B4D"6L5[J=3D.'L<3#-R:*9*V#<&FU66"L(2S0O<
MS/U'^P/V)KOCO[ VM\"<C<QN>]MR=E"W0E=>',40/7[>'K\LZBSVA:$IV[L%
MSQ1MS-N1< '1/<S/U'^P/V)KOCO[ VM\"<D?0J2)F$Z-3C14[0Z79IC@80\_
MD*(S&=K%X#6*CU1%,KON9GZC_8'[$UWQW]@;6^!/?S/U'^P/V)L'"/&'R[KY
M=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NOEW7R[KY=U\
MNZ^7=?+NOEW7R[KY=U\NZ^7=?+NOEW7R[KY=T(X([O\ EW7R[KY=U\NZ^7=?
M+NOEW7R[KY=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NO
MEW7R[KY=U\NZ^7=?+NOEW4C@?O7Y=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NOE
MW7R[KY=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NOEW7R[KY=U\NZ^7=?+NOEW7R
M[KY=U\NZ^1?)[__:  @! @ !!0(0(021PJQKA5C7"K&N%6-<*L:X58UPJQKA
M5C7"K&N%6-<*L:X58UPJQKA5C7"K&N%6-<*L:X58UPJQKA5C7"K&N%6-<*L:
MX58UPJQKA5C7"K&N%6-<*L:X58UPJQKA5C21J58[K3KNM.NZTZ[K3KNM.NZT
MZ[K3KNM.NZTZ[K3KNM.NZTZ[K3KNM.NZTZ[K3KNM.NZTZ[K3KNM.NZTZ[K3K
MNM.NZTZ[K3KNM.NZTZ[K3KNM.NZTZ[K3IH4A;W<#6NX&M=P-:[@:UW UKN!K
M7<#6NX&M=P-:[@:UW UKN!K7<#6NX&M=P-:[@:UW UKN!K7<#6NX&M=P-:[@
M:UW UKN!K7<#6NX&M=P-:[@:UW UKN!K7<#6NX&M=#_VU7_![AC.,^SXXSK.
M<8YUK\/O\?\ .>X_'&OZ<]_NJK_@YJ>KJ3;R^N/.(A+(-1%3 (IS))^5'CR6
MAD=+K\20Y'K<N*R-BO8C.F!\R0P/Q_WQS37X>:AN=4[%^/2QU742L=7J&G_P
M()_[25YSJ$CI,1G.J@QUX;4VZM;G-1_SG-%OCA\@O#TDEAI4V&PA[$+*I3CC
MB6D-X<R1)1XV,2.CVR%C"UCG%MC&E96WS7^ZJO\ @YJ8,<E+;%2$N=C*,3$B
MGVAJ(#D<B5BR)D=G!5"88I] [L!"3B<S)?0Y#?CP<?'X<TU^'FLPG>@F,I+G
M9974YCY4Y&96QJ4R\]K,9MS3$9;"6XKF(_9WW--X?PYS4?\ .<T_%R\]@8_U
M,N/)7)3#EXUV%33CS+<A"A;?:DQI[;SR7U-,QU16(T:;'AM8<PWS7^ZJO^#F
M,O-)==>:83S2WFFL\Q\<?'V-?AYWK$97KIHZ>NFCI\['_.<[EUM+GM^.,<I;
MB$:^.,<Q_NJK_@U86^D-E2'XD<>\](:?(R&'HQ%]]7?3W52B+F9F22,ND<R5
M"G93C!(;(>E1NI&N$41L2@3<.,R!G3D.!'<Y2W%ES51&"K_35)(O./2.UI)3
M9</,B9*>ES)DB)ALF]V94HDF1@G(C1F23R9'>)!,?/:E'O8U^'E.)95-;?6T
MTAQY+T9:TH1*<Z77R>I=RXN2A6>V+D/-+1^??ZS,O.'<S.V+[*V^OIL*DNI2
M^ZE[+DE:NTN:CN*=5RH_YSD)_67WWE2DS'NR=IE(?[;*4SVN.EZ;)D1].R'W
M)$[M*4J6M,Q<R9V9Z0\J1 ><?:0EF4[-S'[I(?DL)CMHS,C8?AIZ!'/_ +YZ
M$LRG9&8_42$17"@K*LHY'^ZJO^#16-)F17(DN0V/BO0VY@U<F="&JC2X\";#
MT]!DMS5CEOR,C)>1YY/QC,M)89CCNA-F,JD1.PN]T2QSSXEQ/3;C0<H&0XL^
M/II,Q<KNQ:6UBYO05"F)=E0I<A*HLM^$N ZIYP4I[##$_2A<C(]V+*22]C7X
M>5V?XR9#'6MMM.Y>;CNITRR^WKLKG9G&7>DEE?7]ED=4AI>)#[3N74-+Q(Q"
M7V=#;V<(85B+B/(TC#RG7V\-0HR.K9Y4?\YR'8\S$S,>7UJ8+F(CD5S*VW>J
M:Q_WPJ#)Z*HTG#DB/)?:ZAU<E4!W,&7C&9(]Y3K?9I4=]8]W,!31!YJ,PEAK
M3+$MN7!0O#79I4=_N][J>R=*=_3D_P"ZJO\ @YIQ;2$)5A2>4XXAE##K+Z.<
M:_#REO--YYQ+B%Y]G_BG25(=3RX_YSF.@CX\I24JU_3VMNMO8Y2G$)5R?]U5
M?\',O=/JH_79KK,F;&>?+/94[-E.O2E3&6\%)&12I!)B4T2=D)L>%]VR7Y4?
M.2$ME$+MB^;:_#RN@M4_+S[FLR'G%9Z>&/@QB*IUY3F9;N&UJ<[*TYAB/)4R
MX_#_ !)?=2]A<EUU"UY4T^[EZ+EWH-+D.-8?<ZIK#N$\J/\ G-..RERED'=*
ME//NR9+L?")SG4=?+0Y"<=0WB5+;0X[*7*EOYBQ4*E,MXE2VT)F,..(E/(E.
M3).LOR%NIF/=DQ(E(D8EN-P5.O*AP,+Q$<=DKE)G2%-.O2FM*GO1TJQ(Q-2[
M+>?3+=SA4M_+<)UYUS7^ZJO^#F58Z26!\U QR \MWL$R,^J(ZJ=(B2N\9461
M#$MQ)2YPIA/;RL1R="GPW7G.[)#K;",ML\TU^'E8:5B5F.^G28V4.KQTD1X^
M&FW67.N2PZVVB*OJH^'4MO,O*>Q%=SG$>1IEI3;BXCBL)9?ZYIEYO332D1NR
MN);:ZWH\J/\ G-)87B;V60RZ]&>P^_&D/8D8>Q!;CR'M,Q'4:3"DJ2EA>)LJ
M/B4PAN4XA,*2I+S>764Q)>,*5CI]7(<4F"YB(N(XIQAA]AA,%Q6HB'FV<]=W
MFB XA,N.MQ>1ZWD8CRG'6&%M/9B2<+DHRT@>[G*M?[JJ_P"#G\]'.D/-.*QC
M&/;G.$X9>:D-JD,H<9>:D-\PU^'GE*2A.,XSCD9SC&$+2XGF8_YSFLR&<.^W
MXXTKJ>M]K;S3J>9RE*L8QC'L_P!U5?\ !R1\Y$=B))>B Y!!_"L2YS+ZYL]_
M69\F0Y$E3'6X4Y]4^"_/F9D3Y<5_/:E'NE+;>[P?Z+I.3AJ3)G06$29;,KO!
MUH3C$ELQD@\T)=F2(\'KBF)XN2[*C<EK\/,-OI9D,N+:C]<M3G:)*6\O/N:7
M)7E*G'%M(=4VOM3O9W7)$=MM]?3Z^5AM+CV%I6YV:(\IW',1_P YS41+G>';
M9>8ZWI+LF>ZMB%)B-184CK7)O;W66&)CG:(4EZ2J0ZXH:ZZ_'7%>6^KFO]U5
M?\')@078L=J'V4*VTI%>9B2Y&ECIK>G6%QB"Q4AR&W$G=M'Q'(K.!4],-<68
MDCV![X2V.R@LC75B2,-4QEN%*=DY%/9&8A3'9C,:7&'=SR,QLQ',E1T5R(UR
M6OP\PRRIMU+'518R.C#:9=?CYCOIU(1A&F^FZB8CX1W8W39<9D2$(;>SC,5S
ML^6%==V5U*8[3K;G,1_SG-,1U-R>P2>I1'4B7(93(95%FOM/1W>O[ IQF.B4
ME799#LA4!U4*;E?8(;74QN:_W55_P<K^NOACX>SX8^/*SC&>?:_#S/\ 7V?T
M]F4I5K&,)U\,9]PC_G/=/Z\Y_NA1CNQ'%FN+-<6:XLUQ9KBS7%FN+-<6:XLU
MQ9KBS7%FN+-<6:XLUQ9KBS7%FN+-<6:XLUQ9KBS7%FN+-<6:XLUQ9KBS7%FN
M+-))=''>FN]-=Z:[TUWIKO37>FN]-=Z:[TUWIKO37>FN]-=Z:[TUWIKO37>F
MN]-=Z:[TUWIKO37>FN]-=Z:[TUWIKO37>FFRO0>X@UQ!KB#7$&N(-<0:X@UQ
M!KB#7$&N(-<0:X@UQ!KB#7$&N(-<0:X@UQ!KB#7$&N(-<0:X@UQ!KB#7$&N(
M-<0:X@UQ!KI_^W[S1XKDG*OAC/O^6LX;^P%QU-M>_C![1#1)YMK'OZ(S&&W7
M%.K]_1#B,-/.K?<]_;<<:5]@=)71^P.FO*?^DIMMQY:TY0K[P0Q[LY,OHBV?
MO#%E.PWEK6ZO_41+;BL(8;@QUJ4XKW]3701]P!9#$%Z;+7-D^_MM1DM+6IQ7
M^LN,9SE]A$9/W!ZI6&_?\.06(^<Y5G[@(B-=!UU3R_N#'B(PPK.%*]^Z:^A]
MP1#T1+A*9B6__J+'C.2<KPG"OO ,@LSU$G6V,?<#&,YR_'3&3[^A:VU?<'"H
M,>.I659_Z*%Q\M-_8#;3CRU)Z"OM]$6&PRZXMYSW^$/<G8F= 8U]P.DKX?8$
M:2]$>6M3B_L!;75(^\*,14,J4I:O_P D/__:  @! P !!0(F3R/SQ(O7$B]<
M2+UQ(O7$B]<2+UQ(O7$B]<2+UQ(O7$B]<2+UQ(O7$B]<2+UQ(O7$B]<2+UQ(
MO7$B]<2+UQ(O7$B]<2+UQ(O7$B]<2+UQ(O7$B]<2+UQ(O7$B]%;PZ-(>8SVO
M,9[7F,]KS&>UYC/:\QGM>8SVO,9[7F,]KS&>UYC/:\QGM>8SVO,9[7F,]KS&
M>UYC/:\QGM>8SVO,9[7F,]KS&>UYC/:\QGM>8SVO,9[7F,]KS&>UYC/:\QGM
M>8SVJD?597.P8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&N
MP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV#&NP8UV
M#&OA_P"5D_'S_P#764J3G64JQA*5*YVT_KWO^U?YC[ _OLGX^:@M]<&91U01
MO,O$-R3B*;*)2/CQ7WX[A"0IEB4TAX]&D.SY;7:&Q,^)'?G*Q\%<U:?U[FK3
M"42&67"$L.9(Y,UEU,[%JD=&71Y'_LKT5IO5NEJC&["/P4N)R(Z1C3QL2+ Y
MK:O\QS4O\<A73<D]'KF487IGXNJ4K"4IZ7:)+;6-.?Y6<?',=64QDYRI/-?W
MV3\?-1";<=I91C*<S!K\?)1AR>N>W(@C),>(\ZH8M<DFPJ;VZ!'S!?CQU(EL
M2)JNCTN:M/Z]S3-O&IF/V%B0/58ZW@PT<9CP; 6AF=5HJ+$9:L,\>DW88AN5
M/LP]PYWX$'IGNAEC^:VK_,<TXUTU]F7T'6W,N=2[KJ,I4M"7,9BIZS#;Z5KP
MYE"&\M(;:>;:3TNCS7]]D_'S&&'5-,L.R%<TVPZZGF/AGX>RT_KW,Y2I/MPE
M6<*@2T0]*A2D1,)5G"H4I$3G=J_S'.]-.%<SE6$\S_?9/QZ!N=&<PPQ*E$&F
M([K ^.^U(',LI[IC]9&@-8B)'YZB!B.DHU%;D#R3+,:1ER>B&N1E@RN4^X;A
MPG&BC*<+>D186)+XV/T$QA[2&8^(N8$2'*2S#BLQHD2-*4H<QVE,8:II0V.^
M^X/CJ:["/5(^,9 7V6G]>Y0]\O'J!$-%)DI<$3(#V"+"DS9M<']2D)74EQS8
M^)7Y<=KA:$$$$XLKP4%R/;J[;HQNIJJD/B.>$A]E-1Z\.DR @R0';'5^*SFO
MPL+-CXHQCE;5_F.1C\XM:\NX>7U76.X7U[N4=:C"GG'&]+<6IQ[K,:SG.'LN
MO=6MQ>7(ZU+3C"'%/=7V61_A^#:<=<WTV<=&1G_SD8PAQ3G5]!S#2I47X_#D
M?WV3\>ALB/%D)F1&'"$EF6N&13&A3"6)$9XA#DZ8G1UQ$D6V6,$HF)P)6<2'
MW<O/2"'3BQ'TL2NW-=ZQ9[+!)I6$.R)N%$9<N$_AY<1N-WDA2T$H?2Q-AK1&
MFQ8ZL2HK,Q$YI*$E$-Y>DPOB@FPD@U)B+'^RT_KW*[^ZJN@3?=DX@4&LB9QP
M<^HL6#3DYLD'-B@EQBH[Y:'D+Q*#R3E%(C@(,2'-C)12(X!<MT3OZ;-%(=E&
M8[ME<.@LJEO"HXX,0>*6^P3<3S'*VK_,<A3;O79;=Z6&%=4II7Q2KHIQ_3+#
MGPRVYC+B'5IZ"\N=0OJ7?\D=>5)ZMUM>8Z^HRF0M+;>$)TE#J76$YPGJW6U]
MG7T.I^+_ "?[[)^/FFT/J6I.4*Y3;:WEOM/LJYRT_KW*B"2,]KEJ2I"N1(@2
MXK.LI4G2>OD*?9F#)/+VK_,<QT4_'E9QC/(2M*^7E2<9Y/\ ?9/Q\S'Z'7.Y
M9[]>8A26VAC"4M0XC;,9,)Y?=D;O-+ YZ.X.9CY 93VZ.U&E:Q B/+F]B1S=
MI_7N4F7%CTML.$@X0#%0([:XJS2G3+MEC#!+ ]FKBW9T6./38R<%9D[7HQ2
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M3L*TY@5?R9XN-R\2:<<OE] FH+L[.W("BHR)IY\D7Q_Q-+C@NEZ"=$RM),I
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MDPB^75*D2>"2)\5(/+#J'+18;3,TTF@8:X_VR5(;[RG#Q88>;7:4$)F!.E5
MPF-@II;7Y9)!.')'?0VNRE=DBU7]<D66=VI //Y5XXT_V)X'PS8N,HV;*MXJ
MS.=BJ@XJ81X=>M^KPT;-05ZZ2Y[V/DBXJO*5=_O5XII-#8-FK!.C+Z+SX"RV
MZF^MH*DN6IB=!E9Q"8RFFJ+C<O$FG'+Y?0)J"[.SMR HJ,B:>?)'B'>TJO'<
M]5M)(*YSD3(3JQ9<D>%N75@LO7@VS-:B4Z)T)'CKE.B+[>;LD_\ *,7Y0-,[
M2%K(%&"D]7CA=QT^Z72[!;M-*EURY9X,1JB5Q8>:NS+:EN"U:*ZK"4UD3IBZ
MW]%W=NNTO0:6TLJ-!J.D JD"+WX0&G@^PV7+=O!HF0%5%H5SBY>*^'-N,AR]
M!LIMDX:YX#1@B]76\7>]7PBQ9"5*)U1,K5K0PY=4+:0\U,H524G")\#?/9;^
M_P &LSJE@C;B5B=4;-N0HG!(UHVJ=X)4PBS0JS"[=*TF DJ"IC!@B94/9A1J
MTH3:,TDRA1]6<AP?+#7$KT>4T^@*LH2D'D,\<)O-WG2M-?$ <<-MIU&]',9Q
M>6V0X7W209RD*3.4,NWJWWA@8*E2JB\OWF80IT:M>"5<,E*5=V939IUJ<,.W
M9*G5%2K0)PF$.M@V4H IR1WDEW319E@31!N;VT 2Y:3*5/'%UH5^1*USBJG)
MDC:LSV;D^:4.7E<RU(I$N802L$M*3(RA-UNEHM;0+437@JYH<O$E=W=$CCJ$
M=U8VA&V"YF63^$+O*RZALU$2F#(#ZRA!_,4VALIF=8SE_"%7.G:%VUDJ$)<;
MG(( IR>5>.-/]B>!N-S:"PY=FU!4Y2,[&K2?LX91<+SX<%A;:6F]("DVC.HJ
MH(5YX:N[6YNZVVQQVIJSF1XHO=Z2E]7BA18EH[*E*:9ZU4J)8XNEZ\3#_?[D
M!()E9<LZM."H$^F/$?&5M+6ZM;>BR3M134F5-F4K7VK-47+_ .A?[TEU2S::
M<5:<L@&1$S175.0G@B^/T_\ 'K2MQ4\ "[29Y>7'#]_O:5*N]YMA8%<E&8E/
M[-0JHBUX>;T[=G&U)=M609&5FQ52F1KQT0RJYOWU^P\E:MH1*0^R/M9HOGB9
M2[L+Q=RA(DFU,A%>E*6B:B8NEP(7MF+WM552LTU4U\@XX\0#NW99O=BRM(%L
M6 *#2:#D-4\<71JZ;;:L)L:8&KC)!K-% R\O 7SV6_O\&M1J5&QHV4^6+?JV
M904'# :7*Q <1*@0NWK*C3"90%*LB6+#"FZ)E4X)<E:@##P?+#7$KT>7,5Q:
MGI1,_)9GH^7-)D>'O'&G^Q/!6D$A46YFW.<XM+)*LOR6V%J0O&DD'-%MY2E+
MQDS,$() ->7_ $%\]EO[_P P\L)-NQ9G@GZ1&^ZG:C?=3M1ONIVHWW4[4;[J
M=J-]U.U&^ZG:C?=3M1ONIVHWW4[4;[J=J-]U.U&^ZG:C?=3M1ONIVHWW4[4;
M[J=J-]U.U&^ZG:C?=3M1ONIVHWW4[4;[J=J-]U.U&^ZG:C?=3M1ONIVHWW4[
M4;[J=J-]U.U&^ZG:C?=3M0Y?N]6+<J-G.H 5VQBQ1\9^E^Y'QGZ7[D?&?I?N
M1\9^E^Y'QGZ7[D?&?I?N1\9^E^Y'QGZ7[D?&?I?N1\9^E^Y'QGZ7[D?&?I?N
M1\9^E^Y'QGZ7[D?&?I?N1\9^E^Y'QGZ7[D?&?I?N1\9^E^Y'QGZ7[D?&?I?N
M1\9^E^Y'QGZ7[D?&?I?N1\9^E^Y'QGZ7[D?&?I?N1\9^E^Y'QGZ7[D?&?I?N
M1\9^E^Y#R]KMMJ$^K8E9G_,K'&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_
M1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(
MU<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1&KGZ(U<_1$_I.+5*S4!6
M>**:_F W-@%91KJ]5&(3PJR"K#+YAM*P_,"'+,[N3)6.._WG?KJ'V4X!_'Y@
M<\!0V&_$%K 0L3(#9$RNG"!D'.FE-U8U1APJ.%1RGY@[Q.;<L\6E5_,%EP I
M^8>\61M[-FUAE7*>+YALX/\ M+*W#) @*%1^D*-J#8693P#CCOCGPJ3^6G'_
M #GT8OI%L7=0P$(H0/\ J*$J("C5E@W:[F3"-=7W4^DX("$ZH^8"Q=$VKNV9
M+<P6OLI^T?M8!Q_0$;/1O"3-)^OUG 91@SG'\P.?_/4!;J@0ZD2LL^MRX)SK
MF,4)NMW%EE D/KC.'Z16I:7_ $%LJWOF^@7<FIK= TY5(Q6CC.!(F<,I4_,
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MW984/:3IY8 8@=TEC#]4MFU\%O4C.>Q-Z?"<FGBTX].,B,@)>81!S)5M?UX
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MA5O>K9HR3U#QDZ[6O 17#3:XC4:FY4;K[:W+:@-FLB,J#E1)XH@!.C(!\9R
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MW%WM5W[GC)8T:CNJXF/0"S8U[,*=T2Y[-N^2Q!DC#CMWL1=G2<NOM_;K,;-
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M),^S6 J:( FWI1G2>HFJ(W1-%^MQ6Y?CD*=2-#E<;'K.K/:+8<BL!(!.B2U
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M.8Y6N3V.:JHJ?M*G-..HCW]37=U-R[]R^UV[VZKPJJJJJKJJKS557VJJ^_\
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MU7:JW7@I,FQ2AO:/(O4(DRMSF/VI<AJ[7,+YRTL>ZK9\)I]*Z=-'$%+B22;
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MJMC:-TV>W@F0/B[[4U-Y 4[BF5CZGNGS>U6-U.V_C!%7=MW\]-=.$J:4EMV
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M'\2:CIEQ9P+2Z=>6MB>1EHPV$ UQ5W=^;O[-&7=/$=!ZGC007(Q&HSEQC-]
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M7QI IGFL"<.2V9630R@M()\=XU$Y/!IP6T@LL9-Q)AMKYES<7%K=6DV(,ZR
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MU<O/C%+J2:6.3B-E-LZ\8'!0$@T^HFTY63&D"0CAM!.5S=CF+O1/<Y?0L(4
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MZ<2L;Q^0:'1TQD%E.01G;#&D)[<?ISM5'".OLD';XA)R;HNBN!$C#04>,$8
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ME?)F),!-A,*IQQY]982ZJP&$SF"<6.DV$_IN5K55FFJ?5*/^L_PQ8?Z@P/\
MP_GG\+B'T2G.1@0 &\QC%<C!B$-JO(0CW:-8QC$U55]B</LJZ../B0^H&',E
M"*D^_.U=CI<,2O$D&K ]%1KB->0Z^XQ$Y\6<T.U2PZ^;*$CT56*2/&(5F]$5
MJJW<WGS3C#\BL4 V?>8W36LU(S'#CI*G0 23]$;GD<P?4(NB;ET3@$9D:^\J
ME6_D$7+74YVXG)NN\?6M@!ME=J_JV8UC,/T^U>?P-(JJG$RAB4N4WLBK)##=
M2J"D+8P:8\\ 9<>/-,A!D)(6%)&9S([#N8)Z*NFO!:BMI<IL8T>V/12,BATA
M2XZ"UAF?%G1GS>HA]D&8-P3&0*@&1JHK^2\9;?5C)2V4.EG]@:+%66L&8^*5
ML>P./FUD:&71[GN16-T\7+BD98KZB6,R[E3@5<7(*:?-RBQFQ88IAHT>(.*.
M0L=X]SQ.>G3:U'*Y[6MY5#?(<MDW5S"D60,5B4CC9'%KXAQQ9,VSB==L6NC#
MD&8U'%,U".>B,W+KQ'RYLB66NER65T6(*!*?<R+HDYU6E *G0?>K=I:,='<#
M;JPC7;M&HKN+.&:OR"FLZ>G+?6%5>5)($T-6Q[QLE#\98LL4EXGH-P2D:KAO
M:JHYJIQB-KU)':9M)J8E$O;NWD+<UA[:%W#-=8[5A1G*[7X*\N+*,6)D$N!1
M26P\CR*OII$O'<=DJ..<@K6R:K=%B E#?(Z+#)&:[4NS1=)U'&JLFR&WK8\.
M9-@XY2&LW @SPD-%EOD;PPFL+TG(QG5ZQ'-78QVBZ>FI:*!<WM9G$TI^XK*.
M;/<:H'0W4M8\48]A6W0K".!7@5-XPM*KD33@9=KQ]1C'["MV$9O:CMI&+S8]
MNO-/<7ZK^S^^/'J+_E'\#F^FRJZBXC<9/7Y=38K'@'I95()L&QH/.P2(UPEQ
M:UCXD<S;$9&G&AF[=R:;D1%]"H\ZN1A<-7)FY)TY<4HX'>8[<5\5S7H5%EL/
M+DL:WIHY=':JB)KI49&V*JTL?T[R.D--ZH-&6DW),6G1HO1ZG<JI8L KMR,V
M>#15UT3B3BGECOE 2YFRVU_<PMR@-ZDFOAO[CN>T3=5/0NF_7['X7+C-_/?3
MN3Z@>>@KP8#9G2@FTF,@\C%"DQI [NQ&^@+%N^O+)(!&*0S"IM5SVH-/3ZQL
MJ:56 IO1EN(6399J]2QKV+:8\WM5'$FRNHPX:LI6$9N9T]-RM<NWC$IU&=L;
M()MU+P&*[71Y:_U$JI5+/0>B<R5IPQ[#GX42$JKQ#IX@D%7P($>MB@3V#AQ8
M[(H1)IIR8%B)Q0^G,W#;TY*'J4[<JB%HG8R6I"8W872ED70+/J/AJSJQDB]5
MIMR(FS1W&(=SZ4V<[/L;RW&KW+\Z.N+29EZ.LR$,BS/27DJX6WL$LV.4PXST
MC#"%JM=L5K!N]9X\@79U>=8%C&.5-FX@GL=,!"S2).<H1$=)9Y>^V Y=[$1^
M[P[N?"8K8X%D%591\8D5D^S/)Q]<?6QCU:Q!MJY0[LL^='L)":A<L=FQB_&[
M%U3CTLNBXI;7B5/I!!P.]K*.12DM:FZ&F-2D<0=C:UL*5#ZE88+B"._8]$7X
M*[N(C95&L.P/Z[QL[D0/,*^2L*@/E;+LIB212.V,2)#?XV,5SE>U4:CN6MOD
M;HJI2R/3O'*0,WJ@T?:0LDRF=)B]'J=RBBBSQ.W*S9X]$775.(%5;QEASQ6>
M42"1U*$RM#895=6,-V^.0HOCH<L;]-=4W:+HNJ?5*/\ K/\ #%A]%:N.A))Q
M-WS7A1J@KT5JJ)LLJN:C3'5-&C;N?[JHC>?T)<XC7.'#BR)1&LTWN9'$XKFL
MW*UNY6LY<^*.=&],LLA45\&++C7TNQQ'M!0)HD."<:,'(267243D7:@5)S^#
MQZDDJJ^E2SPW*9>.U;+:R+7UDUL>FQZU[JRF](JQ/YY>G)-J]-O--55&NN+:
MIJUW""_O+*+'&V25F]H&DE.C[G/3X/)%<G/3CR=EM6.MNBDCRML^*MCVZM1Z
M'[)"]ST58Y%W;=-%XR!;IE+$BP+LD*K- M%EN)7=O#<%]LA0@;7V;SG74.JZ
M(K?;R<Z7$K[6MGRH#MDZ-#G194B$_56[)80%>2.[<U4T>B<TX+4QKJID6H$<
MIJP%C#+8!1GPU+#89T@:,UYZMY<9#35\V,69CMFRL.ULJ*3NGNJ*NV(:(P97
M$("/YF@2+IX2C<GN<+2I;5BW"#ZRU*3XOF2"V[NJL'J]UT]O/7;IIPI#$8(:
M::O(]K&)N<C6ZN<J(FYRZ?M\2XE?:UL^5 =LG1H<Z+*D0GZJW9+" KR1W;FJ
MFCT3FG"TJ6U8MP@^LM2D^+YD@MN[JK!ZO==/;SUVZ:<1:R7;5D6RF_Q*OD3X
MH9TOGI]RQ"%:<_-/L6KPV3;64"KCO(T+#V,R/""XS]=@FEDD&Q2/TY-UU7B^
MDD  #:G+LDQT'0(XC9$:CL7P@RW.7[.2QFY=.2:\N'X54DQIL2IK:>?>&L[
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M5E(CLQV-$C%B(R:Q':(]NS?KP&OS"' N"4OI'0GB#F@#.A,M[6\M(N3SH0I
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M> J8U@LNR$X=)8OM*_H1["3'BJR60$=SCK'$WJMV^$FJ<O8D6LEVU9%LIO\
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MR31?;Q-!#N*N6>MU\Q#&L(ARU^W=N[T8BN?%TV+\/3V<,E+)CI%+T>G)4PT
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MKE1%1%TXJ+N3'4EE1-L6U9^L9B1VVH11YR*%A&A-UA!:GC:[;IRTX\RA%R*
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M]--/T=.N8DAL7+_5*L@F*1Y7DIZFB]0:ND7J$5SB,2HB!1KM5W,1%X]6(\?
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M09H(Y),$CVJC3C1PE7ENXBU0\HKB3)DH<$*#Z[XZ3S/40:^1.:%8,.P,1-K
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M&VV/##7FLTC"2>6!'*60&&^7MZ[HHCG>]&:[4<[7A:>!55T.I5)2.K(L.."
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MI/,3""!80.7&S^+U]*^NN/BY9(01@C%1'@ KK#N[<7MXX"" QN]KD0J>E!2
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M=.=L;V<":T*Y%T,#C4OXN91\:(D#+9>9XK3@&4'1:#&TT%S@$W8E@C2&Y5_
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MKV@[P./&X\2]*P7*)("?RB0!'P:@BQ!37WXAP0K)43'\$)?)W(F33\$4H%
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M>\L2W @5Z-ZLE @QL7F4'43'FAH$(?-\P%AX!("$U55G4.SX)%%$ U]Z9%1
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MV70()>*^@51SZH0!JT<&D@ONA>V6X:.546#FP1FX7H!0IA61MY%F;KC"OE
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MTVY+31)I-M9/ @3/"D7+XE ZRM "1#LL#>;P(@7DUC)T#3\O*BI7Q#^%HU0
MKAK$E] TIP.E;V2J*A-.N9P(G9AESZHYN[FNBN$]OEF>J7K5T@>#W;R9U*)N
MC*^(5L!_$&Q*&M_GZ"K0S0(;P=S_ ,N?2BC$IPSD:LV'K0U(8%T=7Y<64S9
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M".0-"#AZ@<ZDE\FC<MVEX^YY068G\D'?!L<-EN@9_4,AB(</G3W^'D]!H=9
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MG] S^@9_0,_H&?T#/Z!G] S^@9_0,_H&?T#/Z!G] S^@9_0,_H&?T#/Z!G]
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MSH<+HHA"G+"^KN3QXXDR(+'8^//#K]7-.5<G;]==:-]9I$2M9WS] $FLNP(
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M1$1$1$1$1$1$1$_=W_)]N%S>?P/]K [<:*9.SF/B]_D'&C2E(J]EG-.WH/Y
M1T/ [3SZ'^_R!:&Z5CQ#C[MO&M.//$^EUGJ\_P#J_D"6XE3BF%)1 VD,HHZ]
MKD\GM]K]B 'Y ?<6@]^/T^>,3;G^0;5$,2FFG[_D.SOQH-:CLV5GG\A7*6>O
M_P EF4)M>,L%"[$?N,3[_P"0D7_:5?.A>LT:FP=CH\_-V_Y"X&H.M.F\_M]+
M@5 0#P'_ -%=B,"@KT._MCP&0^5\W3X-](RE# @>A^06%55##-;-E:/55/\
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M)))))))).VVVVVVVVVVVVVVVN2222222222222222@
M                                "B 220""0       " 0"0"020
M     ("000" " 2      & "" """0       #P"002"" 0      "0@"0"2
M002 00    !P " 0"0         ,""00 "  0      "@0022 0 ""0
M   "00200 2"0      " " 2"""        "   0220222     ""022 0"0
M2"     ""0 "022 0        02""  02020     2"0 0  2        ""2
M"0"0"20       2 """ 0" 2"    '@0   20"         2000""02
M   "" 2"2 0"      1 20""222""02"    ""0" "220        2002 2"
M "00   ", "200""2 220     " 2"2" "        220 ""2"""2
M  "      "                       0            ";@" 00 0"" "
M   !     "   ""00    0 0            %@"2  " 2"022    \"2 "
M00 0       22"              "   ""        0 022 ""02""00
M                 202"2"0"                       1@020"0"2
M      " 00    0       @22 0"  "      2 "2"   20
M          #,  222 0 20           0          4B 020  2"2
M$""22 2222"       220" "0        *@"" 222"""2       "0 0 022
M         "020"0                         " 2"2"0 0        "0
M            "$22 0" " " "0    " 00220  20
M "P"2 "02 2""2 0    "220 00"""2   #4""   0202      & "2"22"0
M02"0     2222""2 00 0  ""@0 220  2         220            ""
M"""2220"2        0 "   "0        "20                "
M                      22              0""""2           0"2"0
M00 020   !T "    "          22 20        "#   00 "200" 0   L
M"2 " 22 20                     ! 000"2 ""22"    ( 00020 2"2
M0   "D" 0""0 2000"                                    :B0"2
M"0 00""0                                    @"" "" 02 000
M                                   020
M                        0 0
M              0000
M                                 "                0
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M-9'<Y ?<"O [#>;&@>@DO>.?4>;#8L%W8J@]B*,&X[YBE & EEU<E_B4(PI
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M>\,.5 PELOD,EPNG:5QOT++390@QO7 !3>FD6Y3*6PQ?5FX#&VO+DN$]>O'
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M;.$(1$?B'("5#)2PU0$60WGC-R=1L\RET7\+0L@DC>Q3;0,9ZR)WVF0I [^
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M@9N%!CV$0G'&/=%C9+FLS7-,1R*Q=[$WRLLIM#G %5+Q=CYE7_\ 26S9 ?2
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M76N,"?MD)%DZ! WW^6!=^QX@,GA1RS%-VV @D4^5 @"-3!K1<'V+09BZ4.#
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M3);)5.^\%:EDQUKA;(R$^<5*8Y4:LMYW+4'QP]=V[SNI,E4#D0_/! FZX33
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MNL*X'ZP FKLPL1)^\FQTCF+:H<:M[>IPB'DX";\/ I$_@(8U8-F 7 W@)_
M;21(P!.-^QI:6*0J%<GYKM<1D@ZSG.V3=NI+*: .'L_%)D51KN"DAGI:YBPM
M28&4K&&>$/$0G"L C]A2GNG6U!D38A'M?U^;&,#W-<[%;V(#3$K(-B^6KXF9
MO+/F5T)- *UX1'.CC.EXX X"ZPAH<8%LABO["'OSHPVU0XPM:\F>K.#/9K[(
M9^JC !D*OE3,);5U_L )((_'H.E&C@9ARY8S+U$/*L]%XI:!Q(%85U5D_7A[
M\868>3P#N%7!@OYT[3DG*3:1J"PL]R:J<HZ!(YQ+6O9*2J@N^"(0$#8\9)11
MW0?1B':L:G)4V_;_ (PM@JCD969H79F(II)^07!BE^)PS4)I-<1+EC(GPK%O
M/AV(HV<LI<V 99"HX,$^Y^_;>V#*KX9"3+=83=S\K.\6?.3^"[B T9H1"(/&
M8[ -BPG*K4OWV L3&,$ P-YSB\%C*,ED]_:HM$X =^EK7BLENCV7=3-\<QK2
M'D(QLK\];HX)<@B!-KXJQ&9"""PH!>5U7#!%D8#V83BLB_ >M3D01#HN^_X6
ML#+F+%('8\C6QZ%T-73]1PV#[K+MG&25"#>L'B3Q59&J9M^KG6'&9GTWYW14
MHG@*Q<!+>/UZ5L4/BN\\#41WF)QDE0@WK!XD_B$#$XGW>K<K2\V%6%>DJ*BA
M>T_M*$1^T6.DB:^,0T)W;YC"&^S"HT0;,(^Z)RE#'@>8D9'2P7YBY%XA$PU[
MV3:&(OD4B>(SZ;*)'C?QD5.9NT#W7^")JFX;BO8U%Z@1L8ST?0%18P\1J3$S
MWO> $[(9 %Q"JMA] )QL+GD\;++?%09_MLB)P*G+E^P;!S733,L."V"FCT^D
MB<;B^2ZH[2I!I?SF@Y+@.<"F8"_$LJ@JQ85]I=?^ %KYY\<1EA"4XTY%X0I?
M?A2VC\-2E(OXV>XU&R:Q3)>L4_ ,^/G_  6X/L(MD4?:G](]ZI<=U@V9(QJI
MS +2\D[2W!.E06+N8*F-+QF1971PF*&TQQH$P#]I(13Y85H2#L2_[38QSPQ&
M+"$!,Y.P1#FHU,RDDJ0P1%K#CS@0#8(I0#:I2G;3C(^6&4M B"@NGB<A=A*!
MP:%&8=YO[99S=5K@$@0%AOJ$3U@"\DX1(J<.RE@+FA"#Y6QJGT]UP\T=_/LB
MZ.%3,V:/<$V(X5> E!8VL"&(S4!7V8L9D"3)!1C6R!@_1!_ %<_"CW6\H*A5
M4Z7"KK !Q4@PCO#!,,0D+&+],ELE4[[P?9(#:7P:)(Y,H"AJ5B-L!Y,<O@T/
M6P*ZGPJ081WA@F&(2'XV!*CDJO(/R@N!?Q^NYS>WJFK#I.))GK?D2P!5F(FK
M#CYQ'_P0_ FB-CC$O77R?@*OL2M6WN227E(B.#;&.H-H0.V2G!B\(522,-!8
MJ[AXA6-0B2R#=\"Y-- V3&8[]8Z[KE19!E!Q:Y[DHTO?,@!!]#:$O[\S!7%:
MLTA!8>)R"4/9\AP8.+AA(P_XU=[=T< #&O'=>AP/I$V,$;X:5&Z%MA!3B=0X
M]YX*',$N&:QLQGJ.::!B6CL,9[ETXP6<HD;; 7GC.6%:MO<DDO"  ,;LDEV3
M<KEE"+*B6Z"%XM[/PG_8%4\UF*!%,"\,0=!L\2HJB4\DB%9*-FJ55O7(MNE_
M%GY^5Y8$E>U3'J#W63$J <-=:0T,C@^B^2$:74*=ON==)#OI FR<C)A7O).Y
M.0393A[LDPS/</)AEI!MH:O"^8MP$7L5X1Q$K5A%=2 W L9JNKBX!LTI+C9R
M P+](6!X ZYK0MSB6E-\,4/:AP*2D&F4VPB#9SC@HEDU_C1%CB[L&B5*4<$=
M52+L5HG#HHC#\N-RHTB3SZ?NB4 7*,FW40AL4'L935\;0""U0$$V<!(I3<F\
M$"E<X*-*<K:UA$OE&B08CW0Y+X9 H&'2&7-2PQ34_2DYKQ*/(GV(<XSHW+6U
MKF2_>M?GZM@9C7_1NH@-(OO8<Z8EHL[_ )L.#LL$S=D&+-*)9#@I,.0"3.&P
M(9A'0!S.V ('0V'<&T0G9 &<Q36 \AU50MGPD"092=QL5R_&=I.</P7;0^#G
M!GW(8/\ H\;D.6&Y+J6W616%28NC"@Y5E+3 *A517FQ?DL )MWA,%*5*74#!
M9.R%$>Y2P:3*>NMWT&Z'I][/=SA/RH%72XCX ZETJ1*9 ^RI UU')L!/(,1D
M$/\ H@(/=A9L2:).2(C]RN?<A@_Z/&Y#F M_4JTZ1OWZ$FP2EDRD:4W2\>R)
M[20C@$!MD"H<F7_RNC1(#-  C%-JF1LT"<E__=;B9<'] #!F#O%V .UX*8%,
M>T.SU37Z\B#XE;$,A/BBA4#4Z%$%W1"<-+C !XMK4&"%*H!+9')ROAN/0WAV
M[?-NC#4)2J&'Q*V(9"?%%"H );(Y.5\-QZ&\\#22?1>C=0Y'!E#0V179V+*1
MQY2=G=EG:S! I05(HM]]: ^&7R4W/_XT#>#W$(:(6E7"=/=Y0H":(4(D-@'5
M$],, ODA#FP T+(0&$#;:*V2 ![<25Z)_$&))/QC!8VVJ:^V,R3\$-;L@1A+
M%G?@0:Z:P<DX9 S>,O 0+G!VA=V7$^ 8JVL%-:&%:@&#8VN"F8Q/*S/)W\H_
MDF2"/BHH-)XV$BC8;G+VH*L@%?ZFK)@.:=;C$35AQ\XC_P""'XJ!%($KIX]I
M,(2^&-,ZI$)P(H@>Y=,M&4" @+J8CVK$V!N5S 7G"UQ["&A:QL<+"]4Q$\$2
MA?;(#(N].$@HCB$ ZYM FQ'# &^V:FJ<4<,*I/8?O UEP\JDX0_86B!CUY8K
MN5STJK=;$'$<(@77-H$V(Y:X8"Z&9<RQQ+%=RN>E5;K8JLC5,V_5SK#E"BC
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M]@3+37N+-PA'6"62 >3@2V0'T@-8D2TH8D66?@JG<D@@ 69JK%Q,R24#X#!
M)ABM3[YE#+J3ZOV%("N60'T@-8D2TH8/@,$ F&*U/OF,7Z9+9*IWW@R,F$_I
M)PD.T1$IXF$SUM^YA"C)$?:(Q0C'E3)4A3'U(C:=_,@#P*V/EZ&SWY\K$OUV
MH/PG-* .&A]RK56T,BZW8#K-0#RY/XY/T/I&O2XROV \2O@I J[I4-#DPAC$
M73+[*(7LI&L^CG!%YF<!>YZ>F;S.F2NJ=1*2%)>RS"W'ZE)-S)'D]B;?_8J[
MT[O2^;]WK,WJQ@[S8#9L=(3XU*#,6TE HJ&!4V#[P.[\ -FK(&OU2(1"/)-R
M8B%2<8 RCIA9X/:YD=RV4&RP>)9(1 *3W3DPY2P,:4E>@\;C%H$]I#4US?MU
M$+RC DR H1L'83'.-,82K?G;8:08QBAJ>N%(/1Q4=L/$2EB4WB[5^R;G*S.>
MIG514$H!1 U@\@^/L&Y@I/5EIGU;'0RN$M)GF-V<*UA!4V!Z\"$B]'3()\M1
M=WM*=XYF)DG(B2:SPQ"N9+=E$YEG$/(3.V2>CQVI?V8"@2=[*7II42FTP,RM
MC;(!P4ZH+",@#(?>:-"M6WN227A*H&-,'WJ'1" 3"4?87CP%-IX%]'!$6\S)
M4<J0(7!3N-D"J$H-QA>6?,.:G\,Q@2#Z; T+GG<N1@5JV]R22\)5 Q)F(J[)
M132\C8^)6Q#(3XHH5 !+9')ROAN/0WE^8@L3K>,=URWGFM^8AR+H"C1<::.;
M(L"2C+.F,VVNQ8FQ 2G)ZG7RT". OX$JR_\ >&)EL$0T4JY?IT TAN9EX&DD
M^B]&ZAR/O\J:CBSG*,W0$:5S*IW=);?\A<'MJZ\!QZM"]GC5Y 4"NI4J5#<4
MX?:89:_(&G5.WRAYSSYG$AV)^Z9T,FK#C9Q'_P $.$89P+?0N-1OLIIHA3YX
M1("D5R.N>&HB9U7$=HIDW1V<B?C_ *$"FW!JWRC-3DJ?AC=KH: I_G>NK^0R
MI^8/?@S%*P^6OETX\!*0X;5VA1N>P[#]G)'!&@00PF][ .+P"J@:^XW06&4H
M^T1BH;SY%KA@+H9ES+'$L5W*YZ55NM@FGN,.A8E/O8 \%)7C=T*H8DC?L=%*
MS$4[XOUOZG";G1!!DE!O*G%:N]@03+N6;\/"F&J'6">LPP+9V4@%!E5D:IFW
MZN=8=6F1.-Y@(.61RE:MO<DDO*$4??96$(%U%1K6R+1.!!CQ2E:>4PT,\"]J
MB&%"4L.,T2*;X#NGR(T3 Q2!E.4!BB X$\B]JB&,"0E.<08[#?%4@ZI;;GG.
M,LK:@W$:PSY"F&/-VEWC)3=YZ?@5H'2XLE'VVR2S::MG;A)2!U$@2/HS< 9Z
MN5J?O3<I[<^57?\ R#RY^!@7A'K*G,3*GN!4>SC?6Z8N2T>QH,$#C7L,3K;)
MD\$P/%=KL#.5&X("GS>I73#!R;RX]<7H6:$!HQF 9. F\O@:23Z+T;J'(XXN
MO>>/%(&'!<&BI 5 &2QQBG@:23Z+T;J'(XXNO>>/%(&'!<H6$N9+?QK74F&)
M)GK?D2R@1F0+OV/$!D\*.686WS0_=J,CD")5OAVT<TE0(.:X#=HPIXVRE,*@
M=TP"2]X<+1Q9#R$^2\''J(%].L:[=>/ 1@"6R.3E?#<>AO"0?38&A<\[ER,8
M3.2"O%^!!2K@NNHYWJ:5 4"P'A^#H./%M)2 2ZU$VB)!1&GN#05"JITN%76
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M >V__&;']+R:CU!2,<=H\,'[-9GT+.,CO8F159 ?2 UB1+2AB G+]D]=03K
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M$XXQ[HL;)<PW&OPFJ9\U]DS'E'I;%6@-;9 Q*X55!16<+J*;=9%@]EYC<:"
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MO(DRU0+Q2_)ZUW5E.X3'+<$+.4<D JWKD6W2_BS\42JY?:\/UK*-PR'LPWW
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M+/\ 0L_T+/\ 0L_T+/\ 0L_T+/\ 0L_T+/\ 0L_T+/\ 0L_T+/\ 0L_T+/\
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M$6BD@&FYLTCR6>IC;":F2(N*G;%!&S0!4V]'&TE/I<I36C0,:AN7&N$-L--
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M*BL6J=@V-5MW4QO"@4;H 4!C4>=7&:VX ;. (EE1IO(>JD%!#=IQS&N<8.Z
M:[ 1L5K34ZQ[2]@#D(@+OIX=5N([OD#0@@&QOVGN18L*R'  0\C@&#=-CD<)
MT48D"WAC<X^"5+W N]GI(B(CXN'V3F0 &P?)D!"!6*M,(D.N2JT,6^AM))=G
M:(!1Q$%@:!;5@ZL:QID9@JLU@Z"L<B"PK(< !#R. 8-TM0,!-"5":0!&$-S-
M#0J!)6T&P&H^<:9&8*K-8.@K'(@(@*0FT&<GE.3S@Q11)*5:*(\]25T!,2 (
M!-%2VIA4VRYVVB @0L2\1[8$MH2(^2J M+.R" O#Z]:&27S*!D#62MP));SH
M%WG>F6 @)180Z$L";+#:L V"J]>?;,H6=G%@(1<E@8-UM$MA8P,T!H'1""(S
MR:\)4EEA &%%>27%Y8" [I(P4(;*M"[D,JS1NT%JC9$(Y"+(.S7:[":503]A
MMY]A>-8]1U=*)L=' 0JLB#12@-@@6B@OT]Z+E387/%$O[XD4;=="@$\EZU4_
M\0:H6B!4WHG= 5U63&CGK5".-3 L0;(,;>"=H)!Q0/NQ?-V*:$A LN3D1#8=
M<-"FJ\G5:P8:B>PQ)HA-;HN*K-&.6,^LP:^-7 !82!$:W$&1;YG.1]ER)#*B
M!N K3=$S5\C:E0"$4(VN)RF:E(%(**:H,Y#X+,\X\E>9J:2+RXUCOM!,"$(
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MT!'R6:"D)%UC;6>AB'I1+(4H%GO\W F+CU7(EX>8^,6CDJKV/*&?5Y!4HM!
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M'L)IPA @4C0("X'L6VJ@T0+-I0H>5"1U5/ 1,6&M=0IEYQTV\@ZUJT3@M7'
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MK5;>;5 C@;#L*%5&9#0P#:OQ_J#[^0"IVP)>.N7_  +8H!$:13T %9N&\<A
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MZ6&MXQ\)5RGIXX^@^0^'2E.B7N:5"$PT.P.36JJK4# N^A()M#%LA#53-0&
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M!3=O")#3UJ6$BETT D+I96[;S-7R@"D%*!8,LPL2(I$E<"*1RYPIDJ4FH3=
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M'32I0@)D=I6]-LH2U*R)V<G;J1.1[I?')A\](,8H&TT LL2JPH)PX'AF!0;
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M6AY&T@$H+V@/&C:3D,R@RX11,/I@R8BVA6(( 0<4RQP"=#=EVX@1IB'-B"P
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MJVF)NA *E":EQ4U@73 X%4Q='"*C;S3.'@0$[E;#@3 'F18%JSA !+1Q:;.
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MAY3?"ZD+M^_0@BA81RQ(\0#!L=\%S5?A Q>6LBV ,(&[J+D_)48AP)L&[/\
M6!MJ KLCG4D/-],5J07PFQ^R#@\*A2FPB0=;?)?J_A.,ENI09"QWL"1H!*?D
M2U-8LX>-.#T;1;<": $Y[\>,YUU;QX:&O-5\=XV;1*Z*(+!'70XV2O14 .3&
MO#X''\[OD&EGV^#2DIPF1$^B;,CUHRBGEVM:UM;CU%2JM5=JKRO;[!*6J52<
M+44AM.OQZ=+*RGBB,^)7J'&K.DJ!&*:>,5+.B2VT[^J+=VY+*>D8 J*P *\
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K/:E?Y$&L+A163#MT7F<%%PW0H>J-45**5_R&+H42_2S]*_J__P +_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g790774g02s97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g02s97.jpg
M_]C_X1 \17AI9@  34T *@    @ # $   ,    !/$4   $!  ,    !%A@
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," P.3HU,3HQ-@     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,6H , !     $   $B          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M?7 @-MR&6-,_2@,<[Z.W\Y6[<_&;675V5V/'#!8T3\W.VKC/_&TQ_P#N<?\
MV'9_Z42_\;3'_P"YQ_\ 8=G_ *42]KEO\\?\22O<S_YK_G1>J_:[HGT&S)T]
M:KC_ #U8IZAC/K#K+&5/,RPV,)&OBQSFKC?_ !M,?_N<?_8=G_I1+_QM*/\
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MJ=;W 6!E(UDNMK/&S;_-O=]/=9_VTAY^32]C!5;N(=J*KF5]G#WN<[Z*Y/\
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M;?5;#2UK@^&5^G_.>Q=&PD@R2=?$J')FYG'+AG(@_P""RPQ8)CBC$$?X3E]
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MO_./_I9.L]RUCSF8$@SY6Q_M'9_:_P!4O&C_ -AS_P"D4QZM]4XT-'_L.?\
MTBL[$'U1RLFO&;1DUOM.UCK'N#=Q^BV6VO\ I+6=]5NB 3Z+_P#MU_\ Y)+B
M/<_:R8\G-Y03C/+3 TT]QA5UWZN4SZ-]=6Z-VRE[9CC=LJ:BM^LO0@/Z6/\
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MD K<  &Z#0?).UC@X$A&224__]G_[1?*4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             2(   ,6    !@!G #  ,@!S #D -P    $
M             0             #%@   2(                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   2(     4F=H=&QO;F<   ,6
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $B     %)G:'1L;VYG   #%@    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $     3A"24T$#      .T@    $
M  "@    .P   >   &Z@   .M@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D
M;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0
M% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,_\  $0@ .P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$!
M 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%
M!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&A
ML4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
MA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2
MT? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-U
MX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P#
M 0 "$0,1 #\ ](R>I-HM-;6-LB ?TM;2">SFV/8Y#JZMN>UME3:VDPY_K5$#
M3R?N6/U#ZD#,ZADY@R:1]I>;-EF+7:1+65EOJV/W._FU6'^+T"/UNC2?^T57
M!_-=[_HZJ<8\%"\M&OW9,1GEO3'?UB]7]NPO^Y%7^>W^]9;G,:Y[677/;N 8
M_P"U,D@M<7/]SOYMKOT?[_\ P?L6/;_B^#JG,?F4[7""6X537#^H]K_:J_\
MXV='_<X_^P[?_2B<,?+]<W_,DM.3-TQ?\Z+T^#=2VQS[;GUP(#;<AEC3/TH#
M'.^CM_.5NW/QFUEU=E=CQPP6-$_-SMJXS_QM,?\ [G'_ -AV?^E$O_&TQ_\
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MEN_;L?:U^[\WWI:+2>?O08/_ !Q/1USZO4;O3S'G>07>H<BTZ?NFYMFU3?\
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MX.!(1DDE/__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %
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M(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1      ?_; (0
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M[K+>?76Z=N_Q"7=F0R..P4N^\)D]VA<K%D'I%J3!4&EEF1HI);:U)X\4IUH
MC]O2CVW\1NS,9\GMQ9#>VP^R=W=:9OY<-\J-G[JVGW3L?;?6&U\G58+'ST57
MO[K.OI_[_9S?&T\Q128LK025&.R.->G?R1".6(:+C0*$5I3AUNAK^?5PGMGJ
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&'=NPJWM7IGMOK#&Y5<'D>QNL]][%H
M,TXE,>)K=V[7RF I<E*(/WVBHIZ]9&">LJI"\V][4T8'T/7CD=5(YWXL_*+L
MSKSLLY'IW;76^Y\'_+E/POV=M+_2#M3)4_9.^JG*8[)5VX,9EL%+/C]N];8B
M+ 1PXC^*_:Y%OXE4>6CIU0^1[6H(S4:J]4H?3RZL ^6G7/;O:7QER?3764%"
MNZ^RUV3UYN_-Y7,1TE!M;869RF+I>T<_6 34]9N**/:45;3&@I)8JJM^ZTQR
M)RZMH0'U'@.K&M*#HC.?^)ORTIZKO9:O"=9[^IJWY"_%CYB;!Q&TZY=@["WO
MOGJW,8#&]J=3C;.Z,SN?(;,J\QM?KW$Y&AR-745.+J,S,&D:!5DTN!T[?L(_
M;Y]5HV>C19G$?(#>??GQ.[]J^B<GMW&[5Q?>_7'8>Q:GLGKVNW)L3$=EY;K=
M=N=@5M319E]N;AQ28_9$T]?C\75U.1@:2!8TG97"T[0KKJ]/\O5LU!IT7+K_
M ..OR5Z0/0W9-#T_BNT=P=7YGYX;3SG6.+[#VEAJ^7 ?)+O,=E]>=@X/.[E>
MCVRJG%[?I:/,TLLZ5U/29$&-)VIY('L65M0U4!I_(=:H<&GKTR;-^#G?&Q-A
MUNR3BMK[AJ(?Y5&]/C!2Y*BW%1TN-G[NW+N;<N>BV5C8<E%%6TNS:./+Q4]/
MDIDCIQ!"@=%*Z5V9%)K_ $Z_EUJA_EU;)U!M[*[2ZEZNVIG:>*DS>V>NMD[>
MS-)!41U<%+E<+MK&8W(4\-5#^U4Q05=,ZK(OI<"XX/MEC5B?GU8<!T(OO76^
MO>_=>Z][]U[KWOW7NO>_=>Z*;\Z.K=]=U_$[NCJWK3%T>:WSO#;^-H-NXO(9
M6EP='655-N;!Y*:.?*UO^2T:K1T4K!GX)4+]2/=XR%=2>'6B*@CHJO>'Q>[O
MWEFOF_7;;VG@\E3]T]K_  <W/UX*O=&(HCN#;_262ZRK>Q),H*A2V&?"';=8
MU-#/ZJMHP8K%Q[L'4"//"O\ /K1!STRGXV?(.AWLNSZ;KC#UNS\?_,HA^8P[
M5CWKMVFH<OUMNFMRF8R.)_NY,PW6=];-J<L<?-!+ E)-0TD4E-52EOMTWJ6E
M:YTTZ]0_SZ:=B_'SY+=*Y3HSM>@Z;QG9F;ZN[&^?-'F>M</V'L[$9Z;:OR;[
MAA[ Z]W_ +<SVYJC&[46MI\?MRFI,I23U<%7!2Y-M'D:"2)_%D;4-5*T_EUZ
MA&:=.G=?4_S([-[>Q&YLOLO<.X-I[#^17QM[=Z[VSB.SNM<'UQB>M-H/LS,;
M^V]E-MU8H]Q[G[KPF[8\Y(F3K*I<1/0?:_9RQ.AIY?*4 I7)!_;_ )NO&I(Q
MUAW3\;/D3E.O/DOU=1];X^H?<OSLV-\EM@[KGWSM=,!O/85?WIUMOG<&.CHV
MJSG]O;AV=MC;%4]3!7TL4%9*JQTDLQD]/@RU4U_#3^76J&A'SZDI\8>_!V7_
M */&V%@UZY'\P^7YOCOI=VX'Q':#2ONQ=A'9YE&^/](AS3_W<:7[;^$_P#]W
M[N_^2^_:UI6N=-*=;H?RK7IVZ'^+G=^RLG\'JO=&TL#C8^E^TOF]NKLC[/<^
M(KOX%BNZLAV34]>5.-%.H;.39I-RTIJ8X?71^1O+^@^_,RGQ*'C3^77@#V]6
MO^V>K=>]^Z]U[W[KW7O?NO=>]^Z]U2=L[XM_*;.;/PWQNW9U7MW976]-\V\Y
M\FMU]RS]G[?SC938N,^065[NVYM7:6Q\)1U&<AW7N)XL?1335\D%+0Q-42ZI
M)!'%[?+H#J#9TTI^5.J4- ".IV]?BOWI1[6WEG-O]<]DQ=VP_*?Y@=G](=B=
M+=S=:;.S.P=N=R9F"NVO-NZ+?LK[>W%LG?9I:1LYB6HZ^JI5H4(A+@'WX.M1
M4C3I%:_+KU#Z9Z'KJKKSY,]4]W=K9'=/6>+[%H_D_0=$Y7?G<&P][;8VW1=:
M;MVGU!ANL.RHZO;&Z:BAW3D<'19G!-E\#'BHJSRID9(I%I71BU24*KGA7'Y]
M;%:GH'.@OB%W)+/\:^JNYNML%M7K3XK=%_(#I#<6\,9O#!9NC^0=+W!0[=V9
M32;:P.,OG<!MS(;:P+YG+KG(J6I&7E@BCBG\+U'O;.O<5.20?LZ\ <5\ND-2
M?!WY(R?'623.4D4_>^S^\OCUE<7C,%V!B<=EMZ]+?$FDIMC]=+@-\5E#68+:
M^_\ <6%>OW/1-D87IJ3.5B)4^,ZY$WXBZL?#0_M/6J&GSZ&;J/XM;^P/:/Q=
M["I^M-X;7QNWNX_E-VIW+_I;[6V7V+V!3Y_M'JVDV5MK=,E?M0/@JNJW/6XV
M(R4>-9QCPS-(Y+/[T7!5Q7R%.MTX=.-#U7-D/YEVXL7C*Q:GK7;6#VW\P=U8
M-*-SC\3W]N;8>?\ C+M@SN8Q2"NR_7V!KLLNEC*M13"5U!>-VU7](>O#\N/7
MOQ=6G>VNK=>]^Z]U4WTQT+VIU?\ +7MOLC/_ !HR>Z(NP/D=O;=NU>[</\A*
M#$8':O6&\MK83;_GS?3)W#1TF>RM$]#6,_DQU36E:F,QNK1+I=+ H!JX#A3_
M "]5 ()QTD^M_BG\G]C;%^'<>$VWLS#=B]'=??.VDR%9EMQXO+[?VSO_ +C?
M(5?3E36P4D;2[FPN5R<L4F36F!:G34) 3[V74EZ\#3^7'KU"*=!=F_B5\NNR
MMJ_(X;FV=N:7>?>/Q.ZHZX_C?;?;O7>Y*T]L;"[8SFX]UXRH&QJ9,1MG8.5H
MMURUN$AQ]-/3P1P57ECIYJB*F]VUH--#@,?V4ZU0T/0S]A?'7Y#=L;I[_P"R
MUZMHMFU79';GP'@V_LW.[XVG59N?:'Q>[9DWEV'V/E<A@*G(X"!\EC<[/!BZ
M,5,E?4TV-3R) TT<*5#* !7R/\QUNA->GG#_ !:[PINQ\!N"KVKA/X/0?S0>
MS?DM4SG=&)EDBZ:W%TAN#9F#W,E-I+OF9MRU\41QH_RJ%"92=*^]%EIQ_#3\
M^M4-?SZ*9OO9^\.C*SIG:&]<WMWJ?L&JD_F%9NIW-D>Z-F=0XZ;JSNOY$8;=
M5)MS&=H[XV)OWKC(Y#=.&R%%DZC#BC7<6-JJ9*R&58::I22XHVHC*X^? >G'
MKQ\O7/5Q'Q#SNV]R?%[H3*[-V1NWK?:+=6;/H-K['WU+4U.ZMM[>PV(I\-AJ
M#*UM8[U62/\ #Z"-X:N2S5=.\<Q5?)I#+@AVJ:FO5AP'1C/=>M]>]^Z]U6-O
MCX39WNWY4?)7<G9>;W]MCH'M+J?H[91Q7778=%MN#MZ+;2=@T^^]F]D8VCQU
M1N:+;=/0YV"",TM70/4P5]5&)"K$!T2!40#X@3^75:5)KPZ2/;OQ+[<ST_S:
MH-F[*V__ '=[:WO\$ZOJBACW+A\9'7[4Z(R/6[[]AEAG73MT;;H=MU(HH9O^
M!1B416+CWM77LJ> /\^M%?B_+K!E^G?E]N?Y-[ [!WQMW<6Z-M=7_*W?.Y\)
M4T_9'7=!UI3?'O=.PNR=A[,.S^NXHJ+<0W[A<9O&G3<U7EI/NZ@&N^R-3%/#
M%!ZJ!2 >(_GUONK^?0/O\/\ Y.Y+J/L?JK9FWNPMC=/[,K/CSO;HCI?M;NO8
M&Z-R83>W3_<$6]=Q;3ZE[%VE1[A39G6TNP,/0T.VQN:7(2X[.P4\Y@AI8Y V
M]:Z@2<YJ0/EUZAR/+JP?XF=9YGK'8_:.X\KL'M3;N^>QM_Y+?.?PW;/:FRNR
M=Z[LR]!L[;&UL3EZG/[.F.SL&V5Q6V:6C2E25A"M*LDS@L0K;FI J* >76QY
M])[X$["[>ZSZ\[*VSV]UH_762S7>G;O:6#4;UVMO2+(X;MS?VXM]TF.>HVU/
M(*/*;5I<K#0UWD415%4K24[/"01N0J2"I\A_+KRU''H]'MOK?7O?NO=>]^Z]
MU5S\0?@I6[.Q.RMW]_U^]JW>?6_<W>/8_7G54F_Z'.=.['RF\NPNPY=L[^P6
MW\+CJ19]UUNR-W23$U]76+0U>2J6CCBE(*O/)4D+P('V]5 ]>@RZV^*_RGV%
MUQ\1HL!MW9V$[0Z-^/\ \W]N/6Y7<>(S& VOVSVW/A*WIUJZ&GBD.YL!DLCC
M?)DC &6!4M("6][+H2_H2/V>?7J''Y],F!^,_?.X?].&5[GZB[GWM!VGTU\<
M(#]S\@.IXNX*?N/I#M3=.\I,SM?=> K<%M/9;;9R^Y:?/;6CIF&/1Z&=)OMV
MJ$IAXLHTZ6&"?+%#UJA-:CJ-GOC7\Q<E!T;V=O2F[7["W/L_ ?)/JO,8+:7<
M_5.R^_Z+JSL;?&TMQ]0MO'?55BJ/J/=>;I<!LY<=NT8UJ0SR2T=3#+4M2SB7
MVI.Y12F#PQ7_  _9UZAQZ]',['Z\[NZ^^'G6G3GQ:VYF\%N/$X3JSKC(4PW[
MM67L+KCJRBHJ&@WQ+LO>N[X)-GYGLK [=HWQV(KJR)J-:V5*SQND(C:@*ERS
MG'5LT '0J_$G8XZVZ3P.R4Z2JNA(L#D\[#'LS);[PO9F<RTE5DI<A6[[W)OC
M"U5<-Q;EWODJN:OKZFKFEKI:J5WF8LWO3FK5U5Z\.'#HRWNG6^O>_=>Z*G\X
M^L-\=T?$COSJOK7$X_/;\WQU_D<%M?#Y7*4V%QV0RM1/2O#3U>5K"*6AA98F
MO(_I%O=XR%=23CK3"H('19.Z?@E62=#]P_W#R.^.X/D/VIC>C-NY#=7<O8%!
MD\JFS>M>V-L;U;96)R8QF&VW@=LX:(Y:N6&"D22NJY29I)7:,K99.Y:X45X=
M:(P:<>HW8G3?RMP/9/R7WOU3B<A!A^W?D9T#G<I)LC>6Q<'V3NSHK:706-V-
MO>GV3E=YQG![,W=1[[QU(FNLD@J)\-!4BDFBGDA<>#(0H;R!_;7KU#4D= /+
M\6_DSMOIO:]-LWKKMC;GR2V#OGY8S]3=J;![WZHIJ;;V&[J[.'9NVZ7M_P#O
M>):/LSKS<^6DQU5N>F&)ER;Y##3R4T"-/#(UM:%C4C30>7IZ=:H:?/H1:CXE
M=L_[,MO#)[UV=V+OCK?L[O;I'OZ7<76W=FT=E];[>W=L/:?65#E:SL#K[<M(
MF_<Y7;3WSUJE;B1BIJF&NQ$M+2R"G>FE+Z#C3@@$ CAUZAKGH<OG[UKV+W-M
M#_1]LCXZY7M+,C;>9RG6O9U)W/@.N<)U;VW50U>-V]G=V[:RF5I*C=&#VY**
M?)M$V.SU+4^(T[43,?56,@&I:@^SRZVV?+H]6R*+<^-V7M'';VRU'GMYX_;&
M HMW9W'4JT./S6YZ7%4D&?RU#1)#3I1T>1RL<LT40C01HX4*MK"AI4TX=6Z4
M_O77NO>_=>Z][]U[H*N]ML9S>W1_<FS-L4T-;N7=W578>V-O4=15Q4$%7G,_
MM',8K$TT]=/^S10SU]7&C2OZ8U)8\#WM31@3PKUH\#U5QO#X??(#+;![%P6/
MV9MV7*9[^4[UK\5,+ ^[,'#%+W/M^;>KYS:#SNFBDV_"N:I].2/^1RZS8>CV
M\)%J*G\=?RZJ0:&G&G2D[%^*??><S?R-K\-M'!UM/O[L#^7)N#9ZU&[L33#*
M8OX];@VID.VI*Q903CGP5+BIS31R>K(E0(N6'O0=1I^6K^?6Z'/Y=8=D?$3L
M7#?(S='^D#8?8F\.MY_E!VY\D-E;IVWW-L?#=-T3=B[=WDU(FZ^JZ^DC[%KM
M[PQ[QK=M5B1F?&5-+4+5B945H(_%P5%#F@'#KU,](7'_ !B^5(Z$[:ZMV_M'
ML#&=8[:K_BON#X]='=Q]Q=;[SWK@<ITWW%A=Z=A;1V?V+M=Y\5B^M6V%M?&X
MS;%+N'(551#D:9I)'IJ=E][U+J!)%<U(^8ZT <^G2K[^^-_R.['ROREQ&VNI
ML=/B/G-LKXY8ZNW1G=\[/IIOCEENN:7^![PQ^]*"#(5U;NNGP6./\6PDNVOX
MBDV8DGC?[=&6J?2NHT$GX:_GUL@YQQZ6&<^+_=]?NOM/+T^T,#]GN?\ F8_'
M?Y&8=QN?#I+7=.]<X/J"@W+N:=6424^9HJC9];XL:Y^YF\:E#:0>_!UH,_@(
M_//7J'/V]!SUA\,M^[?WIFMI]M]3=E=J[,VGNWY8;PV7F%[WV+0]([FQ??$?
M:#Q8J/K.6GH-_P"'WEO/;_9U9ALR:R23'4V2>;(I5/')&B;+B@*L <>6<=:I
MY$8Z-G\'.ON_.M\9V-M[L]NPL;U31U>RJ'H?9G<>^MB]F=L;/Q6,VV]'O/'9
MG>_7R38C);/.42ECP,5565^3BAIYWJ)0LL2+20J:$4KYTX=6%?/H^'MOK?7O
M?NO=>]^Z]U[W[KW7_]/?OK*J.BI*JME#M%24T]5(L8!D:.GB:5P@)4%RJ&P)
M'/N\:&1TC7XF('[<=5=@B,YX $_LZH0B_P"%%WPIF36O6/R? U2)ZM@;'!O'
M(T;?3LT\%D-O\/>2I^ZM[@J:'=]GK_S6E_[9^H#'WC.2F%1M>Z?\XHO^MW67
M_H(J^%?_ #['Y/?^@!LC_P"V9[U_P+'N!_T=]G_YS2_]:.M_\$7R5_T:]T_Y
MQ1?];NO?]!%7PK_Y]C\GO_0 V1_]LSW[_@6/<#_H[[/_ ,YI?^M'7O\ @B^2
MO^C7NG_.*+_K=U[_ *"*OA7_ ,^Q^3W_ * &R/\ [9GOW_ L>X'_ $=]G_YS
M2_\ 6CKW_!%\E?\ 1KW3_G%%_P!;NO?]!%7PK_Y]C\GO_0 V1_\ ;,]^_P"!
M8]P/^COL_P#SFE_ZT=>_X(ODK_HU[I_SBB_ZW=>_Z"*OA7_S['Y/?^@!LC_[
M9GOW_ L>X'_1WV?_ )S2_P#6CKW_  1?)7_1KW3_ )Q1?];NO?\ 015\*_\
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M_P"<TO\ UHZ]_P $7R5_T:]T_P"<47_6[KW_ $$5?"O_ )]C\GO_ $ -D?\
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M $=]G_YS2_\ 6CKW_!%\E?\ 1KW3_G%%_P!;NO?]!%7PK_Y]C\GO_0 V1_\
M;,]^_P"!8]P/^COL_P#SFE_ZT=>_X(ODK_HU[I_SBB_ZW=>_Z"*OA7_S['Y/
M?^@!LC_[9GOW_ L>X'_1WV?_ )S2_P#6CKW_  1?)7_1KW3_ )Q1?];NO?\
M015\*_\ GV/R>_\ 0 V1_P#;,]^_X%CW _Z.^S_\YI?^M'7O^"+Y*_Z->Z?\
MXHO^MW7O^@BKX5_\^Q^3W_H ;(_^V9[]_P "Q[@?]'?9_P#G-+_UHZ]_P1?)
M7_1KW3_G%%_UNZ]_T$5?"O\ Y]C\GO\ T -D?_;,]^_X%CW _P"COL__ #FE
M_P"M'7O^"+Y*_P"C7NG_ #BB_P"MW7O^@BKX5_\ /L?D]_Z &R/_ +9GOW_
ML>X'_1WV?_G-+_UHZ]_P1?)7_1KW3_G%%_UNZ]_T$5?"O_GV/R>_] #9'_VS
M/?O^!8]P/^COL_\ SFE_ZT=>_P""+Y*_Z->Z?\XHO^MW7O\ H(J^%?\ S['Y
M/?\ H ;(_P#MF>_?\"Q[@?\ 1WV?_G-+_P!:.O?\$7R5_P!&O=/^<47_ %NZ
M]_T$5?"O_GV/R>_] #9'_P!LSW[_ (%CW _Z.^S_ /.:7_K1U[_@B^2O^C7N
MG_.*+_K=U[_H(J^%?_/L?D]_Z &R/_MF>_?\"Q[@?]'?9_\ G-+_ -:.O?\
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M<TO_ %HZ]_P1?)7_ $:]T_YQ1?\ 6[KW_015\*_^?8_)[_T -D?_ &S/?O\
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M $=]G_YS2_\ 6CKW_!%\E?\ 1KW3_G%%_P!;NO?]!%7PK_Y]C\GO_0 V1_\
M;,]^_P"!8]P/^COL_P#SFE_ZT=>_X(ODK_HU[I_SBB_ZW=>_Z"*OA7_S['Y/
M?^@!LC_[9GOW_ L>X'_1WV?_ )S2_P#6CKW_  1?)7_1KW3_ )Q1?];NO?\
M015\*_\ GV/R>_\ 0 V1_P#;,]^_X%CW _Z.^S_\YI?^M'7O^"+Y*_Z->Z?\
MXHO^MW7O^@BKX5_\^Q^3W_H ;(_^V9[]_P "Q[@?]'?9_P#G-+_UHZ]_P1?)
M7_1KW3_G%%_UNZ]_T$5?"O\ Y]C\GO\ T -D?_;,]^_X%CW _P"COL__ #FE
M_P"M'7O^"+Y*_P"C7NG_ #BB_P"MW7O^@BKX5_\ /L?D]_Z &R/_ +9GOW_
ML>X'_1WV?_G-+_UHZ]_P1?)7_1KW3_G%%_UNZ]_T$5?"O_GV/R>_] #9'_VS
M/?O^!8]P/^COL_\ SFE_ZT=>_P""+Y*_Z->Z?\XHO^MW7O\ H(J^%?\ S['Y
M/?\ H ;(_P#MF>_?\"Q[@?\ 1WV?_G-+_P!:.O?\$7R5_P!&O=/^<47_ %NZ
M]_T$5?"O_GV/R>_] #9'_P!LSW[_ (%CW _Z.^S_ /.:7_K1U[_@B^2O^C7N
MG_.*+_K=U[_H(J^%?_/L?D]_Z &R/_MF>_?\"Q[@?]'?9_\ G-+_ -:.O?\
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M?]!%7PK_ .?8_)[_ - #9'_VS/?O^!8]P/\ H[[/_P YI?\ K1U[_@B^2O\
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M^SMMS&J.[))?#<);DEE_MY+@&H_LU1M*J*#HUA]U=^AN_K3MEBTPW%;P !U
M:.W^ECA 5O[*.$*H/QDJ"Q-34)*WYB;YK^CTZ>GV+L;^]3] ;=^)61^0*9#=
MR]D9;XK[3WB^]\%TQ5;6&6'7<,D62,=%4;BCHQEJG$P1TS68>;V>1\A;;%S$
M=^7<KGZ+]YON2V16+P%W&2+PGNA)I\<]M7$!;PUD8L,=O1'+SKN,NQC9FL8!
M=?0+8FZ!D$QLDD\5;?PPW@C("F4+K,:A>(U=%+]CCH']>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T;3X ?\ 9?'PI_\ %D=@_P#R2]@CW._Z
M=I[@?]*F;_GWH7>W_P#RO_)/_2RB_P"?NOHN^^5O71?K_];?SJ((JJ":FG02
M05$4D$T9) >*9&CD0E2& 9&(X(/NRLR,KJ:,#4?:.M,H965AVD4/58*?R7?Y
M8T:Z4^*.V%74S6_OMVN?4[,['G?Q/+,3[F ^_P#[OG)YUF_YQ6W_ %IZB\>R
MWM@,#E.+_G+/_P!;>N?_  S#_+(_[Q3VQ_Z&W:W_ -GOO7^O][O?]-I-_P X
MK;_K3U[_ %E_;'_IE(O^<D__ %MZ]_PS#_+(_P"\4]L?^AMVM_\ 9[[]_K_>
M[W_3:3?\XK;_ *T]>_UE_;'_ *92+_G)/_UMZ]_PS#_+(_[Q3VQ_Z&W:W_V>
M^_?Z_P![O?\ 3:3?\XK;_K3U[_67]L?^F4B_YR3_ /6WKW_#,/\ +(_[Q3VQ
M_P"AMVM_]GOOW^O][O?]-I-_SBMO^M/7O]9?VQ_Z92+_ )R3_P#6WKW_  S#
M_+(_[Q3VQ_Z&W:W_ -GOOW^O][O?]-I-_P XK;_K3U[_ %E_;'_IE(O^<D__
M %MZ]_PS#_+(_P"\4]L?^AMVM_\ 9[[]_K_>[W_3:3?\XK;_ *T]>_UE_;'_
M *92+_G)/_UMZ]_PS#_+(_[Q3VQ_Z&W:W_V>^_?Z_P![O?\ 3:3?\XK;_K3U
M[_67]L?^F4B_YR3_ /6WKW_#,/\ +(_[Q3VQ_P"AMVM_]GOOW^O][O?]-I-_
MSBMO^M/7O]9?VQ_Z92+_ )R3_P#6WKW_  S#_+(_[Q3VQ_Z&W:W_ -GOOW^O
M][O?]-I-_P XK;_K3U[_ %E_;'_IE(O^<D__ %MZ]_PS#_+(_P"\4]L?^AMV
MM_\ 9[[]_K_>[W_3:3?\XK;_ *T]>_UE_;'_ *92+_G)/_UMZ]_PS#_+(_[Q
M3VQ_Z&W:W_V>^_?Z_P![O?\ 3:3?\XK;_K3U[_67]L?^F4B_YR3_ /6WIES/
M\G7^6=C$IFB^*&U7,TCJVO>?:+@!$U<"7>\P!)/XM[H_OY[P-33SO./^;5O_
M -:>KK[,^V K7E&$_P#-R?\ ZV],7_#1?\M3_O$S:/\ Z&'97_V8^Z?Z_7O#
M_P!-U<?\XK?_ *U=6_UFO:[_ *8^'_G)/_ULZ]_PT7_+4_[Q,VC_ .AAV5_]
MF/OW^OU[P_\ 3=7'_.*W_P"M77O]9KVN_P"F/A_YR3_];.O?\-%_RU/^\3-H
M_P#H8=E?_9C[]_K]>\/_ $W5Q_SBM_\ K5U[_6:]KO\ ICX?^<D__6SKW_#1
M?\M3_O$S:/\ Z&'97_V8^_?Z_7O#_P!-U<?\XK?_ *U=>_UFO:[_ *8^'_G)
M/_ULZ]_PT7_+4_[Q,VC_ .AAV5_]F/OW^OU[P_\ 3=7'_.*W_P"M77O]9KVN
M_P"F/A_YR3_];.O?\-%_RU/^\3-H_P#H8=E?_9C[]_K]>\/_ $W5Q_SBM_\
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M *U=>_UFO:[_ *8^'_G)/_ULZ]_PT7_+4_[Q,VC_ .AAV5_]F/OW^OU[P_\
M3=7'_.*W_P"M77O]9KVN_P"F/A_YR3_];.O?\-%_RU/^\3-H_P#H8=E?_9C[
M]_K]>\/_ $W5Q_SBM_\ K5U[_6:]KO\ ICX?^<D__6SKW_#1?\M3_O$S:/\
MZ&'97_V8^_?Z_7O#_P!-U<?\XK?_ *U=>_UFO:[_ *8^'_G)/_ULZ]_PT7_+
M4_[Q,VC_ .AAV5_]F/OW^OU[P_\ 3=7'_.*W_P"M77O]9KVN_P"F/A_YR3_]
M;.O?\-%_RU/^\3-H_P#H8=E?_9C[]_K]>\/_ $W5Q_SBM_\ K5U[_6:]KO\
MICX?^<D__6SKW_#1?\M3_O$S:/\ Z&'97_V8^_?Z_7O#_P!-U<?\XK?_ *U=
M>_UFO:[_ *8^'_G)/_ULZ['\HO\ EJ7'_.)FT?J/^8P[+_\ LQ]^_P!?KWA_
MZ;JX_P"<5O\ ]:NO?ZS7M=_TQ\/_ #DG_P"MG3.W\I3^6V'<#XH;3L'<#_?W
M]D\ ,0!_Q^'X'OW^OU[Q?]-W<?\ .*W_ .M76_\ 6:]KO^F/A_YR3_\ 6SKK
M_AI7^6W_ -XH[3_]"_LG_P"S#WO_ %^O>+_IN[C_ )Q6_P#UJZ]_K-^UW_3'
MP_\ .2?_ *V=>_X:5_EM_P#>*.T__0O[)_\ LP]^_P!?KWB_Z;NX_P"<5O\
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M3_\ 6SKW_#2O\MO_ +Q1VG_Z%_9/_P!F'OW^OU[Q?]-W<?\ .*W_ .M77O\
M6;]KO^F/A_YR3_\ 6SKW_#2O\MO_ +Q1VG_Z%_9/_P!F'OW^OU[Q?]-W<?\
M.*W_ .M77O\ 6;]KO^F/A_YR3_\ 6SKW_#2O\MO_ +Q1VG_Z%_9/_P!F'OW^
MOU[Q?]-W<?\ .*W_ .M77O\ 6;]KO^F/A_YR3_\ 6SKW_#2O\MO_ +Q1VG_Z
M%_9/_P!F'OW^OU[Q?]-W<?\ .*W_ .M77O\ 6;]KO^F/A_YR3_\ 6SKW_#2O
M\MO_ +Q1VG_Z%_9/_P!F'OW^OU[Q?]-W<?\ .*W_ .M77O\ 6;]KO^F/A_YR
M3_\ 6SKW_#2O\MO_ +Q1VG_Z%_9/_P!F'OW^OU[Q?]-W<?\ .*W_ .M77O\
M6;]KO^F/A_YR3_\ 6SI0XS^4/_+1J*-99OB7M%Y#-,FH[P[+!THP"CC>0' /
MOW^OU[Q?]-U<?\XK?_K5UK_6:]K_ "Y0A_YR3_\ 6SJ=_P - ?RS/^\2=H?^
MACV9_P#9E[]_K]^\7_3=7'_.*W_ZU=>_UFO:_P#Z9"'_ )R3_P#6SKW_  T!
M_+,_[Q)VA_Z&/9G_ -F7OW^OW[Q?]-U<?\XK?_K5U[_6:]K_ /ID(?\ G)/_
M -;.O?\ #0'\LS_O$G:'_H8]F?\ V9>_?Z_?O%_TW5Q_SBM_^M77O]9KVO\
M^F0A_P"<D_\ ULZ]_P - ?RS/^\2=H?^ACV9_P#9E[]_K]^\7_3=7'_.*W_Z
MU=>_UFO:_P#Z9"'_ )R3_P#6SKW_  T!_+,_[Q)VA_Z&/9G_ -F7OW^OW[Q?
M]-U<?\XK?_K5U[_6:]K_ /ID(?\ G)/_ -;.O?\ #0'\LS_O$G:'_H8]F?\
MV9>_?Z_?O%_TW5Q_SBM_^M77O]9KVO\ ^F0A_P"<D_\ ULZ]_P - ?RS/^\2
M=H?^ACV9_P#9E[]_K]^\7_3=7'_.*W_ZU=>_UFO:_P#Z9"'_ )R3_P#6SKL?
MR@/Y9EQ_SB1M#ZC_ )C'LS_[,_?O]?OWB_Z;JX_YQ6__ %JZ]_K->V'_ $R$
M/_.2?_K9TD&_E*?RVP[@?%#:=@[@?[^_LG@!B /^/P_ ]Z_U^O>+_IN[C_G%
M;_\ 6KK?^LU[7?\ 3'P_\Y)_^MG77_#2O\MO_O%':?\ Z%_9/_V8>]_Z_7O%
M_P!-W<?\XK?_ *U=>_UF_:[_ *8^'_G)/_ULZ]_PTK_+;_[Q1VG_ .A?V3_]
MF'OW^OU[Q?\ 3=W'_.*W_P"M77O]9OVN_P"F/A_YR3_];.O?\-*_RV_^\4=I
M_P#H7]D__9A[]_K]>\7_ $W=Q_SBM_\ K5U[_6;]KO\ ICX?^<D__6SKW_#2
MO\MO_O%':?\ Z%_9/_V8>_?Z_7O%_P!-W<?\XK?_ *U=>_UF_:[_ *8^'_G)
M/_ULZ]_PTK_+;_[Q1VG_ .A?V3_]F'OW^OU[Q?\ 3=W'_.*W_P"M77O]9OVN
M_P"F/A_YR3_];.O?\-*_RV_^\4=I_P#H7]D__9A[]_K]>\7_ $W=Q_SBM_\
MK5U[_6;]KO\ ICX?^<D__6SKW_#2O\MO_O%':?\ Z%_9/_V8>_?Z_7O%_P!-
MW<?\XK?_ *U=>_UF_:[_ *8^'_G)/_ULZRP?RD_Y;3SQ(WQ0VD59K,/[W]D\
MC2Q_Y[#^H]Z_U^O>+_INKC_G%;_]:NO?ZS7M=_TQ\/\ SDG_ .MG3G_PT7_+
M4_[Q,VC_ .AAV5_]F/OW^OU[P_\ 3=7'_.*W_P"M76O]9KVN_P"F/A_YR3_]
M;.O?\-%_RU/^\3-H_P#H8=E?_9C[]_K]>\/_ $W5Q_SBM_\ K5U[_6:]KO\
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M )UM?_YQU'_7OW[Q8O\ ?B_M'7J'TZ4^(H:V.A5)*.J1O/4'2]/,K6++8V9
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M5/\ ];.N+?(/Y$O8/\BOD%(!R _=O9S@'^H#;H-C;W[^JG*7_3);5_V1V_\
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M-'BD QXL34#E0%92DB@!]*YI>V?/\//VQO=2PI#O-LP2XB4DJ&()21*U/AR
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M #ZO ZZR^ZMP===>[@WY@L1M;?>?V'LW.;YVOM[-P[FV_MK>>7VYC<ANK;^
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MIMF;<@R/=FV=F;;H:[&8:3=66R6XLR7Q?\(9W::G47G+FSQ[.TIVL1JNT17
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MWS_)7=.PMI=?S[*V_EM\]3[:P<2;?3=LE5C*ZOSU3$R8>.A6:IC]U71Z'/\
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M*W(2M)3Q^ZUHXY]?Y=7"21M%))$]M4;M&VGD:D8J;'\BX]^ZIUTGZT_X,O\
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MFOTO[O35Z:_&[*_.GB4_/Y];;/O!;K,'KWOW7NNQ]1_KC_>_?NO=(!_UR?\
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MU[]_6_D__IL-I_[++?\ ZV=>_JOS1_TR^Y?]DL__ $!U[_9:_DQ_WC3\B/\
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M^2/_ 'CA\@?_ $2_8W_V.>_?UPY._P"FPVK_ +*[?_K9U[^K'-'_ $R^Y?\
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M=(X/I7L?H7:V.ZP^.O7GR7V=VEM/;_06XJ'N"FW#N?NSLC,]6[;[!WMF,_\
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MWZH].O?GU[^#9W_GL,C_ .>K ?\ UM]^J/3KWY]>_@V=_P">PR/_ )ZL!_\
M6WWZH].O?GU[^#9W_GL,C_YZL!_];??JCTZ]^?7OX-G?^>PR/_GJP'_UM]^J
M/3KWY]1*O:^3KA&M5NS*.(F+)IQ^#CLS#222N-YX]^J/X>M_GU"_N/4?\]1E
M_P#SDPO_ -;O?JCTZ]U[^X]1_P ]1E__ #DPO_UN]^J/3KW7O[CU'_/49?\
M\Y,+_P#6[WZH].O=>_N/4?\ /49?_P Y,+_];O?JCTZ]U[^X]1_SU&7_ /.3
M"_\ UN]^J/3KW7O[CU'_ #U&7_\ .3"__6[WZH].O=>_N/4?\]1E_P#SDPO_
M -;O?JCTZ]U[^X]1_P ]1E__ #DPO_UN]^J/3KW7O[CU'_/49?\ \Y,+_P#6
M[WZH].O=>_N/4?\ /49?_P Y,+_];O?JCTZ]U[^X]1_SU&7_ /.3"_\ UN]^
MJ/3KW7O[CU'_ #U&7_\ .3"__6[WZH].O=>_N/4?\]1E_P#SDPO_ -;O?JCT
MZ]U[^X]1_P ]1E__ #DPO_UN]^J/3KW7O[CU'_/49?\ \Y,+_P#6[WZH].O=
M>_N/4?\ /49?_P Y,+_];O?JCTZ]U[^X]1_SU&7_ /.3"_\ UN]^J/3KW7O[
MCU'_ #U&7_\ .3"__6[WZH].O=>_N/4?\]1E_P#SDPO_ -;O?JCTZ]U[^X]1
M_P ]1E__ #DPO_UN]^J/3KW7O[CU'_/49?\ \Y,+_P#6[WZH].O=>_N/4?\
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M /6WWZH_AZ]U[^Z>0_YZO*?^>_!__6WWZH_AZ]U[^Z>0_P">KRG_ )[\'_\
M6WWZH_AZ]U[^Z>0_YZO*?^>_!_\ UM]^J/X>O==_W3R'_/5Y3_SWX/\ ^MOO
MU1_#U[IL/7ER2=RY>Y))_P FP_U)N?\ EW?U/O51Z=:S_$>O?Z._^SER_P#Y
MS8?_ .MWOU>O9_B/7O\ 1W_V<N7_ /.;#_\ UN]^KU[/\1Z]_H[_ .SER_\
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M_P#K=[]4>G7NO?W'J/\ GJ,O_P"<F%_^MWOU1Z=>Z]_<>H_YZC+_ /G)A?\
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M_A_GUZGSZ]_$=T_\]0?_ #P8W_K[[]4?P_SZ]3Y]>_B.Z?\ GJ#_ .>#&_\
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MCP/7AQ'6G'\T/YDGSNZR^8ORCZUZ_P#DKN[:^P]@]T[FVOL[;5%M[8-328+
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M )Q0?]:NO?\ #L?\R'_O++>7_H(=7?\ V#>_?ZR/M-_TQ,'_ #FN?^MW7O\
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MR !OEEO3@W&G:?6,9_IR4V0I/^Q]U;V/]I'H&Y'MR/G+<_\ 6[KW^NW[E?\
M36R_\XK?_K5UC_X=;_F.?]Y9;W_]!CK7_P"PKW7_ %C/:'_IA;;_ )RW'_6[
MK?\ KN>Y7_36S?\ .*#_ *U=>_X=;_F.?]Y9;W_]!CK7_P"PKW[_ %C/:'_I
MA;;_ )RW'_6[KW^NY[E?]-;-_P XH/\ K5U[_AUO^8Y_WEEO?_T&.M?_ +"O
M?O\ 6,]H?^F%MO\ G+<?];NO?Z[GN5_TULW_ #B@_P"M70E]7_SG?G_UYN&C
MRFZ>R-O=Z[;6H5\OLCM#:&WJ%,G2'T3T^(WALW%8//;6K6B8F*=4K(DD"EX)
M%!'LFWO[NOM5NUI)#9;/+MEYIHLUO+(VD\06BF=TD%>(JAI4!@3T;;1[X>XF
MV7*2W6YQWUK7NBFCC6HX'3)$J,AI6A[A6A*D#K:S^)_RFZQ^8_2N"[KZM:OH
M:*KJZC;V\=FYMZ=]R];[]Q<,$F<V7N%J4_:U4E.E3'445;%:#(X^>*HC #%5
MP6Y\Y'WKV\YCNN7-["M(JB2*5*^'<0,3HE2N16A5U.4<,AX=9@\G\W;5SKLD
M&];4Q"DE)(R06BE4 M&U.-*AE/XE*M05IT9#V#NA3U[W[KW7O?NO=*S#?\6]
M/^HBI_Z&7W[KW3I[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KL?4?ZX
M_P![]^Z]T@'_ %R?\M)/^AV]^Z]UQ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]UGI?^!,/_  <_]"-[]U[H@/\ ,;[T[$Z0PWQ/I=A]OY_HO&]S?**3
MJKL?L;9W25)\A-\8W9D?1'<._J*AV?UE4[4WU+D<GD]Z;.Q<4]13X>OGIZ$S
M,$"ZG7W5E .JH\NB3=1?,WYZ;5W?@]T_(#9&WZ]J3I7^7G0=_P#26X)\AUUO
M#:.<^37RZ^1GQUP?:'5G7N)QFX\/M'M/?&U%V?N?=NUL]FC2XMH#BZ62.<3.
M/=6*K3'J?\%>A8R/\S;ME,M\C-L;'Z<Z\[RKNO\  [([#ZEWOT8._=[[%R'5
M&Y/D3N+X]=A;UW?@QUA3]@=LTO0IV^VX\Y)U=2;AI\E3"HH:%FFIC-+[K6F@
M!)Z==C?S0=T=C_(#K'J3K3J#%=V[%KZ'XOTG:G;'2N.[EW=MT5'RBVA4[MH^
MV.N-P4^P*K8FWNC.HZ.GA?/-OC*8/<%3%/5BGIDEQWCK/=>T8))IQZ-A0=K]
MM0_S'MR]!9/<N'K^BJGX1[<[QVYM>EV;04.?VYV/3]\9#K;/5U5OT5L]?N:C
MSV$(>*BDAI8*$Q#2)2VM?=:IVZOGT4#9'SF^6F?WYV#T[%LKX[[C[4[!_F!_
M(SXH?%V7(YGL?;'7&U=@?&[J[-=K[WS?=61QNW<EN+,YH[?VT*/%0X:-Y:S+
M961JB2*DH6)]ULJ  :^5>IG7_P#-%W]V?7=<;ZVM\>]E4/1==7? &C[2EW'V
M7N ]J8:K^?\ ONLZ=P-'LC&XW:$NT-P1]-]JK3G(R5533?WAP$IFHA!4B..;
MW7BE,5SG^70 _&;YS=U;=Z]V1F=Z5&Z.\^U,KTS\>L/4UW87:LV#ZZS6YOD%
M_,][F^(^$W+D]H[;V#.<1GMA8>*AJ*W-4LM149C"X^+&K20RQK52>ZL5%33
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MZ?;.V:7$Q[9FV_D8=J^&LK:K(/4*TPCCI1_G@AV_:[2\V/?]Q>>07EHL3*H
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M>#+_ +[/7O&B_P!^#KW\5QW_ "N0?\E^_>#+_OL]>\:+_?@Z]_%<=_RN0?\
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M]U8'Y+8&@[^Z>7JK$&NV7O',X_K&+)9BHK=\??;2KMJUT\>W(*R5ZN2'W7J
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M/\/>RNOYUQ6X,=095JO$9*?[%O'51TONG=*X]0>ALH]^=P[4^7G1<7;7;GS
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MU/N?Y+=Q[*7JN38T?5.,R'Q_WET_AL/@$W;MZ*JW1A:FF_AN<?*!:R6-?=5
M^7$?Y.MG"0ZFU * ZHZ:!I5D=%:.2USS*A#'\DGZ#Z>_=-=</?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]TE\OL;8NX:C-5FXMC;,W#6[EVH=A;FK,[M?"9>KW+L%JB
MOJVV%N&IR%%439K9+5>5JY3B:DR4!EJIG\6J5RWNMU/KT!?8/Q#Z7[.'R/\
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M $$-M?\ UJ]^^KO/^4ZX_P"<LG_077OH[/\ Y1(O]X7_ #=>_@>W/^>4V?\
M^@AMK_ZU>_?5WG_*=<?\Y9/^@NO?1V?_ "B1?[PO^;KW\#VY_P \IL__ -!#
M;7_UJ]^^KO/^4ZX_YRR?]!=>^CL_^42+_>%_S=>_@>W/^>4V?_Z"&VO_ *U>
M_?5WG_*=<?\ .63_ *"Z]]'9_P#*)%_O"_YNO?P/;G_/*;/_ /00VU_]:O?O
MJ[S_ )3KC_G+)_T%U[Z.S_Y1(O\ >%_S=>_@>W/^>4V?_P"@AMK_ .M7OWU=
MY_RG7'_.63_H+KWT=G_RB1?[PO\ FZE46!VVU92J=J;0LTR@VVEMM38W^C+B
MPRG_ %C[V+R]!!^NG_YR/_T%U[Z.S_Y1(O\ >%_S=*[^[.U_^>5VK_Z#."_^
MM_N_U]]_RFR_[VW^?KWT5G_RB1?[RO\ FZ]_=G:__/*[5_\ 09P7_P!;_?OK
M[[_E-E_WMO\ /U[Z*S_Y1(O]Y7_-U[^[.U_^>5VK_P"@S@O_ *W^_?7WW_*;
M+_O;?Y^O?16?_*)%_O*_YNO?W9VO_P \KM7_ -!G!?\ UO\ ?OK[[_E-E_WM
MO\_7OHK/_E$B_P!Y7_-U[^[.U_\ GE=J_P#H,X+_ .M_OWU]]_RFR_[VW^?K
MWT5G_P HD7^\K_FZ]_=G:_\ SRNU?_09P7_UO]^^OOO^4V7_ 'MO\_7OHK/_
M )1(O]Y7_-U[^[.U_P#GE=J_^@S@O_K?[]]???\ *;+_ +VW^?KWT5G_ ,HD
M7^\K_FZ]_=G:_P#SRNU?_09P7_UO]^^OOO\ E-E_WMO\_7OHK/\ Y1(O]Y7_
M #=,^9V[MF.*G*[4VE<RN#KVKMZ3@)?@28U@#_K>ZM>WK<;V;\I''^ ]>^CL
M_P#E$B_WA?\ -TG_ .![<_YY39__ *"&VO\ ZU>Z_5WG_*=<?\Y9/^@NO?1V
M?_*)%_O"_P";KW\#VY_SRFS_ /T$-M?_ %J]^^KO/^4ZX_YRR?\ 077OH[/_
M )1(O]X7_-U[^![<_P">4V?_ .@AMK_ZU>_?5WG_ "G7'_.63_H+KWT=G_RB
M1?[PO^;IQI(Z?'0S4^+HL=B*>I-ZF##8V@Q$54;%?\JCQM-2I4V4D#6&L"?;
M,C/,RO/*\C#@69FI]FHFGY=/1QQPJ5AC5%/'2 /\'7?O75^O>_=>Z][]U[KW
MOW7NE9AO^+>G_414_P#0R^_=>Z=/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO==CZC_7'^]^_=>Z0#_KD_Y:2?\ 0[>_=>ZX^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZSTO\ P)A_X.?^A&]^Z]T^)))$VN-WC>Q74C,C:6%F
M&I2#9A]?Z^_=>ZYBHJ%1HUGF$;EF=!*X1RZZ'+*&TL70V-_J./?NO=<A5U2D
ME:FH4D1J2)I 2L-S$"0W(B)]/^I_'OW7NL:2RQBR22(-6NR.RC7I9-?!'JT,
M1?ZV)'OW7NN+,S:=3,VE0BZB3I1;Z56_T5;\#Z#W[KW42*AH(*O)9"GQ^/IL
MAFIZ:JS>0IJ&DI\AFZJCH*;%4=5FJZ&&.JR]51XNBAIHI*AY7BIXEC4A% ]^
MZ]U.6>99?.LTJS<_O+(XEY&D_N Z^5X^OT]^Z]UR-34EI'-1.7E3QRN99"TD
M=K:)&U7=+<6-Q[]U[KHU%0T0@:>8P"UH3*YB&DW6T9;0+'Z<>_=>ZQ%F8*"Q
M(0%4!)(122Q50>%!8DV'Y/OW7NNO?NO=>]^Z]U[W[KW4W&?\7+'_ /47%_Q/
MOW7NA3]^Z]U__]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TD=V?YN@_Y;3?\ 6H>_=>Z1OOW7NNU9
ME974E61E964D,K*0RLI'(92+@_@^_=>ZS)4U,;.\<\T;R.99&21U9Y#J!D<J
M06<ASR>>3[]U[KM:NJ0%5J9U4Q) 0)7 \,>KQQ6#?YM-9L/H+FWU]^Z]T$W<
M_2G5?R'V]B]K=T;.I=]8C YZEW5MMZC*[AP.=VKN>DHJ_%Q;@VEN[:>7P&[M
MJY>3#Y6KH9IL?74S5%#63T\NN&61&]UL$CATJM@;*VAU3LC;W6G6>VL/L/K[
M:>+CPNV]F[7I%Q>!Q&-1I)'@IJ.$V>6LJ)Y)ZF:4R3U=3+)-.\DLCNWNM$DF
MIX]+#[RKU:ONJC5Y/+J\TFKR^+P>2^J^OP^B_P!=/'T]^Z]UW]]6ZHW^ZJ-4
M2E(V\SW16MJ53JX#:1?^MA_3W[KW47_B23_L3R3_ *Y/OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z['U'^N/\ >_?NO=,#_KD_Y:2?]#M[]U[KC[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J70?\#J3_ );I_P 3[]U[I:^_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ICSO\ F:;_ );2?]:_?NO=
M)OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*S#?\ %O3_ *B*
MG_H9??NO=.GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNQ]1_KC_>_?
MNO=(!_UR?\M)/^AV]^Z]UQ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MUGI?^!,/_!S_ -"-[]U[IY]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U-QG_%RQ__ %%Q?\3[]U[H4_?N
MO=?_U=_<WL;6O;B_(O\ BXN+CW[KW2;\6\/S7;:_\]64_P!A_P OG^GO>.M9
M^77?BWA_RO;;_P#/5E/_ *\^_8Z]GY=>\6\/^5[;?_GJRG_UY]^QU[/RZ]XM
MX?\ *]MO_P ]64_^O/OV.O9^77O%O#_E>VW_ .>K*?\ UY]^QU[/RZ]XMX?\
MKVV__/5E/_KS[]CKV?EU[Q;P_P"5[;?_ )ZLI_\ 7GW['7L_+KWBWA_RO;;_
M //5E/\ Z\^_8Z]GY=>\6\/^5[;?_GJRG_UY]^QU[/RZ]XMX?\KVV_\ SU93
M_P"O/OV.O9^77O%O#_E>VW_YZLI_]>??L=>S\NO>+>'_ "O;;_\ /5E/_KS[
M]CKV?ETVY'#[IR2PK-DMOQ^%F=?'B<@;EETD-KRYX _I[]CY]>STV?W2W'_S
MM\)_YYZW_P"NWOW;\_Y?YNO9Z]_=+<?_ #M\)_YYZW_Z[>_=OS_E_FZ]GKW]
MTMQ_\[?"?^>>M_\ KM[]V_/^7^;KV>O?W2W'_P [?"?^>>M_^NWOW;\_Y?YN
MO9Z]_=+<?_.WPG_GGK?_ *[>_=OS_E_FZ]GKW]TMQ_\ .WPG_GGK?_KM[]V_
M/^7^;KV>O?W2W'_SM\)_YYZW_P"NWOW;\_Y?YNO9Z]_=+<?_ #M\)_YYZW_Z
M[>_=OS_E_FZ]GKW]TMQ_\[?"?^>>M_\ KM[]V_/^7^;KV>O?W2W'_P [?"?^
M>>M_^NWOW;\_Y?YNO9Z]_=+<?_.WPG_GGK?_ *[>_=OS_E_FZ]GKW]TMQ_\
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M[]V^AZ]GIRI=K[DI(1!'EL&ZAW<,^'K=1,A!(.G+ 6%N/>L?/KV>I'\ W/\
M\[3 _P#GGKO_ *[^_8].O9Z]_ -S_P#.TP/_ )YZ[_Z[^_8].O9Z]_ -S_\
M.TP/_GGKO_KO[]CTZ]GKW\ W/_SM,#_YYZ[_ .N_OV/3KV>O?P#<_P#SM,#_
M .>>N_\ KO[]CTZ]GKW\ W/_ ,[3 _\ GGKO_KO[]CTZ]GKW\ W/_P [3 _^
M>>N_^N_OV/3KV>O?P#<XY_BF!X_ZL]?_ /7?W['IU[/3,=B9XEF_C>)!9BQ
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MO_;1U[_AZ?Y/?\^KZ&_ZE=@__91[]^ZK?_?C_P NO?\ !_>[W_3&<M_LO?\
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MW_/J^AO^I78/_P!E'OW[JM_]^/\ RZ]_P?WN]_TQG+?[+W_MHZ]_P]/\GO\
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M^RCW[]U6_P#OQ_Y=>_X/[W>_Z8SEO]E[_P!M'7O^'I_D]_SZOH;_ *E=@_\
MV4>_?NJW_P!^/_+KW_!_>[W_ $QG+?[+W_MHZ]_P]/\ )[_GU?0W_4KL'_[*
M/?OW5;_[\?\ EU[_ (/[W>_Z8SEO]E[_ -M'7O\ AZ?Y/?\ /J^AO^I78/\
M]E'OW[JM_P#?C_RZ]_P?WN]_TQG+?[+W_MHZ]_P]/\GO^?5]#?\ 4KL'_P"R
MCW[]U6_^_'_EU[_@_O=[_IC.6_V7O_;1U[_AZ?Y/?\^KZ&_ZE=@__91[]^ZK
M?_?C_P NO?\ !_>[W_3&<M_LO?\ MHZ]_P /3_)[_GU?0W_4KL'_ .RCW[]U
M6_\ OQ_Y=>_X/[W>_P"F,Y;_ &7O_;1U[_AZ?Y/?\^KZ&_ZE=@__ &4>_?NJ
MW_WX_P#+KW_!_>[W_3&<M_LO?^VCKW_#T_R>_P"?5]#?]2NP?_LH]^_=5O\
M[\?^77O^#^]WO^F,Y;_9>_\ ;1U[_AZ?Y/?\^KZ&_P"I78/_ -E'OW[JM_\
M?C_RZ]_P?WN]_P!,9RW^R]_[:.O?\/3_ ">_Y]7T-_U*[!_^RCW[]U6_^_'_
M )=>_P"#^]WO^F,Y;_9>_P#;1U[_ (>G^3W_ #ZOH;_J5V#_ /91[]^ZK?\
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MW_4KL'_[*/?OW5;_ ._'_EU[_@_O=[_IC.6_V7O_ &T=>_X>G^3W_/J^AO\
MJ5V#_P#91[]^ZK?_ 'X_\NO?\'][O?\ 3&<M_LO?^VCKW_#T_P GO^?5]#?]
M2NP?_LH]^_=5O_OQ_P"77O\ @_O=[_IC.6_V7O\ VT=>_P"'I_D]_P ^KZ&_
MZE=@_P#V4>_?NJW_ -^/_+KW_!_>[W_3&<M_LO?^VCKW_#T_R>_Y]7T-_P!2
MNP?_ +*/?OW5;_[\?^77O^#^]WO^F,Y;_9>_]M'7O^'I_D]_SZOH;_J5V#_]
ME'OW[JM_]^/_ "Z]_P '][O?],9RW^R]_P"VCKW_  ]/\GO^?5]#?]2NP?\
M[*/?OW5;_P"_'_EU[_@_O=[_ *8SEO\ 9>_]M'7O^'I_D]_SZOH;_J5V#_\
M91[]^ZK?_?C_ ,NO?\'][O?],9RW^R]_[:.O?\/3_)[_ )]7T-_U*[!_^RCW
M[]U6_P#OQ_Y=>_X/[W>_Z8SEO]E[_P!M'7O^'I_D]_SZOH;_ *E=@_\ V4>_
M?NJW_P!^/_+KW_!_>[W_ $QG+?[+W_MHZ]_P]/\ )[_GU?0W_4KL'_[*/?OW
M5;_[\?\ EU[_ (/[W>_Z8SEO]E[_ -M'7O\ AZ?Y/?\ /J^AO^I78/\ ]E'O
MW[JM_P#?C_RZ]_P?WN]_TQG+?[+W_MHZ]_P]/\GO^?5]#?\ 4KL'_P"RCW[]
MU6_^_'_EU[_@_O=[_IC.6_V7O_;1U[_AZ?Y/?\^KZ&_ZE=@__91[]^ZK?_?C
M_P NO?\ !_>[W_3&<M_LO?\ MHZ]_P /3_)[_GU?0W_4KL'_ .RCW[]U6_\
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M'KVM_P#E6K__ #W5_P#]3>_?GUZK?[YE_P"<;_\ 0/7M;_\ *M7_ /GNK_\
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M_/KU6_WS+_SC?_H'KVM_^5:O_P#/=7__ %-[]^?7JM_OF7_G&_\ T#U[6_\
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M>^N_^I_?NO5;_?,O_.-_^@>O:G_Y5J[_ ,]]=_\ 4_OW7JM_OF7_ )QO_P!
M]>U/_P JU=_Y[J[_ .I_?NO5;_?,O_.-_P#H'KK6_P#RK5__ )[J_P#^IO?O
MSZ]5O]\R_P#.-_\ H'KVM_\ E6K_ /SW5_\ ]3>_?GUZK?[YE_YQO_T#U[6_
M_*M7_P#GNK__ *F]^_/KU6_WS+_SC?\ Z!Z]K?\ Y5J__P ]U?\ _4WOWY]>
MJW^^9?\ G&__ $#U[6__ "K5_P#Y[J__ .IO?OSZ]5O]\R_\XW_Z!Z]K?_E6
MK_\ SW5__P!3>_?GUZK?[YE_YQO_ - ]>UO_ ,JU?_Y[J_\ ^IO?OSZ]5O\
M?,O_ #C?_H'KVM_^5:O_ //=7_\ U-[]^?7JM_OF7_G&_P#T#UWJ?_E6KO\
MSWUW_P!3^_=>JW^^9?\ G&__ $#U[4__ "K5W_GOKO\ ZG]^Z]5O]\R_\XW_
M .@>O:G_ .5:N_\ /?7?_4_OW7JM_OF7_G&__0/7M3_\JU=_Y[Z[_P"I_?NO
M5;_?,O\ SC?_ *!Z]J?_ )5J[_SWUW_U/[]UZK?[YE_YQO\ ] ]>U/\ \JU=
M_P">^N_^I_?NO5;_ 'S+_P XW_Z!Z]J?_E6KO_/?7?\ U/[]UZK?[YE_YQO_
M - ]>U/_ ,JU=_Y[Z[_ZG]^Z]5O]\R_\XW_Z!Z]J?_E6KO\ SWUW_P!3^_=>
MJW^^9?\ G&__ $#UUK?_ )5J_P#\]U?_ /4WOWY]>JW^^9?^<;_] ]>UO_RK
M5_\ Y[J__P"IO?OSZ]5O]\R_\XW_ .@>O:W_ .5:O_\ /=7_ /U-[]^?7JM_
MOF7_ )QO_P! ]>UO_P JU?\ ^>ZO_P#J;W[\^O5;_?,O_.-_^@>O:W_Y5J__
M ,]U?_\ 4WOWY]>JW^^9?^<;_P#0/7M;_P#*M7_^>ZO_ /J;W[\^O5;_ 'S+
M_P XW_Z!Z]K?_E6K_P#SW5__ -3>_?GUZK?[YE_YQO\ ] ]>UO\ \JU?_P">
MZO\ _J;W[\^O5;_?,O\ SC?_ *!Z]K?_ )5J_P#\]U?_ /4WOWY]>JW^^9?^
M<;_] ]>UO_RK5_\ Y[J__P"IO?OSZ]5O]\R_\XW_ .@>O:W_ .5:O_\ /=7_
M /U-[]^?7JM_OF7_ )QO_P! ]>UO_P JU?\ ^>ZO_P#J;W[\^O5;_?,O_.-_
M^@>O:W_Y5J__ ,]U?_\ 4WOWY]>JW^^9?^<;_P#0/1COAP7/R]^,'^3UB@=U
M[0):2BK(U UU0N7D@50+G^OM->?[CR_Z4_X#U+'L-J/O?[2?I2 #?[7BC#\1
M'F!Z_LSP!ZW5?87Z[^=?_]'?X^O!Y!]^Z]U#_AV/_P"5&C_\Y8/^C/?NF/I;
M;_E'C_WD?YNO?P['_P#*C1_^<T'_ $9[]U[Z6V_Y1X_]Y'^;KW\.Q_\ RHT?
M_G-!_P!&>_=>^EMO^4>/_>1_FZ]_#L?_ ,J-'_YS0?\ 1GOW7OI;;_E'C_WD
M?YNO?P['_P#*C1_^<T'_ $9[]U[Z6V_Y1X_]Y'^;KW\.Q_\ RHT?_G-!_P!&
M>_=>^EMO^4>/_>1_FZ]_#L?_ ,J-'_YS0?\ 1GOW7OI;;_E'C_WD?YNO?P['
M_P#*C1_^<T'_ $9[]U[Z6V_Y1X_]Y'^;KW\.Q_\ RHT?_G-!_P!&>_=>^EMO
M^4>/_>1_FZ]_#L?_ ,J-'_YS0?\ 1GOW7OI;;_E'C_WD?YNO?P['_P#*C1_^
M<T'_ $9[]U[Z6V_Y1X_]Y'^;KW\.Q_\ RHT?_G-!_P!&>_=>^EMO^4>/_>1_
MFZ2VZ*2BBCHM%!0>J:6^NAI)?I%Q;RPOI^OX][!(X'K8M[85I;1_[RI_PCI(
M^*E_Y4,9_P">O'__ %-[WJ;UZWX%O_RC1?[PG^;KWBI?^5#&?^>O'_\ U-[]
MJ;UZ]X%O_P HT7^\)_FZ]XJ7_E0QG_GKQ_\ ]3>_:F]>O>!;_P#*-%_O"?YN
MO>*E_P"5#&?^>O'_ /U-[]J;UZ]X%O\ \HT7^\)_FZ]XJ7_E0QG_ )Z\?_\
M4WOVIO7KW@6__*-%_O"?YNO>*E_Y4,9_YZ\?_P#4WOVIO7KW@6__ "C1?[PG
M^;KWBI?^5#&?^>O'_P#U-[]J;UZ]X%O_ ,HT7^\)_FZ]XJ7_ )4,9_YZ\?\
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MS%_SC3_H'KVI/^5:A_\ /?0__4_OW7JK_OF+_G&G_0/7M2?\JU#_ .>^A_\
MJ?W[KU5_WS%_SC3_ *!Z]J3_ )5J'_SWT/\ ]3^_=>JO^^8O^<:?] ]2Z H:
MZD_R:B_SZ_\ *!1#^OY%/[]7K1TD$&&.G^D0?\^]+3]O_E7H_P#SBI/^O/O>
MH]-^''_OI/\ >1_FZ]^W_P J]'_YQ4G_ %Y]^U'KWAQ_[Z3_ 'D?YNO?M_\
M*O1_^<5)_P!>??M1Z]X<?^^D_P!Y'^;KW[?_ "KT?_G%2?\ 7GW[4>O>''_O
MI/\ >1_FZ]^W_P J]'_YQ4G_ %Y]^U'KWAQ_[Z3_ 'D?YNO?M_\ *O1_^<5)
M_P!>??M1Z]X<?^^D_P!Y'^;KW[?_ "KT?_G%2?\ 7GW[4>O>''_OI/\ >1_F
MZ]^W_P J]'_YQ4G_ %Y]^U'KWAQ_[Z3_ 'D?YNF/.>,0TW^347^>?ZT-&?\
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M_P XT_Z!Z]J3_E6H?_/?0_\ U/[]UZJ_[YB_YQI_T#UGIBGW,/\ DU%^L_\
M*!1?ZAO^F?W[K1*D4\&/_>$_Z!Z>;I_RK47_ )P47_7CWNIZK1/]]1_[PO\
MFZ]=/^5:B_\ ."B_Z\>_5/7J)_OJ/_>%_P W7KI_RK47_G!1?]>/?JGKU$_W
MU'_O"_YNO73_ )5J+_S@HO\ KQ[]4]>HG^^H_P#>%_S=>NG_ "K47_G!1?\
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M?]:.O?\ #C?PI_Y_7_ZXF^__ *P>_?N^\_WS_,?Y^O?\&']VO_PI7_9E??\
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MCK#>W>.Y]T=?=7=B===TUG?NWLEUO@JRGCFVYCY>Q*UVK:+[B:FK,;_D3IX
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M5>Z:?.?''N([JI>^NA?F&-K]TTC8^NVK%)@=QO7T$&9>'^"BJH]#KQ9<T/\
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MGAIGNP+ 'W6P":TZ;>N/EM\;>W<)U=N38O>?7M9_IBH\Q4]6[>S.X*39^_\
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MGX<,UP??NM=9_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5(_R)W'\C:?M?\
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MJU[%ESU)D\5X2'HZ9/=:&F@Q7_B^K0_Y=>^-V[]^,6&R6\>O-^]?UN&WUO\
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M7_V23_\ 6WKW_#+W:W_>0?67_H";O_\ KQ[]^]E_WT>O?\F^>=O_  I6U_\
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M#?\ ))_XI[]UZA].LL3U,#%H7GA9ETLT321L5O?22A!*W'T]^ZU0^G6+0_\
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M_N/M+_G0T'_)#_\ 1_OVIO7KW7O[C[2_YT-!_P D/_T?[]J;UZ]U[^X^TO\
MG0T'_)#_ /1_OVIO7KW7O[C[2_YT-!_R0_\ T?[]J;UZ]U[^X^TO^=#0?\D/
M_P!'^_:F]>O=>_N-M$_7;^.;^FJ(M;_6U,;>]:CZ]:H.O?W%VA_SSV,_\YQ_
MQ7W[4?7KU!Z=>_N+M#_GGL9_YSC_ (K[]J/KUZ@].O?W%VA_SSV,_P#.<?\
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M1JFH?=:TB@]3T)7QW^=GS-[2[ [@W<WQ:WMV7T;@LG\H-M8';NQ-N]<[,SV
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6^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g790774g14v41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g14v41.jpg
M_]C_X0Q917AI9@  34T *@    @ # $   ,    !/!X   $!  ,    !%CL
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," P.3HU-#HP-@     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,@H , !     $   $H          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MC?/\VRQH_=/TT]GUHZHUCG,^L]SG 2UFW5Q_=G9M8O7OV1TG_N%C_P#;3/\
MR*7[(Z3_ -PL?_MIG_D4O>A^Y_T?^]1P2[ODA^L_49?'UIN$.(9+9]HW:R&?
MG_HU ?6GJ<-)^L]\[FA[-HF"\,L>UVW;^CJ_3?Z_H_7OV1TG_N%C_P#;3/\
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M74?K&&?LM^]H<WU*@?=M(FQC YKQ_64,AQ9U')M'^ 9CV$^#=UC;C_VQZJ=
M6?M6R-!MY61;5F8=;3%=SGBWX!A+/_!=B?.OMH?B^G]&R]M=H_DN:_\ ]&>F
M@]3GU6O;J::7W1X^F_'NV_VO3VJ74&NN].JH@N<RUS#VW!NVMW^?8G #T^1M
M:2?5YBDG4<BS'QVV5F#ZM37?U'6,;=_X#ZB74[[L?"LNI_G&%I'>1N:'-_M-
M4,DUY=.*!_-Y)_!U5KPF=:;\'&<[Z5KZ=X\'!S76-_LN8Y("N&QUU_E_@I)^
M:CTT_E_A)>H6VU]/R+<<CU6U/=4>1OVGT_\ IH];VV5ML;]%X#A\")5%KC^R
MV5G5U;F4$^)98W'G^WMW(^"8J?4>:+'5QX-G?2/^V'U($5'R)2#KY@-E))),
M7*6:,Q^57D->S9]GS*ZFD3#FA]#@_7^NM)8F'LVYQ: T_M%H< Z=?4HUC\S<
MDIU;LEM;VU-8ZVUP+A6R)#1^<YSW,K9_:?[U'[3=_P!Q+OOJ_P#2Z;&]^1DW
M?RFU-/\ )K$_^?K;E93C0TJUHLZW37^U6CG%N'_;9_ZFTIOMA[T7#^S/_4N<
MK*2%CLFCW:WVZOO7</\ K3S_ -2TI'J&,-7^HP=W/JL8T?%[V-8K*25Q['[5
M:]Q]BS7->T/80YKA+7#4$'N$Z22"7__1]%Z[7;9TRQE32YY=7#6@DD"QCG_1
M:_\ ,35L9;U7/K>):^BAKAX@G)E:*SV.%'4\NVQEFVUE(8YM;W@[?5GW5M?^
M^B.J#T5@N?9D%MNMF/4*K9[NW.&\_P#'-K;<W^18FPR6Y-6,[Z6+7;4?';NH
M^SO_ .N4_P#3]1'&3BBQU@JL%CP YXHMW$-G8USO2_-WN2^TXGJ&WTK/5+0T
MO]"S=M!W!F[TMVW<4XS&NFX6\)T\VO5+,JK#/^ M?:P?\&YC_3(_D5NN?1_U
MI(_H\QF*>#>;J_-KV6V6?YF3O_[<I5@Y6*7BPUV%[06M?Z%FX!VTO:#Z6[:[
M8Q)V3B.>Q[JK'/KG8XT6$MD;7;3Z7MW-2X_#I_SOWE<'Y_\ -[(,G]%D.I.@
MR+:;J_-S'UMO:W^JRNJW_MU'GT<_71F4V!X>I6#_ -*VC_VV2=E8KRTOKL<6
M'<PFBT[706[F_HO:[:Y)V7C/ #Z[7 $.$T6F"-6N_FOS4.+3Z:IX?ST;229K
M@YH<)@B1((.OBUWN:G35RECT,M8W--H+0<YCV.<"!LWT<;@WV^UWN6PJ?5V6
MV8#ZZFEQ<ZL.VB2&&QGJO#1^Y5O>D-U%)@ C#K<[1U@-KAX.L)N</\YZL*O]
MMI&@9;_VS9_Y!+[;5^Y=_P!M6?\ D$2;)/= % !L)*L<ZD:EMH'B:K!_WQ/]
MMJ'YEO\ VU9_Y!!+825?[;5^Y=_VU9_Y!+[;5^Y=_P!M6?\ D$E-A)#JN;:"
M6A[8T][7,^[U U$24__2]53%S08) /,)USOUFV_:*MW[+_F7_P#*&[U/I,^A
ML_[3_O\ _#>DDIW_ %:M_I[V^I^Y(GC=]'^JI2.)U7,C9^T&_P#)/-/T=WK<
M-_\ !/\ N-_P"J>S]GU_\A1KSO\ 2_FL?Z'YW]?_ ('[.DIZ3*Z5TS,N-U[-
MUC@*]P>YOT=VW^;>SWMW.5JBJJBEE%6E=+6UM$S :(:)/\E<8/1]5T?L3=M,
MSZL1&FR?T?\ QVQ6!Z?V1W_(O\_K]/TIV?\ G_\ ]UDE/7)%S0"20 -2?)<B
M?2V&?V-'V03'J<;;?H1[OL?]3_A4!_I>D8_84;O\)ZD_/=[_ %/_ $6DI[4.
M:>"#K'/?P3KE6^E^U:)_96[[2=OI^IZL[A/T?T?VC]WU?9ZNQ=4DI22222E)
M)))*19.-1E5&F]F^LD$M,C5IW-^C_*"%A=+P,!UCL.EM)M#19MG4,GT^?W=[
ME:224I))))2DDDDE/__9_^T3Z%!H;W1O<VAO<" S+C  .$))300$       /
M' %:  ,;)4<< @   @   #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M        /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      $H   #(     8 9P Q #0 =@ T #$    !
M      $              R    $H                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   $H     %)G:'1L;VYG   #(     9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !*     !29VAT;&]N9P   R     #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     $X0DE-! P     "N\    !    H
M #L   '@  !NH   "M, &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #L H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M-6G<WZ/\H(6%TO P'6.PZ6TFT-%FV=0R?3Y_=WN5I))2DDDDE*22224__]D
M.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $,
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M  (1 0,1 ?_=  0 9/_$ :(    & @,!              <(!@4$"0,* @$
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M?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?KW^SA?$C_ +RE^.?_ *.[K/\
M^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K_GZ]_LX7Q(_[RE^.?_H[NL__
M +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?KW^SA?$C_ +RE^.?_ *.[
MK/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K_GZ]_LX7Q(_[RE^.?_H[
MNL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?KW^SA?$C_ +RE^.?_
M *.[K/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K_GZ]_LX7Q(_[RE^.
M?_H[NL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?KW^SA?$C_ +RE
M^.?_ *.[K/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K_GZ]_LX7Q(_[
MRE^.?_H[NL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?KW^SA?$C_
M +RE^.?_ *.[K/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K_GZ]_LX7
MQ(_[RE^.?_H[NL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?KW^SA
M?$C_ +RE^.?_ *.[K/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K_GZ]
M_LX7Q(_[RE^.?_H[NL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[VO^?K
MW^SA?$C_ +RE^.?_ *.[K/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT/^]K
M_GZ]_LX7Q(_[RE^.?_H[NL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG0_[V
MO^?KW^SA?$C_ +RE^.?_ *.[K/\ ^R?W[]R;U_T:+K_G%)_T#U[]X[?_ ,IT
M/^]K_GZ]_LX7Q(_[RE^.?_H[NL__ +)_?OW)O7_1HNO^<4G_ $#U[]X[?_RG
M0_[VO^?H<MN;EV[O' XC=6T<_A=U;8W!04^5P.X]N96ASF!S>+K(Q+29+$9C
M&3U6/R5!51,&CFAD>-U-U)'LOEBE@D>&:-DE4T*L""".((.0?D>E2.DBJ\;!
MD(J"#4$?(CK_T-_CW[KW7O?NO=%(^9W:+=>=05N&QE4:?<W8TLNT,08VTU%+
MC:B!I-T96(E2%-%A2\2-<%:BIBMS[=A74XKP'56-!\^J24Q>-C1(X\?1)'&J
MHB+2P!410%55&C@*!8>UO377+^'8_P#Y4:/_ ,YH?^C/>NO=>_AV/_Y4:/\
M\YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]U
M[^'8_P#Y4:/_ ,YH?^C/?NO=>_AV/_Y4:/\ \YH?^C/?NO=>_AV/_P"5&C_\
MYH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]U[^'8_P#Y4:/_ ,YH?^C/?NO=
M>_AV/_Y4:/\ \YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\
M.:'_ *,]^Z]U[^'8_P#Y4:/_ ,YH?^C/?NO=>_AV/_Y4:/\ \YH?^C/?NO=>
M_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]U[^'8_P#Y4:/_
M ,YH?^C/?NO=>_AV/_Y4:/\ \YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_
MAV/_ .5&C_\ .:'_ *,]^Z]U[^'8_P#Y4:/_ ,YH?^C/?NO=>_AV/_Y4:/\
M\YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]U
M[^'8_P#Y4:/_ ,YH?^C/?NO=>_AV/_Y4:/\ \YH?^C/?NO=>_AV/_P"5&C_\
MYH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]U[^'8_P#Y4:/_ ,YH?^C/?NO=
M>_AV/_Y4:/\ \YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\
M.:'_ *,]^Z]U[^'8_P#Y4:/_ ,YH?^C/?NO=>_AV/_Y4:/\ \YH?^C/?NO=>
M_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]U[^'8_P#Y4:/_
M ,YH?^C/?NO=>_AV/_Y4:/\ \YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_
MAV/_ .5&C_\ .:'_ *,]^Z]U[^'8_P#Y4:/_ ,YH?^C/?NO=>_AV/_Y4:/\
M\YH?^C/?NO=>_AV/_P"5&C_\YH?^C/?NO=>_AV/_ .5&C_\ .:'_ *,]^Z]T
M8KXK=/X[M/N7!4M=B**HVULL0[VW*LE'3O!/_#ZI5VYBI%:(H_\ $<ZBRLI_
M5!22CZ'VW*VE#3B>K**GJ^'VBZ=Z][]U[KWOW7NB,_S)?F-A?@9\+>\ODK7_
M &E7N+:&UVP_6& JVCMNOM[>$\>V>LMN""22-JFFK-VY.FEK0EVBQT-1+;3&
MQ @Y7V1^8=]V_:EJ(W>KD?AC7N<_;I! ]6('GT7;M?C;=ON;O\:KV\3W'A@9
MH.+4SI!/EU\GJOQ<&?R65W%NZ&BW3N[<N6RNY=W;HRU!2U>4W+NK<.0J<SN3
M<&1J:B*2>:MS.:KIZF0LQLTEAP![S&CI"B0P#1 H 51@  4  ^0Z@>6XFFD:
M225F8^9))^0K\ACJ+_=;;'_/.8'_ ,]&/_\ J?W?Q)/]^-^T]-ZV_B/7O[K;
M8_YYS _^>C'_ /U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _P#GHQ__ -3^_>))
M_OQOVGKVMOXCU[^ZVV/^><P/_GHQ_P#]3^_>))_OQOVGKVMOXCU[^ZVV/^><
MP/\ YZ,?_P#4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,#_YZ,?\ _4_OWB2?[\;]
MIZ]K;^(]>_NMMC_GG,#_ .>C'_\ U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _^
M>C'_ /U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _P#GHQ__ -3^_>))_OQOVGKV
MMOXCU[^ZVV/^><P/_GHQ_P#]3^_>))_OQOVGKVMOXCU[^ZVV/^><P/\ YZ,?
M_P#4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,#_YZ,?\ _4_OWB2?[\;]IZ]K;^(]
M>_NMMC_GG,#_ .>C'_\ U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _^>C'_ /U/
M[]XDG^_&_:>O:V_B/7O[K;8_YYS _P#GHQ__ -3^_>))_OQOVGKVMOXCU[^Z
MVV/^><P/_GHQ_P#]3^_>))_OQOVGKVMOXCU[^ZVV/^><P/\ YZ,?_P#4_OWB
M2?[\;]IZ]K;^(]>_NMMC_GG,#_YZ,?\ _4_OWB2?[\;]IZ]K;^(]>_NMMC_G
MG,#_ .>C'_\ U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _^>C'_ /U/[]XDG^_&
M_:>O:V_B/7O[K;8_YYS _P#GHQ__ -3^_>))_OQOVGKVMOXCU[^ZVV/^><P/
M_GHQ_P#]3^_>))_OQOVGKVMOXCU[^ZVV/^><P/\ YZ,?_P#4_OWB2?[\;]IZ
M]K;^(]>_NMMC_GG,#_YZ,?\ _4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,#_ .>C
M'_\ U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _^>C'_ /U/[]XDG^_&_:>O:V_B
M/7O[K;8_YYS _P#GHQ__ -3^_>))_OQOVGKVMOXCU[^ZVV/^><P/_GHQ_P#]
M3^_>))_OQOVGKVMOXCU[^ZVV/^><P/\ YZ,?_P#4_OWB2?[\;]IZ]K;^(]>_
MNMMC_GG,#_YZ,?\ _4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,#_ .>C'_\ U/[]
MXDG^_&_:>O:V_B/7O[K;8_YYS _^>C'_ /U/[]XDG^_&_:>O:V_B/7O[K;8_
MYYS _P#GHQ__ -3^_>))_OQOVGKVMOXCU[^ZVV/^><P/_GHQ_P#]3^_>))_O
MQOVGKVMOXCU[^ZVV/^><P/\ YZ,?_P#4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,
M#_YZ,?\ _4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,#_ .>C'_\ U/[]XDG^_&_:
M>O:V_B/7O[K;8_YYS _^>C'_ /U/[]XDG^_&_:>O:V_B/7O[K;8_YYS _P#G
MHQ__ -3^_>))_OQOVGKVMOXCU[^ZVV/^><P/_GHQ_P#]3^_>))_OQOVGKVMO
MXCU[^ZVV/^><P/\ YZ,?_P#4_OWB2?[\;]IZ]K;^(]>_NMMC_GG,#_YZ,?\
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M!0QBB.H*($6K>)(5H 20/-5-LUS>7%A;P_3H?HTD+*6*LI8J'."69C0449+
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MMT;]?ZA:PK'$26\4FBE:Z:FM0 3TJN=B2;]WS;4S?3W D_M#0)X3$.6>@HM
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M/:RS%'AK(O@^'J0OKXMXE3CL*Z1JX]*-KVVPO;2\$J,;B)PH=7[6JDC@@:>
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M=:T#UZ/9B\9087&8[#8NFCH\9B:&DQF.HX01%2T-!3QTM)31 DD1P4\2J/\
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M[5_Z!Z]_T">_";_O([Y<?^A!U)_]J?W[_7DW_P#Z-=E_O,G_ %LZ]_4#;/\
ME,N/VK_T#U[_ *!/?A-_WD=\N/\ T(.I/_M3^_?Z\F__ /1KLO\ >9/^MG7O
MZ@;9_P IEQ^U?^@>O?\ 0)[\)O\ O([Y<?\ H0=2?_:G]^_UY-__ .C79?[S
M)_ULZ]_4#;/^4RX_:O\ T#U[_H$]^$W_ 'D=\N/_ $(.I/\ [4_OW^O)O_\
MT:[+_>9/^MG7OZ@;9_RF7'[5_P"@>O?] GOPF_[R.^7'_H0=2?\ VI_?O]>3
M?_\ HUV7^\R?];.O?U VS_E,N/VK_P! ]>_Z!/?A-_WD=\N/_0@ZD_\ M3^_
M?Z\F_P#_ $:[+_>9/^MG7OZ@;9_RF7'[5_Z!Z]_T">_";_O([Y<?^A!U)_\
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MR?\ 6SKW]0-L_P"4RX_:O_0/7O\ H$]^$W_>1WRX_P#0@ZD_^U/[]_KR;_\
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@E[]_P"9$]U?^(E['_\
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U6?\
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ME'8O\Y"E%I?CO\.\H1^:?LO=U(6M_3SY-5!/^(]Z.T?=ZD/;S;S#']MO$?\
M O6_WK[^)QY5V%_LN)1_A;KH=R?S@*8DU'PZ^-&24?\ .L[QEI6:U_T_Q#(\
M$_[[_#QY>]@'^#W"WE#_ $K('_CJ]>_?_OLGQ<A;0X_HWE/^/-UP/R0_FJ4/
M_%P_E_\ 6];I^IP_R P+ZOI^@2O)_O?O?]4/8Z7^Q]U;Q?\ 3V+_ .3K7];/
M>F/^U]L+1O\ 27J?Y>N/^S?_ ,QNB_XN7\M:MJ@!ZOX-W?M.<DV-] :DD][_
M *@>T,G]C[QJ/]-9RC_+U[^O?NO'_:^T;-_I;N(_Y.LB_.KYLTAMD_Y7/<,M
MOU-B>TMFU0/TOH Q+D^ZGVQ]MY/['WLV\?Z:VF'_ #]UL>Y'N&G]M[-7Y_TM
MQ$?^?>N_^'"OE% ;5W\KCY11V^IH,WMK)C_8>''Q:O?O]:?DEO[/WMV0_P"F
M21?\+'KW^NESDO\ :>S6\C['C;_ O73_ ,R?N2B%\S_+6^96/0?K>#;F-KU7
M@DV\?BU<?T]^'L[R]+BV]X^77/SD9?\ /UX^[>_QYN/:/?U'RC5NL8_FK)2<
M9SX1?-7$L/UC_1/]X%_KS%D(]5O\/=O]8XR?[C>Y7+<@_P">JG^%>J_Z]03_
M '(]N^84_P"H:O\ @;KFO\W?J* VS'QQ^9F(M^LS="9*94YL;E,NM[?X>ZGV
M#W]O]Q^;^79/LOE'_/G5A[Z;$N)^5-_3[;)C_P _=<O^'C?C!$;5W7?REQG^
MJ^_Z!W)&%_KJ,-7.!;W[_@>^=6_LMWV1_P#2WT?^4#KW^OWR<O\ :;5O*?Z:
MRD_R$]9X_P"<M\,K@5C=UXH_G^)=*;UAT_\ !C%1S@ >ZG[O'N)GPQMK_P"E
MO(3_ )1U8>_O('XSN*?Z:TE'^0].M/\ SC/@=*0*GLC=>+O]?XGUAOZF"<7.
MNV"DTV]L/]WSW07X-G@?_2W,!_Y_Z?3W[]M&^/=IT_TUO,/^?.E-1_S;_P"7
MI5VU_(W!4#'ZID=K[\I67B_J#;68+_M_:*3V%]V4X<H2N/Z,D!_ZR]*X_?+V
MM?CS7&I_I1S#_K'T_4_\U#^7Q5$+%\I>NE)_$Z[CI/\ ;_=8*&WM*_L?[L)Q
MY(O/R\,_X'/2I/>?VN?ASG:?GX@_PH.E'2?S)_@=7$"G^5'41)^@EW$*8\_X
M5,$)'M))[.^Z$7Q\C[A^4=?\!/2I/=OVUDH$YTL?SDI_A Z5E'\[_AED #2_
M)[I1]7TU[^P$!/('TGJXB.3[02>V'N)%\?)>Y#_FPY_P#I='[E<@24T<X[?_
M ,YD'^$]*N@^7/Q7R9447R.Z/F+VTC_2CLR(F_TXFS,?M!+R%SO#7Q>4-S'_
M %#3'_ G2V+GGDN:GA\V;<?^HB(?X7Z6^/[PZ6RQ48KM_J_)E[:1C]_[3K2U
M_II%-EI";_X>RZ7EKF.W_M]@O4_TT$H_PJ.C&+F+E^>G@;[9O_I9HS_@;H0<
M?E<7EHO-B\E09*'C]W'UE/61<_3]RGDD3G_7]E,L$T#:9X61O1@0?Y]&D4\,
MZZH9E=?52"/Y=3_;73O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U__U=_CW[KW7O?NO=>]^Z]U4M\]^RNN.W.L?E5T
M+V]\'_G_ -M[5Z2SOQGRFWMV_'+K1(MY;ZWWO_*+N_9?:WPPW]C.QMK9ZJWE
M\6MU8"EKMRY:*7&2[>JQ&@2NADEB?W5@.!J,]52_%39^T<U\IOCK7]V],_\
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MYR1FL1Z4O^/>5%MNB+]Y_F;;9S6UW$36+>E'M5 _XT@_;UC%<[:[?=LY<W&
M?XS8&*]7UJERQ/\ QES^SK8AV#NNDWYL79>^* **'>6T]N[JHPC:T%+N'$4>
M7@"MSJ4158 /O$K=+&3:]SW';9?[6WGDB/VQN5/\QUE1MEZFY;;M^XQ?V=Q
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MD=(+*?REOY>V31E'QPVYBY#S]QA=P[VQDRG^J?;[E$:D?\%]FD/OQ[L0FO\
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M'\V[XY;X370X3Y+=$;ZZ@SU021#7[IV-5'=&WH>-*F8P_:Q &Y_/N^Q?[O\
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M4=7EJN.&*JRE334T4$^1J8J=4IXZBNE0RNJ*$#,0H M[]TWT&W?O_,B>ZO\
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M,3@\SE20!C<5D<@2?H!1T<U22?\  >/V_;1>/<V\ _&ZK^T@=,7,O@6UQ-_
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M^49GLEB.@^POCIN6:4;L^*W=_8O4M;13@^2EV_\ QNISFV9 Q-VAGCKJE4_
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MBE>MMWW[IKJI_P#GA?\ ;K[Y+?\ 49T1_P#!)=/^_=7C^,==_'*^6_FI?/\
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M6)EADHNPMB[:W4! ;QT]7EL73U&1HA_M6/R+2P,/PT9]Q[S-LLW+G,6][#<
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M6$;>_=.U%*>)_+K<*4D@%AI8@$K>]C;D7XO8^_=,]!-W[_S(GNK_ ,1+V/\
M^\=F??NMCB.BU_RM_P#MV?\ R\__ !2'XK?^^-V-[]UM_C;[3T ?\U1Y.P!\
M/OC!2L"_?WR@V8,Y&I+.=G]>LN?W 9XENQH@:N!Y"1;]OW._L?3:C[@<Z.,;
M5LDVC_FK/^G'0^N& ^WJ#?>DG=!R'R<G'<]YBU_\TH.]Z_+()^SJVA$2-%CC
M54C151$10J(B@*JJJ@!54"P X ]P22222:D]3>    * =<O>NM]>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U__5W^/?NO=>]^Z]U[W[KW5;G\V"KZ)A^&.[Z#Y"
M[S^1>T]GY[??4F$VQB_B+42P_)WLOMJI[&V[4=1]5=&Q46+R>9J^P][]@4E!
M!1+0M15$6EIVK:*GAFJ8O=;6M<=4M?&:(]9_)_XY5'R;RO\ PHA^->.W9W!M
MG;W4.=^7?S&VMVS\6>SNR\M]U3[+Z:[NH.L-Y;U?!5/9-=,M)C,7F::"@RF1
M"4OW:5!ACF]U<DG\(_+K;(]^Z;ZJP_G5)Y?Y:OR!C/TDSOQ[0_\ (?R;Z:7_
M (GVS<'3!.?1#_@/2BT&JZMQZN/\/67^6W!YM]?S#\\!Z,M\[.WJ9)!]'7#3
M04:V;\Z UO<Z^\;%-N]IK0\8^6+0T_TX)Z@WV?(GO/<^_4=LW,=S3[%H/\O5
MI7N$.IJZ][]U[JH'!-_LK7\UK<N!D(Q_6?STZ[AW1B;2/3XVF[PZTBECRT#F
M5?!+D\[B#--I0AGFR$8Y/'N?KH?UV]C;.Z'?O/*UX8W\V-E<T*'&0J/09P A
MZ@FV/]3/>J[MB=.T<S6HD7R47EO74,XU.M3CB7'5OWN >IVZJ=ZE'\7_ )PG
MRPKVM(NT_BYTYMV%OKX9,UDL=G)$']"0I_VY]SKOWZ'W?^18A@S[W=R'YZ%9
M.H2V/]?WXYVE.1!LUJ@^6ME?JV+W!74V]>]^Z]U5/_->VIG-O]8=3?+39-*\
M^]_A]VUMSLPB+07J^O\ *5]#A=^8V6,C744\T!I9)$O801RDBUR)R]B[ZVN]
MZWWD/<GIMO,%A);9\IU5G@;Y$'4 ?4KU"OO997-KL^Q\\;<A.X[#?1W&/.!F
M"3+\P1I)'H#U9ILW=F#W[M':^^-LU:U^W=X;?P^Y\%6I:U5B,[CZ?)X^>RLP
M5I*6I4D7.D\?CW#.X6-SM=_>[;>QZ+NWE>-U]'1BK#\B#U+]A?6VYV-GN-F^
MJTGB21#ZJZAE/[".JP/YP##(=%=&[16[3[Q^7?0N)2(?[MABS.1K)Q;\@&%#
M[FGV _2YGYFOS\-OL%\]?F451_A/4.^^Q\7EOERQ'Q7&^V2T]0'8G_ .K8_<
M%=3;U[W[KW3=E\3CL]B<G@\Q20Y#$9K'5N)RE!4 M!6X[(TTM'74DZ@@M#4T
MTS(PN+JQ]NP3S6L\-S;R%)XW#*PXAE-01\P0#TU/!%<P36TZ!H)$*L#P*L*$
M'Y$&G547\KO,9+J>L^1WP4W=63/GOC%V?DZ_8 K'D$N4Z5[#J9<_M*NH(Y5U
M&CI*BH=W-R%-?&ON=/>N"'?8^4/<ZPC'TN]62K/3@MY;@1RJQ]2 *>N@GJ$_
M9N>;9).;/;>^D/U.SWC&&OXK2<EXB*^0))/IK ZMN]P-U./53?\ *-7^*]8?
M)C?C$/+OGYD=XUYE^IE@Q^0QE% ^K\CEA_L#[G;W[/@;UR;M@X6W+MDOV%E8
MGJ$?8T>-L_-^Y>=SO]XWY*R@?Y>K9/<$]3=U[W[KW50/:[?[*]_-(Z>[<_X!
M=<?-38\W1F]IP(UI*;M;:!I*K8M?4<HD4V7IEHJ))'.I@9R";$>Y]V+_ )&O
MLES#L/Q;ORY="]A'F;6:HG4>H0ZG(']'J"M[_P"0;[R[#OOP[3S#;&SF/D+F
M*AA8^A8:$!/]+Y]6_>X"ZG7JI[N)3E?YOWP_H-(ECVS\9^[-RNIY$+Y2KK\%
M%+;^R2Z  _ZWN=>7OT/8#W EK0S;S9Q_;I ?J$]^'C^^O(D=*B':+N3[-1*5
MZMA]P5U-G7O?NO=%)^=70_\ LR7Q3[CZKI(#+N/([6J,[LF2./R55/OC:CIN
M+:YHR"&CJ*O)XY*74.1'4-_7V//;+FC^I_//+V^2-2T2<)-Z&&7].6OJ K%J
M>JCH#^Y'+7];>2M_V5%K=O"7A]1-'WQT^990OV,>F_X"]\_[,=\3NH.QJV=7
MW3%MZ/9^_J9GD:JH=][+;^[NXXJ\2CR1U=;44*UA4W(2J7^OMWW3Y7_JASWO
M^SQK_B/C>+ ?)H)OU(ROJ &T?:IZ:]LN9?ZV<D[%NTC?XZ(O"F'F)HNQP:^9
M(U_8PZ2W\SO+M@_@'\IZ]&*N>K<C0(0;$OF,AC<0JC_%VKK?['VN]E[<77NI
MR/$14?7*W^\*S_\ /O2+WAG^F]L><Y1Q^B9?]Z95_P O0^_&+"IMSXW]!8)%
MT#%],]9T;K:UI8MFX83\6%KS%C["O.=R;SF_FFZ)KKW&X/Y&9Z?RZ$_)]N+3
ME/EBV ^#;[<?F(DK_/H<O8:Z$?7O?NO=5 ] L/C#_,O^170%2/L=A?++;]+\
MDNJU>,1TW]^<;]S2=DX3'K$5IX6G*5E6R!=0AI(OP1>?>:?^1I[-\H\U)W;I
ML,IVZY]?!:C6[M7)IVH#7BS=05RQ_P @_P!WN:^6'[=LWN(7]MZ>,M1.BTP*
M]S4IP4=6_>X"ZG7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBZ_+O-]2[;^+/R
M(SO?6^<UUITIB^F.QJKM;?NVZ^JQNY-J[ 3:N3&Z<MMVLH*'*9%,_!AVE%$E
M-35-5+4E(X8I)61#[K8XCK4M@ZVVGU/MO&=E]P?&?_A1W\;?ACMVAP596]W9
M_P#F)[GR4O4/6:M0PT>\NT_C9L'OO/\ ;O6^P-GX<K4;@BBQM75[;Q4$TL],
MHIY GNK>?E7_ %?/K=5I9Z>JI::IHZB*KI*B"&>EJH)DJ(*FGFC62"HAGC9H
MYXIHV#*ZDA@;@V/OW5.@L[]_YD3W5_XB7L?_ -X[,^_=;'$=%K_E;_\ ;L_^
M7G_XI#\5O_?&[&]^ZV_QM]IZ+_N,'N+^<+L;$1QB?"_$WXTYC=&32<AH(MX=
MKUW\.QLD*'TBJ7"9&"1?[0$1;\>YXM/^0_\ =^W.<FESOV\I&M.)BM5U-7Y:
MU(_.G4&78_?WOQML %;?9-H>1J\!+<G2M/GH8'\J]6W>X'ZG'KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z__6W^/?NO=>]^Z]U[W[KW5;O\T3"]&[IZ(Z
MNV?W)O#LOKC<V\OE=\:MJ_&/LWIW%X[,]E=:?+/-=D8^DZ-WUMW&YRFK=MUE
M!M[.--+G(<I!/CJC;G\0AG1ED]^ZLM<T].B+]F_'#O\ ZFW_ /$K>W\S+^9'
MVG\M^F:/YC_'G;?5'3_3_P 0.J/CULRK^3>?W:*/XX[\^2.YMC[FW/NO/[!V
MGVFF/GIJ.BEQ>)&ZGQ-15T\T,7B'NK UKI6AH?/K8*]^Z;ZJS_G3.(_Y;'R
MD;],6>^/<K7^FF+Y-=-.;_X67VQ= FVN .)1A_(]*;,TN[<^0<']AZ<OY6A6
MMZV^3.X?K)N/YQ?)K(M+]3)$NZZ2FA-_R%$1 ]SS[]I]/S+RO8CX8.7K!/\
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M?Z#MCB3ZZ?L=K5%0T-^;:33WM[E?GW_%?9_V>LN'B?6S4^V4"O\ /J+N1O\
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M3?[D?XIM%A<WC'R!2,JE?M+U'V=0S[\7<@Y,78K<_P"-;M?V]HH\R'D#-3[
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M ">?G+)_J.M]L,/]=>T]@D?[&_M;M8KN^RCUOK;_ *OQ],7@U;?NJ^MG<?\
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M_P!E'OW7J'TZ]_LY?Q _[RL^-O\ Z//K#_[*/?NO4/IU[_9R_B!_WE9\;?\
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M/C;_ .CSZP_^RCW[KU#Z=>_V<OX@?]Y6?&W_ -'GUA_]E'OW7J'TZ]_LY?Q
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M%*NV^V=^OMNEDV;NS? SFG;U&:*H.1>CJ06B\7/NO:F_B/0Y?\-P_P O+_O
MWX8_^DN]'_\ V#>_=:U-_$>O?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O
M?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\
MV#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O
MWX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O
M?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\
MV#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O
MWX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O
M?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\
MV#>_=>U-_$>O?\-P_P O+_O WX8_^DN]'_\ V#>_=>U-_$>O?\-P_P O+_O
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BZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g790774g40a82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g40a82.jpg
M_]C_X1&317AI9@  34T *@    @ # $   ,    !.6@   $!  ,    !%A\
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(T.C U.C$P(#$P.C$U.C,S   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,"H , !     $   $I          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M.2P64Y=M%#V$D:674U[FN;^=7N]1J+T?(M#;.FY/]*P-K"X"!92[=]DRF?\
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MG__9_^T9'E!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @
M @   #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ $L     0 ! 2P    !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      ST    &              $I   # @
M  0 4  Q #, -P    $                          0             #
M @   2D                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   2D     4F=H=&QO;F<   ,"    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   # @    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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MVCZ?^%K_ )Q6?JQ7A8QS<7"'Z!]HSJ3+G;F98WETV>_^ETY=>S_@_P!];8
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M&[7[/MV;H'^B]N[:DI__V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P ( 0$  0$
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M(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ A061O8F4
M9$     " P 0 P($"                /_; (0  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,#
M P,# P$! 0$! 0$! 0$! @(! @(# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,#_\( % @!*0,"! $1  (1 0,1 001
M /_$ 1@  0 " @,! 0$!           ("08'! 4* P(!"P$!  (# 0$
M          4& @,$ 0<0   & @$# @('" (" P #  ,$!08'" $""0 0(#!
M$Q01$C05-A@X4"$D-187-PHQ(V E(B<H,R89$0 !!0$  0($ @8#" P*!@L#
M 0($!08'"!$2 "$3%" 5$# Q(A8)0$$C43)VEK87=SAA0K,D=-1UM3;6M[A0
M<8'2E"4WE]>8D5)B,T/3)AA@H;%R<R?P-#D2  ("  4!!0,( PP)! (# 0$"
M$0, (3$2!$%182(3!1!Q@2 P0)&A,D(4L2-SP>%28G*"LL(SLS054/#1DM)#
M)#4&\:)3DV"#1!8V)?_:  X$ 0$"$0,1!     #_ #_SW\
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M,NIX&6/+KUEHB9<3.^/D.                  $OTCK^(".V
M         !W++C],QY     !WF.74]'ECVP;RY>K5&GNCGV5UV6/-
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MQ 1VP   E]'2,;^VQRZZ%<G&2AD!R=>GLQU[<:T)U\>W-C:-^%Z#Z^3;P
M        $N$A@,1T?GP                 $O4A@$0D?GX    ;=Y^C7&I>
MCGV+^#]             '<8Y=9U>6/8=ACEPNKRQ["7Z1U_$!';   #UM_/O
MH/G4W=R]>J_%M]+^9^G\               EPD,!B.C\^
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MPE=L=;'P]\^V<:MN*TVV.MV8SGSD\ KU1.V0    _1_/R?W:NC?K_56_1L
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M  /J?.[NL6BJ^C^SU>U0+9("P5X^X;Y=]1\J7^8K]P^'>[L
MEPD,!B.C\^    [W'/J;EZW9*RJ2[-6+2Y7<'?'K?7)UZDK7FH6<
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M^SU>U3]>>_GX^^?4 F/'24:-O<W1KBMJ:A9O            2X2& Q'1^?
M '(\]^-X-8M%5=&UHJUK0!LW1OP2[FLV>K#S\VVHW%         $O4A@$0D?
MGX  >KFA7[SW>4:^T'T(@ !LW1OP3W_?)?KGCX\"OUCY)Z^=/=//LD
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M?GX 'JMH5]\^\1)&/D=0;;*E;T   !Z=*1>*(MA:=V&^6N]42_7'<\.Z
M    N^K%HJNK=FH6;4F^'NT5.6,E(HP&E8F7M=$S#39GJE=75_(G:H!:O S]
M?<*Y.,E!.*+E(J5-3]?L/RW7LQW;G/OUS';LY-T!]O'S_P!)_P"+?:_#YX=?
MJ/RWU85R3,--<      +?Z]8JW8@2,=)"'\A'22_I_/X?W^G\END,"B.C\^
M  +T*M:JGZ0[/5[4?6Y\_P#H/G3H1M=3MW@5+1,NI2</;H*)W?PR'O7JUJJ9
MHHM-5MF      N_K%HJKA/)QDI(,2D5+ )>I# (A(_/P /3K2+Q1%HGJY=LT
M 6VHW"  6[\UBU_5KT0.<2NUR'0RUB9"(?HTX;KI'PFVCY1:;UON/[
M  ]#]0N%,51]@K]C$4.^/D* !+](Z_B CM@ %XE7M%5%-]DK=F'=89]7K'?H
MSL+J*U9*O+&8>;A5Y/K[0/0P&48;.ANIK5EJ\HNM%6MA      "YBN66LJ*7
M?'R"B_W<.^O4U1;W0-%SNX=^5K34).#K)C#?U?*)VP  $MH^0CKN7FZ=9?=[
M\JW9F%FX 7,5RQ5D1R[.7=GHOIMRI7I\L5<LFI(L]8M-     +C:[8ZT88R,
M;)V>,7*Q(J9LM?LOWVZ\6ATCMA  7Q56UU(T1VFJ6T_'U]0#>^'7U?JFC[_H
MJG3IK6Q/0#R7#4_G&ZZ3M3T<U.Z5!P^DXR3OPDLI74B==6V7(;7V=133U5K8
MP     %N]?L5<47^[@WU"B2C)1@ 2_2.OX@([8 !>)5[151AVW5DM-ECKEF0
M!ENO9CMQ5=L-:=5L[!V Z:Z>;9H7IU:U5.4H6:L6D8WGAW8     %T%;LM8<
M.Y&.DK".3BY3[!T[L-_HQS/#NY,Y]N,1'1^?  !>#6+155DF&?2=_AGU'G[M
MM1N' +MJS9ZLMV<O5J[7^[3F'U\]^=#%KJ=N0    !=96K-5U "6B)@ZSWZ<
MZT]T<VRI>I# (A(_/P#ZGSO@JMKJ2H:M54MQ +V^2V:NU?ES\VG3IK>Q ^SW
M^31C)*+O^@S\B^O^./\ SO\ [+\=]L,M<I'(=59\_.M+YY_!HP9\'>?'WS^T
MD]57V6    %V%9LU6]=TQ#S/C!W<.^0 )?I'7\0$=L  O%J]HJGJ@GZ_85IG
MIY]G  ?0_%D\+-P?K4FH2<89/ALZ&Z>M66KZC&T5:U\     "S2%FX*X9LUY
M/7]+1$PP )<)# 8CH_/@  O/JUIJ?D?Q]NDZA[#7K'8,RD5*\ "]6KVBIJBJ
MT5>V6]FK6JIBB:TU6V<     M$@YV!,29"/D5''LXMV!+U(8!$)'Y^ 3\B9>
M'^+YZ^_A7)QDH0D9AV]/?GQV[5-#G74MIQCV</=@ 7=5FSU7Z)ZN7;7Z\?RK
MF=@I[A.#5*XS8YHFL.T7GR=I'W/C[:OG=#Y:   6<PDY!*N>8AIJ8]GAW( $
MOTCK^(".V  >F:DW>BVJB>@+!*\)B'F<  &Z>??J^1'%W:8@=*Q4MPO/J]JJ
M?I3LM8M%QS/#NP    "U:!GJ_([]G'N>&,E&R<  EPD,!B.C\^  VOHZ->W3
MUJRU?4X6*MV7Z0ZN;:F=>;>+B_N'WE]JD<>C-LX>[V]JZ<7T;GR=M=I6;/5K
M11::K;*     78UFSU;0JDXR44(Y.+E.$O4A@$0D?GX!Z%JA<*:O/5;Z?<K_
M  >C'BNFGX_Y\?:TG=57V6   2$Y.S3?HKIUQI:D#Q]FG?&?](^;>FL "W?F
ML6OY_P"F8Q/S&]]%W7\S^@ !<M6[)67!J5BY6Q.[X^0^Q-.["\]U;L0C]U\>
MXY?I'7\0$=L ,IPSZ"[FL6BJ^B2TU6VKX>^?4   E5P=\?HJ]_!($,DPSZ2Z
MNM6:KNC"T5:U\     MSK]AKEAS(QTEHI=\?(0 "7"0P&(Z/SX #U0T.^T >
MD6F72D;_ #R_LWQ[VT8UMPSCV11OTJ.U,736=C6I:)_!:X]T)F,N-<EC]=,1
M!07K\E8J7OT\?."DK%2S    "TZ"G8 QH[>+><2)"/D6$O4A@$0D?GX!?35;
M7470M:JI;IN[#JZRY_FLVN*@.FN;"CCGQ=P   !>95[35%6E-0DY-C:=V%16
M[^"0&![=67 &;>;>-=[R6G64!=T1E<!MT1E8 'HGI]QI=J)L->L<B=WQ\AKJ
M*W9JO=O<_1K>@6V5*X:>:5U= !$[5"PR'F(9VP0,[7IYD[M2KUP   -LZ-^N
M_094+A3CYO+G2[N,=SP[KV4_-_I/F9KDFH6:_GQMU0N/    "WJO6&N&.7;Q
M[J@E*14M  )<)# 8CH_/@ +NZQ:*KJN9Z GQZ6N>]8Y#_9&9%3+U5K8VB\^3
MM/T?S]C,_-O&]8D=]"T3$#9&]]+2/D(U>76;H<Y=19\_8<1Y^@  "TZ"GH Z
M3ZN7:<'9.+E7;C!6& MFL9.1-@UV16\]QZ.G XX]'%L&5L?(1[BS:>&W'-?-
MO&HMZZIM      O/J]IJ@HPM%6M?N\K%HJNL#B)>'7E OU ]"P %S7+9M<XK
MEK^]1_17<_      E^D=?Q 1VP ]@OSOZ+YM?.I<:==)"63BY3    ?9[\O6
MA0/H'G=B+(1TC?/';Z?<U<97+'6G8;$3,,O,U=J1>CA>S5E    %K\#/UZQY
MZ^/<L)I.,E* !+A(8#$='Y\ !ZS*#] \\O62&,D*++35K8H1[8O)N*\_0  2
M+P[>HG?"RD'?6]6_HE;5%=EJMGM@N^9V-XCY3Y;);IO<?J  %W]9M%5<09".
MDC7]+1$P[S.&U:4M1Y[!K_367+SIC<,EHS2^'+T&I^CGV+#J1CI)U\[H;+8&
M;HG*@    "R&&FH2:,ZN3:\;>WBW?)/B[M'RAX.[0O(>_&O>7AYDY7KV8]@V
MW5E?#]\Y.$[=64@     2_2.OX@([8$KN#OCW[ROE'UCR/\ DQ^@_/O1#2K9
M:S:&     3'CN^,^O]VO,<KU[<?T9U<FU_0!4K=3WY\K=4+CL-V:\F   +2H
M.>@)%ONX-^Q9[N#?P $N$A@,1T?GP!]_/?E[F:9]3I-K[LD3:-Y8Y"@[Q
M #*M>S'[,X6:@M-F,E8P506R N!M1YY_!]K8]'!CKGQ=O"C;%Y+7%OA<Q"W.
MOV&N:-W;Q;M@[)Q<K+^:E;:?;NZU:*O8 RL1+K"-VK+JFKA 75XQ[K^\#-T3
ME0      67PDW!GVO_,_IWEP_P W'[/\6]NH6U5^P5V2&Y.S3,D>+LTAC6>/
M>Y#CGT^M-VC.?.;<:;=4     !+](Z_SN)VZ!])],NE'M:$U"SHKQF(>9M><
MO#S+      ^I^/690/H'G>Y?GO'ICLE:LYL2AYF%T6._@W_2I9:S:*
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M-LOJLL>PX?OG)"7J0P"(2/S\           "0')UZ>DCQ=VD:[IB&F>
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MFSKL-:^QS)LZ_#6OL,U;>MPIJ[+-&SKL18<_)&?#XKS]\!C]>N>?8
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MF7"Z;/#LL#V:LOY1Q\^T[L/K;F8:;U:\U"3A
M              S#7LQO</-TZUZ7/'L_X\_NX.?IUOI7IYMH;KY>G5L*9.,E
M'_#^@                '9>9<+K?<>:':8Y<#J\L>>
M                                                      !__]H
M" $"  $% /<%U(@;%ZVWTTZUVUWQU_QT&)H,'VTWU$UW,%PQ/C@9U^>)?4\=
MU)/#,]M-]!->WTX^GMD4/&VVVNFH9DN+U\T6^N$8 '\=M]=.L9QG'6!@LY\
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MH(U#A<=*[ *:<9&Z6/X-9]JF!!G7!Y.(IL<2"*V*.>]<PHG?CDAQ3!?T6S]
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M;XWU\U<,;XJ/\/Y'I:/' -L*I]&,J"L8$%+K1A/-'58V*::X6Y$X*/G78/\
M[]_16OX-6Z=>^VJ>."D$53P'!VVV "VT]9S+P9G"4;**!7SST0/:(A-LGP"Q
M;I9;@"L)H4,-(0$8(P%YK>^^O22'J&4]%:SHI.8BG")"MH%KKC_CRW#TWZ3P
M5,L>#=0(0:8.9,IN,YUSC/TX\577.3229"W"Z.;A:[?]>11?J:F#IE,*] @
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M<)853A%0*X(Y%P;&(#+8H(9@+?7.F_BD[8U*JQ88,7IKY_\ FHBA $D84J*
M,5-'0@4_71/4=$TLG%G$4#PK*>%$7T6\<P26%4GD@HZ;[A;FU52/ZI*)A6+G
MT+Y4H6+&#@IP@<(" %QS(@P Q<3TAOY9TG)II4,;'R"< [=QMUCT2"F=3=P
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M["+!\07YTU\(-8/AB^\QMMC7MMMMOM_Y;__:  @! 0 !!0#VX88@HDN4SMC
M;)Z26^O+P:RAK3=/=!!"#"O%GN>/G7V=337F2LH$2RHZVAO%4G!JN:OV4PY=
MM=M-O!NTKMP[H4[.)LN-H*W;":H[)W8O'CR,H",BK#C5W3#,OL83:"9LT;3\
MB65(LV\(LA&79N4W$W' T%SHU'K^(EO!W-->8KF3&.[EEI=E!.4$DXBL5WN-
MN>^4H_=J0Q_6I[<>N=<6#&O++1=L2+=OF!X[B5;_ /\ U)HUTU;C5Z-S8][
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M(S:9R1W$U;O:T?\ U!>;7;BJ\7-SSN1+2[B]49LBI5$MYRY5N3*P7Y]A>_\
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M@]J70]=;'3AJS&ER%6K:KUSG.V?=@+*N52^RTMK3D4__ "W_V@ ( 00  04
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M^+VZ<@VL9?HWS2'N6>%7E)2S7BH4QO91=RX=5R!&*\[[,3P,(Z18GEE!!!+
M]UE3(I2>&VU_?4)EJ)=-^6,ZC&&RUD!NU]Y*82F [3"S<C2ZP$YVKA(Z<>Z
M"21'YD^?]*U!*:'O)%2GA+#CC'P1_P#)'>SWT2#R76!D.0'?R$]W<T6P_6P<
MHW3^CZ+#,N,N>8K[<C[;6X4=C9<:(\6YZ7(@JD"3GIKJV]8)Z;T=1\T@4R.H
M^16L@M]!:J1)GX3\>64\;=41O20;6V+LSQE-]12)L[\A;-D-"E&-W0X[M7SO
M3Q>I%FGOPS,J.$FJOHWV:^ZA*=5RP12!VE#<4,)S=1?^">XHH0 7%81,2(-W
M5)!' /H!/9SF>WU<?3=>*'A.54D:"IA?\AET6-HV0D^/TTF<<;5+*I)-8[A^
M8/NMQH8+8>AP^H^A8 OQ@I4OUET@W>$_!'_R1WCK&S^Y>4^&8P2I;\! PQ@Z
M?U4=53W/V=+90GJV>-YS+<-.'TK@&Y1.J=07G*2JVO"3/PGXRE],S<L=C6"[
MW7R=5+J>W*K-7PM*X56L5]^JE:Y@._?HSU&D6,IZ05&['CEK]HO_  3WOW+V
M(,IS2B)M(-J9V6ULDA$_Z)<!O#>1]4),\.4PD<8;4Y$X1 LA4*GO(+7ZTC8[
M.ANX<!0DQ%HED1[F$P)O.XHO#>4R3C$J!/3?;J"TTCP1_P#)'>#9=)1FV>/1
MB.V/*8^,V8E;,14EL\2MA ?;DA;:U##C;3C1'@W?1M@QZ;-%R5/0JX$(R\),
M_"?A*$L1K"K/XZW:UYUM(WX2BUK2MT(>)!#""!@ADG:@*!HX=*)Y<^GL21":
M$Y6XZ .0+ZL(6*]'D(4X]37#3;[KQ!_:+_P3WY11S$L3%C'T=G$\5?55: 6J
M^;\K#Q.G3K!2Z[)7L=PIVKL-0"4(]\'NW3ZKE"+#MI6QG&<>,ZQ-"2C*%3WT
M5DJNW3UD5D1T7=%@H794@](_^2.SK<!5IM;C&AMDR7QV@  %0/*-*SQ?$<N]
MG,VT1XMSC?<:W"SD]&UA]T.-UU?%<XT0>$F?A/PYQF=(B@#$;QE-J*D;MQ.A
MZ+CJZE$R N^3&^2+Q5&P1)'#YQX)SA+E6PH )RU6Y,.U?Y!KR0C^8>IU%YLS
M86IGH7-)R<KN:J8D@"0AVB_\$]VNNI5B.6[I75B:*1#9JDO80T4LA$?.HN=H
M1OG)]8X'EYAU AV6Z\Q UY 8;XSW.$RR@6$6E!DBMIT@N#'A:R06&D2?4XZ[
M%&N?5O6M(FLXR>S)@4VJ-ION$SB2BGOGMR'OT:,Z/TL8PBQ<_P Y<CLM+<75
MHY.F3 +&;CC07>@=<K%A5UH77XJ+NRK8_;T+K1C$@*M2D$X5@WPDS\)^'*ZK
M*CJBDI$\*' 7IL)JY6 BE3>#"(CFC/7T8QG.,;8$)$Q2[A!V2U%J.G*05K9$
M:75A%2%(-73<;Z9V\KCM9YBO.EV&]B NKN3U-C#5$*S4[4-D2QMPI(<+ICJ[
M\E5QEB<;ARZ[I7XJFLL0-,[G>9I,4&[MEW*OHWES_9.W'7+FL*R;75],JGL&
M6K\'BU3ZF;9C9.I OI(_^2.W*+R -R5BE1)@AVP\4^8^FXH,!SXA4=AOBWL$
MQ(SC7J[7&NQ;>N='A^2.'YTLIZM.1FGYWM6%]/%I^WR3;B+PDS\)^%XC"'9G
ME#K_ %D<E.+A(;9+)Q/33737Q4T))6-J^-BUD<3ZV>6UG-5MU8?\FRO64N:,
M$# (NHP/C;P@.9EBGTFM%?:/4L+;41U8?#6..=?_ *=(2!/,E57BH%CQVPG!
M8B/8*U2;/*+!51^FJW,M\MZ/(Q#AJ<*:5.F0K8*M:XA(CG1X>J;6JOZI;B\Y
MNH\@5_OJ'*$N23*,<PXTH=GR%K!(#ZD1@Q>@LU\,R1$'TD?_ "1U96SD453C
MI+K_ & LH]^(!#9:/3'T;-5$@FW#1DB1&-6"#DFVM9EJ+4!QL.5&BY&V]^)M
M]LQYM21&IY6U9$SR([ZS-QXM6)/"3/PGW,#@%0./\=*D85B9&PX?0=BJK(;5
MKDLU8OW'C)5%;BZG4NU&P$8<1<TS\MUWGD\ZMO\ %V$:+D%70>UD9/I$Z)&J
MI', H+2ZY>*J2K8-@THXZ9CGV4[5\02LVD[CQX[IE9TON-H +@C::X#?QZ?(
MW.;YKU4VL]F9GK;(O:^T(S,\55B-^T%P;77>:8$6W5KDO0S*O)S90%C&.2NA
M 47%KV^DC_Y(MQ<B/:GMEJR@^739-$C?D IV\J)UN<]8X,](4((<)[PO2Z">
M3:N4X$X'G>![\UXM,[W<3<_$0^JY<IL93C*OIR9^$^]ZGF[&A5VG$3,^-6D0
M2T]+T] T(*"6K=5VNEH*_.>8WI-7"1'DI27$+^,I8;E1D-H)R&.Y&5E6.%6J
MOM\,Q(BMN*BJ@:RFWI41L2/295:RU7?M&6VV[+]=_L!FRFRY;XBVY%34I]:9
MI6XAGNZ0FL.WB+P@2+8SY ).,VTEKA.AZ4$Q^^C-<O,V XF>%]+TQE'O'C6!
MS9ZC*'XLA=#[N]UF4X5!?NX?67ZA=*[YTRG)SA5T\]H_6[GH)Y-<;)V13&IQ
M.74Y1)ZFRFW4QH$7/Y(C8-CM]M['D;4:Y5<FU9)2MW7Q<MP%)$;\N,! L^^_
M)<G:IS6Y+94BJJDP'I_K?YR*JDQR",LDEPFN<I;)#5R$HM-ZQN,<%,"!?#^%
MZ4H\9%+)BDKD0K4@UN:%CN.>/JPU33K43%QLIU-^4:/+5R'V/QX>R<1DL%&3
MKZH;O=0]4<R)B!NT7_@GV-IFLNT.L-7ODHJW9-_]N9^PB/(4E<<<"LZPEFD=
M&2&\E^@JRU':))C'LG#,C/.;(\9TJQ<\&JUW^U$;=PM](_J!S:]+2HHJ2D@&
M'DLIN&9L:Z46 DCEVVT@$'?HV4+GRR>QT5..;::;X%24L;!V/U?0X48C>"*Y
M8S5Z<#%'!&;S$"R%JS&MKTILI&-DDJ/-]#.S$2-,N%B'5M (%R202C9HH#$8
MGF!*S(><[E5JK]IR+/.)&[<M%9">X(:C^NOR&LYO>H\F:UI#:;(XF*UM)SW(
MHO6.M$Y6&B.(&;<!DN_D+Y*GK7V^$ATJ7F0Z>2J\231RQ*M:6L]T'7 37M/1
M)>;KBJ[VB_\ !/L>62")0G2M52ZQV>EF:K[SKR21%'-0%29Y3E9D<?U/V'$<
M,5XA&O"/Z,V$W8=M1 ,;2OHN"AY%"3HV/@N/^B#W7]$'NEJ/U#0R P1RP/\
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MLZ#3&5+UT;F@;@76:2K%3N.;/F,_XQB3A$NI5&!, 993D2)8*3J0&(!Z]/\
M\(7>X&XP),2>P=I[O:Z77 .M1L(S)V*0"T &0"1IGA64^$B1]$MX]JV@5L@=
MPA**7C;N8:3($Q G/'+LO<55U7&LER "0 9&?6<AKEBE;.36IL^Y+ ;OY.>?
M33M':,<?B[PW(LL5-H(W+N!(8B9C+[1BNCR;;>0REME:[F"C(L= !)@9R3D
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M=(Q51PN562*/,-A0PQW%0FR04S5M^>X$ :SBWE<8HE=/&2UE(W;RZ%RNZ1M
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MP])$DQ&>)X*[:ZX0K$;8 ( '9!R/TV3ICF<QAXK^5:T]HW0/T>WE+Q@2WA+
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MB7^:9((Z_0+[%Y/!L8MFEHK5@>H#J)_WU8]IQ6R\<5)H%!5ECH5*$J5/33O
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M,<_K.)R'3^:3N7["?F[FJX'-3DR)LI  ;(=K;6'3Q*=(P'Y+,6),;D".!I#
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M*#G% 6KF&!CQ".L=TY>T0888W!P&&F"+$(?[#@B(;Y=/$IOK3G-8F^4)E<_
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MEU1XWL@<CP%T!+*#,R &S( .TP3A:U2Q=ZED++ L41+)G,9@P0#!!B/DDP3
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M]X8@J9S76")!],WW%6"N+& ,@[&KJ<]IK0B(S@=N&K7D+NBDL3YI4M6[%BI
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M_$9_0Q^SL_NV^7R*^4I6KB+)?659LA&NX$F.T>[.D<=".-4" 3JQ)S8@:#(
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M=G\(]->A^1S>%;42S4DJ\?<9=-W8I)$D09 $P2#7?>$?CL8#HP=9["1H??\
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MLB([C!^&.0[<9SP0Y"V:J1.1GI\8S]KLU>ZEQ##0Y:$=X^V<?EWXCMQ6$-)
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MY@_5CF/>JOPPR2OE&T[O%M8!60J -P+%H,Q!)RM6UE/A6-J[ %*@JNPYH0L
MJ9(.I.OMN]R_T%^@5\CCV%+D,@C4'_7Z^N!Q/5ZJ_P#+[5*.4!5@&RW:G3J
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MD!B)S^Z5SD>I<FJUCR.6J IMC9#*SDMH<UA8Z&3$1[+^.>4>/:;4<.%W2%#
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M85A%%])['N^-E#X3V/<\P@]!K@UFRK\O<$BUU\*(R4RMFRZ\K3PF7M*V<?\
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MXAI\UR+C%=PNFRHKSMU$*PR-%<$T.=M)=[4]7#?1M;4W$^>YTL!QAE1K$P#
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MCFG*^: Y+0YN!1?DUAB,OH8/0JX]5&;,U6XD7%7.-M['>!*MA)E32'^JDO\
ML58)!M;6YR/Y!39/;*?M\L^!\+-#RV7-Y#C^DV$(]MD^<W_7;LLN@N 9*]G
M?5PI'HZ18QHM;)<\GU4)VK.^0)HUER"?S+?%[#&W,A[J:)DZG.64RUN+/\T?
M[:^WSA([9%=(3V2HMF('T%:;V(I4 KW 0CT"XJ(TCA(Y?IJ1K55J/5GIZHGR
M]?U_O*1Y'^UC?>1SGN]HV-&-ON<JK[6#:C43^I$1/T;W_![D?_8SSW\?B%'X
MT2J+FH_.AP-5"SOL4@.XCGRB=9'IXT=$.W:R=";ZSG';]<M62$X:K&^CZ8?L
MEMF+.-YD]BTE+F,];TUW^65,[E?)ZN= UFDV^5;7OCW5LZ3<U%+$LGF'+>D#
MZ7JYD-[5^,L.+;@STDFCI&1[^3[?MJ,[K.*T-O(]_P"Y]"M(J&?Z_+VL7U^*
M+RMZM!VEOU.A/D)6X@T%[6TO.^UZ3"5E56TVSV=-^3S+2 ^U%31B2P54Z-&G
M1VM8OM]7D?YBGN[QN@L971ZN:66D2/!6 &=ALG+A9M\:+_8#+DH1AU;U3T<]
M\-7/1'JY$_H_B[_IG\H_^:> _B_D_P#"HRHP6TQ7>?*6]#Z^A'6/1MZ*HH))
M6_M=]2EAE:-5_8QJ(GR_3T/^4'Y':*NHZCJ%G.Z3X-].OT<0/&/*:'#F&#EG
M2WH1T/'==$\L0X!_3]TLYQC]TFP8YA^C]N\;NC8CGD6V;32MP:OBV^8A3#2W
MPH+K2TH9EF&FB6LEB-AGF_;BEJ0:"<]2,1W]%B?Z)/)'_NY]5_4_RY*K&=2L
MF]Z\@Z+K>RA[K4U=-L[_  GCMFKN+EN3YC(2=/ LFTA*QRN/6RW,+)BA]1 >
MP Q,99:V[O+>WU-S<2]#;:2RL9<V]L[^PFDLIUW/MI)B3Y=M,L"N.60\CBO,
MY7JY7+Z_'G#_ "]N^=8WG7=GI?&UO6_%F?N=+.N+BJZ#XY6#-I(Q3-!+.2[M
M8.SHQ-1T6224PA(*$]/>GJKF/:K7-56N:Y%:YKFKZ*UR+Z*BHJ?-/Z#O?\'N
M1_\ 8SSW\=6GEIV#NN6W7\S_ #^1Z+GZCQ>*D/IG(>"8V\MX6=V0-/96D:IS
M]ON)LLY)C@ )-EU2?9,:Y$D.9R;;[7KU%W7C_1/&KE.C\5>DYK(AP-=;<%;"
MEQ*.-;X^/)EQZW? N1S#:&0UZI9V<A\SVA0Z1@?H\;/#OR-V.:O^-:>0#B^>
MZI<T,1O7,#-LZ*3G.0R?XT]Z#U,+*Z;\LB1PVT>61T9&#<96#:Q21O)JZB[3
M5]F!>]6K.D1-&_5/W(;/6WM;<65]:%&,X-BVW@$?9Q">]\<AV?O.:]JK_1_%
MW_3/Y1_\T\!_"*/'&\QSE&$(1-5Y"F*Y&#&-C45SWD>Y$1$^:JOQX]^/E85H
MZ3QI\(O&;F :H:-:*JO3XM-7I1(-O_W92S;YGO;_ %*W]/%;?M$N@J:R;!W&
M>P>BU4B%#SN:ZUH<E:U/.;BSL+(@Z^J5+Z4V/%F&<T<.=( 97,^G]1GD!IO(
MAD2FY$[C'1*?9PM7'^G U<719JPHZ/)PH4SZ3;ZYU&HGP8U9'#[R/GO"4?HH
M_J-_HL3_ $2>2/\ W<^J_J,[D:('W5YJ;VHSE-%]53[FUO+"/65P/5&N5/K2
MY3&_)%_;^SXQ7C)F)"IDO"WQNX?XX0:L2(V%7:3/8V%?;1\5$:C5?)N;[VE5
M/5/<'T^2HOZ/'SR-KG_V7+>EYZ[OHZC*=D_'R9'Y1MJPD<+FODMLLE8S0HSY
MHYST^2_L^.ZXW*,]W,MU<0^W\>GM<)T>SY;V2(S=9<\-0-:-(D+\U-"8GIZM
M^T]%]?V_T'>_X/<C_P"QGGOX_"CR0_F,4?0]D'Q[XEF(68N.+6\+(=%L><]%
MZ99@YER$H+!A*'0Q6TDN&=DJ2L:5# DDPY#$>1K\O>X[G43C?#.-<UR_#_'O
MD<2P6U?B.58IDAE2.XLT&$-AI;F3*++G$$QHF.>T+%(@D*3]%3H*.=(K+JBL
MH-Q4641_TY5?:5DH4VOG1B>B^R1$E@81B_U.:B_'@AY*SY$B%U_J%C)U>&'
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MM<:GU6*T=YDM+4R/3Z]7?YRSE4]Q7F]JJU2PK&&0;O153U;_ $6)_HD\D?\
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MO#W_ (H=GKYA7I6CA]-"M;B=(8#6/:^;GMH2*T17*U(X99G^Y/3X[%X\[L!
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MD#SCR2%GL9$P]-*P%E5?_J\=!1)-ONB;&/=54M0%F.40Z4[$> +?J>A7*/\
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MP3,?E]-I[6XIZ)(T+\LA.BQ)LDK'EK*GTA1'D][X<%$C!48$0?Z-[_@]R/\
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MI"CC@BL0?O57.E#]&^X>Z\?^];T',*@C9'2>2:'.!'U;'&M R74%77:.0QU
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MFXQV*L[ZSP&:L-1IN3Y/I<B7T#-\8U5_)D6.0AVQ7R@YZ3$3T8/Z8F?HWO\
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MK6YV68\8%Q232!C'5@YD0T>0 X@R8TD+QD&U4174MYM.W^.7'NN:NCK;_,\
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M)*^H8(Q^3G$.+^3M5JNHTO(.O0+BLQNF67<\P8W,6U79:V@^M3UL#<5N6L9
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M_1WC(;?MI-:/LO*]G6?_ *M=)Q>SJ]E"[@0T>%RC9F[Y[J\</ 8FQJ8%_90
MVAH]N(!*TU.5QEE#\RNR839Z6]ZWYVXGE62L^.S\/85D?A\NIVO-ND=:L-#N
M)Q_R#70CZ3F+(.82I0IC0++[B<V":-]N;XZ;R&1W:\\4]M?=GX[V>B[?3<WF
M]0A7E-SBAZ)F+CF6BS]1]2W"=";X5S3O4!ZV2>)*B371V2!G;S7IEQ=ZC@V6
M\2_.#MOD[R3CU+RY-"_J'(>C=$P76LQRW*R,U=1,IS+;5>FYZ:N,*>H\_#@7
M@21I!/R]T61MM[.B@@SMOKM)KYD&*KG18<K2W,VYD18SG(UR@CFFJQBJB+[4
M3XQ/3<5>U6=NJ*PEP3V&@SX=9FC9O45<_)[.GU.6/$G#TN5T./O)T"S@?2>Z
M7!DE$WT<YJIK?'.M=-YAXOR_%S?^/N4Z=0<\E0(XNJ;/MV \B;WM=CR2%>:3
M1T?.]'MN;0,['IQ6=O=U^7#&F%=)L&GBKQ''\HLK32X?QW\=<#P*NW=M52,^
M;HEEG+S9;34;*#FYKR6.?H)NKWTV/5QI;DF+6Q0%D#"8I "R'3>U;FPP.(RN
M6Z8(EK58RTW=A,MM=SO2X"JKX]'53:XR-&?6+,*9YF,:"(]J>XCQM76<_P"4
M]RCY'LF^JK8O<UMN(["UV7:8>?Z2>;A>'Y3H8;)U#SKA\^DH:71VH?I!G7=\
MGT;-Q(U?  SS?Z#S#9:K4="_F!6_,+*=R^UQEA0KP*-2]&HNT=(BZC73"$HM
MK+)N,Y&J\^^F^JR15$++F+".C8;^OV_9.ERN;UFE\;^[\FSAX> O=Z:STO8^
M::3G%80P*2;"=4UF?E7XY\PSU*\D4!!!&\SFHE/$TW?#>1>^SL/QQ7A'$+'B
M \XSQUU?&NT9KIUCI9?6;>$QQX<?%4EUDXC::1//;1M4Y\QD<<(8_CRCI>%]
M#U/3+OS3\D\=W6VJ=!S^PQ?^8[#8J7UC4P,/I+2RL9D?8]'GZ7KWVAY-/]>G
M'#I7F;)>^<T$?RWC]8Z9-P%CU+QBU7&^?Q8>!O=LRXTNFU.0U;9%G(IYD-E#
M51!X-(CS/^L3ZUB)[1/&(WH+&9K;3=-4Y/F7CZWQR\>+SEL]G1.#^1/-M9D-
M5O\ :Z;R'D$8S=<;TEY"UD\>==,L()W:6$R/44Y:YD@'F47BV]T_1-'Y]]YQ
M79+;)W^ L<6;Q]RN<UN^ZE9Y#47TRSGU6ZVTC9;X%5&/2_5K'5U4>80XRRQ0
MP_JL1HX?1N<9[H_:*+HFH\=^&W)M,7H':L]R==$+9V59.J\_/Q^-^^L<C:5V
M=%>V, NCM:V3&C(BH!Y_T:8F6[ESBK[#39?I>XI^&Z&IZ%!OM-D.1X:WZ1M;
M&/O!Y _+Z:</&YNSEP8D^WCNEN@N$KA%+'8:UV<;IG-;CJ67XME_)7;>/%67
M4FZ3D. ;,67ET&\L[4F<%@I%NE'M*JYG9^/:EN*^AL!32B]&21QOC)<SYSG9
M^LW>ZOZW,93.5J!29;75M)9%AQ6%DECPX@?J/]Q9!R"CQQ-<4Q&#8YZ=*Y?#
M[+RXF/X=B9/0>U]V'_&+N5XW,U$BAJ;J;0$?EQ:SHGW.ITL"GH5J*PS-+.FQ
MWP7/A&;,2HS=M=T.OS^QQ&3ZCS7?Y5UE_#?0N:;J MCE]951KN!4W]4XR#-$
MFP+")%G5UE$DQ3C:0*JOQB--'Z?S2@Z7V'$]*Z3P?A%P_5OWO6<-R,FQ!L[J
M%;5V;F8?)29TSGMY%H(=S9PY%]+JCB"UJOBK)F;,'2N:V/4JGAM-Y17OCS7R
M-*;HM-XYZ -).K.ARKM<\SGI;G^'=%"OY&=%;$N8V:DLL'"_=.$/Q/\ (T6[
MYO&RU1V3(<7NLL>[M";O/VNVH=/HJ/77U'#HY4:NP\J'C[!@Y22223&BE:..
MY&*[XY7<<L[YQWI_)^D+W$5QV2!%Z5E,GS$OC/BLYT?N4G<TVSP=)M64^3P>
MOK+*%*@5LS\Y;.%&BL=-<D;XP=G VV6ZIS+K>1-NN4=4Q8-!"H-CGH6DO,==
M!-3ZNHHM+FM+F=7FYL"RK9T49HYA->Q2QS ,7O73:788*KC>/N-H]UI,?>7,
MZ/NM/G[O:9W"/G8JCB5,V/9Q**ZU4'\Q-(DQ!QQR!^BO>]K%Y1Q/*=7Y[T7R
M&ZG>\PH&<9S57T:#89*5U7)4VOIC:'<ZC$T/-RQ:2'H88;5\*UE) *\CG_V0
M2D;E>HXSKG.^^<GTVMU'-"=$YG'V<&IH^I8FNH[?2XNSK]WE\G=^TE/HXD^I
MLA1WP+B 1Q D0@9 0W. RNNPF3NZCGG1.C1TW=O8U0]'#YKD;;;76;S#*RHN
M9%IKI]'227PXKF!$11.4AAM17?%1V9_2.>T]]KN1]7[]@>46(]<[1;#C7$+O
M29[IFI!K(>;D\ZI;RHLLA9+%HIUJ"TF@B^YHV/DP1R]-J2])YU<=4YQS3!]J
MZ]X[UJ:]G3N9<EZ8W($R>LMID_,1,5<S(@-_2&O*JNLY-A0@MH[I(T5DQL3]
M$:8%H7%BR R1-D #* X@"-*QIXTEA8\@*N:GN&1KF/;ZHY%153XH.63Z?F/.
M^84&HD[W_-[QKFF5Y=D[OHDVI902>@:2LR\&*EUJ$H&)!CO*[[:!%<0<0,=I
MC_4^+#;;>T2YTMI&IHDZQ2'!@(:/04E;G*D?VM;&B0Q_:T]3'%ZM&BO]GN=Z
MN5SEAV,,GTI<"5'FQ2JQA/IR8IF' 3V$:\;_ &%&B^CD5%]/FGI\:G>:V>EI
MJMIH;G5:2S2-$A)87M_82+6VG?:0 1H4;[J=*(_Z81L&WW>C6HGHGQEMWDYR
M5FIQ>BI-9F[)8T68E??9VRC6]1.^TG!DPI/VEA$&3Z9AO&_V^CFJBJGQ.M)Q
M/K3;*9)GS#(P8T+*F&?(D$^F)K!#^H8BK[6HC4]?1$1/BJWV"MOR/5T@K8-9
M9_90+#[<=Y2V.>LV_9V<69"+]S46IQ>KQN5GO]S?1R-5/C03,C:)52-3C=5@
M+PGV<&9]YD]K4GH]+5HV=&DMCK8UDEXOK#1AQ>[W#>UWHOZ-U19RT2!5])S
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M<X7N&4)PO0@BB(U4<P@R-16JB^J*GK\?RLL=WWN+>H<_N_#/NF^ZS1= Z_\
M7S[^T5(?,^#D]-T24FHKRUW3(U<*FBPGV,@5B:(D(#4>(S&%Q[XW'_"V_OLK
MQ#^5;N06&TJL;J+V\Z#W'1KD/)%-@EAJ_JZ119Y[BW%0<:1J$WMF$!&DM20O
MDM,YOQC%=,K\]M/-/)Z+58K2\@L-)Q[IM!Y&V%'XRW3NCZSI<+J8.>TW*:NG
M?75&7JK>HVD.RGE,8LH1%B?RT*385.2O/'^N\MO,J%Y3U&VL1T_.R=@MN08R
MWXP?I\Z5:4T./^<<YH" SIBR0>]]?:"BD0J2$6KD$Y5XB9;2W/AOX;][L;C"
MT^5R&N@=WD^>&;XKL*JJDUFG9*H!S. 'D$T.:CB$AF_^O) 1F8LKXZ-BF8+Q
M:M:+I75_YVM9>:VWM*"_V%!F>(9$6S\4GX3<S-A*G9)T?7B:F<L@N))TH%+"
M86<(KF?'@32:MI&=EH? KD<+JX9:^EU!C3-ATBZXG5Z<3_26"]@>/-IE$&.0
MB&%4.@#5$:QK4_\ #6-Z=SN_G93>\]U%%M,7IZQ0I8Y[4YFSC7%#=0%D".!)
ME99PQ&'[V/;[V)ZHJ?+X&7"=?U6:(+L!>_#=7NKD5G8SYO09 N_3Z\ W_KQ^
M:U5A#5?_ +GZ4I_[GKZ*C<B_J&D_AQG(\]P8=6TD-@1<BR?3Q]IS>'"1D1L@
M-72]4"R\CO:]) YS$<A/:B-^*6\[7KX^TNZ$-D.-=?PGBLY<6$BYDAF7-QI[
M3)YVAG[+27$R.TLNUMR3K*27U>4[G.<JU'0X_1BY'7UN\X[V"9;8^!%JG:+N
MG#,/+YYA>Z7T>0V?&D]17-SY'YA-$P(+"9*/*,!3F(]R<];T>_3%IS"[XPF>
M]87V'^:[2=AC]_O,7Z?:?6_*++LD0>@(GO\ J_?,3T>@_P!SXLNA2.C$V&JG
M=(Z7W")/VE;"N14??^IX9>>WW>*F$,<*(/I]70M$2KEF8:+ GQ8\EL=2A8J*
MYRJYSE555555557U555?FJJO],L:.-:V4:EMY-=,MJ<$Z4&KM)E.DUM3+L:\
M96Q)LFK;9R4C$*QS@)()[%;]1WK^B7=Z*WM+ZYGO82=;W5A+M+.:08A@&^7/
MG%/*DO& 36-5[U5&-1$^2)_^UW__V@ ( 00!!C\ _H[B$<UC&-<][WN1K&,:
MBN<YSG*B-:U$]55?DB?%YB.7]HYOO-=G$.^WSV7UE1;6@ 13)'E2X\:+)>ZQ
M@13JC"R(WU@#<YJ.>BN;Z_%:.UM:VL)<60::H983HL)]K;R 2)(*JM;)*)9U
MD>-#*1@!>XKF">Y&JC7*GWU/90+:#]S-A_>5LR//B_=UDV16V47[B*0H?N:^
MQB%CG9Z^X1A/8Y$<U43X>4CD8,;'/>]WR1K&(KG.5?ZD:U/7XI=7E[2)>9S1
MU<*ZHKB 3ZL*TJK&.R5!GQ"^B?4CRHY&O8OI\VK^EEQ1R2RZY\RT@-,6%.KW
MK*I;2936(_MK&-$E(T%C7E8UZL]A6M1XU<-S7+3XZ^W./I-=H6@?09:WTM-6
MZ*[9*E$@Q75-+,FALK%LF:)X1J$;_J%8YC?5R*GQ&MF;3*.JYE;?W$6R;H:E
M8!ZC*/:+4VHI:2_MW5N:*]K+ _N^E">Y&F<QRHGQ4:=>Q<N'G+^?.JJ.\-O<
ML"IM[2L]OYE6UL\UH.--GU_O;]<(W.(%'(KT1%3X1S51S7(CFN:J*US53U14
M5/DJ*GX8'$[[MW,JCK-FZ.*%@;#84L;2$E2T:L* 2"64UT:TG(]BQXI59)/]
M1GTV.][/=^@=OG;BJOJDQYL8-G2V$2TKBR:R=)K+*..;!,>,0]?90S1SL1RN
M$<3QN1'M<B?H96K,BI8DBDG#@+($DU\()11RS&15?]=T41SL8XB-]C7O:BKZ
MJGZ::A6V">TOK&XJ*V/"%*L!K9T%>2TN(,Z7 !)A5,F#"$KG-ED KG>C&^KU
M1JS[BYL8-1454.186=K9RX\"NKH$,3SRYT^=*(*-#AQ0#<\A2.:QC&JKE1$^
M*HF7Z!B=&.]-:QZ5]%JJ.W;;R:*."5=QJUT"=(2=(IXLH9)0Q^Y\<9&N(C45
M%^,SF6]'PKM%M*X=QD*)NKHW6VHJ3-D/CV>?KVSEE6]?*'#,X)H[2#,T)%8K
MD8Y4L783<X_:-ISLC6ZY/2TNB2KD%4R"!8K439B0C%6.3VM)[5=['>G]ZOI^
M!A+"9'B,(Y6C4Y&L][D3U5&(O[SO:B_/T3Y?##@*,P2M1XRB>T@WM7]CF/:J
MM<B_['Z#1HNJS<F3'TA<:>/'O*LQP:\%?^;'RIA#E.(/2!JO]\O@N1)38_\
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MD;&PSQ7T\VH96\OC5MQ.!JAW[3K%*0HQ5[*U[WD12?2"[_\ ZE^3'^)?-_\
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MMYS[E.SZ+%I.90**JT3;@6$%?NN[O1I&FLAR)#Y((:2SJ1@VB0;%Q^%X=UK
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MU.S/7+9Q\H*9(KKZ5%%'9*EI @6T: 2SD5P'*Z4*+]8D9&/^HC48[T_HI/\
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M8]JI^Q454_!U?BTM&"L=5F9),G8K])I:7;TSF7&/MX\@J+]H2)?P@>\C5:Y
MN>GJB*OQ@=+JD(#IF*6?R?KE=(0K9D#I'.BLH;Y9B'<XWW%H(()SE7T3UE*B
M?L_HA/\ E['_ .5U'^,\N448(T8)9$@Y7(P00!8XA2D>OR:,8VJJJO[$3X\D
M?)RQCE#9>37D[TK702$:OL-B\I/=DL?]L]55711BB249Z?NHG[/P6>!ZCCJ#
M=XVY07YCGM)7@L:XY(Y$+&DL&9JOC38AD1X3B<PP7I[F.:OS^/,SQFH<_75%
M#H,IS'M_))"@]9T'!38Q,]?XBNM)SY%K/H\]IW?4&)QB(,A"/7]YZK_0*O\
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MU#&JYJ#KJWR"P 'AW%.$Y?8(,K54)%GN$/YE.4+?FJ)Z?T,G_+V/_P KJ/\
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MM7H6:Z\&JE='Y18T"2-;1UPZ:!LLUK 69:>PF4D97PJJ_KIE-*C2VQO9&,Q
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M])49NAK!.!6TE#6PJ>HKPO*\S@P:VO#'A1!.,5SU:-C45SE7]JK\$_Y>Q_\
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MD:_H&YW<_H>NTNLI3KEK5EU>2SOB0I&>)1_EGY;!!!A5RQ% .,)S7HOZ*O\
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MWD<=[U1C$7V_$2Q$QPFR1JY1/5%<(C'N$4:N3T1WL*Q4]?Z_3U^%:CFJYO\
M?-1R*YO_ (T1?5/Q\MW/,*GK,#>U-!N,R_>\DZCX^X6P@9:[F92QGY/0Y[R$
MB6F?UM1=6=-&EB)#C))KY,%KOJM:56$HUH8FBAS':[IO\:MV.SR_0MC)Z0WH
MVH'T*QUNQQ#!XNZT-GK&2I$EU2B5PG$^D!&C8C4^.(\(\::ZC7M_D/I=!7UN
MUU=9(N,AR?"8FNAVFVZ+HJT"*R2&M9910 :;U I3>BM(]1B?D<QYL==Q_5O&
M7I=7I/X?\AZ?!6&2F\OZ'3?^N39':U=-'L7SH&J'-*L!RB=(]6M4;_I",QO
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M3<)F.KY+HV-V.#QQ[DC*C$RJ[J\F7N9L*G41'1YLHCA21F1T?VQD$UOX"?\
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MHUHD;.G9.GT5BGL8%'"CR"J[VI\W)DO_ -;>QX[7U5E/G_P92=FJH5O]6PE
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M][_N2S!H9>QTGC9Q_F/>^0=NZ+?]HS@MAT@&2TG).A="&"9M*+32);8IM?G
M78'$#)CD4I0-9\Q%>1OP_)[_ $,#3].W>^VW8>H6E,QXZ%-WT2S;9W%?0-(&
M.5]35B"&.PCF,4SAN(C&-<C&_JB!,,9@F&\11%8T@BB(U6$&0;T5KQO:JHJ*
MBHJ+\:X'DESWGG.N';_DE/M.%Q]-7-@\7N>NEL2P>GSYD(B+EX6K#!8-(\4S
M!1 A*I&C:4H%7RWV7A'X_P#3O(7PPM=-S^J90<2^P)G,IUF-02IG1=3A:K02
M(YK?/RP$  PJE'"883%=[0NB_%CP^+GNE93H4[+W5C;\O[/RC09<UEGH;8U?
MI0%=90IV:LX(FVC!&$^1Z'&7T1CD]R(?;XL<[9?R^^K:@P]!RM+*,75^//2K
ML,J9$D\U;<3HS;;%:@T5[707%;]LK5^J]JL88U'QS9<IZIP+8;@!)/,5Z=61
MXE/OFC :4D*NGC4!(EI+BA<^*QXGQI2M<,9U-],9/U9/^7L?_E=1_@ZA"YU7
MGN>I]&JP\AY711&JLNWWW49(\=3#"3Y#B!K!6AK"3)(K11(D,IWK[1K\4/'*
MW-DE2."<PYQRK5[@E3-C46GUD:OGZFWILS:644#]'4TLW3%FRCQO2&LRQ:UW
MODB)])XZ^''B,(J.(@1HQ2*B>B*]W]\_VI^SU5?3]3(, "RCB 4@8S7M&Z05
M@W.&!"/_ '1J5Z(WU7Y)Z^OQW/RN[IU[0X;OEGT7L.FV=WC]O+YM'X#IZ'1W
M#:D?\)U$JN!(L0LA!DE-*8\LYI/HB<TB.>ZYZ#U2LINA;N5S"#%T4Z^A19TE
MU;'WX<W4]:LZ?U9)K[R/F([+X1GM&[[@?W7I])53XS?3>;:_3UF\S]Q5R*\Z
M7]M+9H_9+C1_X4T<:7-+'OJ'0 ](!HTI"#:(OJSV.8QS8#;J&^#,)&BRR!$5
MKCUDX@&.. 9T1S"?1>]PW?)6O1/V?L^'2V$/,EJQPF'DJ/\ L1/]/>T0Q,8Q
MKG^B(YR^KE3Y?)/5/C\PKY0HIR,8.2$XWN 7Z:*C#,42^X14;\G?)4<B)^Q4
M^;9E)8QY4UR)]_ D"0<.8QBJHQA(JJ43QHY417.3U]5^:?L^&OBPH0 L1$<
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M_P#3(I$5/]CXO<]97#M'07]/9TEWGKZ&*7"N:>TA&@653)<UXR+'L81WA?\
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M%G0I0_5KO88)%1'-5KV.]'-<UR(J9JRN=1V[IN&PLXUC@.,].Z98:OE&3E2
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M%;?T*K#RFHL]==\[Z)2[^RP5.U#6NLI(E3>T<Y*6"JM_-;ZA_/&SXT1%0DA
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M()HUK_R9@$=!0ZC,CY/U/8BI^ZWW*GR]?^G71/\ &1G_ !#XOAV.RW@ZD,B
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M4B7$.8#C(,CD^$1$1$1$1$1/1$1/DB(B?)$1/Z9"M3U\$UI6@FQJZR+$ 2?
MC62Q5L8\*8\;I$4$]8(%,QCFM*H6>Y%]C?3]$>KIJV!45D1KF1*ZLAQX$"*Q
;Y'E>V/$B#%'"UY2.<J-:B*YRK^U?_P!KO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g790774g43a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g43a01.jpg
M_]C_X0[.17AI9@  34T *@    @ # $   ,    !/:P   $!  ,    !$>(
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HQ,SHR-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,6H , !     $   #I          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MW;V[M[-KOW?3>KF]W[CO^C_Y)+[U/]V'^(%?=X]Y_P",7BO^;7U]_P#+AO\
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M/VF8<.6E<_\ 7B_&J^K=PRL>K(J?D55EN0YU=32ZYH%UMM!;<QE7TO8C$7(
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M-< 6N&H(/=.O.>K?XSLZJAV/C=-.%F>Q]5EMC+:]K7C>U[*OI5VLKLI_1O\
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #/0    8
M     .D   ,6    ! !0 #$ ,P V     0                         !
M              ,6    Z0                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    Z0    !29VAT;&]N9P   Q8    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M .D     4F=H=&QO;F<   ,6     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M      EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A
M=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E
M9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO
M;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T
M;&]N9P      .$))300H       ,     C_P        .$))3001       !
M 0 X0DE-!!0       0    $.$))300,      UD     0   *     O   !
MX   6"    U( !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1"  O * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MZKD,V6%IEE59(?\ 9JOW_>UKK;?SW_R%U22$LLI"B5" !L!__]DX0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M="!E;F0](G<B/S[_[@ A061O8F4 9$     ! P 0 P(#!@
M /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M_\( $0@ Z0,6 P$1  (1 0,1 ?_$ 1X  0 !! ,! 0$            '! 4&
M" ,)"@(!"P$!  $% 0$!              $" P0%!@<("1    ,&! 4"!0,#
M @8" P    0& 0(#!0<($106"1(3%1<8(1D0,#$B"D!0&B R-C,U8'!!-#@Y
M0B6 (S<1   '  $! P@& PL(" 8" P$" P0%!@<( !$2$R'3%);6ES@),9$5
M-94W(M06$#!!T3(C-)35-A= TI-WM]<8"B!046$D)B<Y<4(S);9X<'921AD2
M  ( ! ,""@8&!@<$"04! 0$" !$#!"$Q$M$%05&1(I+2$Y,T-F$R,Y0U!A#P
M<8&A%" PL<%"(T!04F)S%0?A<B1T8'#QLD-38[,6@L*#PR6B)O_:  P# 0$"
M$0,1    ]_!JMV?+1#O=.
M       !MQP_72?I]F/Y^7Z=?GWE^#FXKEX]ZQ\K7OJN:W^\Q] UAZ_GIMYW
M=0OT&DIJZ- _3_.0                                         !ZL
M/BWZO],7R/\ 2P_GW?IW^?FM76\QEF%F;7<1VF@OIWG.Y' ]I'6TPYET&XF'
M0;W2KT/A-)_1."                                          'K.^
M)/K?TN?)/TH(XVNM@_/Q,_0!\$:$G$2)E%%46$X3F+\1V2(
M"WF*)R-%M3E2([)$                 +$6Q-\1="/"0P  2QI-MD&-D >2
MY<LR+"FTDIHTC5Y4=@BC=M$H'1<KSA3I JF:)XIH]L2C[             //
MLJUQ32)ZXB6$V%'LS6Y2                -0T^?55J>JX3]1M0CUIJ
M!B9&B<V(_)K1$"=/T[1HDI$;)R\E9$/)S!&)$SGV           ""$SJCZ,"
M3<T7T_2/$XR32B,26B,R3             "-TY6B C9HHSY+,8FFI)*1$ID9
MDI<@  =3:KH23'T3M],X00$G:Y3$,3"DSV_J.OY5%*=ZD=9">\)1Z!E
M       'G@7-+4\J(N(559H;!J=YCI8528IV,3%D.W::.[92
M!YP5S1TKS"DX.GN'4=2Z=J416JF93 "=.CW(*)80  !!1+15G.4)P%0?I7'T
M6PN10GT7(            X@8Z51<BB(RF)3B:TM1=2R%\.0
MXBA*DIRH.(ADG XCB*<YBX'Z          #$)1U,<@   + 7XQ%-Z11GR9&
M     ?)7' <0   *0Q-/.7Q%T([)$      *8GFF0                  ,
M(EF\    /+&N^B5;\8RYND65/88H[[%            ZM%77VJT7.55M\BT0
M]1<V@     +!+F+S                    "%$W\DQ$<EI3+B!B1AZ901:2
MC,C*PM9&Z9<1&J9*1'Y(      (C3+B ,>(+3/*.,'T5YQD:IEU$:IDI$=DB
M                         Z!ESJ_5;<(X(:SS.T"G5U/H!4=)RN32!H5D
MKH2J8R9PCD*1.HIVMH[W5L     >-%=VC1K4GNK4]!ZO8N%-+B1*9IA$[^(W
M8FGH_5SJ2LC!3MS4]IB@                      ##+]N+\NP!PE(<ISE,
M4Q6%44!Q%25!2GT5A;RO*(^BL/PGC7Y6.W*(JS+    XBF*0KBH->DSVB@+V
M4!7E(5A;RJ* NH   ,DM5R_A9                   '\YCZ>\JZ+/0^5G#
M79^%W[,59N+/^LS<'R;%]MUX[=HQV[1).)?^#6O;8'S+C/HIY<\).P\FOA%.
M9C4=2Y4Q,.!EWVW5[:O _1NFGN>?\UOJW&    2M@Y4V:_+U+W6#C-ZSF6/>
MQ:_9E'$OR5A95TIJ@?984Z:[+C7+Q\[QKO'+7;:X    %51<_L@_#OOV76;@
M                $/U1C1%U4>";Z?\ )MWM+G9/A;B ]EA=7O:<IL#J-UV
M\]FZP;3&UHVVO[(^6V<,YU%LC(Q+.U4O:[/U?VVO[->7V7-B;".LS%A#.OS#
M:PNE_O>6[A^$ZKKNZOGIMUFP@+98_IV\JZGIT[CGO/;Z7R0   %)4]$OEO=[
M%:C.UJV&+SUW+_;QJ2_9W.YS>Z';[%TQZ?F\[P\[>[G]CJ+M\;!\G%ZC^[Y
M   "RW*?ZWGP]]"[<8MT   =-ZOI,BOU:3:V/0           (1JB;J9'\Z7
MZ<\L\]'IO(UU%5!73\(R.U=H:H^XBPW;?-$W&BY]HS_&NW2W>O5JJ ]I@72B
MO\+971*6)?PR_;L%RBCKHR6Q?X9I][/SIZ;TT]SSWF>]7XX   #\E6T5W"FK
MB*RFKCF+971]I^H4M5-]M7*6J/N)M5RBGF@   "[47/Z\GP_[WL#8N@  #4M
M-$3LB2P           0C5$W4R,;NT1[E60          /PF#!R8.V&+I/O\
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MK,S7798]@NV\@M7,$R;$KX=Z;-=F<-4:V;7"G#79=LN6[O:NVRY;UBV^O
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MFQ\L>Q[JX=X     #S,JY,3 ) L/8E-L0C5$W4R.C;I]7TP=/IP
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M:>H:]2    /@_3@E\PY <AP2_(?1^@J     7^'N2P+UW
M
M                                 !__V@ ( 0(  04 "?IVN543[*U7
M'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[
M*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96
MJX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7
M'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[
M*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96
MJX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7
M'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[*U7'96JX[
M*U7$\3\[3,P^%%/2DRLG%02"[FBZ/QB\WJ5%2DG2DQF,P6D&H*Y)R9RJLJB*
MLW4^/.Z=SJIAF73DC4MX[.<6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C
M%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:
M,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%
MHQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HQ:,6C%HNS8SJ_P *&LS5)9LC
M(DV5+R B/2V=T-BS>!(DP:DL\*4?F,-Z7TQ,RA6&Z*FIJ7F:37T"HY:F#";V
M5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#
M*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FA
ME30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30
MRIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH94T,J:&5-#*FAE30RIH
M94T,J:&5-#*FAE30RIH94T,J:&5-#*FA=I$ALGOPE\]GDIAZR5XUDKQK)7C6
M2O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5X
MUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE
M>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK
M)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\
M:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62
MO&LE>-9*\:R5XUDKQK)7C62O&LE>-9*\:R5XUDKQK)7C62O&LE>#ATY,#'_X
MM-=:QG_ C&-:W[&#[!]@^P?8/L'V#[!]@^P?8/L'V#[!]@^P?8/L'V#[!]@^
MP?8/L'V#[!]@^P8NL#'FC[1]@^P?8/L'V#[!]@^P?8/L'V#[!]@^P?8/L'V#
M[!]@^P?8/L'V#[!]@^P?8.%C?VAC<&?O3&X-;ZM_YV%RIDV_T:<#HTX'1IP.
MC3@=&G Z+.!T:<#HTX'1IP.BS@=&G Z+.!T:<#HLX'1IP.BS@=%G Z+.!T6<
M#HTX'1IP.BS@=&G Z+. \Z\X] +&#3_1IP.C3@=&G Z-.!T:<#HTX'1IP.C3
M@=&G Z+.!T:<#HLX'1IP.BS@=%G Z+.!T:<#HTX'1IP.BS@=&G Z+.!T6<#H
MTX'19P.C3@=&G Z-.!T:<#HTX'1IP.C3@1I;,2T/]GI- A0$G!F4 R:B*F2P
MB,&?RPQ"@'7#,0DIY-,3+L[E[TO+J&5FI=+9T2G$ U-"Y)\ZHI5+CDR44KD\
M5D2*UK'XS0\]'=#7XS QZ.T,?CM81F+LQB2^9PYF4;$BL:QZ.\SFQ1UDB)9/
MI?.H58BL"#/Z0EX,%,\V*.;%'-BCFQ1S8HYL4<V*.;%'-BB838K*2I952L^[
M#-<Y_$PUK3KC##7H[K&3* T_$4<J@P8*FDY@FZ><?-0U+*(LS@38F9ARY12N
M;098H99.6<V*.;%'-BCFQ1S8HYL4<V*.;%'-BA^&X<<,N.PS'[&ZQC1]@=Y>
M-*_\,FD<S+%'!@PY5+2\0L9DB0?=?E$JFLJ4L]*F"KT@BE(:@F27>,S":*9L
MZ9.)D:(E(!<P6DYJ:.'"=+YW,H)J,A()%R)&/'I/'F,O..1II"F!U22N)RU(
M6,FI-(I-EI9 4Y9PR9/.J5Z;DYK*):IDU$@GS=9_]YI+_B/R76M8"$6+"04:
M 3E\D6I*3D(9/*&5*A(,9X\H#39,LLE%E$E@G):QJ/=CEX42:2Y0* ]$*F91
M,BY%6S^1Q#TU4?R87^J:9B;_ &-WZ?"DQJ 82O(:UKQ1U]UA=KK&0'F/.D(#
MCSA-R$ZX3<AP.5$8QL%]X/E'(D2*4<CMF<KAS8@>DI<^2EDB=ED5I=K1&)PS
M B$X<:(TNUK#LJA3"#DG<XTNUHY<4,(PF/0R<. *P'"QB?TA-EXR;Y40<J(.
M5$'*B#E1!RH@Y40<J(.5$'+B#+M8ZTFXV)$*NQGF$83 Z3APXK2[7@\6XV.E
MF..<A[BR,)D2$4<@/02;A=QV V&YRH@Y40<J(.5$'*B#E1!RH@Y40<J((L:$
M1AQWW8IG]C=^GP@QXY=_JDS'5)F.J3,=4F8ZI,QU29CJDS'5)F.J3,=4F8ZI
M,QU29CJDS'5)F.J3,=4F8ZI,QU29CJDS'5)F.J3,=4F8ZI,QU69AK6O-EA6:
MFS'1EX.C+P=&7@Z,O!T9>#HR\'1EX.C+P=&7@Z,O!T9>#HR\'1EX.C+P=&7@
MZ,O!T9>#HR\'1EX.C+P=&7@Z,O!T9>#HR\'1EX.C+P=&7@Z,O!T9>#HR\'1E
MX.C+P3"5JR 5=^OS4O+(4ZGD]D4Q3LQ_2._3X4HE$N<3CKA-]]Z-*W(3K9>^
MZ[#*//08TK,QN$FUV _+3, N_+CD%]TE#;$?EL&/&B2TL_R(&/)+CD%QR"XY
M!<<@N"[\O-M*Q)<>@<DN.07')+AYTDX"T26G(56)20ED^I#"APDKQ/#B>'$\
M.)X<3PXGAQ/#B>'$\#\R*RLL54\MF,* ;A&7^)H:<@L-\3P9,RCTR?4\DAP7
M%1(XA-P[ B''5'*7YB7G<L-0"2BE!^%+9_+)N]Q/#B>'$\.)X<3PXGAQ/#B>
M'$\&.NQ@8<=AFI)(IDH3G:Q9CM8LQVL68[6+,=K%F.UBS':Q9CM8LQVL68[6
M+,=K%F.UBS"2I\J)0HU*FI<J9=/9%,4[,?G,8UK6L:QOQ<P&#@==AM;2O_##
M\P,2)5PI?$A2.' )P9,D&LB2N72\A.)^Y!<@)T_*'C,Q2V$:=G#Q\N>F14G'
ME\0L3/F9D?F)6G4^FDP@'DDZ<>;J*;RV)%BK$T8,F58?GTA.1V*:6S0[(4[*
MF12Y%1G9LY&.3"?0IV3<E4NG*:EL0N8K/_O-)?\ $?DL!)C7$$;+D"TE6Y25
M$@0:2,*! PVO3!1&(DH5SY%^32B6GR3A='PXI%QZ<2Z?*,[&@S26G8,O64]3
ML29SB??)A?ZIK#-T?_R;XG%"Z5F4:;RDL8@J&41SQ69RP]%,S&$Y+(TYE!5^
M!/)69FI&9RR:._%2IJ7*F73V13%.S'YCKK7FERD$JZ8*P3CL2&_#>^#OT^%*
M8D-]'Q);+HSYB32<W!@2J5E8<(O @12Z<3Y..7D4D*%B4IEDN)ERY<I ,223
MFSQJ2R@\=/R:432/.I:[.I6=2TLCRR0)YR1Q(LLEL=DQDLHF\0S)).=.MELO
M:P[)"AHGT\MU6++I?'9BUC6)^0L?(2B52IM98L-^>4@/%(J>X'AP/#@>' \.
M!X<#PX'AP/#@>' \.%_'@>8W@>'+:.![%CK[!POC"(.!X<+XX7QRVX<#XX'A
MP/#@>' \.!X<#PX'AP/#@>!@T7ET&-$=BF*/_P"3?&;0'X"KGLJ/FR\U+''G
MU7#BRZ63>4/E43,I0?BP3A$_&.R9D4[/_P"A2IJ7*F73V13%.S'XX.C!T8.C
M!T8.C!T8.C!T2XO!9#F/^F1=QB'B\*+#P=&#H8QF'PEDYFTFB:[6 UVL!KM8
M#7:P&NU@-=K :[6 UVL!KM8#7:P&NU@-=K :[6 UVL!KM8#7:P&NU@-=K :[
M6 UVL!KM8#7:P&NU@-=K &3)@Y'E<IFTVC:,6XT8MQHQ;C1BW&C%N-&+<:,6
MXT8MQHQ;C1BW&C%N-&+<:,6XT8MQHQ;C1BW&C%N-&+<:,6XT8MQHQ;C1BW&C
M%N-&+<:,6XT8MQHQ;C1BW&C%N-&+<:,6XT8MP?2RK)%G?K1_#4Q@P7*02,QE
MTS<?>=AMP>X6NO,8<,PR!6*5@&7>%[ V=)R\N6/D3D'!YH-'2Q$-=>8WXU4/
MI^%)OEEC+Y9]R)!..O\ )+/&C;YEOP=^GPIDDI$<D6D4JQFD$MCI!+,:U))1
M@:CTLZS2"5Q:CTLQK4@EG0Q'I9K&(]+-8ZD$L\S224&DDH-))0:22@TDE!I)
M*!Q*I&((:62$5S224&DDH-))0:02H:D$LZVIB>ER?G=(X4-Q*?).GH,O+DU&
M2FA<K,2)V(TV38X_,23DQ<BPHC[)H1>FSZJD3D%BHDK2L,Z6C'-02UDQ+3Z3
MFRQ51RDU#EL]E\UB_)<==B/&'77#5'_\FJ!_AATQ%=D'+*3)I(S.3ZFE3\=U
M^(=C2V6* V\[&G,2.X\I2&=&=@*&8/S.,QK['#<>2/S!Z=?!9K,FDR9\^<FA
MSYD&,_ ?,&7S#_Q=]1PL#KC'FTK_ ,,,SDQ(E@[!-L3<" V#($H^\8ETNE9)
M]5PHD>$GSDO,R^(D6EX<WGS?_NY@5Z@4-E(,^-'IU,8"$G$\FI4\EX\U-O0U
M?,RKYA2*Q^(;42CB3U-S VU1R.=F9 GY6P\V5SZ>S\I'-J:.5GI&"79-T@08
M6%9_]YI+_B/R6-:P%(,9U"'2Q2%*%K#EY2(0>*1)VA($+J"B>-2U51)5&D\H
M(GH;(20@1I9#ZR0G2H-179Q+H[DO6TZD+9G-IW\F%_JFL&&Z/,:\IXI9TQ"+
MR>7%!%E9(PX_*B,0XZ2@N,@266%H<66E(YEXE!?8<EQ68PWY61B%GI83>,],
M)YDM*X90Z%FLR:3)GSYR:'/T3OT^%*VL:C3:>DYZ)'3<G,08"<DQ=A0B5(QB
M";E<K?@)F3P"4ODY.60R! G+"QE+R<V8/)N4S$Y,D]*YJ94$J>G,DFB2@&)8
MF)$;DKIA.24TP_(R,Q-1I$0C3!D@E#(AU-E8LK9+877#,BE1QSF/B(EI-%:1
MEA>7/5F:SK5))M+^A<\N.>7'/+CGEQSRXYY<<\N.>7'/+CGEQF8&.:@X.F8+
MHS4$--07F,,P&!AF QK34%K<P7P::@M8TU!:'C,%X-,0&MYY<<\N.>7'/+CG
MEQSRXYY<<\N.>7!F:RV60(T1D4P5-F2474D_&I)^-23\:DGXU)/QJ2?C4D_&
MI)^-23\:DGXU)/QJ2?A#3R<&E:LUF429,^?.30Y^C=^GP3RI4"=9W/6P[GK8
M=SUL.YZV'<];#N>MAW/6P[GK8=SUL.YZV'<];#N>MAW/6P[GK8=SUL.YZV'<
M];#N>MAW/6P[GK8=SUL.YZV'<];#N>MA-IG,9N>==>>'*B#E1!RH@Y40<J(.
M5$'*B#E1!RH@Y40<J(.5$'*B#E1!RH@Y40<J(.5$'*B#E1!RH@Y40<J(.5$'
M*B#E1!RH@Y40<J(.5$'*B#E1 V%$8QWZ_-D4UB22:'SYR:'/TCOT^$'_ $_Z
M&/XAD1WA:\ZZ.)WB<B,>#'G6M:UC UYU@XG6,XF8\3,<68M>8Z&-8UC7L'N)
MK'OZ(_\ = _L^4\^QT,>#'G6LQ9BQYUH8UC0R(S%CS,&M8QF+ QYC6XLQ^6S
MZ_L;&X#B#K_"V$W%SX_]'','<'^%WB=:ZZUCSK'L'6/!]UKSS'7V.\+6!KC0
MUC7FNO-8ZW^[EM:ZUC6-9CQ?T1_[H']GRHC,7'F8O,]0]_=AZ.8!UUKS/5C'
M<&,:S%KP:SYF+/V>#$=8[S(8YD,<R&.9#',ACF0QS(8YD,<R&.9#',ACF0QS
M(8YD,<R&.9#',ACF0QS(8YD,<R&.9#',ACF0Q&?8^]!>=8[Q.CB='$Z.)T<3
MHXG1Q.CB='$Z.)T<3!Q,'$P<3!Q,'$P<3!Q,'$P<3!Q,'$P<3HXG1Q.CB='$
MZ.)T<3HXG1Q.CB=#7W6?\W/_V@ ( 0,  04 $Z6Z13IKNM3@=UJ<#NM3@=UJ
M<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@
M=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#N
MM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ
M<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@
M=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#N
MM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ
M<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@=UJ<#NM3@2F<RJ?$_A
M5CUJ2FI<BCB.((XI!CRRGKBD/J8@2()6*B4@;F46F,T@I6#3AV2K.44ZAS"1
MG:=ODY)_PM;:\\V5_"KS&EJD2U50Y:GM;0V'Y369DK?G*B+SB4FJI$GX1VI+
MDR2D&K\$B8E<_23]/S%1VFX&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R
M7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9
M+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,
MEQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF
M2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQF2XS)<9DN,R7&9+C,EQ;;"B
M,D_P.R:43)_2J9&E4P-*I@:53 TJF!I5,#2J8#$JF&C2J8&E4P-*I@:53 TJ
MF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-
M*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,
M#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:5
M3 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&
ME4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF!I5,#2J8&E4P-*I@:53 TJF
M!I5,#2J8&E4P-*I@%2A4C ^+K6X8MP8UF.#.%K?M:QWBPP8[ZM;]7F,Q;AP.
M\(;PL:QC&M9@QGZQUC6C_P"+.'%[A:/M:W!F/[$S#%K&!WAP9PXLP#<,/E8M
M#<6!F..#6,#6-8WB;@S$8AKS7A@W 8-PQ;^KP;\?48M^/J&L;\,/3]:QC6_U
M8M'J/5GPPP^2[@Q[U:SU=:WZ-8QH:QO%A]KWJUC ]]7L&.X.C!C68,#W]OZE
MUK>#!W%OU:W /8,?P=#68!_#B?:[B\QC&NL8UGKB]CC^K<P8QGJ'0W!@:Z[A
MZ-;@WB=8QKS&L:UOHUF(_P"K?K_7C^VL;C^T8_K?H/4>H]1ZCU'J/4>H]1ZC
MU'W#U'J/4>H]1ZCU'J/4>H]1ZCU'J/4>H]1@/4>H]1ZCU'J/4>H]1ZC[F#[A
MZCU'J/4>H]1ZCU'J/4>H]1ZCU'J/48M9^Y.L8UC>'#[1Z-=]&!_Z_J'?[FX!
MC7<&,8T8,X(GU^;]?VOA;@UC6-^&#</@S%H:QK/Z\&X##'Y^#</Z&,:T?7^I
MK&L^&#</W1K6,=:SUP9PO?V.C!G#ABU[T>^KS,&NL8/_ )8,:WT8'F8.LP8Y
MZ<#6,XFL8'\>'YC/1F'VX>K68O-8[C]6-8/7%OHQK&8L9Z/_ %>PXFL]6,9A
M@(G]_P"WQ8T&"[GR(SY$9\B,^1'4"(SY$9\B,^1'4"(SY$9\B.H$1GR(SY$9
M\B,^1&?(C/D1U B,^1&?(C/D1GR(SY ,:QYD2+"@NY\B,^1&?(C/D1GR(SY$
M9\B,^1&?(C/D1U B,^1&?(CJ!$9\B.H$1GR(SY$9\B,^1&?(C/D1GR(Z@1&?
M(C/D1GR(SY$9\B,^1&?(C/D1#-E8KW[.LX\7J<6"9@P'9/-7S$27S&$]&A&2
M[(\JFI>$TF?8:BR^8P31PF>(/P"YLQ#+RZ9&BY.7S$^YQ1,>*(T<;^'%$'%$
M'&^#)8R5!N 8)Q>-]@XHC1QOC*'@=)'Y<^B3,8Q+UJ:,,FG&^.-\<;XXWQQO
MCC?'&^.-\<;X)EC9Z-&E1\J]%@FX#.*(.2<; XHC V"985ARR91'GY5-8<>)
M",PH+97-&%(I8[!>-R^8D8AV7S"7CC?'&^.-\<;XXWQQOCC?'&^.-\0S4<NV
M$\U^%^QM'J&\6"S_ -X(LAF94[%?-/QX9AA^?N/.'3A0[*I:_#BL.O&(A""H
MGW'($I;+WI:6AFS#T=TP<80RYA6$R;T%U3F'WV.EBYUV"8+M<*\DO)SK&M+M
M<)G#LR=BFHLH>9"@%F2IA Z1/'97/N; @H/_ +%:_P"]_);B#KKL6=Q^?%FL
M@BFSD=YTU"ERD?A.E96XTU)'##AT&H)Z)&4+'6M<)F9;)X3D:&<89,28C.^6
M7E?R7_[(.#('R&>CO#@UOU_4-^*S*Q^I<)AC'<TX\UTP\UL..\QZ(=?=?>.1
M'HC3<6,V%'>:R''=#CQR'#AM-P6$XQL@8@'#\$U,#QV8NL=,L$%XX7$-XY"A
ML=,,!>,<+1&M--@,<,.CDQ1QG<(F;C!$E8Q>7+4F8;-.3%')BCDQ1R8HY,4<
MF*.3%')BCDQ1R8HX3#7L3;'(>:A.M?.M8^TY$ANNF70ZPRXUYAIY[@CM<XCG
M+B--QG8S39A]]TQ$>Y,4<F*.3%')BCDQ1R8HY,4<F*.3%$,F9,/..M<@_(8W
M 8M_5-^+\.'%=R909,H,F4&3*#)E!DR@R909,H,F4&3*#)E!DR@R909,H,F4
M&3*#)E!DR@R909,H,F4&3*#)E!DR@8QC&&XQ*##SR<&>3@SR<&>3@SR<&>3@
MSR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@SR<&
M>3@SR<&>3@SR<&>3@SR<&>3@SR<&>3@+&Y+$C-^GS9B9:2(R^8%9H5_2-^*R
M/&6'GGC+D-D&8/17G3KKST0PX[$</08;7C3'XCIV#%C9PN^XTV^XXZ>B0H3I
MV.[SXPY\8<^,.?&'/C#GQA%8;@@PPT6B\^,.?&'/C!CQIHC,.EGT?,#!Z7K:
M-%>FV#!@P8,&#!@P8,&#!@P8,!8I&.1(LG-EGHL")!& R\3D<(:4,,*.269O
MAZ2S%V)$+184%DH/O%XDN.0HL:3GX#3<L-DG<&#!@P8,&#!@P8,&#!@P8'8C
M\%L-YKT$\>+2XOK"0#6$@&L) -82 :PD UA(!K"0#6$@&L) -82 :PD UA(!
M-E1)34KE,V-28U+Y@5FA7YQHT6(E9-.92H97\6C%H:UX+/'K!"! /R?GL:=C
MOF(I]1Q(CQ\Z<,2V4/OOQ#4(V\[#4+6.E"Y*%')P(AIPU"?,0(!0L6BJHI+R
MT-R?M),=?E90TYR9)!AERLH+R@X7+,*QR1.8S$_P13,F+$(A: 1)Q9:88?.$
M)\<<C,0?_8K7_>_DNOON/&W^.=OOQGILGX\6/$?:;<EZG?@ND)2[F9/",,.M
MF<(S&-J'ABO0R)LC)H,-XJ8?-FY.0GSQ<M+ODO\ ]D'_ $%E_L7Q+R:,8*PR
M)V-"BRDY!+121R ["*/O&W9<??9%E)^"5,DS9-OQE,V-28U+Y@5FA7YDYG,J
M3TJK?7RH%QDVH_6FI%LRD1JS32_3OP;\5I"?=F;AXW"<AS,_!?B3 [%>B1XL
M9R+-YE&AQ9I,(T8T>,G#$:/%,1(4S.P"L&9G2Y8M,CI.&0.-('"T]-0CLVF[
MTT8X?.0F%)D=(N0IH>@EF3 \R(7F4:#&:<C/$X9PU"'IAU68<)H^;.L0T&)#
MEZW*QW)CQ,'$P<3!Q,'$P<3!Q,'$P<3!Q,'$Z.)@9$X1QCC8T<3HXG1Q,'$P
M<3 Q]C!S,1QL'$P<3!Q,'$P<3!Q,'$P<3!Q,!>!%.17'6N0EE_L7Q(1BD632
MZ8%8#I8R5X)*889-DSSL50.30F[%<-$&0)M$@PI5_1*9L:DQJ7S K-"OQQ:,
M6C%HQ:,6C%HQ:'&,>?NVJ]4-7+>VF' C1ZYF.AHFWJK:_IBN(;[S\+$8_$T2
M*'6=!DXZ#)QT&3CH,G'09..@R<=!DXZ#)QT&3CH,G'09..@R<=!DXZ#)QT&3
MCH,G'09..@R<=!DXZ#)QT&3CH,G'09..@R<0H4*!#-&RA1WK4C'6I&.M2,=:
MD8ZU(QUJ1CK4C'6I&.M2,=:D8ZU(QUJ1CK4C'6I&.M2,=:D8ZU(QUJ1CK4C'
M6I&.M2,=:D8ZU(QUJ1CK4C'6I&.M2,=:D8ZU(QUJ1CK4C'6I&($UE,:(WZ+/
M'H<.%%C1#!0T3:XX]$^'U$""^9BPXT6#\(!>.:B12AJ _P"C! *F#+N+/Z$8
M6F;Y_P"77"A*2K@G5%(ZC4 GTEB+RIY.WNVU-T2EOP;\5;.3Y8XV=3IC.L3S
M%LZG3&MG<Y8.MSI@ZU.L63N<M'6YSAUN<CKDY'6YRT=<G(ZY.1UR<CKDY'7)
MR.N3D/3F=N!^<SN&]UR<CKDY'7)R.M3H=<G."6FL>:$5M%B-F^#!@P8,&#!@
MP8,&#!@P8,!8J^:B1Y5&)Q#! T5=RAAK["!EXD_!B0W6D3.2=D4R>#)),'GX
MI2-!@.2@W$*Q96>@QH\E/P7SLK,D7,&#!@P8,&#!@P8,&#!@P8&1'X+8;6O0
M5E_L29_WYL!ULX8Z^7==@2^#*S,,N]"<)P#,25E7'RY6'"><DT?+&HI*)*R+
MA&$_"@-=@N3%A-DL^$AD$>=QRY> 4@?,JO25(UA2]#:#)2B$@^+1B&O!9-_^
MX*$"\QDL-D!Z:F<'IHH.%PX<-Q($A>APGS4(Q#.L4CC6EY7#9TAR,Z4.%7VD
M2Q<@5C*,I*2+84\+R\LR)))?%<=D4G<=+267.RN8DB,,H=EA6:3$\PLZ<E,K
ME9DM#DY>)+HST1\BI##L5]!_]BM?][^3BU@-1X3\ZB1HCTTD,2+%$3-.DU&_
MPDI4V&8E,(["/ [ _P#WJ%^$9>80CE)&Z[E3,8R8D9*;O%2DO^2__9"_T%FU
MC)$Y'Y3[\P-16N'H\-YR8FH<)IE]X/S(Y$:X=C0H3#+[H@'(I5YAZ.[%SL=D
M+/1VPHTP?,%A()!'G<<N7@%('Z)OQ6;&LFT";'RT/K<RYCTYF+[#!LP:=,S8
MX<=B3H_$CG)D9.QS1N.<BP9V>@%RTZ/%"I2<'B<&6G<E,2D^>=/3J9%YD]#G
M4RA.EIJ:*P7)J9=).SN9NM+3>-#-/'7WI? FAXNQC[['7)U,(;IDW%-,0C&L
MEZTEQIX_R(PY$8<B,.1&'(C#D1AR(PY$8<B,.1&'),8\DPP<B,.1'PY$<,@F
M&!D(RP-A&6MY)C#EF<&PC+PY$<-@1VCD1AR(PY$8<B,.1&'(C#D1AR(PY$8%
MY<;.1''6N0GG'7V9> ,O &7@#+P!EX R\ 9> ,O &7@#+P!EX R\ 3XL7;))
M#((\ZCER\ I ^:SU=;PM:S#@;_;\&_&92F7S-W2$A&D)"-(2$:0D(TA(1I"0
MC2$A&D)"-(2$:0D(TA(1I"0C2$A&D)"-(2$:0D(TA(1I"0C2$A&D)"-(2$:0
MD(TA(0Q(2%C2I8N3@-:Q@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)
M@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8.)@XF#B8,6!OT^:=+.'2I<
MO *0/T.+?BWXO_W?T-8,&XX-:,&X-9@,&L^&#1@T8>F'P^H^@P],/3^ASZ/_
M %^4QF(P&#1@T8-^& P;\<!A\QOT_9, U@>]&_T-:,68_4-;Z-:S%N 8W!F+
M,<1B/H&L]6888L'H/^G]#GT?^ORF?5F& 9] T-;@/J&_5GT^;A^SO.MQX7AP
MO#A>'"\.%X<+PX7APO#A>'"\.%X<+PX7APO#!X8/#A>'"\.%X<+PX7APO#A>
M'"\'68,>8W'!HP:,&C!HP:,&C!HP:,&C!HP:,&C!HP:,&C!HP:,&C!HP:,&C
M!HP:,&C!HP:,&C!HP:,&C!HP:,&_\W/_V@ ( 0$  04 %:KX;0K<U5[KNW /
M==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX!
M[KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW /==VX![KNW
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M@* -V>5HE];%O8M<%3BN-=[1JHVO+*G]N:PJQ+Z5V(7#UTI;0.Q.X*ZE-Q)
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M])C5Z3&KTF-7I,2&4S.KT\4\H/)^B'R+C[+**W/3U.V"V@I*+1JDJ+H+2?\
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M2FJ-^2K:2&=*H<&FQ13J$XO=U[O^5#=6EOO2VW8]=KRE0/YZZ"FFHMS3>JU
M!N=6$M1!*H%!(W9N]_E:M2W1=;WN-UK=FYI-_P 90+B0MPO:&BZI/M"RZ"=.
MEI:FSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XS
MC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XS
MC.,XSC.,XSC.,XSC.,XSC.,XSC./D4R&K\A6$^&7;F0GQ"9D."9X_I^2VM?Y
M@2C61M/.TN+FL2K2R8 @R.,B#D1'R;\T/4JTZNYOS6FF*9(J_FJ0I'4\P4T
M:A)6U989Q_J3NTW5;1\R5Z]5F[$SMNWH"@54:OYNF6L$FG.>F0EJ-Y:TM^-3
MH7&ZK"S9JEBM>LC;N55H5+>JU13;TJI17N:*8N9@5#.8^:M_-4J5[G>US;5W
M7LBBTWMZ HD*=3%A4(+X@: 0G.EJ-SN[>'S7=5_DZKO5]XM8+9TZ7:5VJBLJ
MU+K6]5J*L%F@5=4LUP(O/F'=MU03=USO"I>U*+[MHU;H5JP)J)0OV/:T:!J2
MJJ%773(T*9,Q/S?_ )QOM/\ ,M[V=*V:I:;N2TIA*5RMT:]:A3J%:]U4= C5
M"R:4,AJP WQ\Q;F^7;IM\OO2E4M*U6UL*]B+-4HTW-2\K'\]:D4UJA;:@@-)
MI"B3K8G<HHW]=J=C\R7&]UG0(-0U]?\ PYYYTA P_F\XM+V:SP\-4Z)V1X:I
MT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJG1.R/#
M5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1
MX:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJG1.
MR/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z
M)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJ
MG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\
M-4Z)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9
M'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$
M[(\-4Z)V1X:IT3LCPU3HG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCPU3
MHG9'AJG1.R/#5.B=D>&J=$[(\-4Z)V1X:IT3LCY*M2X_,T["J62?.4-7;267
M,!I'3/.1E]-2CNK?-W;4G,V6E6J4PQE*9", 3+"9QE'FK>7O-?KQYJWE[S7Z
M\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYKWE[S6Z\>:M
MY>\U^O'FK>7O-?KQYKWE[S6Z\>:]Y>\U^O'FO>7O-;KQYJWE[S7Z\>:MY>\U
M^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'F
MK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O
M-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQ
MYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE
M[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FO>7O-?KQYKWE[S6Z
M\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:M
MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U
M^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'F
MK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O
M-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FK>7O-?KQ
MYJWE[S7Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z\>:MY>\U^O'FO>7O-;KQYKWE
M[S6Z\>:MY>\U^O'FK>7O-?KQYKWE[S6Z\>:MY>\U^O'FK>7O-?KQYJWE[S7Z
M\>:MY>\U^O'FK>7O-?KQYKWE[S7Z\5+N_NZM>Z;UGJ,SN9"0FS$DR&&)R_ZS
M3_T0]/Z!^CT1/^MP>/\ Z"R$9DQD8R,9&,C&1C(QD8R,9&,C&1C(QD8R,9&,
MC&1C(QD8R,9&,C&1C(QD8R,9&,!RP9X@QD8R,9&,C&1C(QD8R,9&,C&1C(QD
M8R,9&,C&1C(QD8R,9&,C&1C(QD8R,9&,C'-/]4$<?]=@B"?^NTT[6WJ5:@$Y
M(I8RXY $RCX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3
M<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_
M5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3<]T_5CX3
M<]T_5CX3<]T_5CX3<]T_5AD=2'!D0<"". CCCLK6@]2K*<E4L9<<@"91\)N>
MZ?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ
M\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>
MZ?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ
M\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>Z?JQ\)N>
MZ?JQ\)N>Z?JP:MQN^O3I#-F1E&.6) ']4+<44"UZUS4UL,VT2"@G.0$Y#($D
MYDQ>6-"]#WEN5[5 3J34)KJ^T9$$^F$WE4WU3%@U0TU>;$%UG-0 "2<#P2,L
M"8L;BWWM3>A<U>SI,&,GJ2)[/^Z\@>:VD\ QBYI6]SKJ4:FAP">:\@VD\&J1
M!(!,IR,CA%>SL=\TZES3!++-EP4R9E+!5=5/K%"P7AD(J[V7>M,[K35JJA_Y
M?-.DR;^+G8#3/42 LYQ6WM0WLAW;2F'J$LH0B4U=6 96Q$E*AFF-(,Q#7.[-
MX=M15M)EJ4JW$RN%=21B-2B8Q$Q%I3N[X4ZE>IV=,$F;O_94<>6)D,0)S,4-
MWW^]DI7M26E6+<)DI8@%4#'!2Y4-P3BWH;UWJM"M5]4,6G*<M3:0="3PUOI6
M?#  J,2?2?PX^.!)VQ])@:F8?>8,W;#/$X09,^&><%@SZ>.9B^IVM5RUM<-1
MJ3F)5%"L9<:R8<Z!>VE5S;]HZ3,P=5-RC83_ +2F7&,8D7:?VF)JSD??'M&Y
M3&\/_P"I3(M!.O)YBD,3SR, <#,8D2D0#%6KNK>0K)38!I:E921,35PK $>J
M92,C(F-WW%*D%K5K4%R/XBKNH)XSI $\R .*+B[ITP+JI=NK-PE41-*SSD-3
M&7&28]HW*8]HW*8]HW*8]HW*8]HW*8]HW*8]HW*8]HW*8]HW*8-[O*^[&T#!
M2S%I3;(8 G'[)<<5'W7>O=Z*E-'%%7<IVA(5V$A*F)$NXF% QBNE&X+M2<H\
MB3I< ,5/ID0?L,$ O/[X6T-U_P 44+A9F>D$ M]@)EQ^B4X!9G ^TPVZQ>#_
M #$4A4[.9U=F3+7Q2GAG/T1?7%7>Z+0MJO9U6U&25,!H,A,F9 PF)X3@[PH;
MZIM9"HM,L&:2NQDJN" R3)$BP ],7%BEU.\I*K.@))4//06X!JD9"<Y8RE#[
MFI[W0[T4D&G-@=2XL@8@(S@9H&+#BB\K6^\Z;T+=B*KAP4IE1J8,\](TC%L9
M#(XX1<W&[M[)4HT<:AFR:!*>I@X4A" 2'EH(!D3%;_*MZ"L:<M0&L$ Y-)PI
M*G@< J> Q[1N4Q[1N4Q[1N4Q[1N4Q[1N4Q[1N4Q[1N4Q[1N4Q[1N4PUK=+VE
MM4&EE;$,K8$$',$1<4T',5V ^P$@?U(9Y 1PQSIRBU_YFMR:EE]\LX^:-X6L
MS4O*M2P '_G5*%N]NWVZC4'V"-RVRW]*WI4/F*XI]K4D44(M9-339!(@?VEQ
M,YQOS=]-Q<;SNM[!*%Q3F$JW'\IDKTY:]"VX755D]0,*;$NVN4"V<:=Y4*]5
M+J9Q-SK+5*C&0F*L^T0Y:" ,%BTWO6WC;+;VBUEMJ':)VKJXT5J]99S1-"\R
MGIP7GN9X#==>C<4FW;:_,IJ5]#*4IT36JZ'?29+3F48$R73)AA(Q\UW6ZKJ@
M+:F;!UJMC0:O;!JA5V7-0FE*I!)3FS$UTQOS?U2G12SKI1HTS2U&G4-'67J(
M65"Z*6[-'T*'"DK@)FRWC=[FK&F-ZVM*WDU$@TDJ:E"'M05J7#ZF<L@60I*7
M4(0W^IEEO*K37>EPS&BK2UU5J6RI0%,'%Y/-!IGI8$8&/FZG\R5DIUJV[K70
M*I$ZBI:U*=54GZW\[6"JS)9P)38"#3K:TOJ>[*(;,,I!IX'A!59 \4I1\\5[
M/>0:S6VL!J1V*E>U<5$U4R2J..;4=)E4):1E([XO;2M;D,])11I5#5[%%7$$
ML%TBM4U5 JKH7(,3,"I55W-#Y?N:H8%B=:7=5^RU8XRILDISEP19[JWA?6]M
M4M]V4C1>YN:E("LPJ=M6IL%<&HM72[<Y'72B3*LZM?=MOBUH;SMWMA0J5J[4
MB%*4BS4*?9L*BU:G: A776SE:BD!0+H;QJ'_ "0[[K!64GG7O9432[4"1T%0
M11"DZJQYPEHC='S);EBM"[OZ#H!/4*]:KV189<VX6F)Y@.?NW;\MU;P-OFE9
MK4=26+-,_P RI,X2[4L):I@<$H^?KNK4J=O86]G5H$.P%.H:3S90#(,2%)88
M\T">DL"*EJE\=WEJ9FES9I2D0NLBD]%JP$YZEUZFQTD3$O\ 4&[:XI_EZ5"V
MJ,J:2S=FE7M9).98.0K3]5F4,0)1O3?53>%K4WI<)35Z-"HE5;:DI8HCLI)>
MJ68FI4,E+S5!I$SN7_D__P!M2#_SE7_NTOU3$9Z3^PQ\CM2J,K&^LQ@98&Y8
M$?81@1D1G'^H;V58T]ZC>H4Z7(JBB;BWTL ""H8L\G '$#+"*>X;.Q2G5I6U
M>YIO4KU5527.H4P2_:5V==1+%2BR"-J< [CWK6JJ^\ZOR[2J4F9L:ET)K(8R
M9I9J.',<=G?#>=J:U6VJ&YIBX>I<5'(3G5:3(NEJ50,68LQ4U#35M 55K?,N
MF=.SM[9:@XZ=PEPGX55I?>8^8;:O75+FGO"P9W;):CBWJ5&:9$PKLTYD8#,1
M\]->UDWE3K4J*=K1]2JSJZ4K9 &J 55=@0ZU'(#+A3"2&]=U;R?7\Q4;@&X<
MDDU0R**%43 YG9J*8'\+*T\6QM+.IO"WI6>[KPM3IEU%:XNJ>I.:A(84D9F&
M1:JP)P61/^I%#=M6E407]&HR4F5B:*?ES5;2IQ62N&,L2&!F9B-X6NZ[Q'MG
MW-4I5*U,AT1ZEP'HABID3@[:9ST%C@&F6WI72U_+VEDULU2W+M2J57J*Q1'=
M4U"F%U-($(S:-3$&7ZFG]HB[U>MVC_\ >,OP_J1OL_>/I%G1J!KJC<5-:_Q
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MXDDQ1WG=;LHU-X4Y::C+,\WU21ZK%/X"P)7@(BAO*\W;1JW]*6FHRS82Q6?
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M9A5IM2)J]HK+356 U"BJM-EF@+25B#^B;"_&FHLS2J@3:DYX1EJ1I#M*9(#
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MV5(/J;M$NB2 BLR+VLB"1%3>E1RV\+NN[U5,_P"541C3%OI.(%!5"9#49O\
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M?:;VHHC5Z#:E#@E21P$*0>,C$"8$YB8-Q?W]PU6\JMJ9FS)_8 !@ )!0
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M,N:94K"D7U-41P&8DJJJ2-6H JS%SS0!( '2H83_ %+?9%'BT+^P1<?[]/\
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M^'T^2/A]/DCX?3Y(^'T^2/A]/DCX?3Y(^'T^2/A]/DCX?3Y(2C0IJE)1(
M >@#"%-W71%8R&HC&6. X99F64>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/U^Z
M/&T?K]T>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/U^Z/&T?K]T>-H_7[H\;1^O
MW1XVC]?NCQM'Z_='C:/U^Z/&T?K]T>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/
MU^Z/&T?K]T>-H_7[H\;1^OW1XVC]?NCQM'Z_='C:/U^Z/&T?K]T>-H_7[H\;
M1^OW0M*A>4C58R ! )/$.,^C/Z*TC_&D_2-:X>C&1GZ)<,+2HTV>JV2J)D_8
M!G"+=VSTF;+6I6?V3SAM"DZ1,RQD)@3/WD#[2/HPA*-+3VK93(4<I($5.RJ,
MNI2K2,I@X$'T'+TQA HVU%JE4\"B9^V0X!PQ46O;.CH,0P(D,,3Z.<O*../O
M_&*S4*19::%F.0"K*>>9$QAGZ(&.?Z#W5H^BP'-JDB:O+) ,)NIQU?P# SU%
M3^K&[=\K^5^8;<$V=_34&M;N?X2)CMK=SA5H,P5QBI2H%J+\[?)>^K&G;W6]
M]U5+"K4*FI1NK&I45C6LZATX.4'.(UTCJIU::U%('R3_ *2[DW8-XW%C<5VL
M0J#MZ5.X(:M2>N2%2R1YUCV@"TFFQ>0E!WC=-3WA_J#=4P+B\T\VFIQ-M9AA
MJIT ?6<@5;AAKJZ1V=*E] ^E;2UN&ITPHGIF#/ SU \1E*4N'$RD&.\Z^D_W
MC&G_ #&XU2GZS99S^R"#O*XF,^<8!.\Z\C_>,'_^G7PE_$>'$<O! '^95YF4
MN<<9Y<O! EO.OC_?, _YG7E_OF/B=?IG@SY(^)U^F>#.,-YU^D?M_8)Q\4K]
M,Q\4K],Q\4K],Q\4K],Q\4K],Q\4K],PI?>5P 1,38X@Y$>@\<%*F\;A7' 6
M(..(_#&/BE?IF/BE?IF/BE?IF%__ *5QCESCCP80#_F=>1_OF*S7'M*=33/C
M$@?PG(3F92F29DK1+GLA10RGA.;XRRGGCG(F,HRC*,HRC*,HRC*.RIM3#2_C
M94'*Q$-2OJM*FX1C(.'(91/2P345)F):I#TQ0>O1D*BDKB#,#["<)8@Y$8B<
M/3%!M:IJ(EDI$P3]T-O 4Q^5!E.8^S*<Y^B4Y8REC%)ZE,A7!*DC,# P-X=E
M_P )VFB>'K2GEG+TY10E;J.T0.)LH&DAF!,SAS4)QRECP3I(M)&[124*NC*\
MISTD&1((D1P$@'%EG1N:B#L:A(4S!GIP)PGA.8GPD$<!D+FD$? $JKJ7"F0#
M%0=0Q(!PPGC*+6@]L>VKJ"@!!)!,@<)RQX\N&4446B*@<@ H0XU'3@2LP/67
M.4P01@8IU*NAJ3&6I65@'EJT$J3(R((GF,1A&491E&491E&491E':4V*N <0
M2#E(XC'$8'T8138G$J/V"+C_ 'Z?_N+&[?\ >?\ ]MX6G4H.UFU*HKE]) 7$
MNZ%44 (!J4R#3 D3/2=\4[:V1:/8TU1M*'6FJD V(*XJ^MC(@,TV/- 6W_X,
M5-5NCZ0M,SJ9DY]J><=# 34 : LYQ>VK4::44MZ=34$68:5O-IR!)YSS&J1G
M+#,[NKBA2_)]II--J=,E)LI"'2&R&;,TY2!0%YG==-[.G^7KHQJDA 3)BL^<
M"_,0*X-,K(G6TPT6-M5LZ:]M1JZQH4&:_F"!,@LI4HNF3 B4C/@NZ9H%[:HA
M1R "44L.=BK@@$9,I!C>YM:NMJE)-(=49E752DK'G D"H0<2HD&$I"7YBI;T
M@AW5,D*@DX2IJ;2,0098R F )S$HNJ?Y.F=WKN\/,! 7U+39IR&N3'4)ST8:
M0.;A5WA2H4]=T*:J5DH!4#M=*D"4G48@:B*A'- P^C424W>AY[\)/]A/[W&<
ME'ID(I6UM2"4$$E49 ?7,YDXG'];7^6OFJTYPU-;W" "O:UB)"K1<C#(:T,T
MJ*-+@R!#66ZY7GS+<*/S=^Z!:M=IST(LV[&W0^SH*S 2#.U1YN?I$9&,H82_
M@7\5'XCAC=-K4.FKJ+3 QT-4=#]P<),\"DPMQ2HJH:PFN$OXJ07@PP,IRYLS
M%NRV:5+6XI,E2H, 5U/J.0$Z8&#2UL*6L'3.:4J=)%MJ:<S2)*0W/+#,$-/4
M /5#!23**=+>01[AY=D-*\U0 292TKS, 0)MKU2("NU.]-!.U3=G:J H"=HM
M)2.;+3(%BP$I"4;LWIO(4J=7757G R8Z$[)L=1;2SZL9\W$S"B+>M=E3>&JZ
MAE$IHH42;G/.3!])+GAD0.:+:T_+*:U2B["E(_SE.KGZIZ9@E9%IZ)* 1VB1
MNC=5I;TSN^Z56J#%O7JNK<[#4  JAF!E(%=),XW32MK<:+BHPJ3$]8%1E ,Y
MS!5/5]4!F*@'25J[N93^4%>LL@2#) Y7&<\"HX8W14N VNH*Q<$R#:%4J)D@
M()F1.'-,R1+4+-;1%5RK%M,V4@,RB1+L.">G46!;2S#2 *HM*;BK52FU(%N
MA6J$<845 .=,S4Y1KK*O8U*K!&UD:4D"I$W&I^?,X.I"@:)DL:52\,KEZ=1M
M9;201KT@+J'!3Q!5B9M)DTQ:WC(:ZTK>C363'%9F3G0.:" P5B=+3)Q*JK[P
MI=IHO%%"1F22II(IFN0&IDQX@Q) $7*V8_X4.0N)/-!D#,XXYG.1PC=8N:3F
MYNA4$P3)2KLH(DP ($C(A@>('&#>#MY]F[#V4N:6E_X@;@QDOV Q\K5K2DJW
M1[0 A5,V6H #+3(DRGD6/]XXFQHU)-?TTG48<3!=*S_BE(M.94:M*LP$XO\
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MSE,'+T14N%O'%=Q)F#D,PX02#,SX9YP+<7C]@)R76=(GGA.6/#QSQ@4#>/V
MG)=9TB>>$Y8\/'PQ96;,O9T00N,R2Q))Q^X2$A(###Z)L2F[T//?A)_L)_>X
MSDH],A%*VMJ02@@DJC(#ZYG,G$X_T,?221@5'[%A:5&J BTVICFK,*Q+,-4I
MXDDY\7$)=J]96?LC3YR*P*&6# B1GI$R<Y0ZFL C4]$E554)Q*H 49D8#(D?
MQ&=!;A]79KI4_P 6F9,BV9D293RG#+<+18F4V[) QTRESI3X )3RPBA<:J:U
M*2E5THH 4@#20!(B0"R/!AD912K5-(%,DJH "@DZB9"4RS8L<SPF.UN'FT@!
M(2  R"J,% X@)0M!&76HTHY52Z+C@K$3PU,%,YKJ.F4X_*T7 4>J9 LDYSTL
M02)S.((E,D8DF&HTG!7^'4H8H9C%2P,O54R& *A@)@&+>^JZFT%B>$DE649Y
MXG&?!%&XNTG;T^TT*LAHUB1P4(')PF#I!,_5GA9FWHZ330@MI"EID2! +2"R
MF.<QYQRR%NM.YPI A9@' A@9S$S@QS]'$)5;=0CT6R#JKA3AB-0,O5&&4P#F
M!!L2M-J($EU(I*9STDC F9D1D22,224E<"2TP@&E=(4$$264M0*J0TIB0X(N
M[VX8M<5*!0$8<[2$4G@DJ^B98 \<4]WE1H%9JD^&9 &$OOG]V&$68HU@/R^K
ML^:#+4=33GG,\>4: [:)93,6:4VIJM S22*)9SGAC.9+3G-N=G%,5*=)0DY:
M*:IGQZ0)^B>6/'%\W :_[$6$OD2= TE7[PS3'%PC"<S.8!"L1[)N2/9-R1[)
MN2/9-R1[)N2/9-R1[)N2/9-R1[)N2/9-R06T-J/VQA3;D,2[)N2)=DTOL,'^
M6V/H/!ER0)4V_'AS@$(\P,,\(F4><I<.7% 7LVD/08TZ'TRRQ@!D<@?;'LFY
M#PYQ,TVG]ACV3<D>R;DCV3<D>R;DCV3<D>R;DCV3<D>R;DCV3<D"WHT2:A_[
M/WYRD,S)02$0G$ #DB3B8XN"/8KR1[%>2/8KR1[%>2/8KR1[%>2/8KR1[%>2
M/8KR1[%>2/8KR1[%>2-ZSHKA0<C#(J"01Z01!+$IN]#SWX2?["?WN,Y(/20(
MI6UM2"4$$@!D!]<SF3B<?UP$\9PQ/'Q_[(;$8B)3/[OI'THMY2+$92)!X<Y9
MRF93RF92F8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]
MA4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;
M;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8]A4Z;;8![!^F8IV]
MLFFBH  F3D)8DS)P &)R &0C&,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.,XSC.
M,XSC.,XSC.,XSC.,XSC/]?<6=0L*55"C2P(# @R)RY#%*VMJ02@@D ,@/KF3
MB3B<?Z%*>'TCZ?N_1.,&491/@B?!&7TRE'I_1)@F?Z)_791E&7Z4_P"L\_TC
MQ1/TQF,S&'%!,X)GG!XX(X((,OW0<>&!Z#$N 0?H:,Q_0OOAH^Z ?1 C#.4?
M=!EG PR@<4H]$OUF?]3S$91E&491E&491E&491E&491E&491E&491E&491E&
M48_1E&491E&491E&491E&491E&491E&491E&491E&491E&491E&491E&49?]
M;G__V@ ( 0$!!C\ Z:T;<>164YE<GD6E-(U>TVI@SGBQ+A0Z361<Q9#*NV31
MXHD<$3K$3!;N&[G> INSXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AY
MKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K
M>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7
MA?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=
M?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T
M/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+
M];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKX
MR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AY
MKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K
M>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7
MA?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=
M?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T
M/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+
M];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKX
MR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AY
MKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K
M>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/-=?&7A?K>AYKKXR\+];T/,],]'
MQ31:CJ%&?.WD>WL]+FF<W%A(QRA4W\:X6:*',SDF1CE\5NL":Q"G*(E #%$?
MW.7:RAC*K'N]+2,JJ8RJHHMLCSY)JAXAQ,<$&R?Z*9.WNI@(@4 [>N2>[ZKQ
M\VBVW[B0TQ).X'JO)>4HT#LS_;+_ "M1;O8:$;UI\AG*%3:-DE#H@9X#TQ1[
M!3$PCUPQGK'M.;2]YY96# +GCO&&V9+HUDAK-0--U1Q3+&PU^]Q4I$UEK6:.
MBW3*Y11<IR-G1,L5%-F8O\YR(SBF[#"TS<:+K>]UFM8?5..6QV#(6"672EHD
M$&=BWMO(*T#$ZO:8RO.F]592[B0D (@BDL)U5$P4^7WIU0J\?!7'9<%WJZZ;
M,)%44>7"R4_7AKU:D)P#JG;J.8:#_P#!D\(J912#L$!\@]9MQ"I-/VFE\A=/
MX55CD[4=X=:^2V9LOH+_ #25T*1H5MR&:AD31]0DTJV]3*]CY#TEL95,"$(4
MG:9#9GMM5;:*IQSK7+MQCJV3WI"BLL"M4K&Q<>9;E$JL&7CL39M+(RKFH@T]
M+2BN\?Q1,0>N._&*0OE.VW5+=8;K"W[-=QXM[?G^#H!"91.VTMEK-MFK!"$Y
M#YX,BW.U8OX)PQ,G*,TG"R?@#X8U"]W/D8G0;->N/6N\O8'/(?!+SHS,G'7&
MGLDSM+^0U-I9J_3(G3';ECV,JZN!O!1.F5=V9<Q"'T.VM^0U6L6FYQQCRKF3
M+XLTRJ[QAC8!J#*(.#]747\D-41O<!)RHHA$)-W'I;=#QQ5;^*"2?T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!]77T!
M]77,%,#G\+_&'/E@2[YO!*LIFK1-58J7;X95EB(D*<X !C@F4!$>Z'9^YRM;
MV Q8)>2M%(FHU*8,2./)0KW*Z,@SF(X'9DO38QRX9K)D73[R8JHJ$[>\0P!R
MEX]-6-9F(SE)_@O]KVM>V(,GM)_P8N+RXL?L^&3:.D)_]HEW@MU?$<M/12E[
MY?%$>Z' Z]%@*P+G@C3\VJ,)&FO2'@:F3-M&=:(UD9-T$0"E+-,*.09*(IDE
M?  @K <_>\$M1LDADK:<EZ-R+Y+[M#QU5Y%R^=T>R17+"5EW^BUC5J;%5M]'
MZE<*4QG%V-2GI(11CT>Z<S(IB=P_'3&D&<+58#C;1-8SRMRAKFUL,E9873]%
M=7UNYE4CQ\0E'OZNU52CA[AW 2!TC.1%#Q 0)!7RE\=Z!3^45?XX0G%>'Y(R
M>_6VVIUO-8VGN:3(S-5Q@(6OTV.ODK#/W14GZ[MSZ'XXAW5B@8JE4Q>^0-TD
M+Y0L7J?'VJ7FN\M]#I^,O\\HSA!"L36B<7X@G["WS06M6*M#NG#IT#*226*Y
M<)F4012+Q@+E^52@47C)J=TV"$J^V<K+)N=I<S=QR&;QI/.Z-I%HJZ4KFN+U
MF"G57S6(3:OO'?E*8Q4?TC&S'"]3W#.F67Q_'>[5S:Z-3=BY,9KR37WA_.WV
MT0#*J8!06Y>.6Q1R]GDH4[FV6%^9"9;%4/)I #1 A-67DZ?4F#_7N!>6<%Y4
MK?16[E&N,<U").IJ34Q:^@27>SJT<H'V( -4F@*E['RP)_SGW[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[#?BC'S_7W[
M#?BC'S_7+*?2:N%("5V>F,HF=(D<\/*O(?.8\LPUC9$H"T?+Q)WJ)7)4S&%
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MMYBJ!IM^QJXO8QO)-DX+3<OG5JU?:DZ+*,6"JCZN3C<[=51(JC=0P=Y)0Y!
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MBFT,11J14H)>$G_E/R=WE\XXX9=G^Q?_ /0+_%E]:\<H=G7T[_#GC!3EL_\
M\27TM6WPW#]AE$"#"_:IW'V<8@>B^&(!V?//Y<YIOG*>8VGCES2Y)\7L7KL9
MH5ZF*%B''+]N>,\KHUHS[)F#20A4[3F><V.QOHNR'CY9]58])52-3*1 &YX[
M,[%RJK.J\=.1GS 6M&XRW;CY\X?D2KD_'(T)Q!<7VYXIR?\ F;K5!AKTU'W:
MW-G%@I=,(E(/9"<DV4:+PJ"'@$_Y?SD-RFY!W^2O<[P:Y>YLA:;%M-IH,1>N
M2F4[5FU)99Q+1[&Q5V*M^OV*#4<)6N"=(GEK>>&9FFF;H[!)-+B/.WOF#S?=
M2_)?Y:/S2MEUYS'\G]IJSZ1T3B+KL:SX]3E=+ 6")<Y^[H"-C,1;[$"/-8TF
MC=&;^TT#+I..._[7\T*'QNU>:^7E\GW9^(^C<AN6.D\:J7HVI:N5G9.6%IC.
M/U(S^U9_SAN.H32"=/FZ[8P;IUUI*-A9-DU'GI:5.U-UR-Y'RCR7_P"8WY5_
M+^7H\KK^@AE#?BG*87J-F_PT8Y@A*-*B8M?M%?;/H.;,V5F(15,H,7C=%---
M.VP$1I=IN6JPG)#EI%;M2KKKMFT*UY9=(SD;K\5"P]EI=HL,L_RJQV^G1[&?
MDFZC5@YL$A(K3+H'#AZHX4XH_,,XW8[B.+6/A[P#^8O*Y-;<B8+7+DYSLV+3
M:SH\#D%;V7-VV94F")4,ZN<,6;81,K/W1U)3R+)-LFV(LN<-*TG)>?;2[05[
MD_DV0KH<?YWZIRSY&8UNNP\GZU2>2-WU"8TJ@U9QQ\?<@:+/':R>:^"\C(.?
MB72;>/9(&426YG8GQ@W3E [@\0^43Q4N4"^F+W?=WTFKQE]^8CJ%4Y,\ADIF
MYJ6^PS>MT_CRM*N4)U0%WT<RB&YD@ C%$J=RS7-^:^X2'RG4?FS\-\A6YC0?
M*30KBM"9!=>(]CT?:\UCN>@VZ;T&)QY;E:PJ<)*V1"X-E8!Q.+PJ<HV(X%-/
M98V#F)FQP3'Y@G/E& LMCEY"PV&SP!N2EW6@K+.6.7.I*V.4L$0JB\5D7)CK
M/C+>.<QA.)A_ROY,.=9_1>.FCWBPZKS:" J/+>C2VC<=)3[+XI24R^#2*G!I
MFE),C-".!S& D)?"ED&ZH^1/R<@<VDMNLO$C4..' #A]/_*LP+B39[3CN+;/
MRIF]%ML'M$#D/'VNBE$\ED$KC$URH)4><C+"A#TZ7.O]F(*N#2)-1_0."RO_
M #.?RM57Z;=-=RDWF7/!_&5YAN50B9NQLUF#+)@H(]TI"@(F[! 1R''H?E_R
M'C^;?*MY\XO(/F*X[$Z_='[7B%3Z-$:O7^(V@PV2A,/8/A[(YE>&F?I46QQ#
M6">VI.?=G.O*>(8S7B=7IS4]MC*A\QZW<?,TBT&EZM\8\S=Q\I:W4F1Y]3=4
M,U6;!3C<DW+*;8SRJ(-S3310Z+D5R(@D7Y?EXYK:7A>#TY[\T*7J%IM/'32]
M/KF#O^,,_P 7]W3SB%Y-V/6&=08H6B7U1O'E.S6%6NGD",C(']*(F(?+H:\M
M>;G(C'L6U[,/GOV?2]$#D=I^(V6TRV*<Q$F_&UQ-:%'SL!<4I'/*HMW:O'@Y
M1\9!NA% @Y9*GCE\*N')V#>67=KQ!_+FE-(A+[%DBY&Z6:4Y/8%Z.E?(US'+
M%C'UX;';FF 48G%$[U83-#" MQT7<'R60\.<;Y]?,SX=1&^X;QEW&^8YQPXY
M\:*/CUPI<[+WGE91L?HUDX_&Y/Z]$5UMH-WK-1B"Q[-=LV._\5ZX>)?+<XWZ
M)SAO^I9;:\!^8AK,E>^(_+W2+=1=<JF*\R,:+QNJ]@Y%1\91K?K\GDM-L*]5
ML$ZFBP<6(C(Z;MR\2<.3.<PJ/+GEWM6(\);?\T7YWU)W+9V&Z73 F%8GL,MT
M@;AKB,ER/K\[6;#F5#8Q06)]7H%&:8L9N5K[*-%-V0A&"TO7.>O(7?,\L\S\
M@"4UWCQG)M!N.%QG*?D#-Z+M4#=IZ^U"KK5EKR"T5?&ZQ0SR5.ERR[-E$V)Q
M*C&('=B]2Q<X 4 /D^=& "  $ #4^'$ ( >0"AV^3_N_>-4XY:-3FJ^2;37K
M!6=%K=;<.:<I.1MH+V3R@2E85BY)G)2(_I*.D52.#&\HG$>D:L6-:KP",4C"
M&C'J)'S9S%H,DXXK1\F[!8KY,[)(J9_%[_B%\ANWI)HVC(]NT019-D&J#)LB
MW1;QI2ECD$D4TRIIHL"E $"@ %2  [H!UWO1&W>])]-[? 2[?3.YX?I?;W.W
MTGP_T?$_E]GD[>SI%-["1#Q-N*@MTW4:S<$0%8QCJBB55$Y4A5.<1-W>SO"(
MB/3F45KD"I)O5(=5Y(GAX\[]VK755%Z^HY>&;BX74@EE3'9B8PBU,813[HB/
M3UVRA8EFZDI ):1<M8YFW</Y4&Y6@2;U9%$BCJ0!J4$@64$RGA@!>WL\G4N^
M:PT4V?6 R!IYXWCVB+J;,U;>A-C2[A-$JTD9NS#PDQ6$_<2_1#L+Y.O%2;H)
MJ^"FW\1-),BGHZ(F%)#OE*!O!2$P]TO\DO:/8'2G@HI(^,J==;PDR)^*NIV=
M]93N '?5/W0[3#VB/9U)3*<'#IS$RU;L9>6)&,BR4JQ:D,FU9R3XJ .GS5L0
MYBIIJG,0@"(  =O2!_ 1[[4IB-C^$3O-RG*!#E0-W>U(IR% ! O8 @'9U)&C
M(B+CC3+]>4F#,&#1F,K)NDTTG,C)"W23%\_<)(D*=97O*'*4 $1  Z;1D'%1
ML-&LFZ;1G'Q3%K',6C5(RATFS9HT2100;I'5.)2$*!2B81 /*/\ E22QT4CK
M-_$\!4Z9#*H^*4"*^$H("=/Q"AV&[!#M#R#TKX**27C*F66\-,A/%6.  =57
MN@'B*G H=IA[1'LZ3K9*C6"5U)ZG))0)8"*+"IR*+XLFC()Q8- 8D>I21 <%
M5!,%"K@"@#WP[>FPGKD$<6<TO9&@FB(\PM;$Y465<S[81;B*$TX5<J&.Z+V+
MG,H81,(F'M(!630H))+(I@5LB )HN! SA(G83]!)<P )RAY#"'E[>H=T_@X=
MZYKRXN8!P[C&3E>#<BAZ,+B'560.I&+BV'P^^B)#=S]'M[/)UIM:B8LK9QFM
MP3C"O'"*8(67QHQOZ7;8$QFZ0.HYM8RR4*HZ2,J7T^*<IB?O%,4))W&Q4;'N
MIET5],.63%JT<2KTJ*;<KR260234?.BMTBI@HJ)S@0H%[>P #HB#=%)!%,!!
M-%%,B21 $1$0(F0"D* B(CY ^GI^6-@86/+*21YF3*QBV+0LC,*'(HI*OP;H
M)@[DE%$BF,NIWE1$H")NT Z,N**7CG2! ZWAD\4R!3&.5$RG9WS) <XB!1'L
M[1$?X>CU%.LU].J*-EV9ZP2&CBUX[1RHHLY:GA2M@C3-G"JIC'(*7=.8PB("
M(CUW$$DT2>3]!),J9?(4I _1( !Y"% /_@ !_EB*RB*1U6XG%!4Z9#*("H02
M*"B<P"9,3D'L'NB':'D'J+?R,3&/WT&Y5>0KUZP:NG<0[7;J-%W46Y7246CW
M*S14R1SI&(8R9A*(]@B'1CBT:B<SA-V8XMTA,9TD4").3&$G:+A,A0 I_P"4
M !V /4A,M8J-;3$NFS1E95NQ:HR4FC'$43CTI!\FD5T]38IK'*B50Y@2 P@7
ML 1Z1%)FU3%N9<[<4VZ1!0.Z$3.3(B4@"D9P8PB<2]@G$?+V]*1TS&L):/6.
MBHJPDV;=^S54;+IN6YU&KI-5 YV[E$BA!$HB0Y0,'8( /66<DK!77#O6<:I&
MIYY09HDS+-HR-JNSN:B[T-@]KC=XG S*LTO1XXP+.VZRJ I&\,Q?$/VBDX12
M<)"8AA363(JF)DSE43,)#@8HF(<H& >SR" "'3J.DF;60CWS=5H]8/FZ+MF\
M:N"&27;.FK@BB#ANLF82G(<HE,41 0[.F3:.C6#!M&M"L(YNR9MVJ#!B0J92
MLF22"::;5H4J10!-,"D "AY/('2\3+PD1*Q3IPF[=1DE&LGT>Y=).DWJ3E=F
MZ15;+.$GJ1%BG,43%5*!P'O  ]1SR1BHY^[AUUG40Z>L6SIS%NG#59BX<QRZ
MZ2BK%==DX41.=(2F,D<Q!$2F$!*0A0*4H 4I2@!2E*4.P"E .P   #R!_DZU
MBL2SD&_I3*,CH^.9KR<W/SDHX(SAZ]7HAH4[R7G)=ZH5)N@D41$1$QA*F4YR
MD?L*[F%!8+$,9&%MTC.W"S)=BIP(,LI5%XJN,')T@*8R+5Y))D$>P%S_ ,'W
MOA_JY??:GK[WP_U<OOM3U][X?ZN7WVIZ^]\/]7+[[4]?>^'^KE]]J>OO?#_5
MR^^U/7WOA_JY??:GK[WP_P!7+[[4]0+.QWSCA .[5,I5RL-9MK;(IQ8["NV<
MO$(*!0?7%!28F5F;)94C5N"BYDTCF O=*80$QIC#BE* F,8U=O@ 4 #M$1$;
M3V  !U5R0VG\8)<]XC9&:I98PUC?FM\/#@S&6EJN5K=E1GXV+"0;BY7:>,D@
M"Z??,7OE[6,]6[AQZL$%*( YC)J#C;C+1,BV$QB X8R+"WN&;M 3D$.^F<Q>
MT!#MZL]YN5QP"MU"F5Z:MEKL4M!WMK%P%;KL:YF)V:DG)[3W6\?%1;-5=90?
M(1-,1_@ZJU]I-SX_6>F7>N0=OJ-EB(2]NXFPUBRQC69@)R+=$M/<<QTM%/4G
M""@>0Z2A1#Z>OO?#_5R^^U/7WOA_JY??:GK[WP_U<OOM3U][X?ZN7WVIZ^]\
M/]7+[[4]?>^'^KE]]J>OO?#_ %<OOM3U][X?ZN7WVIZ^]\/]7+[[4]?>^'^K
ME]]J>OO?#_5R^^U/7WOA_JY??:GK[WP_U<OOM3T6-NFEQ=:AE@61E6&2P4C7
MYR5:J$ OHY+K/3<W)P2:GE*=2-;M7Q2B(I.DC]ARU,*6=WFD[0(I6$I-BII6
MC=S$0BQ41<5V1CGS=Y%6:KOEVR2KAB_27(=PF5P0R3HI%RIMVEHQ^6222(09
M&4IMPBWKHY2@!E5V4?<WC-(YA\H^&<""/T%*'D#[WP_U<OOM3U][X?ZN7WVI
MZ^]\/]7+[[4]?>^'^KE]]J>OO?#_ %<OOM3U][X?ZN7WVIZ^]\/]7+[[4]?>
M^'^KE]]J>GLI*63!(V-C6CE_(R+^%N[-BP8LT3N';UZ[<6Q-NU:-6Z9CJ*',
M4A"%$QA  $>FMVRC6.+&G4Q\N[:LK=GCF?NE8>.F"YFSYLUGZW>)**<+LG)!
M36(143)G 2F !#LZ8"34.+YPE;8_H46)3V(WVE>8L9$).F,.R[#Z9;(X8=WX
M\<GWGB/HJW?3#PC]UZK!V_CW,I1LI(P<BI%1ERD4V$U#N3LI:'>G:6Y8K64B
MWB9DG+<XE505*)3E*8!#K[WP_P!7+[[4]5_5<>TWC?HV<VLLD>MW.JQ=YDX&
M:)#S$A7Y0S!\E:?#7!C-1+ELIV?R5D3E_@Z^]\/]7+[[4]?>^'^KE]]J>OO?
M#_5R^^U/7WOA_JY??:GK[WP_U<OOM3U][X?ZN7WVIZ^]\/\ 5R^^U/7WOA_J
MY??:GK[WP_U<OOM3U][X?ZN7WVIZ^]\/]7+[[4]?>^'^KE]]J>OO?#_5R^>U
M/48AM%;@XR"E'S.*1TNDR;V1IL=+2CL642QN$7,M6<[3TI)V=)!%\)G\8#A8
MB:[EN91,IO\ J>AVIX_=%+0E[$^80Q2)'CWLM.Q(0B$JZ[X"<KR&C5W:;<Q?
MH!XI_P!W[UQFU;5^-.J/,TRWYE'!;(N&Z\'8L/D*I.Q,O,/;1L6HI-)+:(ZP
MQ.M:Y9SIUF,+*1D;&Q%6JQCN7C5:8.53:D]PBL(89DA;&9..KO*;!H$O>Y.C
M"20^T'&U1]OK,)7X.V%4!KX*,$YD69BF5[RH"4G>N]RI$#+M(_Y-N_;%P2SF
M.!LX38_L=\RK0-\D\UM#%%J4H1R5,@]AQAF@FB!DS%;AVF A0 :OPA@>0F><
M>3<5<T^5/G7#YOJ/*BT<::/=J0U28L>4=@IW'6$J,E2>;TQM%@K\S2I(LFZ.
MY@916,39ECG"QY!;F/+W7DM4*K,1,'\X.J<I.-=YY9V"X:_*8U5(G6*WQRJ^
M=\#WU,;U3%$L?KL34IMM:H>6,I9X":<.W;^1&91*WN-/VNPW2"W&GX5PN=57
M"7=D>2V.43B--X%#_P##K?<1%>-AD[,]TQ1E.CH$VJV(])>8UY$=TD9%Q J_
MY1R<KEX;6S]D[Q%9_G\W/51\VCDJ"VO.L42KIZA?';Z/EH__  <S%U)ISUV1
M=-5V;NIQ\@W<E!NJJ<OS%H+B?&<'M1V*/Y-<;IN[[M1)/2\[^7KJU$FL,C*X
M_98O4\Y_QC=4/DIGM7HT::\0R4S8&*LC,,G"\JF19%BRYGMX>'FU:A\NWD:U
M^?!%Q[=HJ$;;&6RL\ AM#@/#0(5---)S3MOD#N$O%6,LZ[PE QC&ZX[XP[WJ
MI\<8G8^!_(#F%FFL:1ROM7"7.9'Y@/)3DW+ZU.7"R:#6:A967(JUX97-)AW:
MN=3X#&/8)^^76:2!@2!I::C,\GLUR/4,SYHX#48W-]#Y;67/XS3^'H<9\ZF=
M(JN+<%E*;-4W9@WVVSUMF8:^*2BLU'S4.#<CB,1A%F:M!R_4;+=ZA%H<8+U/
M\+LS8SCPV/:KCL?RGT6-WO9K"U.R8)O>3D!ISB(CI&&6%=O5:5)0QXY5PK+S
M2P?OMAJ<PD"T59824@9%,2%/WF<LR68N.PIP$HG*DN(E[?H, #U!0:\D[F5X
M:&BXI:8D!*+^55CF2#122>B7]$7;XZ(JJ=GD[YQ_ZJC\8G=^Q2%V&6?L8J*R
M>6U2BQVE2<I*-0?1D;'T1Y/(VAZ_D60@L@BFU,HLD/?( E\O58U[(;.A<\YN
M2$@YK5F;,)>+0E$8N7D(%^<C"=CXN6;^CRT6X1$%FZ8B*8B "42F'IE@RMSA
M";%(YS*:XQSPSDP61UFD+9HBFRMS2:=SNFA&-IGV;%13O=H+N"%[/+V])8DO
MMF1H[.N4#H9&KI%-3TY8@L E .E03S(6I0HQA@<]H-!#P!\3^1Y?W9F]Z99Z
ME2:/3VIK!8+E>IJ&K=4JS)CY3S<S89]RRB(1JS[_ )7*ZR1$^W^4';U-P^0;
M;D6JRU99Q4C9(O-M)IMYD:_'SP.!@WTVRK$U*.8EG,@T5%HJN5,C@$C^&)NZ
M/8Y!6/9* ]60</ .U0.#M=MX/HR[D#)CXZS?T=/N&/VF)W"]@AW0[(BR62"K
MC]_3CO9.!GIR,C'3RJJ+-@3D9&(E'Z!UH,ZK1+NKK(J)"9,O88>Z'7^(D%$U
M"4?VZNQJ'[=1+"%?/+/4UTBOHA']IV:2JTU75D' +-B^.JV,0X')Y![1(Z18
MLTG2;-..3<I-D4W!(](XJ),2+%("A6::@B8J0#W -Y0#M_<2K9I>++85XMQ-
MH0)G[0)I:%:.VS!U+I18J^G*1;9\\114< F*1%52$$P&,4!KV6W;;<CIVFVX
M[!.J9U:=)IM?O=G4E7"S2,)7JC+3+2P31Y%TW420!LW5%90ABD[1*(!UFS'0
MK,A6W>O:5#Y!G**[&5>C9M'GX2QV.(K*!HM@^(Q7>0M2D5P7=B@T*#82F5*<
MQ"FZO.0PEOAI+3,S@*-:K]2VK@QYRJUW2U;4C0I>6;"0"H,[2K1Y<K0P&'OB
MP5[0#N^7]\-B26V9&ILY"**&R)/2*:?3RD1CR2RQS4$LR-K*1*+4*Y,(M.PK
M<P*#^@/;_P!"75J=GKUG2K]AF*E/*UV:C9I.$M==<BRL%8ESQKER6-L,&\#P
M7C)82.6JOZ*A"F\G4GEUFU2L%NC/6\QX^3M/*UE9B0CM8W"H#=\PHD\SC8M^
MG&NKQ3#^GMU77ALO13@*JI.\ "TKM0KT'5:^P\7T&"K<2P@X=EXZRCA?T2,C
M&[5DV\9PJ8Y^X0O>.83#Y1$>F83[NOQSBTNT*JP"87CFBUB?.&[]VVK;,'IT
MSR[M9J@Z539D\0YDR*F G8!QZCV5FK-?L3*(DF4S%-)V&CI=K&2\9WOLZ5CV
M\@V<),I*/[X^ NF!54NT>Z8.WJ-MKNN0+JUPS)W&Q%F<Q$>O88J.D! 7["-F
ME6YI)BR>B4/&224*FKV?I /3-1*.8)J1Y7)&"B;-N0[$KSNB[*S,5,#-BNA*
M'B 3N]_L#O=O3Q:%EHR82CY.1A7ZL6_:R";&9B'2C&6B7AVBJQ6TG%O4C(N$
M#B55!4HD.4I@$.K'7,EVW(M1L-/$@6V!SK2:;=IFK"HX5:)A8XNM34F^A!.Z
M0.D'I)$NU0AB_2 A^YI6-U^SH26E9!$T"<T>KD8RR#BLQ6I-[&ZH3Q=^Z8(1
M+XMA;U&1,0K1PN='T806!,3$ W53UW'[E":%FEZC1F*A<ZXX%W"6"+!RX9B^
MCG)B)BJAZ4U4)V]T/TB#_P!9_,MT5A0N,,MGE4YE9(M9K)IF43,]R&CYQCP4
MP(\4]QO0R/FT#7(R/?OV0AXS5RJ05)#N*$.H3N_+\NT_RBY2B:\8=8R?,FL3
M.V7IY8\NX9ON:(U*K\I&+Y1T@^J.OQUM;KU(9N/:2$R.;N;$^%N)*\T=-.0+
M]KMU/@>0V2\R.6U?B...B<E= B-$USB'4>.5T=\<<KRW@8:JQF6.JA/22U7O
M,=I3>5![(.&TF9P\.*SB.+Q;T&$V+3]TN]R^3 O/<D+3HVF7K4WM3Y*SG(_'
M9S6*7*)VR1DXO$[DUNTC+(R-%C4H5"*)'H$"+;E1(8WST,R7@J9/\^K[RRX[
M'X-UN#@HUWRD<;9_PG<6T\3O>)+LVG^(<3'TC0XMT\>6".51C(5JU?G>N$4!
M7 S@R&P:L7F43YQ58X^QW&-/0;<>NJ?+.=93#/INVCQE":&D.<:)GKE_?%--
M-!^FEN#8&039#$^S O.-Q>U-MDE:9R"^7\YYJ<Z,VYW;9H>":_QZV;7-0J5Z
MGK1HJ["=E/EQ:%-.*NQ3TJ%IC=PTJ-1F&KUF^18@@X966LZYI^-<H\XL&P;8
MAFBM/TN8Y14&)P=>^R2E#QN>V71:]&3&X2.7-RJPR\Q)-EUEB,TD55G!T#+'
MXIIXTE-8//;C\Z&;PG4KEB#!3+]$LV.63YFO(JF2M,EK75(V/L*=7/35A8MS
M'4!-@T$AVQT1(DH70>.5;Y)QN'N\+M?RXZWP90Y)<P]OI[BZX<^0K3G?F=1R
M&0A+6VY^6K;9YM9Z989JT3[N=B9)&. 5V)FZ+Q?4XG*K+L]/K/*7BI\X^@W[
M![/RTW'6=Q'8,#F(=OE\?:L4E7(0G$34(^,;SZ]0JM,?*2;RGK&*Z*NFU[4.
M,52R/>]T:Y+0O^7AY$<E:RMD>^ZN@T+RDQ-SQZ" FI&YUFUK3LG8L<NLO*Q[
M>J.) \;%D2/"K1GV>V"/3W->M;=N3R+T7C-\CW>]QL=]V?46W[!Q?([=M)I/
M-[6JK?U&5RG^/,!:<WJS']J5ZC%@QID8#F7CHM@= 5T^"?'NP<MY#5.,^Z\B
M/F4-6$;Q4Y=;+I-?C\,I^ U><SC#[CRSAVV<ZM>YC'].4E'<=*&?-Y!F0S:/
M],72;*I'^7EK?(;5]#EM;T3Y-+>(JT]?M.O%6'7]!I7(Z2A[(S5JYIZ!JVE7
MHM#*VEI^/48/%G"R;>:=-Q<H(/$OF=<?J%G/'&44U?@!PCSF2VK?FLZ]GN/X
MVJ\<LFR6C8I78;/+(-TOM;:(*RK%N-AJ(-)V-BUS/1*F(!=J1+<F*QE.GXUS
MVIF=53/MLY7:8POVP\!H+C-3##4L_P"&YZ8\S#6C;5(K3-L4T@\E]K-[6Q>?
MSS5.+*P+\H+=Y#=^2]AU/F#SJQF/Y$V*YZSI]F"Z5EGE_+,&%&<T^9DW%6HN
M?K*0445['Q<=%M)%>/:N7_I#LH+F6O6!;MN>G<U[5\L[YD^H?,#S:;MUKODM
MQ\Y2YB_J+?&7C##)Q61KW'G3*+>GEDKM*JL/#12%GA(PIACI,K0CL.=+[CYK
M=VW?()3C+\N)S6]8NNM7C>%[)(I1W*5.;08:S?)FRR4RJW*9L[D8U%^="'DI
M!5/T=F*GHY?WSYR^5PD139GYC5Q^9;C#_A)"5R%BE^5+#34,1X8OLTTG*9!J
MS_;^M5*E2\),OI2P-EVT-'13:3*\<$067352%/;-41YG.?F[Z7Q\L/'-_H-E
M1K->^6>UR:W.ZQH(\:'<NGGK?(8+/&\+H3/2#097,C<%_059A071XSJ1QIAK
MR6A?L+R=X!Q7.3F[G'/[==*XV[EBVS?XM1ECM<SNDO&66V?+[M%TOU)@TM0@
MJDS^S:C!62.!M(IQSY-PVV7D%I6R9UR-A,E_XF] Q^Q9SK%JWZ!?YK$W6XN\
M.Q ^Y3T#!VC9K/51]"IAIY5H+J1<-TP.HNL!UU.=G'FMU'E+@NC:EQ<XO\V)
M&T6JD,6^FL] E-:HN*?-VVS/7M7F-!1,^@:Y8F-O:OP.G)Q)G)GB"!DVR#@V
MJH\5]LT.6QZ]?.#^5+2F&A1^U7K6D=0RNT<.8@EHHQMHMMFN$[K.9NW\>5!5
M->9E6Q5D#M_% 4123XB8VCS-T'/]L:X[\]BH<BKK<;I+S4IQZTBC75_&X-?>
M35<?NB+1#_$XIXC*5=E8_0U#0Z K,0.V 50^7XTT>R2U+IW&SYN,=E>A[%1O
MF#[_ ,B>->H7JW<#[]H-:O>5\J[O8JE8I.NR^BGB8-S#R1T%*_<)&1KZ1US2
M;D'F4HWS=>52\3M'S6/FK\4="@87=MHI-8>\:<DS_D#=<SR^'B*C8H",HT-6
M++F\8M&V&&+'6,$S*-DI46RX(]<4:KI'+AQDY93Y;-UG^.V^<D>46C\4:V^Y
MF5/D_I>9*7^QVVHT"P?\56KY=G=;I1UZ+9C"C*1,J]>';/E9%TNC=-13VK?F
M-CS#YVG!WB]7*Q%Z#H+;(6>)[5@/%\F[4)/)SR+NCV"B7JQZ%+R*;N6:2#R%
M<BBLQ=LED3B;D/5Z[<[-/Z'!<Y^:L;KE8NNL770KA2)AER?UIA3&]EKEVM$[
M)423L^>LXV5$XMV2UA3<EE5C.CN?23\;>=^"T/+,HN'$KY>WS GN(.<7BYB<
MY-\F-1UJ%O49GK37JC(9;4X-M!T&4B$[(UK(OKHK.6U%B9,[?N&(M7%\IYO+
MW3'MMY??*0S1O$8#S8UKD]K6=/\ 5M"FJ[RCDM)UNZT>F7?,E>0U/EHE1W5@
M*",!)L7SI%*/4<!V<KL)K.Q;G5^*646WY)N5:7:WNI:-)3F(\5-'N&WPG(W1
M&&PV"<?WB F;E'Q$0RNUZ-*+3C.*.I).7S=1J1ZAAV8Z5RAV^%^6L[YY\]J'
MB>ZCN6C4=AJ$!FN09!,\9\ZD^7<7/P]]O><PFQ3VHM*8Z=VQV2Z.:<P9*N98
MC)%%QP>;/$9)!RVQ=DV5),LG4?,F%"?GD@6F&;YLS>H2K@I 4<@LDFJ*QC"<
MH&$0_P"L&\WI%\IF?0SIXG'-9>[VB#JD8YD%2'428MW\\^8-5GBB:1C%2*<3
MB4HB =@#U\37'SWSYQ[2=?$UQ\]\^<>TG0B')CCX B/:(ALV<!VCV=G:/_F3
MRCV!TKV\DN.P^D)E17[=BS4?&2*4Q2I*_P#F+^<3*4Y@ H]H  C_ -O2<R'(
M7C6$PE'_ &2E+!K.7A))1?C X^S4WP3_ *42/](#Q/! X)]_]+L[?+T[&/Y%
M<<&(OWJTB^%GKF8M1>R#D$RN'[L4+ 3TEZN5(H'5/WCF H=HCV!UZ3_Q)\=_
M203%$''^,6:^/X0F PI>+^T7B>&)@[>[V]G;T$U_Q$\;OMD&(Q82W^+>8_:8
M1AG .S1P/_V@]*!B+HH*BCW_  _$#O=G;Y>I"/8;]QE9,)9P^=RC)IJF6-FD
MD[DP[))U(-D9XB+QQ( /\^=0IC*__,(]-8V+Y&<<8V.8H)M63!AKV9,V3-LB
M4")-VK5O84T&Z"1  "D(4"E#R '0!_Q+\>^P![P!_C+F_8!NWM[0#]I/(/:/
M4=)/.0_&QW(Q!G)XE^YUK,%WL69ZD"#PT<Z5L!UV1G:!0(J*1B^(0.PW:'3B
M00Y <9T7[Q^G*NWJ6JY8F[=2B3 8M*2<.23P++OTXPPMBK&,*@(#X8#W/)T#
M2-Y%<<(]H"CA4&K+7,Q:-P5>+G<NU010L":8*.G*IE%#=G:<YA,;M$1'I1)7
MDKQX4253,BJFIL>;'342,42F24(:QB4Z9BF$!*(" @/32,B.1'&Z*C6"0(,8
M^-UO,&+%D@';V(M&C6P)-VR0=H]A2%*'3%VYY%<<'#N+465C72^N9BJXCE7"
M)FSA1BLI8#*-%%VYS)G%,2B8@B4>T![.A'_B9X^=H@ "/^,V<=H@';V (_M)
MV]@=O3>;5Y#<;%)IHT78-)=36<O/*-6+DY%7+-N_-/B[1:.%$BF.F4X$.8H"
M("(!T ?\3''OL*/:4/\ &7-^PH_]H!^TGD'R]2+]GR(XW-'TNJ@O+/6VMY@@
M[DUFK<C1LM(N4K 19ZJW:IE23,H8PD3*!0[   Z(QB^1?'"-9)G7539Q^NYD
MS:IJ.G"KMTH1NWL*:13N72QU5! .TZAS&'M$1'KXFN/GOGSCVDZ$QN3?'LI0
M#M$QMHS@  /^T1&R=@!TRE8E\SE(N3:-W\=)1SI!ZPD&+M(B[5ZR>-CJMW31
MR@H4Z:B9C$.0P" B ]!8M$NU1H5?,[0CPG;I9(:K0XOW0'%LR"3G'K%D+MP"
M1O#3[_?/W1[ 'L'KXFN/GOGSCVDZ^)KCY[Y\X]I.OB:X^>^?./:3KXFN/GOG
MSCVDZ^)KCY[Y\X]I.OB:X^>^?./:3KXFN/GOGSCVDZ^)KCY[Y\X]I.A<AR3X
M[@X%/PA<?XQ9KXPI=[O>$*O[1]\4^\';W>WL[>AF@Y$<;@F3,"Q9I;_%O,/M
M,T81P9V6.%_^T'I0L"NCBJ"/?\,%!$W9VCV]/HEAOG&-E%2BK]>2C6FIY6VC
MY%>5$XRBSYFC.D;.U9(5#>D&4*85N\/?[>WIM&LN1G'%I',T4&S-@UUW,F[)
MJW; 4K9!LU2L)$$$6Y2% A2E I  .P [.BF/R6X\G,4#@4QMDS<PE X=TX%$
M;&(@!P#L'_M#K +->=\Q!XEQFOY]3RBH17(FJ5[/6&B(1+B'KUNL%&@KC'UR
MV2M)0?.%H(9%!PE%.W"CA A5A X/UD.1/&]%:54*M**I:YF*:LDL1N1H15^H
M2P 9XH5HD5(#*"803*!?H  Z0KK;>.,#>OM13,V@D-0RE*&;F2= _2,A&)SA
M620I/@\8HE('=5_3#]+R]=O_ !,<>^T!$0'_ !FSCZ1\@C_>3Z1Z9EE.0W&R
M2+'/F\I'E?ZSE[PK&3:=_P!%D68.)]0&KYMXAO#6)W5"=X>P0[1Z[?\ B7X]
M_P H#?G+F_\ *#R ;^\G\H #Z>GKMKR+XX-G<DJDO(NF^NYDBXD%D$2-D5GJ
MR=A*HZ51;IE3*903"4A0*'D  Z  Y,\?  /H -FS@ #_ . !9.G*45R&XV1B
M;Q\YDW:<?K.7LB.I)X<%'<BY(VGTRKOG2@=Y18W:H<WE,(CTNV<\DN.SENZ1
M4;N4%]BS59%P@J0R:J"Z2EB,19%1,XE,4P"42B("'9TV@S\@.,YX5D5@1G#G
MU7+#1;0D6H@K&$;1XSPM$"QRK9,R $( (F3*).P2AV>3DSQ\]\V<?P^4?_\
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MG)MSCU!7W4M06AW%?#35:XP/:A9K5M5>KJKFDS'%R,2H>(%T*GH!C-/!$?\
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M6R2SQRNN*210.<PAV_Y3@/\ KJ1_V7Z?^Z$+=JK6[A#E<I/"Q-I@XNP1A7B
M'!!T#"6:NVH.404,!#]SO%[P]@^4>OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7
MTC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7
MTC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7
MTC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7
MTC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7TC^P^OR'QGW7
MTC^P^NP<&Q@0'^ <NHXA]0P?3=FS;H-&C1!)LU:MDDT&S9L@F5)!NW02*1)%
M!%(@%(0H 4I0  #LZ2D>5%WQ2E9Y(RK9HU6W2=I4-59.<2*==HT9)WEPC&R,
MND0IE$TTBJ+E*4Q@   1Z_//Y<_K7Q]\_P!?GG\N?UKX^^?Z_//Y<_K7Q]\_
MU^>?RY_6OC[Y_K\\_ES^M?'WS_7YY_+G]:^/OG^OSS^7/ZU\??/]?GG\N?UK
MX^^?Z_//Y<_K7Q]\_P!?GG\N?UKX^^?Z_//Y<_K7Q]\_U^>?RY_6OC[Y_K\\
M_ES^M?'WS_7YY_+G]:^/OG^OSS^7/ZU\??/]?GG\N?UKX^^?Z_//Y<_K7Q]\
M_P!?GG\N?UKX^^?Z_//Y<_K7Q]\_U^>?RY_6OC[Y_K\\_ES^M?'WS_7YY_+G
M]:^/OG^OSS^7/ZU\??/]?GG\N?UKX^^?Z_//Y<_K7Q]\_P!?GG\N?UKX^^?Z
M_//Y<_K7Q]\_U^>?RY_6OC[Y_K\\_ES^M?'WS_7YY_+G]:^/OG^OSS^7/ZU\
M??/]?GG\N?UKX^^?ZBJYQXV+A5,:M*H.VT%#93;<9&^RJ HF4?LX5G6G9)Z2
M#T9,QUD6X''PRB8Q>Z B"'_]ZRS_ &G5']^J.U<?="ELSU2G\M^-*U>LD<HZ
M58*%>W%PQ?PMK@D735K;Z9-LUSMY.(=B9J_;'$AP[>Z8KL!:1N9<H<SCHXFZ
MX0>3%X>,%T;T1EI&;O'7A/+;C]M=$'T)]W1<1KD18/P(Y(0Z_P#DF _ZZD?]
ME^G_ +I^-Z>I7JLXED^-999Z]G]+MUAJ$'+W._*6F2GKG;4J](QJUDG4&S!L
MQ8>E'4;L&R1Q03(JNNH>,GI.T[E%5V<!^,!9I:ZZU%5>Q_9)RI3 5NS2$RV@
M;$,*J<"O09.%Q9F$ 6[@^3I"GQ45RQE;HZC&4ZVH\6ER'DKRO7I)%-Q%V5*E
MLO'M"E8E6ZI%&LF#06#E,Y3)*G P"-LBY1[R0B9?/T"/-#AI>8W&*FLZCU%F
MK9.6T2'D'K:3H<*HX?()E>RZ3-J*BZ104[RA -&R<A<]GC8J;2D'$#+2=_U*
M-B+"UB7IHV7>UV5?3S>/L#"(E$S-7:[-1=%JZ(9%4Q%2F(%7N]]C>5= HUX*
MN>DWJ_'W^DT>YE;-A?+#4KA:58FMV0"L2BN'H;E;OH *A>T@";J&C%++O*4Q
M9/L0:U K6W84;%9RV<Y"592LUY65)-V)*U&4+]E'9(+ED@, MA5#R].,ZT W
M)B@:0U=0[%;-;S*;G3]'![8A3"N,TJ#8GD;;G#FQ&5*6/339G,^,/8@"@^3I
MU2=24Y*97=F3)C)NZ7J,SMV<V]"+DRG/&RIZQ='\'-_9<@"9O!<@@*"HE,!3
MB)1 )Q6!LVZSZ%6A@LEM=P%RUR<94^M&=IQY++<7L3,/&E2KBDBL1N1_(G;-
M#N# D505! O5QT&M%Y.6?/,Z,U)HNB5B0W:QY[GIWI"*M27N\PCI]5:<=5%4
MBG9(NVPE3.4YNPI@$;E.4-/D]H$%G$0E8-'GL_?[M>8+.X%=-59":OLU5'4O
M&4V*6;H**E<22K9(R*9E 'PRF,":R6EZ<JBJF15)9+5M 41525*!TE4E26<R
M:B2A# )3%$0, @(>3H?_ %'U+R?3_P"J>A^3_P"/_F;H.[I&HCVAW@[-3T(>
MTO;V=H=EF^CM_AZ#_P!2-2\OT?\ JGH?E_\ A_YF\O0?^I&H_I#V%_\ 5/0O
MTA_[ _\ ,WE'KL'2-1 >P1 !U/0NT0#RB(!^TW:/9U47VCSVT4EGH&;U_9**
MYG-1O)4K9DML-*%J^B1'H-O>G-7)XT(\!N*P).1%L?O(E_1[9'/-5E=LS^^Q
M#"NRLK4;#J5U"8CXRW5Z,MU5?N"QMSD68(3]6FV;]OW5C&]'<D[X$/WB%[0T
M?4A#_M#4]#]INO+I&I!VCV!_ZIZ%]/9V]G]YOI[.@ -&U,1'R  :EH?:(_\
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MHYM&1A066$ZSAP<X9F_J>UZ76'^)UZX5#%GD':'+!QDE1T3[0#0:MGYTR_\
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M%_I8G[2&$Q>\H(>(H':/E PB _0/:'1FPOW0M3.%'96?I$B#)%VN8AW+MLS
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M#(5ZHU,<[8[N+O%%8N3MSJ$34,@99 PD$Q2B)>SM !\G7RY/];'(G_9'$?\
M0P'%L\T+Y4+'1:[R+YDR>EUGYD%EQZ,ME'JFHDI#&A7'&0TLCF4J+J93:OEE
M)1BF3M5:-5>U3P>P/D#,;;NM3@JQQDK'S*H+D0M)Z$D2LYS)Z+?-N94AWHJA
MWJ,4U)I\#*,E(QT]2(,U'.VYB@9)0A>O^7AUB=V?(J_5.(6GZ!FO)"OVG5Z[
M!7[)IRS<GK?I<'9+1FLW(-9]KFZ5$?MGAK0")H9FDJ5(S@A@[G7*WBMN5EG9
M_%^5$/:=FM$]/3,C8D8^:X5;B;EC5[@^EII:379P]BRJ$ML"N^$Y2BA/ID$_
M8MV&PSFAL=FB*16;]SE'>[O:K;*MX:NT.E6*7L+V#)/S,FLDQA82G51Q&QGB
M+*$102:D*)@ .OD7C+[15ZK'X1SQ^8MHF]D<7A."B\TINF[!&O<YN>F(_:#1
MA"PESJRSLT:^D !-U'J*E(<43G ?DN;/:M#SQ_2."O.#E,_Y+Y8:ZQJVNU>"
MU?E35M+R^_0.%^,>WWNB1%2:_M%]JQ;-RT9$CC)@(+=TAKUQVN_(7'N1^R;#
M\S:V<Q,^EL7V2*W^(K6&KY7;*;.:G9KG%/'Y:-.\@K+8&"J5>>F0FW*+([I^
MV2.@ !_T*+O&#WJ2S38<TDCR5-N4:3TE---SW"3-7M$,<Y&EMSZVM">BS,,Z
M[6[QN/>+X:Y$E2.NQK&YIRAS2-C2;OA!Y(SI2)4=#Z(ST;.7COPW=MR"VNTQ
M%B^ #.(YP86#\".2%,O^ZJ4N".CD(LL1-3_$RF%\5(BIR)+=T1[Q 63 #]T?
M*7M[!\H=?D$Z]YM+_CZ_()U[S:7_ !]?D$Z]YM+_ (^OR"=>\VE_Q]?D$Z]Y
MM+_CZ_()U[S:7_'T0IL%<IE,<I3*&TRFB5,HB &.8" 8X@0/+V  B/\ !U.8
M[H-7G,BH6=22:L+E#YRFJM9U"G-]FZ3:)*/44B;8A(F3,>)*T4<1L>0! IE'
M8*JAS1;R-U+G+%?AG=$WE[4:V%\2J(&MM=!6<.SJ2+BS.BL2]IQ(Q3.Y-V=A
M"F'R#QDP*4N\OL<_66%IVQAM#QM-EJTYGVO$;*5.K9K*VA\\LD]78XK0QWYU
MRH$9OT0;^&!RB4D$SR&(E=#::-.,8>QXBS.NHCH2QP*GZ?"D33<$@+A$,2"H
M25[G@$;IB5]WFP")!!/C=?5"=A1*<;SC9!'M* B E'01[!*(]@^40[0\@B'E
MZ^&N^>O>-?[P.L$863(;/08\NMJ.BSDS9L_F6:CI',M(*A&E:56TS<F#AX54
MYBG,B")03'O' 1* _N0M?Y,8+EFX15:>K2%;1T>G0]D7KSQT1--XO!2#YL>1
MAQ?)HD*X!LJF5P4A04 P%+V? )QI]W<;_'U\ G&GW=QO\?7P"<:?=W&_Q]?
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MM+HT_*JL+QN=A8$;VS01:"5I#M%>XJI3J @Z)Z3#U5LL4/%6,!7DJJ4%G/=
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MZ*RJ?I!EE%*K%24@Z?1=2XG9J%7CG"@G90 V>^ZDYLBL8W'^;;.)Y:):"Z5
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M.T.D>9;FIM"<:5M;>84;0@G8H[MEJ#&.6E%H:3JH*?;C"(5;(&(C)G)Z(JY
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M+KDJ2@N-JF)2P:8>90?-5$[T$]+S;I1$)/Q08E4 B/=*4H='7/#1PNSF%09
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MLT/Z!#L$/[L_0(=-F)<JT@K)FHBLT9ADE^!JU5;*&6;JMT JWA(J(+&$Q!*
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C4BHB-C5%R%$A%CL6:+4ZI""(B0JADNT $1$ '_\ EO\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g790774g48m48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g48m48.jpg
M_]C_X1!617AI9@  34T *@    @ # $   ,    !!1\   $!  ,    ! JP
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HR.3HR,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   **H , !     $   &1          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M?G;E(_6'#! ./G2Z8_4LGMKSZ&UO]I)3J)++_P"<.'.W[/F[@ 2/L63P>/\
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MV?_M%^I0:&]T;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (
M   X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  0$L     0 !.$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -'    !@             !D0   HH    )
M %  ,0 T #0 +@!J '  90!G     0                         !
M          **   !D0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !D0    !29VAT;&]N9P   HH    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   9$
M    4F=H=&QO;F<   **     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    ".$))300,      [L     0   *    !C   !X
MN:    [0 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MJA;Z%@MJG\U[?HO$):7J*\E"Q$4>+3>7Z7^*V$D/TB-6/<WR)W#_ *<H6/\
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MV*QF=1P<3)Q,?)=MNS'NKQAM)ES6NM=[F@[/8Q"NZQ13F68KJ;"ZL;B]H!!
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300&       '  @
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M"DTU)2U-6':)?#+(J'2OX]R;N'L5NFV[?N.YKS%;7"Q0O*4(( 1 6:E2. X
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M6S0'7);21C)SK4CUZYS\B_=4]UMGYNY=W>?998[2SOX99C++5'1) S:5UMQ
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MU!/XY)(/U)/U_I_3_#V4&E>T8ZD(%V +J ],TX=<[C^H_P!O[UPZ]YT\^O7
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M?NO=>]^Z]UU?_7_VQ]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZO\
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M%'RKU0(=?BL[&;S-3_@Z[6'3JY'J8G@?0&W'^/OS*QII8#&:BM3Z]6"HIJJ
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M#?\ UO>NM@@\#U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP;]2\?@\V/\
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M[55'.4H*<)-154A\M71M'81RO9G0*3R2??NO=*/W[KW7O?NO=>]^Z]UK8?\
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M65@"%  "A;>_=>Z>/?NO=>]^Z]U[W[KW75A>]A<\$VY/^Q^OOW7NL4JJ%0
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M@^IEDT%@>??NO=/WOW7NO>_=>Z][]U[KWOW7NL4OT7_@X_WH^_=>ZUFN@?\
MN*M^=W_C-7IO_P!Z?J#W[KW6S5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZXE5(((N#<$?UO\ 7_;^]%02&(R.O#MX=8OMH?\ CF!90G%^%'X'-A_Q
M/NQ)+!S\0Z\#3]M?SI2O7?@AM;0/]YY_U^>?;:QHH556BAM0^WUZ;:)'9G9>
MXBAZS#CCW?ISKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__
MT]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8I?HO_!Q_O1]
M^Z]UK-= _P#<5;\[O_&:O3?_ +T_4'OW7NMFKW[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW6*7Z+_P<?[T??NO=:S70/\ W%6_.[_QFKTW_P"]/U![]U[K
M9J]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_5W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]UQ=UC4N[!547+,;  <DD_@>_=>ZQ?<T^IU$T;/&
MD4DB*P9TCG+K#(Z+=ECE,;:6(L=)M]#[]U[K@U=1QQO+)4110QZC)+*WBB0*
M5#,\DFE%4%@+DVN0/K[]U[KMIHY%&APVETO8'^TNH?4"_I/OW7NM9WH(A?\
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M^_=>Z,2?YE__  I,U%1_(>V)Q:__ #D_L(C_ &#_ -_ K?3\>_=>Z]_PY?\
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M\-52Q''U58H2%M97B_NO=&)_X<N_X4F_]Z'MA_\ I3^P?_L]]^Z]U[_AR_\
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MDSL>!C%,@>/5'/OF.2.32>48!U^C 'W[KW6?_AR__A2;_P!Z'MA_^E/[!_\
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M_P YL_?6V<#O':F:A^3.RZ>++[;W-BZ7-8/*14U=O6EKJ>/(8RMBE6.:**5
M]G16! ]U[I2_\.7_ /"DW_O0]L/_ -*?V#_]GOOW7NO?\.7_ /"DS\_R'MB<
M\"WR?V#]3_7_ '_AX]^Z]T7?X[?SW_YY7RQQ78^;^/?\F3K?LG%=1=J;KZ1[
M&K,?\A,3ATVSVILB.@EW5L^=-S;@PLM;78:/)TYDEI5GI6\JZ)6O[]U[HQ'_
M  Y?_P *3?\ O0]L/_TI_8/_ -GOOW7NO?\ #E__  I-_P"]#VP__2G]@_\
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M4U*1GW7NBS9G^:I\,\'\ J#^9KD>P-W0_$#*4V/FI-[_ .C[>4VY6BR_:/\
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MAYHXTIX<>QNLGNO="O\ R M[=N;@^34%51?-CXU=R]:;\^$^VNR.Z/CSU/\
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M#F?BC\@^DNF/E ^YE^%GR/[-BV(FQ?DM_<_;&8WM7Q/M/ ;LRO8?2M9O'8V
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MV_UOV=-NB#K?L;KWL2796=FVSNZ/8>\=N[N?:FY8%5I-L;H7;V4R;;=W##J
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M8Z["[BQ3UE-D]LUD%5$34&2%/=>ZHM^,'3G\S7H[^9%\+ZKY&]#?&RMHL/\
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MKK\OLWI/;.<AS%5(TQ"K,DK.92Q]U[K:KI762-G1]:M([+PRJ$U$(%5U5@-
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MA]("Z.?(YL"=(=C)>4*ATC7<C^OOW6^NQ32)_FI1%Z46X4L3H4JH;6Q&A >
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M%^/]A[]U[KVH?U'Y_(_L\'_;'Z^_=>Z\&4BX92/Z@BWUM_O9]^Z]UXLH(!8
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M%F!04K9+(U%ZU*[W7NBQ_P L+^7Y\GMT_'?X+9CY8=^[WDZC^..XLGWAUO\
M$7=O2=#UQVAL[N?&9[M+;^R(NU>X:O+UF[-U[ ZTPF[ILCMG%187#5<D\M')
M75=9!2PQ/[KW3S\<_P"1OV5\>^XOBUOF@^3?2.6V1\4.Y\YV%@<5A?A5LG97
M<W>&"W5M3L+:F<R7R5^1>/["R/8'97<$-/OV2JAS=.N,Q%;D!/59'$UDDE+]
MC[KW0H;._DS9B+973W379_R$H=V=)]'8K^8)U7LS$;-ZTGV%OZI^/7SBV50;
M6QVT\UNVJWUN[%3]H]3U]1E*W^\\>+2GS#34G^XZDDIY9:GW7NE/2?RK.]>T
M<A24OS2^;-?\D=F8GXR?)#X@XK!;6Z6V_P!,Y1^J^^]O]:[=??\ F<G0[IW;
M1Y/Y 0P["\^4S:4U-@ZIS E'AJ%4J#5>Z]T+GP=_E^]S?&#L:KWCVEWUT7V;
MA,-LNHV%LO$=/?!_I+XT;HSD#U>,,6_NY^P=I3[CW%O'?;XW%"*6EV^=J;9D
MJ*VJGDQDA%&E'[KW5K/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[K_T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=<74.I4W 86-C8_[ _4'_ !^H]^Z]U%%( BQ^5Q&K%@BA0#^5#D@LP5O4
M>;LW+$W-_=>ZE*NE0OUL+?[X?@?X?CW[KW7+W[KW7O?NO=<)$\B%-3)>WJ6V
MH6(/%P0#Q[]U[KA%#XV=C))(SGZN1Z5!8JH"A18:C_L/?NO=9O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M?__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
H]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g790774g59i17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g59i17.jpg
M_]C_X1#417AI9@  34T *@    @ # $   ,    !.;@   $!  ,    !&6L
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HR,#HU,@     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   %:          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M     !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  0$L
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,]    !@             !6@   PP    $ %  ,0 T #(
M   !                          $              PP   %:
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   %:     %)G
M:'1L;VYG   ##     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !6@    !29VAT;&]N9P   PP    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-
M! P     #VH    !    H    $<   '@  "%(   #TX &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( $< H ,!(@ "$0$#$0'_W0 $
M  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _ /54#,KR;<=S,6X8]Q+=MI:'@0X.=['?
M2WL]B.DDIRWX/7"\.;U)H:&[0WT6ZG8QN]^KMV[(99;^9[+/32MPNO$S5U)C
M1Z>T@T-/Z38UGK#W?Z7]-Z7_ %M:B22G*Q\+KXN8_(ZBQU8?NLJ;2W5H.E;+
M/;MW?GV;?_2B$WI?UB%3&.ZL"1MW.] 2=O\ *W_G[?TFW9_UM:.=U'"Z>QC\
MRT5-M=L82"9=#G[/:#^:Q5;/K)T2JJRY^4T54M:][PUQ :]INK.YK?=^B;O]
MB2FE99U&CUJ<WJ]5;:'MNLM:P!_V9K-]S'-V[:+7.KM=OWW?HOTGZ-,#GLR/
M6M^L%)Q_4TK-=3 6;J<IM/J;O=OPG^GZS?\ N1]H6Q;T_IV3:,B[&JMM+0!8
M]@+MO[NYPW;?<E;TWIUSR^[%IL>7%Y<]C7'<YK:GN]P^DZJNNO\ J,24XC\J
MZL.R+>O5-J:XOD5L;66&S(:UCM_J?0V>@RRNW])5B^IZ?J?IT:R[,%U@=US&
MKV6/(9MK]C7/V4U7,-F]SZOYC=ZE?J?N>K6M0=+Z8',>,2D.J %;O3;+0'>J
MT,]OLVV'U/ZZ5G2^FVN<^S%I<]_TG%C9)G?JZ/W_ '_UTE.2V_*<6;>O8Q<*
M_2C;5#[B\_I-H?\ NN97Z3'J#[>J-I#G];Q:KV_H;QM98P6M.0_3^9]-WI[/
M5KL9[/LG_&V+79TCI5;0UF'2 &[/YMOT?W>/Y*E^RNF>_P#5*?TCM]GZ-ON=
M+W;W^WW.W77?]NV)*<JZW)?=<&]>QJF[GQ7MK+F-)=M:]QL#M]7_ %OZ'O3X
M^3F7[,>KK./9E.M%@:*VC=1ML_0ULW;O5=]/U_?L9_@?]-HOZ-TBQ^]^'0YQ
MDF:VF2XASG.$>YVYOTT2KIO3Z;A?5C55W-D"QK&AVNCO>!N]R2F@[I_UA#)9
MU1IL:#M#J6P7%KA^ECZ3/4].SV,K_/K1+L#K3B_TNHA@==OK'I [:B+6NH=[
MMUGNLJ?OW5_S2TGO8P;GN#1($DP))VM']IQ0QF8A<U@OK+G1M;O;)GC:)24Y
M5O3OK,&6NIZJQUVR*@^AK6;@/;OV[]GO=[W[+/\ T4K%N%UJSUPWJ'I-L+33
MMK:75\^JW>1ML_D_HUI.)#20-Q T Y/WJACYW4WXE%]W3'TW6;O6QO5J<ZL@
MQ7^D:_T;?4;[O;8DIL8-695C[,V]N3=N<38UGIC:7$UM]/<_Z#/;])6%19G9
MSWL:>G7,8X@.>Y]/M!,.?M;<[<UBO)*?_]#TBW-N??DX6(QOVNBMEC3:8K/J
M;MD^GNN_P;_\&J[C]: "1]ATXGUO-">VEW5>J&[(&/7]FI:^UE@8^L-]6PV.
M.[]%_.?SG\A!=5T=H<X]=N@:F<QH&G_4_024[6'D?:L.C)+=OKULLVS,;VA^
MV?FC*ITC_DG"_P#"]7_4-5M)3%S&/&U[0X'0@B1KHF%-( :&- !W 0(W?O?U
ME-))2/(R*,7'LR,A[:J*6E]ECC#6M:-SG._JM57(ZYTG&O\ L^1E,JM](9 #
MC -;BYHL8[Z#_P";?]!4NH9N7F=0R/J_5BMA]-=C\JP"RL4VFVN_?0YNSU?T
M/I8]5G\\]_J^GZ.-;ZEMG0>EMKN8ZD6NRJ3CY5MA+[+:SNW,OM<=[_YQW_4?
MS>Q'S1=[),3JV!F6FFBPFW8+0Q['UEU9.T75"YE?K4[O\+5^C5Q5*.EX./?5
M?34*[**!B5$?FTM(<VH?R6[5;2-=%"^K5MSF@7MQ:SE9&.6A^.PM:[W\>^XU
MU_0]_P!-4[>L=0IJ?=;TFYM=;2^PBV@D-;)?'Z8?F-4*;'XO4NKY3J;K&;L?
M8RMA<Y\,#'.J;NVOVN=[]O[B'U'K0MZ;E5_8,UF^BP;G4P!+#]([D$NX"" 1
MP4ZBSZ(^ 4DE(LG&Q\JA^/DUBVFS1];M00#.JIU?5_HM5C+68E8LJ<U]=A!+
MFN8"VO:]TN]C7+15+J_4F=,PCEO <T6TU$$[1^FMJQ=VZ'?0];>DIN$ @@\'
M0K-_8_1;6,P/3W#"$MJ%E@+!9[AN=OW/W[/SUAYN=U49'7OV!B YQLQO2R9W
MM?%=#;'6,<S97Z51=Z;-]EUS/T]6/Z/Z5&R;?K2S-ZS9C@--&/2_#:Z;:WNC
M(<ZJMM5%5WTFMW_G^]. Z7]/%:3M*KK]+^KX.]^RL'U'6^F?4=NEV]\^_P"G
M^<HU='Z?4]CV,<'5D%I-EAU'T=P=8=^V/ST#I^3F-ZGD].RG"[TJ:;VW-:]H
M_2NOJ=5[M]7L^S[_ .=_PG\W[%J)JY__T>]>=G5NI/?CV9#/LM!-8:'"R#D?
MH:M^UKK/Y#W_ .$8AG)Q3('0LB3P?0IY^=O\I&!R7=7SV8MX]3[/3MJL#BRN
MR;8LVAVU_J,/Z3;Z?\U7_P!;D:_K'!F_#V]_T5AT_._PP24V>D?\DX7?]7JU
M_L-5M4^D?\DX4?\ <>K_ *AJN)*4@YF9BX.+;F9EK:<>AI?;:\P  C+,SFCJ
M.:SII;OQ:-M^=(EKB#NQ<,_U[!]JN_X*BJJZOT<U)23I&-<RE^7E-VYF:[UK
MVF"6"-M&)N'_ '%IVU^SV67^OD?X=7TDDE*22224XN/DT8?4^L76NBMKL<N:
MT%Q!<P,_FV-_/=^ZH]2Z_P!,NZ;EU5OL+K*+0T>A<.6'_@O-&IRJ\;J75+<H
MTTT,..1=-8=[F;-M^QWK?SG\SZ[?^*0^I=>Z-=TW+KJS:7/?CV[0'C7V//\
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MT2.G9&O<?8SSOK)6*K?V;59E.J<UEN0VJQ]57J%K:[-E8;=G_P YZGHX._\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
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M970@96YD/2)W(C\^_^X (4%D;V)E &1      0, $ ," P8
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M                  !_#^@   \@>O      !_#^@QZ9"  !CQ/8(]F
M  #^']                      ,.)IR+RW*Z$IR*9:1.8B U?^(C+7M$,<
M12VFJ.$FP.K'ZGRYE(P$MS%?9'TGLB8I6#%?)*NSQAL]<G#:-4T]H;"'CS[#
M'QCY-R-C                              Z$K'K[5HS<2XJPKK;,HT>6
M]PKJ.M/<K"ZM[5$P"-9C#1CU/4&G"VY2OB3SQ*(C%9$TMMPC?I74];*2=3D>
MI1%*M(*CVZ>V1]YQR=!4
M
M    #7M-:>+VH9IIDG[#T)UIS#SYXLD]5             $8ZW=HQN;)FL"=
MCU<%)V%-TD                         #1!-7V,UNZ<'B$ZR+:R)\$9=/
M2HQ@F?IC             $%BT#2V8C:)&U)A@PRG?]6=E4
M      5D%]H$9&3%1$[.3,SK%M.  >(Y76^WXO9=$8\3ZE'=GD4\T]$CR!D,
MQXG)2/$'MP                                   "JO&3),QY%/MT8/
M39)4SZ@ :5>HUM60WU\0VM_G?[XBNZ7V40:^6U92D8I/@G8E715/P3V"<)$B
MZLW"@ &I"=;SKT]B?<;-HVE0
M    .&<P XARP:0I^@WE14.9,G(^I;W:OUD82;IJF84
M   1WIU*6\"CU9VIXDE"1MN@                   0SK>*3.:H  (1$RK&
M94          #3E;,*O=\G@52MR?)5O?2?V%H!V7GHV,/-\A3-)E3+)7@Y8
M 'D2(=:8Y6.];4Y/GT>M3VAU2,,)L:*            :V]YXW(W![G)G![D
M    "&E:-U-KA0  0B)E6,RH          % [V^G9N/-[!D-KDH ?6WY7VU_
MCO\ 6F)#;/RY+[T?M+%7A-U_EZ?5/YG?J/?*7Z;<F+@ #%2:V+)8X8LU@  K
MR+6&U0        !&?[_1LA'B=Q>HXW8 04[8^99C]:_061^#W      $/:T>
MZ;1BE1QESVIT"_H%>H3'47+E,RH          $2FQM PU^<V!)UY[W>O6/DV
M2K8:[<9<[S69'+Q*0?U-^;-X_P"5OTKY-;@  4$HS7F9PY4  !7D6L-J@
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M5ZE;2F(O6S3,J         -=>QZ*IYLSYRNFZB^J@       ->DPB+V-&/F
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MM4      #\[7<GRE-SK'Z)M(]3Z0          "%);15:TNQ@ "$1,JQF5
M      TL(U>S\[/[UGH@         (O5I.%>4  "O(M8;5      &O?<>6_+
MJV-H3]+[5WT?NWPNU           A?6C?6M@,=*MD]:C@+>C5Z%;45%X93,J
M       !4TY_2VRN#W']BP         %!IEO/,61P  5Y%K#:H      JS[4
M^<*S6JOI?]'*<&Q:           -;DZ/)ER5UF3S3XG\/M(L4RYHS*@
M "+>U?%\C@2^<7L0         !0R9;EC'M"@  5Y%K#:H     &A'K=95EL'
M/DZ\SL"Q,J           *\Z_9HL"J@ "$1,JQF5       X154S\*UQ@YH
M         $'J\R:FAR= %NI/*HY*=DD:B)L_J     #@7Q4E=G?/EJ75WT3H
M$M,PI[D           AD6PV3_JQPIZQ/%/@C^IU5)@D9E0      *M?-ZC;O
MWND)V=:_0P          \"FEY&2YG.+5!."T]:=4<9.T"L<J;#:H     KE[
M-^>_EKC?=C+#R0           !$\G15:R6I5@9?>*^53V*O@%L"(MHJYE0
M   !"/GXFD?(X,.GM]-_H/ZYWZ          !2&9;J3%Z<  %>1:PVJ    !
M&C[34E.G#S;4O2>MF?ZST(            B 6U638H4  $(B95C,J     !
M[V7GN\X7<2,8N5%6O8"8P          *3+)<Q8_:@  KR+6&U0   !H#ZS5]
M0'LNDE?\-N6(A;]!3%D            $%*W/3..H  (1$RK&94<&V/[XO]\3
MT%\/:8^1RYKY"^'U],W"BVD'>>-KVVC$&S?G*XEJ3ZDR7P.Z
MI%,ET!C]J  "O(M8;5   _A_2 KVNH:IEK?HQ^(VYAA.MQ)Z@
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MDV?V/I"J+V/19*S<3SV'EZO<?L9->/S)-8G9 RF@
M8^.^/1@ ZP\ 92  ,-)S*@ ##AF,  PR9F  ,,F9@      5J5_<@TM3ND@
M#2U.Z2  -*$[KH  TF3NTC^  U13L0CTP ,?$LRN_"       !BY, JTZRF=
M0#JBO,O+>KM^@ :?IPT22H &M2=6R3E  C66U7)T50!@<J+,EU!C[$
M       'Q/D     8&,\@ 'UGV        %6!?/Y8#4[T''(?%HZ2SFKZX C
M_3!NO9U4RF@ #QA[, $.BVPI(,J!@$K+KS]J[UH       %>J+^YF)W%0!$L
MMH.FS"H -/DQ>IGZ5Y( ('EIP5?0 &KR8M4[6$GZH&!$U=5YR%9/50
M*\JW,3/HIW0!]17I6L&J\X           T@3N^@       0ZK1<ILKJYY0!%
M0MH:3-(VO0 *V*TLZ-YT    #B$9:TGZH K;+;&$WJH       U-3L<CT@
M!B=.1D=D >?/0'0G@$Y=0!X8YAZT            BR6BP3905R8@ ::I],;2
M(           Q@9-/D            5QUX[4Y#3X [,QXC;0CR-TXGI9K)PB
M,Y?!I.:K-HH            .&<P   \R:3IV@."=X=:8?,O&K1N"<4]XC2I;
MU2-P4                 #J <DXQQCYG/.A.W!X9.0$#[CD
M     T?(;%\)GBSN$^W5Q:MZV)^,U[0\>M)8K'DGK$V^V(
M                                <4^T^T
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M$HB':/' \=LW' @ RB 3>W0W=_98VC-D\<-U%.D(4C7CE;.IG)*.$<DW-6H
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M'[,$<<"/("'///X1'TFF_%*(=HCS ?[9I@&)! )Y9N(FF#M_U5__V@ ( 0$
M 04 \S"&PJF6[\NZSF%LLF9C:527C?IDE(3O#8KP9P^$<L9GS;,V%;(F+ZX_
M/8/+W7UN,[A+3+>#'&HKYC-1GS65RI)9YS"Y#(>&R-A5R1AKUZ%K0+9F+9RP
M,7U]98RRP6>P9IPL6.=PF3O:YM*ML9HR63QN%Q\IW)<^=\6+SF%S@=%OP<$:
MFTZF# \M\:5+"P!Y2SO"U8M8V]+P[,OJTYQ93OKG/[T=E90<TL.SC8WDKRN\
MN_-^L.OMX?2DNNY*=ZQW3/+X!^.R9MC,VC;G%Z.*](ON4V!7"<,)=6^\LNQ;
MMMC?I(9V"/DV0/K5[;Q272;<.Z;8R>EQ8.Z/8SL.MW44]N;KW-85/#M^7&K%
MT>QC8=0=3)M\=@Y$=.3T%_?TVU3=SKY;9.[!/UO<_P#)$^4 H;EB(G.V%_:U
MK^Y!]BM$RYW!G8X[ <;I%TZF91W38#<VXY5SU5;PDY3=WI7Q3HWS)CIQ:D?R
M^A6VK1";5YRILVM/'?,T2Z-.V]R3@<(^U8=P1?>(K3GE11)ZE]N(RN44QCF\
ME;5E<'LG? X!"%<0IYCC]>Z1KH^[9,T@@.#W)*TWA16QOWV)FG8/LXD74=V[
M==C+[W)Z^"COF7S!L:UJK:YE?$T,FSQY*G;+S,].HV-9;'8]ML,;IU(V*YQU
M[#VEY-5BULL9-ME<FH3FM2COMA#^4VVMO+?,T&Y-&VAS#A;)[RO[?\,^59G4
MJ,@CTC#LJ-3@U4JN!>AEFK*]MD5AJ:WYU1%8,FIQ$-A+B4Z0/4N]M;WE)M@U
M5?\ ((^A)GBIJZO:8DF[+8N;T/VB/<>Z[IOK;CN4,2_E(MV>Q4WH@[+=*]Y.
MI7-J<[-.-7+;7]O?:UJ/82]IQI]=)>*QL2,GR+D2>0]/7J@S\MS"U)6[5FCE
M<&\9J/0;56*J'L&2D]ZUW!&18&9MXM6GM%U>Z>U&U])M?::W2)@R%%F4J64=
MEJT:B'OYPRJRV6PS;'%&U+7ZRZ8D_P!:SH5J0DM:^=BK@6>MG9H]Q!2?J_UY
MO%=TPX@:T''DQTK=-1[VK4UZQ&2']C1"?@QUR2V/",FD1R"AM3R>N14KYX1/
MU%N_;@3LUH^<?E&3Y37(J5^\-X* 6#-I-(RV*^M#2U,TIO3OR8DS#30ENSIY
M[,C4Y]?TR^.\XPF-N5C7OLR)FQY&=(RBI"@&O1AZO,/6AZ>D!CSLZQST3+EA
M-?+?R8_FU09@^LTYM2OM5+&7ZLZ69VFJ]S2I/W(6HM^B)I8Y]BVR5;\FAS$5
M ).PO7[I2R+:T>UQ:YGKL_.&QMC2YK^KBFZ3W5JTU/:(Q%7'FH [=D[S&[-M
MU,KK:%A^BX,F/RI;-37H\<I(VMOFOK9 W8ZZJ];RH,U5+9EK >1L=4M:M1ZT
M*7<%?7,J>!>EA-)B]V#6'%Z8EA7:W0O5Z^,N/$U<M*.C$V".WU6.959]Z?:D
M7\H<FSEV+;)5C,Z*,)/),V':W-0JE,H1[):?G=D)E^X-J65=4])R:99=:VZH
MSJ465-C?KB8^?F79E8-8VPO%*"B.IW-MY=\2-)B]%36RN6HMY5]GTRUK*V2G
MB$C24NY6UL.>5K!IX[NN4U$=RPG"ZF'XF1@["&..'3-RZI,E==@=L*AZ4UP-
MFO1T.K%T$CU$8*6<(:1_9A )@\@\J"0DO+8" AYH  ?4VJTE9!-'B*JN)4>C
MC?*,GN,//0<!S]M<2I5^C+?FRE'7@4F<M9,)BNOD9;09FG&3?AJ>V=X1I&NS
M8EDS%DMI#QSBJ2?-L9IMJ<6H4-LV7[%LDJ>S9UKVMA6K#<>YI26=ZNVRH)JU
M8TOJE'L^6K2FE&I&$_?7M+>,Z!L"C.XV0.P:NKB>;DWC.U09\&Q%WC(9\3O
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M<7S<(=4N/&2VTJ1(M6>W8WJ:YIIC\6?/JPGVC8-G;UDQD:(7%:=(Y_Q?(_\
MX3&Y_I[Z9R&PAD3/S0@SAT/=$G*S&,XDY(F^_(E=4NRHW5W:V-LJ>UW6\C1D
M-WR?-<]CF[#?LZ=0J6NMVSRW6T/&?E (B5$S'?(<T\Y(U%XPX W8%_FLA'GY
M80Y:@E4+.*4_29G+; +UI[,RJ'F^U*'F99\3IXSU=2=/!=+Y4V?]2I+Q6J(X
M;DI6=)ET+7F[DLOB,P3=%RGEK/NC\7R/_P"$QN?Z>^F^4BB6?6S9A\6DI9XB
M:NMGCWVK-.;PD1O<%4,5#X\.0<95W6-4UQZOCS\9Q<"LL[43/:XZ^+976QZE
MV6K*2A2L_$L*&H^X(KT-BNQA7RXW5'TU0=%_%J7_ )5^D>SM)0-DIW))V*2C
ME+Z[S$31^=L:7H\E*)%[S=QKA34W]+M'[NB^Y9?X+6U=ZS>&_JX^A^S)K@\O
M^?FB)^Q[ZWS9O.D#8&^MPY@V@[9U(7720W/]/?3;+M5Y*?78XYYQVHW;*=%[
M?6PY-KFC-UK=WC1O#TEJ7MF/.D752>M3Z*&>[QV/+1?PC K5Z=E5I5[/QJTM
M5,\%Q"LU9F-$?%J7_E7Z3Y&.M!)+MU32&MI@RQNT6U]97D\;[W8)+@DA;0Z5
M'G7(OEUZ0POAFWPLQ+DE]LSU\XX,9M3UVYLP^3NQ<Z?6S(QIR<H3%;6&>0*D
MA=U!-JGN,#J(;)(EDFH)L5ZEHZE&X4T8N]1#8;9)=U3<DI:7\=YN?Z>^EJ5*
M=&FX]TSB-^CB6E-%;ZQU#///6S#'Y(W)3E3GG4N\6I?^5?I/D(__ '*-N;GT
MC2AFVE]6758=^<J:;M%D'>BS!^37[!K6L]C"6H*HY@^+PA921W>%H<R!ZGW1
M_&$+MT0]WFA<P&C&Y+'9C'>1L97)NRT+$S%VF5*+M_%\C_\ A,;G^GOH]L*D
MG5'=<&KM_+M#UL1VL.M7O8<ZAHC2D-8ZWSH,5LB-IGI$F[EOR8YY_K1V9YI2
MMB[)T@6[,;#F7X!S)>V',N-;F4FV&,Q7-<V[[#67NQ434O\ RK]"\-#$[<LW
MSXT"*E.MAX^2<Z9Q&/VU:S3%MAV,,,VY)KJ2UX,(TYMTV,7#R*+!-\#B8WSH
M/D6@O6^-OJNUHNYU\&[3WKO%(6 _'<3E-G\6"?D/%TOE6,Z4@]-<T7LK4-DC
M&_(?7L8TG8(]ZWG;:EE@N8F5Q*I502YS[;5O-R3.K;$O6,35VK6%D34L.X:N
M=42WU*VEBZ:$6Y_I[Z-W":GM8VSVJON(UXJ-IPUF8G6FU[H'0.83MHB18HZ(
M^AJ8MA6/&+^@V\.JI:BMY=DUUW&7P63;4Z#%* GC<G/7AW:>S]U^:+C;V?..
M<]0T((U1;R^OH=S63)A>8?\ %8R1)OW(OH?L5VDXW<,V+_\ +V0(V2VB;9L"
MB&DYJS*DEUJ:P]EC+751\IH[-"QI-UPGUGZHM<4LFW*B)ZR;3 Z-+WO1\P53
ME P2]_$H590%983Y&Z?,)HF*3:CG0X9ZKS*LT\E)*V_;%*.S].DC49P"!+(F
M!P>>G;E<#CW>55<+N96M5=B#=7#*>R!N?Z>^C=M>9G%MMTK-.5%_R_\ 0N@=
M6@C,4CM-K_QK"V>,=?VV5Q_BU+_RK]#\B5M"L.OU>:39E2:([@\JPGNFE.'R
M(XM]DXTHG I'\M>1\GQQ+9TSUD:VG&-J<VTWR-STQ9)R.ZFG5J,Y!4O%\C_^
M$QN?Z>^CWJJV?GTN31U(T^0-*>B.#MDH0 DI9B\#@TQ\6I?^5?H5^79.6TI'
MJ;7YLC%F3:K=;"MV*E.#U4:Z76J<DB2IN@Z:^0>$C2A3JI+3\AIOB/(VF$W!
MG@RM-3@_)_L_\7R/_P"$QN?Z>^B=VYY-F8-G^.TU=2;M/^CD<J:6JY@KSW%0
ML^+4O_*OT.P!;52><9OCG:Q7%JHK/2[E*9 -Z=:;<ZW.P<'&?W2'- S6:-MR
MU-\+^;V\JHFE"CMD6F\+F#V\J>J.,W ;>6L.:T@-S_3WT6VK)93:ULWQ.)Q>
M!Q71EQO)^,.M1!13R9#/%J7_ )5^@VCN3/Y-*%9NQ2V&NFQ>+QF#QG2[B#TU
MK%$#07FR,GJW3 (RG/3FIKFS4;-2BXN'+F=U$*TIU"EJ=6^R+V#U$*JE>/VO
MZ_DM9Y\>9N?Z>^A?QOY8XP)4_C0H'?7#3^DJ8QF2V7:/&O"'Q)-Y.#3%4K![
MYQ.EMF#.>C7DEA2T\&6V5MF"G*07J;-SHM) OM"617?+/L\]9]QFL%O2A*Z]
M-4L00-8&O\BZUV@],\1R24-]H)VL+=U.,/B^1_\ PF-S_3WT.VRR*)[V\ZJ&
MT'UGS#>D4LU-D<N=$F/(*>E:S-.:RXV[,+5&Q&U2;QL3<,@M^+;$V_!K826R
MMR354TN;"V]$#=J7_E7\_>G>-<R>SS2JUT7'N-Z?=H=2&7TMT?N(;<IZ]^+Y
M'_\ "8W/]/?0;#GID#7NSCX][*3V@[4.E0C:&R11R)97=G?V?BU+_P J_G.J
M<:2&F(!LI7XU&QQ^M@QSG!@/3[M7!F1%$+UC;$FU-U=/"GG8TIBC#FS'29O6
M6#/&%"EBQ^0KWAY1DS&5PBD/)6_9&I7Q_&Y_I[Z!X-6YW0;FI999)>EOGE,Z
MM#DCN2S692/Q:E_Y5_.VPO63/*JTY33\]-1%M:"B>6;6U3IUY4MOY8-K*GO:
MX7MJI"<LL9VCV?31H#44:3,M,\:>34.KL\:A<H(;6A-4/J)?(7*Y:)&BEN?Z
M>_/W!;#\9K:9;I/UXW^O1F?3*/L IY&HT!W:'O81?Q:E_P"5?S=B[M;]IK?V
M2-/LWW/<W$?R5=1NP7]&<:?-;!A0H\.R\7R/_P"$QN?Z>_.R62QV&QS,K+);
MO]H/3JIN(UX)LE1#O21F"@]-URXMU<<1]JSF\\>&];;',&J[).XMTB3)Z8]N
MKNFC$PF;'EJ:ZJ.A-=",YI]WF97*8W!XQ\+SEE<\N>O9D"7:[FE.X^/PSEZ+
MATQ(.*2E->GW2G]4R&E&HPWDHQK5%KM;9EDD/#;"UD6^Y;;@TFV1<X[=F@8%
M(EAV],P2<M?(&/9.4O0RW/\ 3WYV\%ZV27D]:?W[M$.!,Z94SQ>IHG;;UH;%
M60)$\%=E=&7A,<RSLE3*.HE-"JO"&:=$H193TATMHV2J1*TJI'=%9HS$:K<U
M*U+_ ,J_F;I'TD>Q+^CUCYXK7G5;=\X7\&ANHTVJ;E7I1_\ AU^1E+%5EKVZ
MAW2]A;X$'5I &2/S8_D4FUMOJ8(4=T.H!!4DTG-S_3WYNX+:EE66X90&8D33
M7I9^.H\PJJ+LDZ<3D9LI<DF:G.3?%J7_ )5_+V6OUQ[-$O2;.)$:[#5)NL07
M:</5;D<POV(1?4>9%,S3I?%\C_\ A,;G^GOS-H^Z/"-2-^I;4SFVBY5\+0R"
M_-JK!/CJ-'UX.BZ=P\^>K8M-9S'53GQ:E_Y5_*V [#$98&E;.VKN2^08OGRC
MD9LR]JB^(*5#$+Q^J=RI;DF5;(V6'9QKP=C'B^1__"8W/]/<9+*8W#6%M=6U
M[0C/FLK%2ULLA89*E'Y@D+_F8R&2QV(M5[V;,(;0G)DV8[1-UN52-26@Z,5G
M1M7B$O:7]2H<SEZ>/3:4]RIUXM2_\J_C$0 (VD[\6P,*PB?BA[P'>I#;I=:I
M2\EGZ;/A1C7SJ6;!K/O_ +"]1>W;G9[^WW;;G'$Z0FY_I[CY)Q:N<PN_QJBQ
M7*V!N\[@[ /D-RE0U/G^/$N;;T3:">MN.MPD6F14AKF*2"]^4L9%LN'SFK?J
MZ5N6LAD2<N+V*8C#XDO8K8OJ+W'JN^_6\C2DMW8/U&R9"59<XPMPSU7HNN:*
ME18SQ)2_P*0HI'2!/6E[)$'=T:=2D\E3:K#JSL8TT:_KRWG[8E->S&RY8U(;
MUK\U5[O=J:U;(#VHR>I=@?D>;E\<J*LZP[C>QMQ;SKGT.,?UY9+9+HCVNK ^
M-FR<YU'VB_8W<Z\T?=\;-M3+<^;]+2?;)=SA ('[J6Z&'";D]J:4(23]>N]E
M7"11U'[=+FK@M13[[.WQ6J)3Z4Y5U[8TKR)WDUF;5C&Z[LME2_HK^ZENAC]U
M+=#'[J6Z&/W4MT,4]IVZ.K40S?)LI<UB?W4MT,?NI;H8_=2W0Q^ZENAC]U+=
M#"=;W-EZN*/^ZENAC]U+=#'[J6Z&/W4MT,?NI;H8M=\.RJ^<1^ZENAC]U+=#
M'[J6Z&/W4MT,?NI;H8;WN2=R8WV>8_EMV5>"RE)6"+<]-<]":!I:UI]L&4MX
M$XEQZ+/\.PMU]F];Y09_ THY\HMUA91OXH2P8%1R3\9C7$&8+>LC7,42NDZ&
MHH@N$^U*LE*<+DG).*!83XH^#-8;%&/#(HB*2MQ3#PHNWA#VZX_PIZWQ$TG/
MWAM6\(?9+SX3>W=#C^KOG&#6QM]1A[GY#?)EC\AODRPE*P_(Q5AZ?Y#?)EC\
MAODRQ^0WR98_(;Y,L?D-\F6,RL/R,<(_[\AODRQ^0WR98_(;Y,L?D-\F6/R&
M^3+#DEF^1>V=PGY#?)EC\AODRQ^0WR98_(;Y,L?D-\F6'U+/\C!AR?3(-\F0
M)OR&^3+'Y#?)EC\AODRQ^0WR98?&>_D=,5:D2DN^2T>";^0WR98_(;Y,L?D-
M\F6/R&^3+"MDGY*J1I3JW<:I+N=>O0+8M*8MT24Y[6E]S+DVX.61-W"3?7.Y
MW"%?"*YM"51R*H,Q?$@[\$T\#TT^=<K*)L.V)X%W.8\#NR0Y%2&_LGV(TUU.
M7@V1.P.2-M+:0Z9:4P<]X#ZZ5M26*JI)\,3/C%A[N\O\3UDLTLWF+0Z9M+<;
M_P -2M1HCT+LE^=L\$HMB:>ZMUIS*Y8+A(+/TN[NUL+4F;2&H.PRC<FPN'</
M(12"2$P+'UVC(NN#@6+LPO"">G*H^DI?1TF^'"IV1"X</ _-BYAP9J9IK\0%
ML]_]72*<JB-H#F\XD[I\]KL3U?RLR;H-ASM%S7*-6SO'"F,Q>!X+Z%G+ZO:T
M'$*NA62\!EV ,M)KF#RG3@]6B^64]Y4L_ YHJN1UEK84LGF\V5?J\)X:%L41
M!ZR092Y7_4,FBVI$SCZN4<DE[44I=2O3.WE.AU#J2N:FLW\]8UZ?ZIK[DX09
M(-R)C+9;+Q-+OUK4:-S1->GYQUF7+'&8W%R].7=?C=2Z^;H-S9R/:=(NU=N^
M86UZC86XIHT9!/J\9Y#I"BZ(Z'# [(#XS5J>%:"D7@=FRQ;4VS#*FBT$(*/E
M7MA8Y*@Q[7P8F5+/X-F9E7K$G5D;?75*PZ+H'5,7:8]K$DTG%-.REXU@7I#6
M\EK"YK#F/#_7.FPKE>M!D-)9)N))B[I2H*J?6Q5!-,F8B,?B*IY6ZG<,1UN.
M[.V3FBHKY_2E&DJ0\N>!XS'4A>C@FI-3*C5"GTZQHNE;A$[DDEIR]2_#+-J3
MO=(^QS62PRHYY2%>H.<P#BCO::ZZIW4?&%< +V;,6-5.L26\JD;\,H[9'6./
M5[#+BE"BFE5\SIW>@4:#6-MBE++AU?=7=*$D^T;X\>(PA>U4=5:8['X^;QG4
MZ%-.":UW9.W-V>+L'!H)E$],#E6Y%)+JBW(O1/U!Q#?[HR(6_EH;B$+Q3BV^
MYT^X/9&@ZI%2W65(+Q4"FN**'TUYO/X(LX]Q&RAF+94 RS[&V89Y'V3-E_ F
M6QNL!@;[(?\ &8T1MR_@;3,8HIE; V63*Y:S5A/C,;5MJ9"(U+&2X+"26=E@
M<'C++((VFN54JMB\9<C/C,;5J6UK:V5'[%LL;N>':, <:>7"/?U^E-F"FJF8
MB:TT\M^P-PRU3\CM$:YK]4PK+@TAAQ\,35'?HPYDS[#"^SY6"\BA(:"O=!\C
M%F@+(SDO[&JJE;(=(+F-:2G**=M<+,WN8Q_?]/7UC99.RH4*%K0_K7__V@ (
M 0("!C\ _P"$)_E&/^$A_P# =MKZ6V=;.8L$<@A7*FC!3P.DY&G\H;M=]\-F
M_=RN@\YXM %:CN<:U''A3%D'L$N;.4 1V@/+="E 02N</+X:U]X&B:E:N!/L
MNT?!6?+ Y?,:3O FK:FSS! IZJ]?D]7_ !SM1N,CI8<Q>8R4++'4:RH.1(6I
M%>O$'B.6YWE;2X5A%JBC!5R#RN>H6L22FG+;/6/ZM:X"J"6.+7;["T:2]F?2
MB5 +&E3[Q% !Q8T4=9Q-:W4ZQSQ,5=2'U(ZY%2-([P/K^O!!N)#3LC&?M<'[
M,+\.'X9ZJ?93A]OHL76W;-<SVQ)&I(V85'',#JP+;<[*2"X*A@KJ5.DD@&AZ
MJ@CZ0?1TP@D%MM<0.NX=24#T[L: 4+N30L!DB58YZ0;C:MWMC'>Q&AZU8=3Q
MM^>-ORL./J((QMB;>D;7YG01B0 QE]0TAPW=T%J:M65..)#;[19G>+B)UN5D
MN87BA10>8\?>(N&D K%&-7+)[^H@5TJY"^K+VTX_7BYL]WACA-X @O&_TP,^
M7*<]$+D5+K2C <P,I!22\VBT"V\:\OG$:7N-.7,8947*D9:KE "QII1(GC35
M(&! I6I!R%!F:\*=>(MX'AC;#XJYAD>V%NI;X8KDJI7_ .Y![[+K)T9#OBF&
M)%#7T+>W]E"4M(T;0S*:2R#\BGLXAGS"F@H36D]E?6[Q7<3%71A1E(X@@]#Q
M&7R(]M7<)AMX@F;EAVT:M-=6FM*USK2H^LX6YW*]EN+@*%#2,7;2"2!5B32I
M)IZSZ.EM9T:?9GJ3&#FKTR9"<A4@!QP(SXBAEW;=9J*3I7CHC49B-!UTKPXD
MDLQS)P0@('VGIT)P,S[3^/R(4C?3(S  UI0DY&HS%.->K"[0/$>W#Q#S.6TP
MFH>0 >\&TZA,<EU:0=-6J).]A@34U]"P1/>W7*C*@!)Y(P$%=2 *:"I(H:=V
MA !KESKNX>26@%6)8T44 J:F@&0\B%T*AA45!%14BH[14$5&501U>27?3'HV
MQ(GC#'\[L*40=87\QX5R%36DVT[A!2Y7,$5*NI]UT/6K4^D&JD!@0/T=JN7_
M +L3G[EQ^GX<OC_Y$O\ .N,O#EW]<;#[Z8EGEV*9844LQ.D4 %2<VZ@/11N;
M@D6X-!2FIV_JK6O#+4U"%!'%BJL"<E&0 X =@Z$DU))))]'Q3[A;7">'%)Y]
MPFE%B3@7,DM(Z(2"PJ6*U %:8\1)OOC>98K&\^'L0")3+;A:ZU558E:Y5CTQ
MUIPH<*+?9;_<9!Q,T@B4GU<L@T]3)[<-;>&?#MC:;>3J*-KD);@6U IU #W<
MZ5)P91<6T3TIW(5I3_UR_P!^#KWYQ7^JD2_X8QC/Q'=C^[(5_P -,=_Q)?G_
M ,^7_P![$>V;??[A=7DP($222NS CO=W5[H%=9/="U+98DAFC9)D8JRL""I!
MH00<P0<B#F#\UQ\\MUWUIQM))YAAIS0-)IHU95U4K7JKC:;^SNMW:\W*Q-Q:
MAC&4TZB@Y]%!4U!R4GZ>K#RW#E;2.A8CB:\$6O%VH:=@#,>ZIQJII0"BJ."K
M4D*/:22<V)+,2Q)/HKE6\+R24K106-/H )P]Q\._(4T+:3I![":4!]5:^334
M5Q8;E>6K;GXCECU\AN[;VYJ0!)QYC4S*D.#6A6,@,7M+J[$6VD4Y$(Y<6GJ4
MJ,W44R#LP'53&7DB9A0."1ZP"5)]68(S[,1LPH&%1ZQ4K]X(^KR6&\7E@\>V
MW5>4Y_-3M'%=0S353F*"RU KY-X1Q<P^(!&3;312NBL24!BE"YZ:!F4@J*FC
MU 7$2;#%<&!8UURSN7DFD*KK8U HH:H2M7(S=B2 OH6QDWNV:;:1(.:BFA9.
ML=51VBH+"JAE)J-HLH[=9MUN4#;?R@$Y2475*25 CMU2BO'05/ *R%E2TM7U
M6D1-&I0NQIJ<CCG0!0?=0*"-6HGT7MLEYO@V^V)TM*0M""1^F6<%8]=/\PCN
MTR()!QN%O'OR1W4F\W1^% 5C,AE5UDX%XP/>#Z@K@::$D$37=S,+;8+?.>X;
M)5 STK7)G(IEP6H)S*JUELGAW:8X-FM7++*5'Q$[$%2TC\=!K54-:&A[HI&O
MR ":@</5@ GABUNVMHYEBD5M$@U(]#72PRJIX$=>%MK.S6:_NXRK0R"JP4XL
MW#40<XBM*FCG25T_/\/.K>YW+;_BK):ZHM93752 -8!(HQ!R!X4Q9V@\'F"[
M6S:&V8W#L8(200?=&K6RG)N\4&;:)*'T9,@IID72?HJ&^]1B\@$@@VB.$&[G
M8=R*)3S -1% [F/N ]09CW0:V^Q;'&8/"UKW8D%09"/]63K)8U(U9BI8]]F]
M)-)<5%G$NN0CCI! "CAWG8JB]A:O '$MQ)36QX#@!P"J,Z*HHJCJ  ZO1MEL
M^WQZKJ=PH[%'6S=BJ*L3V#*IH,3>#[8A;-;R5Y7&1F(*J@/8BZ-5*FI()]T>
MDX-N&4S4EE_O$?IH:@']-&).?OR,#[H]':T.CQANT>1_-;VIXD=:R/U'(JU.
M#19@=7I*2[G4&"$:B#P9OR)ZPS9L..A7(X8DEE8M(S$DGB234D_2?1MWXBWH
M4V#;5$DG_P 23_3B'4U6H2.ONH::QB\W:\/ZLK9+6H11DJ+ZE&7K-2<R?23:
M0254L:=2K[S'L5>L\!UXMK6 G3[[FE*N<J<<PBY*>TN1D1Z-5).Y6F;9 !J$
M$^JA!KV9\,;5X*V6X$EC BS3R+6D\TBA@PX$H%8%01E55(K&#Z3W9D 3?0C?
M%F>A5K?/*,MW1;Z:<].)<5>JZ:;@WAF.1-G+G0'-?[VBO>$=:\L-W@M :<!Z
M,_:NXW"YM[E=PO&C1.5'(B(D05!( H,SJ:*R.Q"Z='&M-UM[^ZBGNXIF1I(B
MK1MHHHT% %"@ #2H 4@K3+TG#MR'O1U:2AXR,,QD2#RUHGJ;7U-Z-L=IM!^I
M,]":5"J,V<^I5!/KX#,C'A;;-LDW%-IV::6&5H&1-24T-):MQYS'4K.] 14@
M5-3<#94F7:Z_IB6AD"T&3E<B:US''Z?24E^XRB(T>N0^[U'):%S7(Z0I]X8)
M)J3Z-FWH]WQ%NRF*W[8K?(O+Q![V1'7_ )3#+4/2:HHJQ-!])Q';QD&*.N>7
M>8^\U1QJ0 /[(7KKZ-5+IM&T6ZF:X<F@6),V&KJ+<*]0U-P4XGOT71M\8Y5N
MF0"0IDM .&NFLC.A-!D !Z2,G^HP(7U#@3]? ?6>('HU(HD+2L0  *DDF@ '
M62<@,0^";1P=YN@LU^ZGW0:&."HZB#G_ &:L,I:>D[;;=NM7FO9C1449GM8G
M@J*,V=J*HS)IBUW$2_$V111*Z*0(I.%"./+.020TJ<F"DKJ\WX>:R>/=YA#.
M"4L83QFG((U]NA*'O=5&>H94U7-]>S&2]F<N['\S-Q^@#@!U* !P])<Z3)."
MCK8^KU#K/U#/A#N>VW1BOXS56'W$<&4\&4Y,,CEBUL! +2P6,<Y$8GG2BA+$
M\1""*QQFIKWG9B%IZ+NK_=)N1X:LD,ES,<@%7/0#_6;AE4@'(%RBLLUG8R1[
M):(([>%$)$$%0-;JH/?>@+=@"QKDN<EQM3SS[,2 DTD+1:B1F"I+ $$,!1C4
M"O:!Z0CNMP0A&74D?!I!U,>M(O[9S?A'6C,AD>GJ R '4 .H#J^W/T;*W-6W
MV:W&JXN9.[%"@S)+&@+4X+7LK09X@\,>&(C#X1M6!%11[J4?Z\U:&E<XT;A[
M[ -I6.18+B2,-[VEF6OTZ2*_7@VPN)/AJUT:FT5' Z:Z<LZ9=9[3Z&2.-2TC
M,%4 5)8Y  #,DG( 9G!!&8-/9Q\D<,,;/,YHJJ"68TK0 9DT!-!U# (-0?)\
M3RV^'YG+U4.G735HU<->GO::UIG2GD+,0%'6<.L]K\/$J*[/,1$B(^:L6>GO
M#-56KM0Z58BF--BHN[_/]5UI"AR_RH7%9",Z23!5S_R"0'Q<[WNU^T=Y=)KM
MZG46KF))2:G2XR !U =[J"XNMLW"+1>0OI9:@T/'B,B"""/4?1D&[^,;IK':
M7 :.( &[N1U""$YJAR_7E"Q@$,-8K2:QL&M]M\+V94Q6(D[\S5IS&--5S,H[
M[EB%3\@9N\?1&G=D(\0.0MF[T,08@AE0?EG89([=VG=4JY&J>3PXM;FI%RZ$
M<AY@0"8P/S@AA,P[KO0J.)("0LWT G%TEUM5RGB5U/)E=&Y1CI5DC.G3'-DQ
M9F/>C[JL,PU]/X/\+;@;8M25UMY1!)/7OO""@TH<@3DK,"RJ!F09=G,:]?-E
MA@RZ\YG4#Z2#3L.*<E?^V_\ )-J&!N1<US4D$MS@?U#<9IR^\&*47&J??+N\
M(:A2W@$8^D37#+4#M$&?4,;?->>$5;:4D[SR2O-,O]273^G P0YO%RJL*T;J
M.VV-GRKW>5I(D\;901. :%AG)S5_TCE'[YHW=\FY;1MERIMYE)B+C4UM(Q[\
ML-30%ERTL"@>D@&H9O)([-(Q)+,22234DDYDDYDGB?0BQF14!ZVK0?30$_9B
MW@9TC4D]YL@*Y]\@$D"E!D:5H./DTM(%%":FM,@2!D#F3D.JI%:#/$$,G+1(
MT8 Z0">+=]E%78GNJ6K2H%0HRHB$GU"N+6\L[LQ;DCDJR%"8Z4HP-6 :I;(B
MHH"/4]Q901'>WE8F=T$C1KD5Y*L3"KZZL9.473((5!.)KN\N'ENI#5G=B[L?
M6S$DTZJG(9"@P[N "W'2 HX 9!: <*Y 9U/$X:1@H8_U0%'"G  #Z<LSF<R?
M1"21M1U((/81F#[<=WQ7=*!D .4 !_\ +^WCC2?%M]I]4E/N PR2^*-P9":D
M?$2 'Z0& Q2XW:ZD']N:1O\ $QP7?-^TYG[<:J#5Z+C"R6L<:,PJ\D4;DFA.
MJI#N!P4D$+F 1PP#)NMH/H=G_P#IHV&:7=%+=02-S7U=\1C[<1A#(Q%:Y*E1
M6N=-1)Z@2<A0<,&F2_\ @0^O_P!'+__:  @! P(&/P#T#P_D33!-<ZX]6">K
MJQF#D,:NJN!ZST_I^S&D]N  3CK'TXHM:X H<&E:TKT^S"@5K@\:X!Q)JX98
M]73ITK@5KT."3PPHZM(PM:Y_C@XRP*G/'77^G!J,\,.O"Y C^G!6F ,"O;@Y
M#/'KIBI%.@P.G4,4H:X-:X<YT&%Q]=,9@UP2> PHSI_ 8:G4,*W;7[,5%>G3
M^&&KTX8'&F ,Z8%*XJ:X0GKKTZ5P<SA@.%#]F(S3MP" 0*]>,JUQP-<'57#G
M.@PO3MQ]>#6O0?5@$5IU]/HP!Z\,QX"F!ZQA02:U_#!P1G7&=:X;MKA@*U&!
M6N #PQE6F 1PQUUP@_-3 -#YFOJZ=.'DKBK$T^WA3%,9\<5]>*C H2?IQ45K
MUX7,].S&0-:4P#GJ&*BNK ^C#*1D?YL9<,#M&*&NG /9@=HP0!7R5(SZ5Q3K
MP<4ZJ=.O !ZNG;@GKP.W&1RP2Q)&!CU8RK_#'77%,].&&>D^W IA2.K'$UP1
MU'"D=6#7@<(HX GIT'MP=0H<' [,#,TK@4KCKK7ZL*.S!P:=GWX0=E?MP0*\
M>OR==<4SIAE-=)P!A:#AC.NG!(P#A@.!I@>H8':,$8)]6,ZUP?IPQ[1@$#+I
MV8RZC@4KBB\,$&N%;L%.F>*$GZO2.0\Y&6*]7I\#%!V8'3MQ4=OX8&GC3!Z=
MN,\+4<<&@P!3/R-V8'T?S8:O4<&N"U,L,>H8)ID,>K37IT_'"GJPV66 :94_
M'! QPQ6AI@98SX8;IVX7M(K@8(IG@?1^..&'!XX4#C_#&73AAJ=0KZ?!IGBE
M.F>*#M\A&*X%!PP1@-U^0FG'ITX8'3JIBIP<4/#!'4<$=6&RZL#++!/;@>H8
MJ?)PS\IPN7 4Q4<<<,#+.GXXH:X-1D<#%!CA_P 5,ABM#T^O&8P<Z4QEV>0X
M'KQZ\4'GI/9BF..",'/R'U8IZ6(IG3R'UC%*=6!]&*CC7 R[/LQ3JS^W!!X>
M>GIVX^H_SXH1G_3@FF1K@@#*N#0=6'JM<5ZO18ITRP">O#D=6 !74<*36I^7
M?[/;;C"^ZVJH9HE8&2,2#4A=:U74N8KU$'K'ER&.'DK3+%:9?R05NG"F ":4
MP_:0,"G9A5ZNG3C@Y_)VU_!7C_\ V2.(-S1\+#<\TDC2?U0=.D C+MKC>'CW
M^;;]RMV=I]S8<Y)%FJ0RK)W;GG'O:'%"P+2A)48*UGXM\3_[ONO-+<_DI!W"
MJ )HC 7)@S5X]_3P48->."0.H>K!SXG&9PQ&..%SZL ]5,-II]G#%<N P:<:
M98.77\H8&8P.O %1BE1_)N@&""/("#U\,5KF<"F>=?YL4K48 KEV_3@A3E0_
M=@^BJ8()ZZ8J<#MQGQI7&7'T53.F,JT]?R_J/W8/F^0\FXG8H8I-[Y#_  Z2
M5Y;S:3RE>A4A&?2&(8$ G,8W#]O+>T\)ON>WLK7/*GE8/$I!N19.;@)<2VRD
MB= 1RFRI(5TEGD<*@&9)H!]).-SWW>]S6#:+.'FS2Z7=40F@_P M6+,20%10
MSMU*<6>Y;98//8W,:2PR!XA'+$XJLJ,'8E",P=->J@-:*18VPJ.N=JCZA"0?
M:/IP_P >\)8G(1AA09\2Q-<J&H"YU%,@3\Q6F6,\ TP21C,8K3O8S&=*8RK7
M Z=0\Z;;_$'BRPLKX '1-,D;4(!&3$<00?H([1AMP\/;M!>V*R%#)"X=0X"L
M5JI(KI933L8'@?GC7A\Q]1^[!\WM9+^W;<O$UU(O(V^&14E,6K]2XF=@5AA1
M0PC+"LTP6-!36Z[?XH\*[@+C9[I-2\!)&3F8IXP28IT!',B;-:CB""?$,N_2
M7";&ME,;AH&99Q#RVYAA*]_FA*E--6U4H#PP!>^*-Z7PCM]Q'+M[P;;>0W-U
M+(08(;@LB&PCMRW_ %-P^@SA:P<O6=)D:%6D/6<Z?17@,^ Q8;IX3NI[U=H8
MS-M*9&X8U!N+9 56:\B4T6*2K-'7X=HW5UFM=G\5;EKW"=N?\*K:X['F#4;=
M7J5,F>J81:85DJJ*SB6::ZBGFY<+1L&:H72I!!;4<EH,ZG(4J<L77A+_ /I&
M_K^V)@$,6X&\"1_[BKZI)&FY04;<R5BB?DJHG )I$0<(%:JT%#V^O+Y>6!W6
MK\P.G4/-=HV7>;U)=TN)4$L:2*&MX6_U7&=6H04B.G4O>+H"FNSW?9[Z.YVR
MXC#QRQL&1U/ @CV$<0000""/D3[[<;%:/O1NH%Y[1(9=(5QIYA&H"@ (!H:+
M6ND4>P\/;1;65BTA<QP1K&A<A5+:4 %2JJM:<% X ?/'LP<^OR!13Z:X%!08
M#4RH33Z,5*Y=F"Q&667TX8URH<'S>WOK>1+3Q3"543T.F2*N:2Z02=(J48"N
M6@D JT=MX7\-6FJ11K?AS9Y"*--,V0%=- 31551&@)"J0TI!;L' <>';QX\#
MQ '#!&@>Q?P^T4/DX8K3%U+/%S(%C8LM VI0I)72<C494.1X'+$_BE_ F]-X
M,Y!G6V,4#)\867N4YYC:VH9'Y?.8%M$8!@K&8RBT32*#A04R%/5\P1J-?LZ=
MOS Z=0\UN[B+9MK-S,CDM-96]P><:%)29%J0H#!TJ!(65F(*][X7;;**WMM3
M-IC4(NIC5C10!4G,^S@ /),L$Z.T;Z'"L"4>@;2U#W6TLITFAHP-*$>2V\(-
M,9=_GG24QKPCC4-G(<Z%M0(4 MI[Q #1B2T\4;%=@[?(*,&HKQ2  M%**D!U
MJ#D2K*5=&9&5C_UGBC;HO[]S"O\ B<8'/_<+902>'QMN3[!(3CN^.MN;^[*'
M_P -<6]G:^)XI;F5U1%2.9JLQH,Q&0!7B20H&9( K\UPKBNBGUU\@R&!D,5I
MEBM!BM!@_0?NP?-UV^R57W!E#&H)2)"2.9)2G$@B- 0TK A2J)+)&0M6D;-F
M--3GM8@#/J  "J**H50 /G\N-1[/HP:?+'3J'FOM^X^2[L_#][8W'[@,@:TL
M)!+-+</4,(_A[;5<?JJ&2-](C$A4NP35C]MY?!O[-VDDV];,+[?#RW@^#OFF
M9>2[RS0J'H2VFX9IR&:@-:"8W_BW9]BA8]T6L//D KPD2=)0& RK'=9\1HRI
M%N7[C>.=ZW'?D01B:%H[=>6"2%Y<@N6]YG.4H4 @!.)PME_MM_<6X-?UKEBV
MHTJ=<20GJR[.HXC2'PJ: 4&NYO'_ ,=PP.._X'VZ0=DD0D]O,+ _;C]#]N=C
M'_Z5K_/'B;Q%OFP[#MFUVK*QN);:VB2-P:QT?E@\QG $2K5VDH$!:F+>\L[A
M);25%='1@R.C ,KHRDJRLI!5@2"""#3YGW:UQDE/E_4?NP?-+YO!26+>)P$Y
M O-?PQ.M=8ET$-IY>NE/S::Y5QXOV/>MJ\)1;3X;WE=OW-H5N%FYND2L;(M(
MPD71^9PIJ1W:5.([>QC63=9B1$AKI%*:I9*9B*($%SE4E(U/,D0$(7UW#'5)
M(11I)* ,[>LT "CNH@6- $15'F&2DCR$CA@FF*]6*TRQ7JQ4C Z=0\R^*W"[
MB@MP0-4CJBU/ :F(%3U"N(K 7T'QKIK6/F+S&7/O!-6HK0$Z@*9'/R"4J=)R
MK3+V_4?MQOGA[:=Q38/ 5K-RA>)J:[O5T*6:'24>)"Q*JT;P%" RS72EHE@W
M+;]M-SOR.7%Y=$2SB4UK+&:+%#*VHAGMXXF:IU%B220237/IZ_JQD.GVXN%C
M-7B8*V1 !*AP,Z ]T@]VM*YYXG16!>-M+9<"5# 5Z^ZRG*O&G$$ 9FF-Y\*;
M5O4<WB#;P/B(A4::Y'0Q[LN@T6;EEN3(1')I<@>3PK*!M]YX">=5W"TN;6*9
MXT592MU:M+W1*&9%;4DC*HK$ 6?%U-XWFL4O9)WY5M9PK%!;0"23E**,X:1T
M*M*$*PHW<B049Y/F.[CO>2M,L9C&8Q2F>*4SQGV'[L'S3>(?"&X):^)F@;X:
M5N"2=3 E6"MQ".4<(Q#E' *GQ;O5[N+67A/;Y77?FN6DD^*EU2:+=4#LT]^\
MRL\4VIRFDDN\<NB67==RBT;K<*NI-6H0QJ3RX5([I*ABTC"NN5G(;EB-4\PH
M..*E./77R$Y?7@&N0P#V"F"<LQBM:\/LQQ!KA<@/Z!YEXACV3PC-O6YJA9((
MGE1U(1QS0L+I)-HK0PJ2'#$LKHK*=CNY?!UQ/M$7@_:0=P9Y8X[6=;.2*2'2
M&6&:0D\MXF1I8BY<,BHX:VVO;[8W_C.]HMK9I5F8L2JR2A<UB!!H,FE*LJ45
M99(MZ\8>.?%%S>>)]R@5&MA*?@K.-6#JD$/N"84"O(@5=-5_5;7<2FN;=.G\
MPQZL<.GM\CL@H6()H.)%!4TXT&6?5EAC3O$U/K-*5/U #ZL;CM:7\]JUQ"\8
MFA;1+'J!&N-ORNO$$9@\"#GBXW3=]YDMMFVZ82)<P,5>\K70D?$JI4E9U>H1
M2T%)%?5Y#4=1_FP*=,_F:#%"/)DV5>&/IP">%?LP*G/&DCO4/\,4(SH?Y\'S
M2]L-AWL[=NTFC1<"-9C'216?]-B%;4@9,R*:J\1C>=Q;]VEOMIEW:.[W"-;"
M*)+N\0-5??8IRHY,RM$65Q1!+!5?,:#CBG5]/S Z=0\RLYVKS().8A!I1M+)
M7V.V-KNVB-WXIFNM.VV2FLMQ.XY$D@C!UF&$3CG,O>+/'&E7<4O/&/B^47?[
MA;@2\\IHP@5J?H1$=T4 57*=VBK''^C&E6 &1&*'C\SQZOYL'YDY5Q[M/E_4
M?NP?-$2Q"MNUS((;=6S',<$EV !.B&-7FDRS6,J#J9:V]E 6*1K34QJ[L35G
M<@#4\C$N[4&IV+=?F>NG3IZOF!TZAYEO'BG>Y@EA9PLY%0"[ =R)*Y:Y&HBU
MR!-6(4$BT_=+<09-SDVNWCMHFJRVH8222,I.1E?G% VA2BZP*\QJ4'#YO(XS
M^9-1C(95^7]1^[!\TN]^8UM(M=O:YU&A6'Q$PHQ!YTJ!%J*\N!'4TE:OF>:9
M_3\P.G4/,A#(.;^UWAN8EU'NWFXKF@.='@7\ZFJO;D@AXKT4-!WJ]E/LZOHI
MEP]7FQSP>ROU>04P,\L5'"F..6*GAE]N#3U_=@^9P[992%-PO&,:L.,:4K-,
M*9@QI70W#G-$I][%O:6T82VB1411P55 50*]@ 'F@!'>P:\?ECIU#S';/ OA
M9M7C/?G,$0!H8H3E-,6&:=S4%<9H!+.H;X=AC:_#>V"L,"=YRH!ED.<DK4RJ
M[$F@R1=*+1% 'FU1QQ4GU=,O(--<L#++%![N.&6"#[OX8-.&?W8/F41D<*'E
M2-:Y:I)"0B#M=R"%49L0: TQN&XWR@./TH0#JTPK1F;AD\SYN/ZD<((#*?->
M/3[NF>*8R. #P. !PI7!!X4Q2F67\<=XX6G3AYA));?JZ=0HA#$LA(9%SS<,
MI336NL:>./$O[L^+;!X-XNII;2TMY -=I;6\C1O&P%0L@D1HF*D@E)94:ERP
MQZO-S3&?R_J/W8/F7A*.5R_@AIT_VM;-G21+_N]ZX5#S&OE?4;*50P6(Z8:2
MEPVR#]Q;B"7Q:(5$S1 "M  G-IW#/I YS)W&DU%2WO-YIIKD>GT].O%,4!RP
M14TQ2N6*5RQ0G+%"<L#IU#S#_P#U%9[)9W]A)X?V:*XFE-U<0RR32WFJ1K<O
M(ZV43*6D22"-"_,$V:,%/AJ_V?;[JTVVYM$F2&Z65;E.=61A.)F:8R,[,Q>1
MF>0%9*T8><&AP>T'Y?U'[L'S*[WZ5:I-1( 1PMXR2KBJ@@S/6:M36/D5S3S8
M44_,#IU#Y_=O$NXT,5M'54J 9)&[L42DY R.56IR4$LU%4G'[H>(/$$&P2^)
M?%]G;75I'>1S2".8/S8X-VAKI^%12DB0PEV1]"%M"*BVA\736TGB2AY[6X80
ML^HT,88 A2NG(C(U R \XKV8U=?TU\BAN&!7C@,3WJ'^&*]>"P/>H/XX->-#
M@^8P[)$U'N58R$4JENM!(<R#62HA4CO*9#(M>6<)'&@6-0  !0 #(  9  <!
MYM0L:5Z=*?,#IU#Y^U\)K5_ WAIQ/>TKIN+SO*D!R(.DAHSQ4J+R)P"8VP:#
MI3[>%,$^<9'&9\F9.*DYXJ2:XK4UQ4$UP?H/W8/F#RRM2-023V "IQ<7\X(N
M)].1KW(UKRTH>! )9Q_S'< D >;Z1]_\V*?+'3J'SSR;<-?B:^D%M8Q@:F>X
ME[JL$J-0CJ"%R#R&.*H:5<6>SROKWN=OB+V2I+27,@JP9CF_(%(5<@%])=JN
MS,3TZCYR348X_+^H_=@^8"WR-NA!?(]X\57ZC1F]6D9JQ\X(KC/!K@]H%<4Z
M\5 R&*#C7'=&%KTX?.S75S*L=M&A9V8@*JJ*LS$Y   DDY 9XN_W;W6%AX6V
MUGMMGB=2-;#4LUT0:9HPKU_K%(G4/9AC7% !]OX^<G'#R4Q2N#F*8I7!P?H/
MW8/S^X^(-^W**UVFU4EY'-!7J1![TDKGNQQ(&D=LE4G&Y;$(O@-V6=S;1R."
M;B'-J@\.>.\TD2EAIJ\32*LG+\VI7%=0R]?DX8I3/'#/&0P"!0XR&!TZA\[;
M_LSX4N3'"X$N[W:T*VEJNAN4:]TNX9#RS7F,\,&AXY)^78;-M%L(=JM(5BA0
M9Z8T%!4_F8FK.QS=V9CF?//77R#/\M.O%-66"M<J#[,&K4P23G6N"!PH?NP?
MGO@X,Y *NPI1!U5_M-^5>RK$4H&N?#GB#;EN=EG6CQDT/]Y'H2D@XI(O>1N\
M#7&Z;S\:VZ;U)<.;6:6-$^%MJ$*@0"ANF#$33KI0+W($C5Y=?F] HI]'S Z=
M0^<V[9?#MM\9X^W>9;>PME 9VD<Z>:4ZU3,J&HK,"79(8YY8Y+/=-ZMIO&&Z
M2F:\N9IT3XN[(9Q!%)*5K#"68)E^H[2W4G>E)$&W>*(["S\7A6:6T@NX[K0H
M;NL&4(S*49&:L:E6;201I9O.C@99_+^H_=@_.W.V[%*#)$Y2:XIJB@8>]&OY
M9;D?\L$K#[UP5/+BF6"&I%:EF-6=CQ9VXLQZS]0H   <9CSBAT^SH/F!TZA\
MW;Q"W>_\6WK".QV^$%[BZF<Z4544%M&KBU#D&"@D$"[_ '&_<>X2[_=3<8R&
M"D/#MMN__P"';$$J9&6BW,R'20/AXF,0D>>*2^L()WCKH,L22:2:5*ZU;230
M5(I4"ARP-P-A!_N(%.=RTYM#D1S=.L@@*#5LP%!R44\ZI7/&FM37Y?U'[L'R
M37$\BI;QHSNS$!5115F9CDJJ!5F)  S)IA65@5(!!' @Y@CU$9CR7%[>3I%9
MQ+J>1V"HBU"ZG9B%45(%20*D#B1AD=2''$'(CZ1Y/]MYZ?[A\/S^54<SD:^7
MSM%=7*U]SF4T:^[6N7D6.-"TC&@ %23V #B<0FPOCN%W+-)#%!9J;J:66(TD
M14B#:=!(#R2%(8]2F21%(.!+OTIVW9#F+."6MU*.(^*NXFTP*:KJM[)V>H8-
M?:2T6-L\&^&MGCGVK;Y3#>!%Y:Q*A*&"W4:55HC4DE2C,-- "9#MWB'9+CF[
M7=1ZXVH5)%2I!!H058%2.T&A(S\ZRI3I]6,OECIU#YJ]\+_M+ML>\>)(B4FN
MF)7:MO85!-W=+W9)5(8"TMC).61XV$;@*UKO.\17_B']QMS5UN=Y,(,%HA7.
M"-=87;[:0TA01(99P!SFBAI$N*XS]!:B*YTP<^H_=@^1F\)S@^!H09-VBAJM
MR8D(9)9&.4EG&VDR11E9 U'=98Q1-NMOW%E"V 53MT,H;XV&T;4RBX<D@PNK
M1M:1G]2**JR&I55)FNXD _K.H^\XVZ?:_%&W2?MY#*IN[:&:(78GJRI-.!)S
M)K,$QJL<:D1W YDB$!638;+]V_W/\/KN0B4VL+W]JU[!9D 0Q7C+,=4PSTH0
MTL<959'9J*CFV\4?$/0@&WM+V]%>KNVD$A85Z@P)X CCBHO'_P"_R!>+N12F
MV';BE%E 8"+X5E_Z<6143?$_IM&LH+A8K3P?M&T(T6L37UZUPU:9*UG9(P4G
MJ!OLL@6/'&^VNS?NS)'XMFMCRX8;6*TLI*U$MJ''Q%Y&TZ=R*Y-RPB>A:.A+
MKXCWC>9+K9O!\E;>6QG74;VXA9E9DC+$0?"R4K=+WIRIB75'5_)X:\5^)=OD
M%_9N!<K"W+3<;= >5;7@5:E8WH>;&5E:(O SF-AI2*"%([=%"HB*%1$4!51%
M4 *JJ J@"@  \Z!KET]=<'Y8Z=0\DDZV\DI7\B %VS_*&903U\1D,JF@Q?7R
M12SR*JDI&=1?3W0(48JH)U:FS74!5C4#R*R0-(=:C2M*T9@I/>(%%!+-G72#
MI!- ;Z\MUGEFGE0LIE9U![L=8D=@D2*HUNJ:0VEGHTC=[5-*J+VD@??C<]JW
M?:$N_#TL2*\<R2*D^HN7C92(RT>E4)*L5?45.0(,5AO%W<_]FPVT:+8PS&&*
MX<%@XNWC"W4L(BTQB#XD0R5+S1R,H.+7:]KLH;;;(%I'#$BQQH* '2B!4!-!
MJ( +'O,2Q)Q%!&Q98ZTULSL:DMWF<LSYD@:B3I 7@!A;>-W9%)H7=G;,DYLQ
M+'CD*T HH   'H/@,9X/>/L_CCWC[!^.)+>==4#J58$9%2*$&AK0BHRP[2?M
M9M<DC&I+?$$DY#_G@4RX :>P=6!+'^TVQB4=9@+'_P!J0XBFM_VTV%9D6BL;
M&W9E'8&=6(';0Y]> ;'PKMEN0:CDVEO%0]HY:+@00R%(?ZJ@ >P''*YK<NM:
M=5?;CWC[/XX]X^P?CCWC[!^./>/L'XX]X^P?CCWC[!^.!WNGMQ[Q]@_''O'V
M#\<>\?8/QQ[Q]@_''O'V#\< ZC[/XX]X^P?CCWC[!^./>/L'XX]X^P?CCWC[
M!^.-6K[/XX]X^P?CCWC[!^./>/L'XX]X^P?CCWC[!^."0>'3M^>H#7.N%)/3
M+RW#31[E-/*B-HB@N9X5"U4<OEHT43MF9 "KOW&8'(C1;^&-V8_VH4A'MGDB
M'MQ$EKX9D5"<VFGA4#U_I-.Q[*:<7!FC@17H1WY9J,!3(-RU532I55S-234U
MP"U"_;3[AG08]XXS/\F17I]N.'3VXX=/;@&G3VXX=/;CAT]N.'3VXX=/;CAT
M]N*TZ>W'#I[<<.GMQPZ>W'#I[<<.GMP33AT[<<.GMQPZ>W'#I[<<.GMQPZ>W
M&0^S^..'3VXX=/;CAT]N.'3VXX=/;B@'3VXX=/;CAT]N.'3VXX=/;CAT]N *
M=/;YE08I\K/Y6> >KY.>*]7R17ABM,Q\H <.G3U??_($4XX-.-?DU!P>TC&?
MR <:C]7RZ?)H>&*5R^2%K@TX>8@]>*U^34G!)XCY-:98S^53Y5*T^308H#YC
MF,4Z_E5IGYS3J\Q.6> 2,L5/R"2<9\,</DC/'J^<&6?R<N.*==?,:@_,Y#Y@
M'J/R<_.O7BIXUQF?/LO.\O>KA:UKG7%*?EKC^QALL]/8/5CN]8[,(!PI7' ]
M.APM10T/MQPZL,1P&%4C+^G [1_'!IP]"TIGBE,\5IEBM,4(SQ6F6,QBM,L5
MIY*4SQ7J_DM6HSQ6M3C(T^O#"OVXIU8+ X->SMZ\+]'3VXS/5A@!V4P*\,5/
M'!4</X_\5O_:  @! 0$&/P#^,L#"N6:OS[ZIS!J]:F4),QTJ[K,^1HU?G@[
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M(&4L51/%IVN CIB/>S584FV0R4*2PQ39PJ^A3R\<'W#4'*:0N$?YZ?N+^/\
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M_K^47U;3M\NJ*.17.SU-U>G>+<ZW'9(JI6AK6Y%A^T]<?+4E4JK!T"K=4#"
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M/_K*0">Y7@+4(N=I3.E<K;1J=[U*K6UK+N7EZI>E8->\=>0%;"/;+LOS 1N
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M>NIN=>RW<O8;,G [[S%6@J&=6JLLGI&L:UD*XG=;ZUB+O$+)+(RS=%\!&ZX
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M!)99SD."T[K[ K1PAA5PG92BP-HY8_,>K9+,I29L-ABL3L&M#H:5*;1E<E+
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MH!>B<_UR]062\_P/.)HS3KET!LEGE)"&@<HR^.9R;..D+DO(Q#PCE%XZ9D8
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MROA%2Y6Z(Z4UWKC,+QJV;TG&5<D:OV4!GL979FSMY]]IFET&(;O&458BK_\
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M8R-P:1ZFBM;1 8EE32U/9)0GY=^6_*N8A3G7$@^T#$.F83 4Y3$,)#G2. &
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M$2C^/X_A]=8V3K[;\2;AT)RM:>68QCR5S_/8JRE'LOIU9UNM=,;8UMNM:/\
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M#(L\@9'CWQ88)#.R255Q+F*@K/:_;-%@7+5=W%24[I<VO(-#2:2RJJIU)?\
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MO%8D:3=+#G^)9M3YNVTR7=HR$K4+)*5^M1[V;J\D^;)K+Q[DZC154A3F3$P
M/U<<7R;FO"LXR'1#S![_ )A3,II%>H-X&P, B9LEOJ<9"-X.R(R<04K)5-X@
ML0S(A6_I\)"D";YEJG->&5[G:S$DBV7#XG+:6RRNQ#,K(.)5:?HR,,6NS+J0
M<-$5%EG+=54YT4S";U3(()<LN.;,-6YL01(BAA"F74PV3H?'*FGDW*-%&'_9
MU*0)/F&0!R5N#@'XBY]_SB*GU!\UW3F_#K1SW6"1!*QB<WEU,D,MK7Y 94T(
M>O4=Q#'KL(M$F<*"W4:MTCI?*?VB'O-Z]M4ZF5V#J-1JV2YE7ZQ5JQ$L(&N5
MR!B-ARQA$PD%"13=K&1$1&,4"(MVS=)-%%(A2$*!0 /K"/[FLO\ ZD0?ZA=]
MBB6R=DW6\.VN0<OYRBD20EK[O%Y2<,*>W9P8)KN9F-K!@4EY! B8_<-F0MBB
M"SA$#0L!IK@UAZKWV=?= =<WMZNE(S-AVB_>LK)03J8!(BK]E16SL(\IO<=)
M=^#QX3T^\.'ZOM_7>B>7_BG%^X<DOFZ+5;AXG"W-FP5V)GL-OMKK&:8BMT:Y
MJ[[?+BGI4/56":EMB+.U5CS39U&92)LS)FB=GP;1Z9IE<![^RMKE:%)NYFNP
M6BQ</#25KJ3:5>1\8I(C!J32(%7*D4BZ*A%"_@;]/_4)_P#<ORE_@C:/XYQ(
MT*/-:.@]<G8['>;:$S13?RMKURZ*!&02R$4(F5>Q]<,X^\<?S#)&.1% XE%P
M0?JE\]?FB6C<,>*#2W&O=4Z"#W\WJ_:OEAMB?YA-)NC2"9D+=2.?2":)2,9$
MR9F\<K\H*(SR:GU_I]/^\S:/\+ZW^L\F\Y;/R[W?<VMNU"0LU*Z2XRB]5A=0
MRNP_V0Z^Q>MN?KKB82MOM&I2\$B[B;%4G*#)JYILN^D/<X^R*0M"C>:N .O.
M>L9Y>\>ZG.E3V7J#/=DPN.KS%UM-,GHS$*;FVFMRLM"LES95T]DL%O(LYDTS
M1+1!TH(O/4?TN^/[O*'_ (V9C]81_<UE_P#4B#_CY"8F)!E$Q$2R=24I*23I
M!C'1L<Q04=/I"0?.E$FS-DS;)&4554,5--,HF,(  C]37DON#60<^//Q]62>
MR7QYU:6!TC#Z_NK-=L6_]-A&.$$4W3"*=M$%8U4Y2F(X2B2 (.8M\0WZOB>R
M1^1:_K]>WQ/H2UP<7C7-076Y5/)>8+U(T??.AM,K2RD0_J>+TB<9BX5EU/F=
M2+18JS)JY_X@$K]ESG\A5I=NB(RW5V1K35LTAYN(L<>UE(R<9E:(H)+(RL<X
M25(H)0,<ABB/UXZ<XH=5RN6R;K+I:6P;6;#:WEL<:)7E R>^Z37!SV!B21E:
M(B[+0797TE(OW!FX_"BE'+?,=RVQOH66KN)&X;Z%\D]Y\;-&S.,K=U2Z+J3F
M!M&A9G2.C;-J+R[FHLNVM^H9C(DDZ:WJK<T/!O&2J,P]<D<E^N/.D=CJV*(\
M;>0>1ZT8Y)0*37[I'[WS\RYWS_5-8SB6O5[D[I/4S9G>OT;&)E.59,X&J$KL
MJ\8%1</4 <F#&>C.M*-AMLQ[L/QW]3>0G"\\PN,NM3ON.(\TYK4MQ0P?0KW=
M;5;(35G-]R*^1H!:&<'6"1]D0=HC&*LC(+!ITOV%1L%U:PR_C)7\D&*-\#B+
MOFD16YUK?,\S*:YDOY[M==(>6]A%VK9JRJSO#((<[Q@G)&5A45"-R&ZMQ#R,
M+9E>IOG;D7)NXFFE\DY7HD(RE<PT*WW#-;MG2^4VR]Z38'UGSC1:>HG&2C66
M D_!NTG+AE&N$5DC^='>LT3LJ5#TW?\ EF=K*=RK,K3+25@ADMWB3?G=4GD&
MLU NC.HY000=))J_&)3B4 ,'\;(S<R_9Q4/#L'DI+2DBY19Q\;&Q[=1V^?OG
M;@Z:#5FS:HG454.8I"$*)A$  ?JIZ'S:Q?2W1_4$W<.1/$)1E55F3K-*.*Z\
M'TSY';4W(0!@(^N1B+Z/K4DN4PMGA5W12JA7%!')^5<J*+V-H<.+JW7!TV20
MFM)TF<,60O>B6$Z8"HK)V:=44.F10ZHLV)&[0AQ2;I^EHZ;U?8NTH;1;!-L;
M'%,L[Z'6JM1SR:95*&IHR&9P"E3E IKE[%0:1G)VZPF77.H8P^T_L#/<N@I&
MP3$)FU&J=!AY>V2RD]:92*IT!'UV/D;+.+)I*S-@?-(XBKQV8A3.')CJ" ";
MT_6.;0IFO=4XYF5LZ6B*MT//\0Y9-:5U*OEKC.-$DV@YNXBLUU-*FQL7?8J'
M=3;Y6-(JM&)J-FZBBRI6;O5&U9ZF\R.]/$,N9+N:_P"23*Y[/\NA6W[6,$RS
M.?NI7#,H0=7X53_ HF1PN<\<HJ(IF!/W)?6T=!0MRNTW1<2Z(<\ERD6PRG0T
M]%OW2)7-/C(K'<CS"1K["^:+<K/8+U'1T6BR8"1VX.HH!P:(JN2&WC\LW )<
MFZ%Y9-S<.-6P.JO^J(\0-D3Y[#%_B_,AT92H@,X @Y_)Q@0&3^_^Q 7 9;K=
M73V?2[+LNBWW'*!S5G&-7&P]82&P9 E-.=NS&7P95K'VJIVG$65<?.+4,M]D
MQBFZ":@N#D=L1=8+K]%5V3H!ITE!WNV9=GO/6*WO4-?=4[(GY(?;+99<WCHU
MK/TZ*Q6?.$59$I,K9\TFO2,1;N) 2MAR&UQ$[I>\16RXJYZ>A$^;<ENNRRM4
MY:BS1R5@Z2TJ%K<=^:T+)JZ[E46KI=^D23.^*NU;LEW+5VDAV/HE LL1;J-H
M.)9#>*3:8-XD]A[14+;JV43M9L4.[3'V/(J<AWB3ELJ7^:HD<#!^'UA']S67
M_P!2(/\ CWWB,YWU9ME,=*U)MH/D_P"IR?\ J(3E+D=X9@#VAM3-CBZG-FW%
M&2;QL;76@&D9,DDRCDDSA+JK,H/B''\_4YOC\9CEZQSEG=JEF#F1T[(X%(ZS
M>QJ2;<J3-QL;HP.9:U1!3N7/SNE7J3AZG]VLA^K7"_1V?7[5GM2@W<TAG.6,
M*_*:);S,R@<T-3XVTV2H0$A.+D]111<R30JHE]I3^\2E-T7JV<>%CRG3.\]4
MXKU+@K6I4+)NC[?RQ7:YK.DZ.]LN18QHDO=&/_3QG&J:,Z)*79>L1T<E!3Z[
MY1F;XV:)S9'6G]-B\Z?5W,:%!/<^A)0\Y"T1W$U6*8.*;$32IU%9B+K"S<6+
M=T8QC.$D"J"(B;U^N4].;]&Z)C8\DZLEME*J]+IN6V&'M&BI1LA5/S"WO+U4
MK#,J1)\^LLY#BR8N&1/_ '87?N^Y;-SDKUZ';M:F.<J!T_;^WLLXV?L:"EE>
M?]:WG]J5YG2F-U9U9#5I&HQ4[>)B<AJFM+_D\7.R"C@ 5;IMVB.92[G;->T;
MGKFYYO\ )<C\HVU&DM\WY_>]/Q]NA=<3-:X&MQFD:U%-ZU?IR&JS6T2<@2M0
M\LN@F9PH5LNW3JFP;7L?2V-T#F?8^,^:L@THE(@X?GWF7?8B'K6IT2.M6?UB
MKW30+%,TRNQU>;3\T]5?,8!@B@F N!6=JZM5NG=\W'KE.]<B$X%H\OHX4"G2
M^0\DLYAG9&%/KQ\SJ%886;3W-GA8B2E+M--WLM)NX&-$Q$TT%$U]*WO5>A--
MZPZ-TNCT#(7VQZE YY4G\#BN5/+%)43.H"KYC6*M6VP?G5KD)6;DU$5'DU+N
M3+G%%(B+=+_4)_\ <ORE_@C:/XW1>8#7M]2<2RZGQNG>0?7*XLS3F*EE;QVV
M"G<X9ZX?*HLY+=>B9I1M%QD<!P$$G)16]6GY@+>R^4WK&A1E(Z'Z4H=:I/-.
M'D0<J1W%7#]>:((Y'BM:0?II*1ECLL"W:R4XO\23Q83E.Y!)^\EDU/UK,UK#
MN7D1P9!UL+!HTL?C:HTS?M>FWIJ=;U"5ZZ1,)G&F.D,Z533,X55,R2)^9MV9
M/E]3 0^L0E=T_P M6_<WM^7(F0FM)\F%:M68QM'WC^U@B$=0<TH\_DV5-[-(
MVG.U59%[)IH.CQ24:5$RQBR!4T?KHJ].>8%ZM>*1YR,\\M>&YG/;+BSQ3H',
MJ_"U//[!C@62M7:<@,VU *K4W4HS6FCEA/OWC! SL *Z5;_]?W_3N8-6#RS(
M]I_]%Q=@R_\ M+_Z:D>-B\1A'C>AL08+_P!0XQ9?VQ_)OVJ_9W[?_P!M_/ON
M?Y_UA'D,_L"3T?3B]I^2KH?6N,*7J>7L]!HN;=_P&?5VGQ=7TBZVVJ8E;=&R
ME+'(9:R%":9L'_YN\(P=+_:I"OQ_T]"<[1/2>IQV'^0_/MZYXS;:L\JSS+;I
MVIU<P['S8]5NFM25&H]RIU&L#$*C;G39XB\0]PRD6SED_5L&..\NQ:O=<6BQ
M^(5?Q[Z-7*;J%#SMIE&\H:WJ6V05W>R^M352;V7 59C;I&&?N(=)S8FR$*@Z
M1AW'W(HIPVO:D:=NO6' O G.W,56T*MWFYPV?.VM3N-2K%C<)4$'C&$FH]\_
MNTP9HK(LS.RMSMO?Z*()^S"/[FLO_J1!_P =GW+G*=;;[=Y*^LGB-+YBQ&.3
M1ECU@9I=Q&*[7I+$3?!%T6J&0<+-BO3(MY%PS6%0Y(]E)N6O:>MZW4*SW+TQ
MJ"=0VGM2YZS-6)FAOFL6O3*Q#/4VEN8)_MC7X+,UKL^<5=VW^W?I28'DO1JY
M=JE2IN.R'-%'4L=USS4[/ ZY8;A/V.TY.WI=7^^DX#/X1=@A7S'L*SY)LM.N
M2$FE&'RH>Y)-15-?]7U W4W0W^J1D-R/K.VQUHFN*\;V[..9I.(8Z5;(^@RO
M/M0/CZY*K1UZ C&"U27,13[LJRI@^,R9C5(Z*MD71-6($R2]R(JG;UDS1302
M*VHBZ2"Y+(H40%\!R$.#H3^I0'\/T_\ 4)_]R_*7^"-H_C&<'2G=9D>C-40D
MH[*H*RRC*.KE1C63<Y[-M.E/7IRM(/,\X9 9TZ<.1*FZ<%(@7U+\YTH[R/=L
MH:II?C#P+I-64R.$9TU6T:7Y/>]I )5&>Z=NU,L,C%?G&%Y@Z8/F%>9NSBS2
M03.BL43J3[96ST^F4'1LPV#/JFC<KO5;;%-C5)6$?69Y7V#NBW-)Z4UO32 C
M<SW_ -$U%FLX!(P&]"F-^M8F&:R?5]<P.0WJ*8=HW#@Z.=2?8E2P92C7=2(F
M<G3BH^7MC"NIZZG726Y]6VCBS,JZ9PJS*"0.C%UA/$="\EFL^/A3"&4A*W+R
M=)Z(ZN3+JXU]BV4' \[6+;H2OZ]-Y_\ V6M9=6U(+).8=C+A'"W6*JNJG^GW
MQ_=Y0_\ &S,?K"/[FLO_ *D0?\;"\7\6T0_8GDVUPXP&9\]TD0G(C,WS]J=9
M"Z;G(L'C5O7(F&8^Z1-%K.V;@S%$73Y>,C1&0"]]D]F7\.E_)STFA^8[EN<N
MH24CL\BGY&JA,<QT5&C1&$I\*@T;-7*[1NS2=D9H-VZ#:.;-6Q-?Y(U&Q7*I
MT+9XB$AK%8<_>0["X1C>"MM?N#52$=S\-8(A%960KJ*:GSLURB@<X  &$#!4
MNK\EV3I2XWJGU2]5&/@-)LF=R=2<,+]%(1,JX>-J_FU<ES.VB" &0^-XFF!_
MQ.4X  !^K]!*X=JO^KHG=A_,]=_LL@6U-UEA@TKI9YZP?LI6&%U8XVFQ@,9>
M6)1%FV?I221XRO&(JFL15$@A0%+A"*UJVJ4JJGM-<7L2UO6K]C/!,#3<(M;7
M BO:%8J3%5 TB<1.]%/YA_$X_I_ZA/\ [E^4O\$;1_%OK9>)&.FM%E8J0<Y[
MF)95O'R$^JU*8BD_8'IP5+5<^AE_09&77)["@'P-R.'BB+=2R[UN<Q;ZYP0:
MW(_VUZT=.0J4]UL[ITN92/YNY_; J5[3^<:@_:@WEY!LH!U%B*)@LK*BJHRQ
MJB81E3IFRR[IC#H&C53(Z1(.%:%GL12=$C)..K\538Q=W7JHTKC,C=P5$B37
MX2D3/Z^I 'IVXRE6L@5)3EJ"84BX2-?F0J2[Q77&@65I3K*[9! N%EP:MRO"
M,%S"<S<2G 3(G OZT?L4_,O6W8G*&E\:5;G]"K\D1X:?;\,UZF[#;[[,S<]S
M\ZM=;;3D'I5;L; O[5,_F?L5(<62I 0.D)[SW#)\T]1\?\NP'%L5S%"9]UBV
M)GN@['K"FW'U-OHL;@\?:;,SID)GE85?QA9IX*#^:_/2)%]Z3,2(?I=\?W>4
M/_&S,?K"/[FLO_J1!_P/)28D6,5&1S5P^D)&2=MV+!BR:)&7=/'CQTHDW;-6
MR!#'44.8I"$ 1$0 /I%TS<(.VSA))=NX;+)KH+H+$*HBLBLD8Z:J2J9@,4Q1
M$#%$!#\/X%7]HLL!6V*"/W"[R?F(Z':HM_F3;_.JXD7+9%-'YUB$]PB!?>8
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M$1'\  /_ )B/\$S0<\L<#LG2*ZQH.+J, HI8Z_5I]P(-D&\^,$Y*ZLEB3>*
MFG!1JH.#+%,FZ79F  /'ZIYY>S8#$*U/6R62G.,)>P34'M1INAJ'<Q\/VFXA
M8>*:\N9H]3,1M"55%5I*OB.3$1)$IE.X<9LEB#&H1N-#1:HME+&@1\=%49OG
MCF$9.:<6H1L2@UBV5;- +-S,TVZ9$BMQ+[0 /3Z<87JUHUFHU%U9H&T.)3&-
M%F,ON2KJ ,Z^&.-9X0IWHPC]-ZH1VV]/:L40_$#%*(7%QS?9-]=1=SKT76W%
M2U/8YW1*=7V47,2,Z#BH5R2;MF%<D'\A**F=*H%#Y@_E !$PF_V#6>$>4-MK
MG+[^N<0:=W'==AF,EK.TR=R>U[48#(<VQUK6+B[:04#274Z]?2=I?H%/-.6:
M;9K'.8U4ZCL8:N6#D/HQS/\ ;7#>-;I:=TS#.W,[R5C=H<:K%C9*;=-(?S)G
M]7>N9S/EORQFNF[7%"7CB'5.=0RGUA']S67_ -2(/^#AN17IMSL:4=0^B$JM
M,UNIWF?KM9FG+S,CV<UTDJ^@^K,(>6KR" 1:\HFBF0&[[T5]3![>[SJTZY4M
M%_LV7K3)KE5KA5F\];F^: VEY>M)VM-BBXB$XLD>W54:-BHK.TU%"G.D=$1.
M9],Q3(J8 *AG<BT; 0#& I1.*RQ *!C#Z!Z_RC]<W3+5LVM4DUYBM\94[)#M
MG<M!P/KIX'MD'(R[21D(!I9)04V:C4RB#58&J#A(#G$P /0:-JT[,L:@'_7.
M@32$-H-C99[*3$^K0,Q:VZWP<5<9E@Z>TV:?LDTV*S-FBU4<M'9B"?W?S'A)
M?M/"XU\#=P5JLC,N[8@@Z!(_PKKL:RFNX>MDE?0QTR+)"H4/:!RB(&!>POG4
M&A04- <N20*[@6MN=7EM>3V<'"+1S+$G"2KF0($J1P=V"8,3E]RP$_F_05/@
M/QQ](]2VU44F;*<C*M:9&M/7H)^URZ!A1H"QMVD>18AS>KB;1 A ]#']0$?J
MR:)W)R#5<\XMBK1F\I,<QYM$MK]OUNFG%WAPH]G;YW1?[4;A-0V=V91I)RD7
M*R<2'VK<RQD%S(_']8_3^I..+7?J+4,RT/4#S>P8'>(S+D9*,;U]O2JS892V
MUR&K]@?/G\T:02A'OW2" LC%7;?(H)2QL% 1<=!P<.Q:QD1#1#)M&Q45&LD2
M-V4?&QS))%HQ8M&Z94TDDB%33(4"E    ^NV];YLR[*;-C.XW>#L65V"W[?3
MX&>K"R.;T2L3$["04G]PZBG#I[!NB?;.R_"5<I')$_< &/R%A>Q,V\?JN3\_
MYK1=#9-9QO94&]PK]<9,)XB=@:**M9@!D$CB+A,YB*B/N 1 ?7]9ZPP'";,2
MH[#JF*W&J9W-JRSF 0"S.V/S,8ES.LQ!Q"-;&* QRKPOK]JF[,H(& H@.K<$
M4OPR][9MN6RX7-<^)732Y#-ZQS5EEGM%3-3'-_6Z*C=#D'%FJF<.7!I9HY9L
M1=S8,4TBD(=?\,WIEIL!K99ZC0J?6+':CE4(>S3T!7HZ*E[ <BHBJ0TS(-%'
M(@8?< J?C^/Z-YU?3++&TW.LTJ-BOE[MLP=1.*K50J<2[G;%.R!D4UEOM(N)
M8JK'!,AU#%)Z%*8P@ VV@0%5VS$]%J^>5+:F>?=*YF\R"VW; ;\_DHJD;U16
M$C(R+><S*PR\.Y9F5.LA)Q;U,&\FR8KJ))G_ -0H9,Y3E#IKE4@F(8# !TL4
MM2:A!$HB'N34*)3!_*!@$!_'^#H[1:>:3);*'A.MW&L*PS2-?RR%@K5!GYF&
M<QK&8.2*>O6TBS3432<#\*AB@4X"41 >)J?IG7V@:A1=@Z&P.F:/G3#.,03&
MYU::EFT5,0<"FWH5?4AE)1H_.J\6:.F"RI$Q5%0%"$#^#LC<,>=NHW4LLYWU
M&ZT&89QM?F58&T0=7?NXFQ'B+3[J_*-:ZZ(5\NW<D5(L@W.0$E3"5,W)N3:U
MU--Z?FW0N[P<)J%&-F>-,&+V'#/K$@=&K*H4^,<T*O,?RA&2>MX=PS4<*MU%
M@^5=0Z:R]JTV^4S.JNU$0=62]VB$J,"V$"B<07F+ ^CXY$0(41_G*!^ >OUD
M^-\!]X_F..-,ST6 Z/:X-H2S:L66V25HK@04!-6%O&(1D^S3@HYS\3F$DW)#
M$5716,F40*O<LHS'OA6H<Q0&IO*EKG1&G3I+5K;)VVHU5)_9-0V]1"-NEF@D
M*[*MG[AL^D(1@X<.U!5D'!Q.D$?I["#E^B^H$R_.\Z6W<K"R7")?J^X[DV85
MLJ'[*90S%554$U(Q TP9!4R3F1<E'Z[MT[&.0Y^]9EJV_P"IW;-;6_V/&!7L
M]>M ).HZ0.WN6EM[!\"[E0Y$D9(B*J*)2HB4J1"?7+N56EA)15ISGGO'*5:(
MJ8G5+-)15EK6>UZ(GXQW/'D)4LHI'R[59$%4W"J E( )&^("?[$I^D3M]W7$
M-7I]$OF1DUCFW21RZ_V3%-1/%.-!QNVRIX6P,IFBV&1@F;Y$?MDY:%D6Y7D2
M]8.C*+'Z#X@XKR$LE(1^+YCF>(8]6I%@P,6NY_?LZ=-H..D[7+M$'+J-JE<6
M5%1Z]%R]52$3J*.%?4U$HB/^GZU633I-+JE1"34[,PYL:2-6H&/A5)'[4L"J
M#,K]1D*I4?D5%$IP()SB7WF_\>S4OWTL0_Y>^M@T?:/!5H>6Y14<\L\C?=&D
MNR,?D6E*K[B.5BW%E6B8FH2<Q,IQ"S]-8[5FV6<+)D,!0 /4Y:3? R7N/1*I
M:Z?6[!0[;&[1A:C&P42R1#&:@YANVM&EJR;%.8CG*+A))0B*B:1B HF4Y1 !
M"=Y0\CC]L)A]Q4-RY&*N9/U 0*=1]8WQ#C_*/XE$/7_=]'1M'CP\IUL!8Y57
M*<=VAR%1FSE< 4*98Z,77Y8P&,4Q0#U.82@00 1 P^C5>Z>!3R6ZH]0*":SJ
MU^6W(XA-ZD4XF(BJA6L]9N&Z)"B) *DX+^ ^O\OX_1C./])3M-[?&.0X/]0\
MJ2EX.F"9OD*FDS>2C:-33.< ]X C_P 0H>TWJ C]2UJHO^D2R//VE;BI6Q2U
MJ7VWEF5EHJ*AF"\I*/OS^=HLQ/A]JQ9G.":*IE5!*!$RF.)2C0MBYD\#%LO&
M$WB/?.\\M5/ZYR&NUV7C8R7D()^I&P<O1J_*QR+6:C'* D69-Q%1(P@ AZ"/
M_CV:E^^EB'_+WU_X]FI?OI8A_P O?7_CV:E^^EB'_+WU_P"/9J7[Z6(?\O?2
M:1?]/;IX&4.5,HJ=K88BF!CF H"HLM $22( C^)C& I0_$1 /J^SN!>#F[Z=
M$Y=J%LQ30GL-V)E\<6K:M0U&Z-QI3U&Q4>&<NI" 5>) JNV(NR/\A136. ^O
MU_X]FI?OI8A_R]]?^/9J7[Z6(?\ +WU_X]FI?OI8A_R]]?\ CV:E^^EB'_+W
MU_X]FI?OI8A_R]];AD.9>#BZ7/3.:K'7ZCN]1B^R<J2>9O9+7%+3E;BI)](T
MIE#S!YB';*.$E8MR^0 A! YRF_#Z_P#'LU+]]+$/^7OK_P >S4OWTL0_Y>^O
M_'LU+]]+$/\ E[Z_\>S4OWTL0_Y>^O\ Q[-2_?2Q#_E[ZE^2F?@ZNCCI* RR
M/VZ9R1/LG*QFX_*)67)7X^Z*RPTD*JHR<3JA6GVR;\[\BP^AT"_R_7_CV:E^
M^EB'_+WU_P"/9J7[Z6(?\O?7_CV:E^^EB'_+WU_X]FI?OI8A_P O?7_CV:E^
M^EB'_+WUS/Q/V3XP+5Q@_P"IZ[L4UFUTFNBJ-JZSQ;'ZDM:I9(]:I=72*W8J
MD0!NJLY?-E45%T#$163.8Z?\9U-R[ 6!C5+#N^&Z+FM<L<J5T:(AK'9:X^95
M]]-E8I+OC0:4P9#[T$$U%A:BI["F-Z%'0-0\AW-;/ LG=^,VK^-Z4Q6/V^OW
MZPZT\DM2C=8U?4HF\8[-)&IV<H/ZQ&1U:1<N6MB=IG<N'S1AZD;F\Y_/6(U]
MS5,ERG?>6*[1*T[GK!:'$+"K9+>)@62EBM<G-667]CZ36$JKUVX7]H@43B !
M_!/U"TQ3*=K%JA)6MV.#DD0<1TS SC!>,EXI^@;^:NRD8]THBJ0?P,0XA_O^
MLIF_&9_IZ\6Z=EV-2IFKL-^8VLU#A\AU6GVZPQD'"5V%?-G43#V&.CXME+KO
M&;ALN^6=I*."J';E4^OBJ'B<Y%S$IR#_ .OU3>TY$B0G$/C,#6,U:ONQ%, '
MW!\)_41#\ ]/0;AFFUR_BIQS(]$@I>K7:CR5/M^JQ]@J-@9*Q<W5YF-<M[NW
ME&$C'N%$UB_<I>\#"'O /JN;';O(9$87?:?+?G514XEYQB,E<U&04BW,,L[J
M=JDKB=>O/"QCQ9 BS:,(<"+''\!,;UB+7TK*]0=S7.,*LJ>>ZRZ,OUV;.I%R
M _<OS0=8=TV.$#G,(@BL"Z7\GO _\OU"TR!X2Y%:UJO$=$AXQSSSE4J#/[Y4
MJ[Y4'<M5GSY=R]6(4RRJBIU53% 3&$0#ZDJUAN09?C-<F9=2P2\!E5!JN>PL
MI/*M&D>K-2,74HJ(8O995@P00,Y53,L9%%,@F]I"@'^RKAD6NTZ#T',] A7-
M<NE+LC0'T%8X-Y[!<QLFU$Q/F;JF3*/H @("4! 0$/JK4*DP<=6*92*Y!U"H
MUJ';D9Q%>K%:C&L- 0<6T3_F-8Z)BF23=!,OX$23*4/Y/T9:O3K!M*PD]&/X
M:9BWJ8+,Y**E&JK&08.T3?S56SQHN=-0H_@8AA#ZJF+87G]:RW*:,VD&E1H=
M08%C*[ -Y68D;!)IQ[(AC E]_-RSETL(B)E%USG$1$P_I7>)PW+ZAET;I6C6
M77;ZSI\4E%(6S3;D#(MHN\V5(1^\L$V2-;E77-^)BHD+^ % /TM@U/-\RJ5,
MT7H":@+'M-Q@HQ-G.Z5.5:.=1-=DK4\*(GD7,/'/ETD!'T A5CCZ>IS"/Z,G
MU TR^H-^A9G.6^12FOIQ207A[F36:;V)"DKS'K\IH DXT2=?    K)$$?7VE
M]/T<IWRZ9=3[-L^&-K:SR#29>*2=VO.VU\BQA+BE5I(X_)&EL40(MG7M#U41
M,)?Y!'U_CN[.E>$^LN-,ZH/:FCY_H$U7-HRR_76V1RE!HJ%3B62BC!BM$,?M
ME73X1,W55!R14AS F8 3)_GQ\:W[N6A_T=]?Y\?&M^[EH?\ 1WUU9Q-%]:<,
MPMRY0J.,6ZRWZ;Y@NJ&?W1MM5>-9(=G3'R9%'[MS M""D^,J@1,KD#$3$_L.
M)?\ /CXUOW<M#_H[Z_SX^-;]W+0_Z.^O\^/C6_=RT/\ H[Z_SX^-;]W+0_Z.
M^O\ /CXUOW<M#_H[ZIGCZ7ZTX97O=UYGGNFV>EM^8+J;,F->@KPO1%:B]DCD
M)(?M8O(-Q< F1 R2;4Y#',!E"%-_GQ\:W[N6A_T=]?Y\?&M^[EH?]'?7^?'Q
MK?NY:'_1WU_GQ\:W[N6A_P!'?7^?'QK?NY:'_1WUQ5SO9NM.&;3/=M:)?,ZI
M]GJ7,-T=UFA/Z#68ZT2$E>7#LK1=NRD6DB4C8K<BJAS)*F$ 33,8/\^/C6_=
MRT/^COK_ #X^-;]W+0_Z.^O\^/C6_=RT/^COK_/CXUOW<M#_ *.^O\^/C6_=
MRT/^COK)M"O'67#&AL-;Z+R?G"*C<YYBNLA(PMAUIU*M8FSSA9!-DDA6(D\0
M<'1RF,L)U4B)D.<X%^C>WO+QKB7U'VB;G'0RF$OK^ F*# X%$0_E#U'T_P#G
M]?Y\?&M^[EH?]'?7^?'QK?NY:'_1WU_GQ\:W[N6A_P!'?7^?'QK?NY:'_1WU
MLG65X[ X)T"K8S!Q,[+T_/N9[L]M\TA+VF!JJ:40C(HL6("U<SY%USJJD32;
M)*',( 7ZJ-U8=S>.5@RN%7KUI:L)3FS06\DQ;V"(9RR3)^@1BJ5)XT([!-0
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$_C;_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g790774g70y95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g70y95.jpg
M_]C_X1'\17AI9@  34T *@    @ # $   ,    !.=<   $!  ,    !%^T
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HP-3HU-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   %#          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MDI^JDE\JI)*?JI)?*J22G__9_^T9J%!H;W1O<VAO<" S+C  .$))300$
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))30/R       *  #_______\  #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      T$    &              %#   ##
M  8 9P W #  >0 Y #4    !                          $
M     PP   %#                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   %#     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !0P    !2
M9VAT;&]N9P   PP    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     $X0DE-! P     $)(    !    H    $(   '@  ![P
M$'8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $(
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MONP?^Y7_ (,?_)JACC%=FW.NQ64^K]/*-M+B\5?H\</VG[0_<U]CZO4_FO\
M@UK^A1_HV_YH2]"C_1L_S0DIJ>ETK_25_P">U.*^ECBVL?VVJUZ%'^C;_FA+
MT*/]&W_-"2FM'3N/69'AO']ZI8;J6=6+Z\%E9>/1.6+*3NK:7V5>VL_:';W_
M .#=]#_/6MZ%'^C;_FA.*:0016T$<$ )*?_3]527RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^IW_29]'Z7YW/T7?0_E?]\3N^B[C@\\<?G+Y7224_5/;MPG
M7RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_]DX0DE-!"$
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
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M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ , P$
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MR9B>IJ%FC6/Q\"WE>XVG<[JPV)^5(9(W0B20/)XVH(:R!]6E!JH=.DBO;4U
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MBN#K0]ND,(@ /)?Q&H).?3HZ'PV^:'66WG_EL_$?;/4O9&R=@_)S^7AM[O\
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M1EJ&FP]9]EE*<)'3F.6<!1CO'+D6Z;GR7LNW7D1,^V5$H5PCE/%*DJ0&74$
M-0-+$L034DFM-TDM;+<[Z[M73P[BA5F7@TE"=5=-%+$5)_#C%.K .QOYEO=7
M1O3>_>]/D)\!^Q^F-FTOR(Z#Z8Z6Q>?[KZEW!O3MO:'??8V*Z\Q/96?VYLVH
MSR=0Y+;,^<I:BOVUE*FIKT:7P^9721D#4?+5E=7=K9;9OT=S.87>73&ZK&R
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MXH 7U-"O#U'1)MN=7Y+>G3/\OCJWX+?RQ/DM\3?Y@W5FZ?BI_I8^9&>^(_\
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MB1RQ,*'PY&(4N'S2H!3N!)QTY)(]K?I=?3.;69,D EE8A?B% %4*@%2:EF
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M9*ZCGC1*@R(!(B,/=;'V=$<_V4;YX_\ >V?N7_TE#X8?_:>][ZWC^'^?7O\
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M_]??X]^Z]UJ+[GVET1D?D]\V-U_S$?Y-WSU^>G<.=^4G:.%ZM[BIOB31=_\
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M-!5TM1+5P4]53SS4$Z4U=##-'++15,E-3UJ4]6B,STT[T=7%,$<*QBE1@-+
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MS:VR=H[1VEUWA^S\+\D<=UM64NWZ6+*?.RD[+I>PZ3*RXUVIMK38?"4U2_\
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M?8/:6Q?C/\R,'\@.NL;\ROY?':--O;#]Y=V]A]V["_FHYO)UG7%5G_EIU/\
MWBW7EYOBGV)L385?4YC*;$JL?M7=>%HM_P!!2I1&#;J5$?NMG4/RZNR_D_\
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M3<5+N_9F>VGME!O[9.XL%O:JVY1XG<.%K-B25&Y,-DB:1E.*G-(M@0<FE>M
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MYL>HDJ_X7D>M<QM:?962VI/*E0M=]C5[7J'I&82B7QL2'U<^_=>J:U\^B?\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKOK_\ M[)M7_QG?O\
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MCT3OYY?%GX?]H[5Z8^3VW-AT.X\[\BOE!\+(<OV/AM[=CXM=_P#67:/9_7N
MK85AQ&[<90I@MX=>5ZTLL<4$2RTL]R/)9AM2>X$\ >O?,=6L]%?'7ICXS[4R
M.Q^CMCTVP]K97<%;NFOQ%)EMP9B*HSV1@I*:LKS4;CRV9K(FF@H8E\:2+$H3
MTJ"3>A)/'KW0V^]=>Z][]U[KWOW7ND3V)V3UWU!LS.]C]L;\V;UCU[MB"GJM
MR[[[!W/A=F[.V]35==38REJ,YN;<5;CL+BH*G(UL-/&\\T:O-*B EF4'W6P"
M>'17_P#ARC^77_WGK\,?_2G^D_\ [-_?NMZ'_A/[.O?\.4?RZ_\ O/7X8_\
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MD@@I4RTU7D(8H-]>8 >5,]'K_E<_+_O+Y^8G??R:W:=I]?=-8_#[)Z,P70^
MEP&Y,U@?DAUM0U$ORPWAN/>U$:^OJ-NTW969&U]H4J5205^W\ N=>$#,4^C7
M56%#TB]^=J?*+K'^9E\?^EMC_+.J^1F+[EW;V-O+O#XA2])]78; ?%KXAP[#
MW7+LWNBM[=V;B(^P]L9R@[AQ6&V]ATW5D:V/?K97(1T-+ V+EFIO=:Q3AGHK
M6/\ GY\T1\>M];$R/9NPZWY(;_\ YU.Y?Y776_>N/ZFQ6*VKU7L5MT1U%=V;
M0]256;S-!N7<>S^N=NYPX:BR^4K8*G-RT39"6JIDFAE]U?1GY::])CM[YY?,
MSXZY#Y"_$C=7?>)SV7Z9^9'P1ZPW3_,'W7U5L#$9'I+XD_-W:&YMP5':W:FP
M\+A<?T;2;SZR["V'5[1@W#6XVAVI%2[@Q62RM%>FK/N-]:"@Y\J''V=6+_RV
M?DQV+VUN;YL=*=@=P8GY/8CXE=Z[/V-U[\K,!MC:6V:;N'8O9?1?7'=M)B=P
M477.GKS*[\ZJK]\5&$R&2P--CZ#*4<=#5?94\\LVO76F' ^O5>'6/SA^;];\
M9?BI_-;W?WY@*WH?Y/\ R;Z:V9N/X2CJ78\&S>L?C=\D?D+C_CYUUDMH=MXO
M$+W)G>].O:+<N(W+F*K(Y&; YFK_ (ACX<;1P_9S0^Z\0HJ//J/A?YF7RQVO
MO/XK=<;RWYM+<F8ZO^?_ ,H_CY\_<]/LG;&V(*_HJA^5F)^+WQE[#$$42T77
M5!F:OO+8^3:>FDB-6**H::3QM*DGNK:1D_+'1R,3\\.[NOOY-'<'\Q7M&CH<
MYV=3]5_)'O\ ZOVM6;;I\)A:+:^4WQV!5_%7:>6QV+>@JJS#TVPZG:T>2K9)
M?O:R-YZAG\CBWNM:1KT^5>DMO[YJ=^_!S;TGQBH.OJSYA=N?&K^7,/G?WSW?
MW!WC!US/V-C-K[MWABNU<#@:?'=;[TGCWQN3([5R,^VZ;[>DV]C8)::CGFI*
M>",R>Z\%K3.":=61;F^5>$P/QMZ\^3&&ZJ[A[)V_V1MOK/=.%V)UM@=L9CL>
MGQ79^)QN8QE178K<&[]JX2./"4>40Y KD&:+2WC67@'W5:9ITY];=_Y3N3HS
M=W;&UNK-\=69[%4V^*3 [+^1$&WMC5L^:VO03RXW(;AJMJ[HWQC<3LS+5P0F
MM%4TT=*))&B4J ?=>IFG5#W\O/Y7_*'YV9S=7Q\WS\OM_4&]=_\ P8SN^._*
M";J38/Q^[.^(GR:W+N[ [;Z^W!\)=P[?H*"/Y+?'1:>IW#-!NE'WKMYX<+@)
MY\_+)N":@;W5F  I3/5QW\M#Y+;L^7WP1^,_R$[ I*.C[&WQUXE!V:F,@CI<
M15=G["S>7ZX[)RN#HHKQT. S6^=I5]900 MX*.>.,LQ74?=:8:6(Z/3[]U7K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_U=_CW[KW
M6N!_,.[3;I;^9.=PT/R2_EP_#.OWA\*NK\15]E?/[#Q=@MW?2;;[L[MJJ/9G
M6&WW[9Z<?KZ/I^;/35F6JOXM(-RG=E*GV<W\%\]-[JZY %"<^75G_P#+A[0J
MNVNC-P[DJ_DM\+?E1)2]H;APX[$^"FVEVKT_C$IL!M2K&T<WCD[8[B$O8..-
M<:JMF_BD.JBK:-?MDT^6;W6F%#T%7\VF7;6S.F>F>_\ )]]=,?&S=_QT^0^U
MM]]:=G]V]1[S[^P[[KW9LCL'J"IV-M#H_K[<FW-Y=G;_ -^[<[&KL?CZ#%&J
MRD*O+5T<2U%/'/#[KR^8IT%W\LOY?[]^2?;?:6V=U_,OXY]Z)L?86*R=9U#M
M'X(?)?X-=Z;:JL]G::+#[^R>UODWV-F-S[EZRJ::AK: 55!A?LSDI(E-:CIX
M)?=>8 <!U8O\L\7A,CT!V'4;L^2&]/B7L?;^)_O9OWOC8&X=B[/W'LG9&UG7
M-[FFCWAV)M7>.W-J8^MQ=$\-9D/LONZ>E=S32P3:)5]UH8/11_Y5N\?DKNKX
MF[NW;W?F^R^Q<'/W+W'5_$/>?=NW:+:/R![+^(--6TS=![L[OV_2[?V>U%O[
M=-*E9)!+5XG%9.MP+XVJR%+#73U*CW7C3RZ+%_*H[3W]2]@X+JCY7]Q_S#*G
MYA;]^+.WNY\_U#\Q-J]2;7Z;R45'N;$8SMO<OQSI^L=CXVOI#UKOS<]#@ZW&
MY_*QY:'%5]!4"A>*8U0WU9Z<12G0O_S*_E?T@^S:GXQ#-[T_TQS_ "-^$E!#
MAVZ=[F&T7JZKY6= [O@B;M@]?CJ2*)\$A<ROG!$D_P#DS,*D^+WKKR@U!\NK
MA??NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=%F^0_Q[J>[XMOUM/\ (#Y(=(_W1I<Y(T/078.)V-#N4Y"*
ME96W1'D]I[E_BC8LT5Z3281&99-6L-QL-3\(/7NBC_RT^K-^97H+I/Y)[U^4
MWR>[;WOVIT?B:[.[:[7W_@MR=8TFXMPQ4M?4;BQ6SL7M';TE'7T51!HIPM9X
MTIW="NIM0LQH2*#KU.M6+YI]R_)CY1?+S>G4.[^^/BMG^_\ '53_ ,NG='6&
M^NH\\OQ;V[V_OGY 87<70.^.B=PYJHW+7U_=>RZ?$T>\\[E,K6QU^UZFF@Q5
M/B<I%4$F] %P<4Z\/Z0Q7H3/FC_*(^7.R^W.C=F[K[+SO;VR?D/LKM/K+L'_
M &6_IC*[^[#R.Y=P10]H=O[CWM!NG([;CV%UWV1N;&8^ER57B]U8*D?4L4%)
M1(PI9K!E:I!TBF>O T\A7HG.W?F;\W>FNP=Q]V]U_*'M2CS7\N[=_8/1G7FP
MMS]69[[7IO%]R;9VWMW;64^2.U=Q[,>IW!T]24-'0G.3Y'=,F\FAI8*C &HF
MC>5]$ ZB3C_5^WKV, #)'^K[/]5>MFO^6Y\__C#V%\F?FAALI\G.K=V;\WOO
MOXQ8S"[_ (X$ZQZ\^06\Z3XY]>[,W#6=!TVY<M50;CIUWQCZG&IB*.NR&2@E
M@]8D#B1J,I(6@X=>X='M_F!_\7/X$_\ C1#H;_WD.V/=5_%]G7NC-]ZU7R7I
M<5MT_&C"='YK.29B5-UKWCN3?>V\328#[.3PU&!EV)MC<U96Y45^D/%4)#%X
M;D/JL/?AI_$>O=%*^$WR#^:GR6Q6S^U^P^N/C#LKH_/U_:F!R<.S>P^S]R=J
M4>;ZYWINGKF&6AH,ML3%;0J<5EMT;2GG9GKEEBH)8SI:;4@VP4>>>O=65>Z=
M>Z][]U[H#N]NT]^]3[=P^9Z_Z"[$^0F3R>=AQ-9MCK?,=?87*86ADI:F=]P9
M"I[$W9M#%R8R&:!(66&>6HURJ1&5#$64 G+4Z]UJK_S*]V;T_F!;DZ=PLOP^
M^:N7Z:^1F\]U?$/=75G8?<&Q]J_'_'=R=:=GQ)'OG;N$VQV'F<9@>\MMU>P=
MW86FKL_33;>KJ:%*H1^6CBJ5<  %":CK7 \,]70? 'XLTF__ ('R];?*[9'>
MLR]E[XW=D]V?'[Y&[WW)FJKI3 [4WQ5XKK+IS85=1YMZNBZSV3L[;.(?%2TN
M3K(\B':K-1(M1XTJS4:HIUOHH]!\"_B+02_S6\CC^E<=!7]$Y6N'4<S;L[$K
MEV.#\*>N=WO#@J3(;PJZ.GII=V9RNR#0^,Q-4UDA*D:0O@[?ID>9Z\?3Y=<M
M]?#?XI9CI3^4UOK,?'CJ?([S[C[G^)N.[6W)5[.QBYGL&CSWQ=W_ )+,4>\*
MR&*&;/4N0R6%HYYH*GR0R34L3.AT+;=6)DJ3@?Y>O=&%%)COAO\ .C=VSOBY
M\1<YOG:<GP]ZB<]7]"-UGL;&[0J\MWSWW79'<^2IM\;HV9A=.XJEM+-22RSE
MZ5FDCL0WOP[AW-3/6N'1IOBM\X=W?*VHVSEL)\1.^^N.J-VTF\C0=Q[ZS'3J
M[=I,CLW*Y';==C*S 8#L7.;RBK*O<F(JJ2G88YX6:'R,RQ,K&K*%KW5/6^M3
M_NOL'NKXK_,[NWY04'RS[>QO8&R^_=]?$#M'NG:7QNKL=\&.A\KVKG>F]R1?
M(OM?8*X7([ S.!S>R*),7V)C\?DHLZ=_;:AST=:E+-,GN] 16F/3KWRZW ?E
M-5?>_ 'Y&UHW30[Z^\^'W;U4-[XI,='C-X_<=+;AF&ZL;'AYJC$1T&X=7W<*
MTLCTPCF B9DTDM#XA]O7NA7^-/\ V3ET!_XA/JK_ -X3 ^]=;/$]#9[]UKKW
MOW7NB)_-8_+?:NR]Z]O?'OO3J_KC:_5?3N_]ZYW9&^^CJOLNMW?N3:&&S&Z*
M,P[GI>R=G/M_$UE)CXZ.6):.ID6[2J][)[L"M,C/7L]4CU/PS[O^>WR\ZXS'
M?WS*W5CLOO\ _EC4W8^5I_C?UYB>F:+K.J[1R>2VQU;+629C+]AOV.[+O[?<
M;09$PQ24='I*1>2Y<KI4D#%:=:I^SK9LZSVE5[!ZXV#L2OS7]Y*W96R]K[2J
MMQ?PRDPC9^?;F#H</+FFPV/9J#$/E'HS.:6 F&G,FA#I4>VB:DGK?5"FWJ:G
MKOY0?Q4H*RGCJ:'(_+SJ#'9"BJ%$D%;C\A\_JJCKZ"I7@24];23/%(O]I'(_
M/MU?C:G&A_P=>Z&.7X%_"^A_F6;<V!0_&#IBBV76?!CL'=]9MBDV5BZ;!56Y
MU[^Z\PR9VHQ,,:X^7+)BJ^>G6I,7G$$SQZ]#%?;=32M?/KW4SXM_,/XD?%?<
M'S&ZQ[I[UZTZ<R-+\W>[*G:^U=WYV+"_8;)I=N]:X[$2T:3J:>CP<"TYCC9G
M6- +<>[%6:AI7'6OEU97T3\M/C9\FY]T4W0'<VQ^V9]E+B7W7'LW*_Q-L$F=
M6K;#O7@11B-,DE!,8B+AQ&2/="K+Q'6^C$,H8$$ @@@@BX(/U!'YO[UU[K7Q
MWQBLCT6D7P1GA/\ =OJ'YU_"#OGXQZIHC+5?%KM_Y8;85]F8ZG:HJJ^J'Q][
M;;*;;(9V:FV[4X$LJ)*MW1FK'T/7NM@_VUU[KWOW7NO>_=>Z][]U[ILS&'P^
MX,;58?/8K&YS$5RK'6XO+T-+DL;5I'*DZ)54-;%-2U"I-&K@.I 90?J![]U[
MI$?Z&.GO^?4=:_\ H"[7_P#K7[]UNI]>O?Z&.GO^?4=:_P#H"[7_ /K7[]UZ
MI]>F;</277U7M_/T>UMB=9[:W+6X/+T6 W#)UQM?)Q8+,UF.J:7&Y:;&_9T@
MR4&/JY4E>G,L8G12A90UQ[K754_QA_DMX'XU;Z^(>\Y?E/VAW;COB]UOO_K"
MKZZ[=ZXZ3JNO,_@-^]?;7V/,G76)VEL;:^6Z@H\;+LO%U340KL[3UXI2:G76
MU%3D)O=7+DU^?5N/^ACI[_GU'6O_ * NU_\ ZU^_=5J?7KW^ACI[_GU'6O\
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MV]*Q<EOGM7LK.T5!BJ+*[OW57JFM:6EH\=CZ*"FQ^/I:3'4=)20>Z\23QZK
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MROQ^TMGXF?-Y^MQ> W!NFOIL=3:?-+2;>VIB\WN/+S+K%H:.DGF;\(?>P"2
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M9'"S4[U%),L6\NO#&.KD_;?6^BK_ "H^)FR?ESBNJ=O=@;R[.VI@.JNW-O\
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MZJ/XZ^'Z2WKV?W9DY:K>.Q=S/BH]M]GX\8?#Y%ZFHR&;@AJ,A4T\"SQ1C=
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M5+L7<?Q]^<N\_E/@>L^JZ;J"'M39^#WWU_MGXBX_LFF[#PNY=ZY?=%'NC/\
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MQ23U%!YX\M4XY6UUI?750](#^7#T?B.N/DOGMR=3?R:=N?RV.M9^D]T8+?\
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M]>]^Z]U[W[KW5>WRV_[*M_EG_P#BP7<G_P "QW#[NO!NO=2ND/\ MX?\^/\
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MVMU!N3$;BZ%^,GRS^4]-V5MO;J;#Z&^26=^/R=!_&_M6DH<?0IF.S\'M/K?
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M[E,)NB7'IG*>/-5>%IZ.8"*5IH?=;4@5KT!O\LSX\[.ZE[LW_N7;G\LGY/\
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MK:JC#P0*[FI/A21&N 585&>MJ"RL0<8_P]6<?R4NA>R=[;<ZE^<69ZNG^(^
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M1P9#(")6KLM64U/+7U-2U-3^+W7B:FO39_,M_P"R3Z[_ ,6"^%?_ ,&C\?\
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MNO;&\DP_PWV!\U]T"H_AV<W1M+9.-.[MH;"V^ZU6U<W'/5;B@&C&&:['2/\
M!]G56))S\7 ];I/MGK76C#W[\G/DYD=C;Q^<.T.W^Y^Y]U=<;/W'T=O??+]
M_'KLWXR])=K[E^=^T<!2]%9O;.Y=AT-?N2CI>J:5?O9MO'(9J@S38VFGRT#U
MGA]NM3T%#3_5]O6TR1ZT/^#J.W6WR$K^Y?\ 15N#XQU6!ZX[ZP_\QC95-VKM
M7^6SCMI]WKMW>/=&P^Q\INSIKJ'='80W?/52PSXZGQ>3W6M)C=HT5?)34JY.
M8*XV*#@>'6B:Y)S_ *OY]-4&8^;^)R?R?^:F;ZLWAM[;75'9G\P2OVSOG8GP
M@Z*RVTH-R===+=2[#VSCNT.D\WD=T]N=246XY^HY*?<F3KJG)X;'RT4TT5;
M*JHD]Z)XY_G_ *O]7Y=6 !HOK3_#T;+X9_/C^83OCN?HS8F^OG;\1'ZSW/W#
MT?UW7]=]=?'RAZN[&R&WM]]%MW#E,WL/;/9F'V[+6==TFXZ"?;&0R5-3EJ:K
MD)I6+^'R^T5%:&M.M$CR'5U_??\ .U_EG_%WMS>'1'?WR*J.LNV-B5E)1[BV
M=G.G^\:BK@_B5'%D,15XZNP_6V3Q.;QV;H)A-0U%'43Q5<09HBP4V:].O!6(
MJ!CH[_QK^3'37R[ZCV_WO\?]SUN]>J-VS5Z;5W?4[6W7M&FW'3XZH-)/D\/0
M;RPF R]9AI*A&6&K%/X)RC>-F /O9!!H>M=#W[UU[KWOW7NO>_=>ZU+_ .:C
M_-!W=USO!8-B]C;OVUN'=>%[KV7TG-\1?G=T+O?9[U'5N S.[*3M_NCJ_-?'
M[<61VW,#-3138MLT6JA%]E'>57F]WTCS'^?KPK0FG05],0Y?Y]?(#H?9&S?F
M9VWMCN')]8X#=7RSZL^46/Z6[\?;VS>J=\[>[MZ"H^NZN#;/5E#O';?<O91Q
MF7R6&HZ:L@GPV(J4K'IS21+56II!/EUKK9W^(WQOS_QJV9V)B-X]M5_=6^.U
MNY]^=W[VWW6[.PFP8:K<>^DPU-/C<5M7;]77X_%8C%4."IXH5\\LC69F8D\-
MDUIUOHUOO77NB+[Y_F7_  1ZTWGN/KS?OR8Z\VKO7:>Y:O9N>V[EWS<%?1[K
MH1JJMNQ 8=H<AF(T!804SS2.JL5!"L1;2WIU[HR737=_57R$V-2]E=,;UQ78
M&Q:W(Y7$TNY,,E:E#/D<)624&6I$7(4E%4^2BK(VC:\8%QP2/>B"./7NA6]Z
MZ]U0;VS_ ">^VNV.H,I\?<_WK\?,AUW1[I[9R?6._LC\9-VP_(_J?;_;_:F?
M[0W#C-J=N[;^0>W8A70UFXGIRLN,;#UXI::2MQ]080/;FH5KGK70._S ^GOG
MSMS+=>_%GKSN9OE5M+O/I+Y6X/ 8O<^V/CUL'Y7Y:CVAUE@,=BMF;C[O["V3
MF>KM][5CR>[XZBK^VPVT-PUK5,LCY,> 2CR&FH\.M^G3U_+W^24VV\A\IOBW
MGOD-A.I>\.K.N/CYA^E\+\P>F.L^K^S]AE>DJ7)[^QF4V9L>DZ??M[8&!S^&
MEJZ.:DRU:\E('F2OE@TSMX@FE1CY=>-*D@=<>H?YCG<_;7R*RW16'_F*_!:6
ME>7HF#JS<T/Q:[1@;N_.=M1;AKLCM/;:Y#OZDQ6/R%)#M^*'&2I457WQR,;J
MKF,HWM( K0TZUU==\KMX;GZ\Z.W?O[;7=757Q[&S10;@W)VQW3L^MWMUWMC:
M5%5QC/29K#4.]>OYHFJ:>01Q5)R2)3R,&9)!Z?=  30];ZT8OE;_ ,*1/FEF
M]Y]_?&?KG?\ _+X[=Z3S&)[*ZRQ_R!JNO>Y]D8O/;.K]LU^#R^[/M:CL?/8Z
MCE:&JJFI3&E90R>!'8O%)[]05H&'3XC&D.RL/V=6I_RK^J_D]\R=[[Q^26Y.
MQL[\->P>O.LOC-2]4]8T6Q>K^\ME+M;>?QFV;U]C_DYM@[_P,-;MC?'=77_6
MU/111/"M3BMNHU*LDL>1G9G&( 'H>F",XX=;,WQIZ-Q/QIZ$ZIZ%P6X,UNO&
M=6;.QFTZ?<^X8Z&'-[@>A5FJLQDX,9!38Z"KR-7+)*T<$:11ZM* *![;8ZB3
MU[H<O>NO=>]^Z]T!7<GQB^.WR(FVW4]Z])=8]N56SAE5VI6;_P!FX/<U9MQ,
MXE(F:BPM9E*.HJ<=#EEH(!4I$ZI-X4U@Z%ML$C@>O=)*;X>=!8CH#N7XX]6=
M>;5Z0V!WAM+L#;&[XNJ=MX3:D[5G8NSZC969W6(Z*A2EK=RQ8>2)8ZBI25K4
MT2-=$"CP-"#UXYX]$BRW\J:H[3W%TA4_*'Y$4OR.V5T?N# ;@Q6S=R?&/X^[
M6K]SG:VU,KM3 X3<>^]N;:3=LFW:>+)K53T<$T,5354L#-98POO>JG =>Z*%
MVM_+ESO5'R<[#R_1W1?RZ'3N>C^,7876^5^,WRCV!BL)@>T^BL[NW/"3L3K#
MY*]@5F'WBN!W!+B*W%TL])58LP)+$JPDR:[ UI4BG6NFW%[C_FT?"/X.SS9;
M8W4>?S>]^]:F6ERV+.UD^2W6N1^17RUFFJ*_/]5Q9NI^.G=.]-S4N_3]KC\)
MN?;M%05F1AC82P4DLA]VLW7NDY\#_EEV1\=/D7M?I/Y/=Z5'7>V^]NP/G!V'
MN'K?Y/\ QUQ/Q8W/@=S2=KXG>/7>\MM=C/N*MZ^WG_I9QV[J^K?$8W(U\- 1
MX(9+0H)-%:CM7R\NM];-%)5TM=2T];0U5/6T=7#'4TE72315%+54\R"2&>GJ
M(6>*:&6-@RLI*L#<&WNG7NI/OW7NO>_=>Z][]U[KWOW7NB^=]?%;X_?)K&XZ
M@[KZQP&\*[ OY]J;NC-=MWL;8]9Y5G&0V#V7MBKPV_=C9#SH&:;%9&D>2VER
MRDJ=@D<.O=%6?K3Y[?%U4EZ4[(H?G'U%CXTC7ISY*9^BV3\D<-0Q+80[&^3V
M,Q9VOV-4F>H=A3;ZPT-:\,*+)N O=GM53Q%#U[H3NG/Y@'0?:6\J?J/=DF[O
MCI\@9O1_LO\ \D=OGJWLC)2^7P!]C2Y"KJ]E]L8^:3U156T\OFX'B(<LH/OS
M1L.&1\NO="WWU\H^D?C+3;6J^Z-SYG;,&]*S)T&VVP_7O9._FK:O$4]-59".
M>+KO:.[)<6L,%7&5>K6!)2Q"%F# 5 )X#KW0:]$_S!/B3\F-VX_9'1W:-=OO
M/9;#9;/XR2EZR[;PVWJ[$X*6.#*U5+O'<FQ,-L^9J2HE$9B6O,SR!E169'"[
M*D"I'7NCF^Z]>Z][]U[H".W/B]\<.^T;_31T7U1V;4^)8H<KO/8FV\WGZ (@
MCBEQ.XZS'R9[#5," ".:DJ898[>EA[V"1P/7NBSP_P NO:>PWCG^-OR)^5GQ
MH6BC9L9M7:'<F3[-ZJAJA=T>HZL^0%)VSME*22I/DFBH!CFEY7R*IM[WJ]0#
MU[J.=O\ \T/JUXSA>P_BE\M-O4RM/44?86T-Z_&/M"M1 7>CH]S;#JNV>MZN
MJE/[<32X#&1 V9W N/?NT^1'7NN)^=G9G7P2+Y'_  1^4W6(4>2MW9U/B-M_
M*?K>@I$C>6HKJO,]-Y6NW]14=+&A9VJMKTY _%[ ^TUX$=>Z%3J_^8%\+NX*
M\879'R1ZP;<YGAICLK=V<_T;[_6IJ+^&F;8'8\&U-YK4-;]!H=7(_J+^*,.(
MZ]T<&.1)D26)TDBD19(Y(V#HZ. R.CJ2KHZFX(X(]UZ]T6?Y"?(7=/13827!
M?&COOOO'9'&9W*YG*=-4G6U92[1@PBTTAASL.^>QMD5\M5DH9G>F2AAJ]8@<
M,58H&L #YYZ]TB?BY\P<G\HX\)G,=\7?D=U-UWNSK[$]D;+[-[9Q?66*VONO
M";@BQU;@:;'T6V.S-U[IH\IEL/DTK8XZO'4Z" '6ZO9#X@#SSU[HZ7NO7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_7
MW^/?NO=(/L?J[K'N/:E?L/M[KK8G:FQLJ4;)[-[(VCM_?&T\DT8=8S7[=W/C
M\IAZLQK(P4R0M8,;?4^_=>Z#CXX?%;H#XA[,S?7'QNZVQ?4W7V>WAE]^5&QM
MN9#/2[3QFY,[2XZCRDNU=OY;*Y+&;*PU3!B8-.*P\=#B89%:2*F2265G]ULD
MGCT[?(/XX=&?*SK'+]-?(GK':W;76F;JL?D:S:^ZJ.2>&GR^(J!58C.X;(4D
MU)F-N[BQ%1ZZ3(X^HIJZE8DQ2I<W]UX$CAT$7Q6_E]?#GX3U6[LG\9.C-N];
M;@W[%CZ3>6[GS&[=[;YW%C<0TDN+PV1WWV'N'=N\),!CIIGE@QXKA112L9%B
M#DM[]UXDGCT+_P A/C[U7\I>I]T]'=V87,;FZMWQ3)CMY[7Q&\MY[&7=&$+$
M5VW,UE]AY_;6>J]MYJG9J?(4!JA2U]*[PSH\;,I]UKH%L3_+T^)&+W!4;HJN
MKZK=V7R'Q0?X/YH]C;_[)[*Q>Y?B]-N'([GJ.KMU[=WWN[<&WMTT]7D\K.L^
M4R%+49J>C?[22L:F"Q#W6]1]>GSXV?![XZ_%#*[EW%U%MO=;[KW1MS:NQ:O>
M797:'9G<V],;UEL%LFW7_4^W=W]L[LWEN+;O5^QOXQ5'&X2DJ8J*.6=YI%DG
M=I3[KQ)/'I ?S+?^R3Z[_P 6"^%?_P &C\?_ '[K:_$.C[^_=5Z)/_,.[M[>
M^.WQ&[=[AZ*Q,68[-V/@I<]@*;(=<[@[/VY'#B(Y<MF:C=^W]K[GVAF<=M=,
M+05"U.5CK F*+)4RQ31(\;64 G/7NM1_^63_ #(<)M/YG?)KO#:O=7:O=?7_
M 'ON#>?R/^4>\.S/B/D8=V[$Z,ZQVIM7#[1P_5-=L_L2EP&VJ;</;&]ZK'5T
M--!F<5C*:EQ<1\^4R T7T@]H.?V=;92M*]; '0._/CSU]L_L/Y2?*#<71'8O
MS@WIOC*=V[FZG7L;HC)]N]!9&AP53LOKGXT==+O_ '?M:EV?NSIOK2M; Y,M
M6XQZ[<-9F9I)3]Z0=$YT@T7JOSZ&O8W\T?%=F[FS.TNO?AK\Q=[97;5'L3*[
MEJ=IX?X_;CV[B,'V14Y>#:F;3=>$^0M?MO-4%4-O9%Y_X=55<M**&5945]"O
MK2/XNM]"_P!\?S".G_CCNO)[7[+ZZ^2M/3T&=VGM6DWK@/CWV+N+KW<>YM\&
M@I]K8':N\<9BI<5N+)9;+9.+'HM,SHN0)@9E8'WH(3P(Z]T87H_N[$=[[;RF
MY\+L/M[8%+BLY-@7QO<G66Y^KL[7RP4='6G)X?$[GI::HRN"D6M$:5L&N!YH
MY(PVJ-@-$4\QU[H7ZRCI,E25>/R%)35]!7TT]'74-9!%54=91U4305-+54TZ
MO#44U1"[))&ZE64D$$'WKKW01?(?I+;7R0Z,[6Z#W=7Y+$;9[9V)N'8>6RV$
MAQ$N9P])G\=-0?Q3#+G,;E\5'E<:T@FIGEII/%*BNNEU5AL&AKY]>ZU\>B/Y
M2?R!QW;FT\5M;.;I^!FV_C!N.@W3C^R>C=W[?WYUW\@.PL;LB@V-L?(=#]1]
MA1;NS_1'2&1V#YQV7LW+9"3&YG,SKCJ&GEI:49<N%QII6OR].M4Z##^9_P!:
M?,>7=>Q]A_-CY0=45OQ;VWD]A]A=#]HTNS.YNBZ+L/O+9NZZ'<62V1V-7=";
MAW-7X'Y(QT=&D'55!2T[XO/SS3RT,$N>I(Z7WY=/$#KQ]*]6<_&/<'\Z?)=!
M]99#M#8OPGI=[5FWUGR%-V=O7NO"]F)BY*J<[:?LG%;,V!F-JXSL*;;GVSYJ
M"AG>GBR!E4!&U1I4Z*FE:=;ZUK?YNGPP^3?R ^6.9WE\JL-U%M3N2MK-BX[H
M/I?X[9G?SM\V=HIATVOC8>B:C=^ H=I9[Y6]1[FK9)=P5>Z4@JL3LP4Q=#@(
M4J$L "/.G6U8K6AR1_J_+JY?8'Q:^7O\NKXT?$7I7XQ]M?'3H+N7Y(=V[XRW
MR.Q&YNL<]V)\<=G[OJ^@]U=I;CJ^M*&#=VV<YMC"[1P_2+TE7535$JYW(5]1
ME:N2!0(AJH8GMP!U6GJ>@S^"G;'\R3^9;NNMZQ^5G>%!U)\8\_T+UKWF]/TQ
MTSG_ (_]W?(#:&_-T[IV[)M_ ;NS.]=Q[KZYZ0KLCLJ>,[@HX,;GMW8FH#8Y
MZ&CJ#4-K"4(45_R];(\NK'.]/Y7/\HG;W5 VMVITMT/T-U]79'"8W!Y^#=T/
M22X?<N/RT&ZL/)M3<@W%@*?';J?*X7[WR0-]W521R22>0ER=:V]>O?/SZ6G0
M/67P5V[WYM+L#9WS RO?_>$&U]T[-ZYQO9OS2J>^<QC<-NM<5E-W1['VEF][
M9>1*S,4>VJ5ZJ:FIWD--2CD(I/O>IB"*8Z]T1'O6+^0KW!E.Y\)V-7YC#[S[
MZD[2INP'VUB?F'M'/;FSV;HZC#=E;GP6U\3@X-O9;+4?F$]?54V+JZ0.8Y:E
M7CD'DL#(%IY?EUL _$!T:C8/\N3X]?(_9'Q_WIV!\A_D3\N>BMC?8;RZJV!W
MY2]?#:5<]'MK([/P>0S>+;I/8/8UL9053R)2U-32AZJ.*:6-RB6]XA7"J >M
M=$.[&^#FX.DOD_WA+U9U;_,#P'7M!VE\=^[_ (Y9KX\5O3G>W4!W-U[TS/LV
MN7?&R/DEV =SM+M3<65R,%/CH*NDI11/3"F,:0J!H&M":=>I7@1T7?O?X[?,
M?:W\N_X6]=?)Z/J[#[&'R(ZCP<^)H.UNPOA[\D.OINT>U=Q#)[(S?;77&]-W
M=2T$6ZL%DXZ2OJ81%38\5<D-/#,\<$J[4@L:5KUKI-_RYNH^Q?BK\T-BP[?Z
M2[=^1O;D7QO^0&[\QM[_ (<VV9\A-N8C'S=Y[.VOM'>>WJ3>F_,1@<)5X3KC
M=$6WJW[^GBJ,K55#5%-$AIJB0^I@@M1?SZV?Y_ZO]7\^B_;Q^,?R0WSA_E!W
MMME_YG>QNONK.P/GO3[YP>T?YB?7M!M/J;*]6L]9T]MC;V R_:E3N"LVSUO5
M4&1.YA$]4V3!1:&2JCTH-U'F>[_5_J'7N% %%/L_U?GUL.=.=Z]U-\7.N.K8
MOY='RSS^S<MT=MS;L^:_TY]$U6:SF&W#L>F3(91-YY?O^'?BY;*0Y"25*R::
M+)132!KQRJ M6'<26%:]>Z^8YNKH^([ [O[OW7@M\["J-O;LW!FJ>?>G6._)
M\5W53[A[(?#[-I=H]B4.U)M@O6;4QXEDR.0RF2IX,K4M$*&6>9SJ;:A#&O=7
M]O2I25" 4*D#AY8\^MP;_A.O\0H/C!W'T;6]@[SZ-WEW!WOTYW7VI6; Z[WO
MM+LK</2>Q=IT71>-ZRQ/9&.HXLA)USVOC%W_ )NEEGQU0L<U-6U-#+++)!(J
MN9$9'GTQ(P9J@8KC_+UNS^V^J=%-^27RFK_CAXZV3XV_(ON3:]-M#<.]-S;R
MZ:V_U]FMO[-Q>V4>IR5-N ;L[(V9F&RCXZ&2JAAHZ2K\L49 ;R%4.P*^>>O=
M5R=[_,+']X0_!SLG+="=]=$=68/Y<=-]P4_9G>>WM@X':F<V5DNE>\<C#D,7
M_=3L+>V:I:N'"5D=;,E;1TG@@-F82 H' M-0!KCKW1R5_FK_ ,N(G2GS)Z*,
MGB@J#3+O*E-6E-52>*FJY*,1_=14=3-=(YF01R."JL2" W0^AZ]T?RDJJ:NI
M::NHYDJ*2LIX:JEJ(CJCGIJB-98)HV_M)+$X8'^A]ZZ]U(]^Z]T 7>OQ<^//
MR;IMKT??O46S.U(=DU^2R6T3NO&_=U&W*W,T<>/R\^(JXI8*JB.4H84BJ%1P
MLT:*'! %M@D<.O=%ZWU_+H^)%/\ 'GN_J'KSXN]+>'L?;FY,G'@LKM+&5])E
M>Q4V/7;6VAG*G)YD5=?09+%P-%2TU7%/%+1TY(C= 3?88U%3U[JCW8/\O_Y(
MUF ^.6Q]L]3?S#NA=UMO+X2TG>.Z]S_)GXT[[Z@V7MKXR2T35>X=BIF-P]D=
MD1'9NFNFVO04R-2)4S0&2E\2M$'"V6)(IUKUXYZL#^=G\NKOK>GP_P#D/MCK
M;Y??,SN[?>9Z\R*;6ZGW=OGI6GV[OG(TM919 ;<KI$ZCVX6_B%+22)$IKJ8/
M-H4O8V.@ZU'8!U[KY]\OPD[(HNT>G^K-\_$7Y??'/LS.=C=79;L[?7R,ZLWE
MN'HO&[-RN4G??>XMS8G9.PLS78_;&5R-JK[9IZA%H::KHYN)D<4%"RT&:]*?
M$(#5(./+C_J_GU]#+^29T#G^M?C=D>XMR[^S&[ZKO6II*';."R75M5U+2['Z
MOZ8W/V%L'K#&8?;69J)MT+B<SM5HLA1C))#-2XZHIJ9(UBA0G;FI ].D_1M?
MY@'=NZ?C7TI4]]Q?(OH[XT=6=:/5Y;N#?'=O6&ZNTX*K!52TU#A,3LK ;2W[
ML7)U6[JW-3"*EHXS6SY*:6."&(.;G2Z?Q#KU&.%X]:F4W\V/;G='46,^7_9?
M\VW<?464W'W-L'8/8OQ1Z?@[*Z@W9L["T&\L;C]V9'8>T\]E]^2P;?R?2M(^
M>DR_VDU$,I4R0_=1U<>AG 8R*T'V];\.0,5*FO5RNV/YB&?Z,V72=6_&WH_Y
MC?*+M[L'9I^5.SHOF-\@NB/!E/C;//B\9FNQ-N=G4/:>Y33;)QT'@JL?CVI
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MZ+#=TY*+KZ&HV3N[I%ISE-X86+)29!GI]GRUSPTTTL"M.B*=KI.-/7L] /\
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M[X;?TVQ-I;3K=RY?;6+V1@H]JX+;F+H<9GMUU5:8)*6:.>0JK@QC1[:+$BA
MI7KW6MQWS_,\Z-P_S4R_PF[Y_FT9+<_6?7VU]QMOWM;>?PI^*V]]@;+^2>U*
MV%Z/8TF>;I7,[4>JH]I29.*::FQ<K4^<\="*L2S/3BU0!P ;\^MA&*Z@I*]$
M7VY_-3^"'5_Q=[V[B^/WR<[(ZD^3.%[S[PJ.G.K=D?$?XT8O>._)^U-]9_<&
MR>WZF+=_2&4RNW-L9G:E7IS\&,SV-H,(97H8Z*,"&.79=#0D]GVG_!U?1)J
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M\3N"OHMY5>VJ*DAVU1[BD:FIZG)+033 H6B1FT^]:2:E1CK5>E)T)\U_BO\
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MEIV1V7MN+XO[7ZZP?]_\GTK!F\5M?<'864VA4;?QB44]'4R4N-AG=&JG=SK
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M<!E,U4R4F0BWF]##+64X$,]5JH=(V2&I0=;B95#A_P#B_EU<3\IA_/5^'_\
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MD_B.[/BSWGUKVXE0HU"&;&[![&_T);ZF:8@:H8X:@QKSK8^D;HODW7NLM/\
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M )/XD46[^NLC_+Q[-[+I.C-N[2Z3F^7GQZV!TQV_V!D]Y4..HLCVITIOG?\
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MHQ2Y4T,#4J4]7M&GI97F\A\>@7H0!Q0CK?0T=!_,#Y)[:KMV;M^2NTNZ=_[
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MO=OSZ]_>#^:+_P ^D^ W_I1'R'_^Y>]^Z]V_/KW]X/YHO_/I/@-_Z41\A_\
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M^&Q>]/\ O</_ #0/_0A^(/\ ]R+[]U[6O^^QU[_AL7O3_O</_- _]"'X@_\
MW(OOW7M:_P"^QU[_ (;%[T_[W#_S0/\ T(?B#_\ <B^_=>UK_OL=>_X;%[T_
M[W#_ ,T#_P!"'X@__<B^_=>UK_OL=>_X;%[T_P"]P_\ - _]"'X@_P#W(OOW
M7M:_[['7O^&Q>]/^]P_\T#_T(?B#_P#<B^_=>UK_ +['7O\ AL7O3_O</_-
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MW_#8O>G_ 'N'_F@?^A#\0?\ [D7W[KVM?]]CKW_#8O>G_>X?^:!_Z$/Q!_\
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M0?\ [D7W[KVM?]]CH<?CM\)NSNBNRZ;L#=?\PSYN_)'$T^#S&'/6/>^9^/\
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M=U]N'K7N7LW9V)S^9V]U7NCJ+N/O+;,.3?%&''YG:D8KY*>CEJ'ACUUO0*T
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DO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g790774g72d51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g72d51.jpg
M_]C_X1H517AI9@  34T *@    @ # $   ,    !&K$   $!  ,    !&&4
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HP,SHP-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   &IH , !     $   &$          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MWO\ 2]&STOIH''(=MK5QA[1)83>J=0#0'6,<X ;G!D F/<YK2Y^QN[\S>_\
MKK4Z?=9?BMLM(+R7 D"."0E+&8BS2A($T__1ZSZU=:S.EYM#1G?9F7M>[&J:
MS%:TFOTA9]KOZMF83;FN=<W9CX+Z+]G^%735>H*V"TM-NT;RT$-+H]VQKBYS
M6[OY2Y;Z\6EK\6O[3EX_J57M8,8O#"^&%C7,QLG OS,NW^8PL-EO\];ZUGZ&
MJSUNL24YN3G]2IZBZFO"=DXK:/5::MH>7[FL]/U,BS'Q]_NW>DY_\W7ZGK?X
M%<!B]?SL3)Z!TBFFJW'R\/&=;8\.#V.>US?2]87,QV[_ $V?SE7^%_1_:5W^
M1UW$QNHOP+66%U='V@OK8;)&X5^DVJCU,A]OO8_:VK^;]ZJ_5C"QW_5GI9<'
M>_#H) >\ [JV'Z(<$Z,J[CR1(6\O@7?6BWKN=1F8UYZ46V-P1^BH))<UK&MS
MJJJK=^PV?9[/4K_TGJ7?SJHT_MGJ'U.ZGZU=V!;&47V9%]^18ZN@OL=BU5WN
M]6BO:VSI>5;ZWO\ 2]3TK[++%Z*_H_3K&.K?5+;&EKAN?J'#:X?251GU1^K;
M,=^*,"MV/8\6/I>7/87MG:_98YS=WN<G&8[GK^*WA/AT<'(Q[L6GH^-D7/R;
MJ,S%KLR+!#['-JR ZVP>[W/_ *ROA%ZKTGIV$WI%&)0VFEO4*@VMA(:!LR'>
MUL^WW/<GNQ<AGUAQ\%AQQ@WT6Y!8ZJTW 4NQJ75_:?MC:_TK\O?O^R_HO3]/
M])]-.&6([HX#X(4E>9=]7+A:,.VO-MI8ZQU&-=ZML-.QVVJNW=_.?H_^,5'(
MS\-_0;^M=.P7658P?8^O+?;BE]=;#98^G]'D/<[_  ;-];$[WH^*/;/@U<[^
M?Z;_ .'1_P"VV>K0\]/-%S<%K;>B#(I95=9FD7,JL?8P$8F>?9;8VE[O^VJT
MSJGU_6"S$M?C,Z;5C?:G;F6MM#9=46NRW9GHMV/9ZWJ_9?YK]%_PR RQUW3[
M9\'+_:%%^-GGJ&%=3B8+7?; ]];]WIL9EVU5?8KWV;FT/JLW_HZ_^$_G%SUG
M5NDU_4.G)<W(]WI-<X-NW'+:X5Y-OVK?Z+O4;1D?1R]C_P#1>K^C6]]7SE=7
MSNM.;T]U%6)F-MQ\?)>^JN^PUTLK^T7>C;8UE=.+1G>DRN^K]<Q_YSTZEH#Z
MM=3/U7IZ2:\5N94RG'=8;;7U.JI]-WJ[/2J<VVU]/\SM_1_Z=,.2_LI(@U-N
M,W-Z5]D:68QHRWT-.Z16]F+;7N]6;-VU_P#A%H;+ W>6'9^\08^]3MPYZUTE
MN76QMUE.8ZYM3WN9N/V:=C[/3?\ ]!5[>G=$P/K%U#.?AM<^G$Q;6%@FQUU]
MN?CN;62X;K\S91C>YWZ7]'6G#*!W1P%R=F1D59^#D/OZFSU;*;J'C'8?LS"Q
MK&,<RO 9]IS+'/9ZEMW]'Q\J_']/)JI5++Z#<[ZLX.'0Z[HV33;A,R!4_<'V
M.MIQGY#FXN2ZI[VYE_V['N]3U_4I_2[/T?H[WU+^KQQ6]5^W9=N?99G/W>H2
M U[6L%CFN$/L>_=L?9^?Z%/Z&I;F;]7.D9S&5Y%5A;6[>T,ONJ]P+7M<[T+:
M]WIO8RRK=_-6?I*TWCB1K=IX3X.8[5Q_CS\3$+9Z3_0F_P!9_P#U13MZ1@-8
MU@K,- :)>\F -ON<Y^YSOY3E8IIJHK%=0VL!)B2>=?SD9Y!*-"]U1B0;?__2
MZ3ZYY^*SJ&/2_)K9Z55HNH?=5407NQW8]_I9N=TVNRO8S(K]>KU_SZ?](NNJ
ML9;4RUD[+&AS9!:8(W"6OVN;_:7._63ZR'!R+,/&JQGY==)MJNR+6L]*QVYK
M+'4.9ZCJ*_T3K+:W_G^FNE24U7Y>!7G>E9#,HU%^]S"T&IKFM<!DN;Z3MMMU
M?Z+U?\(JGU5_\3'2?_"='_GMBN786!=;8;ZJ[;+ZVUV-L <'5U.=8QIK?+=K
M++G?FJG]5?\ Q,=)_P#"='_GMB2G522224Y'U@_G>D_^G"K_ ,]WK.S^O8N/
M]?,+ NKLKC!O!R7 -I'K/Q[6%SWEOZ/]1]#U/^Y-^/0M'ZP?SO2?_3A5_P">
M[T^4P/\ K-A,>W=6[I^:'-<):9MZ=N:0?Y*2D.%D8G3[_K%G9)%5&/EBRVR.
M&,P>GO?]$;G+EV=;R>H_XM,@]$QW6!E%U63;>&L:Q@<[[4*V&S]/?]FL]6K;
M^@_X;[17]E6OT'HG3^F]6^L'4,J\OHQ\MIK&01Z6.!CT9GK5[OT=7HU9GV6J
MW_ X>/74FZ;79U7ZC_L[I#L=]EM=N+?ZCG,;5ZGJ;SLIKL=ZS6VUV>B_TM^_
M^<24Z66[,=_S<=GM8S,.4#DLKG8+3A9OK-KDN_1^I]#W+.OP.K9?U^<W)LIL
MZ,,.NS[,6^]VUY](6:>[9F;[OI^AZ?I_HO46GU$Y+K^@G*8RN\YSO494XO8#
M]DS]&6/92]__ &U6BCIW4Q]8#U,WT?9#4,?T/2?ZNP;K0?7]?TM_VAW_ '&_
MFDE(N@NS?MG4WY.#?B,RL@9%+KC206^CCXNS]6R,ES7^IC6.]W^#V+:2224Y
M&=_XI.D_\3E_^ZRS*:^KW_XP\LY%%9Z9C8=#Z7@P[<3<S&M>-SG66^I;U:K9
MZ;*JZMEG\[L]73SO_%)TG_B<O_W60<7J/3W_ %OSL=N52Z\X>+6*18TOWUV=
M1LNK]/=OWU,>Q]C?S$E-SI/1W],=>XYV1F#)>;7MO%  L/T[&?9<?&^G_*6B
MDDDI22222G__T^F^N1PZLRDY5[IMIM+:;&GT/3;Z;;L9UN'?@96S.L-%5E64
M_.P;/9OQ5TW3LUF?@T9C&[!<P.+#KM/Y]<_G;'^Q8/UNHS[<S"=17?9CMJNW
MBAMKXL+L<5[_ +)?A7-W4_:/I7V5?\!^>NEKKKJK;54T5UU@-8QH :UH&UK6
MM;]%K4E-"_HF/D9]N:^VYIOI;CV,JL=5+6N]5A;=0ZO(KV.+OYNW_"6_Z6Q#
M^JO_ (F.D_\ A.C_ ,]L1,C S[.H6Y%&4<>NS';4"/TA%C7^IZE5-K?0J_1F
MQEO\[]HWU?S'V7]./ZJ_^)CI/_A+'U_ZVQ)3JI)))*<CZP?SO2?_ $X5?^>[
MU9?T3I5G4!U-^*QV<T@C((]X@;![OZH5;ZP?SO2?_3A5_P">[UKI*<CH^+U>
MC.ZA=FUX[*<ZX9##3:^Q[7-JQ\)M;FV8]#=KJ\3UM^_\_P!+_A5KI))*<KK7
M].Z)_P"'S_[:9ZU5E=:_IW1/_#Y_]M,]:J2E))))*<C._P#%)TG_ (G+_P#=
M9:HKK#MP:-TS,"9*RL[_ ,4G2?\ B<O_ -UEKI*4DDDDI22222G_U.N^N'6\
MO NQL&E]=-695<ZVQY:U_L-%8;1=;U+H;:G?K#O?5E6W_P#!+I:V"NMK 20T
M!H+B7$Q^\]WN<Y<Q];[<JQS:J&WT^BRUSKV.< &Q2[[6VNKJ/3V658^[W_:Z
M[*]_^CK_ )WJ4E.=E.ZZWJ,XE=-F&,=^UMEA9NOWT[/6<VJZRMGH>OZ?I,M_
MX;_!(?U5_P#$QTG_ ,)T?^>V(F5U+)HZ@[&JQ7Y;!C^MMIVBS>+&U>GNO?3C
M?I&6>HSU;J/Z/=Z?K_X$?U5_\3'2?_"='_GMB2G522224Y'U@_G>D_\ IPJ_
M\]WK761]8/YWI/\ Z<*O_/=ZUTE*22224Y76OZ=T3_P^?_;3/6JLKK7].Z)_
MX?/_ +:9ZU4E*22224Y&=_XI.D_\3E_^ZRUUD9W_ (I.D_\ $Y?_ +K+724I
M))))2DDDDE/_U>D^NPMJR&7V-?D4^D[:QE0#6MFMEF/E9'VK%^U4Y][\>O[!
MZ&57<_\ P"[%8O5_J_D=0R+K,?J%N%5FT-Q<ZMK&O+JFFW;]FLL_HE^W)O9Z
MOZ7\S]%ZE:VDE-'*ZQBXF2^C(#F,KI%]EP <QH+_ $&,L%9=;6^QW\SOJ_3>
MG?Z?]'N0/JI_XF.DD<'"QR/@:V*ZW[$<ZP-#/MK:V&T@#?Z;S8VG<^-VQSZ+
MMO\ 45+ZJ_\ B9Z3_P"$Z/\ SVQ)3JI)))*<CZP?SO2?_3A5_P">[UKK(^L'
M\[TG_P!.%7_GN]:Z2E))))*<KK7].Z)_X?/_ +:9ZU5E=:_IW1/_  ^?_;3/
M6JDI22222G(SO_%)TG_B<O\ ]UEKK(SO_%)TG_B<O_W66NDI22222E))))*?
M_];U5))))34R.G=.R;+AE4LR#DULKNIM]['5U.?95NQ[-U7LMNL]_I_]16JO
MU4_\3'2?_"='_GMBED]#JR>H/S776,+ZO2/I'T[!_4RJ]M[*]?YG^;]7]*LM
MW1\#$ZIA=+IR\^JAU%C68[,F[;[=AQRVUV1ZC&8]6/D5^G578S]/3]H]/]6]
M5*>G27+MP,.O,ZI79G]1L;@5U7^D,FYFQCF/<YC+G9#?M'JNH?;ZC]E5?\RR
MSV6[*HHQ']*R[:^I]1=?7<[&IR#D6-A]^V["->-9E5UY'V2G+Q_I.K^V?9_6
M_P +[TIV_K!_.])_].%7_GN]:ZYC&Z%A]8P\'.Q\W.96VUMQ%V1<YQ%8LI?7
MID;:'N>[^<9]!/=TS%KZUC8'V[J(%M-A-?VJX@OEKZK?5]?U6^E7CY-;]M?H
M?IZ?6].W[-ZJ4],DN6&'A4W]6];.ZC:SIK67FO[3=7MK-6\U,M?DL^T>I91=
M;ZUOI5L]3T-_Z%5'48XZ1>X=5ZB<NN^W#&4;[&D6#?:VUF%9E,KM911[MO\
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M/S:K/^+14DE//4_63JCVUFSH^0&O=2TV%CQ[7BLY=GHBNVVO[+OL_1V?S_\
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MKJ\%PTXX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <L            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              &$   !J0    8 9P W #( 9  U #$    !
M              $              :D   &$                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   &$     %)G:'1L;VYG   !J0
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !A     !29VAT;&]N9P   :D    #=7)L5$585     $
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MGTA9I[MF9ON^GZ'I^G^B]1:?43DNOZ"<IC*[SG.]1E3B]@/V3/T98]E+W_\
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M69^#1F,;L%S XL.NT_GUS^=L?[%@_6ZC/MS,)U%=]F.VJ[>*&VOBPNQQ7O\
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MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI,OE9))3]4CA0?\
M3K^C]+\[GZ+OYO\ E_\ HM?+*22GZ:PO^4^H?T3FK^8_I'T7?\H?^ZW_  :O
MGCMR.?BOE9))3]5*'^%'T?HG^MR/^BOEA))3],]$_HUO]#_G[/Z#_-\_X7_N
MS_IEHKY5224__]D .$))300A      !5     0$    / $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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M(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1
M ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M_\  $0@!A &I P$1  (1 0,1 ?_=  0 -O_$ :(    & @,!
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MIJ.NI*#=&!I,L[U"8_*Q5M$))9#XOW)-2W=.5.7=[O+3<-UVF*>\@H$9@:@
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MWFX_Z"Z]XOW0O^4'W(_YS[+_ -L_7OM_YE/_ #MO@Y_Z#W??_P!D_OU.>_\
M?FT_[S<?]!=>\7[H7_*#[D?\Y]E_[9^O?;_S*?\ G;?!S_T'N^__ +)_?J<]
M_P"_-I_WFX_Z"Z]XOW0O^4'W(_YS[+_VS]>^W_F4_P#.V^#G_H/=]_\ V3^_
M4Y[_ -^;3_O-Q_T%U[Q?NA?\H/N1_P Y]E_[9^O?;_S*?^=M\'/_ $'N^_\
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MM=*OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4;U/\
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M -H_Y35_8W^;KW^S*='_ //?X_\ \]^<_P#K7[]_4[F7_HU/_O2?]!=>_?\
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MT]^_J=S+_P!&I_\ >D_Z"ZW^_P#:/^4U?V-_FZ]_LRG1_P#SW^/_ //?G/\
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M5J#T#]VM[6SO7M;5)5\/#"0@G57BI'X2*$>?5"'\ROXA_P L+XB[_P#A]L/
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M]B?]7%Z3\N?\ERP_V_\ QP]6?X#_ (]38O\ XCOKO_WA\![/[?\ L(?](/\
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M\>%HS^@XT@D&O#/#A_/JW#XN]A_+7M:GWKDOEW\.Q\3:_%[DP4&TL/M+L?\
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M\_7M$G^^G_WEO\W7OL,G_P Z?.?^>/+?_4?OWC0?\I$7^]K_ )^O:)/]]/\
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M'8F$[#K<WES78BFQ/7]'DL>F H-L#'.Q=):K[YZA/TQH']U04\_]7\NB7?\
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MGY?X>M@/WOIKKWOW7NO>_=>Z][]U[KWOW7NJ!O\ A19_V2/\6?\ QIK\%/\
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M'3Y<?]7RZO=[!_X\+>__ (:&Y?\ W35OOW6AQ'5+O_":C_MR'\$/_#2[6_\
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MZ__1WYLSE\;M_$97/9FLBQ^'PF-KLOE:^?4(*'&XVEEK:ZLFTJS>*FI87=K
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ!^A_^XC[Y[?\
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M]C_'[MO^/SUG:&_L!U]BZR%L]NK$XX4N-R6X89Z@-*',"/H!<*K>ZL-!-/\
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MB!(897CU?0D<GW7CHK_J_P _1BQU'_PI3N+_ "]_E8 ?DCX_=Z$_[ ',"_\
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MJ6IH*?*8C,K/NN+-OD<J<@IIV@IGB72=9'%_=6HE"?\ 5_AZ.;_HC_X4J?\
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MO;:^'WSUEL2;;^QOC[VU_'I:[L_?&&V+C*V-L_NO$X\4N-R&;BFG!E#F%6T
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MLS=%N+:'8^'[KZAWGM_M_85-OW TNT^V]OX/;>'RN_\ 9-/*^/WA@XJ5_P"
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MJ>-I9ZBHGE9(H8(8D+.[$*J@DD >_=5ZJB_E/=J?&7<>R>^NE_B+\>\I\?\
MHGH[M_[OK_[[-93)8_N#;/>6WJ#NC&=W[<Q6XJFKW5M7;'9+[JFR&*H<BXDD
MQ,M+5PQPTU3##'[JS XKT;GY9?)\?%?;O3VY:CK'<_9&-[5^2?0_QVR%1MS-
M;6PT'7S=[]@8KKG#]@;B&XLG1UV4V_A=P9RDCFI,53UV0E:H4B)(EEFC]UH"
MM>B@=<]M_%SXO?/[+?#'X]_'^MQ.X_ECO[N'O[Y*]P;>SE:-GXGY-5?7>W>U
M*G [BQ^X*O(U&3[ W_UG)!G*NGQ#4U'B:*>@FFBU9*/W[K="17H^_P AM_\
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M[UZ\P6-SC/TWV!2;,WML3<+]?Y[==3B\AFJ&*L\&=H<8^)K4DQU=612^ZJI
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J^,?N_=^6_P"YK]^ZL=5!6M.C>>_=5Z][]U[KWOW7NO>_=>Z][]U[K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g790774g75h77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g75h77.jpg
M_]C_X0]Q17AI9@  34T *@    @ #0$   ,    !!14   $!  ,    ! AD
M  $"  ,    $    J@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    L@$;  4    !    N@$H  ,    !  (   $Q  (
M   >    P@$R  (    4    X $[  (    )    ](=I  0    !   !
M 3@ "  (  @ "  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C U.C$P(#$P.C$V.C,T ')R,3<W.#8U       $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   +5H , !     $
M  $N          8! P #     0 &   !&@ %     0   88!&P %     0
M 8X!*  #     0 "   " 0 $     0   98" @ $     0  #=,
M2     $   !(     ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" !# * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M#K?5+_ES'C4^G9IQV78=9=9^S+I9M^AWG\]JY#ZH_P#+N/\ \79_U*['K?\
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M-:3<Y\4X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <L            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              $N   "U0    8 9P W #4 :  W #<    !
M              $              M4   $N                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   $N     %)G:'1L;VYG   "U0
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !+@    !29VAT;&]N9P   M4    #=7)L5$585     $
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M>P/L>WV5/:WV.68>@9H:Z_UL9U=;WU.+;'NBRO<^VOVT?28VMZ[K*Q+/L^W
M]+'O#@66.8'!LN'K.V?O.J]14+,7ZP6TFNP8).X.#BUSB8;K86N:UGK.L_D?
MS2*G&^KW1\S"ZVPVNI>^BNS?76]Q=J&MTWU5L=])N[WKI>I59.5A6T5U@/?M
MVRX :.:[S\$7!KR6U%V6VD9#G.+C0"&D3[?I^[=M5E!! ((/71XYW3\H[/=2
M/MPV8P-A!>X,?9$>G^XU,_'MK!M>:PRF6O.YQU\-*O\ @+5J9>5>Z_T^FYN#
M72 T4U.>PN#OHN<P!AV>ZUC*_P"<_2>G9_W64L;,8<\,M=@?8K02QU;F;WVG
M94USFE_^$WWL]OJ?RT;8?NN/Q^UO]-%U.!166!Q:P>YK@0?ZL[5RGU@^K75L
M_K=]U I R0U];7V$.VU-IJM)VUO;[7G]]=PJ/5+Q33NJOQ\?+(_0OR2 W;NK
M]?\ E_1V_P#7/23L>26,DQW(IDECC*(B=@\"WZM]2>QMU=F,^JTEE;V6.<'%
MCS2_;MI]VVURV?JCTC-P.K7/M-3S50:GLK>XN#B]O^DKK]GZM;[EI?:LL#<_
M(Z=D.D.HW.;M;!===;N]GO;NJ=[/^"_F_?==J]+N;?A5VDU&\M'VGT"TM%I'
MJ7,FMUG^$L=^>I)\SDE$Q-4?!;'!")!%V&C]9\#-ZIT:[#QF-;:]U;@7NAL,
M>VQVK6O_ #6KAO\ F=UESJJQ9B[\QI?C-]5TO:&M<YS?T/YK2O4B 1!U!Y"P
M+LS-?<YN#G=/;0R#C-#P7!A:&M]H:_\ .99LV?X/U/\ K8Q<Q/''AC57>H5D
MPPF>*5W5/$6?5;J8I=D.MQFU1MWE]G):+_\ N/\ Z)^]>E]/KR,7I^+C/K!?
M3376\APC<UK6.V_V@J&#EM/4/1?]A;AOWNQO1<PO<XO].GV[_I68[/\ !UK;
M0RYYY !*M.R<>*&.^'K^Q\NZ_P#43KV?U_.R:#C!F18<AC;+7-=Z9ANYT4N;
M^;^^LMOU"Z[97597;AOKRFAU#FVO(<TEC X?J_[UU2]6ZK<*:MU.3CXF48+;
M,B(-;7--K>6OV:_^J_YQ99RLZNO>Z[IU][-:-SF@,:UMCKG;@*O?O%#7[/\
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M[?LL>K_VCG;]"O\ G=_^%_\ 1/I+YG224_52XG ^R^C7/[*C:)^R_:.-UO\
M1X]WJ_N;?TO\ZO"TDE/T+3Z/[2KV?8-WKGZ?J^IR?YKU?9]I_G-W_H'_ -UE
MTJ^54DE/T5]:/2]?#]3[#]"^/MGJ;XVMW?9O0_\ !_\ P-56_9?2,_8_YP3Z
M?VC;$6?0V_\ :O;^[^D];_A?27S^DDI^F>AQ]B='V:/4?_0Y].9U^E^?_P!\
M6BOE5))3_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %
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M %O_Q &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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M\N-LXS?FQ=_U79V>S S.T-L5,>WWPWAFGH/+CXY*?WOW7NB;T[;YH/Y)\_\
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M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO__3^?\
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M]^]^Z]T:7W[W[KW6N!_PI!_YDQ\1?_%C]P?^^-[-]^]^Z]UI\]\?\R+[J_\
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M'NS;.]MNU%15TD&?VCG<7N3"3U6/J)*2OIH<KAJJMH9*BBJXFBF02%HY%*L
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M];JKWN]>^8W607577\T?_LA/N/\ \.WXW_\ P4G2WOP^H_U_?NO'AU8WD_\
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M]%OQMZ,ZZ_O1L^MBR6TMR?W(ZPVOMG^/[6R,$<,&0VYF/X9]Q0SHB)+32(P
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MZEWM!!CL;15,<+23U@EEF#D1J@4L('^RGUW_ #W6-_\ /)7?_57L^_UKI_\
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MZ][][]U[KWOWOW7NO>]T'_A'E_Q^7\P;_P ,+X\?^]=V5[YO?WA__),]I_\
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MNO=>]^]^Z]U59\;/^WM?\TG_ ,5^_EG_ /N)\R??O?NO=6I^_>_=>Z0?:?\
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MWOWOW7NO>]T'_A'E_P ?E_,&_P##"^/'_O7=E>^;W]X?_P DSVG_ .>K</\
MJW;=3![1_P"YU_\ Z>+_ *MW/53_ ,PO^RO>K?\ Q67L_P#]^MU5[W>O?,;K
M(+JK[^:'%++\$^Y1%')(5W9\;F81HSE5/RFZ40%@H-@78 ?XD#WX?4?Z_OW7
MCPZL8RJLFZ,BCJ59<]5*RL"K*RU[AE8&Q#*18C\>_E-?SPO^WM'SN_\ $Z9C
M_P!U&&]]Y/NR?].#]KO^E6O_ !]^L/N:_P#E8-R_TR_\<7HU'\N7_LD78?\
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M=>Z)C_*5_P"W7W\OG_Q3OX]?^^PVW[][]U[JPKW[W[KW50'\T?JGJOL?N?\
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M7WOW7NC^_)O_ +)M^0G_ (@_MC_W@L_[][]U[K'\7O\ LF?X[_\ B"^I/_>
MV_[][]U[HFWPX_[+U_F]?^)W^*7_ , [T9[ ;Y)?\RPE_P##AP__ %KKO8']
MQ/\ E6W_ .:\?_/W6-_WK/\ IT4O_2TMO\$O1D.[/^RB/AA_X?\ W#_[X/?W
MNO;W G7,CJ)\_P#_ +(/^;'_ (J/\D?_ 'S>\_?O?NO=*/X8?]D>?%#_ ,5J
MZ*_]]=M;V8WKCH./?^TZ;<S;K_A)J*ZOH_LOX,:S1]D\:>3[@9&GU>77>V@6
MM]3[D'E[D4;[M<6Y'=/"U.RZ?#U?"0*UUCC]G64WM7]VV/W*Y,M.;6YR^B,M
MQ-%X7TOBT\(@:M?CI757AI%/4](JL[*^3^\^S^XMK]18'H&FVGU3NS;^R_N^
MQ\YV,NZ,QD\GUWLW?M=DGI-L[?FPU#C$_OBE+3HM1-,QI7>30'1?:Z_V4^+_
M )[S_P!=QO\ Z[^SO_6N7_H^?]4O^NG4B?\  80_^%'_ .S$_P#;3U6]\P)?
ME^?GI_*).;H/C0NYU[M^6_\ =%<9E^U&P\E4?A#W*,F,^]3A%JH:1,1]P8S
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M_P#"/+_C\OY@W_AA?'C_ -Z[LKWS>_O#_P#DF>T__/5N'_5NVZF#VC_W.O\
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MMI?^Z#'^_>_=>Z7/OWOW7NO>_>_=>Z][][]U[KWO?>Z@_P"9/=._^(BZP_\
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MZE_^SCW-7_!U_=>_\*.W_9!N/_;)T!O]8'W6_P"F9'_91;?];NA#'RLJB?\
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M'TL&5RM)B_B?ML8JDRN2BA6KKJ;'FID^WCF=TB+MH N??O?NO= 7\[,1\O\
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MK3'C,E1D8ZUY/^%"&U<COG8?PFV;B,AMK%93<GR>W#C:')[SW)C-F[2H9_\
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MFP\O1TFXOE;U%M[-T=-DMJ8>J@I\Y@\CETR&$RD$<H6HI9U$U/(&1QJ4^V?
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M48H]/DE%/2U,LOC34+M:PN+^^6'ZFS6:Q=!EJ?<O6])#D(!414V5[%VEB\E
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M!=V*&"30WBW,<08CSC+&DB?TUP>K$/<+ ]BX&OVED-Q0X??\5!M[P0UU'6[
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MG=ZI!16%K:RO-X2TK)+IT1BA8T/7MYY/W;E^Q.X7VX[3-;^(J:;6_@NI:L:
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MD_X^W/[B?_CO-_U,?_BOMCP(?]\K^P=:\*+_ 'TO[!T&\L47_#IV.?Q1Z_\
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MK 5\KZBUQ8D/_0.'_)O_ .\7-V?^E$][?_9O[E#_ (,C[Q7_ $W$'_9!8_\
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MH/\ F3W3O_B(NL/_ 'A<![^=#G7_ )7?G?\ Z75__P!I<W74SE__ )5_E_\
MYX+;_JRG14_@Y_V21T+_ .&#C_\ W)J_8A>PUT;=%8^-G_;VO^:3_P"*_?RS
M_P#W$^9/OWOW7NA[^9G_ !=OAK_XNQU1_P"\7VC[][]U[HS_ &@CR]:=B1QJ
MSR2;%W:B(HNSN^ R"JJ@<EF8V'OWOW7NB8_RF8Y(OY8'\OA9$9&/PX^.T@#
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M_P#BZ_QI_P#>PF]^]^Z]T=?W[W[KW57'\DS_ +=,_ '_ ,5LV%_[B2^]3O\
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MT&_OWOW7NIN-_P"+C0?]1M+_ -;X_;=B_P#@/-_U'Y/_ -V%3[>G^,?Z5?\
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MNO=<6944N[*J*"69B%55 N2Q)  'OWOW7NM.3<O\N+<E1O[N6N[U_D)[F_F
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M?^'57?\ NNQON=?;?_E7I_\ GJ;_ (XG72G[H_\ TZS<?^ES-_U9@Z*3TO\
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M?O?NO=>]^]^Z]U[W[W[KW7O=@W\J7_MXQ\0O_$QX/_W&K_>-?WP__$8?>O\
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M>_=>Z][][]U[H/=B?\7?M[_Q+V:_]Y?:/OWOW7NA"]^]^Z]T@NUO^96]C_\
MAE9__P!PG]^]^Z]TN8?^ ])_U!T?_N+%[][]U[K)[][]U[I"YW_F8?5W_4#V
MC_[H]N>_>_=>Z77OWOW7NO>_>_=>ZW-O^$_/_;OF/_Q8;Y"?^]_5^_>_=>ZN
MZ]^]^Z]U[W[W[KW7O?O?NO=>]G\^,?\ S+BN_P##JKO_ '78WW.OMO\ \J]/
M_P ]3?\ '$ZZ4_='_P"G6;C_ -+F;_JS!T4GI?\ [*=^9_\ VONB/_?/8SV8
M;V/NLGNC;>_>_=>Z _Y-_P#9-OR$_P#$']L?^\%G_?O?NO=8_B]_V3/\=_\
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MZ]U[WOO=0?\ ,GNG?_$1=8?^\+@/?SH<Z_\ *[\[_P#2ZO\ _M+FZZF<O_\
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M;N]D0]RGT0='C]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?__1^?\
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M[Y[&>S#>Q]UD]T;;W[W[KW0'_)O_ +)M^0G_ (@_MC_W@L_[][]U[K'\7O\
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MW1*/FU_Q:_C#_P"+K_&G_P![";W[W[KW1U_?O?NO=>]ZG?\ PHB_YG[\=_\
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M?^X-1[I)_8S_ /--_P#CIZ8N_P#<#<_^>2?_ *LOT!?RA_[)G^1'_B"^V_\
MW@-P>Z@_>)_7#_I=]8?\RUZ\_P##&VE_[H,?[][]U[I<^_>_=>Z][][]U[KW
MOWOW7NO>]][J#_F3W3O_ (B+K#_WA<![^=#G7_E=^=_^EU?_ /:7-UU,Y?\
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MW_\ $&Y#_P!^+NCWV/\ [LO_ *=Q[F_^+ G_ &A6_6%/WI?^5FY6_P"E<?\
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M_?Z5^HO^?Q]-_P#HVNNO_LF]^_J=SK_TP^^?]RZ]_P"M'7OW[L'_ $T.W?\
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M:>*:>6221P J(SL38 FP]^_TK]1?\_CZ;_\ 1M==?_9-[]_4[G7_ *8??/\
MN77O_6CKW[]V#_IH=N_[*K?_ *V=!_\ &#^91\"MM?&GX[[=SWROZ9Q&<P'1
MG4F%S.*R.Z8J+(8S*XO8.WZ'(X^NHZJ*&II*RBK('CEBD19(W4JP!!'OW^E?
MJ+_G\?3?_HVNNO\ [)O?OZG<Z_\ 3#[Y_P!RZ]_ZT=>_?NP?]-#MW_95;_\
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M^RSW[^HO/W_A/>8?^Y7?_P#;/U[]_<O?]-'MO_97;_\ 6WKW_#H7\O3_ +S
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MZ4)T[_\ 9K[:_J+SS_TQ&\_]D-U_UJZ]_6K8/^C@/]XD_P"@>C%_[/%\,?\
MO*#J;_SNW!_]CON#DODS\8WI;+\G?C2Q^ZH#8?(/ITFRU],S'_C]?PH)]NP\
MC\\!ZGDG>::6_P"(-U_"?^%=:_K1L+8&X+7_ $KCAGS7_B^ ST"/R&^9GQ&S
M?6B4&%^1O6F7KQV3T;7_ &6.GW'4U7V.([PZZR^6K?$FW=7VV+Q-#/53O](X
M(7<\*?<\_)OXPW/_ #D_\:/_ $H3IW_[-?;7]1>>?^F(WG_LANO^M77OZU;!
M_P!' ?[Q)_T#T.<WSC^&!FE(^4/4I!ED((K]P$$%C8@_W>]]?[,W\8?^\GOC
M1_Z4)T[_ /9K[]_47GG_ *8C>?\ LANO^M76_P"M6P?]' ?[Q)_T#UB_V>+X
M8_\ >4'4W_G=N#_['??O]F;^,/\ WD]\:/\ TH3IW_[-??OZB\\_],1O/_9#
M=?\ 6KKW]:M@_P"C@/\ >)/^@>@+I/F5\2%^5V<W&WR+ZU7;DWQ1VUMR'/F;
M<8Q$NXJ?O7=&7J,#'6_W=\;9:#$U,=4\/ZA!(K_0^_?[,W\8?^\GOC1_Z4)T
M[_\ 9K[]_47GG_IB-Y_[(;K_ *U=>_K5L'_1P'^\2?\ 0/0Z?[/%\,?^\H.I
MO_.[<'_V.^\]+\G?C E33NWR?^- 5)X68_[,'T\;!9%)-AO0D\#\>ZMR)SR5
M8#DC>:D?\H-U_P!:NFI^:-A:"91N J4(^%_3_2]3<;\Y?A='D:"23Y1]2)&E
M;2N[OD-P*J(L\;,S,=O6"JHN3_3W\HK^9CE<3G?YA_S>S6!RV*SV%RORG[RR
M&)S>"R=#FL+EL?5]B9^>DR&*R^,J*K'9+'U<#J\4\$LD4J,&5B"#[[R^RL%Q
M:^T'MC;75O)%<Q[%9*Z.K(Z,+>,%61@&5@<$$ @X(ZQ>YFECGYBWN:)@T3W4
MI!]07)!Z.K_+R^6GQFV_\,^B\9F^\NNL3D(\%N*H>ARN?AQ5<D%9OK=-722S
M8_)I1U].M133)(@DB0LC!@+$$D?]R=T1]'/_ -G.^*'_ 'D)U3_Z%^*_Z_>_
M>_=>Z&/8'96P.U<$^Y^M]WX#>VWHLC5XF3,[<R,&3QZ9.A$+5E"U33L\8J:9
M9T+K>ZZA_7W[W[KW2W]^]^Z]U[W[W[KW7O?O?NO=>]__U?G_ /OW7NM_CW[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U3CWI_**B[,W]\BJGJ?
MY@]\_&?H7YLY-\U\U_CEUCM_JK*[9[JS>1VG0;"WEN/9F]-Y[/SF\^C-R]I[
M)Q=/C-UUF!F)S,,*R%(:@&8^]^Z]T'';WRZ^5/3?S;VE_*L_EY?%7XP[DP/3
MGP+Z[^0V.D[L[FW_ -4[>P/6>'['R_0V!ZOV;1[/ZS[(=JK#4VVL<M%)5F.
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M_E%;KP?QW^678.POC%G?EED^Y^R^K_C+V_V+UKM.F^2'Q['5?68;?&U=L9'
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M^S?*B'K>'H?O#X<_S*Q\)-B;.DV-TOB^O,-FOE!UE)O';>?WOOC9VX*0U?\
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MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW6OS\*/Y_\
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.._=>Z][][]U[KWO\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g790774g75q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g75q33.jpg
M_]C_X0Y517AI9@  34T *@    @ # $   ,    !*:X   $!  ,    !$;\
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HQ-SHR-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   (ZH , !     $   #_          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,]    !@              _P   CH    $ %  ,0 S #D    !
M                  $              CH   #_
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   #_     %)G:'1L;VYG   "
M.@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    _P    !29VAT;&]N9P   CH    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     #.L
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MNSU)_2*^UK6-#& -:T0UHT  [!4:.CX]'4;NHMMO=9>UK75NL<:QL&T;:_\
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
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M Q$!_\0!$@ !  (" P$! 0$           @)!@<$!0H# @$+ 0$  @(# 0$
M             0(#!00&!P@)$   !0," P4&!@(" P$    !!08'" (#!  )
M$" 1,$!0$A,A,3(9.0I@(A0T%19!,W 8@) 7)1$   <!   $ P()"04%" ,
M 0(#! 4&!P@ $1()(1,4(!40,4$B%A?7F#E 4%%A([-T=;@P<3)")&"!4B4*
M@C,TE=4F&!ER0U42  (! @0" PH'" P,!P$   $" Q$$ "$2!3$&02(3$" P
M46%QD:$R!T!0@;'!(Q3PT4)B<I*R%6#A\5*"HL)CHR0T"-)3<X.SPT1D=(0E
M%G" D#-#I+0V_]H # ,! 0(1 Q$   #W\  J-6U(6AHW*C)0
M                     >?=?2Q:DI&ADNV8QT)IDD(  #1AL0R\  $64RF0
M                        !Q"EEDNQ8QU9@1M$  &N3)SOP  :6-T@
M                    '$*662[%C&+F@24P  (WFTDY\@  0K3-1
M                  '$*662[%C'5F!&T0  5(8=#O):?N;>  "G[#HYR3FD
M[EVP      K=ZG[5.WLODV:Y]<             .,4B+3/1/5 '$*662[%C'
M1&IS>H  *OM[@D=5+/29P !39O,-H6!M'59@     !YC.P]7]&6G[+L'C7
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M*]        \P47LZFMH: .(4LLEV+&.K,"-H@  KCV>.1!)369  !66M9HJ
M !6#ZAJ+ //]EGVORB%_5O=^!3DS?[9\_BD/K_L%RVY\UR;/J0
M  !UAY]%YOHL_5 XA2RR78L8Z U ;^  ! 6+2/F-UH  %&':^)9-I\TJ=9E
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M??;!R[>,R8P)R-&SS#D\<[LTF2--7%6:WHZ8ZU%N8;11MDU&GOT:&3*A$J4
M5X)WR260!Q"EEDNQ8QTAJLW>  #3YFQE0  (X)D>@             < XYV9
M]   < YYU9]3G@ ZX\GK+:&K<@H!Q"EEDNQ8QU9K\VH  #6IE9WX  -*)W6@
M          ""Z=))@ZG"$[$-=0RR7[1*@P$CBGB)V2C C#2;Q"%.+&T$67(G
MBKL]'3'EG9+,U;?E1YT%Y#HXZUV#&,7-#$H0  1S-GISU   A>F:"
M  -&[WC^;KZ3ZQ+7J7+OM\![''W%;@$?$_0Q R [4C"G)222.G/H:Q(!+SV5
MR5'X.L-EDRT;*0!Y3%[+D7"JBI)>V-2EADNQ8QU9@)M(  &MS*3OP  :5-U
M         IV]CTDL^I<R:W2>?&Q-9J>Q3)M'R/VCN2+"TJT:(3G"/Z:Z3KHR
MXDJC6)M,PXLO5 'G+6GV6<J@<0I99+L6,8X:4)'   T&;&3FR  !$=,N$
M        086IQ3V*9\JQ.6ZQ(UN6+JP>37_%KAII%E;5$1+>8D.0P3(Q%=2?
M6@Q_H   '$*662[%C'3&KS=(  -2&:&3@  CRF0R                -'IW
M@@       #B%++)=BQCJC7)ML  &KS,#(   :-3O)
M      '$*662[%C&+FBR3@  (\&RTYX@  0V3,E
M   &-'EP7L.36BM8.J.B-3F]0  :8,[,L  !&LDH   8,9R   9>7/,8
M           'R*?5KAU0!K5,-RQ)   @82'3NQ   JC3:X@  "JY:U%4  "J
M5>UI0                  "*B=9)GPJ  (*)G6@  " "TJ%=K@  J\39RCE
M   K36LL5                   JZ6P$N#5  %/JULRO>   HZ6M_1L9
M\\R_H 4[D  'FB7]("G>@
M                   'GL7R!&N3M4S_ $4>K3B5Q1.UD:V/1&J
M                     *^$XJG1Z(E+W2*4NK;,1E"<2-8H]+:H
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M/2(!V%-0!1X. ==5!TYP#KV !U[   >PII&KPB@>@CST].O.'30^_FI'H'.
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MT?HS<%'?OXR>CF;'!\Q?,_9F:$K*(C*R\Y%\TIC]0)AEO 4=&2-K=N!W'/\
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MTA/^6N7'_P"=*CY1@KN7-UVP\4"0VX](223^DQ)=0;_:]A=7$42B:9WG5FC
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MYD'8K\E*85K78[59!^$8U9_SV#-Z\  4 [R6YN=EM)+A_:=H8V9L@.LQ4DY
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M:TN]?H[;,6K.4Q(#:(W2E-+5B6J_TH W%!8X.Q*U^<<O\YO?\(Y_N3^.*_\
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MUZRN5$F^FH=2/M<PQ*%T@<XM%X(1%\1 %XLB:RAQC%6_J*4_F0!<T6%VS3P
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M'X1":&[;-'%;AX]2R'9M5WJ3<Y52G?+&B8M14R#E4YU8YFJ*B@IG.8ZGS$3
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MY+M>2SB=0M-&P2/T^/RX+'/R21JR]>KRMIOV?9Z\&(@I9RX(2<=*))BF)FQ
M=?*'Q[5OM\Z+?] M'/>H]4^Y<RZ2YYL-YTQ"WY:XY/B;-=,J]NW6=%>V-"_:
M16><Y>ULF\C]3(N8NUH59F=,SN%%#YO3?M@YK;K]5.2WGO#>W!R?!MX_0+NE
M;\WYJ[*P^B[7NV 9_I9)TMSI],G;.P>1$:FT?I.H:)MJ[)HJFG],5/>^(^>8
MV2I_+=JX0Q+K-KD8V.QV&GY=M+O=]>QNRR.?LK#+RQJ;&ZE4:U'.9&/;&3:N
M9*&.\*0%EES']VBZ8ONN?YK1/:_9<VZE4,ZD<,@KZMND5H&$5O2[SE^F6Z9L
M+22KU6E9)-TFRD8!)C-L5'YCF<*HMTFY_=0MN*[?1,PH?MK9+R=T;4L^DL/K
M^@N=J1U+,+C<+OD&CVR8L#!_!4B6>TH"I2,$DRGVAWZATW?RT$T5/<"K^C:-
M1>JY'.N,><NLL#>36516.Q.<Z+TYT1HG.,'E,\RH\R]?W7&Z?.Q<-,"]=N2V
M4S,KQLJ]5.=)PG[H' ?3VY5[JU&>]HW1.Q,]VQ#(:KA]GK+V$NKS'])RZ=IE
M)D9*KRU76?O8B:K3_P#LY1M\Y^S>K/ODMW/CVZ>(FQDWM8AU(WOCHJ,0?)I
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MD\Q#)Y9+"9/F))]2XA=/GZ8CJE$262IBD()TQW%T1T\J,>>+(4 !)@I\DA1
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g790774g77b51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g77b51.jpg
M_]C_X1#817AI9@  34T *@    @ # $   ,    !!2T   $!  ,    ! S$
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(T.C U.C$P(#$P.C$T.C0T   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   +5H , !     $   &_          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M4&AO=&]S:&]P(#,N,  X0DE-! 0      !H< 5H  QLE1QP"   "   < @4
M!F<W-V(U,3A"24T$)0      $(Z^@)B'0;(J-N*P=5!$L,8X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      T$    &              &_   "
MU0    8 9P W #< 8@ U #$    !                          $
M         M4   &_                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   &_     %)G:'1L;VYG   "U0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !OP
M  !29VAT;&]N9P   M4    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M%E;; " \!P!YU$I*9))))*4HNL8US&N< ZPD,!Y) +X;_9:I*A2_]#T_<Z3
M+BYTDS4_5SGG<Y)3?0,[^@Y'_%/_ .I*.L#ZS=;=TG"RKG5G(8[92VL.#-OJ
M,MW/W;'?N(QB9$ :D[() !)V#MBQ@<RHGWN:7 0>&[0[7_KC$/ _HP_KV?\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
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M P,# P,# P,# P/_P  4" &_ M4$ 1$  A$! Q$!!!$ _]T ! !;_\0!H@
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M7DRL6U=P97;)RF-@JWEJJ6BKHX)I)98VD?WOW7NA(ZM_[+ ^6O\ X8GQ@_\
M=?V_[][]U[HV_OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_
M=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOW
MOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][
M][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO
M>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[
MJL'^5E_QXOS,_P#&GW\PK_X(W=GOWOW7NK/O?O?NO=5-?SQ_^W7GR3_[6?Q_
M_P#@FNFO?O?NO=6R^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7
MNO>_>_=>Z][][]U[KWO_T/G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=4<]R==_-++?SG_ (Y_)3:?P\R6Y/C/T_TAO_XU9[MY>^NE<14Y
M"A[XW#UIO'+=IXSK?*9^#>IV]U54;0J*#(8Z2),KDY)!+00RQJ/)[W[KW1)M
MQ?"#^8IUQ\4?EK_*&Z:^.>T-R=#_ "8[;[WEZN^=E=W/L;$;!Z<^.GRA[#S>
M_M_83M/IBLRM-W9N7M[K:@W+D\1CX<%05.%SKU-)4/64<<-3$?>_=>Z-QN'X
MZ?*K^7]\SNS?DO\ #CXK2?-/J[Y+_&+XX]&[WZYQ/=?5_2O9'6/9?Q)P6[-G
M=6[MK,MVU78#9^:ZMWML?<T%!E9,=+4YK%UU&:B/'U,+:#[W[KW1N/Y;_P )
M=X?%WX*83X_=U;I6L[?[ W+W!V[WKN3J3<^ZML4=#V?WYV5N?L_=F-Z\W?05
M.'WC0X[:4NY8\51Y)9:>LJ4H?N?VS+H7WOW7NA ^-VP,5US\I_EYA,/F=\9R
MFJ-I?&'(O5[_ .P-Y]CYE)WP?:5$\4&<WSF\]EJ:@*T*R"FCF6G2:21U16D<
MGWOW7NCW^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KW
MOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z
M][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[HL>Q_FK
M\/>S>TZGH[KGY2?'W??<]%6;JQU;U-M#M[8>XNQZ.OV-*\.\J.KV7B<[5[BI
MJG:TL3+7H].K4I5O(%L;>]^Z]T9SW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U6#_*R_X\7YF?\ C3[^85_\$;NSW[W[KW5GWOWO
MW7NJFOYX_P#VZ\^2?_:S^/\ _P#!-=->_>_=>ZME]^]^Z]U[W[W[KW5*79G2
M%-)_.=^/$T7<?RAQ^VMY_&KOCY#[CZMQ7R=[KQG3.4[,Z5[&^-6Q=C551U-2
M;QCV.NVX=N]@9-*W"QT<>)R=1,*BKIYIAK]^]^Z]U=;[][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>__T?G_ /OW7NM_CW[W[KW7O?O?NO=!KW)C>QLS
MU3V%B.HM][;ZN[-R>T\U0;)[*W=M4;XVYL'/U=')!1[QRFSGS6W8-S1;;9S5
MK135M-35$D*I,_B+@^]^Z]UJ%[YS/_"?>HW3N*G^27\P7YX?/ON?;574R[Y[
MZVIV[\]^UMK;0S<\S5U=)M;)_"K;^(^.>RMOXVJ=VHL3A(9J7&TT:1:6T!G]
M[]U[JZK^52-A9B#=.[_B1_,VW+\\_A%D,!#0X/KCNC<T'<7>GQY[7_BZY%<6
MW=F4?"]N4>R,IM&H,"[-W]BZG,XIJ6FJ**O2FEFIW][]U[JY3W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW12.K?^RP/EK_X8GQ@_]P.W_?O?NO=&W]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW51'Q<VMMBD_F[?S3<A2;<P-+7T
MG2G\N*HI*ZGQ&/AK*6HRV!^6$>5GIZF.G6:";)QP(M0RL&F"*')L/?O?NO=6
M[^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NJP?Y6
M7_'B_,S_ ,:??S"O_@C=V>_>_=>ZL^]^]^Z]U4U_/'_[=>?)/_M9_'__ .":
MZ:]^]^Z]U;+[][]U[KWOWOW7NJONQ_\ M\9\3_\ QGU\T?\ W^WPU]^]^Z]U
M:#[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__2^?\ ^_=>ZW^/?O?N
MO=>]^]^Z]T&G<O7?6G;75/8/6W<N"H-T=3[RVIF,'V+MS+3U]/B,[LZJI)/X
M_B<PV,J:2LFP]?CD>.KA#A*BG9XI T;LI][]U[J@;XP[^_G"?+CHGKCY!_"3
M_AM[X0?#G=V*GR7Q3^.F^.F.S][[U'25%D*[';#R/9]5UWNC96P=AU&\,;CT
MR5/A]K4;08K&5T,+RR54<MO>_=>Z.K_+6S6U^_-U]]]_]O\ QIZ?Z/\ YB/2
M'9.]?A%\O-U=*SY2?9G965V53]?]DX/=6WLY6T^'S&]MA[QVAN?;^;P$NY:6
M?<. @K)L:TR::@3>]^Z]U;?[][]U[KWOWOW7NO>_>_=>Z][][]U[HI'5O_98
M'RU_\,3XP?\ N!V_[][]U[HV_OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=
M>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>ZJF^,O_ &]J_FJ_^(._EI?^Z/Y:^_>_=>ZM9]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=5@_RLO^/%^9G_ (T^_F%?
M_!&[L]^]^Z]U9][][]U[JIK^>/\ ]NO/DG_VL_C_ /\ P3737OWOW7NK9??O
M?NO=>]^]^Z]U5]V/_P!OC/B?_P",^OFC_P"_V^&OOWOW7NK0??O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W_]/Y_P#[]U[K?X]^]^Z]U[W[W[KW2:WG
M'@YMG[LBW/6#'[:EVUG8]PU[3+3+0X-\75+EJPU#JZ0"FH#(^L@A=-R#;W[W
M[KW6H+NKX?\ \NCXN_!?XW_(_8/\PS^?!)T)W;'U[L?X=]!?'WY5]J1]E=H5
MO8M+D,QUSUKTAT%0[2VS-35N:Q%)45E'0LF/IUIQJ+!Y8UD][]U[JX_^2?@?
MBUA_CMW%D?C9NKYC9_<.[/D?NW<GR9PO\P&NR]5\PMA_(<[%ZXP6<VEW93[@
MQM#F:/.P;$P> J:?R39".:DJ8Y(ZN56TQ^]^Z]U<A[][]U[KWOWOW7NO>_>_
M=>Z][][]U[HI'5O_ &6!\M?_  Q/C!_[@=O^_>_=>Z-O[][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KW
MOWOW7NO>_>_=>Z][][]U[KWOWOW7NJIOC+_V]J_FJ_\ B#OY:7_NC^6OOWOW
M7NK6??O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW58
M/\K+_CQ?F9_XT^_F%?\ P1N[/?O?NO=6?>_>_=>ZJ:_GC_\ ;KSY)_\ :S^/
M_P#\$UTU[][]U[JV7W[W[KW7O?O?NO=5?=C_ /;XSXG_ /C/KYH_^_V^&OOW
MOW7NK0??O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W__U/G_ /OW7NM_
MCW[W[KW7O?O?NO=!!\@=W['V#TAVOO'L[";GW'UO@-A;FK>P,+LS:VX=[;FK
MME?PNHAW2N*VGM.EKMSY^6'"2SR/3X^&:L>)&\*.^E3[W[KW6O+_ "]_B-\?
M\CO'XD]YU?\ -^ZO^</Q.^ ^T]YX?X%]48G#]+;%EZ<I=Z[078V*J>^=][6W
MI5Y/L[>_6'4LJ8''PY7";>K,9/#]U-3PU?GC?WOW7NC^? #L?XNU_P MOY@F
M!Z0^1.*^579W=/<E%\DNW-Y=1;6J,KTETA@L?UUU?T-U;T-F^W]N9+<G6>6[
M6H\#UM/6RX^')KG*A%K*BIQ])%"A?WOW7NK???O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=%(ZM_[+ ^6O_AB?&#_ -P.W_?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW54WQE_P"WM7\U7_Q!W\M+_P!T?RU]^]^Z]U:S
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZK!_E9?
M\>+\S/\ QI]_,*_^"-W9[][]U[JS[W[W[KW537\\?_MUY\D_^UG\?_\ X)KI
MKW[W[KW5LOOWOW7NO>_>_=>ZJ^['_P"WQGQ/_P#&?7S1_P#?[?#7W[W[KW5H
M/OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][_]7Y_P#[]U[K?X]^]^Z]
MU[W[W[KW7O?O?NO=4U_+/X@_R'/]+!W)\R^J?Y<.R^Y]T^3>%;5]PUW2/5>^
M=[_<U31S[HW#297+[5R>^!55<!CDK:^.L$C*49S8CW[W[KW1_P#XI9'X?3=3
MTV"^#^1^-]5T?L_,Y#;M+B_BS7]9U?5VVMQ+%297+89*7JB:7:V*SQARD%55
M062I(J4ED!\BLWO?NO=&5]^]^Z]UKR_(7^<QWEUGF/G'VYUK\<.H]T_$/^6M
MW/MKI#Y//O\ [MSNP_E-OS-Y=-B-G]S=#]9+UWE=B' X5M_TZX&/<.>H3OAZ
M:6.@FII2B>_>_=>Z-CWY\Y_D_FOE9N'X;_ 7X_\ 4G</9O3_ $KLKO[Y#[R^
M1?;>Z>FNO=C8;LK,9B@ZOZ9V]!M#KGL;=V6[D['QFV<GDHYJRCHL%A**EC:J
MGEEG\,7O?NO=&Q^#'R\VG\Z/C%US\D=I[8SNPCNQMT;=WEUSNB:EJMQ=;=G=
M=;LS?7W9NP,O6T2I2Y.3:N^=LUU+3UT:0QY&C2&K6*-9A&OO?NO==]6_]E@?
M+7_PQ/B__P"X';_OWOW7NC;^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[
MKWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=
M>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[JJ;XR_\ ;VK^:K_X@[^6E_[H_EK[][]U[JUGW[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U6#_*R_X\7YF?\ C3[^85_\
M$;NSW[W[KW5GWOWOW7NJFOYX_P#VZ\^2?_:S^/\ _P#!-=->_>_=>ZME]^]^
MZ]U[W[W[KW57W8__ &^,^)__ (SZ^:/_ +_;X:^_>_=>ZM!]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?_UOG_ /OW7NM_CW[W[KW5#'S^^0'SWZ]^
M4>S>@NB(^]Z&F^0>X%R?0.X]A9?^7Y#B,T>M.F\EG>X.KJ'"_(C&U&[H::DD
M@&Y)LGD3)72U<9I*$+CUE*^]^Z]T._\ +(WG\P^RJ[MO<WR#[RS>]<'LC=&Z
M>C]X=-=D[.^-T?9'4O>O7V7Q.2JZO%]E_%6*@ZUW1LW=6P-U4<U3CJR*?*8N
MO5(VEA<5-,GO?NO=5[?)+XE?(;:'SN^8W<.S_P"27\=?YFNR_D/GNG-V[?[?
M^4??_P 6]K;BV35[.Z;VMUYN+8&P,+VAUCVINO'=:15>VX*JEIYWQK19)ZUU
MBEIY:=H_>_=>ZM8_EE_QJ@ZC[(VQNOX$_'/^7%O';7;N0@W#\=OCCVATQV?@
MY3E-D[(S&,[#WG5]);(V!@MN[PW5CJU(A0U]"<DV,H:2I:5H)X%3WOW7NK(?
M?O?NO=:1WRVZ<W?NSL7YO=G=G]"?.BG_ )TN'^4F<KOY<G:'QSZ-[$R736YN
MG=AYS%-\-H(=Y[=VAE/B-NGJ':6-=*K?>1[1<;HQ,\M<LE13K%10Q>]^Z]U:
M#1[J[+_EU?S%OD7\IODMTKWMV5LOYX?$;X?05^^?BOT?V+\@\1M;Y3_&#;.\
MMD;UZ2KMH]68/<V[]M/V1'O*EKMJ9/(TL&$K&6:GEKH9(I OO?NO=&Y_E+?%
M[N#J3^7E2[+[JAW7T;W)WUV9\B/D+O# [<R& _OMTW6?(?N/>/9. VQ#7U&*
MS6WH=W[8VGG,?'7H]%-!2Y/SP>-A'<^]^Z]T8+XS['KM@_*3Y>X?(=A[_P"R
MIY]J_&*O7.]C5FW*[-TT38+M&C7&4\NV-L[4QXQT;41F :F>8SSRLTA!55][
M]U[H^OOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZJF^,O_;VK
M^:K_ .(._EI?^Z/Y:^_>_=>ZM9]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=5@_RLO\ CQ?F9_XT^_F%?_!&[L]^]^Z]U9][][]U
M[JIK^>/_ -NO/DG_ -K/X_\ _P $UTU[][]U[JV7W[W[KW7O?O?NO=5?=C_]
MOC/B?_XSZ^:/_O\ ;X:^_>_=>ZM!]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?_]?Y_P#[]U[K?X]^]^Z]U47_ #<-M=T=G=>=6]-]4?$KX\_*.AW7
MD>U=^;G;Y/=*[J[XZSV7D>FNI]Q;YV-AL=M+:.X=FY#;_8_;.XH?X!@<^^7I
M8\=42O$(JJ6JCA]^]^Z]TH_Y/^0R=9\5<[3#8VQNO]@X;NOL#$=/8;K#XB[X
M^$'7E1UK#1;9JH*_:GQ^[.DG[,P,/]\*S,4U?D,[)+6Y7,4U94QR2TCTTC>]
M^Z]U51\__P"57N3Y(=U?./Y'=_\ 1%1\FMV;7[M^)&Y_@WM#._(.MV3BNUOC
M'M79W6[_ "3^*/7VT\?V+@L+L#=>YLSC=W$U&2HZ9]PY;(4,GW*Q/++#[W[K
MW5A'\EGXZ2_'KK'Y.+M;XA9KX0="=I?)G(]C_'GH;LF?%5_?>)V14=6]:;;W
M'G>XJ_$[Y[)6FJ<_V%M_*S83%56<R%5AL/XJ82+2K21I[W[KW5T'OWOW7NO>
M_>_=>Z][][]U[KWOWOW7NBD=6_\ 98'RU_\ #$^,'_N!V_[][]U[HV_OWOW7
MNO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]
MU[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>
M_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>ZJF^,O_;VK^:K_P"(._EI
M?^Z/Y:^_>_=>ZM9]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=(Z?L3K^ESG]V*G
M?6SJ?<GWU)B_[O3[GPD6<_B>0C6:@QW\)DKEK_OJV)@T,/C\DBD%01[][]U[
MI8^_>_=>Z][][]U[JL'^5E_QXOS,_P#&GW\PK_X(W=GOWOW7NK,JS(X_'+&^
M0KJ.A25BD3UE5!2K(X4L4C:=T#L%%[#FWOWOW7NJD_YW^:PU9_*_^2R4F6QE
M4\=?T!+(E-7TL[)$/DYTNAD=8I6*QAY%%SQ=@/S[][]U[JV"7<. ADDAFSF'
MAFA=XI8I<G11R121L4>.1'G#(Z,""" 01[][]U[IR@J(*J&.HI9X:FGF4/%/
M!(DT,J'Z-'+&S(ZG^H)'OWOW7NJQ>QE8_P XOXH, 2J_R^OFAJ(!(6_>_P -
M0+GZ"Y]^]^Z]U:![][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__T/G_
M /OW7NM_CW[W[KW0%=Z?([J;XX0]75O;VY(-HX?MOM;%=.;;W#DI:*AV[C]X
M9K:>\]XXX[HS>2K:#'X##U.,V+60K53/I-9)!" 7F7W[W[KW07_$WM;L3MO(
M_(/,;A[F^,_=G76 [QW3M7J?,?'6AW1!4;-VM14V/S&.V!VKFLONK=FV]Y]B
M8?;^=QTU?D\(]!0&>H>$4JE"1[W[KW6NE_,X^-'>>W_F?V3\A]U?R_?D5\Y]
MV5/R-^#W;?PR^2'1M=@>PY/C=TAT5N[JG='=GQU@Z?SO8>UINJMQY#.[.W)E
M*;.4&/K*/=TN[4%?64K4;K%[W[KW5V7\LW8_?M*GS%[Z[QZTW7T!0_+3Y79?
MO#J?XX;[W+@MT[ZZGZ\I^INJNKX,COR?:N9W#M;;&]>ULUUY5;GK]O8VOKZ;
M!G(I#)4259J53WOW7NK0/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=%(ZM_[+ ^6
MO_AB?&#_ -P.W_?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW54WQE_P"WM7\U7_Q!W\M+_P!T?RU]^]^Z]U:S[][]U[KWOWOW7NO>
M_>_=>Z][][]U[JN7YT?.WL'X:;FZ+P>WOA]VA\C,;W_OW"].;-W'L#LWH[95
M%3=V;L7-5FS>N<O0=H[[VIE:8;@PNVZ^K.86%L32+3B.:999$4^]^Z]U87BJ
MFLK<7C:S(8V;#5]704=378>HJ*2LGQ59/3QRU.-GJZ":HH:J:AF=HFDAD>)V
M4LC%2"?>_=>ZG^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NJ1
MNT?BY\9\K_/%^,O8V4^//2.2[!R'PN^3/:U?OBNZMV35;MKNT>O.ZOB5@M@]
MDUNX)L*^4K-_;(P>7JJ+$9B65\CC:2=XJ::.-BOLW'P%Z_V9VQ\W_B/UCV+@
M:?=.P>P?D7T_L[>>VJNHK:6ESVV=Q;ZPF*S6(J*G&U-%D((<ACZJ2)G@FBE4
M-=64V/N/_=?=]RV#VQ]P-[V>[,&[6FSW<T,@"DI)' [(X# J2K &C CU!Z-^
M7[:&\WS:+2X0-!)<QJP]0S $8H>'1_?GQN[=FQ/AU\@=V;%W-F-F[MQ&PJI\
M)NG;\T%-G<%55>0Q] ^1P]54TU9!2Y*"GJG,,K12>*2S $@>_I.U/\A_^40E
M34(GPAV"JK/*JJ-[=P6"K(P '_&1/H /?&1?O4?>"*J3[F7=:?[YM/\ MGZR
M0A]ON56AB9ML0L5!.6\Q_INJ\:C:F\8LI/31_)?Y=B&*OD@16[WJW(B2H:-0
MS-MHECI')/U]X?\ AB'^45_WA%L'_P!#;N#_ .V)[M_P5'W@?_"EW?\ SAM/
M^V?IS_6\Y4_Z-:?M;_H+HB/P*VYNN7K[Y(3TWR ^3N&9?Y@_SCHIDP/<D^,C
MKVH^Y*HG*9)5V_,U9F\C-4235=02HGG=GT*201^^//\ +7^!WQ1W!NBNZ"^+
MW6FR*G?. HJ'=3U]/E]_1Y.EP>4%3BXHJ?LC+;NIL5]O/72,S4:4[S$CR%PB
M:0GS=[T^ZG/EG8Q<U\[WEREK*S14*0:2ZT8UMTB+5"@=Q:F:4J:K;'E#E_;9
M'^EL NOC1F'"M*]V1GAZY\NACSG6^(W3\F-MXOL[<.^N]<92_&7L#,8C'=][
MBI.TJ';.7_TS]4XVHRNUJ7+86FAPF1R..D\%5,BM)-"B(2%6Q-9_H@Z=_P"?
M.=/_ /HJNO\ _P"QWV _ZQ\Q_P#31;A_V4S_ /0?1K^X]K_Y1?\ C3_]!=%A
M_F>=(=,83^7]\E\MANI>M\5E*+']+M1Y+';*V]15U(:GY-=(450::JI\?'/"
M9Z*JEA?2PU12,IX8CW[_ $0=._\ /G.G_P#T577_ /\ 8[[]_6/F/_IHMP_[
M*9_^@^O?N/:_^47_ (T__075A>Z_CST''NG<D:=)]4(B9_,(B+L#:ZJB+D:D
M*JJ,8 JJ!8 ?3V53=W\L_P#EV=K;KW)V#V3\(OC?O/>^X\S5SY[<V5Z^I8:_
M*S4>C'4TM1#BZG'8]&AH:2*(>*",%4!-VN2.]N][/=_8;"SVC9O<O>+?;(8P
M$C6X;2H/<0-08Y8DY)X^G1+/R7L%Y-)<2VBZV_H1-P%,L\;.3CBS$] %\>^K
M]LQX+MREQN4[(VUBL=\I/DAC<5MW97;_ &IL?:6$QM'V)51TV.P&T=I;OP^V
M\#00@DB&CI88M;,VG4Q)3W_#1G\K/_O7W\7O_0"F_P#KM[6_\$'[Y_\ A6-[
M_P"<_P#T+TU_4'ES_E$7_G'!_P!:N@?WOUWB4_F4_&2@&Z.WS%4?!WY95;5,
MG>W<LN6BDINX^@XT@I,W)OA\O0XZ99B9J6&9*>H=4>5':-"I:/FG_*S_ ):V
MR/AI\N-Z;/\ @M\;]M;NV?\ &7O3=&UMQXC9$M-EMO[CP/6NX\GA,WBZDY-S
M39'%9&FCGA< Z9$!Y^GL:>VOOK[S[I[C<@;;N/N?O$VWW&]644L;SU5XY+F-
M71AIRK*2I'H>BO>N2M@M-IW*YBM$\1+>5A^G",K&[#(C!&0,@@^A'1F>U=N3
M;"Z]S.]MI[^[NQ6YML;CZDK\+D6[^[JKTIIZKN[K3$5:S4&1WU5XZOI*W%9*
MHIIX*B*6&:"9T=65B/?RZ??<7K&7K8L]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W_ /_1^?\ ^_=>ZW^/?O?NO=4Y_P Y;MOXF;2Z(VULSO+LCXPX+O"GW70=
MP_%W8'R>J,SF>O-Q]D[ CK<.,UOS86U,'NS<6>ZUI<-NRNQ^1FDQDM#'-7Q*
M)8:HT\B>]^Z]U8%\5-S?%K>?2.U-V?#2HZ<JN@-P/E<CM2?HG&;8PW7[U\F2
MJ$W"L&)VG1X['8O.P9J.:/)T\L$-;!6I)'4HDRNH][]U[K60^778G36;_F-?
M.7:_RA['_FY]VXWK[/=#XOJ';'\MNO\ EBG3_P ?MJ[AZ1VUGLYU;V'B?CS5
M87;]!W+EMV/69^MJ:Z?(3U^'R>.TO \$])![W[KW5V_\IRIZ3JOCUO.3HC$_
M/+#[3'<.?3(T_P#,+?O%^Y)-P#:>RC53;9/?F0R6[O\ 1NV/-,*3[9QC_P"(
MK7:5$_G)][]U[JT+W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW12.K?\ LL#Y:_\
MAB?&#_W [?\ ?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW54WQE_[>U?S5?\ Q!W\M+_W1_+7W[W[KW5K/OWOW7NO>_>_=>Z][][]
MU[KWOWOW7NJF_P":I_Q>OY7G_C63XP_^\!WI[][]U[JV3W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW57G87_;Y+XL_P#C/#YD_P#O
M_P#X<^ST_P L+_MXU\%O_%L.A?\ WY6W?<7>]W_3G/='_I07W_:-)T?<K?\
M*R[#_P ]D7_'UZ&;^9%_V0W\D/\ PPO_ ).8?W]=JK_X%U7_ %$3?];&]_/H
MGPK]G67]O_N/!_I%_P  Z*36?\7NK_[6L_\ [EM[C^[=.]$(^ 7_ #+CY*?^
M-%/G=_[^67VWG_B[1_\ :KJ?_<VC]O?\1S_IQ_@/39_M%Z'6I_[*FV]_XJIV
M%_[_ $ZD]N'MGISHN/\ -0_[=W?*'_M7=(__  4G1/OWOW7NK'-W?\?7N?\
M\.'-?^[*I]M^._S=5_VM,I_[FS>W9OB3_2+_ (!U2/@>BR?'O_BS=S_^+8?)
MG_WX]5[</;75^@7WS_V\W^+W_BB?RZ_]_/\ '[V4OY]_]D'?-O\ \5'^1/\
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M,W\R+_LAOY(?^&%_\G,/[^NU5_\  NJ_ZB)O^MC>_GT3X5^SK+^W_P!QX/\
M2+_@'12:S_B]U?\ VM9__<MO<?W;IWHA'P"_YEQ\E/\ QHI\[O\ W\LOMO/_
M !=H_P#M5U/_ +FT?M[_ (CG_3C_  'IL_VB]#K4_P#94VWO_%5.PO\ W^G4
MGMP]L].=%Q_FH?\ ;N[Y0_\ :NZ1_P#@I.B??O?NO=6.;N_X^O<__APYK_W9
M5/MOQW^;JO\ M:93_P!S9O;LWQ)_I%_P#JD? ]%D^/?_ !9NY_\ Q;#Y,_\
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MG_C13YW?^_EE]MY_XNT?_:KJ?_<VC]O?\1S_ *<?X#TV?[1>AUJ?^RIMO?\
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MO>_>_=>Z][][]U[KWOWOW7NO>__6^?\ ^_=>ZV0OYI7R<_F?](;^V!MKXC=
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MK7HYWCA>:E>II6,;LB%D() ^GO/+9=UMM]V?:=[LU<6=Y;13QAQ1PDR+(H8
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MUF\S@:+)97+9.NJ%>HK<AD*^IDFFED9G>1R2;GV(?^@'H#_GP71G_HGNN?\
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MZ3#Y:7#Y7:O8E'E,2]?2)'4MB\E33%*BGU>&<!=:L40KI)>^]_7/;JQ'-?\
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M:E:U/39&NI,!62PP2,LDL=.[*I ]G0_EQ_$7Y7[2^?\ \+-S[J^,/R'VUMO
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MU]N6*P0JP_XR5L7D,$!!_P!;WG?]3?\ !F_WL^Z#@.EB_"OV=&FR/_%_KO\
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M+:G8.^M@4^8S&WZ/J^DP-9EZG8>XMMY#)_P>'/UOV\4TSPQO4,X36%9=@?\
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MPKS_ )I/_P =/3L']O#_ *<?X>K9/?S;>_?^9Z]U?^):['_][',^_J4]N?\
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MV?;(X#JZ_"OV=&DR/_%_KO\ M<5/_N:_OKW[K?1!?@%_S+CY*?\ C13YW?\
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M]U99[][]U[KWOWOW7NO>_>_=>Z][][]U[HI'5O\ V6!\M?\ PQ/C!_[@=O\
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M^VS,_P#%JK/]:F_]S:;V];_V\?Y_X#TW+\(^W_(>A6^8'_9*_>G_ (:^W/\
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M^]]K*?\ %SR/_4=5_P#N1)[^=*T_W$M?^::_X!UU+F_MI?\ 3'_#T8B@_P"
M-%_U"4W_ %I3W!]J.FNJM?Y6O_ S^91_XU5^57_NAZF]QI?^!5#_ *U=_P!:
MH?;J?V-Q_M/\)ZH?[2/[&_P#HR':'_9;?Q&_\0]\N_\ W.^-WN3[:ZOT#W\X
MCG^5M\\@.3_LL_9O^\8.6_OWOW7NK%L3_P 6K&?]J^B_]QH_>H?_ #=O^R[>
MT_\ M1]<?^\#M_WVI^Y9_P"(\\H?\]%[_P!IDW6 ?O[_ -//WO\ YI6__5B/
MHJ_Q,_SOR?\ _%N.WO\ W"VC[K/]Y5]0ST;CW[W[KW7O?O?NO=>]^]^Z]U[W
MN!?\)\?^R/\ N#_Q8VM_]]MLKWQ,_O*?^GV<D_\ BKK_ -IUUUG1]V#_ )47
M??\ I:G_ *L1=%&ZK_[+ ^7'_AD?&#_W5]M>[V/?/7K(_HJG\U+_ (O_ /*W
M_P#&LGQI_P#?9]_>_>_=>ZMD]Q,?_P  :3_J'B_Z$'M^Y_W(F_TQ_P /5(_[
M-/L'18_A7_V2)\:/_$']:?\ O)XOW+]L=7Z*%\9?^WM7\U7_ ,0=_+2_]T?R
MU]Q:KZT/_:SI/^A*CV]#_P 2/^:3?X1U1_\ 0_\ 3C_+T9;Y=?\  [XG_P#B
MX?4__O/;^]RO;/5^C89K_BS9;_M65_\ [BR^_>_=>ZKO_D[?]NJOY>?_ (J%
MT3_[P&%]Q(?^!M?_ ,$Q_P#UKJ?;S_V%M]K_ .%>J#^TD^Q?\O0V=6_]E@?+
M7_PQ/C!_[@=O^Y?MGJ_1-OYI&P?F=V?N[X:Q_&#XR;6[KV]\?ODUUW\L=VY[
M<7R#VMU#-6Y'K#&[YVW!U1B\/G=J9Z>2NW11;W%9'F#)]I2?:-%)$S.K!RP_
M_%WQ7_:QH?\ W)B]I;[_ '"O/^:3_P#'3T[!_;P_Z<?X>K<,349"KQ6-JLMC
MUQ&4J<?1U&2Q25D>13&5\U/')68Y,A%'#%7K15#-$)E1%E"Z@H!M[^;;W[_S
M/7NK_P 2UV/_ .]CF??U*>W/_3O>0_\ I367_:-%UR>YF_Y6/F#_ )[I_P#J
MZW1</A1_V2'\:O\ Q"G7?_O,X_V$OL9]$G1G_?O?NO=>]^]^Z]U[W[W[KW7O
M?U;?Y(G_ &Z7^"W_ (B+(_\ OP]Z^^#?WG/^G^^Z'_2P7_JQ#UE9[>_\JOMW
M^E'^#JAW:'_'U_(__P 6Z^1O_O9I[M.]P3T-NBK[W_[><_&7_P 4+^6?_O\
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M>O92_GW_ -D'?-O_ ,5'^1/_ +Z?=7L?^T__ $]3VS_\6#;_ /M+BZ).9/\
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M]_Z6I_ZL1=%&ZK_[+ ^7'_AD?&#_ -U?;7N]CWSUZR/Z*I_-2_XO_P#*W_\
M&LGQI_\ ?9]_>_>_=>ZMD]Q,?_P!I/\ J'B_Z$'M^Y_W(F_TQ_P]4C_LT^P=
M%C^%?_9(GQH_\0?UI_[R>+]R_;'5^BA?&7_M[5_-5_\ $'?RTO\ W1_+7W%J
MOK0_]K.D_P"A*CV]#_Q(_P":3?X1U1_]#_TX_P O1EOEU_P.^)__ (N'U/\
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M3W_O_NI_?Q^/?T-]8<=;!/OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__0^?\
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MDM3;D^7AJ(15=0?'M:<R+YVC[_[!$@BOZ]!_V764!]/T]+<_CW[_ &5#*?\
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M/?O?NO=>]^]^Z]U[W[W[KW7O>X%_PGQ_[(_[@_\ %C:W_P!]MLKWQ,_O*?\
MI]G)/_BKK_VG776='W8/^5%WW_I:G_JQ%T4;JO\ [+ ^7'_AD?&#_P!U?;7N
M]CWSUZR/Z*I_-2_XO_\ *W_\:R?&G_WV??WOWOW7NK9/<3'_ / &D_ZAXO\
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M8_[V?;(X#JZ_"OV=&>S/_%XRO_:RKO\ W*E]]>_=;Z;?;>?^+M'_ -JNI_\
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MGQ@_]P.W_?O?NO=&W]^]^Z]U[W[W[KW7O?O?NO=5??!;_LKO^;Q_XN3U%_\
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MAQ.Y=O5DB*4^YH:JGJ!&S*K@,P*'_P!$?5O_ #P>"_V^3_\ KC[)OZJ<L_\
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M9C$::^;'8V;<51.M.'$3SA&<-H ]WQ?\-U_!G_O&G97_ )^=\_\ V5^^=_\
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M2["Q,3'_ / &D_ZAXO\ H0>W[G_<B;_3'_#U2/\ LT^P=%Q^%?\ V2)\:/\
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MWLI*DKMC;JDJ0RFW9>QA=6'#*?P?S[='_4W_  8_[V?;(X#JZ_"OV=&=S/\
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M^9^6O_B\/R&_]SMO>Y/MKJ_0 _*3_M[-_*<_\11_,F_]XGXU>XM=_P  ZO\
MZAYO^M;>WK?^WA_TP_P]4D_LW^P]',^97_9(_P G?_$!=N?^\)G?<D?0?ZP]
MM'B>K]#O4XR+-;:GPT]3D*.#+8.7&35F(R%5B<K2Q5] U+)4XS*T,L-=C,A
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M\]O[W*]L]7Z-AFO^+-EO^U97_P#N++[][]U[JN_^3M_VZJ_EY_\ BH71/_O
M87W$A_X&U_\ P3'_ /6NI]O/_86WVO\ X5ZH/[23[%_R]#9U;_V6!\M?_#$^
M,'_N!V_[E^V>K]&W]N6'_P"+OBO^UC0_^Y,7M+??[A7G_-)_^.GIV#^WA_TX
M_P /7O?S;>_?^9Z]U?\ B6NQ_P#WL<S[^I3VY_Z=[R'_ -*:R_[1HNN3W,W_
M "L?,'_/=/\ ]76Z+!\*/^R0_C5_XA3KO_WF<?["7V,^B3HS_OWOW7NO>_>_
M=>Z][][]U[KWOZMO\D3_ +=+_!;_ ,1%D?\ WX>]??!O[SG_ $_WW0_Z6"_]
M6(>LK/;W_E5]N_TH_P '5#NT/^/K^1__ (MU\C?_ 'LT]VG>X)Z&W2^$TP3Q
MB601V(T!V"6/U&F^FQO[;,S_ ,6JL_UJ;_W-IO;UO_;Q_G_@/3<OPC[?\AZ+
M?\P/^R5^]/\ PU]N?^_*V+[='_4W_!C_ +V?;(X#JZ_"OV=&>S/_ !>,K_VL
MJ[_W*E]]>_=;Z;?;>?\ B[1_]JNI_P#<VC]O?\1S_IQ_@/39_M%Z!*I_[*FV
M]_XJIV%_[_3J3VX>V>G.AM]^]^Z]U[VWX[_-U7_:TRG_ +FS>W9OB3_2+_@'
M5(^!Z 7X]_\ %F[G_P#%L/DS_P"_'JO;A[:ZOT/7LI?S[_[(.^;?_BH_R)_]
M]/NKV/\ VG_Z>I[9_P#BP;?_ -I<71)S)_R0=W_YY9_^K,G0/?(3_F26^/\
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M8VO3R:?)!MC;L+Z6#+KCPM"C:6%PRW'!'U]^]^Z]T%G4O_'[?)?_ ,3?3_\
MOM-C^_>_=>ZNR_DI_P#;SOHK_P 19\C/_>6VM[][]U[K>K]^]^Z]U[W[W[KW
M7O?O?NO=>]BQT9_S-G9/_:SE_P#=?6>Q3R5_RM.S?\U3_P =;J9_N\?]/HY
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MZ][][]U[KWOWOW7NO>]P+_A/C_V1_P!P?^+&UO\ [[;97OB9_>4_]/LY)_\
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MX5^SHSV9_P"+QE?^UE7?^Y4OOKW[K?3;[;S_ ,7:/_M5U/\ [FT?M[_B.?\
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M^*C_ ")_]]/NKV/_ &G_ .GJ>V?_ (L&W_\ :7%T2<R?\D'=_P#GEG_ZLR=
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M #C'_0?6>/\ P5GL_P#[^W;_ +)$_P"VCIQ_V;[Y=?\ >JOY0?\ H]?@I_\
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MPHQO>OP;84>V-[U&'FPM+E#4?)V P9V,44OW5/&)H8?1HGEU'3F_X>1^$/\
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MOV&EIXGR'?6N.&-'T]2X8C4J@&Q_TBBXO[=F_N]_O)/-(ZVW+NDL3_R49?\
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M^ 9]]_X-D_[+'_[9NK?Z[>S_ /*(W[6_ZU]"7]_\X?\ O5U\A/\ TI;X/?\
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M]^Z]T&>Z?YAWQ"V+OGY9]?;X[<HMGYSX/=>]?]I?)FKW'@=S8S;_ %YLOM#
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M_=>Z+_\ &#M+Y'_+[J#Y-_*[:D>]C\D/Y<7\E#*?!O8T8AGKMQT_\QO+;3[
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MDOO?NO=7%=S="=&_(W9XZ]^0?3?5O>6PURM#G4V7V]L#:O8^U4S>,\HQV83
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/[W[W[KW7O?O?NO=>]__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g790774g80i17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g80i17.jpg
M_]C_X0W#17AI9@  34T *@    @ # $   ,    !!50   $!  ,    ! D8
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#(T.C U.C$P(#$P.C$Q.C Y   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   +5H , !     $   $U          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M!B8@<3'#E8QD)"1T<?ZY3D_5?J5&,UUUSZ2&5UM+G.,MT8QHW.7D7[%ZW/\
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M^&V?X/\ ?_P:WE\JI)*?_]G_[15<4&AO=&]S:&]P(#,N,  X0DE-! 0
M !H< 5H  QLE1QP"   "   < @4 !F<X,&DQ-SA"24T$)0      $"F9MGY6
MKA%>['(_C6VV0) X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              $U   "U0    8 9P X #  :0 Q #<    !
M                      $              M4   $U
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   $U     %)G:'1L;VYG
M   "U0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !-0    !29VAT;&]N9P   M4    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     $X0DE-! P
M#%D    !    H    $0   '@  !_@   ##T &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( $0 H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M$3N;#AL_D^[W)^+(<<^("V:6,& A>U?\U\G'3^HQ7^IY.G/Z&S]W^HB8V!U
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M ]B9_$*__E=J_P#SIF_Z/]D6A/X!^SHZ^DM/^46/_>1_FZ"B'(Y#_AQS*/\
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MVQ?]HL'65'MS_P JO8_9U1!M/_C\OD[_ .+B]_?^Y&U/=K7N!.AUT7CY!?\
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M5WW;_P#PLVP_]E"_YNK_ .M#[F_],3N'_.,]5^0_)[I\?S;,GO$U^^_X _\
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M;DV]5U-*RRBGK*>&<1NI*BX]^]^Z]T(_OWOW7NJ[OYFO_,B.J/\ Q=OX&?\
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M7RT_^!!WE[][]U[HW_\ NJJ_Z@,C_P"X-1[][]U[HMGPT_[)!^+W_B"^OO\
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MO[I/)Y/(_%#Y%4./QV/[5V+65U=6U?4&\*>EI*2DI\])/4U-3/(J1QHI9W8
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M^(1WQ_[@+[][]U[HRR?YJ#_J'I_^M$?OWOW7NN7NGC^?[_VY]^:?_AN]3_\
MO_.J_>1/W3?_ !(;VV_YK77_ &@W70']QO\ E4MU_P!*O_5R/I*YW_C]OC;_
M .+9=&_^Y6X_?RR_?='K%7J]+W[W[KW7O?O?NO=>]__3^?\ ^_=>ZVN^\OY7
MFRNP>T]W=Z= _)CY9?!KMSL:N&;[4RGQ8[,P^'Z[[@W1#AL7MZCWAVCTAV5M
M'L?J3/;TI<)AJ:F.<H<5B\W4QQ(M363A% ][]U[K)T/_ "O.O^M>U=K=]][?
M(KY6?.+NO8-549+K#='RM[1H=Q[)Z=S=?AZG 97<74/2/7^V>O>FMF;IR>'J
MY*=\V^$K<_'%(\<5<D;LA][]U[JSGW[W[KW5-'RK^*?R]PWR1^2G>?P_VQTW
MV"GS;^(.SOBUV30]O]DY[KC_ $)]@=8UW;5-UMWE0IB-@;\_TD;$AVUW7DH\
MUMJ$8O)R56(I/MJHI6SO1^]^Z]TAN^_Y>/R<WK\+]M_R[]@570N1Z"^/GQS^
M$-'T=O?L#+;UBW+VYWI\1.R]A;FRO7W?.QJ' YO;N+Z,[/VMU704L]303Y.N
MH*K(R2FEK8X13^_>_=>Z&+X,?#/MGK??'SN[?W_M79'Q)H?F3G>IZC:GQT^-
M>\*#<F(Z7K.L^M:S8VZ.WTWA'U[LO9T_</<>6R"561:AV\::*BPF+^XFK*HU
M!3WOW7NC1?"/"2[:V+W#M^?/9_=,V'^4?R$I)=R;JJJ*MW)FG._JVH-9F:K'
M8_%4$U6!/XP8::%!$B#3<$GWOW7NCF>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z
M][][]U[KWOWOW7NJV/Y;7_ ;YV?^-)_EE_[MMK>_>_=>ZLG]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]T03^:G_V[8^=/_BK7='_ +P^8]^]^Z]T>[&_\6Z@_P"H
M*E_ZT1^_>_=>ZF^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO
M>_>_=>Z][][]U[KWOWOW7NDAO_?FU^K]D[J[%WM7U&*VALK!Y'<FY,E28C-9
M^JHL/BJ=ZJNJ:?";=Q^6SV5EB@C)6"DIIZB0\(C,0/?O?NO=!S\=/DOTA\M.
MLJ#N7X];Z@[(ZQRN4RF'Q6\*/";FP>-RM;A9EILB<7'NK"X*MR-##4-H6JAB
M>EE8,(Y&TM;WOW7NAU]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=5V_S(O^/%^*__ (T2^!O_ ,$;
MLOW[W[KW5B7OWOW7NO>_>_=>ZK*^4O\ V\<_E7?\'^;_ /[X;!>_>_=>ZLU]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O>S7_PG"JJFFS'S&-/430%]
ML=+:C#*\>K3N#?5M6AA>VH_[?WRB_O1(HI;'V/$L:L!=[IQ /^@VGKUEU]U)
MV6XY[TL1^C:</]/-T4C<.%P^8^:VS5RV)QF46'XM=D>)<C04M<(O)VUU7Y/$
M*F*41^30NJUKZ1?Z#WL__P 5R?\ SL:[_P ZI_\ H_WR6^CM/^4:/_>1_FZS
M"\>;_?K?M/2:^?.SMHTGP3^:U12[5VW3SQ?$CY(/'-#@L7'(CKTYO)E972E#
M A@#[]_%<G_SL:[_ ,ZI_P#H_P!^^CM/^4:/_>1_FZ]X\W^_6_:>A9Z"V;M"
MIZ'Z1FJ-J;:GE;I_K(-+-@L7)(P39.#C0%WI2Q"1J% _   X]Q9JB>I<25$T
ML[A0@>:1I&"@DA0SDD*"?I[>CCCB4K%&%6O "G^#IMF9S5F)/SZ+A\<:"AQW
MS\_F)4^/HJ2@@_NU\+3X:.FAI8KQ];]CT\9\<"1I=((41>.$15'  ]X?=^M=
M=_S-?^9$=4?^+M_ S_X+OI_W[W[KW5B/O1+_ )OW_;R+Y3?^'=MG_P!]SLWW
M]"_W*/\ Q%SVA_YXI_\ M-N>N</OG_T]?G+_ )KQ_P#5B+HJ'Q+_ .+1WU_X
MM?\ (7_WN*CW6S[RFZB;H /EC_V7]_*C_P#$A?+[_P"!.WK[][]U[JRT_0_Z
MQ_WKW]*OKK_F6?5G_B*^M/\ WAL![^5SF?\ Y6OF_P#Z7%]_VES==:=J_P"2
M1LW_ #Q6_P#U93HM7PS_ .R2_C;_ .(3ZW_]Y7&>U?[)>EW0:TWQ"W=!\\JS
MYM2?(O>-1CZOIR/HH="-L+KB/9,.PJ>NDW12(N[X\(.P'S-/V'4SYC[DUQ#I
M+]F4\"K[!KY(?]DW_(O_ ,0'W'_[[O<7L<^UW_3T?;'_ ,6/;/\ M-AZ(.:_
M^54YJ_Z5EU_U8DZ7/S=_[),[Z_\ $?93_K93^_G%>_J$ZY3]&G]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W8#\6/Y67S[^;'7F6[7^+GQRW'VWU]@]UU>Q\KN
M3$;GZ]PU/2;JH<9C,S5XAJ3=>[\!DI)8,9F*:4R)"T-I@ ^JX$3<]>^?M3[:
M[O!L//'.$5ANTL F6-HKAR8F9D#UBAD459&%"P.#BG1UM_+V[;K";BQME>(,
M5J9(TR*$T#NI-*C(%,\>BH]F_,[I+JCL#,=8;@;L?,[RV[AMN9[<5!L7J/LG
M?E)@J'=QS!VVN4R^U=LY3$TU;EHL#521P>8S".+4RJ&6YE/^@?+^<7_WA!OC
M_P!#WIC_ .V5[!G_  6OW=__  IEM_V3WG_;-TO_ *E\Q_\ *"G_ #F@_P"M
MG5<?\PKYQ=+;IZ,Z]I<9AN[HI:'YD?!'+S')] =P8J%J3!_+WIW/UJQ55?L^
MGII:QZ'$RK!3A_/53E(HD>1POOW_ $#Y?SB_^\(-\?\ H>],?_;*]^_X+7[N
M_P#X4RV_[)[S_MFZ]_4OF/\ Y04_YS0?];.CT2?S!NA8I)(S@N_B8W9"1\;>
M[@"48J2 VR%:Q(_(!]_09_E-]-=F?'C^7%\4.C^YMJ5>Q>U>M-D;CP&^=G5]
M7C*^MV]EY^Q=Y9F*AJ:S"UV2Q4\CXS*4\MX*B5 ) "=0(')'W^YCV7F_WCY\
MYFY<OUNMBO;F-X95#*)$%O"A(5U5QW*P[E!QZ=9$\C65S8<O65O=QA90O ,K
M#]JD@_D>JXNJ-S8W>=9\@]VX:/*Q8G/_ "\^0U7019S"9?;692&FS.!QCC);
M>W!18W.X>H-10N1#5T\,WC*L4 8>[#?</]##H&/D%_V5#_+;_P#$M?+3_P"!
M!WE[][]U[HW_ /NJJ_Z@,C_[@U'OWOW7NBV?#3_LD'XO?^(+Z^_]TT7OWOW7
MNLT7Q_S$?RFJOE$>]^Q915=6Q]-'I!]J]:KUO#L*#--NZGH8MQIMT=C-7P[]
MDDS7W+9$R-)(:4_Y*!'[][]U[J'\T_\ LCWY0?\ B$=\?^X"^_>_=>Z,LG^:
M@_ZAZ?\ ZT1^_>_=>ZY>Z>/Y_O\ VY]^:?\ X;O4_P#[_P ZK]Y$_=-_\2&]
MMO\ FM=?]H-UT!_<;_E4MU_TJ_\ 5R/I*YW_ (_;XV_^+9=&_P#N5N/W\LOW
MW1ZQ5ZO2]^]^Z]U[W[W[KW7O?__4^?\ ^_=>ZMT^=>Y^V-O=[9/XPI\'?YEN
M]:7Y)_*???:'1W8O0O\ -%Z^Z,J.U]U[8Z'P\V]<-LZBI>ZMH[WZHZ0VWLW;
M$]<,#F10X6/,(T\=ZJJAB]^]^Z]TDOC/\6>S^P^_:?J?<%-_-:_EV=X[4VKM
M'Y&=5;M[Y_FF9+YC;7["V[U[W+LK&;_VC/TK@>]-[[&W;@<OAJUL1FHLT2E#
M3YJGF-.YEI_)[W[KW6UC[][]U[KWOWOW7NO>_>_=>Z][][]U[HJ'Q+_XM/??
M_BU_R#_][:;W[W[KW1K_ '[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U6Q_+:_X#?.S_QI/\LO_=MM;W[W[KW5D_OWOW7ND?V!MG+;SV3N?:F!
MWUNGK+,Y_#5F,QG8.R(-K5.[=H5E3&4@SNWJ?>^V]X;1FR="_JC7(8NNI2>'
MB8>_>_=>Z)=_*WW;VKV/\#OCIVOW7VWNWNGLSMO86+[*W1N_=V'Z^V_/3UNZ
M84JSM["8?K79>QMOT.VL*$T4B24L];9F,U3,2"OO?NO=6 ^_>_=>Z()_-3_[
M=L?.G_Q5KNC_ -X?,>_>_=>Z/=C?^+=0?]05+_UHC]^]^Z]U-]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U6__ "@B6_EF?# DDD]*8*Y/)_X%Y'W[W[KW5D'OWOW7N@"^37R1Z[^)
M?3NYN]NV*+?U3UWLS[2?=E;UUUWN_L_,[?P\\OCJ]RY+;6Q\5FL[#MC!Q SY
M&N$#045.IEE*H"??O?NO="3USOG']F;$VGV!BL-N[;V,WA@Z#/T&$W[M3-[%
MWGC*7(PB>"EW+L_<E)09[;F6CC8>6DJX8IXCPR@\>_>_=>Z6GOWOW7NO>_>_
M=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[I-;R
MV=M?L/:6Y=A[VPE!N79V\<%E-L[HV]E(C-C<Y@,U1S8_+8FOA#*9:.OHJAXI
M%N-2,1[][]U[JL#^2!U[LWKW^6?\=8=G8*#"C==-O?>&Y94J*ZMJ\[NC(;^W
M)C:S-Y2OR=56UU;7S8[#TL&MY#IAIXT4!$4#WOW7NK9/?O?NO=%+^=7:G</1
M7Q*[W[OZ,?K([_Z;ZZW/VG!0]N8'=>X=F9K!;!Q%9NC<F!GI-E[GVEG:3*YK
M"XR:GH:M*IXJ6JD226">-6C/O?NO=#'TED^P\WU#UMF^V:W9>0[)S6S<#F-Y
M5?76%SFW=CR9O*T$-?4KMC"[EW#NO/T.*A%0(XUJ\A53-I+%AJTK[W[KW0H^
M_>_=>ZKM_F1?\>+\5_\ QHE\#?\ X(W97OWOW7NK$O=_/QI_E ]0=Y?'_J;N
M'.=V]D[?S'8FU?[P9'!XG9VV*[&XRH_BV3QWVU%65F;IZJIA\= K:G16NQ%K
M#WSB]U?OK\[>W_N1SGR1M_(6U7-CMEYX*2R7,Z/(/#C?4RK$RJ:N10$B@ZRI
MY-^[_P O\S<J;#S!<\R7D5Q=P>(R+%&RJ=3+0$N"1VUJ0.B7;&W)\G^UYNQ<
MYM[L+I?9VW]N]Q]K==8'!9'I_=^Z<G'ANNMYY/:%#7Y;/1=Q[<@KLKEABFJ)
MA%0T\,1D"(&"ZB.'_#%O1?\ WD+VS_Z FS__ +(?8 _Y.#^X/_A--F_[*[G_
M *T]"7_@8^6?^FMO_P#G!%_ULZ)1\D]O_(^+^8'_ "Q(,KVGU!69Z9_F_P#P
M3(TG2NZZ/'4'_& \"&.2QLG=M3-E-37T>.HI/$?4WF'H&>E_D3]%5%3! WR&
M[:5994C+#8>SB5#, 2 =P@$B_MN;^\*]PHXI)![9[,2 3_N7<_\ 6GJ\?W8>
M6'=%/-M_0G_?$7_6SJP#,X+Y=8W#Y;(Q]T=$O+C\7D*Z)'^/V\S&\M)1S3Q)
M(%^0"-XWDC :Q!L3;GWK7;JQ$.W]T;DP-//)4P83/YC$05,R+'-40XW(U%%'
M/+&C,B22I"&8 D FP/OJ?L]Z^Y;1M>XR1A)+BVBD*@U +HK$ G) )H">L.+Z
MW6TO;RU1BR12N@)XD*Q )^9IT+72>]LEV7TSU'V/F:6AHLQV!UCL+>V5HL8L
MZ8VDR6Z]JXG.UU+CTJIZFI6AIZJO9(A)))((P-3,;DL'LQZ2]"=[][]U[KWO
MWOW7NO>_>_=>Z][V9/\ A.1_Q=_F)_X;/2__ +T&^??*;^] _P!PO9#_ )Z]
MT_ZLVG67'W5/]R.?/^:-I_Q^;HK60_[+8VC_ .*M=B_^_9ZM][.WODWUE_TV
M?/\ 5G^!_P V%52S-\1_D@JJH)9F/3F\P%4"Y))/ ]^]^Z]T+7Q\!'0G2 /!
M'4'6H(_(/]S,*.??O?NO=%6^/O\ V\!_F)_^&U\+_P#WWO9?OWOW7NHO\S7_
M )D1U1_XNW\#/_@N^G_?O?NO=6(^],O^:/\ %'Y.=E?/OY);UZ]^/_<.]=GY
MS=6WYL+NC:_7FZ,W@,M%3;$VI0U$F.RV/QD]#6)!6TLD3F-VTR(RFQ!'ON?]
MT;WB]I^5?NY>UNP\R^Y&R6&]V]G,)8)[VWBFC+7=PX#QO('4E65A4"H((P>L
M"/>+DKF_=_<OFO<=KY8O[BPDF31)'!(Z-2&-3I95(-""#0\13JLGH+Y8?'CK
MFK^16TMX=G8O%;AQ'RU^0--E<:N)W-D'Q]7)NQ*\4E1/C<'64GW*T=?"[*LC
M:1( >;@$$_V1;YG_ />*O?\ _P"BHWI_]9_>1O\ P0?L5_X6#EO_ +F%K_UM
MZC3_ %N.?_\ IC-S_P"R:7_H'HO'R=^77QTS7SB_E@;CQG9N/J<-MK?GRYGS
M=:,)NJ(4,,WQ5W;31N\,V"CJ)0\]5&H$:,26_P #;B_P8^9R(SM\5?D"0BLQ
MT]3;W=K*"3I1,,SNUAP "3^/>U^\%[%L0H]X.6ZD_P#1QM1_,RT'Y]:/MQS^
M 3_4O<_^R:7_ *!ZL%E^=OQ/CCDD?M_'*D:.[M_=K>QLJJ68V&V238#W] ?8
M,,U+UWUM1U,4E/5T76W7M#64TRF.>EK:+9V$I:REJ(F >*HI:F%HY$(#*ZD'
MD>_FZYCD2;F;FF>)PT,FZWCJPR&5KF5E8'S#*001@@@CKIMMBLFU[2CJ0ZVD
M"D'B"(D!!^8(H1Y'I^^%LL=1\1/C)50MK@K.B>K:VFD ($M-6;-Q%532@, R
MB6"56L0"+V(!X]JKV3]+>C->P:^2'_9-_P B_P#Q ?<?_ON]Q>QS[7?]/1]L
M?_%CVS_M-AZ(.:_^54YJ_P"E9=?]6).BL?-W_LDSOK_Q'V4_ZV4_OYQ7OZA.
MN4_1I_?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_1#_P"$G'_;N3M[_P 6YW=_
M[ZSJ[WR"^_Q_T^+E_P#\5^'_ +2;KK(?VC_Y(D__ #T2_P#'8.J9^W/^RR?D
MY_X9?QC_ /=)VQ[V>/>$74M]$L^=?_,C-E_^+>_!_P#^"CZU]^]^Z]T<RM_X
M&5?_ %$S_P#6U_;=COI7_P#:WR/_ %M'MZ;C%_S37_!TW%P/0'=(_P"9[[_\
M7 ^2O_O68[VX^V>G.@I^07_94/\ +;_\2U\M/_@0=Y>_>_=>Z-__ +JJO^H#
M(_\ N#4>_>_=>Z+9\-/^R0?B]_X@OK[_ -TT7OWOW7NC)>_>_=>Z+/\ -/\
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M+_)BLQ6<P.2HLQA\G2/W1O!%J:#)XZ>IHJR!G0C7&[+<$7N/9MO<,=#WHO\
M\I?^WCG\J[_@_P W_P#WPV"]S,=_P/H_^HF'_H<>V+K_ ''G_P!*?\'3D/\
M:Q_Z8=6+;K_X];<G_:@S'_NNJ?>@/V3_ ,S$W]_X>FZ?_=Y7>_H]Y6_Y5CES
M_G@M_P#JTG7*O>/^2ONO_/3+_P ?;H'OB;_V2Q\:/_%?^FO_ 'W6W/:+]GW1
M;T8#W[W[KW7O?O?NO=>]^]^Z]U[WLR?\)R/^+O\ ,3_PV>E__>@WS[Y3?WH'
M^X7LA_SU[I_U9M.LN/NJ?[D<^?\ -&T_X_-T5K(?]EL;1_\ %6NQ?_?L]6^]
MG;WR;ZR_Z$;O7H+ISY,];Y?J#OKK_ ]H=99^IQE7F]E[FCJ9L'EIL/70Y+'C
M(4]+4TK5<$-93H[1.QBE TNK*2#[W[KW3[U/U1UWT9UQLWJ'J3:F-V-UKU[@
MZ7;6RMGX;[@8G;F!H=0H\5CEJYZF>.CI5<K&I=M"V46  'O?NO=$Z^/O_;P'
M^8G_ .&U\+__ 'WO9?OWOW7NHO\ ,U_YD1U1_P"+M_ S_P""[Z?]^]^Z]U8C
M[X4-34QQSI'43HBU]?94ED51>I<FRJP Y]VN(HF:-FC4MX:<0/X1U2)V"L Q
MIJ;_  ]$0^!A)PWRMN2=/SO^58%S]!_?T&P_PN?<S[RL_P"5JI_ZGR_]'>V/
M @_WRG[!T[K?^,_MZ0/RQ)_V?W^5(+FQ["^7MQ_6WQ/WK]??OO*S_E;J?^I\
MO_1WOW@0?[Y3]@Z]K?\ C/[>K+#]#_K'_>O;90\T=*3R33Q$D_4DH"2?]<^U
M=Q_;S?Z8_P"'IF+^SC^P=%J^&?\ V27\;?\ Q"?6_P#[RN,]RO;/3G1EO8-?
M)#_LF_Y%_P#B ^X__?=[B]CGVN_Z>C[8_P#BQ[9_VFP]$'-?_*J<U?\ 2LNO
M^K$G16/F[_V29WU_XC[*?];*?W\XKW]0G7*?HT_OWOW7NO>_>_=>Z][][]U[
MKWOWOW7NO>_HA_\ "3C_ +=R=O?^+<[N_P#?6=7>^07W^/\ I\7+_P#XK\/_
M &DW760_M'_R1)_^>B7_ ([!U3/VW_V63\G/_#+^,?\ [I.V/>SQ[PBZEOHE
MGSK_ .9&;+_\6]^#W_P4G6OOWOW7NCF5G_ RK_ZB9_\ K:WMNQWTK_\ M;Y'
M_K:/;TW^A?\ --?\'3<7 ] =TC_F>^__ !<#Y*_^]9CO;C[9Z<Z##OZEJ9OD
M_P#RW)(:>>6,=M_+@%XXG= 8OAYO*:4%E4@&.$:C_1>?I[][]U[HW'^ZJK_J
M R'_ +@U'OWOW7NBV?#3_LD'XO?^(+Z^_P#=-%[][]U[HR7OWOW7NBS_ #3_
M .R/?E!_XA'?'_N OOWOW7NC+)_FH/\ J'I_^M$?OWOW7NN7NGC^?[_VY]^:
M?_AN]3_^_P#.J_>1/W3?_$AO;;_FM=?]H-UT!_<;_E4MU_TJ_P#5R/I*YW_C
M]OC;_P"+9=&_^Y6X_?RR_?='K%7J]+W[W[KW7O?O?NO=>]__UOG_ /OW7NMZ
MC>_2_6/8^].HNQ=Z;4I<UO?H;=6>WKU'N0UV6Q^2V7N/=.R-Q=<;CK*&3%U]
M"E;39S9.ZZ_'U5)6+44<T4X9HC)'$Z>]^Z]T1G9WQ"_E]?RS*[M_YF25,_3N
M$H]K9C";@WWVOW)V-NGKCI'K;>W9$.]]P;"ZHV_OS=6=VMTSUYNSM;+0Y&?#
MX"EHJ2?)/"J1A$AB3WOW7NK%=I[NVKOW;.#WIL?<F!WCM#<V-I<SMS=.U\M0
M9[;V>Q-;&):/)X?,XN>JQ^2H*F)@R2PR.C#Z'W[W[KW5+_RO[S^7G9ORH^6W
M1WQJ^0L7QEPGP:^%G7/R/DJHNJ^O^QYN\>YNW\EW/DMJ;8W_ #=@8O/2XSI#
M:VV.C'IJ^FVXN'W!75N=ED7*P+1PQ2>]^Z]T;/'_ ,P?8FW_ .6=UE_,9[:Q
M2[5P>^OC#TYWI)L+'UT4F0R6]^YME;3RVS>H-I55>R1U^X]W[\W?1;=Q!G*)
M+5U<+3-&FME][]U[H"?Y5'RT[P[GV/\ -X_,3M?J;.]@?&WYC;[ZYSE5LG^Z
MFWMA]7[)/4O4'9E+LJ'+4,\1S.VNN,UO?+8.'<>6D-9F#B)JB63^Q'[W[KW1
MP_AEFL/N/:?=>?V]EL9GL%EOE/\ (2KQ6:PM?2Y3$Y.E_OU50?<X_(T,L]'6
M0":%TUQNRZE(O<'W[W[KW1P??O?NO=>]^]^Z]U[W[W[KW597QGPV&I?YE7\S
M;)4N'Q5-DJC:_P (/N<E38VC@R-3]SUMV4U0*FNBA2JJ!,U)$6#N03&O]![]
M[]U[JS7W[W[KW7O?O?NO=5L?RVO^ WSL_P#&D_RR_P#=MM;W[W[KW5D_OWOW
M7NO>_>_=>ZKN_E)_]NT/A)_XKUL'_P!UH]^]^Z]U8C[][]U[H@G\U/\ [=L?
M.G_Q5KNC_P!X?,>_>_=>Z/=C?^+=0?\ 4%2_]:(_?O?NO=3??O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW73*&5E875@5(N1<$6(N+$<>_>_=>
MZJ!_E']3;)ZVB^?$FU*?<:/%_,%^0?7E*VXM^;\WN<=LCKC(XV/9&U\1_??<
MNX?X-A=NIN2M$$%)X4M.0VK2FGWOW7NK?_?O?NO=>]^]^Z]U6]_*!_[=E_"_
M_P 0I@O_ ',R/OWOW7NK(??O?NO=$(_FF?\ ;N'YN_\ BM';7_O)9'W[W[KW
M1XL%_P 63#?]JK'_ /N)#[][]U[IU]^]^Z]U7E_,=_X\/XN_^-#?@;_\$CL;
MW[W[KW5AOOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][MI_DM_\ 99__
M )1[LW_W#QOO#/[]O_3BO^IW8_\ 'GZGG[N?_3Q1_P!*^X_P+T6CO;_F9OQ
M_P#%@]P?_ T_(+WM;^^._6=/1E_?O?NO=5G?R<_^W:GQ5_\ #2W7_P"_+WM[
MH>_GI4M55;/^-"4M-45+#<7:-UIX)9B"<=LM@#XU:S%8V('U(4G\'WT/_N^)
MHH=[]U6EE51]+8<2!^.Z]?M'[1UB]]YQ'DV_DQ8T+'QKG@"?PP^G0R[SW=M/
M9OS5V77;OW1MW:M%6?%OL2FHZO<F;QF#IJNHB[:ZPDE@IILI54L<\T4;JS*A
M)4,"?J/>NG_!,S_SJ,G_ .<%5_UZ]].OK['_ )38O][7_/UB+]+<_P#*._\
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M5]#D8(:NGD9&>GGAF"L=+B_OWOW7NAR3^9U_,:2&F1/FCVTJK24:JJ[8Z0
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M;_V2Q\:/_%?^FO\ WW6W/:+]GW1;T8#W[W[KW7O?O?NO=>]^]^Z]U[WLR?\
M"<C_ (N_S$_\-GI?_P!Z#?/OE-_>@?[A>R'_ #U[I_U9M.LN/NJ?[D<^?\T;
M3_C\W16LA_V6QM'_ ,5:[%_]^SU;[V=O?)OK+_HTOOWOW7NO>_>_=>ZKX^/O
M_;P'^8G_ .&U\+__ 'WO9?OWOW7NHO\ ,U_YD1U1_P"+M_ S_P""[Z?]^]^Z
M]U8C[BTGZ:G_ *CZ_P#]R7]O3<8O^::?\='3<7!_],?\/1#_ (%_\6;Y7?\
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MK_[UF.]N/MGISH:/?O?NO==_[JJO^H#(_P#N#4>_>_=>Z+9\-/\ LD'XO?\
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M[_A1?_V4G\5/_%?^[?\ WYW37OWOW7NM9GOO_F1?<7_B.=S?^X1]^]^Z]T+
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M0U>-W7FZALE4BM\D2&$(T<,I+ J 37^Y1ZS/ZL6]^]^Z]U6]_*!_[=E_"_\
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M07>1F=CRQ)-_<6D_S<G_ %$U?_N3+[>F^)?](O\ QT=4CX-_IC_AZ)3\$O\
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M@/N/_P!]WN+V.?:[_IZ/MC_XL>V?]IL/1!S7_P JIS5_TK+K_JQ)T5CYN_\
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MH[>_\6$[7_\ <C">_>_=>Z>-X_\ '[=)_P#AY;P_]]KN3W[W[KW0DP_YQ?\
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M_P 5Y[I_]]MN7W[W[KW7S=MI_P#'I;2_\-3;7_NCH/?O?NO=(7:?_,YN^?\
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M'T?_ %$P_P#0X]L77^X\_P#I3_@Z<A_M8_\ 3#I@W7_QZVY/^U!F/_==4^]
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MT_\ T)+[$G*'_*S;+_S7'^7J7/8;_I\/M[_TL4_P-T63Y>_\R3D_\2S\<?\
MX(OJKW9I[R/ZZU]&;]^]^Z]U[WP;]<7_  9_^M;>]'XE_P!7ETV_QP_:?^.G
MHK/=W_,^/AC_ .)6[2_^!P[=]\_>^G.C3>_>_=>Z][][]U[HA,G_ &]!I/\
MQ0G(?_!"XSW[W[KW1EN\OC_TK\F-@5?57?\ UIM/MOK?(9/$YC(;)WOC(\SM
MROR."JUKL345V,G/V]9]E5H)%20-&6'*GW[W[KW2NZ\Z]V5U/L?:W6O7&V\9
ML_8>R<-1[=VGM;#1-!BL#@\=&(:'&8^%GD:*DI8@%1;FP%O?O?NO=$R^,O\
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MWE[E>V>K]'?]S,=_P/H_^HF'_H<>V+K_ ''G_P!*?\'3D/\ :Q_Z8=,&Z_\
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MIHO?O?NO=&2]^]^Z]T6?YI_]D>_*#_Q".^/_ ' 7W[W[KW1ED_S4'_4/3_\
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M+BGST(="*2H]^]^Z]T9[XM]-_(K?GR?^:_S+[2Z_SWQ-K^^>J?CI\>NE^O\
M/Y[K#L7M#;.WNAZ?MG<F;[4WK%LK-]A]605FX-^=U5=+A\7%E,C_ +C<*E36
M+&]8*>+WOW7NA]V%\5.X^N:'<-%@/F5V;)_>K>V[>P<Y49'JKH.HFJ-R;TRT
MN8S+4ZQ==T\-+CTJ)--/"%)CC%F=SS[][]U[I<_Z%OD'_P!YD[^_]%#T+_\
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M V1-N>'>$E#_  3_ $!?PXY YZG5_N]/D$/[=K<^_?[,[V5_QRVO_P">,?\
MU5[]_KD\Q_PVW_./_H;KW_!<^Z_^^=H_[)/^NG0A_P"RS?*?_O8_WS_Z([X;
M_P#W/GOW^S.]E?\ '+:__GC'_P!5>_?ZY/,?\-M_SC_Z&Z]_P7/NO_OG:/\
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MVW_LG_Z'Z6O^RS?*?_O8_P!\_P#HCOAO_P#<^>_?\/7?,O\ Y4NDO_19+_\
M7SW[_@#/8S_E(W__ ++O^N77O^"0]Q/]][;_ -D__0_7O]EF^4__ 'L?[Y_]
M$=\-_P#[GSWU_P /7?,O_E1Z2_\ 19+_ /7SW[_@#/8W_E(W_P#[+O\ KEUO
M_@D/<3_?>V_]DW_0_2'V_P#!_OC:^\NP=_X3^8?\@:;=/:,^UZG>M=+T_P#$
M2JILA-LW IMK -18^?H)Z7%B##QJDHA4":0:S8\>^_\ AZ[YE_\ *ETE_P"B
MR7_Z^>_?\ 9[&?\ *1O_ /V7?]<NM?\ !(>XG^^]M_[)_P#H?I<?[+-\I_\
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M#;[5=,]*;_0M\@_^\R=_?^BAZ%_^P'W[W[KW7O\ 0M\@_P#O,G?W_HH>A?\
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MI_\ 9#[]_P FXON\?\I/,G_<Q_ZX]>_X)CW(_P!];9_V3?\ 0_7O]EF^4_\
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M?N%N6WW^VW$>W?3W$+Q/IMZ-ID4HU#KP:$T/25WO\+^_^R-IYW8N]?YA_?\
MEMI[GHFQF?QE/T[\0\5-7XV22.2>D3(X[H*"NHO.(])DB=9%4G20;$4V^\X^
MH&Z&H]+_ "#))_V<??BW).E>H>A]*@FX5=>Q':R_07)/^/OWOW7NNO\ 0M\@
M_P#O,G?W_HH>A?\ [ ??O?NO=>_T+?(/_O,G?W_HH>A?_L!]^]^Z]U[_ $+?
M(/\ [S)W]_Z*'H7_ .P'W[W[KW7O]"WR#_[S)W]_Z*'H7_[ ?=O?P)_G:_,[
M^7'T[N#H[X\T72M1LK<O8&0[*R,G8O7,V[<X-Q9/!X/;U4M/DHMQ8E(L;]AM
MZG*PF)BLFM@WJ(]X^>ZOW:/;CWBYBM.9^;I-R&Y0VBVZ_3W B3PU=Y!53&YU
M:I&J:@$4QCH4;+S=NNPVS6MCH\,N6R9 :L%!^"1!^$<03\Z=%JWE_+N[!WCV
M'NGL]_G-WUM[<V]<3L_#[FCV_P!<?&@8BOAV)!FZ7;M3#0Y[IK/34-9'3[@J
M5G,4RQS%E.A=(]G;_P"@K+^:-_SK/BQ_Z(^I_P#LU]QG_P  A['?[^WS_LL7
M_K1T<?ZY7,?K'_O4_P#UNZ9O^&VNS?\ O8-\DO\ T6?Q,_\ M >_?]!67\T;
M_G6?%C_T1]3_ /9K[]_P"'L=_O[?/^RQ?^M'7O\ 7*YC]8_]ZG_ZW=>_X;:[
M-_[V#?)+_P!%G\3/_M >\47_  JM_FAQ>71B_BP/+/+4/_QA"I_SDS:G(_W^
MOTO]/=F^XE['MIK/OF !_N8OE_S8Z]_KE<QXS'P]9O\ K=_/B?/IBP/\K;>V
MV1N)<-\__DO3KNO>VZNQ,X)>N_BA4_<[LWK615^XJZ$R= _Y-35=5"K) O[<
M0%E]Y?\ H*R_FC?\ZSXL?^B/J?\ [-?=?^ 0]CO]_;Y_V6+_ -:.O?ZY7,?K
M'_O4_P#UNZ??^&VNS?\ O8-\DO\ T6?Q,_\ M >_?]!67\T;_G6?%C_T1]3_
M /9K[]_P"'L=_O[?/^RQ?^M'7O\ 7*YC]8_]ZG_ZW=>_X;:[-LZ_\.#_ "2M
M)'+$_P#QC/XF<QS1M%( ?] '!*.1?\>_?]!67\T;_G6?%C_T1]5_Q.]??O\
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M^Z]U71\N?^&Q/XCVS_LZ/^RT?Q3_ $:?'W_3'_IC_N]][_HK_P!.&Y_]EO\
M[U_Q7]W^['^GK^,?W?U_M_QC[O1_NWW[W[KW0&_(O_ADG_0GWM_LS'^R=?Z"
MO]G4SG^S _W]_N__ '1_V?#^X]/_ '@_OIKX_P!.?]P/']Q?_+?L/KZ;^_>_
M=>Z6_P >?^&?/[H?$#_98?\ 9.O[B_Z4^Q?]DY_T2_W+_NS_ *<O[A9C_29_
M<;^[_P#N._TQ?Z/OOOXC]U_N=^T\NKG5[][]U[HL?R3_ .@=W^[S_P"S-?[(
MI_=?_9B?DAX?[W_P/^#?[,EY=A_[-9_"?L_\D_OG]Y_=_P#OG]IZ/NOM_O?W
MO?O?NO=+/"?\,._[,?\ #W^[_P#LH?\ LSO^B_H?_9)_X9X_](/^B#^"9[_0
M/_H=\'[O]ROX)]_]G]O_ )-IO]QZM'OWOW7NA%^*_P#PR[_L]/?W^RC?[*)_
ML^FK=?\ IO\ ]&'\!_TE>?\ C=-_I-^P^W_W%??_ -Z/#_?'^ ?O?Q71_&/\
MIT^_>_=>Z-C\7/\ 9)?[\?)__95/]$?^E+_3)6?[-U_<K[7_ $G?Z8_#4^+_
M $S???[_ #_B/V?G_A/\1_R3[;R_8?M>3W[W[KW1Q??O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=5S]
ME?\ #87^F>F_TI_[+1_IV_V<KI3[7^\_]W_[]_[/#_H7PG^@GQ^?_+_],G^@
MS^&_P7_E(_@_VVGT^+W[W[KW1-^_O^@>G_9:_CI_LP_^R)_[*[_>SOG_ &6'
M^^']W/\ 1[_>[_2'+_LQ/^C/Q_M???Z2M7]X?M_3_$/\[ZK>_>_=>Z-GU?\
M\-/?=S_Z(?\ 9._%_LC$%O[D_P"C[^['_#>G][=X>?\ A?\ #/\ ?K?[+A_?
MC^-?Q+[7_<3_ !/S?>?O>_>_=>Z(AVO_ - V/]X_C_\ Z8_]D3_O1_HDZ(_V
M7C^]_P!G_%?]#7V<G^R[_P!U/NOWO[I_PK5_=WR^C['_ #/['OWOW7NC7;)_
MX9P_X<,[*_N1_LL/_#D7BWW_ *6/LO#_ *</X=_<G#?W[_OG]QS_  #^X_V?
MF^Z_R+[?_-^K7[][]U[KK^6Q_P ,U?QKY ?\-=?[*K_>+^*4W^G3_9=OX?\
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M] ZWA^*G^S:_\-^_8?[+SU;_ +*7_I<_N;_"/]E?U5?^BG^Y'\9_W&?Z'_\
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B[][]U[H5O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g790774g80w10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g80w10.jpg
M_]C_X0Z017AI9@  34T *@    @ # $   ,    !/EH   $!  ,    !%=0
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,CHS-SHS-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   $6          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MK-TA^)ZO5BYSALR7_:&VO!8T!K3O#-K&55O9[D^"WI#>H4CI8H#!1<UWH;>
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M24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M 0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $6   ##     8 9P X
M #  =P Q #     !                          $              PP
M  $6                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $6     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9$     !_]L
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$'87?\
MTMU/F<+M[L?LO:6SLYN$I_",9F\I%35=4DDH@2=X@'-)2O,=(FF\<1:XU<'W
M8*S5H*]:) XGH6XI8JB**>"6.:":-)89HG62*6*10\<L4B%DDCD1@58$@@W'
MNO6^LGOW7NBJYSYK?&K;6!^2&Y-P=DT>(Q7Q)SM%MOOZ6NQF8AGV'E<IB<-F
M\/%449H#59*#-8S<%'+1RTB3Q5'G 1B00/=;H<="G7=W=846*S60&[</69'
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M5V])4=R]?=>;GZLVKN89*NCBQ^RMX9*DR^?Q;8I)UQU0]974,3B5XVD0+92
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M- '^'/O54_AZ]GUZUG_E%\9_F?7_ #;S=!D]O;[WOVMO7?&*S_6/:6W9):'
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M&I""R7]N2QTHPZTK5KU;*_RZ^.44@BJ>T,502$VTY/%[CQA!_HW\0PU,$/\
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M ?L'LFCZ]P\TD,K[3ZCAD7)M3FG99:2NWWF8?OHY?(]G^UI@A(]+6L?;%5'
M5^WJ]"?/K-F/B_U;-L#>.SL/MV"'(;PVSD-MY#=.0R64GW5409"EEI*F1]V>
M:;/T,L\,SAGI9(F&KTVXMXDM\1QUL=IJ./56OQF^"_2^Z>Y^W<34]>83!0?%
M;MJBZ]VAEL#N[?='G$I<AUGM?=T>7H:J+*)Y*ZCKMSWC-:9CY8F8W4@>[%ZZ
M34X_9UZE >&?EU913[]WYT#4PX;N>MJ=Y]735$-)@>[H*7_<CMU9Y/%38SMO
M&TD96E2/TJN>A'VLI(-0(I&]ZH&J5P?3_-UKA]G1J:2KI:^EIZVAJ:>LHZN&
M.HI:NEFCJ*:I@E4/%-!/$SQ2Q2(059201]/=.M]2/?NO=>]^Z]U&K*@4M)55
M1*@4U-/4$OJT 0Q-(2^@%M(T\V!-O?NO=?/4@[=^:X^6U-_,\&V^[?\ 3/6=
MR)L.;9Y[,P4F-C^.#[X? IC3UAJ"-UV($N<7I^]4?Y;JUV/L0_O?_%#;G:8/
M \'12IKQKXE>.NN?3\N@T>6_\:%P-]N?JQ/XFK2GV>%QIX>GM]:>5<]?0QB<
M21QR*RL)$1PR&Z,&4,&4GDJ0>/\ #V'NA+US]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__3WKNY\U!M
MOI_M7<-5LB;LNFP76^^,Q4]<T\5%//OZGQNV<G63;+B@R0;'S2;HBA-$$G!A
M;SV<%;CW[KW6I+_+[ZAZ8;Y,_&+M_9GQM_E@;#J=P;RPNXL+MNF_FB]K]W]L
M]6#+4-; F+Z_^.N[*6IV1#W'L>AKYJ.FHZ4:<3*LD%') JFWORZ<.H5XT_EU
MN2>_=-]>]^Z]U[W[KW7O?NO=8YF"Q2LRNZK&[,D8)D8!22J $$NPX'(Y]^Z]
MPSUJ:[Q^6_7D7\SK:>Y$^)?SSDP.#Z(['V#6=51[7S)[JSV5E[=Q42=M[3PY
M[27.3=#TOBDBGJDR,%-Y*J&]&;@*+QM5P=A:V$]N)S=+)I\:.NGPF%?B]2!3
MC\NHXDYALEYO6_-K>FT&WO#K%M/I\3QT.GX,]H8ZA44\^KE/EK_+VH^X]Z;8
M^5OQBWG-\8_F[L.AIY-L=L8O'F7;?9N&CB25^K?D9LVGEAI^PMDY>$?;23R'
M^*XVXDIICXQ$P>L+^;;Y) H#V<M!-$?@D4?\==>*2#N4XX$CH:;IM=IO$,!E
MK'N$%6M[A1^K QXT/XHWX20M5'XD:@#T.?Q>^4F2[:6KZO[NV.W1GRGV32#_
M $A]09"O%?C,M! P@_T@]1;D=(8.P.L,XX$M/5P@55"7%/710RA3(LW/:A;0
MP[C8R&7:9317_$C4J8Y1^%U_8P[EQ4 JV/F$WMW<[)ND0M^8K<5>/\,J5H)X
M"?BB;S&6C)T/FA)&>V?BK\BJSORAVQC.W_CM3Q]O3=K[OV]ELQ\9LCF,]LO&
M[?JL%51X:>O7MBC&;FR<.X8TJJA#1+*U-J,7J "^T.R/M=U>2[&6FA:)?[>0
M!R^JI( Q\. ,"O1/N+\X1<P;?MEMS:J6UTD[BMI"S1B+P]*J3\0HY!+9-!Z]
M7)[<QU9B-O8+%9"JIJVOQF'QN/K:RBHSCJ.KJJ.CAIZBII: SU1HJ>>6,LD1
MED\:D+J:UR&&*EF*K12<#C0>E?.G0]C5UC19'U2 "II2I\S08%3F@X=/7NO5
M^BJ;Y^)6TM_[Q??&8[%[DI<U3Y/(Y?;JXC?M104&T*S*T:X^O.VJ)*-HZ*&>
MD0+H?R*MK@ \^[!B!2@Z]T93 8A<!A<5A$KLCDTQ5#34*Y',535V4K131+$*
MG(5C*K5-7-IU.Y U,;^Z]>Z=_?NO=%I[&^+6QNT=U+N[<VZ>T8Z^EKZ++X:B
MPW8&;P^'V[F<?2O1TV6P>,HY$IZ*M6&1KM8AF8DB_NP8@4ZU0<>ATVEMNGV?
MMO$;9I<EFLO3X>E%)%DMQ9.?,YNL02/)Y<CE*HFHK:B[VUOS8 ?CW4FIKUOI
M1>_=>Z)Y\F\AV9FEP&TMD]+;QWI!@]]=;[VGW)CLOL['X:HH=O;AI\OEL=3+
ME]P4.2.4@IZ72BM L4CL/6 "?=TH*FO53Z4Z,SLS<&4W/M^DS.9VEF]CY"I>
MI67;FX9L3496C6&>2*)ZB3"9#*8XBIC02*$F<A6 -C<>ZD4\^K#/2J]ZZ]T2
MSYJ[VP]/U=G-@0T>Y\MN[+MMG*XW$8#9VZL^:NAH=UXJ:MD6NQ&(K,;%)34]
M.\C1R3))H6X4^[H,@^76CT9_8F^=N=@8/^-;7GR-1CH:F7'/)D\%G-O3FJI%
M03!:'<&.QE:T0+"T@C,;?V2?=2*<>MUKTM/>NO=%V^0W7W;?:.U\CL786YMB
M;;VYN?!9'#[FJ]T;?S.:S$4E2\7VU3A3C\QCJ.-8XE8.LR.2Q!!%N;*0#4CK
M1KT('6&/[-QF"EHNT,ILS*Y2GGB@Q51LK%9;$42XJ"EABC6N@R^3R<LE<TR,
MQ:-DCTD +<7]Z-*X&.MCH2?>NO= ]W-L7?W86VY-M;*W]CMB4F7QV>PVYY:[
M::;HER6*S>,?&F.@UY;%#&5=(L\CK)^Z&8BZV'.P0,GK1ZA](]=[_P"L]MT^
MU=X=AX_?F*PN*P^&VRU)M&/;%70T6*I!2N^2ECR^37)557I5BRK"JVL%]^)J
M2>O"OGT-OO76^@D[I["VIU_LC*R[IKJRC7/X[+X/$+183.9R:KRE5BJO[>E$
M&"QN2FA,IX#R*D=R!JN?>P"3CKW0._#+L#;.>Z:V1LFBER\&ZMG;4HEW+ALO
MMG<F!J,5)4UE68HI)<UB,?23S$,"4ADD9006 ][<=QZT#T;WW7K?2%["E["B
MP!_T:XS:V6W!)5PPRTN[LID<1BQCI5D2KF2KQF.R=0:N*ZE$,6E^02/K[]]O
M7N@6^,VS.[NMML4&P>RJ+KI\!@J/,38W-[0S&=JLG793,;FR&;>&KQF3Q%'3
MTE%3T^3>,.LTCLZ V )M9J$U!ZT*]&C]UZWTE-[;IDV9MRNW#%MK<V[GHC !
M@=H45+D<]6>>9(2:.DK:[&T\@A#ZWO,MD!(N>/>P*FE:=>Z*=\4MQ;LQ,F[-
MF;JZ?[1V=4;F[&[+W_09W<&*PB;=BPN>SK9+$4]974.?K:B#*U5-/_F?"P5E
M(+"W-F XAAUH='<]TZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U43_/+I
MZ";^7'VQ-E=L;#W/CL=O/IC)U:]K[K?:W4N 6B[8VC+#NGM:..>GDW;UU@:D
M)+EL$I9LK2:H@I)%O=67CT13^4_N_:&;^5M51;?RW\A_(2?Z+LU,W_#<O6S[
M2^033K44GDDGKUK:J"/89@(-93\N)"MSQ[]UMB*8)ZV8??NJ=>]^Z]UCEABG
MC>&>*.:&12LD4J+)'(I^JNC@JRG^A'OW7NN:JJ*JJH55 554 *J@6"J!8  #
M@>_=>ZI*^;__ &]Z_D[?]0WS*_\ ?3XG_>/?NMCSZNV]^ZUU[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW17/D3\1NK?D]/MN3LZHW2\.TQ5-A*7 9:
M'#)35%=I6LJ6J8J&2OE>HCC160R^*R Z-0O[NDC)6G6B >/0E]+=.;6Z'V#B
M^M=DU&6DVMA)*EL13YBHIJRJHHJJ9ZF: 5<%'22U*M42,Y>;R2EF-V/'O3,6
M))X]; IT+'NO7NB=?-KX_; [QZ=S%;NV&NILYUQCLSNW9V?Q-0*;(XO)4V.D
M::F?6DL-9C,BL*+402*0P4$%2+^[QL4;'GUI@#QZ77Q=Z%V#\?>J<-M;8=-6
M^/-I!NG<&7RM2*S+YW/9>CIYZNNKJA8XD"K<)%$BJD48"@?4G3L7:IZ\!04Z
M,7[KUOI!]H;;V_NSKW>."W1A,7N'"UFW<N:K%9BAI\A0SF&@GEA=Z:JCEB,D
M,J!T:VI' 92" ?>P2"*=>/05_$O:&UMG=!=>46U=OXG;]-785,C7QXNAIZ1J
M_(SS3"?(9"2%%EKJZ8* TLI>0@ 7L![M(27-3UX"G1D/=.O=>]^Z]U[W[KW7
MO?NO=('M#;,>\]A;FVI/M;!;UH]P8V7%5^U]RU]1B\/F*"KM%5TM5D*6CKZB
MC)@)*2)$S(X!%B+C8XC-.O=$L^)OPWIOCAO?/;D@V'M85>>DR])2[L;?F?W'
MF]K[0EDAFQ.S<5CLE@:.GE"RQC[JM,JS3JBZM5K>W'D+@"O50*5ZL1]M=6Z+
M]\K>]XOB_P#&GO3Y%3[7JM[0]*=7[P[*EVC19&'#U>Y(]I8:JR[8:FRE135D
M&/FKQ3>-97BD5";E3]/?NM@5('6JG_*E_P"%!N'^2?SPK>C:?XG[IV;+\YNW
M*W?M)N:K[,Q&5I^M(]K]-X7&MC<GCHMLTLFX9:X[(,@DADI@GW0!4Z#?U>G6
MCHNHG-/]7GUN3U%/3U<$]+500U-+4PR4]335$2305$$R&.:&>&16CEAEC8JR
ML"&!L1;W[IGHIN<V%O3H.#+;CZ4E7(];F*LKMP]0Y*<&#:B.DDU;N;JRLJI%
MCQBT O42X"=UQ]0%*T[TK&S7J&^+CZ_Y^M<.B+]5_P QJFWIVM1;1S7:28/8
MTE51_P $WSE^JTH*3=TU*DC9S#UU+3[EK*W;3UTR^/&2^.4RE3K4$@%UHB%J
M%S]O5=0_BZL6G[YRF>,L'5O4N_M\LLD*)F<K1)L':C1S?[O_ (GNG[?+RQJ.
M?V<=+<<^V=(\V'5J^@ZKR_F'?)_Y5].[+V1U;U;3;,SORK^4.ZZCK/XY]&[&
MIZW*5U6@I$J=]]E=@[[S1I*;;'6G5NVY6J\KDHJ"-DFFIXHBTLJ+[4VPME9I
MKACX2"M/-V_"H_/)/  'Y=([QKEA':VB SR&A8UTQI^*0TI7':HJ"684X'JI
M#:O5V]<'VOL[8NXNON_\A4;>J-NY?=N4VOUW02;XJ*B@S<5)F=Y8#:F8S\RR
M]>U.Z0T-/DZN9C) =;('(0&!MXF#5W.W\0K7\5*_P_#Q_ET@7<9T5-.P7F@/
MHH3&6H/QGOX'CQK\NMP*$DQ1$Z[F-"?( LE](OK5?2K_ -0. ?9)T>=9/?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=?_4W._FEVOTGLCJ#-=8]S]G;<ZK'R3P.]NB]@YO=F;K=I8/);WW
MGLW,8['8.7>=,J4^UZVMCJ6:"HFGIR&0^)_(%!]UL<:^G6N9T/T&OP/S'QX[
M0[]V)_(GV!U9TIE=FP9'N'8..WS5_)"JIJ9XL+19SKNI&4R+Y[M?.SU4:QM3
MTU0:FJD>1A9F(]U<L37)ZVY,=7093'T.3I?)]KD:.EKJ;S1/!-X*N!*B'RPR
M!9(9/'(-2L RG@\^_=-]3/?NO=>]^Z]U[W[KW7O?NO=4@;M)_P"@AKIKU'_M
MUQW%':YXC_V8/KF31_P4R>JW]>?>J"M:9ZMJ;2%U'37J[_WOJO18?E#\6MG_
M "<VECZ&MSNXNM^S-F5W]X>HN[=@U*XSL3JK=\*_Y+FL!D"-%=CIV CR&+JM
M=#DZ4M#,A#!E-=KW63;FEC:,2V,HTRQ-\+C_ )]9>*N,J>'IT']^Y?AWI+>>
M.4P;O;MJ@G4 O&WH0</&W"2-NUQQS0C2D^0O\VC^<EU=V%W)D8MR?'+L/>GQ
M<WIOSJ[8V8H^I:O"56]L/29>#"=DYN;:LTX9JEO[MT<U,(V$)7S&+TGV.+?D
MK<I^5MWW+:-4UA,8Y858:9FC0OK&CS9*TJ,2 %EQU%-W[I<O6ON#RSL7,@6T
MWBV6:WNG1O$M8YIA$(F\45(64J25/="2$?/6]YU7N2MWCUAUSN[)RTLV2W3L
M3:.XLC+0A5HI*_-8#'Y*L>D5&=5IFJ:EB@!("V%_<9#/EU.Y%"17I>^_=:Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZX/'')82(CA2&76JM9A]
M"+@V(]^Z]UY8T5F9416?EV50&8_U8@7;_8^_=>ZY^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK@^<_5'
MSBW97X'=OQ2SOQS[)VC2[;J\%V/\2/E7LR:NZP[*K$R<>2P.[\'O[ TU3N+:
MF[,*[-&8*B*HQ55$D9=%D0%O=;%,=%;^,7QT_F-YCN/8N_.V^LO@)\&>M=FY
MB2NWCM7XG[(3?7</=6*6))*;9>7[,SN#P^-V'LF;(1B2M_AL+9&J4"/6JDD:
MZL2N:$GJ\/WOJG7O?NO=>]^Z]U[W[KW5)7S?'_8WK^3O]>*;YE?^^FQ/O75A
MP)ZNU][ZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW0)]T[&[([!P4^V-E[RP.T\-F\/E\-N5LKM\YNMGAR4(IXIL8YGBBII
M:>-GN'#!B1_3W92 :D5Z]GRZ?NK=O]A[:PDF*[!W1@MTRT@H:3"5.#P;X1:;
M&T5%'2^.MB::83U,KQARRV47L![T2"<#K0KY]"=[UUOH)>X]_8C8NTZH97'[
MCR#[BI,KA,?%MS!5V=G%=48VH$(J8J%&:FAD=@H=[+J-K^]J*GKW0<?%;?%#
MF.N-N;*;";MPFX-G;<Q\6<I=R[;K\(D,]1-.13T]15+X:N:,$%Q&S:01?Z^[
M..XGKPZ-#[IU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JM_\ FL[EPK_"
M_MCHQ)*RO[-^6.W\I\9^D]HX:%:S/;J[*[4QM5@<6*:BLS#!;8I9YLOFJI@(
MJ'$451,[#2+Z/5EX@^0ZUFO@#_PGP[2^.7R3W?WET=\ML5N/OCX+=A4.U-G;
M;W]UI0P]7=H[@SO4>V=P;CQFZJO&31;EV]@ZZGWI48VFJ:,M54_ACJ#=M0.Z
M=.-)4 'AUM;_ !:^9.W._P"NW%U?OG:>6Z*^476T4*]K_'C?%1#_ 'EPL4OH
MI=Y;)RL:Q8_L?JW/D>3'9[&>2GD0A)EAE]!]TT13/ET:?>U+65VS-W46.H:7
M*9"LVQGZ6@QE<9EHLC65&*JX:6AK&IF2H6EJYW6.0QD.$8Z2#;W[K7V\.M:7
MXX_&?M/$?)O:.U&QFW,[O?HO=FPMY]Q[*K\5DTV_A-L[Y@R%?MZ?$5/G:>IJ
ML=3-YHQ.TBW7]T'VI:2JE01JIU4( :D'3Y=7_P#R@^3/5'Q#Z5WEWKW%F),7
MM':% \D5!CJ=J_<>Z<W*CC#[1VCA83]UG-S9ZJ40TM-$"2278K&CNJ<*S,J1
MJ6D8@ #B2< #YD]6JBJ\DD@2%%+,QP%4"I8GT ST1C^7%U;V[VJVXOYC'RSV
MXFW?D?\ )# 0TO4_5^1D7(P?%;XQBHER77G4>*E4")-T[K29=P;NK8522LR5
M6L!/CI8U"B[MQ:RFW+AIDPQ' -YJ/]+\)/F0?+I'8WAOX/JXT*6LG]F#Q9 3
MI=N'QCN H**0.->I\?QV_F*I\B9OD(>X_B<<G/UU#U ^W_\ 1MV5]FNR8=^G
M>8R*5?\ >7[G^\SQGP$'_)-1U:?Q[38Z7ZEI2AIU:PFO0GD*F32NLJ"%+V&H
MJ#R%)^GOW5.N7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO_5W9/EOG?BCM_HG>=9\U*OIZE^/DE,M+O!
M>\DV[/L2K-0)$HZ22DW+'+25F8FD)%'' CUAFMX!Y /?NMBOEU1/\*=Y_P#"
M9JB[\VTWQ?P'QNV=WA6UL,/7.3[%V?V'MMJW+35D:8^+JO)][T4.V4S,U64^
MR&%=*EFL(.;#W[IQA)0:N'6S8#?D<@\@C\^_=-=>]^Z]T03^9C\Q<Q\&_B1O
M7NS9^ST[ [.K]P;'ZKZ=V5,\D5%N'MGM?=.-V1L>FRDD7[JX>DRV66JJPI5W
M@@9%(9@??NM@5-.J<MV_+OY>[B^(.[/C[T[V1\M\O\_^D?D_TWMGY@9!^B=A
M5_=FSNJ.V5SN[I]\]0]98:/-;$CZJRN&I8J/;U3/45<U/3HS5L@FU>_?+SZN
M -532E/RZ.!T!_-+^)_Q]^$W4_:OR#^6O=?<5'NCM7L7IZH['[,^/^ZJ3MJE
M[3V57UTVZ>M>Q.O>HMD9*#:>:V1%3M3-+)30T]0J*ZR.7%_<.M:2QHHZ+%\=
M?F?\>?G'_/AV%V+\;=V9S>&U=E?RW>U=J;EKL]L+?'7L]'G,CWEU]DZ*FI<9
MO_ ;<RF3@EH869IX('A1O26O[UY]>9&4"HQ7K9E][ZIU[W[KW5!W<'\GKXB;
MB^76U)JU.P!MSON3OWLSMC:C;WR4]+N#>3U6WLE%68_)5#OE=NXR&JW14::*
MDD2 *J*H 4@R5L/.N^[7RIN%I;W&HP21K$[=S1H^K4BU_#1: 'X033J"^</:
MWE/F'W#V3<+VTT)=03M/%'V)-+%H*2O3/B5<EC^(JM>&7M_CC\U/Y=DZ9?XE
M;LK._OCGC8R:OX\]AUN4R4^"QL.DK!L[- 9?<VV*B.)5B26F&5HW5+R4=,MW
M 7^DVC=ZOM\BV.Y')BD8F"1CD^'(:F)B<Z7JE3\8Z'_[SYDY:"1;W ^[;$N!
M<PH!>0H, 30+1;A%%!KATR4']F>CR?%S^89T7\F*RFV4:C(=4=V+2/-D.FNQ
MS28K<M0:83??U6S<C%/+@M_X>E-.[/48JHJ&A2WW$<+'2".ZM;JQN&M+ZV>&
MY KI84QZJ>#*?)E)!]>A7M]_M^[V4>Y;1?1W6WL:"2,U /FKCXD<>:. P\QT
MD_D!U16IWWTUC<9W%W;@</W7NW?<>]<+A=^+18R*EQ&UH*_'4> @;%2R82FI
M:R0R 1N6)-B2./8LVG<%_=.Y/)MUJ\EM&FAF2IJ6H2V<DC&>HXYDV:0<Q[%%
M%ONX1P7\TPE1)J+18P5"#2=(!SCJP7;V&CV[@L3@H:[)Y.+$4%-CX\CFJO[_
M "U:E-$L2U.1K?'%]U63!;R2:5U,;V]A&:4S2R2E%4L2:** 5\@/(=25;0"U
MMX;<2.X10-3FK&GFQQ4GS/3S[;Z?Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZJ0_FE;^^2'7.TJ#=VW_EGL3X+?%# XFE'<GR,I^JL
MEW?W;2;NW!N.BPVU\!M/:%9##LK9VSHXFU9#<%<];.L]3%%'2Z0[GW5U /E5
MNJ\NG/FCN#XR[X^)>Z<M_.'V1\Y/CM\N=U5&+I,9W1T*=H;MPFV:'(G:F1WK
MMOMKJ+%G;VSA@]Y545%44.\\9BZ*HG80+61RE;^ZW0' 2E!]O6SY[]TWU[W[
MKW7O?NO=>]^Z]U23\W_^WO?\G;FW^3?,K^O/_&)\3Q_3W[K8\^KMO?NM=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-^7R
MV,P&*R>=S5?2XO#87'UF5RV3K9DIZ+'8W'4\E775U7/(0D--24L+22.2 JJ2
M??NO=4^]-[]P79^X>S?YM/R"&?V]T-UALS=NWOA_MZ?#Y/.5VV>C(?V.Q_D+
M)L[;M!EL]5;Q[PJ:!8L9'%%+60;7IHQ&A7(./=D1I&5$4ER: =:FEC@C9Y'"
MQJ*DG@.@@^!G\S;X>=A_*CY);!VIOC>U9N?Y(_(K%9CJ2DK^F.W<+19V@HND
M]C4%3-D<ME=F4N,VN4K=N5B!<K+1.PB5@")$NIDL+V)&DEMG5!YD8IZCI#'N
MVV3R)%!?Q/*<44U-?0_.F?LZL^^4?Q!V'\FJ';F>;,9SJOO+K6>;*]+_ "%Z
M_P#MJ/LGJ_.."Q6EJ)T-)N?9V4>R97;V26;%9. E9(UD$<T:3HQ#4^SH&NC/
MEUOS:'9&'^*?SBQ6W^N?D%E!40=4=HX!9Z'H[Y7XW&P>2HR_6>0KGD&TNR8*
M9#-E=DY";^(TOKEH6K:(><>Z\1Q(X=!QMKM#8737SD_F,]J]F[HQ6T=@;$Z<
M^.VY-T;BRE2L=)C<5CME9&:>32NJ:HJ)BHC@@B5YJB=TBC5I'53[K="54 9Z
M)3A]J]A_S)/EAL/.]S87,8+8>$Q-)VI2=+Y>EJJ>#H+X^92<MUW2[[@,D,)^
M2WRT>E^ZK8B1/M/8T%12Q$555+H.+$"QMWW5Q^OE(/\ 3<&DI_0& ?XB.@[N
MQ_>5U'R_$:VN)+D_T0:I#_S<(JP_A!ZV,(((:6"&FIHHX*>GBC@@@A18XH88
MD"1111J J1QHH  %@![)R222>/1\    * =9??NM]>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7__6W1?F7UCM+>/3.ZNPLAU=ANTNR^AMI;^[6Z(H,GMC$[QK\%VW@MF9>7:^
M9VQ@,]35V'J]SK61I#2&:"6S2D*+MS[K8].M0GL'^9EV/\C_ (Z0]!=R][_%
M'>\&_.Q=A9#)?**+X;[A?KWK?;^"VCDMV=L].9[K7?6W<KC)-_=;;NPE/CZW
M<-.:<4?W9\:15'C":KTZ%'&G6X/\)>S]X=T_$3XW=K]@;4&R-Z;^Z<V)N3<>
MV%IJVBAQN3R&!HWF:DHLD3D:*@KP!4T\-1>>&"9$D]8;WOIHTJ:<.C1>_=:Z
M+5\M_BIU9\T.C=S]"=O1YV+;.>K<#GL7GMJ9BIV]N_9F]-H9BDW'LO>^TLY2
M'RXS<>U=PX^"KII"'C9H]$B/&S*?=>X=$QV__*LIMI;=[1R^UOF)\I<!\F>Z
M]_;%WMVI\O<;FMB0]Q;SQO6NV*[:&R.NLEC?[EGKU>M\#A*YA'BTQ"Q-4CSL
M3*2WOW5M7RQT:_X??#+J+X6]*TG2W6QW%N:CJ-U;H[#WGO7L7*_WJWSV)V9O
MG(-EMZ;_ -VY>HACBJ,[N'(OK<0Q0P0QJL<:*B@>_=:)J:]5V[EIJ:E_X4+=
M-14M-34L?_#7G<1*TT$5.')^0'7/J<1(GD9?H"UR!P./?NO>0^WJ\;W[K77O
M?NO=4<]K_#>MW3W76[WI?C3WEE-O+D^RY=QST?R^WCA*W<E?N:MQLN$RNSZ6
M'-K+M+"L:6J>>BII*>()-$I0B(#V++6WV8;5=6DN]JLUPT3_ -FQ"E-5037)
M[A2GH>H[W&^YI;F';MRM^5&>ULTN(Z^-&#()= 5E!7 ["34U%1U=5MBC&/VW
MM^@6CJL>M%A,52+05M?)E*RB%-0P0BDJ\G,\DV0J:<)HDG9F:5@6))/L*,H5
MF56JH)SZ_/\ /J08F9XXW=-+E02.-"1D5\Z<*]$T^4'P Z*^3-)/D<I@J;:V
M^XY?O\?O#!TXI:C^+P!7HLA7Q4K4[O70U$,6FN@>'(P*EHIT)]G5KO3K;K8;
MG;K=[8."/\2?.*0=T;?Z4T/F#T%MPY5B:]?>MAO9-MW\C,L5-$O]&XA/Z<Z\
M*ZUU ?"P/6A/\UNO/DSM_P"2/SKVD?G#W=D=W[.W=5;;Z\K)NV]W2P[*S>%P
M\<WD:OFRWWF&BW#1B.D+1D3B"PF:0@DR=RY[>P;OL&Z76W;F?"OD"PJX4E&C
M8L4F9<9/:"*$"C$=01SO[TW?+?.'+FW[[R\HGVF1WNY(6=5E6= BRVB/D:1W
MLI+ M5 :#K>F_EF?)3K+N3XI]!;6QO9]'NCMG:?3.PL?V+MS.Y6I_P!($&>Q
MVW<?29K*9"@SB4N:S-!/D4<KE(4FHZ@FZS,;CW#,J/#/<6TH GB<JP]"#0^F
M/0TR.LH(98[JTM+^V8M97$:R1M2FI6 8<"0#0]PK4'!ZL9]TZOU7;WA_-5^$
M7QS[.W'T]V[VKD=L;_VM_#!E<.FPM]9>(2YC'_Q3'T])D<1M^MQ];43T/KTQ
MRMI^AL>/:R+;=SGC66#;9WB;@RH2#]A'1;/O6Q6LLD%WOEI#<)\2/*JL/,5!
M-<CAT<GI_MK8O>W6>SNWNL\K-F]A[\Q*YO;&6J,=7XF:NQS5$],LTF-RE/29
M"D8S4SC1+&C<7M8^TTL4L$C13Q,DJFA5A0@_,=+8+BWNHH[BTN$EMW%5="&5
MAZ@C!'0D^Z=.]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4P_P W[NCH+%=>
MXOX__)//]P_'G:>]TP79_6/S+V]UA7]E=-=5]T=4;LH]S[1P_8U-B:'<20U#
MU^.IYQ19G%OA<I2321M,DB K[JZUXCCU1SUMUUTG\F^Z,'UCT%_,5[/^86]_
MDI)!M7Y3YKIGX>[=I.L<5LS,;VP?:/=6Z-S;ZR&V]M;,Z9I-TYK!TD.'7%25
ME?1JKI' SOY/>NKDE<%:=;L,<:Q1QQ)<)$B1H"2Q"HH5;L2238?4^]],]<_?
MNO=>]^Z]U[W[KW5)'S@_[>]_R=O^H?YD_P#OIL3_ +QS[]UL>?5V_OW6NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0?9E+V56[+S--U%
MF-GX'L"2. 8'*[]PV6W!M6DD%1$:A\IB,)E<)DZQ#2ZPBQU41#D$FU_?NO"E
M<\.B)?#/N+YB=X[I[%RG:.<^/--U[U3W%VATMFL/L79G8%'NO<E?L5L?3XO=
MN/S&<WED<9B:;)SUI::BDIIF14L'!/OW5B  .->D7\N,OD?F1WGB?Y>.PJ^5
M.L\-1X+LCYU;PQ4M7')A^N7JZ?([*^/M'D:62&&FW1W1/3^7)1ZFEI=N1NY7
M_*%!]UX"@U'JQO=N6P/4?5FX<U0;0R61VSUKL;(Y"AV)L+ PU^5J\)M+"2ST
MNU]G[:IS2T]56R45 M-0T:&-&?1&MA;V[#&99HHE<*68"I- *FE2?(=)[F9;
M>WGG9&940L0!4F@K0#S)\AUJ@_RNOYX^![&^6_R2Q/>'4[==];=Y;TJ.TMG[
MQVWALAN*+HB/;^%QVQ:?:_>M=B<?4IMY,W0;;@*Y-E@IX,OYZ9ULP99$W_E6
M6';=O:VN?$FB305) UU.HE*G)!)P*X^SJ(>5>>;:;=]W%[;>#!-('#4)T8"C
M51<*5458TR?0BFV1LCLSKGLN@&4Z[WYL_?./\4,[U>TMQXC<$4,=0H>$U!Q=
M75&F9P?TR!6!X(N+>X[EMYX#IGA9&^8(_P /4N6]W:W:Z[6YCD3U5@W^ ] '
M\ZNK-@=N_$CY!;:[$VIBMUXNAZD[#W+B(\C1O45>#W1MW:&9RVW=S;?JZ8#)
MX?<>"RM+'44=71O'50S(#&P/U:^WI2"0:@YZ^4;\)NZ>V:/Y7_%'<V\<GWCW
M1*W?_651G^M=R9;?&>7MS)X?,5T&R=HYZCSX;'96%,N8'IOO"R04L<KQ7M[<
M@C$T\432:49@"W\(\S^0Z<N9!;V<]PB%G1"57/<WDOYG^5>OJ]_$CH/(=(["
MSN3WM64^>[K[AW;E>U.[-UQ!G.3WEN!Q]K@*&:5Y9EVWL/ QTV'QL.OQ)!2F
M1%4RN/:S<KI;F<+"*6D8T1C^B//[6/<?M^71)LUC)9VI>Y-;^9O$E/\ 2;\/
MV(**/D/GT:OV7]&W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__U]TKY:=#]N=X;/VS
M_H(^2F]/C#VOL'<\6[=J[QV]A<5O#:6X98:66GGV?VEL#--3T.]-C9<,OGIQ
M44T\+HLL4FI;'W6Q\^JS,+\&_P";!VJ?[@_)/YG?%/KKI>>N^\W,_P 0_C+'
M@.VM\T]3EZ/([AQIW-V4^5P6P%WI#2F+)U=!1UM4ZN0";ZO?NKEDH-(->KU,
M;008K'4&+I=?VV-HJ6@IO(P:3P4<$=/#Y&"J&?QQBY %S^/?NF^IOOW7NO>_
M=>Z][]U[KWOW7NJ0-V_]Q#/3/_C+ON+_ ." ZX]^ZWY#J[_W[K77O?NO=>]^
MZ]U[W[KW7O?NO=4C?+7LW^7>/EOT3F=^YOI.+>G3^_>Q/]+E5D\1%'68&NDV
MC"U$^^%BQ@AS,@J;^%JH5064FQ!O[%FQ[K>66P\TVUO=O' T<98*2!EZ5^T\
M"1DCCCJ.N;>7-NW7G#V^O[O;8IKI9IT1F )HL08*:\0M:J&P"<9Z&'MO^7AT
M7W_C=N=S= 9V/8.XZG'Q;FV!NC:E9DL'C N0C_B&.R.V\WAD@W#M*&IJ)5G(
MB2KI+ **,"_M(-Y@OD2#?[,7"J*+*E$G0?)QAP!^%P:^O1B>6+[9I9;ODS=3
M9.Y+/;2 RV<I.3JB)K$2>+Q$4_A/0+[=^4WS4^&>6Q&R_E+L7,=]=;.ZXVA[
M&PU-CZ+M>C$/B"SB2B9-E]L01T"/42+2S4>XBS 246KCVU-L,LB/<;)<B^M
M*E0--P@_IP\6I_%'5?/I^WYPMH98;'FNQ.T;DQHKNVNRE;_A5SP0GB$FTMFG
M15OF#_/+_ED8OMG9NVLAN'=>1W%T9O#:W</;TT/2.XJUL;L6GP5<*ZEJ:FIQ
M"55;G<9)7Q0U&-($T3@@CT@^U.P7UQ';;]$EQ(%6R<@!B-)U+7%10UXG'2/G
M+9+6:^Y/N);"!FEW6(%BBMK'AN1W4.L4X $_9PZOT^,O>O5WR:Z#ZL[\Z5-:
M>J>U-JTFZ]C'(X&;;%:<%633Q0-4X"HCBFQ<AD@<^)E!'U_/L..[R,7D8LYX
MDFI/VD]#:*&*WC6&"-4B44"J  !\@,#H=?=>K] !V%\K/C7U-NF;9'9W>?5^
MPMW4^/I<M-MS=F\<-@\O'C:T.U'6-1U]5#+X:L1MXC;UV.F_OW6Z'C3H2NON
MQ]A=L;5H-\=:;OP&^=GY5ZJ/&[EVQDJ;+8>MDHJF2DK$IJZD>2"5J:JA:-P#
MZ74@\CW[K5*<>EK[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK7S)^1_77Q7Z%W)VIV7M;*[^
MQ#Y;:^R,#UU@\;C\KF.Q=\;]S]!M?9>R,=2YB2'"I/N#<&1AB,];)%24Z:I9
M75$/OW6P*G'11/B5_,0Z:[(W5T/TW1?'?<OQT[%[]I_D-40=>O0[&DI=G[B^
M->=I\%O_  6ZZ_8U2V*?(RBJ2:DJ(%EIIEN@DU"WO76RIH:GAU;![WU7KWOW
M7NB\?)_>WR)V'U76YGXN=)[>[Z[=ERV(QV(V5NWL7%]7[8I\?6503*[ASFZ,
MG#5.M%AJ0&0T]+#+53M98U)O[]UL4)R:#H!_Y>/SHHOG%\=\CV_N#8K=.[MV
M-VIV/T9VCM.LW%C-Q[9QG9?5&XYMK;J;96^Z%H\/O39U7DH"U!D:<A9E)4@.
MC#WX=>(IPX=$[^:>2QN1_F\_R>6Q^1Q]<(Z?YE"04592U31_\8FQ%C(L$KO&
MK'@$@ G@<^_=>'5X?OW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!CO;K#<'
M;6Q_[L;;[=[%Z5KX<K0Y=MX=856+H]RR4^.\LDN',V7Q^2I?X=D"P$P\>M@H
M 8>_=;!IY=$@_EF[-[CS/56W^^>V_E'W%W5EMY0=C;:J-H[T.VJ?9N+?:O;.
MZ-KXK.8G&X;$4E33Y?\ @VV(HY6:=TD:61M()%O=6<C@%IU:-[]U3KWOW7NJ
M/^K?D=_LL/0'S W?B<#+O+M+>OSZ[JZNZ&ZX@+"K[&[HWE7XJCV9MJZZ7IL-
M33I)D<Q5<+0X:BJJ@W\=C[UZL1D>E.K!?A;\9YOC1U&V,W9G/[[]W=E9VN[1
M^0W9LZK]YV#V]NE8I]QY)6"J:? 8<*F.Q%(MHJ/&TL4:  &_NM$UZ!OY<]K]
MD=G;MKOAK\9WRDG855M:FWEW_OG;N5H\+DNI^H:V9HX=L[8W%D&3#XKNGM](
M):#;XJG1,=2FHR<MD@0D[VVW@MXUW._IX.K3&I%0[^I R43BU.)HHX]!7>KR
MZNYGV+:JFY*:IG4@&.,_A4G EDX)7X15SPZ!WX6_'3>?Q][1[OAIO@;U]U3U
MQW]OK;];7YK ]A];YRHV_L;;G7N&VY3XS>.)AK*VOW+5U>?QE35RI2>6*6?(
M2327<L?:K=+R&\M[0_O=Y)X4."K"K%B:J< 8(&?3I'L>W76WW=\#R^D5K<.N
M1(C:45 H#"I+9!-!Z]&]WS\"OBWO?(U^X(>M:?K_ '?D/MC)O/J;*93K/<<4
ME(RM#,DVTZK'8^652HN9J:75]3<\^RV+>-PB54,^N,?A<!A_.I_GT<7'+>SW
M#-(+3PIS^.,F-O\ C-!^T'H/LE\=OEEUG0Y^LZ1^5&0[*HS$LV*ZL^36VL7O
M#&9&"EIY-6W9.S,(F+W+C:?*@"!IWI*G0KZF#%>7A>[;<:5N]N"'S:(D?GH-
M0:>E1TF;:][LP[[=O1E7B(YU#5IY>(*,*\*T/6K/\ >\/FSW7_._WY@>Y?BE
M@+[>SV#K^U.D*3;N)VSL7XE4NT,;+@MC]M[;W3/BJ<;HS4% K18Z1GC;-+6/
M- @< @2W=CLMGMFY-9W0!,$&EL%I"P)9:>0KQIPIZ=!.RW'F+<-YV9-QMRRK
M<W)*#4J1A"%1OFP6M-5:U]2#UO.^P#U*77O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=?__0W1/G-LSM7?GQ5[GP'37R#HOBYOEMC;DKJ7NS*8>BS&(V;C:'!Y&?
M+UN7%;-3MB,:E '>;)4\B56.5/N(CK0 ^ZV" 02*CK7'^*WR7S_>G:/P\ZBW
MU_/ D[HP^+[)ZNRE'U[U#\ ?D%UAD^[=P;,16PNU\C\D-PTU7@\CU_N')0!\
MED*I$I\Q2H6:10]_?O/CU<TIA,=;=GOW3?7O?NO=>]^Z]U[W[KW7O?NO=4@;
ML_[B&>FC_P""N^XO_@@.N?>NM^0ZN_\ >^M=>]^Z]U[W[KW7O?NO=>]^Z]T1
MOM/XT][=@]FX3L+%_(O$[8@V)N#<.>ZWP(ZCPV4BPG]X\/'A:NCSU=+G:>;<
M4<-/$&C<K ^OZDCCV*+#>MIL[*6SDV4N94596\4C5I-05&GM_GCJ/]XY6YDW
M/=K;<X>:EB6VD=X$^G5M&M=)#'6"X'$?":]'(VS0YC&;>PV.W!EH<[FZ+'4M
M-E<S38Z+$092NBB5*BMAQ<,LT-!'42 L(E=E0&P/L.3-$\TC0QZ(B31:UH/(
M5\Z>O0YM4GBMH([J<2W 4!G TZF\SIJ:5/E7'4G,X7#[BQ=;A-P8K&YS#9*$
MTV0Q.7H:;)8VNIV(9H*RAK(IJ:IA+*#I=6%Q[K%+)#(DL,C)*IJ""00?4$9'
M6[BW@NH9+:Z@22W<496 96'H0:@CY$=:>'\R'^5?VI#\OMX[ZZWZ;Z^S'7WR
MLW!LSIS9\M)N">OR[3UNUY*?)8OL2'-TJ-MC9JUD4S0O1SU8AAC],:65/<X\
MA\S;#+MN\OOUJG[TCB)FE**3<6_#1C\:X!K0L:$MCK%#W?Y$YMMMZY5AY0W&
M4<O27"BUMUD=5L;XU)E[B:1O0D:25054(*Y/Q\3<S\QOY=_5G67Q:R=+U7O_
M !76V!J]L[7Z>[)KLAU#F\C2T\U148C%=#?(^:+-=:]IX^0RE*+%Y_'8'/E@
M8Y&MI<1=N&Q^))=;AL"B?9F=F55):6%"<)*A[JKYL-2T_%U/VS<W".+;]GYR
M8VG-"QJDDCJ$M[J0 ZI+>04CH]!2-M$E:]G5F>S/YB_0=;FZ;9'=L&\_B9V7
M/638U-E?)7!Q[ HLC7TT,,LZ[8[*CK,GU/NNGD:6T!HLX\\XL1""0/8<Z')4
M^6>B'?S5_DM\*,/N+8_4W8L76E;W#A>ROCOW+EI=P8S8U5D:OJ7;>^*3/9/*
M093)51RE9C*?"T-1I5E%,P:VK22?9UMVQR[G&7@W"U20!B4=RK!4%6:FDX S
MQ_+H*[SS;#L%P([O9-QEMV**LL40>,R2'2D8;6#J+8X8]>K9_B_VQTIW?TOM
M;LSX\QX-.I=QRYA]L2;;H<)CL+5?99>LH,G54--MZ:HQ6B;)TTVIHV)9P2WJ
MO[+KNW6UF:%;F.4 #NC.I37."0/SQT=[?>/?VJ7,EC<6SL36.90DBT-.Y06
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MW"8]Q5N)IL]7_P"5PTF6I,I22-*K^6%+*I+/O=CO\LEQS#;NNXR&IN(J:B<
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5)2UE7\WOFI4Y:DJ)*GXL?
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M?K/J7ION;9O8O8_3'76"C[2VEMVJJY\KLF3,9'*28V/-)44=-%$]4OZ0C/\
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M<?0XVJASNW]^T,"F3&[LPF1:.&:GE :$AU *%3[3<R65_8;YNEON$<B3>.Q
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M4A98UHR'_"I_$/LZBWVH]Q^7^:X]\VFS:2'=!?W-R(I  SP32521:'-,!U_
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MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4@;L_[B&>FO_&7G</\
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MH\WM_/8>NC$M)D<5E<?-/1UM).AX='(O<'D$>_=:ZIGW;_W$,],_^,N^XO\
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M*%K+_P 9X_EA7_/_ !B[OK_;?\#O?J?/KW;Z==?W%_X4+V'_ !GC^6%]>?\
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M<7_A0M_S_C^6$?\ #_1=WU_]7>_?GU['IT57YJ]^_P ^#X-?'/>GR6[ [/\
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M-+5UF/AJECDEC"QNX)46L3[S^77C2O#H6_[B_P#"A;_G_'\L(_X?Z+N^>/\
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ME2P"&?(4OJ>0QEO?NKL<*",CHN7RAVI_.$@_F-?RS*/LCMKX)5W>5;%\H?\
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M_=;( ICB*]&P_N+_ ,*%O^?[_P L+\?\TN[Z_P!C_P IWOW6NWKL;$_X4*\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g790774g83a26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g83a26.jpg
M_]C_X0X517AI9@  34T *@    @ # $   ,    !.SP   $!  ,    !%SH
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," Q,#HQ.#HS,@     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,,H , !     $   $R          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M)4<< @   @   #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      ST    &              $R
M   ##     0 4  Q #0 ,     $                          0
M       ##    3(                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3(     4F=H=&QO;F<   ,,    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $R
M %)G:'1L;VYG   ##     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     3A"24T$#      ,JP    $   "@    /P   >   '8@
M   ,CP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
M/P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($
M!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"
M!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'
M!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]+RK:K39
MT]E_HY5M9+")W-[>HWZ/N9^[N5%W1,]P8/VK>W8");R9<;-SM[[&N>W=[/;_
M (.KZ='K4WN^?^=54: 8+]QXF;6[6_0]_P"=_A?T?_7$]U/UE=8?1R,>M@<_
M;N:72TV.?3N;L9_-T^E6]OJ?I/3M_2>ID5Y6*E+T.NP,L4Y.6^VBO$WV.LV[
M6EC@QUH=M]?Z/T_7OO\ ^_I[.NTC&Q\FJMQ9D7,I'K$41N>:B\?:-GJ;=N_9
M7_.+'ZU]N%V/@YF10Q^=0:++BS<&L&ZW)LL]1U5%OT*F?S5'\Y_,K2Q;,,8&
M,_IN._J=9N:#=9.\0]^[(=;E-WV?9W[MB5UTL^.R\^U",99)>J5D8X_.<<?2
M9_XZ9O6B[-R\;TAMQ*JK=^XDGU!8XAP8Q[6;?2^GN1,+JWVK"Q\LU;/M%;+-
MH=(&]H?MWO95NVH@R<K[1D,;A$"MC75W%S0+7$$^E_(V.]GN1*+\I]-;[\8U
M6N:"^H/:_:?W-\L:]*SV'V2_[Y;[F(Z"$P=.]>GTS_0_2FUJ>LT6W9%6R#CV
M"J?4J]TL9=N'Z4?Z38CG/8+ZZ35;-K7N#VLW- 9LW;WU;]N[U/8FHRKK+,AC
M\.RIM;@UKSL(L!'TV^[^RJ]_[-_:&,RW#<;W,M].P5RUHAOJML+?;[]K-B5^
M _)7N83J>*(V[^OY>OM_Y1M7]0QJ*C==ZC:VP"?2L/TB*VZ!F[Z3D3[31.TO
M#3Q#M#_TE1ZC^QJ\.Q^:TU8P+=[@VUA!W-]/:ZD-L_G-GT%:(Q-\&TAT_1]5
MPU_J[TK\/Q5Q8MA,\74>G;]']+^^K'ZE@9-3;:,BM];YVN#AK!+3S_*:BLR*
M++'U5V-?96&FQC2"YH?/IE[1]'?M]BI]/Q\%F)6S%RW75#=MM]46;I<XNU_F
MW;7>WZ*)BX]%6;DV,N]2VQM0LK.R6!H?Z9_1M;9^DW_X7_K:5CL4GV]>&=C]
M'^O_ "BW$DDDEJDD!V=A-=M=D5!VHVE[0="YCN_YKZ[&_P#6T[LS$8TN=?6U
MK3#B7M !#/7UU_T'Z;_BOTB2DR2#9EXE0W6W5L$N$N< )8"^P:G_  ;&N>]2
M9D8]D[+6/AVP[7 P^-WIZ?GZ_124D20W9..QA>^UC6 ;BXN  &ONG^PY/ZM6
M]K-[=[YVMD2=OT]H_DI*?__0[YS[?^=#:X9Z)Q"_=M;O]0/V>GZFWU=GI^_;
MO5GJ.?EXKZVX^$_+W@EQ8=NV"T;3+=OOW_\ 00'6O_YRLJ!&S[&7%L-F?4 :
M\/V^K^\W^<]/^I_AKV9F8^%0<C(=MJ:0"0"=7'8WC^4Y)3ROUA=F9O4.EM90
M['RLJI]-7J-9=6#:*[LCU:26W>E2VG;8]]=']1;E?0G#!Q\2W/RG.Q[6W>LQ
MS:G/VN=;Z-@H8QCL=^[8^K]Q5YQNI?6' S*G/C%Q++6C5HC)]+T]X<W;;[&N
M_FW_ *)_TUNIW%0%;[D]5O#ZC(_W1_<^;_IM$=-L^TY-K\S(=5D,8QM&X-;5
MM#VNLI>T>IOLW_O*>-T]N/CU4"^^P5,#!9987/=M$;['GZ;W*VDAQ'NFFE1T
M^VF[(M^VY#QD6"P5O+'-K :VOTZ=U;ME?MWI68F<<NFZO.>VBMKQ;CNKK=ZC
MG;?2?Z@:QU?HP[Z'\XKJ27$?#[%4TLUG6/LSOL%N.<F6[/7K?LC<WU-WI6;O
MYK?L_EH_ZWN_P9;\P?\ OR,DE>FP33F=,IZA7@55Y6'B4VMW;JJ'GTFRYQ;Z
M<T_G-]S_ /A$3"KL;U',<[!9CM<VG;E,>'>L0'[V&O:QU7V;Z/\ POJ*^DD2
M-?2-?^;Y+>$::?+M_P!%2HU?LK]IVBNH#/V-]5_I.!V;K?3_ $NS9]/UOSE>
M5=C\XYCVOKK&(&@UV!Q+RZ3N#F;=J%GHNX@-P3>@X>A_K?U7F<F_ZI#)RFV8
M=QL+\@9,;@'.C(&2S;ZS=_K,%KV55-_2_:J_\)<KN??T(/>[)KMLL!?[FOG:
M3A.LLL%@NV5>I@M]'WO9ZEWZ3_NPC6Y/UK%UK:L3'=6UU@I<7?2 ]4XS[/TH
M]/?^K,M]C_\ #V?Z.M6,B_KH+ACX];F@N@O@&/L[GUPP7[7N_:&VJS=;1^B_
M]B4E-*RSH3:K'-9;M&5>' 6%OZPVMUUMOZ6UC6^VKUJ;_P# _P!)_0_I+4$/
M^K#\-H=CV"@6EM;2'N+#Z;-S]K7V.I8RK9['_0_T7O6E;?UWTR:\=@>+[&@2
MUP-&TFFW6VO]-OV?H_S_ /@:_P!*R%F9UZNRH.PZWU6/I98YCB2W?Z?VJW9/
M\W4YUK?^FDISB[ZMUX>-ZC+LAK::S0T_3>W]+Z +&&ICGNV?G_\ 7?\ "JUT
MM_U>&74.GU/]1SRT6P^ ?3L<UCG7._.JK?\ H_\ MQ%%G7J0VO&P**Z*VD"L
M.:.>&U!KVM_1>[Z7I>O_ -U_5_07\%_4'AYSJF5'VFMK#N@$>YKK)][F/_.]
M.I)3_]'T!\_\YZY V_8R6NV20?4]S?6CV;OW/Y"U# $G@:R5FNIM/UB9D;'>
MDW%=67%OMDO#Y;9NV_F[=G\Y_86D0""#P4E-%KVOZQ6]C@YCL0EKFF007LAS
M8_>5]9>/B8N+UAK,>IM0^QAA+1[BVMS*Z@]_T[/39[6;UJ)*4DDDDI22222E
M))))*4DDDDI2JLP[6YUF6<JY[+&-8,4[/2;M+W;V 5^IO=O_ -(K22(-?53B
MV_5_,LNML'5<EK;'6%K0X^QMGJPVKW_X%U_Z+>W_  =%?\W2CY'2<JXN+<ZR
MH.+B&,W!LNQSA>_]+ZFQCW?:JV4V4?IO^%_3+3204YEG2LI]3V?;7R^VVT.(
M=HVQCZVX_LMK_1UO?O\ _/7H_P ZH6=(SQ;595U"V&/I]2MY.UU=7I^JWVN^
MG?Z>]SO^$]_Z-:R22G(?T7-<_?\ M*X. (;$@:_3]0>I[M__  ?I>G_VG]#]
M6^SW<'#LQ0_U,BS)-FTEUA),@;7;6[O2K:_Z6RFNIBM))*?_TO556R\+[2ZA
MXNLI=CO]1OID $P6;;&N#MS/<K*22G$;@XS>JU8GVS*-]>&WV[W %C7,J]5S
MV_X1[F?I/:H=4;B]+QV/R>H9C=2\O#][BRO]/:STF;?9Z0]'U:Z_T?Z-;R;1
M)3EY>'1A8]^9D9F7Z%+-[FBQQ@,W.<Y@8/4>YZ%TS&ISL.JZKJ&7;Z;G56V;
MRSU'U%^/:75Z^FQ]S?6;Z7_GI;222G#Q*:LO(S,9F;F!]1]OO@UM.[&]A_2-
MM_6,:^YOK,_X/_!J.0<.CJM.#;GY=;[&PVLN>6O=83Z/ZQ]%GI_9[O9_A/65
MO*9]86W6NPGXKJG:UMO#P0-K=K)I_P"&]7W_ +B)0WK0S9O=0<,QHT.#P0SW
M;9_-=;^]_P"<)31ZE7CX%;6W=0S&/N=-;MY>8#V;ZF5@-]3V/V,]ME__ !MB
M(UF&<-G4SFY8Q7M:8-I@;G!N\_G_ )W^D]+8MA))3A=+;B]1J+:.HYEKZ=CK
M;"YU9(?-C&%EC?W/T=FS_P ^*?3>J].'4'8569;D67DM93:'.V/J#O7_ $SO
MS;/^KJL6VDDI22222E))))*4DDDDI22222G_V0 X0DE-!"$      %4    !
M 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@
M    !P ( 0$  0$ _^$-?6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M%@B"PG.#D[/#TS0U<$-35-0E%X"0HV2$=)2DQ(75)C88_]H # ,! 0(1 Q$
M  "_P #5Q.LY)RB,M/,F8SL!LT@
M           "N$O#JM984@J6W!1&ZF85'7S,I.VH
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MO;L^WT,E[#9]FV^AJYV'G-\NG]6 '5=QKX>Y/D=B.$X?]@
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M\G_IXVRCONGY8Y+H^0=YU;YKJT^5?1EB_&7GKNNUVP
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M#3^R=;YXTX&^ ^?WVMQ.KS_OCWSJ>F-/LU^5UZVV.->MMCB9_F_;H
M                   &L! (U)HU-]T   #^;SO?IY)=BKQMU;??FP[+?D[J
M'=ON']DZP        &@?'^>?>U-]>0]! <'781/<1Y#CRX[SC.GSWOCTJ>Q8
M:K[/$];_ *U\S;=W<?L;X/F:7W3K^I6O-USYQ62.R_3;87<Y&   $7W?^[2@
M] Z2!6L:F%S%Y*XKL^C2M,[JM:Q;.:9+5=5C?]$):W#IZ8;$HD-1'ZG):.?3
MFQ&(SHJ="221!.C";%:G.@Z^0RIF?1S8   /YF^.OI1:4[=^>C76,+9#S[ZZ
ML88N]*Q]9$X&IAZ]Q5<D\5Y?S1PF\@2]!=%GY\]=[PSS>SI]^R\26B_*F3<P
M\+N_KK;L&VOVO::T'^=>E2O8D[3(AC?L'D P=SNR^BLYIX3>    #$.ATZ.'
MC?,\O',^Q_8L!\<:%97J_P N)^^P?0[/>YR   ..O?2'MG9H8\I9&F;Q;CG<
MOJ_7.RZ&C_.W:\Q:L*A8D5W]5CL6WT1$*G-*<GHU]3-DK%PG"B=4"09&Q"/R
MB!Q>6L[NKAA/45L+*;*)TQ3)S%9[)KV$$6::SR]I=219    _GX]5Z=Z<G_(
MO5+Z/_1R0_&G-6^/&^6<F<5N:^OHKH5E[S!D?4[MW%4;_>.%+Q'A#-6W_3>7
M@OSUTB;?!G=.V[/5\' [C3ZAO-*I=Z^Q5*#BKLV[G1>:]L/EO'(Z5ZSWJ'&_
M,:%K'_FC(GSVCW5G]&KW:N,U*[AQ5@CSOWW(?&[CZZ2."UZ1=Y6ZS+#B+M(
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M6^),*29Q3856/Q?7=&Q2=W%<''[1"6M.$:*'<8M:'G1R6#4!-91:QTKO@@
M ?SON\_*"P3V[W%8XPQGT                        ?#3<0NXI^A,PV4?
M!':MQPHK(M20Q$=:)5D?LQ&MMVKI*GYS-2,.IE65B(6]".83VM&?SV)@H6S
MB4M7!:>QHP6G,B,:IVX1N@C)(/! DM,TKE0   '\N3Z)X$O?>1LHRNXE[4
M                                  /!Y     **C6N=-+.*   !0RS5
MAF[#ASOV;-#M                         X>NRBNXCR;)GROJ+NVISH@H
M7Q"G!:)7U<AFMJTQBD$BV1"3A76A.SY$TGB"0]& S\IY=&WQIH<F:L)WV1B,
M^A.#2:E4 =1*F;4L8J;DH '@^<^D%+;+_5K=V..>RWP^[
M         ^*-#2;8X,JT]3^4%F#M/U"D Y#T1SEM_P#SD6O,.B(=6?-$F2NC
MZ^]JE>9>16(^V6MB;-+3K"+YIB=D9KK@G1U/6TVF&G#RGJ:=)SN:<XIW84ZX
M3^J@#35-11>W INJ@ 5PEL>)VK1A9/!EEI0
M  8B3V%&+TY?1\YT9/:D<P8I3D-&/DY51B9/Y-@D=,.*3$>G?9'=3[S*R/)B
M9.64= 3FI  _)1U:UGUI2'H $2R>.3N@C:I%<M:QHJ
M         .*/2?$<J?L]A]9Q9])]APAS9\9UP[>   8:,R@'%G*  \%5AJ63
M5,MH   %<I:QJJ                        ./U*Z"9"X*H_["Q1; \C93
MD&QSS_9=MJ4;VM[$Z&12Q),2=*QCKSVM.K(OM!"16:Z0)GV5K^K8I6WD5U=3
MA1.8$2HJQTI_"=+3:$Y!/?%<1ILRJ ##":J[4LFM/<)    KE+6-50
M                  /Q*O)Z-Q_8'\[]]Y?1N*?[5E*5C71+,=V1@];:Q6,9
M?,RN8$8=3,TK"8OQR)$$:R)UI3&Z6/U8^D_$<R=A,6IW[5PTF9U4 >"D*U;>
M+3V*0   *Y2UC54                                   #69.R"/I
M   /!0E:UOUI;O(  Q$=].P%<I:QJJ
M            /R59%YRU=TD  0L)D9(2EN)++*@
M                     \'\_&-6[-.GM2@ #5M/=C-R*Y2UC54
M                                 >"A\U+>ZFY:   !7*6L:J@
M                                    "+A.+T[3HWP0   *Y2UC54
M                                        ?.1Z)D30   !7*6L:J@
M                                           #$Y%TMO"C*YF5%<I:
MQJJ                                             (E5HAT[8F_R-
M"4Q Q:8":"-=:2A41J+25JB-E:2941GK28*B-U:2)41HK27*C0U.WQW1&IZ>
MRIV+5Z@G3E.^JHC26DM5$;JTD2HC'C4DXG3$:JTE2HUD3;"4
M            '"'Z/N/K(S4R9(  C63)2@ ",],F"  (TTR6(  U1.P)V.0
M!&HM)6J !&*M)TJ !&>F3!                          &J:=-$R[J@",
M9/*';#?E &%$Q=IYPF35 Q01!+\XB;A4#'B835MR59+$ :CIUK3KD;"$JJHQ
M*:SK:ZG'DQBH$9*WV(TC3/6KS8                        !"*MI2M:0:
M8 K'M3FD=D+&2@$-RT"ZW)1-V>=(#XRN:OJDFW6TP,9IJ'KZ(IO>M/-J!&6M
M VOT0WX5LMJ#"::@T:NPTQIZ7H6D!3QC4C_F>KHOMJ9;0
M          /!Y     !X/(    !X/(  /!Y    !X!Y
M                  (:E\X*[)':T<V1[+9/1RIOD@
M                          5ZEO@A!*M\\S/XKKFG3")ETFD^*H
M                                      XT'QGL/A,3IRZC&AFX
M
M              '_V@ ( 0(  04 ^*0^+,*C#N966A2[ ):PH"O!I]67_;K&
M_(LA/'M[(!+J4>%#/YN80Y"74F+=N%AE:Y7;N6_%-I$\5=R_8O8U[X/P"TP-
M+Q4GU27Y:A3!R5E_Z/NXG,;+19%DFSOIN\04K=16N75:OS( >)]A5@F*JQ>
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M96WJ*.L:V*-L<!)7Z.?IX]HY^2JVGBM-E0CR-JU4?570OKRWRHV6%O@*!0T
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MILA0;VI@D2;@?$#4+98D15E9AB8Y?O*JH**:3S"JIM7*;UOW6D<1(E&*=EV
M69?O$0["YB5!;IQLGTXV)6./33Z:?8CY_P#CRA_Z%V;5=^[::M7W<BPP#96"
MHS:558!GFXE\OR_,/B/PJ B XTF5KCDN1D7\O(]D/_R7?\?_  P?\?\ H/\
M_]H " $#  $% /)T/.A\/35P*1$.AX("'PYW_+\QK /YO_MS_BK_ *^JGE?7
M?PSZAZ]0]>K^4:A$ $0X B B(B/*O+B48M>1DHW!PBFL*0KPZ>\G]"8_Y-?(
MSF[?!.J >%;69>42WTZ?XURLN,+?*K=='B0)<X4M=ZS=Q[OP=5S"+\XQNEI(
MH\')/4\:EV#^E;N-S'R4D39!XKZL9%4J\]M\3ZLR\E0"W[34QY49MCB?@89]
M53;M$XBJCSEFACC95*D45'*5>IZ> M%-U4KCRL6OH5:DL*M0959D!P0U\_&)
M2Z/2*K#\ D[G$6DDZ9&BQ11=AFHI7/'@(U1U!<2:FM<N$9U9#&+<_+RU,D31
M+U^3&Q<G,O GC\1$! ?> ?+GSX/U]A5PF+#(X,# @RTZ"K<&]D$A*1':E,T=
M$-98BC<F,K;8L8[KV-)@5$LC34S. ?!@[30'DO)*DIW7,V3M8(#87%9)HM?2
M_=W"60RR=N_RU*$ZY=D>6Y04O:UV5R ;?-C804F6@BLR3M6D%%<Z&W'M)G%R
MU$)ZC.H[C9(-.BTB 4JK<YX4R8H1?^%N_?L\MGAU:!,*)8#G+@[4MJ@%5FU#
M4H[-SE)P0U<'/2MSF)=1P7U1:35"6 L3%?!)B(> GL>O@I>[RA*&X5X*/O9)
M0;?UOS+W6(TU"/L:N-04)<X51_'<N567*^+[(M@R9S*MS/RQ(K94(15TS:E%
M13FY>089A6:FA&9?[$R!_K&AH9GAE[1.N O$A5!R6J;2V/-*5;8'YC:E"<<N
MR0*<KG]ZFDR^?W3C=>ICJWD?9+NKL"CBR91@W2B'^:-EMXRY85LRRV55:C<4
MY86(UJ?!RW-@@YR:9?-A])[##-CN_P"7<,4(N"?E5-5%5%(55IQ+KR^U&78H
MQLGW6(TCRKKOE(4B/.J>=!2'IZ$>NN%>488N0P[29KLNS)YT+"(:P_V6R04Y
M#_%8)F9%=S*4:AS<?R(D_+THKG)V;JIUT/CY63B7"YSW*)^84DI#%U=B94G;
M--R7CX9=2"=V'81\4Q1C$"B]U]T]#]>4==]?+NGOU (>H!$1#KUCQJG76S1*
M62CRNS&E"*.6*S597X.VKS% MK=FZ[%%O#<%$Y&.IG%3A0F/]Z5[_1(7<0N:
MG<EZ6CQ@_P!M'Z[:5_D<=-]:==KKW+"V1F5RP9%V5X+N81(AEDRKQX+SD7P)
M5\A'Z^PBQ0WJ:>S90YK%'Z'>)S :5%ETW\(Q,LIZ2TTR7*;YZW!05V)K^U6\
M-M$!<P5LTR*RT<,4) CBH1N4T5I"R2E&-2$$:^VW;O"02"OHU(97+C7MG>')
M91H<KE<?6;K%S63<2AQ8SLVHJ4P#6GV* HAV[57Y4^F'33DO_C\E@;+/)<.)
M2E.B5>UO!=L5?WL2UGG]_P!I*:L9ZVAR^/'(TC;U/-3+0Z<9PO?'U$?K["),
M<4 XRPW@W3+'1F>KUZJ;241"LS%5C8V/AX_\&ZL<$D[JE:>.:3:!1>.65%A@
M$HVBSU*G&HCNXV(XP,8A,8*6ARL:JM#.G9&HL?G"!\S%Y\-GRT[/[9K_ '!7
M]K@NF=60!XAIY2\92 5OB@[0?[:/WQHE$:JYL?86$"?9"?\ &ND*1JI .?RC
MP [ >N4@ CP0  H *N '8CP.#T(=!3ST@ ] ( '?/3\O2/.OD "/.N 'S&GG
M7 I[X%(=>3Y]>QALD9$E#:235*L696A642'ZG3R*3M1S?S,/&X9JLIP\/&6"
MAQ\NE3$50TG!373_ ')Q/Q51L5T4UJ4AH'+6A_D9A<K"_*P/U.1\!3D(\I41
M#5P#PEJX>KRK"S4\?V#W \F<8X)99P3'!,['LE\DJ5TE,:'*:P\R@*J:?')J
MNT8PQ$755]JB#,2K=>:W<KM7!6BD$;#KVZ2(5HI1'(R+V7?Y4(#6(]A_-P!]
M("'SH ?4'\M78>FW]:!Z'Z4TAV-5-0<$!JYV CT-(4\_^H?,:PZX'S  '@#T
M <Z]0#UW2 CY ^O\W*OK[#8[)(^7,(V"+[1B[5!@>&E90C3G(,;)"2V.96)_
M6PK+=6\>\%/=!@5%=[%_3!Q_6P"DIMXM-%% 9B!)\O-L6+.+8\*K5JKE6%AU
M<426S\LS3J9P;. *8(AY^G"RG@D%' )\J@%T7F5B^AL,Y"L*U-0'Y@>TB)W?
MHY^HL&GAJM"K"PD\N:C#,HS<.YP*J:@\+MRW9MX2S(,_,]R@/7!'V8 (CZ:O
M4/U\?2'HZI >@I"H.N5?RTGD1%2<-0TK((O$P2U%8Q3E_P +DE1;F7<8K+<.
M[Y%265FV G4GEX&=41$E?*DR05<!+D8#^GL"GBA([5)1AXU5_+_+#;H,$^IY
M_14E'/\ ]2'/ZZDHYG&II>,"B_DY17[7KG0\Z'K@ (^/0^3Z<Z\.O8"'7L!I
MX/U\?4'H[ >=@(5#WSUUAQ6K9M\!5)HLRC(Z]T5!4--Y(U9.7BV[UJQYL''M
MY>;4P2#IJ2NNQ/&T1Z6#0=0GQ;CDQWR[T(U<#Y#2'?*A[&U_W .Q$*NJ1$.4
MA\^NPY4/?*_ES_FD.Z*?K\AHZ#NKY4TA\@ZJ$?F B C_ -*:0#NBKOR!USK@
M]>Q4R%1R[?%B5C86B/\ >6'D?@\NC:%*JT*D/<E3J'P&Y_-ZOD @'.^"/?**
M@I'OH?75U2(!P!Z'OH."(#SOGJ^??R >N>K^0![$:>@ >@ >N=_+OY]_(*OF
M B'E]/7!^7L548Y>4>(W/R3(C^%@_F ?K[ X;:FSGI),UI0K]Y&6?8*BZF;;
M-56TPH<!6IWPKH]/!HZX 4#SKL!Z#E%(55<&GH #O@!WP>@X'78A2(=  "'0
M^D>#2(<Z'@AUSH>=#P*1'G0\Z'KTU=#3T'E'YB/U]@;W37+NX=^_D6O>.39'
M)QC]I,ZTG<=KG2#";5IS2ZWA7@B6%O*OG6(@/ [Y3_+P?K;^58= /\O5(#RG
MY"/8ASY^FH1KY7_VY2/0TTB(#]1 1YT/!^@C_*'R$?H(#UY ^M5/50_7R4CS
M_K35]?0/*PZ'WQV/?8\['Q 1#Q 1#P[$>?3@B(\[$/'L0YV \$>Q['G8AX]B
M/AV/F$**>5==^0!Z !X(]CRKX8$/F/U]A5[SKJ"BFI3%5-NXN%%7DXRH++^/
M9NT7[7+@=C5P/ERG^8*A^=K_ +@'8CUU2/*0[$0$?"H>^5AZ>5!T(!3P IJX
M !U5UW\@X'I#@=  @'/2%7!Z *A#KR!URH J$?K["KWH( (7&[**\NW;HM4>
M UTC5Z@Z 0#G?0#T/*!"FH!](_U*A"GK@#USL #E7I$!$! 1['L.4U=#\^A^
MHB \[ >=_+U?R^KK@CWP>A#RCZ*A'Z^PJ^"@$0]MV TC]?+]?&KX8'TB(_7R
M@/7!^O\ )RYUW\+CP?KY0J&G@B(CRKX8^0<'Z^PJ^%Z>NP"K@_7V%7PQV/LJ
MOAT/GST\ .Q$.AY5\.T_7Z<H#JNO_OZ@Y54'/4'/4'!$ #U!SU!P1#T^H.>H
M.=AZ?4'/4' $!#U!SU!P!#GJ#GJ#E(@//4'/4' J#OU!SU!P*@[J$ J]0<"H
M.ZA !]0<]0<J$ 'U!SU!P1  ]0<]0<JZ"GU!SU!SL/3Z@YZ@X/0A[V$>_-W\
MO* ]!Y0'KSU#V/EJ'L?*-0B'E[^7O4 $>" =>0  >==B(=>0 $1&D0$:0#R^
MD.AI#KQ .Q]/RZ\@!V/I#OT_,0 /$/GRJD:1$.N>GY>(T] (=<](>]:!Z'YT
MT>2FD1 !  KZ[\0$  0I[J[]/D'@A4 >(#T/JZ#NH0'KOPH_[#3ZJ_G2(AZ0
M\ ^8UC2-RH0&GND0\>N@^?I !Z'KO_Q131Z@ZYT/.AX("' I[YT(<$.OANGZ
MA]!&K@"'=0@(!]0^= _(/A_L>N"/?_A__]H " $!  $% /(WTUXI.S(C,W*Z
MU,"2-==%NAF-Q^MF0;^2JVV:^(5.=)">,1XELS%&8\;)O-I\-MDD<9*_</X6
M8@?_ .-2;;Q9!]KYD/GH ZT7P@.D41/EK2LJPE7FNB@Q,MUU.N_[@<.: I*2
MEDE&_P"&4UJLUYH^1&1JGUUY4FD9!5LDQ/\ :'5-KJ81_9.ZMM?,S'(D-#>+
MDKFAC7%J/4/6OY]ME_@GR.#GKLK1J(V4.NY<@BZYG72]R<VG'1-.UM8U232<
MI8V$"6KF1$.V#X[YF^0TF4O,J)*S)RYXFB..81L5&5/A+>=<=(3EB;4B?6*?
M^#OMLO\ !+ENXUC,D3TR@ABZB)BQ,)@WB='_ 'T)%N"P0^PF2B2CQIY>2_-[
M,UTQ3.>.# Z%C:-F#",-<F:T3,LNH&QN,^TQ?B2O9YB3?8BWS$,XM4#F0IAP
M84YVNR#!@-6LZ#OJQM>$6BZC:C'EE2%XM?<3&^L,7>CC+/ X#;S]([7]79N7
MWJG8V!$M.S#8-,IE6)UP;.7D<1A;,]VGQPN[)X78=PHV!P?.ZB>449E#4LGJ
M:1OD#"+8>Q$ZROR+1=HAMT]>F#$G&L6[EN];]X308M_Y&MJMDQ]KRW2TUDXR
M^_U:]A]ME_@F2;WLO'-HFBEJW\R+VOK48CDY)Y5*Y*(0@?\ V!M*XS1M/)%S
M59+(KB3(S+P55!].D"9JB=,2_)1):UH)JI*T:NH#VQ>+2SL-<5T6:UHQL-&O
M#7+&[$Y?@ EN8\'#S &Y%*0& .XEZW^R7C@7);8=*R.5]X=AJ6"]-1QDS:O[
M+HK$5*4G7"Y;AL,Q<E41SUV)94X[&^!NE$LH*3:+<93ZJ<L-]<=AK]:$1(CV
ME!<@.V>-1BPP494&1'"66)RRTT^"BA?$.R*^DX+GDVC.=]U[IS%XV)(RIQJ;
M\Q%B746IV$=%1G/R.]XM=78PGT7(>/M*:%E?=55(54LHT&V:#:"AFY!T[T6/
M8?;9?X)V+*TM1T5(MLX91/+-=$U9BOM+5+Z[F&$^<IJ&^=YN[FJ77_<K*BS"
M)2Q0)X@5I%_I/#/\,GT\0)(C]HM699]RJ=LNN%<N#G:L]>#^H\FR( )GF/!I
M2%_ BM) MY_KY.7%JFV]4SH(1XTUSDE<ICK'4NS(K#*?*>A:-J4<IL"C(G,H
MRT7)EXAG10T>Y7QI5,MB?9? 7-ME<V(:G8DCO-,I>6[EN[08Y5S!+W[0,?W&
MV%-VJC%;HOW54 U4XNG$K95M];S3NZQ,#N;T)>31A)%Q3*$K2*;KV8[.B>!S
MLR/G1,[821[FI52+A] N44KTO.[FB%J4 [$8EB][>E!;"5D3-Q7S2&B*#:#5
M_P#%&Y"1*"S@(A%E6;Y'81ATXK:,;H2;V.[L9A?@&-H[8)B5+PU@Q"LZMYFK
M^ V7<LZU(FEM#OQMV;5S,02ESEDB/=50"-+71<FI"&3&M*.[CQ*@'S?2PTNI
M813-)8R^<>;0Z]=H!YKM<QC9M07V0)O3Q+N,\0X+QHDXY<]Z?M:]9M(:G8"I
MV4VKS4O K!F:_")US-<WA_X2N=E1,5'/)W0REM6"I^6:SL!R)!-ZDVV'=P_'
MY:AY6LB<M^93%BD74!M1G0-449VM0KF!QI1QFS.8+RM 9\PE$GS+GUX]6W%'
M,N[\-Y=DTPT5\!W!ZHC_ ),#7+;N#V(@\&(7A27X%&?Y83N6M&QUJ:(F3E<G
M'7EQ(^B*K.I[=(2J!1F4QDXIS&1["3.?EB<S5A.VO%*(YL3?)GFBLS1HT0ZM
MIYB5L?'MNDTTN(CDF76PT?WPJCM'XH8QBLYH6G,^9$9XX9=1A#2)QF%V!<0[
MM4D(;2!MR$UP1%<"AMZ8R+DLIJ9>56+<_3$VBBW:,9X%_-IBH=\RD!JJ<18(
MU];LMLG"N!,QL<4 G?%6BX6S*B>:C+K80BV#0$7MJ2RD*_OO>4LQH^0M32+A
M.^;,MWKADHWLDXX>P-'/%/L4QSM'!!#0[=A\W,Q6O9ATS9T"\N+RG!_@Y0Z\
M6KE>XT6M?#61+7_B:IE-GM.S**)XXC>Q;@!(0ID)3"9D"^FU$XS+J[[*2<PZ
MKB;G(3TS;/9@%L1R!7+>VI@?I]\;E4G5EBA3+BN@;<NDL%-Z:K'8M'[J4Z.1
M.7ZJ=6-7L%7MMB<D)=>.@O:%(B8"4UC[4)ORM;0GFIMF8: <FYNO% K8YK#7
MLKGIB_O?E#L0AK'/*RL;!QHB[,)5REVK[6I.[&(L/A.>8S=P.C-JZ?%V7U)Y
M!)AZEFSC+N]/2)>U]*NGLBV:NEG[C'YD7K^85ZYDQ V/S=FZW$#T"2[HUD:N
M99W11T,(91HV>+-^Y4S=GXCX:YZRVDE[2QM)MC6))!G=;FW<W;"(,B]J&.UK
M[.'N+BVD&6DUMRF*E'(2YMFGZ:\%6DDJO$WCZ9-#E+J)M-)Q&D'L$ >1_N8C
MZN^CI 1"+(\1Z8VJ'VP^%\@I#KEZ6=;&F46W&(++LTVNY38PWSQ%>T> AC>+
M)EQ$/, /N;&A%TC.744B3 .MG6O\EOO!NUV&."],<-O$<G38,=IL$J.6-I.O
MR]S"V30 S^8L\8/9M,^ON #1DWNUS["D+/9@@$!#Q?V2S!Q:1K#R,8J3R(]D
M^[3V'R:O!U#ML6FMJFNBUXF-S*M%]6IY[J\V+J#.&NCWYC<JP#XILZSX4X]A
M4Z!#?+E79UFPHQ\9&I!/(!*<0Z,>UEX+,,T>*T#]M?8A&6Z]=BC)*_<3)'47
M+QSI6Q1^YPD*TN!!"3O];;UKH(F'V.-INDW^2Z8#!4VY;].S5@.TJVB9,'<[
ML\ERK8,P;U /-KIQ'CB;,ECM+RT2L.G_ (-:\F[>UM=HVZ/?(3G1RRZ/*#JC
M[CS'+SQ*:NM4[E-.?3>V>*TMB+LUG;*]F9"'92O4U/*=*X2JMJT6H*7;*ZEM
M@S QM>YA(T[G7$1\?9=)%5I]>)/PW"VVP+H957OM-:D-JY0I2C8G^P8!DR@[
M;-S7+73+I5&N/+*0Q_#_ $JS57\E$A .$"%%V6?J63)HS[;)/M^KL8IJOD4B
MXI155K4AJOFA^MH^Q$B,G&L*20E(<5Y/MZH7.V]*!0:/:U$<$ J#-2B7,N9[
M),R:<V2ZG9!.Y*#6UJ\8E%1^R]6, \BNC6C& OIOZ]">FNQ#!U"6UOICC)Q#
M+O0RSLVK1KC'VT4BM_[&3T++]V<2_(J1V2L&4T2RW=119)D]=.^@VD*]90]K
M,*#F'GX!A;\%.ITZBDVQ^Z_7Q(%Y_P"-IHIH#P&BFH>6[=NU3X30A$EYB8<:
M-<..SK_U4TUTTTA2%---%/*K=%?FV0/TPL8H2&,V8I*HW@6KC!>PP\4?*.:N
M'OR,IM[(WWARL9=2DV,S1T_3)>>3#-?OYZ;^H=ONV"5B/'XN)9TE$9-';9Q'
M=C^%<J)L8GD53913C0RRG\FV2,)[+U@-;^HMXV!?DQ@7!TVI,-7NO<RJM:K8
M)8EP-=+ X7-C$"TN60W9QM3=?.V,89<4XV*PVP O&\CMFI3RFO:[AU@NMF)1
MQ^Y82D6S_P .U\YCJ13]HP$H([RK3*$F5%)S\]I=K>M1]UZ0R 9-3O*W#X-
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MFF@)ADUL:V[QTV'R[,ITQ!DOL%@@B8VSYF1.MUC1RR5M]7<<-D<99'#&?9;
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M'>^YUO"6))$,-K ,S7("%B!W@#D,ABXN+C?MWGT(6TM>O$&H*TK&8E6O"I(
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M"@  R  H/PM+[;H)A]N-'^\#C;[7D_E*!(JF2:6+L8:D5"1:=25&9=CI(J$
M(-<7]AS1M]W;Q*0\$D5XZ :JAX]$$U!1NN&TYZV!-1GZ+F'>$\5Y*?OEL>CY
MOW@>.6)OOP-CT'.]\/SXK1_]@,=3G6OYUG"?NLF+K>+KF2RE"T6-&M&1I)&R
M5 1<$ \225("J210'%SROMMY9-*[/<)ZSVE79CJF5&B- =1[4@@DZW(R4TK)
MMNU2_FW$Z'^5;L/IQUN3XG_,O4_QX4Q6XY'NP/L3VC_[93]&*2\H;PI\$,3_
M .KG;$5W<<M7[*M1HN+"Y>,U!&8C&=*U%&X@8W?:-TV':%Y<MJ>H$VTI_P#M
M.2R%P7D](-8ZH!^KPP:<PVJDG@S:/OTP.RYCL&)[UQ%Y->!V&X0/^;(I\AQ4
M'+"(7"@D"IK05Z30$T'30$^#"\A'VB;>-XO%=K0@7),<$0K<J)# &CUAD[ :
M2<IM)0BN)K>.[CG13E)'JT-D#5=:HW@S49@]&?PM)+:B$O(-'I(HI1F0<EE5
M@&J.(%:9<"<;ON[VEE%O=YML$%O&D,/:&650+N1NRB;0%+QH5=D72TFFC*,1
M;+S%MUW^S+MS').4F4P7 ](KNZHQC,A/9RDC521"2J G%K>6SWR7,,BNC"X>
MH934'.O\'[K"S1*Z@U&H Y]_/ >.VC5QP(4 CHX@>]O+."\>WEEC91(@!9-0
MIJ6N6H=!Z#GC;]SL.9KU;FVD#+U8J$ 496H@)5U)5A7,'OXTN@(\(KCT^U6S
M_G1(?*N").6[ _YB('YPM<5&PPJ?L%T^XRX]!#=1'[%W=KY)J?1C]N[7R]N+
M+:S@VIFD$C".,T"LTDI?3+5RRY@"0@5I7%M<R6[PR2(K%'IJ0D5*M2HJIR-"
M149?"UG+SCRM:;OLT;$F&==80D:>VC%0.U12=.JJFI!I74-TV?DWE:&VVFSY
MEW.]>^C0P3R6\LBKM%C;L'+I;0(DMTX( #F",%@'P9[;=MT5FF$KCUN;3(XT
MU,@K1M04*P/%10^[/-& 75:@'A\N#Z*/YCY\#TR5\8Q(ZR*6"D@5&9 Q7U:/
M53A4\?F_%\F(W>9%8J"1J&1(\>/^)C_2&/Z5?T1B$W-RG;TZW!<_%7+&5S'^
MD//C*93\HQDP]R:$VSDHU*U&>0-1G7IIG3AWJ8D<1%0K4SIGD#7+Q_$^3:>4
M]@F_:5^4A664/!$D<V32F9TT*N@_7)H@/:$T7.+>[&VB;EV4R6TQ$@%>Q<KK
M1=/6$<BD*0>LK-PKD9M&H5 I6G'+"KZL14@?6[Y\6"MM&TK>#)1XV.7S5/@Q
M,"ZZRN2+D"?M,14COT P:0K6G\88&JW2M/XH\V)1';)VA4TR SIEGBG8BM/X
MPQ$'@42!17(<:9YXR0#Y,?\ %?R?W\10,=6D4K3CC.)3\@QG;I^B/-C.V3YA
MC^@'R5'D.+@16C]D&R[Q%!F,ZT\?DIB43"6)@^5#I!%!G05Z:C/O=['5O)?E
MTGRKC*]^=%_%3&4T;>-2/(V,TA/RL/Q'$1E70VC@&)!S.? >3$S!'?J#(&M,
M^-&('S9XSM)A_@U\A..M'(OC1OQ XSEIXPP\HQ_Q*?.!Y<(\)60EJ4##O'/*
MN(X#;@!JYUKP!/>^(=_S;OO)LTFT;U;3;9M\L>Y)*T4MW$\=O<26W9ED1E7T
M25!9ZHO6-<3<E;QR1=;1NL=\\ZO+!<Q2=B50*G:2%8PCD,RH8Q(22U<\@C2N
MP)X$DY]&7?Q&# Y =:]4Y9CC\GT8  H!^Y%E>1@0M,J4XU[V&DCD8DBF=._7
MO>\ZR@XB6VM@7U9TH,J'CPZ<1&XM3V-37,99'/(UX]['4+KXG8?CQU;N8?X0
M/E!QU;T_*JGR4QE+$WC4CR,<7(E5 I7,JS CQ95^8C">D?ZR_E$<",N/3\W?
MRQG8O^DA_P ;&=G+_)/^-C.UF_1\Q.,X91_@-YL=;6/\!_YN#Z5?T1BWDE(,
MC*"2!05\71^!?F.. 4^LL%#VSPT):95_BC*B_6=:NH*@5^#.6N1KO=(SLUIN
M=KN[H\3S%6M)#V5O'V=603'5*RD%#H7+KFLF\7MR\\]Y+VIG+!S(6ZQ?JU)%
M#^2*+2@H!C;=@V-I)MVN;@1Q(JD:LM6IG/5C4 ,6=R%4*23BYYA.Z07EO H>
MX6"1R\:Y O1XT[2-<@[)72M&(TU84VS:+JY/]5%))]Q3C9[/=MBO+#:9KA%E
MFEC[(I&2-;*LNEF;372H4DM3(XFV>SY=CM)NR(BN4>0SHX4Z'D9G*RBM.T5E
M *UTZ" 073EB>9._ 8[@'Q&%Y*X2*XY4W*-V8*-=M,M230"K(!F<:O[4VW]I
M-%?5^S;LM=/Z'UC5377JZ^S[/5^5IZ^)(K?E?<))%8J0EO,]"#0CJH>!RP&_
MLC>QIWY4[$?/,4&+;:]SV3UR_:)>VN&DD64R%07,.A@D:J32,:6J &<N2<;O
MM>U"WN=OAG98G:[LXY&CK5"\3SI(CZ2-2LB]:M!2F.IL0;\VXMF^[,<9<J7+
M?FZ'^ZQQUN2MS/BMY&\BG%'Y+W8?_27'^[PF\\Y;A>6,\S-V5M'&JRHBDKKF
M[854N0=$82N@!RP#@8EVOM6NML>-989PA4-&Q(HXS"R(RLKJ&(J P.EA[T[=
MRYM$]Y>!2Q6-:Z5'Y3'ZJ+7*K$"I K4X.V<Q;3/9WVD,%D4K53P93]5U.8U*
M2*@BM01^#D@8]5A0Y Y=ZAQ7M!Q!^JN1&8I\N?CS]Z:<<#J-ISKUEK\F5,01
M,#J50,R"<O$ ,_ /?QRQFDBL"#QS!J,CEQ[^"QW,5/\ 4P?[K#37%IJYK2B*
M *0OEE.U*:=-.M$,F:A4JA8*6.YBI-?Z&#_=8GN[E]5Q(Q9C0"I)J30  9]
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M>=Q]&/2;'=Q#[%RK?0\!\N/K;I&WB@D_''CT?,-S'^?:@_2D[>3#3-O4=[%
MNOL.SDC9Z'BX<#5&OY80DG(-123BNV[M9VR2KK,$TFAHZG\@D$&-N*:B& RS
M%"?07MA*?L7=O_C2+BL>WA_S)87^[(<5;8;HCP1LWW0<5EVBZ4>&*0>5<06-
MM9R-=R,%5=)J2?'\Y)R S) &+?UW1);RJ*2)4IKH"\9) HRFO$=9:,M0<O>+
M;V=O)+.:T5%+,:"IH%!)H,SEPP5&QWA8<?0R?S<$$9_"713Q_O\ X(=W2<0[
M?M4;-=R5X&@"C-F9OR449L3P [^-LYBAW*>9=LL@CQQJ:RD%\R34+;G61*S
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MQR^>9MN&TWXV90L5IN$MQ%(@N9Z2EUBM2C%BR:#&310=9R YHN+?9=VWNNT
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M<\4;<D0_;U)]\+@LFYV[ "N4B'+CT'%/V;)^SZTUZAJI_'[.G"F=-6JG17+
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MOE6AO:S%YC8(1*8T%[JTK=& 2E1B\JK6=QEJL^D/[)%F!TT)"LWOF-.KCJ"
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M=%%+3G\0FF(#]/<(=/!2L^6&"(',(!Y<QIE6KR@&'Z"G3GY&,.0WYA !\%)
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MJM>K1(Z:T=O7"/W*<G-MVL(@=*.<)E?).!$4JOL?,&CI"'0J-9Y=;R=!,/J
MK:QW2PMQ /\ >*;P(P7-KFU'G /V)9/2,WN*"8A]'F$NV16%=P4/K[U1$?K'
MP!*[[A.D%2(/[-.XX'QTM ]/J*LXB*-3G:P?E'S"B/Y? &8\Q\<M1R]>B-RX
MDJ,P4_V04=T_=H3I^<2H!XGF96/ K8O)BW3MA5;'3MDIS6Q2K!(SN*9KEE+=
M?X5JJN_13[#K=$DU.AA.F =Y;LV@<<@]-UFP2KXW*_+]BIL!2Z!%QM<]2R:#
M8I!G5YB/R5]67!BM:DI#M79'R(E2*B_9G4<$*FKP/J,BDF4"]:SRZIS@.A0
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MP5NE+LYCYF_(1%>$<O&J$:<K$J/4I?LC^L'T^"^EY$X8X$_3L!'6J"H8W7Z
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MC&_[PJ0)A'P(.N.6,EZ_3Z+/:U&#_H&-CV@@/]WCO)A]98F#X@,2_LD*)?\
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M^_IX#OY39LQ^C_ZPI.08!U_VAF(9B!/]/3IX#R.9'')/KT__ 'NKU"-Z=?\
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M=TKCQA?);D,ML&LK0%CG*OGA;QQLLM=I8V8U9B9I^P3L]@+Z-J<41(9;X&$
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M255,NB#9)4Y?ZHDFD;(FB)%TP>-V$L1JW?'BWJ[=1)K(E9.@%J\,R7,54$E
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MO$XQ.[S7:?;>U'W):NFN<$6$KJ7"[;]QX^;E66("NB4]BMID:LH9$!*HLB5
MY1ZBH(>^5E>@H.4=7C>"/$*\[<H]."SM]MF[<1]ZY"Z<_>*]B8JO/O'K"C=4
M1 .AVPEZ   'C@3FVR\%I+BCQZCB<1'TY[N,C(X??VV)P]>T.KR3/98//LFE
MY+D)!N[W)MDJPF^DV,:@P+."M(. 2ZG/PS]T/C<R877F31XS;L68XO$_-7CC
ME;Q>?XM?M5T-M/EJR#^3D*CQD7KI="3<^6#% "*D44\YPR#QQPJV-: VV:O7
M"A1VR6/>DQ<JO>0.C;.7^)6B;9*.9(Z\THYT*UV-R]01?*K.XY@9NQ,<0:E
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M=D@(%VO(TFO4BJ+!$S4>^2;&0="+-5(%4%")^^H*0MSK![A-<(J=,$A7[$\
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M)3M]AUC"ZQO6$W=[.TF"LMO;U"EVBP4BU5U11H_=-X=%S'+2 J)H.@:@1QQ
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MC&%$B*'><SANO[7ND>UG1N)5Y]N'B30TM3PC$N2=LY#8::=WR$6E:9E>HV>
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M[6<!9EW31(/-5Z$2 .\WZP_UIT   .HC\ Z?$1$1'^\1'J/]*/:4"]1$P]
M.IA^DP]/I$?R_P!&  '0 ^  'P  #Z  / &Z!W  @ ] Z@ ].H /T@ ] Z_W
M?C]   #J(_ .GQ$1$1_O$1_HQ'H'40 !'I\1 .H@ C]/0!$?T^ ,( )@ 0 W
M0.H ;IU !^D 'H'7^[^Q#?"-.X8^X9:I"R76H9KE&C9EQ[KUERC>-(NU;:66
M(H&+6N2TZ <W:W)I+JM%F96:"A'S-PF7N!/O'C[#!QU6Q#%-AXWW_9K<RY-Z
M)3\?YA95;*C='%;95>Q<4E9*>L:]8=1C0KQQ.-GR[!J1V0%U4#ID2=$JR?*O
MC>I9E,T':"5Y/<<R/-&QT(Q6:_BN$66SB]_AL,,W4>!.=GRP6J9U06\LIC Y
MY!5+>,:L^#,XZ1EWNV5_3Z3,9*RBH<YTI>1>:-'S;BH-6,2JF8CI51X4C<Y1
M!02B AX9:3A.L9MM.>2+IVQ87O*+S6-#I[Q]'G!*08MK+49.7AEGK!4P$71*
ML*B)Q[3@4?AXY@X9D61LM&K' CB7+<@>36FR=S4KL=":O8:;.7W%^.-:BD*_
M*K2EFM]+KKF<F94R@-(6.4;I^6LZ6\HN)V2%ON)UKDCJW'7/]\L'&*-V2JW/
M0<V8:%5X^PQQ+#78]9A=@K[0\HB0[Y:(:"8ARB*9#& OC3!N6?%QGD)QTVJ^
M<<^3&+$L9[>SH.JT%VD;U57MRD)6SW'/KS6)!A-P<L5@W2<M'HI?:4;JF_LW
M[&/F+%2 _O"<? +W' @&4/!VI!( ZB'4YE5RD+]?<< ^OQ@7F W\_P#_ ,?^
M87>)RI^9Y7\3Z_Y8&$P=PD HK]/JZ"?\H^/\K-+3.&XU,2^M\D=WA]1EY+/J
MH^EM+C6,-M!RPM^DUXU1]=(AK)QC/HRDE'34@MD4@3!,A4_'N(5O-X2@U+ <
MA_S1M3L&W5^PT9_8^,>?<?8FL4 CJ1VK)::>--.<?8+5_D3JS0K#TP.&R(%(
M*8E*)?<)V^C\N.#_ "&A]SN''F1LV<^WW39VE<=\=T*DYK.5B7G(J,D+]H4.
M-IURMDB7DTHQ>"9:1C5%''[0X$)_FG,MNBOH-#=.++OC%*0ZH.9C&=5X<SO\
M/IZ)67[?FD%$J5U['K*("HDR=I&04$B@]H_Y1.Y9WG6?Y_>=3PWD\ZT:UTNJ
MP59M6D+FX0U^0?KWF=B&366MYSRTBHX.:05<=KA8QB]HF$!]^7::VKZW)[3S
M)Q?(:Y*-1[HA[IG'O"&%2VQLR5+^Q6>0]FFFK5X8G7HX3$IA[BB ?V:8*RD5
M&R2L4]3DHM5^Q:O%(V11 Q4G[ [A)0S-ZD!A JJ8E.4!'H/A.7<14:O*HLEX
MU&368M59!*.<G!1RP3>G2,Y(R<'*!CI 8"'$.H@/B';-JW MV]=547KZ"$/'
MI(P2ZH*%56ATDVY21BJI53@8R $$P&'K](^)IF$#"@SLAW:MB:A%L0;3ZD@W
M]*_4FD 0\J4.]:_LUA7!05$_LFZA\/!8"AU"KTF"*LJX+"U& B:W$E<+#W++
MECH9HR9@LJ/Q,;L[C#](^*[RPDJ Q'D#6LHL>%-]%9R,W'/IG';5--++*YQ<
M(EA)-Z[=ZNE962<BR0EV;T8QZ*BK0R KN/-CVA(6-9EA63QA7UXYDV8/*TW?
M,ACW'W:=M4DG$ J9F/8!VIDC 4  /H#Q5L(X^T5CG>6TX996$KC20FII<7]@
CF']AL$S,V&RR4U9K)/ST[)N';V0D7CIXZ<+&.HJ8?_P?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g790774g84m86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774g84m86.jpg
M_]C_X1 I17AI9@  34T *@    @ # $   ,    !.KT   $!  ,    !'2(
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-3HQ," P.3HU-CHR,P     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   ,6H , !     $   &(          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MWVESM"_UG>ZIU%GMW;:/?^B_1*LSH^2',W.I+:]I9!O$$&UT ?:'?Z1OO_\
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MC&S0W\&S=9Z=;G@;B!PJ3^IO&#3E>FREUI:'593S26[F[_3=L9?^G9]%U?\
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M'USK/N$S^>C856+6;/0<QSB1OVD$]]N[_IH\0"""4F-B8^*US:&!@>=SH[F
MV?\ HIP_>[3@:)[RX5.V@DG33S4*  T)A-G5> !&_HF40Z70G=PHL^E*2'__
MV?_M%[A0:&]T;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (
M   X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  0$L     0 !.$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -!    !@             !B    Q8    &
M &< .  T &T .  V     0                         !
M  ,6   !B                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !B     !29VAT;&]N9P   Q8    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   8@     4F=H
M=&QO;F<   ,6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M,&#'91O=K'9HDQJJ_J4M'JO'IEW .A=\6?\ ?TE\86.K;]9GFIM<'"1P55W
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M%5 NNR[*A<2"*0 PM!=$.>QS_?>YO^BKV>DQ[_YQ2P</)R+&TW8VX.M%U^1
MGW2VP;W^[Z7OV+<&/TN='USK/N$S^>C856+6;/0<QSB1OVD$]]N[_IH\0"""
M4F-B8^*US:&!@>=SH[F V?\ HIP_>[3@:)[RX5.V@DG33S4*  T)A-G5> !&
M_HF40Z70G=PHL^E*2'__V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (     0$
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M(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4
M9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" &( Q8# 1$  A$! Q$!_]T ! !C_\0!H@    8" P$
M        !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D
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MD4QC/3K3V\,D9NMPA2!E)(KWBGK]OE\N@$W5\@.O*3<>(DS^)GR^0VSD*R;
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;:[4B.X>XM^C@*I'&HDW/\
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MGU-''&JN[O(PBBCC1=3.SL50(JBY)/ ]U +T* E^J'P85#'CUP*JT)E1T=;
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M^Z]U@F@69;7T$$>H %A;GTWX5K_GZ^]@D<#UZ@/$5Z1F:V1B,QJ%1$8&9?\
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MN0?=+E/EF>]WN"7EJREMVG_4"J&2/3^HE02%4$LII48; /0\_$#>7S1^(_R
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MV!NG*4V:JE&2H,?'5P>=S$Z%W+*]QYSW[=8I8;N6$K(5,A6&)&DT?")'5 [
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MA8Y-5/,RH2L50NE6])LK?3V$>C7HS^V,G)F,!B\C-;SSTP%1:UC40LT$["W
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MOCM-U.Q:EI*>MA=V9UE6?2>;>;5J;R'U.7<$DFY/MR!@P8#UZ0\P0^'<QM0
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M7>QMS;9RTPCJ9II5KLA&\,/\,E:3W5M/;7_5_J_V.K0" 00?H>#^./?NJ]>
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MR?6O1@MJ;0QNT<9+24UIZB81^>L;2TD\B?I 9?T1J/HH/LVC00+&D*U3S/\
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MG6:W$^WV$+!KB&/OS\)]#Y5_R=#&R@$ "W]?S^?\3[T>@BK55B3UCG_4LT!
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MODKKK*!"01<:JA;76X++<<@>TE[_ +C2="GDU0V_6_"H1S_+HN<4XC(!8("
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MV9A>K]\;0VOT'V!M/KS&M/W+E<9W'M:HK\[GLIN)8<!+'E,5+@2M*]I_=58
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MV^$FI_;3H4J?*T4" >6,#_4@V(XX^G^'LUP$%6IT#)K.>1R=!ZS_ -X*9?\
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M+<_Z]Q?V720*6+4J!_A'4H[7>LZM&Q[!P/KT/'7.YI&I?X37'R.H7QM(UW
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M[.X?-9Y4^[:2FEI0TL9<.QB;W7@#TJ.N?G3\7>Q<OW)MY.U-E[+W7T!O7?\
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MEHH]11PWB/'0B@HBJ6"OJ)H"64$D?#?U\._F)COD3U//U;A?CG\MNE=]=8]
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ME _%(@/[*U_ET)74G4.YNV.RMKUL&)%1LW!U0R-75S,IIJVIB16H(H22PD@
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M *PMQ[VI (H.W_4.D3+BA^+IZIB0!;ZW;_8#\6_V'LR_AZ+IQW9'3FC:O\.
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M59*B:&GIX/),XAIJ.BHX$15CBC2"FI**C@5(:>FIX45(XXU2**-0 %4<)?\
M#_JR?4_/IX8  X#HQ^S-O-MW#K!4%&KZN4U=>R$,B3.JJE.C#]24T2JE_P"T
M03^??NO=!3\K=I]N[Z^.'<NSNAI.NH^WMR;%R^)V*.VL#3[FZZJ,M5HD<E#N
MC!UM#E<;6T>0H#-!']W1UU%%421R5%+4P))!)[K8I45X=4G[<_E2=U;@ZO[7
MVIOG9/25)%NKKW^9K2=<[7W1G</O%=D[S^:^.^..X.J:F.3;?5&V=E;1R.P]
MZ];9U<M5[;Q-)#122Q3XU)Q43GW[UZOJ'J?+^72E[5_EW?+/LSL'Y"9>LP'2
M,=1O[I7Y)]';?WG29K ;8PFY<#V-V-\<>RNELIN' ;<ZEC[%RN6VOA.G\A@]
MT9/<V?W#D:C.5*UV,\6/J)*>'W7@RXZ##Y4_R_\ OBBH/E#O>#J38.7QT#_+
M[<&*WIUM_']W=J?)X?,3OWKG?W7VW.W=A83:K[HKMC_$?&[?$F6H7J=S?QC&
M;?QU/BL944[U6+]^ZV'&/RZ,1\;OC9OSLW^7UV#U/M;J:@Z7WWGOFCM#N&?<
M&_,5EMM;$[CJMJ?);I;OK=W>VRNOJOKO8.YMA['W91;9KJ3;VWJ_;6)ECEQ<
M0&JDGAR,WNJDT(-:XZ$CHWX0=X[7Z8_F&]!4S;>Z5ZL[\VYVCLOXTT<^>P78
M/8VPL[V5C^X8MU]A;D[1V5LSKW=FY-B5>8W]B:W;6+W!69S=^!^SKX9LQ)!+
M0PTONO:LJ?.O19.R/Y=OR%[,V-L6GQOQ9^+?6M3+\8NT/A[+U12;YQM;U]\>
MMV[RSG7N1P_SIZIJL'U=B8<ANO'P;(D(QE-18K=*/1X4QY*'36?;>ZV& ]>-
M>A2W!_*MW?N[<_8%?FL5TS2T_9>0_F5'=&YZ#[V/>N1B^27;/5O;7Q<S62RM
M-M:CK,KF.M=X]<09FJ2>H>+#Y&G@^Q\ZBZ^ZT'IZ^70?4O\ *^[]D[-^+F_^
MU4VUV949';^ULY\H).K=_83JA^O_ )+9'Y:U?S'[1[BV!6[CZIW5N#<VR,WO
M>MI,.*7!U>T-Q56(VQC*&HJ)*"=XZ#W6]0H0/]6*=+C;'\LOL_9.T/A(E!M+
MHL]@=4=C_+.O[NW7M&GHL'F,=/\ )>A[$Q6V>\]DYBNVG#D-R[TZK&=QM4:*
M>7'5TQ3135Z?;KY?=>+@ZO0] UTE_*Y[RZTV/U'4Y_J/KW?.[>G=Z]?[:[$Z
MYWWVMLG<?4OR/V[L'XU=B_'';'>&W,)C>AMO[?V3N/:63[&DW)%2[IQ6>W%E
M:-)X*[)25T-#(WNO%P:_ZOGT8[Y'?!OY2[M^"'Q*^(FR:?HW>D6P.B_]!7?D
M>?IL$DLV17XYUG4>V=\]3[Q[$ZW[ .U]M;;WQ/\ ?91:?#4VYJS!,(J&II9U
MDBG]UH,-3&IZ3=;_ "Q^X-W;<JZ_*S]4[-[:W)O=<E6]IXRJR6;W]M;:N3_E
M GX*YBBI=Y_P#';GS 3OV*',-1"O@@J,*GWOE3(VB'NMZP/]7SKTM.A?@?W'
MMCH;^8!L[+];]"=)Y/Y8=';7ZRZ]ZHZRSDV1V!M/<.UOBY+T-D<GN3(8S86U
M:!,9NG=%.E=')28Z>J7$/$M0IJ(VA7W6BPJI]#TFJG^6_P!ZX:O_ +^;"I/C
M?1=R8OL?>VZ]K;UWCA:K<E'!A\K_ "J=J_#7;.WMU)_=-,QN'9J=YX#[_)8#
MSC'56#B@JG66JC6E7W6]0Q7A3_+T%W7'\OSY#]=;ZV5VO/\ &WI;L7;^WOD1
MV3VJGQXW[V9U_P#;8N+OKX__ !PZUR_8N/R&S^BMJ]-83LCIW?O2F:EIZ3$[
M6IJ6JV]NNH-'5)7"HCJO=:U"E*^72\K?Y7._M^5\VQMTX#I_8_5LG:O\TF;=
M.7VB]+)E][[&^>&(K\GUQOC'[:H=EX2DH-[=<9+.08JN@R-5//&^ AJJ.L:G
M:G@A]UO4!PXX_ET$6[_Y5OR,WO2?'_<7<]+M#M/=>]=K]CT'S,Q'3_9F.Z?^
MR[Q[B[KZR[;W+\@.M][;RZDWIEFP^$PW5>,V['#A*?:^ZZ6@Q6,BHJTT_P!R
MD7NO:@*TZV/??NF^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWT^OOW7NH\E7317USQ*5O<%U
MN+?6XOQ;W[JP5C2BG/44Y6C%[.7L;712;_3BQL;_ .%O?NG/IY\5C('45\G(
MP;QHBK?@OKN5/UO:VEA<>]T/D*MZ>I\AT^+)PP#-W=4P_,G*9+<.\MPJLKP)
M00M03TE."J5$,D=U6H &J>*4J+JP(+#W +VEON_-NX<P/*5OK/M:,$Z?S7@?
MS''K&+WBO+N;ZK;U%(&!! \Z^1Q4@^G5/F7^'W:GRNR.:V'L]J?;U%E)Z"*O
MWGEZ:6JIJ):2OIZBH3&8J(I59;(>")U105B1[:V"W'M)?[W907Z[784W#>P:
MZ4_P"E37RP.L8.4O:SFKG/>+E[2T^FVX/3QI!1>%"%_$YXX&/F.MH/XF= X_
MXW=*[/ZJHLA69>/;&#H\:V6RB4T>2KC '9JJKBHU%+#-+,[$1Q#1&ME%[7]R
M?R9L<VW0R3R(0[5J2,DG)!/$@$T )/#KH5R#RI!R/RMM6QP3/(L0TU;BV223
MY9)./(4'26^9OPLZ=^>'5>(Z8[TS';=!UY0;VQF],UA>I.UMV]33[[AQV+S&
M(J-B;_RFSZVAR6X.O,S3YMY:S&F2,M54]/-')'+"K <]#B2,O3-/]7RITM_C
M?\3_ (T?#_8\?7'Q?Z+ZTZ+V< AJL7U[MBAP]7FID,A2MW1G]$NXMUY0"0@U
M62JZJH(X+V 'NP KZ_9UI8E7RJ1Z_P"K_9Z,)[V21CR^?5Z>?7C[\O:"W7CG
M'7#AC;58@ZK*;&QN 6'U]T/$TX=6!I0]8PP4?5RQXTL1<7X_K;_>??NO5QPZ
MFP@^*Y_U;#\_X?2_T'O1Z:?#8ZSJ0/ZW)_V']!;W[JG7,_0V/UXYO_K?Z]_?
MNO=<T/I_UC8_Z_O8Z:?CPZY^]]4Z][]U[KWOW7NO>_=;ZY(VF_U/^\_[W[]U
M1Q6F>I'O7377"2X4$'ZG\'GZ'Z^]CJZ<>L-S_4_[<^_=.4'IUU[]U[KWOW7N
MLD1O-Q]+?\0P _U[>Z>?SZTX[:]3O=NF>O_0W^/?NO=5<]C48QW96]Z:,VA&
M?JI$C%@J"I83@  "PTR?\C]QSN>E=QNU4 #7_AZS%Y,N/J>4M@D8UD^G )^S
M'^3I,HVE@;FW^!/^P/U_'MJ T+D\.A!(NH4 &KIYICZ.23];W_'/]/\ 7'MT
MFC@CUZ+9<$'IQ@G E2]]%P7+$:0A^A/] 3[,F">%J=J 4/VYR/G]G225"58+
M3Q*&GV^70[;0VX-Z;"WKMC'YF7:^8W%CJO!Q;FBHHJZ;&I6((II*>BE:*-T>
MD9H[ZDLK$@BWN67N;>T@VBX@@!M- JBX!;U('F.-:=8:<QV]Y<;WNJ;VS?O
M2$+J))$?H*Y"\,#'1&_DQ\:-O=:8#:61V!OB+<A-9HS6V-Q5E--1[@QV*QE3
M6SU-)/C--/BY:S-0P4XA5!=&LI+ GV>;=>W&X*T?[O*D9KG3\A0CC3-1_+H*
M3;7;(P4.LB<=)H1]I&1\AY]%OW!%)A,=MS-=NXO$9?<6\-L5<5%L'9D]/5G:
MF(^T>AI<GE!1RRUE/+3U<J.8F"(SR*6-A[$-GO$MDX28.(/A8 '(/E3S!X'\
M^BR\VU+X)'.Z Q]\9:ATLF5"UK0UX4Z<NV>W^UL[T[V!L;=_7^2S^V,]A=NX
MC:6Y,'+)B,GL7(8^&&JHMT[RK**62>LQ4[4FEF<1A9.-3*Q]D][L.TQWT.Z[
M5%)!.NH@ 4^($'(I3C\^A/!S3OF[['=;3OT,3("@4D5)"L#45KDD D\?Y]5T
M8V>*>MJ*S+5-9ELRS8F+)Y1ZF22/(2FC:.BJ?$G[==#31JT*2DDM;41^?92D
MSW$LK!VJ#W9-3]OKTS&*QCT'#Y?9T:GKKX][I[,Z\W1V;C,?BTVCL"KQB96(
MSF.HRL?W -3/A1$1)59$1.%2-?U/Z5)8@>S&+P=4,-0LTIHM!QIDY\OSZ1RP
MI<"2*>4I:T[FK33_  _M8 =6D?%8X3);'%7A\C#--@I6VID,2KTYK\')32"6
M&/+>,"H:JJXETQ/98S&"MV()]IO<2\N[6#;K". BV<+4C@:X/#^&@.?7H1^S
MMM9WDF[;]?L/ZP*QC\(_@C4]L@4\"?49]./5>'\PB5?@Q\V_B5_-7I3+C^E=
MRP8WX ?S#)H2T>.Q'3G9V?CJOCUWUG@9HZ&FI>HNT&CHZVM>*>I%')2P(0'M
M[CF)@ZZ3Y?ZO\'#YBO4B[F&LMQ2[C "MFO "K FIH2 )&_4;XF2=D6@4]7EO
M1&GF=&99M-K21-Y()HV57BG@<$B6GGB8/&XX9&!'!]VTT)\ST?I<I-$CJ:*1
MZ4(]01Y$'!'D00>'65 H;F,D6-QIXO\ 0'FPN#^??J#TZHQ-*:\=9&CTHP*@
MGA[_ -%!(/\ L;_[U[]BGRZJ&U,#4]1/(4)4E]-[@B_U/X%C^/==9&,TZ?,:
MM4@"O4U+R7_M6L0"Q6U^#^GVIU+2O29AH/#/7 MP00QYXN+V_ //X]^^T8ZV
M!2AKGK+&;, PX;A>!:_UYY^I]T)-#0GY=5:AX=201>P%O]A[5(00!YTZ8((%
M3PZ<$!,::3I-AS];>VC\9Z:/GCK*MQ8L;M^6'!)_K[T"NK(QUIEJM!PZGPNN
MA+WX!O\ [<_GWLTJ2!CI%(#5E'64,#R.+6O_ +'_ !]T[23@=)R'7SX]9U4E
M0>#S^?QS_C_7W1J \/+JM2?/K*JV^A_UO]8VL?Z<6]T^SKW7?TL!_C_K,?\
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MO=>TT'SZ0E%_,@[_ .X-V]08WH?K7K'.[EH/DUO3IK?NP,-W&,MU5W+MZO\
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M?EUEAC4DG2+#TG_; _[:WO75)&( %<]9BMPP%OHP L.!8@<_X'WL'2P/H>F
MQ!4ZC0'JH;^8UM/?^WMG=C;SZTQ;UVYLOLG)1X'[2 2U,&=AHV"5%'"0ZU&3
MI(O(\$9!URA0 20/<([S;_N/FV_N;M0FU7V=0Q7\QQZQK]^]LWB#9MWW/8[8
MO?>$2M!4C-2ZCS(4M3Y_/K7DZP^<W<W5W4FRLYM7?U?4[HDQ--21IGJ(9.MJ
M:^)Y:2JHZJ-TI:_[@54#B1"RRB1BMC;V$_ZI[/%N$F\V$TUO/&V60Z3ZBCK0
MTS49ZQ V?W1]P>5A':V&^(T PBM1@ORJ<@#YFM>K._@[_-1[][,[&VWUCVS0
M;&J<QE'85ZX!L]C\CC* ZO#4YC%9%JFAI]5T'B$RR$M< >S^*]WOE^X\?]Z-
M+;$5 =ZGA7(J5/YY]>IV]N_O!<T;SS+LG+N[V<3B:0KX@JI4CST&JGY\.->M
ME>"7[BGH:K2%6II::<+:]@\:N5(-]0%[<_CW.-G/]5:6\_XGC4GRR0#_ )>L
MUH"SQ%F/<<_MS_J'62Q8L58K9B!^;K^../:GA@\1T^>"]M,==A2 ;L2?Z^_=
M>Q0 #/7%=7 M=;?JN!<W_4!]1[]UNF2&P>N(4E7"\_2S7L2=7*\\C2/?NJ]<
M7<7+"U[@ D7NIL'X(^H'T_I[]UXTQC/60,;#2YT_@<_0$C4?ZGCW[Y]:H#Y=
M2X;Z.>3<\GZV_'O1Z;?!ZSJQ M]>?]X_H/?NJ=<PU[,+@7YYX/X'^]^_=>.>
MN>L"UP>3_@?^)][!Z;9#Q'7/WOIOKWOW7NO>_=>Z][]U[KUS_4_[?W[KU!Z=
M>]^Z]U[W[KW7O?NO=>]^Z]UDB'[J?\A<_3^P?Q[IBOSZT_P=3O=NF>O_T=_C
MW[KW5:_>M+-2=J[GNHB6J&-K(M(*ZEEHH5+_ )!9GB-S^?Z?D@'>@%W6X  ^
M%#^9'66/MC,D_)FW 99&=3^3'_/T&R7+#\_3^H_(_P!O[+X_BX]#5ZA33IYB
M<!5M<#D,+<?\5-_:B AG)85 Z0LH(/F?+J=$?1;2'+DH587&FVJQ]K6420R:
ML@"H_;TC=1J%6II/'H7=G9 8K;N^\I5Q5$F(H-C;AJLJM*9?NO'!BJGQQT:0
MVE=W6RG201]?Q[DWETO-M]@-6IO'0"N<<:?RX=8Q^[_TD6_F1$7ZHV;$D?%Q
M !KZ_P"3H%<OLI]A].="9C!;.HZ+*;\II]G1XW<U91K'C.Q>TDH8ML[HR99J
MBGDCHZ*EF6*F3TPK(!_G+DC"'=9)MSW.#ZAO!0Z@!_"F2M!GCZ9)%.HCCMY8
M[6QN:M5HV#9\SP/[/Y= ;BOBR=N[RV!E=_\ 8NV]SX?<F6W+B-N8[ C^%Y"I
MQ^W,=5U.\=VOE,C,HJ\?BJ2CEABI2QA:65#RS+[<^L>2XE5"QF1 :'A5LJII
M4UR":<!TQ' L\ -R@>-GQJS\)X_MX?,'H#_DAOK<28FDVGL[LS8W\%JZF7(Y
M7&9IUIH\AA1624>/VGE)(D<2QBEAC,,+WLUS?Z^U>YW?AIH4E9F KG]O[<_;
MT8E%DA "BJG!IP_U#H1?Y8GQGVUOK;6_NV<M'4T%93U78?446V:JGCGQA?+X
MBC%;F8'E\DZ44=+7HM$Z*ATZM+6-B"9KGZ(-$ =3L#7@: @T^=>E\*I.@9$4
M!00?F2/\G18L!7;\ZJSV8V#MO!;CVUE]OPO5R[4S=1_"Z+)YC:JULRYUZ>IU
MT44L, :JIU0^-]2LUQS[&,-8KJ4 ZD>$%/2OJ/\ 8Z)[B**2JRQ@QGB#]OGT
M=SX*[)S<]1N3L[<4%9M?+5&.H<>FV_V%?<^ SP.43<&<5F::44V5LT,P1=,A
MTHVAB#KGK<V;EW:;:7;E:5WIXM.Y:?/[.EOMKMD9YMWK<5OF\81TTU^(>A]0
M/3_-T=?N?ICK;Y$=0=F=!=Q8)-S=5]S;'SO7N_<-Z(ZF? ;CI&I9:S%U+12M
MC\]A:D15V.JD'EI:ZFAE0AD!]Q4H5."^74V7L'U<$D9IJ%2*\*T(I\@02I/$
M U&0.JQ_Y3O=O8^QF[0_E5?*O/-E?EE\!,?B\;LC>-;Y4?Y/_"6KDAH>B/D'
M@)ZF61\O6X#"RTFW=R"-ZEZ"KAIA53M5/4!+L*YI_J_U?RZ(MKNC$YM)B0"<
M5Q0\ *>18@AN-)0P)+2#JY722;6)_!N.!_L?H?;>:GTZ/ZCUZY&$GZA#P1_7
MC\@$CZ$^]<!DUZKK IQZ;#"XM=&%_IP?Q^?K?WLD=*Q(OK7KI(I0Q*"0$V_P
M!YXO_A[UJ SKQUMG1AW =94$CW(:Q'X)L1_L/;FHCSZ:(0?AZZ)DX!8D@FWJ
MY!M:X]N "GKUX!:\.I$1LIU'U"P^O)!YX_K[J-0J V1TVU*\,=3$DX4:GX'T
MXM;\CW8$^O=TTR\<"G4J-PP5=0+6Y'_%?]8>[ 5\\]-'%<8'68%A8:B!S87(
M^GX_V)]V ((KPZ:.@U-,]2XF( 8F]_\ 8@C\7_K[T::JGATFD4&HIU.1@1Z3
M^>0#87_UO>ORZ2LI7!ZY?[?_ &Y_WU_>L>G6NN:C_ <D7O\ T%K"W^/NC4U+
MU[J7'&I4\+:]N1^3_L#[JPH1IZ;8FO'KGXS]+ "]K@V_V/X]U%"*GJM>O>(_
MU_KS?G_H7WXJM,];KUQ,,A/U! (M<_2WT^@OQ[J !P7KPTT-1GKB*<#@A !<
M"W -R;C^EK\D>_9 [>/7CI(&.I<,\U.0T#L"5TD$Z@ +6L#<"UK ?T][U,/Q
M'I/+;QS !E H:XZFIEZU#=PD@OJ*\#TD?HX%P5/Y^G'MQ9*?%6G2-]N4C]-Z
M?;U/AS(8KYH?$"!K8.'2/@DF^D.W/'T]V\1?7I/)8RH"P(;J='D:61M D*MS
M;6I4&WU()_ O]?I[V&!- <])FAD3XD/22[)ZZV)W+U[O'JSLC T6[NO>PMN9
M/:>\=M5L]7#19[;F<I9*')XRIGQ]31UL4%;32LA:*6-P#Z6!]VZID9Z!W<WP
MR^,&\LEN++;JZ=VSGZW=VZ^QM[;G.4FS-52YW<_;G3M#\?\ LC)9/'R90X^K
M7=O3F-@P-3 T1IOM8PZ1I->4^Z]J;UZ3U;\$_C1F\'L7;^\MI;L[)I.N8>RL
M=M:L[7[=[?[3SD6VNX-K#9'9.QLUN'L#?6XLWNKKO=VTHH:"KV_E)ZS#R1TT
M+_;^:))1[KU3Y=)"C_EM?$7'8.?"T&R-Z4D\V7PN?CW5!W7W6G8%#F]O=1Y/
MH##Y7%]@_P"D [RQ=?2=&Y:;:7EIZV-Y,%HIW+:$9?=;U-TH:?\ E]?$&CW1
MB=UX_IS'8RJPFS\?LG&X/%;DWGC-D4^-P_5&1Z(P>8&P:'<<&S#OC!=*9BKV
MG1;B-#_'J; 5+T258A"*GNO:F]>G[&_"#XOX.IVQ7[=ZPCVSD=F;ZZI[(VUD
MMM[KWO@\CC-W=*]3+T-UW6I6X[<M/45%#B^E@^UZJAF:2@RN'FE@KX:D2R%O
M=:J?7I9=2?&7IOI#;.Z=C=>;>S-'U]NPU$%1UQN+?.^]]]<;?PM5'71U.T=A
M;!WUN7<>TNNMBS#*5(.#P='C\4(Y1"*<01011>Z\23D\>D#@O@M\9<'LK;G7
M;[(SVY=E[*GW0=A8#??9_:>_J/KW$[PZIW+T;F=I=?G>.],U-LK8W^B3>&1P
M5-A,:U-BZ2DJ2T,"3(DJ^Z]J/&O2JV_\1/CAM67#3;?ZKPF,EV_N;$[QPSPU
MV><T&YL%\=O]E-Q.6B\^6E#3T7QW_P!^NJMJC-%^XRFJ_?\ ?NO5)\^H&SOA
MA\8.OYMNU&SNHL#@IMIS;0J-NO39#<4IQ<VPN@\M\7=H20BJS-0)#@^@\Y5[
M;C\FL-1S&1]52!,/=>+$\3TBL/\ R\OB%M_*X+)X7J88ZGVS_ I<'MJ#>G8!
MV-1U^!Z0J/C2F:FV'+NF39^4W!FOCY,FS<K7UE%45>5P%/#3U4DHB1A[K>IO
M7I[V1\&_CCUKD]@Y78>VMZ;6EZ[V1M_K3&T>*[B[BBQ.Z>OMFMG_ .X>S>UL
M3)ON3']S;?Z]AW3D(,#3[LCS*XJEJY(*?1"VCW[K53Z]*_HGXH=!_&J;,U/3
M&Q3M*ISVW=H;,KZB?<V[MS31[(Z\J-S3]=[&Q3[LSV<."V3U]'O')4^$Q-#]
MO08REJFA@B2,*H]UXDGCT8KW[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=<&EC07:1%'')8 <FPY)^A/OW6P"< 9ZA/E*%
M#I\P8W*G0"P4@:K,?H+CZ?CWNA\^K+%(Q("''427-1* 88FD!L"S'0 WU*\@
MZB/\/?J=*(K.61B&[:#IODS55(+(D<)4GE29"_T(N"%"BWU_/]/>])XXZ5KM
MH&7DQ\O\_4.2NKI 1).X&O4-'H_%K @ E>?I]??@*GIZ.QB0ZF6I]#U&=C(
M)&:0+] [%K<@V%S]+B_^O[N%I6HZ4)$B&JHH/V=<?3R!_MK6'%KV'T-K>]&@
MJ* 'R^?3@K^77+2?P+\7X' _U_\ 'W3KU0//KVEB?H1_L+#_ 'KW[SZ]44K7
MK.BV&D_7\?ZY/O739-37KGH:]OK>WTN1_O7O?EU4XR>'4F)"JD-:Y)O;FX_%
M_P#&WOQR21TG=@Q!'"G79L"0 1Z; K<D'FQ/X !]^ !(!X'K0_"3Z_ET1;OO
M>&3WAGLCU)1Q4.-"Q&2FS,\+5%4]:M.9A%3 .OBJ90O#DBQXM[A;F2SW7GK<
MK[EL3)!;05T2#&FGDI\C0<?7J)N<>87DN9MD15J:Z6*U/G15^WYXZI[W1UCM
M*@W'DMP2;:Q,V[:F"IH:G<59C:$U<$,;L_CI(D@CI:5VF!9IEC\[$W,A]I-J
MVEMBMCLUCN$D\1XRW!U?+B>L0-_V3;9;ZZW"XVR-=P8,&(5<>0HH 4?;2IKD
M]%R^%7QX[,S?SGS&\Z/96=FZS?;U30U>])(?ML)!N+RTZXY**>32^6KRL;B4
M1*PA4@LU_93=FTW-9=HVF-9U!(+D5(QDAO35BGGT6>S7*.\WO/6V;C)M-P-N
MMC(#,U0H8T"T8_&3_1K3SZV]::G-+08ZD+ _:T5-2ZKW),$20L3?ZZBG)]SU
MM<)MMOLXF'<L:@_DH'^3KI';=L)3C04_9TX")!]5%Q]?]?VNU$YKU[4?7KKQ
MI?\ 2/I_L/\ 7][J?7KU33CUR,26!TK_ *P%C_3Z<>]5/KUZI]>HCI^XX"A1
M?AQ?4.!]!]/>_(=.KE02>N" "ZB[  E38%3]2;'D7O[]UOKL'45MK_"LI6R#
M^K$_U_%OI[]U[KB7;4WK=%%KVX(/]0I^MS[]UZ@H>VO^3J;%<AKDDZOZD_V1
M_P 5]Z/ETT_''63_ 'W_ !OW[JO7)3_4WN;@D V_XU[]UKK+=O\ ;_XGCG_B
MGOU>M:1Z==AM-[DG^GY][KU5EK2@ZY*P:]OQ[WU0@CCUR]^ZKU[W[KW7O?NO
M=>]^Z]UQ:]N#;D?[:_/O1X8ZL@!.>NKGWK\^G=*^G66#F9;F]@W^\@^_5'Y]
M-2"BM08Z</>^DW7_TM_CW[KW1 /DEC9*3L>&L9?V\M@:.>)O]4:*26DE4\6)
MC 6WY /^M[!/,$02^66F70?RQ_+K)CV?O$EY9NK4?'!<FO\ MQ4?Y>@,4V^I
MM8#DGZ?ZWLD'R.>I0/V$].L9O^6%@I'T_/Y_V/M?;*-3X\AT@/'J;#-%"LT]
M75)1T=+"U155<LBQ14T$?+S22$615 Y)X ]F^W;9/O&X66UVQ(EE>E!YCB1T
M'.9M\M>6]EW'?;Q0;>WC+4_B/D.C5;1V@-P]3YF;:59C,E-O;;U318NMDJ9T
MQ-329$BGJY5K::-IUCEIO( Z*6#6L/<F-]+L]Y:;>\92&WD[PHR64>G6'M[O
M$_.<TW,-PAK,A5$/ 1DUH/EU&FZ[SF*Z]V?LCL.MVOFMI35U=_?G(YBNS,^8
MQ594U#+M&'858(E%'+B&:&&.9UC:((773S=WZNVFW"_N=L25+AE/A@4%:CN+
M<<^8 ^7GTF:W$=C%!*^E=8'V"O 'JIWY>_'W?G1^3VU5[$K,[N/IK[:FVWLJ
MJR&Z4S.9P<,E+5YG<5/-E:XI54C-513R1.@,$]&JJSETM[,MOOI[N&"(*RWD
M%?$?@S \-1]?(]))K2&U=2M/":HIZG_8Z*A3[-Z^[+HMR5>S>MI][9'9FWL%
MG]PTE1N.3#Y#%X^@K/X?D(ZBGUK'N:ORM76120/'9XN2UE!/M?,(KN1'* E0
M?VTZ]"6A)64UKPKT8+X?=X;^Z:Q?;.(VCL3,)V1V%O\ V/M+;NR]PUK9/";/
MQ6RZ.K3>FY\G4_>(U2U)C,I3TM$BN#6U:B[>-+ /#:Y+NY+RU:(>OEZ?ETZT
MZP0RFWHLAIP'^?H;>]X-A+V'V)5YC=U5V,^.WEA)II\?'04VZ<WO'(82.'-=
M;5F2H4>'';+VWC(!,33PE 933N[LA/L3;>P6UA,MN%E4$*/-5!Q3SSQ(.>BR
M5QK+/*72E37Y\1^1Q\^@IZ:[+R?7_?.UM[=GS5^/QVY%K]O5-0TTM/!B]K92
MF2BPU3DL,')DP&.KEIPDFDI! OE 6Q/LVW19-TV"[LPOB2JE8@?)P1\(]2*C
MHOV2?]S<Q65XLOA0RS 2$&@*Y^(^E:?9U=C34MF1G2GFC,4<\%3!(D\$T,@#
MP3TT\9:.>GE0W5U)4CZ>X4+2J[036^F0>O607U<,\*S6UP6C?JL'^9G\,.TN
MZJ'J?Y<?#;)8W9W\POX5U^4WG\?LM6>*CP?>&QJ]'D[+^)?:-09*6/([$[<Q
M)GAH#4RQ+C<M+>.HHHZJIG%U/D>B/<+<U^H3C7N_D*_9@ TR**XII))C/@?\
MW.I/Y@/0.+[MZQHLEM'/XS+5^P.[^E=VJU)V/\>^[=LD4F^^H>P\14P4.1H,
MOM_)JQI9YZ:F-?0-%.(XRS1IIDI]G3UG=^.NEF_57^8'G]HX,/7(P1T<7[06
M_2I(_%N/K]./I[;../2[QC_$>L,D<?%XU^E_I_7_ 'GWIC2@IQZ<5G'!CTU,
MNC]37!)'%^!_KDW/]![]I45H.[Y]+@U> Z;F#HQ:Y!8L ;\V!-A_L/;E>E H
M0,=8[G^ONVH^O5NIP4,J-]20MS^3Q:W]/;)+U<@_9TT3D@\.GJ@I(:M6=C'!
M%3J[SS/(L4<<<*:Y9I78A8X8T4EB2  /;@T^&UQ)+IC4$G[!QKT57MT]J.)9
MFX#[3C_8Z9-H[VZZ[!.4BV%NG';BEPDFC("CCJ8R@5S&9Z62HBB2MI?(-'DC
MU)?V7[7S%M.[33P65VKR(> /I_L])#+?1Z)+JW=8W- 3P^SY'I4K2,3XR+D7
M!^NHD_\ $V/X]G0)7N8\>KFX%*CJ9]C-" )(W"D7#:3:Y_LDD?7GZ>VB5E(*
MR$,.('^ CIKZE7)TD$]8-#1^FY_4>;\\GZ'C\>W,'@.K:E?+#AU(%["_U_-_
MK_O'O1Z:Z\./H2/Z\_7WXYX]>ZDQ,UCRWZOP?K<?G_"_NP (%1U1@,=2+G^K
M?3^I^ONP1.XA,CJ@/6":LAHH:BLKZJDH<;2PR5%=7Y"HBI*:A@C4N\TU5421
MT]-"J@EF9@![::%6S4K3[/Y]5*/))'#;QO)>-A$4%M1]* $DUX4'18<A\V_B
MSCMXX;8P[6H\ME\WEH,&F0P5+6Y3;.*KJJ40TS9G<L4*XJAII:DK%Y?(Z!G%
MR ;^TS75LC!#,I<_R^T\.A_;^T?NG=;7<;N.5V2"*,R%6Q(R@$G2E2Q-/L/Y
M]&G:*JBE,.B.2.]EE9K,3>YO] UE((87!'M0$!%2OY>G4;0S07(,PDD653I9
M:X!'R\Z]!AN?O#H_9&1J\/O/NCJ[:F9H)8X,CB,]OG;^+R&-J)HA/#39&CGK
MEGH:F2$AUBF5'*D$#GVR\ENITNZJ1\\]"';^6^:-ZB\?9N6K^Y@_BB@>0$>1
MP*4/DPP3Y]9-D=Y=&]D9<X+K[N+K/?.=BI),@V$VCO?!9[+O10V$U6,=15<M
M5)30D@NRH0OYL/>D:"6HC<,0.'^7IK>.6.<-DM1=[KRQN%M:LVGQ)H'C0$^0
M<@#4?($YZ%")I7:;5Z=,ED6W 6WU'T^GMWPTQ0"M.B@A5,6D54J:G]G631R#
MQ<?G_7^H_P!8_P!/I[V%H:J #UZB$&J\>N2@HRLA*D "X-OH..+'Z?CWLUIC
MCU1XXBI#H"O6?[RL!L)F((/ZN;&WU!'-Q^!]/=06^$],/;0..Q:?9U)BRE4M
MEDCC?@^H$*Q/XU#Z&W^ %S_0>W!QSPZ8>QHI*OGJ<N20 >5"O(!:XTV-O5;Z
M@7^OOW2<VTGE0]9DR%,W#/XWTLS(W]D*;&["ZDG\ 7/OW39BD'%3U+66-B K
MJ25U  \Z>.?]8$^_=-]<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
MN!]3:YL/]?\ I_K^_=>Z]?\ 'Y^MO?NO=8VEC1@K2(K$7 + '^GT_P ?]Y]^
MZ]UP^Y@U:?*M[V^O!/U(5OTMI_-OI^??NMT/IUBEKH(_HVLW4'21I75^2WTL
M!_2_OW5EC=N"]8_XC!^#?\"QN;_GCW[J_@2_PXZXG)PCZ)(WTY ''^!N0;^_
M?GUL6TI%:4'6!\G(&_;@U+8_J8*0?P?SS_A;W['5Q:N>+ =87R55Z2%50H]?
MIU7M?D&]A<?[S[]TXEF#@OGJ)+E:AV4JQA 5@=-M-R18E6OJ/%O\/>^E L%%
M36O7%JN:56!J&8'ZKJ !'U%^!_3WKIQ;6):ZHP>FYT9SJ9@Y))]3$G_$<^]]
M*46",G1$ 3QQUB 5> JC\<7'Y_P/^^'OW3M ?+KEJ)'X%OP /]X]^Z]0=<B6
M '+?[ 6_V%[<GWM0"<]>HORZX^HD W/YL;<?ZW O;WM@!2@SUX@ &G'K(J@V
MO;_$?Z_T]USYUZH21BN>O! &N!_7^G'^\?GWX_;U[6:4\^L@) LO'^\"_P#R
M/WZG5/6O7-5=AQ]/I8FWY]^X=5+*.)ZYK$X=;@6N">?]X/OW52ZZ30YZS%U#
M!;6)^A X_P!:X^GO75-+E2Q..O7)%A?^M[V)%R/?NF^O*">!PQ8+<_XD 6/]
M0??OMX=>)-#7AT2GY-=<Y&BK:?LK;5/5U%3CTTY2BQR:ZUI*3_*()J;_ %<Q
ME3ZFX]1!X]Q!S387&P;U:;GMT);;Y/C5>#$&N?F./S'45\][#(T0WRS0F9%J
M%4=V,C3\ZX_/TZI4P';V_.\^Y>P=D]D;-Q7Q_P!U-D5R/5JU&(R&;V/N#!5,
M2049W/62R4[55?+DXVCKGQ\R/3-*IB1E]E&^[=#SV'VZWYE:.1N'T1\(5/D2
MW\R.!ZQ%V_FZ_P!YYQO;'?=B79[IR&@$\)DB:F"DE3G4>#H10G@1CJU7X?\
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M[]ULF@-30=2X8V"WT/I)5OHW*N %(/ULQ^G]3[UTT[+7B.LA N-(/]+<WO\
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M(S F[LOMJ:Y@ME!F>C<0/,C[.A?RA[><]\\AIMBV+78HI5I7.A-?'#'XJ#R
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M#WNOKTH,P/G@==6/]#]?Z<\?TXN??A]N>O=<0@;D*#?DG_7]^_/K=6]>NS&
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MG^STY'$&DC+ X[OLKP_D.EBY%R;BU[6L1?BX/]2/Q_K^S,M4D+P_U5Z-E%
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M_;J,R!G6FH<.D[ D"AS7HN3M)N7>>4R54%J8J*3[&E#K>*-82+L%'!.HVO\
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MV'V+AZ8L-O[>@I \D$F8AQ9B%7-972PA^B>XKY[YBCW?<8]OL@O@6HTAZ#N
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MW>1P;7"98RUNS:OZ56\J^H-<T^><&R+XU=/Y3I'!=Q8/)U^WJZ+LCY6_)'Y
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M%04Y\"-*"XLOC@Y!_%AR>/9%N5RT\Q"DUK04\Q7_  GHSLXUB@&H]I%3]O\
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MI'^P)%[VX']?]<CW[KW64)P+FQXN/Z?U%_?NO=8C3 ZO6XU?T-A]> 0/JO\
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MXNGDI2U5E52OAD5I,E) !#2UPA#"- P8H + B_MF[Y?(W2/<9)%,:D$H,\.
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M8VQ\GVCUU58^FQN/:!\E504!;(X%JAEI/XF*@2%T5#+Z9 "NM@&M<>RO;]Z
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MEP@8>!I120*$''D3]OIU>1D4JJM4D<>B3CY85V'EH:1(YCFO.TL-(TS 0MY
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M([GW5"2<GH5<W%4SX;+0T4:2UDV-KHJ2*33XY*F2EE2".360NAY2 ;\6/MV
MA9X68T 8&OIGIF=2\$R 5)0BGK4=4V]DY?:SX?;&$KZ:LVOO;#5CT<E!/2-3
M9O TNN:EJHJZEE"V@,ZWBNQ692&1B!?WD'L-O=7"RW,<BS6Q0&HX5I7^8Z@^
M[N+?;WM;)D9)E9JFF#4CRXXZ$#I_?]1U-1Y.IV9LL[AW)N..@@R&0W#D/LLK
M74F)DJ66(14Z2"".)JMF@1B597N3[)M^Y=M=VFBEN[CPECK\ J#JIY_EZ8Z$
M6U;Q/:&1;>5&,@&&J*4X8_XOH53\G^W\KBLAO;'=>2TVT=N9.&CW!15(#5ZR
M1 +5QHZD/]O(W"LMQ<@\>R'^JFP0ZK6>\87CJ=!/ TS4#Y8^WHU;?-VDDU1%
M?"C(+8XUP #Y>?'J%'\V-Q9J)LQC.N(HMMPO;R9/.K2S5)BC+M''XH)2E0'X
M(-P![2)RA9+&4^K8W#?#@9/H!_GZ7_O>^D7QW55@'X?,^N>C(]*][Y#M3%0Y
M;*=?939^,K:N2CPN5?)4N7Q64:&T9"SPPTLU+*\H945D(8*?5?CV&MTV%MN#
M:KM3<#)CI1P/4^71K9;NMUH!MG12:5P17H8-[5F=H-J9BNV^])#F*2C>HIFK
M(S-3AHB&?6@8<%0?K< >RO;H[>6]MX[H,8&:AI@]&EP76%VC8!@.@SZBW-N'
M/8U\INC/X!9GG=&QE$'BFC)OH27[PB4)(;LFF]QP./9SOUI:P2)#8VLM /B-
M"/Y?SZ++$SH[//<((_3S^63_ *CTA/F+W+E.G^E,_N+;^&Q68R%?X<12'.TZ
M5V$IWR#K3K+74+1S15AUN/'%*!%(18G\>TFR6*W<\DCL?TQ734AF/#!' #B?
M/I[<+EHU6.-:A_Q8('^R?+K7EW3GMT8W>6._O#N=II*PTE95YB&AIEJ:1*J$
MFNIL9BX$^SQL"Q,8U1(_W$-V/'L4O=W4#=ATKZ]%,D!>%FJ :CH=NGNS\!UU
MO'-[QVMC*O&9:GI)H=N5(CBJT2.HIFIJ^JACJH7>BF:*4E5(9""; <>U)?;9
M[:19T)+<34>M?MZK'JBH48:QT:>G^2U1V-E*6C_O34SY#'4$BU%92S2XRIHZ
M9P'JI/OZ7QO4))42?1B]Y"?I]/:BUM-OU1K:! A8$JV=6.'H/Y=*%GG<JK/V
M^O6#LW*[2H</C:?:>>H\AGLK3"7(5=5YPE!4$,XB=SKFF#E?7-R&8\>U?U5R
MS21ZE32W;YB@^S^76I)5#(J@^E>JV]R?(_=6#K*;;K_Y+EZB9_WD73]M'),1
M%92]W8JH-K<#\>R.7>VURVU3J((+>1KC'GT_%$6HWD#^T=1>X=XY?*]>XW/X
MW/57WAJDBRT K!-5&DGA*N7>6\U04KVOJM=%( ^GMG>Y98=NMVMIAK)'&O1=
M9!I-RG4BD8!Z+Q29F>JP'W,==,,W'"U-'DWJ9_O?+1V1*=G$P\SRH1=B"UC>
M_L/1SWTFHB9:4/KZ=&OA+@G[>GG;^*EQV"H]QM31'<V;JI5J:W(32SJN/^XT
MU-)$L<A,,\VGU32ZC;@ "WM1;-(]FK2?'TS(Z.:PI3[>E]3R@QPNQ$5"BQE*
MF.TL<;S.ZB)2IU"5I8SP1^GGZ>S72H\NDFI\@'(Z\^W'RD[5"QYBFAQPC)S$
M5:D4%?'4D2"CCI!>:7R2<O/8&,"W-_;9MT$HB\!C7S\NG?%3AX@ZC8.HEQ&3
MK343U==0RNR5M%4QG(&2$MI8P@IJJ- ;A;6T_7WYHI 2/#/3_B"@[?Y]6$]*
M?'+9V].AUWC@M_YK;&\9!E,>VRC.NY\)3P4U?4+#DJC&$&MBH9J0B0@/')%>
MW( ]F%NAJ(&@81LM2]10'TIZ_P"'I)*H:>/(U5 IFOV_9Z_/H">M_CUV;U94
M;KGGJ<3FY*T2QX/<E#6U7\+H&FE*P^;&5NLTHJ'D"O*0PC4@'TCVIV[:KW;9
M+LJ=?B,2I&* \,'SZ;W6597A5301X8'S(]*?Y>E9L/.9_<^\\)UK6U2C<&X:
MZ/"U[9#5"<?D8O,DP)C&GQPK&%U*?2MS^1[%.P3S61N7NU+R*AD:F.&:?['0
M2WB<!6$>!*^E?05QGY?9U?MT7TI@.D-I28/%O][F,Q5+E]U9HJ8CELP8$@+0
M4]RM+04D*"."(?I07/J)]Q5S/S'<\R[B;N8%;=!IC2M="_;YDG)Z'7+FQ1[#
M8^!K#W<AU2N!0,WR'H!@>?GYT U>PYT(.O>_=>Z][]U[KWOW7NO>_=>ZXNZH
MNICQ_O)/X _J3[T33CU[IOE22=_5(1&!<0M'I^MP&8WNUP;6/'']?=&?B*=6
M%./6>)#KYL;"U@.!?_$_ZWNR&H)ZM(1V@"G4E5TWYX]VZ;\OGUCFTWBU:O\
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M.*9"NKFW ^AO<#D?ZU_;H\^D3*02I'4WZV(XX'/ _'^O_3W8=)C2N.I*RII
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M'3W1^E9 02=0/I_UAQ_L?;FAAAL=)Y."]3C_ +W]?>@/BZHI\NLRDE03]?\
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M_/I3^T?2OKWOW7NO>_=>Z][]U[KHFPN?H/?NO= WNS.K55CTT+W\#Z-2%BH
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MU#(QTE*_+'6=&*L"OU) /T^E^1S]/;X &F@X])' )(/"O3HA%^;?I^O^%_\
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M/).S2,27D-A]+D7_ ,."VGV5E@Q+*V*]2E)&D$(11VCI2XU7>10BEE4BQO\
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M4&W !L"1_M_Q[\<&OKTD."1U*4\?7FW^^^@_I[=%*+Z=,,#4GY]=_P"QX/\
M3W;JI%./'J#EJ>&LQ=535,(E290$# >J164JR_[7&1>_UX]N6[,LRLM01TGG
M560@GCY=!C5[>D,J*K'3(J^8%OVU8&YTH;N!;Z"_U]F;R:F+&E>DL,>F, #
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M]AQ_3W4CA_JX=/'2N//J92+JL6Y!)'U(!(M_O%Q[WDUIQQUYS5,_+I48Y?W
M0/HMN/I]&_V'NP7*FF>DY/[.GOW?K77_U=_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=1ZJGBJZ:>EG19(9XGBD1A=65U(((_/NK*&5E88(ZO'(\4B2QFCJ00?F.B
MGU^.?&UE902ZA-35#QN"+$@'4C6^GKC((M[#+P&,2:O[0&E/.GKU-5C>)?6T
M%RC ZE%:>1\Q^WIO*$&UCP;<+Q_7W0*:DD9ITN4@>?6*5"R$6(N00;'Z^[1I
M1E8XZ<1E!K7K"L3JP8D\?7^AX('^ /M6A&H9ZLSAE('6>,@.I)M_K_3Z>WF^
M$]-'@>LS,I8V(/%N#^?^*>VM) !Z\M: =<X_I_L;#_&]O]C[T<T &>J/QZD@
MG@?BW/\ A_A]?;JU\SBG5"M<_+J1&1J 8@ $'_7-^/=NF'KH:G'IS634U[CC
M^GTN;>[#I$1@BG2AQDY^C.+,!J)YL1R;6^GOU>'IT5W28!ID=*2,B][CD'D6
M_ N;?UM[5*P\V%<=%+@Z3@]/"'Z6L38<#GZKP/\ 8^ZBH8D](#QZ=58:5Y%[
M ?ZQM]/=B3P ST@8$%L>?4R)@5"ZEO>YY'' %_Q?V[0D+CRZ3L.YCY=24:_'
M' ^EC^!8'_;^[J?(BAZH1Z'K-^!_K>[CACIEOB/731M,+$-I!XM]#^/3?@6]
M^60JYI3'3<BH0 3W=1JC&!U!4:GM^DV!%C<<G_#V_P".U,=)Z%<#AU!;%/J9
MM'+#DV!( '.D_CWL2 U+<>O4;'7*#&QQN)'U!D!%V<7>_P!+DV&NQX)_'O1E
MTDTZ]4_">'3H*:FE(?Q%/$ OK0)K(-KZB;'7^#[H)9!7NX]6 'SZ1DF)B;)5
M4LD?DD:0L#(I_P!3H0,A)!TVM:_/!_/M1&X*U8BO3;&OEGJ9)@%$7GE2-'=0
M@2.)!IYX_HQ+?06!][$BEM/GUJAI7RZ2V2P*I*CQ/+"]B2A8.7^H87!'I /(
M_'N^JG#/7NH5%A*O'RO+01&"62((YC/IB#C4-*^HAM)^O];^[ARU0QX=:P,#
MK)'MNKJ&O4B<Q0:GEBCD<@EOU%B2$U/_ &N.1[L& /Q9ZI(*@4%3TWY?:N*G
M15$$--)^HI%PP!L-09;-8CZ^W!(PX/TT8ZC*4^SH/ZS 4M'4F6EIA'&8VBE;
M03<1@H&1#R+GDGZW]J(YS&4>1:BO2>9&0?"2.A@V%L>&"&CSF3A3[@KY<;2-
M&JFCBD6PGF869ZJ9.0/I&I_J39O<=VDF#6\1I'YGU^7V?X>K6NWQ!Q<R+WTP
M.A=]D71KU[W[KW7O?NO=>]^Z]U[W[KW7%F"*S,;*H))_P')]^Z]TPSRM4%7]
M0TR$HAM^AA8%M/U''TOQ]#[W44(\Z=*(HJ]S5'6#QM>^EO\ 8CCVQBH_S]*C
M(*$:AY]=Z6^ND_[;V[4<*]( K"AIUG2/4"'!%K?7_8\WM?\ 'MCX:4/6\4R.
MLD4?DOJ!#:;A1_L;F]O9@[LHH&JO#J@IY\.G-4M]%/X^M_Q_K^T_6NI'OW7N
MO>_=>Z][]U[KWOW7NNM2_P"J'UM]1]3S;_7M[]U[KOW[KW4><$JP0>HBU_\
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MS_0>U*71!H6Z:9#2H4](H[+CER$<4L4S05E71/4Z 6E>)Y8DJG#W!B$W(O\
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M%EQB%F?2A6P_4C.?KSI4&X ^GY_K^/;JRD"E,]49*D$''7HD\+N(H5AT6 (
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MZQ;_ !(;CWZ,4!ZK7J4J$#@$_GZ>[=5Z[L?Z'_;'W[KW6%TTM959A8FXL+$
M'^EN3[]UNI\NH+*Y4A5<$L23="0#?CZ\6/O;T;3PZ\.F^6X!X/I/U(L/J0;G
M\ >VRNHU/5EIPZ;G9CJ:VDGCD->W]?I]./=3Y46N*?+I\%D&.'4/Q*Q8WL6N
M38?D_P"N!_3WJAX:34=4!QPZS0QLHLMV]1/'#$<"Y!M[VJ$Y(QU8=HZ4=#"_
ME1K$64?TT@#FU[WN1_A[N":C!ZK)4QMD5/\ GZ>@Q$C)8$?JO<W7BYO<6-S:
/UO\ 8^[=,=9??NO=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g790774page015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774page015.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P@ 1" (6 W # 1$
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M$0   ??P              "+[/12C6;T
M                                           ",;/1R?6;P B>1N]>
MY?5.%,7#OD1_UVD@\=7F5QT9]$INXTQ55(3D]%,<;01OWVV-/L_^6KRJ^.3'
MECSZ8%LIL],S(KY.-,1H]<]W\\")>^\>_/7.%,;$GVQK>RT>:4W<J8F!?*V9
M@\=*O#2@                                             !&]CI9)
MKMU87D/R-]$\C>*17/KBY5?%*;LWIL'ORUUZK)Z['-IC8MO?,KX4'.F'1+7?
M,I,O/EKXU[[>4X^FCWMM+T*1268^C:?3.CWMM7;SP6V^6U>F=-\7G&KTS6Z^
M6$XQ>;?_ "U@                                              1W
M8:>1:_<1_P!O%H]O'*I="8 F%J6Q[T??#W<O/U)
M                      Q>OA@^E*PLE68K$@C,2?&R'&MP
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M8 \W_I?SSFSJN8AN7BYD>F-[>+IB9#A3UAV=@^D?S/Z)W9PG9@
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MI]<>;R'RU;-Z;+(CR;KY4J\-'$\CH7+SU;%Z[2=8O,P'+ZE_\M4TWSYGC\[
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M/F_,W3\U)<#-GV!G3W5;+1O2<_!=AAQS/PO2?YA]&[LX3L@
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MYD0 !Y^=_P )S%U'-2O'R=A:O8L'KX9RVJMQJHYDX_=_#]GW9P?:@
M       $;V.EDFNW7E9]5^:<X=+S[WB>[EY^F+>'#R]&OV\FC(Q_0GYUWW6?
M']7: "R4T*E"^%DR"ACHR8:W3K-,G'@AXTDN(P+CPA<8$Y$,%+?,.(V&,9IL
MI&L$Y(F9IM:$1F'),>(>.))#)+! P24(8$[LFKC!.07"(LG'%4)EPD  ><WT
MGY[S-U//.?A;/IZ4B6_T\T91[-Q.^^ [;NW@^V               (QL]')]
M9O/+OZE\XYMZ7G7;$R*(:\KR=<7(3M7&]?+T&^=]WU1R75T*E\%!.52A?"D@
MJ5!%T2G,*%H%\2G,7%T+94A>7"D3B23+9  5 H9,%BQ%L@3%8FDDD*Q-LK!6
M(2F5(4E:*03E?"DPBE6",E8(R  \]?HO \N=5S#KC^V#D>5(M95DK-&3B]\<
M#W/<'#=B               1G9Z.3:S>>5WU7YMHO=:0F=H:C:0;-PIS@Y^L
MMOJU*SW7P?:]8\?UE#A>+<3)FIT2C5Q(1U$4.R0W1,:O+(;QF.2HM.)B'Q+L
MC2:=P3'3Z-!ITC$S(GZ&-/9,UY,BT43FHP2:DD)\C%E!82"6NQ[,(V^B IV"
MC4\3L*40@V$KE-")$ AN246@WC=()P89U,J[I3+0*G 7T+A.5>LY=W\O2:Z[
M/8<G&<O/TA6?AL61C]V\/VG=W!=H 0K)Z&!9?3Y=?!V\\'*KXY<>$:]MO>K(
M/'5XEO?6F;U^[-9\[T#MOJ&NLSJ]M8'#S+&Y_7N7U4-R=_VGS7YZ ([L-/(M
M?N/*WZM\VYIZ;F]MZ'<OOA[M>1Y9?EZ85_+46[TWH?\ /.^ZOXWKJ$)B6,20
MC$RXN(*3.8C,2X3%81J9>(-9EI<T-YC&>7FQ$0]+</4PA#"2F-DL8>3$(H98
MJ2$AM4ZDV$T(:90J-,I]")#0ER0X"9<1$VL:_,\U,;;E#H;1F(I$KRV\A"05
M/.KZ3\\YRZ/0;6T^T9LGPR:>LAQ/73FZU;)FX7>'!]QW=P7: &D]G]$9_3/C
M'ON9!XZN0>6K"$Y71*UI,L;G\*^1KG,ZWI+2_(N>=Q]5:?3.RZ^&U]?P\-R>
MAT]L>][XY3\Q $>V&FD.OW/EO]3^;<9]QQTWU&SF6%F]5\=U?*G8<JFC371Z
M#TY^6_2>LN.Z^DM0UF'TE[LR8B4&39I>D[IO&MZ2Z#>5'0(1>R>0B<LJ$JA!
MIF31$.D]0G,H3!<QQXF-?7;FF&XBJ<8DD(QYR_"Q$)3>$"31%4OUJR&##)N'
MJ)A5XV!29ZC6"9!!B3@S"-F)#%)I:&:LN,QNZ(Q[J2K#S>^E_.>8^GYR6X67
ML'6['8VKV7,W6<SA7\8-L]?Z8_,?HW<'#=D 0S)Z#769UFJ-AV\KQ]))/'46
M+:^S.IRJ^,\Q.92F^J,_M^VN9_.H<%=7^FYKC<[N76_/X+E=+J#8]YWIRGYE
M ([L-/(M?N/*CZO\SXX[7C]M:+<R'&R7_'R&GU\8OF8FK]SK/3'YA]$ZVXWL
M Y5I:,TM/+UU_62)BUHZ1JYSD]F04B8^2,F1"(1*4^-JS72\6VPC1,S.(0.&
M\+1!8F9FIQ6$]O$"1LJ6LTS]$<K+/66V4_$2<HUXG )-,,$3.R(RPH5 S2<H
MC$M>Q.V?2L7\Y8K(T/\ !L-^6C(-]HQK02K#S>^F?.>3.OY?8VJSWW'R7_'R
M(CF8<"V&!$]A@>DOS3Z+W=P7:@&K\[LF3UV.NLSK)IC<_D5\;9F'9/0.?GAR
M7PT[+Z[&+>^YZRT'P\.=-S]89_3/V3@\A \OI]%;7Z5Z%\A^5@".;'2R/7;K
MRJ^K_-.5^IYJL5V)K=GAO-PI[:]VNKM6]%?F_P! ZWX[K U'$XU+-<K4.B=?
MS$IBVQYK#XF20UE,Y%2]X9*3+Y3*8UQ$R@U[$[%1IA.T420C!,QF'8@9B"MZ
MQLDLMH$-\[0-.QIB-PS!$1,\E)'I1TK+82L6BR$Q'HG*-BP@4IQ:L8K+;*D'
M>\06MMCS6$)W5"8VI;*IYR_2/GO*_6<SAY'CLG3;1)#'EX[%[^,=R<;TC^;?
M0N[>$[, U)L.Y9O38:CV/=RO'TDE\-/9-M?Y?49$><YQ>:5BB<VZ!U'RX.5]
M[]J?_+5[@UW!YE<?A+J?TMZ%<C^5P",;/1R?6;SRX^I_..2NQY*5:_-A&QP+
M/2*4M,]=GL^7B>BWS3Z#UAR'6AJ^)0K9=#4F008;QG5L^35J&^MLF]4?.SC:
M-;UG9,G:(C279&,2*6J(G8DF*(S;2A5CDG(L9P^3$0O%]4MK9R(42TA,GH8$
M9,3>24B\L&&?*4Q"DS$YASB4S/FN$.$(2.MF9$W6A6LNLU9%IM!VM6DP'G3]
M'^?<P=?R]M+1'.PEK,O']I9A9<)V>N]*/F/T;N+ANQ -,[+Z!1,9]]P]>6OD
M/CJL>WK$LC>JQ29XW/,'KM-*;/Z'VSS/YV#SL[#]7;JUOSS=>L^=S[$YC@#K
M?U#W_P E^7@",;/1R?6;SRO^K_-N5.LY-\PLR/Y&/*\3)CV5X.'GZ-V1C^BW
MS7Z'UIQW6AJBMM0TNQ3$6) G:=J:?K?(F-FPU3$[UO32];[@M5KI.IYG+0V)
MW5->9JVG\G6K>%HU?$MA,D826,:!8F:-;CC$[<1I"9;4S)$](],1*#NG6R)#
M$UM"\-CV:SK+7)P.EU>6)E8E4&.8Z:B-:$03UYZ47K>DU22O!"8I,!YQ?2_G
M?-73\TU^GGD5]';P]87L,.9:_,A>TP/1SYG]$[NX3L@#3&R^@Q;WW45R-W*<
M?2Y]<5R\\2!9?39$><I\-)EU\->9G5]:<_\ #0X[Z/[X0ZRT'PYRIB<)=5^E
MN[>5_-(!'=CII%KMSY4_5_FO+O3<QES.[N>WVFMYJ=R\_N-%]-SZGGZ>A?SK
MO>M.0ZVV8U16=;TNQS&,F3PQ;5?*VE=JZTK.U9:9@L;;M&JZS:3.))A$B<3?
M+.B5X84IE",C7+;B(!$QR2T'Z#J-\P_2U[$[HF-1Q*DFJ%2;(C<SC(G!"QI)
MF06QX@Q6B3F_ZI#ZTS/.V-:+X)(5B;D8MV72R%XMF*Q/G9]%^?<D]GRDFQ_3
M9FFV\'V.#(,?VUGM=9'?7P](?G/T+NWA.S (ED;QJOFZ#VWT^1^.IDWAIU%-
M=YG69-?&;XO.8EO>$971];\_\+#C;H_O_9/.?  #S@[+];>C_&_DD CNPT\B
MU^X\MOJGS?B'O>)VWS>[NLZEX_JN8.NYAP\;:+ZG0>HOR;Z=U;R'6V35@B<'
MSO?:"(Q5KHKD#I,1Y+G>&SSO;>CE6V41V8>*642WH>D-1EIA")U%LJ6$B^)D
MUHU1$R>#Q5DBYC&/926<BQ+7$8DQ=*2Q.I$SD<$-*$UI7-(9=#Z6E$PI:)52
MROKYY7G>VT9$+ZRAZ57I;'O&3YL/TJI*ZL^<7TWYOS!U'-S;6[#*B^ZN?W&@
M>FT,4RL:);/ ]._E?TGN+A^Q  #D[?\ W":8W/9%?*J(7D]"Y5Q)1CZ;'MZM
M]LGH;4?*P  #"MD9M<< CNPT\BU^X\L?JOS?D/L^0VGH-R]T]NE.2Z3E[K>9
M=?"^CNET/I-\Q^C=3\EUEB 6B4)*U8EXNK="U+XM65B*19&U<FD5LRH7"U;B
M%(";D61:\5@"\%H7E@@$JE8+"D$)6F+9:7&-:+RU*L5Q;%(G'O6R+8UJ61*=
MJJ1*D+)*UE&Y>LTFN52]LQ4I-;2^)\\_H_S[F_I.=GVNS<BOKM;4;736[TT$
MV&OCN;C>A_SGONZ^$[,  .(.G_1LH\-+-,;GL.V1KK,ZS)CRV%A\K(/'5;IU
MOST      ([L=-(M=N?*_P"K?-M&[;3R3P]]R:+<\K]AS/3O(]+J[<ZMBR,;
MM3B.RZEY3J:G&]+\\5NXPE=H:9C>LH=,3A$!ED"Q!Z7Z,FNLJVE5JPFLRZ8:
M(G:QKNML<QRDM[5C1D2@38B!.)1:#-+/(Y#?B-3IRQG,TOEL.3$0::S-,+EN
M)&I91:#[,926^8F:-*)FEH:X;1F.D9A<R(FTS*SCVBJ*A$\#=[PO,_5<QMC4
M;1T\,K4^YT^\N>WFB>AT;%D>'=?$=GW7PG9  !J38=RZ>>'EU\%%&+UV=\4>
M?/ SJ8TK\-)CSZQ7(W4RQM     $8V>CD^LWGF/]-^=<R=1SCKA9"'M5P\KX
MMR2N+ZU[XX'M^GN5ZBB$RU-E;)VBZ)3FMZ<>T843=,9L6%<FLH3.3$(S*Z"+
M+14BRB&JEY'!A'I%X%I622:H4+8$H:F8Q%10Q)+05DT^E5#"3CIRU:67*XRV
M14A>N,4F+8NLASK*5JJ1:JJD236@%R>!?H'!\V=)SJJ5HE6MF/VQW[%RXCL]
M?Z$_/.][8XGK@        AF3T&O<OJMZZOYJ    $8V>CD^LWGEI]2^<<S]/
MS.56^Q=/M&'+\)#B9.L]UJLGSGT#^=][TIS'4*P0DF!DPQI+UMB7JE$.L3E4
MLP>L*155*]9$6S%];UDM%45U$52O5DP3F5:Q;*TO$Y7%U5LJEDE($++"%LF6
M7.4+XEBFN\9F?S74.R[_ !;931?.:/7,V+A\2WWV$[Q--)/'G,!%]JYM)3L5
MK;'O6@K"X6AP+WO!\S];RS?*?:[84E@S2*['#;;^??W ]QW1PG9@      $>
M]MIREOOMW6&@^(:"VWT_IO2?'0    C>QTLDUVZ\K_JOS;G_ '^@S\?(R!K]
MJ9OC95#7[>??7 =WTIRW4U,>8J$B&35BVFE96M5Q\[(250Q^E,RMKX4E<5A;
M*^"U05M-D%8G(B;X625ASU$QN#=,Y41EIWC:LS$Q03EC7JD)FMZI--HBK+IA
M^LQ+95T5NB,6S+KXYM;U1DUAE]*KB,L_SMCWBR0BB5(9%7!O?\)S'TO,N_GZ
MMOIY8'M5Z\/7*\KPO8X7?/!]MW7P?:  !J?/[=]\M;<C+KX-U\NQ,A\M7'O;
M:Z+VGTGI?2?']![;Z?TWI/CH    1W8:>1:_<>6WU/YOSOOM#L37[#8FHV>C
M^BT>[-!NX1L-=KK:87<W"=GU#R?6<L1>,05(D0Z)V_:$JQF68OG:)RMB=BS6
M)RU96>N;TYXK;HFT:AK,?A$K3UI:N[[5K#+K.164IFV:E;<FTF025B8 2<E4
MQ&X;,LVM:B5BM9O3B6JSG/$68251$*F4X.R$9/L(Q*6UF,P=95+8F.>E=G5;
MR]:A?"U-)5A<<*=[P7,?4\WN+1[;,KZ0_-PYUK\[3.[T[+DX_=O#=IW/PG9@
M  T>F<I%,B//(KY-?IF*15RIAL_IL./^B^\]A<[\$UQF=;M[7\(    $=V&F
MD6OW/E9]5^:<D=ER<_TVVEF)D] \YT'/72:!.*Z9Z/1>E'S'Z+T[R770N)U-
M$X9FF&FU&9)_B*4LC,QF&U)K EXW;SWD0Z$DEK2)H(FVYC8J+R^)OB:2$<V4
MMBC&G%AM68AL3%(G<EZP:'0MJO4JE8E.U64Y*\[Z\M,DK#F$HR.TKYB92B_G
M:V6YD:#B<<3O&V)C"2[HZ/O6J;H!0\__ *-\[YQZ3G9=@9LCQ\J<Z[.U-NM1
M <_7QS88GHU\U^A=V<'V8       Q>NR@.7T\\Q.9@&9U&WM=P@    1W8::
M1:_<^4_U?YGQ5W7%[JYO?TM&^><W^@^DY_-\/7273Z#TZ^5?2^I>/Z^DS0OA
M0ME:B@C)CV_+)^G@CZ>%(OL'G.W9;TRR\4A= +R\1+TW($WP(<D190V_,3^T
M9TJD?K.@JSN2:ZOK;I*];!*5Z$8GD^LR.3?"022([)P'B8CZ7FDL\I28<(S+
M'M&[+Q*0,^ !9,71/G;]*^;\P=5S6Q-3LL3UKM?3[35FXU41RL6$;36^FOS#
MZ/W9P7:@      $?]=IS-O/L/2VD^0:+VOTGI?2?( ;[Y4<]MLG-IOB\Z 1G
M9Z.3:S>>5_U7YKR]T_.5NVWI-JS^E)#C>NFNATN;C>W>_ =SU+R7753:BR5R
M: BA@V.T>;=DX"-_-2MW/"VF)9D0J5A443:BP7@HFU%!6)U0G*&<Y'K9<W1,
M:6B=\S$XF-Q6CF*ENGK54@A81"B8]!"894NR%4X8E)PF,(I6<U. 99=,85XS
MZR\3%4B M+XF\X ^A_/.6NKY?(O.V]#N,>T1//PHSE8<4R_+TJ^:_0>XN%[(
M  -)[/Z)(_'4K5\W&N)'O7:U)?CZ%A]=GI?9_0M_:CY?I39_1.EM+\@C7MMX
MAD[YF]-A",KH^I-%\7 (QL]')]9O/*OZK\VY2[#E'["R6_TI?,V&=YW:LG']
M%?FOT+ICE.MK"X"A;(+1&8OB7&DU 9O6JD2O +RZ%@"T3>5@G(%H:FB<J&"<
MMUMS[6V_+5T?6VW9KOZ\=/VKRK2W4]ZT$I "L$9)6B@%0@E*A8.M) &;UJM$
MJPJ!6%)*PH)S/G_]$^<\P]7S5:RG>+HG"MY._AD1K.Q/1KYOW_=O!=J  ":P
M7JU+%@O5COMM>>MO]5Z(T_RC1.U^E]*Z7Y#H_:?1[HJQ>VSA.3T78/._!0"-
M['2R37;KRO\ JWS7E[J^5?L'.AN?A)^M%O.\FP<K!R_'T+^;?0.F>3ZU&8K*
MD+RV5I41EC3&;6<VDM?I"<QDQ-T 4A0!6)"XK"R0*PQSENEM\VC%(R/8F+D;
MAL26DXGI&U02D *0LE01F*2"^"<DYC$L<?.<NLM/I!,9%9N+H6RJ*P3*BD3P
M%]$^=\S=9S-OG:*9V,I:B_AZ2G#RHOL,/T4^;?0NZN$[(       ;KY3-Z;&
MAH[:_2-QZW@()E],Y^>$P>VTC/ON.IM#\6 ([L-/(M?N/+#ZK\WY7ZKEU5=E
MZC;/>)E-_OCZIW.KK5Z#_/?H'4G)=70M+)7(3*IL1208=HPT+3.?6;X5*E8+
M1-Q0H!? +9*P#FBEMWVB'P;T[:FL?3J^)W/,: K;=MJRF8!*070I*T"X3+)B
MR06EDFVU:1+A$Y$+H62O@%16)"H' GT'Y[RKUG+XV17=?.;O/\KZLW>J;/2D
M.S</TJ^9_1.Z.&[$       0GT@N5TK]Y:S4NP[F*^^ZE?AI+%G&N(R^FQZ(
MT_RD CNPTTBU^Y\K?JWS3BWN>-W'SN[S*^LRU^?"]AKTIII[?Z7TQ^7_ $KJ
M3D>LY3I?7T3GPB) D[GM7(' A,H<-9M^:QA;5M+=L^OGS/Y7Z8F-%UEG3#H=
MK>E-VVK5-$+1(!@')_G??UZZPB6PPH;7M$'K,SF-O6@ H)2"H% 1:4,>Q*2*
M$)40F*IR8942I +H7"J:E@'G;](^;\N=5S6S-1M,2])CA9\=R\. 9^!#MGA^
MF7R[Z+W5PO9@#3Z9T-R-_&??<2'QU657Q<Z8<8]]S<K,L;01WVVV@MM].Z@T
M?QK1.U^EQ[UVNV\#A<>?6.^VVSJXV^M3\R ([L-/(M?N/+#ZM\VX[[3C9]J-
MK-L#.Z8Y3I>9>KYK%O72G1Z'TQ^6_2>G.4ZJ,1.O8EL,PH-HC9(IC"2K$,B9
MO,1")L-AH:8EWF(3$IP5)K,3^5PO   ,<Y\I:$Q-@H9DM[VK/9@  +3'DVCF
MBX3E0"L2G,(R"DQ6)I)(O%X+05B:(JFT4*'GO]&^<\V=+H)AK\V>8&=/M=L.
M>NEYV/Y&/#MGK_2#YE]%[NX3LP      "/\ KM-%;7Z5O[4_+X+E=+%,C>2[
M'T*]?)*?1@]MGNO6?/ ",[/1R;6;SRZ^I_-^8>EYS:>FVLUPL[7.UUVQ-5LH
MKF8>K-OJN]_G_=],\OU%4TF+4WP319(*D;V>AQ?7PI,75]);J.AJFT$U1<!?
M"Y*A6     5%2T3     :SGNMMSVJF62H5(Y$MD*&,9TDD";83&T*RNA47B7
MZU<V)JBV7!?>_/\ G#IM!MG2[:^37Z^<JPLG3>\U+!F8G>_ =SW/PW8@
M          $8V>CD^LWGEM]4^;\_;_1ITF=:_-U]LL"<8&=%,W!MCU[OX7M>
MB>9Z9*\*5!;,T HBX:\S5M^3KU:>B'IXN^GZ;&* 5        *%0   "A4
M    UM$KF)#*D_P:QRDVFQ;QE%$W!$7ELK12'%7;<3RYU',N)E^'NPY'A,,/
M+C&3C,^3X=X<+VG=?"=F               1K9:62ZW=>?\ ] X?4FVU3AX^
MN1Y^Q-58NW^GA;->KN5ZK<>BWI*R8H!4OB1   !J>B.1        ZIM2B"+3
M*3;46)Q&5# LO,A*0N8*,9      $TO.QY   %$V2$!=$W CECK.4TKNM,M6
M^?Y7JAOM4M#/E8_5/*=/USR73@              $=V&GD6OW%(   2(!4
M       *0                        "L@        U DA%!R3E#>8)*92
MB(G=H               (]L-/(=?N
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MU'#_ "I*.0E<M*W1DLA<9$:6RPKV0ELK![%NLG<& 1H*]-]8A7J'AIM07L
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M.%31^*2HJJUMIUPSWP0.+0,D4I0*7P9%)J,!8 0K*LA,)(+!.<!P<X3BCV:
M *'A7$GNU;LA_P#8FWZJR62J&*F5+-,;5I/*(11H&3P0G_*8&E,K@$D#9'"$
M=&RR (R()%2::2L96X@/].K 0!^DEA7 HC7H+6LU:#58@44;&*<P4"9RE*0
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M<P^E<84EG8PCI8<BQ-^6'?8A)K'RO&@.K(PD.;W;"&U+R&/1#EA+XI LBY'
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MK%YQ!<,?DX.6_'3FF96(?K1V*8K)LGSEHHJ"+ 8U^B*\NVCFGM[3$!LYEEW
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MR=Y2MT#HEW)CNQ6:D6CDFC-A)-@%D[%-PSE%VW7:,VSA&-81^S(IFQ+P%Y<
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M,G_LLKM1.*C5&K-VXGGV-HM\;W+?QT;D4K.%?&0>&[T5F&SNC\8O5ZF,DBX
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MBC)N#C"X9EZKAQBCJ#<JQ\A,X3#8YD+2:R/%<KE,E:XW/(8=C>*/V63/,0S
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M3$1-0IIJ@*2 45%(*,0E"DF>E$DC"[QV*D) Z"!B&304#I% HD;A2B0*4 E
MA$&X'$B'6622,FRBVL8P*DWZ2:20&Z20*'02<'Z2!% 3(%&!%-/L2+T!"MCE
M32 PV3JWJ4M6D%:ZFH"UY&-R$P7#>!<Y'X ]BFCJ.-'+).)%Q17+Z1!964F
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M-VK%9(T/1HEV%*-7"0<2!_:U$7]OFOLBAJ,-BFT@FD)R5J)0&)1%" /+IJF
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M^[J]7^.D6X"0 H"<A* 44EP$I0#10E * G(Q;5TZ$H7 E"%: O\ QTA5@U:
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M0I5S=;F(O+]90E'3)2(E6/.<W?R)+6UT  )BN" 0'*8 +D!*1:P"X+I34*F
M+F G6)I%P8%"N4RE4<&.5);IE.N00,[)?JF B2_3)U?TS/2B)%="H.$RB=9(
MP@Y_5!8IJ.IK'E?706$UZ.-S>#NE*%P<0[@]=R80[I2NY/7<J4"Y@ ZIU \$
M"/H,?H* FW:DZJZ@%[RY%DE:$"LZ .FE*6]O^8( ]K41J]N.@)UE5RJF<)JN
MAT-2F205:BFJ1-QTC":>^\^1(8 *=2X$,0 ,H6P' M'.%%,4 ,<M:Z,<!$#E
MH3E$>I0F*8VLM:RZNI0&*)M9: Y;]2U$,2^LM%.6A4Y$,2A4+13% #*<B&(
M&4+8^F_R,"76F7].@4#45L=191!!RBGJ*#=3J))IV3D[^W_,$+_;5$_XXUSJ
M(Z3T10$F -#K-6QQ<M#FM'@:RL[]W^X6/^3GFW<!U$I58>IVYXYRJ":E 832
M!1_0E/\ '_,$MVU1A4^P$W45*J*1&ZI2 >"<BNN<$B:S&0 P%4FQNZ_<*",)
M2JB*B2Y^K0E"5(VBG#>E%A642,55P14>E)D2*S^8((=M46(^V*@H)%"@Z34;
MG<UT6Y0(U[842"C28'4+-&U.?W"B!,".H&JZR!TC%9 911J@X*FFN *&(U1
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MP)]$J:16K0"#1?6X>%(2NF7I\2%_MJBO\9TR]8_4,0C<CH3.8HBBS5)O1-9
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MQBFQCM8CN(\F+G,F,.4$%<?21=M\;(Z(E!=4B4"Y6;$C62PHQL<M0X^<K4D
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M%$7U2EN^C!,9Y\[:K?)VX6^22/TS%= 44G"8&[N*N#R*I5RF)C.M5"Z 1!T
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M$QU>8E*B)_ZD=?O/F%=/N%2/*03$NM,@K&30*X#3I$4 ;D6)TP,('-$C=O\
M/VX6#]@RI@*KJ.W122*B51N44TD <'5 MRZFJQ@*2HW[OYA4P _J3Y/P_4(*
MP$,Y/8Q8QKTDAZ"NO6OJTDAANV_<*:&QDK'40,!J3)WYW+!L4J2H&3.8QT3'
M_4C?O?F%#"#ZI3[T!U$5 YQ44$CL4$%5EE.X<D$P/KV3A?M?D8YJ*B)F:28)
MLA407;(I)MF0G27;HE2*R*(+()I DRLFX:E)0L2&I5 I52L2V4:AK[!,Q^B
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M #CXB%WNMQZ]45\JS8S!QTQ5[-)2.3IQX?J^LW"C4J9/,;V'3GT#P 9?-"%
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MJIDL,<QMJW1>XNRU ;@]HCN:C=46W6T^'<>\2QXE(>#I:0U"-"Q8J'P+%XW
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M\1Q$L<#X#R_/VF7;)R<%_E#_ -X_;"^W2]H-LFINT4D3M#K)\2U*VE%S'?\
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M;NG-(D;E5.@8U=.%$_Q2PG!I==]I-D?D]K/VM&2Q)UU%/LCW=GVO?D?NSQE
MJ==16KLC1M^UD[=TB93"!4ZZNRNR-.VFUD$ITG%(?CP^Z [)R1S7XQXK/].?
M:#*9\2[R!GJ1//.#5O+XI=<<VV7(CB+BC\%! !R5V&1$XN8[[L34<<SGTY^"
MQ:N28ZZT8$YZ 0>PPT.+:Z HVJVR&RZHG#V3GX;3K_/FW^ZN&VVMC4.@-<WO
MG'$_;N>8]APJ9_Q-<?1!X8L7?PO_ .T&P;W/\K=99&+L6C\S5'B665D$LN;.
M3MR:_=R_%X-? =$\(98+FL#W 5.DUJG$G0,X/*-O<LW]M/+7.7LD7K;T+I\2
MY033QB-IV#0X-W6PW]K/,<O<OWF7T<+C:6.<.7/"<Y:03PS-:)MVL4MWFWK1
M9R;+K7[05Y/+6[8+!B\/>TL5JZ3LSCF#QK2<_P#I[0V/^6NLV_\ #V[@M[29
MG="QRUCC60[DKO+ON&MJ$,9MT%?B%AV$8JKLJ)PW]QN7;8Y>[9Y>T&U"ICF%
MH<2W>:&4+4B&H4K#/V7C6!SC&VW%W$;1*]=<6\1:26MN!Z Z0%<$CF.9L_I7
M+[W#H+B1_;M"M&.)02"_RUP!Q+4Z/:'MA?\ 9P=[IE N"E"RK'S=*3Z-<H16
M8ICJ5<,,NF&UNMMJIQ<F]ZO:T0M=O=7>'O4IT^TGN[4'XEJ57M#V-'XO9]Z$
MXEK$^V,FU>? :72@#B6IEOM#VA5/HP=H,H!KM3I]H>T2)]";6@3AZH4B6D1S
M7XAXMO\ U+YEKZ)46N5$O_">%_-.)8>+39N/8TZ"1"G'P6.%57Q!AC%6TG"9
MBB&6+$)%&CK\-/[;R]R[K V1TN.R.LQ\QS_/.Y1N)%EQJZW*&C_:CY4\Y>YV
M^/O<9_6^3!V]47/VWE;+;/)7)%34\A5U =AZ?$M-J:&EES9S.Y,'5G/,> _Y
M![X;:./I/EA_ R-F8DUV61SP[<HI!N<,,3/<)]"^J%)O5U'3O)/K#<= @<0/
M(:T 2.!W>HY:8W3V:T],NF)M=GEHQ[,XW7=AZ?1/HC==V'.8[8W7=FG#MAS#
M&S,,<$Z(YK\0\6S4PL6WG8MV%_\ +<ZK\10_0V7L8;KQ<"-!(+M02<"_<Y6Y
MRMMS0&M<OLC)<M0D(++K&77\&Y0Q^#KE.P,1B<EB[7:Y*W>^7MH&.^*WF"6U
MMIK*- JQ"9*L6OVK]RL'@V@@?;T?>84GI(,]$+R?[A<%Q-QKRGYK#D[0!TP7
M\I3S=C[DG_W#_P )=!L\PQUNZ,G @]A\2U^FE%S'?]C=U>]^7P?^ [OAK7:9
M?V+J_L&JV2':M<CYH5MQZA,S[,F_W1(:,H+=Y6@!5V47#5,RPFL+0W'2=$L\
MM.>!B@ --+0H51254>4LH2MZ(F)P6I/[VUTSQB=Q\US/M;W][/3G"FX]9YG,
M4GM;(ZI0$N/DF9]D(WL$AH$H %QZ!,S[,V]AF-$/K.(,X";L<U^,>*QO.VV6
MG.:HK_;T77.^%Z8*8+]!:/#XVV-C&K4B.QZ#T19',V;MI [>HVMT$[%NV%1K
M0<9 81,L%IEM[W5,%S9:U2C#(NT>F+/.<KPSRE]CP/@V[;P6N%2T2T(X' D:
M89SMOA6N4N!07NQ&E&@GM2!S'[I^X%B>X Q/SN)]$?+/_<G<PGO/-]W0K1%S
MD.6Y9]SF#NW'M:*)XMF7>C7XEI] (#+FTN[N23[WFI\&O@'OAI_@:I&NQQF)
MA/-B-< \*R4I]GW0FGVL7Z3#1<MV^'L@RF@<I/XC@=(E'Z>;_8&?7G@!_3Q$
M?IY,]@9=>6?^)G#N';MBW,"4TKJ7'>]G\,M<'X=H+5[/O:)^S[&C7"\*SB?9
MTMITY;P^]. >%9D6^SC2$G/VL7:73@#AVBE/LXTE9S]K!VD)%S *#T"*3ICF
MOQ#Q;?S-UO*&C#Y;F&U:]MQ7I$HEA]!R\B?BMD'4'^\H3MCEA?%QKRUQ1QP5
M#2@ $O?#17+-IAI??^7(:XM>M.U2:07$$ .,BH(246KG+\R[F-@M*T@-I<@I
M:T-#&OFX,11B25BP[E_W5W+\H]JM8%DTX;0(/5E'$YG]Q#[FES7.]+X_];;_
M /+/_:B[^Y_,V[K;04MI(DJ2F?$LOH<2+=S:R;N2/XLOPGP+[' /? >J6!/I
MC9=AJ,4VRI@[TM1CXA22P'EVR=1A0[&*[4V_P&&W2CCA%5<N@P'K(QQ6S9T1
M2%5-!BDNG#N7<=HRCXFTA 6.942J'BVQ<Y7E[Y+,2>=:G_F7&_[,H7Z"SQRT
M6>(U2Y:47.E"G01#;C.".9-588$(*RK^)<:O0AEM#"!LN==X;Z"&<2A])I?0
M 5I,\)8Y1RSN;MWC^X-LN-U[K;F**]D%0*J% K^\&K'*OMN+;B6I@I[4,9>N
M7',X-R1<3E'.,;<N-;4U!4?<;%Y]XDN+;DS_ )J>)96NOAW,-W^GO:_=_-X#
M.7RY@IBV?KC@[M>TT]6'; :Q!<.)]W[3'%XURN.#>VCDXXRR,#EU)N.()^Z/
M7!</:<@_#'YCW?4A<YRUS+>6H4O;,&8GNR"59F:1P^:^99>+S3L8C !/>55@
M!S^:3_+\O*6L%KCS*'<-$W8)+";E&*X:XX7_ #-2%=B8,DEVYZ.M7/YOAG#X
M>(G,:I0VWP+YN.,BN/0VC1DL!C&\W\O255FTN#4&A2%[!C!<RYS1 _[O/1Z8
M;PSS+P?N)ED@4J8>ZT>:<@'L),Z<8 MNYFEQ*;'3+">&B/@,YB[;(SV"#.6Z
MY<H<^Q;YGYL'!*FB>!*8HFCSP+I=S3&Z[<NWM]&F'"KFN-[/P\='0OEKK)YD
M?D48:2FD0ESYEI66PM0]G()*.);^9>^H2I09$M5)$#48_P":M\Q;M 9;4U_"
M$DO7"<T.:;<J*?#RR'XI%?LCA%W-* KAPYCJ[/0N<.!/,2)0T3PT8":YK'"'
MS)V7+L3#@GL]N>B"3<YJ@?\ =^?T=N<<.Y8OU@H2O_#1YEU1P[(YHV*9[&TN
M4M&GL$.-7-R_[K##'M':-,-N,/,NM%?90=1 G,0XL/-.( 3X:=.F*Z^:%DK/
MAR"+)44PWY;B\,M7;;25S32-?U*VF*'NBG)[3_>'EYX#F92+3E]D<"PXL9DF
M)UF.*+URE,]/J@.W3G]W[(=?MK3)H.DYF S)I';G',J?;'?XK3SCN3>X-]N_
MSQ]-OT2@I@OT%AMT,-KB-6LTMQ]HY"+7"2MU9<:RZXXJ)W-EJ:1I4Y  5\V?
MALMO<E5%9#20RJ1%1T3. AC>76VXUJSB%^P';#YDEO$$Z2<ESC__ )SBBW^X
M6 G]URL<F;2-DZ.R+O[Y^]\Q:2W;(%*T@'%Q) GD F>F!SO[H>'S3);5;'$#
M31)PT34:H;_^N_\ ZZVG]L:E3DI!#<&M!FBS),R?/X;+*R"67-G)VY,_AR_$
M? =/RY@AF^GFSBT)IYXNUK@U.B4!]LGY*4E&C+5I$6S;&WQA%W%)XXXRB>"F
MGOC\Q^I,N7[UVW<+<*"5G[. 3K,-YD<U?O7;9]RE X&8>DN^"+O,<U;LT?==
M-=3 DEA.;YGF&VQ<5OPR6H$+788KU=,?ZI\]=^2;<X1'"1P_(F[,=>SHAEIW
M/&UR=SEN.TH0EIF-30PE9R%6$]46+M_G3S/[?<NN"L! :\-PIHJ4J,I@P]G*
M<]<M.9:+KCBPM1@1=)D4DBDHD6K/*7KEYO-O)M/M$!MQ743:YE37+O+U2,,_
M9^6YQSOW!K:C_AEM <76W4[:^QIDI"1?_=+7-WF\)S XOM;2N-# )3(JVDD%
MZ(O&W^X#F.;Y)RO8&S;M"V3M-&#BA2K2D?Z2WGK@Y[C<%*5 <'(-M ,<Z8?S
M5S]P%WF*C5PVO><9$[# )8SQ@?*<TZ[8:^D6RU*BUG%+6E' .#5.W(F2K%O]
MM9S',6G/)F\M.TH,]B6R'8K,#1'/<J_FKK3RH?7L^P%7)2YQW6C(.AO(L_<O
M^91KN&&.:=P/ 6BFNDB2XRQ, #]P#'\TVM@(I<\;0)2@M"THP&XTG1@O!N<Y
M>?8,G[%.S,@F1]JD0+XYZGFVVQ>#:2'44UJ%V:@PU4+4F647/WUMR^^R+M%;
M2&O+ FT6%IV [954J0)')_\ -73S//-MO 0$;9&8&(+E30X0^[S?[E0VS=-J
MIS'$8-<K:6$)2DT$Q(Q<N<USEQ_Q.&!2H>ZAMQM)PI((-0.>$6><O?N@L6;E
M=#;C7>R:3A;TY$>N+?+.YJZ[FG/=;8K5JV]E"C0%Q*_9'R]OFKCQ> ?2&$5L
M.R=X*TBDA'#J2&VN+S=CE$(63L$0!&=NN'<3G;[6U ,-"J.A,<$ UKE$N<Y@
M5DK\$C[QF1/VM*3."P@O/O4M17-I(U)Z_J5OH,,/]&:=ZQ?1:N&[R,4L!XI9
MU]4/^?*F28)_/3'-%M7#V?+HBV!O5=\OMC[V?3'-?C'?XMM_SG+BEB?$YFY=
M[*K>ST"$^@LWJFLIN-*N%0$\2$*]D,')WVWN7;4FS<#A/VG7%+EQ"%![HS Y
M6U:O7D.S<2G#[Q CERZW9L_N3FNXK+15HGL% 7!KB,6@Z"@6+?[U^P\X?]9"
MDM!I /N C:8_69'4)P>4_>+O,.NVRA;<<XH>@PWEN58Y_,/*!HF3#OW3]TYD
M,_=)4VPE,SN+BYR342"9B?B6FU@ LN;*3=N3!^[G.:^!W_3F-G>=+JSCC8T2
M&K[W68"'XP["-![C!M"UFF]+TQQ;OZV0R'VPSF?ZC#C[PS'3!9H*CHSCK/U)
MK1SK;3D"M-I<]*30)Z,H==_U%G&+1_2S&&73E&USP:[:QMJLZ<A*4^O5'!/.
MN  :BAR9RIQD V+=G]PY^;GWU/#*@.9:I( "*VXQ1G#7&\^W<X',M -IK@PO
MN-X81""C!+*0JG'+6KO/<$VCM 6"&%P0MNAK6?E>-(:0$,B[_51:+6);<VS(
M%<'BDJRG$:QC2D6WCFK%V^RS<J-NR;3'N<0VW@T(ZVTW'DM#*D $YPV]\R+5
MVS8O6@&-N)M#X3PYRD$*X)5D,!%X<ESE(NL-S<>4NOO6[EQLY;++=+<M&4<Q
M\E=9\G?NU%UFPQKGMK+DN%^T4QUG&&_O+/W)K^7^<KH%E_Z9>55QMC!E.DJJ
M+(Q6/W7EGW*@@'*TN[>"V04Y^>&\OS7/M-A7_,6^$X/O;2VW6W 220 ) WJE
M!D+_ ,\WY&IXIX1W7->&HC5S" S!Q,.>>;3FKW+7&W=AWZ@L\&VB#,EUSI>F
M4.L.YQK.2N\M;94VS\5AX5MA?4E3IM1X))+-W &+%E_/+^VL8C[%ZQ6Z7^"Y
MK)->9@UMI,RI6"?]0 <?^Y,A/'9QP,LL4(BB_P#N;+_[;P2!;N6";S7$8-NT
M"37S;M4T[-,?*.NM-@<FWE_F$?K>7\+"5Y#N@IBL-<>=^/;L6^'\,IQ1:-NY
MBU$#J+O2VG.+PL<Q8N5<UQ#Q+)>*>%;9(.'O K+J2#R_[E^X!G.6N=XC'<(T
MEM :*0QAI1,#H"1RUCE_W2PVY;+ZR_EG.JJ<JM^ [J$E]J<)S/[@Q_+HXA;)
M0/0\-Y%*D-?2ZG/09Q8O6>?MO_=0_P",6VW;:HVIM81H#0K@F\=D4QP[?/ -
M<23\-7!349IIS"9913>YT .:RIO#4U#6$U9PRZWG'7+C'&0$VR,Q7LZHX]3W
M7")EP *]6KQ[EM]^FRUKZ7[.UI."?!W3[V,&\7)S0>U+6S.4FX+\7?!]G\KH
MMN9>J+F&HHW8"SN(G]/<0]>!C@<3_EZAM;.]3^CAB?U%Q]G,06ON5-:W9P^(
M%_5_X4$O:P<V!<MGXE01LOB'W)X5:<L<%ACV7JB]KJI-V L[B)_2W$..>!B4
MX-EUQ;0JI,OB3F,/Z.!3>QR/A9UQ5[+&H/Q'U'&&AF.*^]''Y1'-T84]&J U
M[ UB9G[8;;:53%?:.O5#N79GM :#F.O*&N]X^?..:_'XMM_S-G98GQ><M7.S
M992-4^F$^B!YVBBA]-?Z?$I-%?W:D7SRCEKML61S[K9XHM-I;O;"M" /3>IE
MAFL?-_M[D]YIW7C0X=^(R,?-,'R_[W: #BBTZ <.(PY>T-68?2>8_>[S2A1"
M[3/^G;'63KR^<_<'J?9:-U@T-'D3F?$M?II1<QW_ &-W5[WY? ='RYBI/@TT
MIH\C''L3M'R0Q58'#)S)"#2FF*S<_G'Q?BL&!!PU&%N(VPWRZS#'6Q\%OG7'
MS)&SNU'ZDSE7W"C!)O#:BC#:J4CJZH8T<UR]RVXFI_"&SK.DG%!G*#8//<GP
MR/<GZ.J6J&/^;Y5QKR8I"F9GD!/$:(H'.\M25,VJX*Y2-'84[8Y%.;LL^;;;
M=N4N9<(!0%LY-<'$J)'1%SF3SW,7Z;_!%%H7"E+;JD/> /9P,/Y#YIC6.8VZ
M3<LA5N!I0M5Q:\-,PLB$S6+G/\Q?#+%J[1\+EVOQ%7$?A2W(:=H2"Q>%O]PY
M7@DI4+<JG$6[0I*!M936$<>GF.;=S=AMWE'<-.'L$%.(N&Y)=G*.5N7N<L_\
MPV[==39:>&+5OBR4A:FN;4" BB./RO[F[Y%[;ZJTLFQG%>&M#BTMGM)AHB]S
M',<P]SN1 <TV;+7U5.:Q6@N;FY2HUP+O+7@;Q:-B[R[;;QB-+AUKYXY?]Q//
M60'%I:ML,:[:*M:1M$L+=H(!T;(/,W+7-V#=L65:&V@:S/9614^SIEKCE+OS
MEIHOWVVDX32::73523-CFAI3=.$'F^6YPV6V+P8MRUP0>)A2]CW%V&!R"K%U
MK.=N'G$VFWK2&X)L6RZIV )Q39*K'+_M7+WVM9<N!BOLL1H)QWBL_28-MG-B
MW>",+;W+4$ZV@5*V6U4A6G'$6.2^=Y<MOWN$XFVI%VOXK&MPV"\)NJ':HO<G
M\Y8X5NS57PU%(^):V<%?4LESBQR7SS?]1YFRUX_Y=I9MB06I:0F-*C'".7X?
M[B"'VF7&ARRFHS+4%,NB'7'\QS-SF;=NFH<JSA##94W!+)0,(N7OF++7Y V6
M@NP.2B9J'9D96^8?S?+,O ;I:B+*:;TD\XTPYC^=Y,5(9,2<CB/M[XXAYKE0
M_:WF2=,C+:^]/3J,,<;MNZ>&)L;2!J.O3XZ4M[!"HU8W6]@C!OFB0$32-UO8
M/!(-\-MQT&&V>8D<G=.GKCY>ZVIFKTB*":+.A0IUF ;5WXF45</XQZQU)'&Y
MB=PE4]/V06W<W ]$<UHK\5C;S^:)+?8O<I<_W+3DZ#."=?T7'+2;@MOH1M5+
MZ32ZG4>S'*+;[)+WHXUT%BL<Y;;9@%U ]K6@P@<Q<6S^U S?F[5;&?XL!K,H
M_P#^?_\ U1K/F62<_%K#G_F7-*R&:I3'^@__ +2Q@YP[KL ]VEI_IW-6!RQI
MCCM^+^U$RN:-3]!UX'IEXEIU (#+FTLV[D@/O9RD@\!T_+F*2G\X/"3A9@^2
MPKA4_7ZO7%2;0[.R%0AX]V*7)P1CD?/.*&@!L(4Q/U)C6W.2DW^H!4)Y3/7)
ML&PR[R=IS"TAS4;B"J/],H/,?-\K<=20*RN".DHQ4"$8ZTYSS46NM9E%FN [
M(MVV/Y L*JX,DW''U#HB[2_DRYW*V@S;%++ENWPWFD9.832 I4"&7OV[F+5J
MZ>;#MEV1MMM[8:@=335.2((=S=H\HR]<#"AH0/\ ZQ.:.Q:%*3!]DQQ+O-OY
M2\7E]5AX8=K&V6+@$5K@B*5!@&R[E0Y_-5OV67CLL:+1(+9ND2Y^SM.E%"6^
M'<N5WJF!H<MGA7@"N+RYSFKA(%8< [E[5^V[F UP1OZUL,MECLN&@J][+"&7
MOW;F.6NV:+K).JN 7&)(O.O!0J)HB]R?+WW<)]G]0<.IKC=KD:@*=(Q"B&'E
M^984>T5.I-T%44.!W,TB]\9MRY>M28Y]MS+!:Q%LR.-(5NPC?>< 8YFR7V77
M+KK3PYC:V*U]4\$D$ &"P>8L-LV^5L<TQUJV@#^';86@?C)N%P. 1R[T?_E+
MW+7KH<Q[&O=)L]NV\+-KFS^X[#.'\ER=^W0XM(;=>VBTA4T4[SB"6U(V2@B/
MF .2=R8N'8N!K"6M<F\%VB N%,P9SAMFWS%R[9%QM\<1[ QA;4&VF(=D$D&[
MI:$#%AG^K7>3>;7-VKK7,I8:V.VZD:U:V9Z0(M/O,:><;Q.)\,?$V7ML!5RK
M-6J0BQ^W\GS5MO*/Y=EIX!2F2.* H&SPQD91;JNV/GK=BA?AEA(6:N-8:=&(
MB_S5OF7E[U2TXM>U2B"E=U0N$HX;;W(L;4)A&O!;G)44Z#'S/S=ASFEX2Z98
MHH&:[T7.9XO)/K<TN:E6.!#= !*B46[=H\J-K$V:0)24KI T:8,[+FB0-H(T
MY_4F(DEBAP]<!MU$&C%.K#KC9;VSA W7. ^RHU3(^SKBN^ Z[EHTPLEJ&<<U
M_F>+:=R[0@8FT_DV?_*<%_-.$./T7S-H-<:7-(<J$."$2(.&@B&'FZ=BI$^\
M5S)D, !( 88PW]ALO%OE6A*FA'EONU:.@ Z3X7?L/,.;<Y9P J<%N4B=-2ZL
MP3K\2R^@DAES:R;N2/XLOPGP$9?+F%<)>DQ\Q?'0/*><);I>-&#OMA.'LZ.]
M8%5-MO:[JBNRO'"XYQ6T([,=\=9^I6W4<E=$D!_4Q7:ZU75JA+=O]L<QTL1V
MX]<.?<;R#V-JDJYKL@?W9:!!-/(&TY A*3"G=7,N]!@TL_;_ &VDG9P* CT@
M]\,O7[O+FTUS);)E*DH!41I3*.):/)U<-$+7-8@+=*;23TH##Z;/[<UP>DY+
MK;/":+T)#+M/[>S$2=CA-R='G/4^PQO(,N![3+#&I*L,H!N6_P!OVZM<P'%2
M?+L@W+3^3LR;4&EJ:B5!TSG#N1YEW+\0.*NH<7;Q,G-"9G#*46:K?(.K+>EL
MAO3DF!Z],&TRW^V(X*"HECAY:%AEZXS]O>A:,:G:!U375U126\@YCG$BHX*G
MLZNO#M#K;>18" :L'!RY=*:(;>YNYRSVJ0A1R$S4M:*LHN-M_)$.1YK:YK1E
M2%3#1KU0+MNU^WM()D9&6<SG-.@P=G]O#7)LU;,E].O4<(/#;R+767'4#L^]
MGO2&HZ(#>%^WU%A(3 4TXG6NG3#FV;O*6[=6 <VEI.2D:I3BW7\L+MDX!CE<
M62"E$(-(S0XF+5MUO]O=7F 2,]Z>?JP2&L#/VYKFHY00H"@] !SZ3%-]O)"\
MTXTO>LE6H*#Z5$6KE/)/6ELYO GB,M<!O+?)6W FDM(J(G+/IP\\-',/MW#0
M$+""$ZL_J5OK@,8 ;I\T!C%XBS./HA:6O;I:8FQ7=GDD?'((]UO>8JMBKES
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M)7621V_BZ0SFK5KG.);*BHU!1@H+YZ^@]5Q_-<BVWS5X_J6K0KR*UJJQ<?\
M*5\PX>W98PE3C4$<#G+!T6^;O<OS#.:LV[=MAM'V;0 ;GCZ9==Z]\M<?QW5.
MMO;\*O2!5L%<V)CG#/G;?-VG!J4V0C&@$R8T21>M9E3%HT<W<++8MH\TBELY
MHA<=9Q'1%[F.8Y5[G<U<KN,+:K9=-'-!<"#T)F(N7;=F_P :[9X-)V6"W+98
M [91,1/SPSD;#.=99M76WP U1Q0)3*[!S&!T0_E>6Y8BQ>'Q$8VTXS)39G2<
M2)1:N.M<VR[9MVVMH* <,;/M333G#F?)-O-NWB]S;K 0I JI%4E#0K9!5Z(N
M&SRUUEI]+3;%@</8)F&SI*GKA@N<O<N<K;;L-E;#0=#&;..>\9+%SE+%GG!8
MO -=T!U>SM2GZ1UV?V^Y8YA_(V2XS)J5Z+[6U,2T"!S(;SOZ3;):6--MUIK$
M:US7*'8+IS6+=IW+O;R5FY4P,V$/OH#-^:EVH((NVSRUVV^[^H]C Q[\]IP=
MJ%5-*TN7[K1<Y2NW8;L7GL#[]M,$*XLR<5(U!$M_,?ZD.';#0DD0KUF9)>9D
MP;?[ERKS:-SB$LWB\,;;!Q]P!?O%<T++EVU?N%O+\#; <'6UJFKMIRX.,T+,
M?:IYKE[MOE;3OABP*=HR+B&YG2:I2@!G^I5 *%-(P\P)T%46#>O\K?:_&IKB
M2NLJ.W15TAR"XV0D_>PSQ\M&$,N7!5;:X$C2 9CKBMKKCWU;Q8QI2FX*9'(N
M;CHE("+=K:%UKFEVRM:"VOM@&;7;S2JY+%WF&<9K3;8VH6U1P<TF1=*H"G:<
MXZ5BT1;N6@UI%'#,I9?$':T-=G.8)M&U>MJ#LT-6XH1JX;IU$%3($""\\L_B
MO+PY T"FX1MMQVD:)2%52."PX7ZZG<)#3C3;1PDYN\Z<ZA-2(;S5-TVV\85F
MVA5]5#4#OZ:^^':$00]W+VBUCKQ1]*;&\&+A^HITX"HI =S5ESSLD%PP'"H4
M3 *W)S4=<6^>L<3A,=-M,PU51"YV70-4,=?LW'&U2ZI).>*S-5#=IS2J&H!'
M"<56N6N -"M- =35<-QP=A4![#E:47"2,I:[@"XYSCF5: )5!=J<S4/>6</Y
M0-)<1OIG6'8%SO9E6I<,,#X&=!@(*N7./E]D<2W*R<\NM(J(?<<F*2 U0C6$
MLU13:<7=,G?; M6P/F#B>Z*1.86.:_$/K-E]!*,N;2R:M$D^]_P^"7^ >^-A
M:H]HW4FG7$L$P'?'WH^[K@5!PT+AYX^,M42]X_4F-MMYQ[BU$"AB9H:3Y4Q1
M9N<]::R:!N?F@6PWG>8Y?':5H52DJ7=NN"TV2S]LL"NX7V&N?M?TV$MVGNP
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M_27K5-"3Q\T 7^9O7$]IC0T3GA(R],<,<\Z@#W ?^&>?2GWI,M/YNX6*M0
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M"%CFOQ^OQG7BZV7,6IH)J%(#G>S24!63C#;C2P,?7B?\-M3B92":8_TMC?\
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MNC43'W3+B3J=1*\E?J^#K,;7M/"@@JYHR'6!->&5G=78C?&KQ69;@W#Q_-N
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M5DTBPPFR#%^Z<%);=.*R,W_,//9-)UD5H39"<+2;$)*L['V;3+%[8]*6;6%
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MZ%_U9_!Q&H[AG4#$AW"0,B0D2&8F"$M><3Q?\W8-&17<MJMJJ4&/$L9B1O\
M][C'I%(-VLCNC##.%A.@\=T9_.+\F?3'/M+\'!+$=2UW1&Z.PN>XI^GB"F)D
MC[GHUDHYB(QK]/$-.)[L_3 Q/=TCUESXDS$AV]X1Y\M.>L^LN)(N4::B/_1F
M?64\0<\RF0V#ZN]'W].V>#],[-"GUF<]T(_-Y<_9Q ^GM*?SI[?N?T!9$:Z_
M#9'Y0%RC[A<)YS^8ST^Z6HE[>7V^)B>Z8".DQ[9GG'K'V<%!1H4:1&GYOU@G
MZ9X+=S^H)>@O243^=S^WQZP".STC)>KUQ \9"8_^A/\ ]C/V<SAZ]6C==>K"
MM=3(V+=.I8E=A+]A7:$^+I-^%JIP:])L"4Q,1,<1-ZPM-E/\>V,:7SXOG52W
MG,#AZ6 9E?,&'Q^(+,V@RV/)C'$$R">F)RW;QF+$Y(*B\C2\";*?F?*J\1MR
M7E>RBR*YWG2M+HX^Z!2KIC!MT6.TIGCS,5#-75XBWCKU/!RGS1<J,"@S&8VI
MC<.P+-/)FA^/M56M\5SDI/4B+J'I5Q_F T'?39OR'0LV+>VDVTQM('NL.?\
MO0I+OBHN@'8N(B/LW1QFR<B0[:/4V;/%%K"9+J+<N8@_1(%$]FD\!<JK(%J=
MC6NJR,_!8SHLZ:R$0E@MGZG3@Q@]-O+7C^;JH@]WSVHUI&8GO,VY.8E8C$=)
M73F(VSK.L3_1OGE?+6*-@VRA4VO)E7!E(3&Z=HG9O^,B2_VFH_1Q C$"(Q$#
M$<HB(Y1$1Z(B/Z--ERKC+ ?$"L5O&U;S ,Y4# AMO)8^$18(A&(#=)3]J.*%
MB$UMATTDGIBHE+4T$LZ:)'>$*U ?=G3NQZN-H"(#&N@A$",:SK/*.7.9X>'A
MSM%LW!679*F3C#O N+(&N5;BCMUT]?&146+L8QF,8M#5O8IOQ2.RLT3*N2W(
M\-J03SV&$]A?9SW_ *O$_P#^(I< _P O8V\NN4Q_B3#FA0TB?>BRZ5A8VSZ%
M[Y]G ?Q9EQR%KTIQB_#IV<M%MLF M?SUYP"N-V.QE.JS;(=<$CXD@G343M%N
ML&,Z=DE_0QS/#N,@J9(8LC,]!$&6/U4Z-NDG8V=SG'N3]@XZ$%5_@"_N:=13
M5]?J7NDLK!A/2'T[)[IZ<XGC#V983+ OKX/(R->2;8J[5V<==MV_J]#P'1;K
MR=)!II]GS5=HL:F[3\MYRU3:B-7JM5\9:;78F-"U:#0B1Y3SXFMYKB3'%(_E
MSA\SD+*6*Q+Z^?N9^7><:AJ@82ZY1\&%B"GIILB0S'&(.EB<%6"__!ZW^,IY
MHR!WFW->8\1#EP%I&Q&+7AUN,"[Q]3;J&L%"+#:U6U\WH>1MOE**^1\6ZQD#
MSM;-O\LNU@$Q4\(%E\6(=HJ(B9'WBP%9>*P%5N9S04WVS7?<C'UA\MV,_>HN
MJU\BU@9:@VMX;5C5[B9$FI91*_Z%YG_T?8$O9'=TGV>WC?\ 4'T?ECZ9GV1V
M\=WL#WYCU3[PC[=.!V\M.13'U0/3L]O&WL#;WO[//9]PN?"8]ISI_P!V!ZQ'
MLWR/]#O:#^E//[G;Q(S)%$Q,3I&G;R[9UXF!#O;AV[BF?0 L#T1V\#(Z;)[\
MZ#'(B[L3V<M>>OMX@)W[([.W2"+L"=?1M[/IX%93W?>[QQR_)7.L^OLX@-P:
M'RCOQ\/U]GU?P3QN@@V?6&-=8]HQI][C<+%[IYE&LZ'KZ.ST>B>-\&,;=1"=
MVDQ/U]8^GE]KCIZ\XYG$'&FV/5SYP<\:SOG_ $OH]?;/'?&)GTZA';/.?5P4
MRN.7=C;,Q^E/I]/'UQ^X7^K/'(QGZ>[^'CW9^F.<?=C7^B2Z_E3&^;3_ (,1
MK3REBK635@LQ9CQ(G:2[4BGNS :%I/;QY'P[D1XNCYB\P8'+JN)7:L8^Q0QF
M1O>'Q=CJ-V M3 6LQ+4E=V>*/G=UG$'@[UNG'\.KI%%I./OY <>GI9?KR3LN
MJ3@C7*]DSJ/&5Q^3FO7QU>,R>.QWRVS#\C3Q5,+2[>,S0$RI<N,[W7K% $D>
MSCR]G[5_RX6(\P,K$6(A<TWT*EX"97\#E2>R<GD4CIO5*XWSKMTTX\NU:2DU
M+>;ROFH6VL;@6Y/PE3#Y:RO]SPE0E^*O6M8DIF=OO&7;Q9ZV./YR?F/'^7,+
MD,GB[>%J7QRL_!R=G%MF7JFF(GU5@>TBB-)Y\96AGV4L]"/+.0\T4;M*C\M<
M<8UD+N8ZQ5ZUA4:D8RM@^C77C#9'*Y#R]<QN8KD]M&E6FA9HPRG-U,8FP3G3
MF]@CH<3 EIWHY<5,HJI?MTKN2&O\CJ^5LD2$XP[4UIL+\SP<J;D*PQU#C9TM
M8D>7%W"9)U2G3ZN350I,H6!.W5HK0:KV.S8L94NV6=29L5R@)0/9SXZ<$OO:
MD'.?[>[V:\^.I+!F>P^W4M>S3E]6?O<;B8K=VQSG0-.<1[OW?7QOF0B-.0R4
M1M]>[7ZWX.-9[ _.]78R>?ICLXF3WP*_<@M?<GW3^W'*."U@99[@Q(QW8CO#
MV:?5YSP [)T[LQH7;LWF1SKKVEI''(]/TXT^^.L<=FL>L>]'WOLD/Y43'W>
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MGGWRMBM>\.QEPKM=1QKZ8)GWN,9YTR@F%MGE#SWY+!;I[VOD[^72AS3!B?\
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M3S0(6+*UA#"\&Y3D%(3RWS&XM..C0\DG43'8JM<I5EQ_[--&!CC_ .Q2[_\
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M@! 1+Y++"[H1$1.V=9_H8[7Q74\)D]G3T\)MWX_?XGT];LZ7]O[&2*&CL_\
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M9+-IS-VC6K)L6,G,2ZTT&ULG916K@#B=*X(BGN\H=5^1MOU\EE\'FFLR%O'
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M]1@(JA74R0':XPV;?>7N[==--./-75\OY.S/EZQE*DZ7YL4[V-2Y]<7.58$
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MHK(BF9AK0=L:LX+=TQD2'TG%A.?8%7!#2QY#9R&#KR=F[8=EU)<FW,JK$QX
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MG"MX(+)D)D'1L,6VQ$C2^'JUKYG>'L*(Y::<*L-N^>=:YBLT,2XNKME4F#)
M!DA87;II];3T:6*R;'F^ON78.1!(UZ^L"3V3OVD N^'M],G//ZT:BR'^;DL3
M7KJ=X513%@%0V8F;>S0X9N[=1][7Z#59=YLM[2<F*^TK%5]<T:;7%&WW.O.G
M?B=8U[>'UL=3SU8]BGPU1-K$Y:3%>U5NZXZT:]:=8[9B)]/%-CX\TKE LIUB
MQ]FO;L&O;#I>_I$W66$$#!3,3&W2-(F>#JOR/G%ZVK40OKZN6'6W0:A)2]I$
MN"'?Z(W1ISB>%3%CSDPTRX/%^%.;<D_H;MIL'4.D =@Q&O..W@.H[S6Y>137
MVRP.J^M/B] /PT!\/<5*-Q3V08ZQWN#9X_SB0*MI0\FZ@YJ[/B9 E(D-=B>G
M$^YK,3$>V*YV*'F*XX4",.L5K?BK*E[1-IK58"#D.KWN[^/BW*1S9U\F!B36
MWZD+K*N'+F%6K&R'H.MXDNT9,=-(]'%YH7?.2(K=,HKO8I;2W$F2&I,KGFHA
MD9G3G&L\]W#G>*\YN6Z'U82Y3.B;32U0C EHQC5AS#6.>V.V=>(.L_S0RL\8
M)8>+HT/#D+#5*(JV"4Q0Z#.D>[L+V1Q?1%CS15Z<VK1=(Q3CWG'3F!0\>\PR
MY;(UT^_PP[Y>:;HM36"TNTEGAENF4$+1,"26LEH.Z"F/M<-*G5N4X&RT6+NK
M>MDM$(W,#Q!F4J*--)CEQZB_Z7XIXGT:''X)X_.^]/\ GX']".!^F/PQQ/T\
M'^C_ -:/L#])?U?8^T/X(X'[#/M?A_H>7=H[IZ-_N@.K.IU*.V8/D4+8,SK'
M/W?;Q6I4:*+>8M+6SD"K)5'N@RJTZB=RP\?\"-Y3U=.L$0.O":=%UI5]%JXV
MU?)@WZRK860K5ZS:>,E51E?IUQ,D0#)F61$QII,+:S%XS.5=T)')X+*5*X6'
M;$=07K0;("'6WR$!T5&L%3VEPJ+'EX;=J6,Z1*L5L=66KK[FU;"!;,.=B=T[
M_B!IH03K$07"_G+L:_H-!I8; %J*&K8A5U%W(8Y^EC88;@5U7,5J,Z<^ZI]&
MG\Q\NVV6265HJ+W0RO9E;8K9"MT6JO+HT"[K!;,2R((9C2>*NW:RIXBJ2;"X
M E-4V5D1''=$;"1DH[/?&>79Q_-N.B*ACS$B(+IL W_%R<]1DF1"V8]W='J_
MYSCM?%=3PF3V2O3PFW?C]_B?3UNSI?V_L7S"U Q_Y=7/W?J;V[NI9^(JH?P&
M=R--3B>>G*=.$YOPFK+M2<:,'8\)1H>8RK1C0 K +B\<747VG7[XSZ=H].(X
MMYGS"MCJZ.K5%<M>EEZY7-E1&/K%8WVEU:2)DF_$T@RF!Y\'C;-2O2J+$G4K
M-*HJ'XLJ4 ]<U2-4RL+6V ?J<;UE)3,3H7!5)_F%Y<ZU>Q5K @\]76-F !BU
MW7#*G@!U =H6YDLB?=GN1NK,IE6R[<@H;5_*VJZ6S;CNU_!J9I8WXN8#J[>H
M>]C"U[(B$>8<#7\&V@;774(:XO O7)MJWZ^T2MKQSR:2V0!;P$M.R8XH7;]0
M@=A4"W,MK.FT#"ELW,/CFA<AENMD+'S-ND0T= UTGX8\6&N$88S+9(M '0%:
M^!DDQ,;>H,'KM*1$I#3=SUF?LS]W[L<?=C[L?8+[4_AC[ ?;C[D_Y_L%]/X>
M/I@OP<?AGU<<NR"^[R[?O<>J/3/^7IXB([-(GZ>7IXB9]>GTZ^B./5$=D<:S
MKVQ,1K[)^Y''/[GXN/SN7+U<H[?7/!<_JSZ>-![/3/K_ !1P)3V;8[.V?HX+
M]'E$?3'&D3S_ "OZAXF9]?*/Q^SB)*>4#]V9]$<#KV:=GKF?1''/ZL<O9[?N
M\;1GE'WY]?';/';QVSQVSQI/_I'V_1P4>B)^V/$:SRYQK'WIC[O$:\XY_;B>
M<3'!3$^J8G[?I]O/B)CE/J_#MXF)]<\_3'/T<1S^M,Q,?:Y\#Z"UC[?XIXG\
M$\3,:^]&OITY3][GQI/./P>V..WER_!^'CGZ(+2?3'+\'V.]/UN4_1'I]G/[
M&D^]H//U\NR>/HG\'V"_LQ]__-]@(^F?O_YOL%Q]J9^]/V"^D?Z_Z& BPN2I
M6:&51:VK$B4+O#+\4$SS)B3D=%ZB$QNDM>0\'C<>IE:[6M[,I9&W8\:]&1D<
M3C;52OCPK+"M;QM<.@9A/?*"GM+BNUM"NW.D+6$#9%B,0![ 16&N  CQT5U1
M,G,3"NR.]K/$>9XR5'R[?$V5K,V)K4,;DP4LIASW,% EDG=39.L,%HJ#6(F9
M+A>*/SYC;U5JT=>,;E47\D4%7\-X*LEBT,/Y>O7GM8&NDP'>F(G&7\+1^5+9
M'0JU@BH=,5'([J;@6J5,+229)<FS[W!5*_3;B6%.4ZS7VTTKN.Q72LINFRKX
M<(>A FMT.W:[-GNGP?@ZS:QY:\AE)=F$6/ X6JPE4F]0$I\7%T]DKW\RKB9P
M8D4<?S9WO%H_Q!7Z0#9Z_1&&9.)$AWG*"*8UV_\ .<<OQ+0(ZN2**HC/1L0!
M8_5K2W:"=;?W>4Z]2?L6&:-)S/Y<WN2QB5=);+\S+])ZDLZ@CLB.4\_3IQE:
M;96$17&^FP_I2M5NCO.86ZP#5B3J<L@9V[])U&/3Q2R%H.MCL]5QLYEC3LNL
M(R:<36KAG*>^QU$P\&@;/@$#>F00.L1/$^4*UTK%:@C&Y7/C6.%5LY;R6TZU
M=MCQ!3\HJ0]1&D(F7RSO;8'6"3<_AY.0Z^.&S5;8M#85D7((JU,VQ>CP[;8"
MV87$B$Z]Z(V<JOE>VUM7%9V_&"/'04,JT,TFN(IRU(B>ME+>UBEV53W&2R3U
MU'2*F($%6<=@[-*SD[5<[*FYG,8^S,*4LUVE'..KVG1.P%SW4R<R?+B7$\;%
MG+Y"WD+UQ4*ET^':ZO76]B5(.72_K'HP>IW^6[AG*(GYGD/=YP6G@(W043.L
M>KUQS[/L@J3"&,@R6N2&&,%>WJ$ :[CA>^-VG9K'$&9" [>9&4#'<B9+F4Q'
M(1F?HC@#&8(9@3$AF"$@+21,2CD0D,\IXGZ9X*/6,_>Y_8^@OP_^CA58[" L
MV!::*QM6-AX(V]8TIDNJT$[HW3$3 Z\^(GUC'XOZN(GU=O&WLB/\N?!>KE.O
MT<>R.R. (O1K'MGB"]79ZHXG7U\H_KG@_3/*?N3Q^=Z_5]'MXC]&-9^CEQMC
MLTG[?+MGC6?M1Z_\W ?1^"9^]P41^3SGU\X[/9P.O;KRC^N>)(NS7[<^R.)U
M]V)B/\T<24_5UV1]'*/O\=O>/M_K_I:\0?HGNE'L_&/!!/N]L3]Z?N<$)=G*
M?\\<'Z8D9^B>(F.S7_+[?!?E:_K?Y^(B>R9+7[W9P,]L>OZ/P3Q^=Z)]?LGB
M/1.Z?ZHX[OVQ_KCV<%Z8F9UC@BCLTT]L:S'*>-)YQ]^/;' _;G7[?^;C;/VI
M]7^;B>.?; SI/T\M)XY\N/I+\'_I^Q$>H8C^O^OB/IXGZ>"GV:?=^Q],S][E
M_0P,SKH57(1,ZS&FC*?=B>SZVNGIC7U3QBGNB"')X7+X7*44S*;EU*<>8@1>
M'&+S(FNY.S5H!N3&GKXM8?-V45F>7UMMNOJDI+,X+%59.?B3;:MV14*!/?!A
M)@4QMF1UX1?S$K?4M(BX'CG$FAY>P]>+%8*E52;(,6-:R.KW$4,LF,3IZXR.
M)7A[ATZ=%E@,=9M)L5\?9J.BG=#]X; ,:HERI^R2WC!%V\\A9S619;O>2K%:
MID7/VKM9NA;04TJ\DIS@G(C95X8W!!08QU)TYSQ9NV232N>8+V#QTPLS7CZ>
M*K-N+IX_PUEN2JKZMI9/.&][E$S/?XA2@@$):BI50,;%^$J]*LB1")V;37&L
M:=W;K,:Q$Z?S<5'4ZGSVHQLL$1C4F9/9"=LS)IZ.W29TYZ_\YH+\2 "=;(%-
M25ZG9D"H[6@S;.R*V_G&L;NI'J^P?P%:1_+O)3XDU'N@H._'2%_-0B43S@H^
MCC)(>4=!*"N5S7W&JOQK5J;1$DP_Q)6-"#O'LUF)GGN\J8ZK&[,E1#)')HAB
M:]6Y43>=<MJE8,( VF[H OHBL(VJ[VG&=RO5"U6\QT<1ETB 4 M9 Z'1KWH3
MU)_9UVTRER DXB#&=OIXJ?S!+.A5O43Q<5\;&+HG635&JP;%.RD:G2NW6%9^
M#9F?@QISCZN %$+JU5>9RSUBLWY?U48_%P#VW4$F-]>GK4D-=%B;#'WO1<+(
M?'?YFJM?B;*Z\5%747K/4.8!,PZO;C80;E;=[EZ3)B>Z1:,B5C(VG_-#; B4
MOJM8RO776V]*NDZ]J#&>B&I:[!@8F)*=T3/S/)<A[-(\#$SIKK$S/K^_V_9I
M3AFVE@JGDEVO!7$U;1&ZY@F5Q7UG5>K!5ZM@2&'5Y(9D>JN2@X\K(M5B?E\9
M=<=U(99O('X?.XQ+FV;-UGC.G-Y)-6;G\MXP3=-2JT<3D,D-!%.J$(#-,?<7
MDH\O4ZD6%6;67QY+HT\JAA2OJFJ".#%#!C;Q0G&,MO,<+:0!T\J.(&IYF)E'
MP6;R(0RO&0QJ 4[<G:V.>G1+=J.34O,.\&57,UL>P,MTK.N.JW?X7LQ/O*L9
M>UEY\7,SW(H*W:Z\'7P^2R<8U=[)%2CYPQ]Y++%' >!NOM7<M4:RG5R"K\]-
MA68#J?W=@S$#E:X6[SL[>RMFXV9R[H8S'QY@)W@,9:8R4XB;'EL>BKI]*%&6
MLS!:EQ\YR@6(6.(R>.QZ[>5/(6Z-.QYA.[0Q]HO$V%V7IH::MW-TY!U"VZ\1
M^;//7T1V\:1V?Y<YXW3[LZ3/XH]O$1V#V?=XU+L[-/7/$^R8T^CLXY]OHC^N
M>"6K/7L>[>,M2VF;4]Z $(I[4!JLBG37<4:EV\N%@KS6]I'L#8K%6#-DE$3'
M3$5R4R4,&>SZT<-A7FEE,4K$"1EZ1%,/*-O?U0D8YGV:0>H^J)XV?Q(600N-
MME6'Q!^*6[;.A&:DOZ"R:LN1#V<NW@87YER%40&.HB]0:3]^TYDITK)V#TUS
M.DQKW9]G KGS)?M::RU-;$V.OLT*)VZ)9 $,K..R8W?HCJ]E;S<-=74%*UY/
M'DTQT&"+=JI6X]%Z]V([>?.8T<9YVYD*VWX!83$-B0F9AD0]ZJEA9GT3#N\I
M]/#1K>:K:AAA: ['L<X.0=PIA*Q*88T-(TCE(Z]I<&QGF/(V:R!)KO!8VQ!K
M"8$E;F36<(CM(?>C68C7TEI,_P 95%A)N=LM8_>U:(W;9"3$>R3YS[G*(CLG
M67W,WDK8=^1MX?%.33Z"P#JR1^"L+,UL@N<3ZX]'!F'FQXIDCZ8ECG24+ IU
M@R%<<]JCB9CTZZ>X/%MS_,.2<H!V@ZMC6K2AQ3 QUV368KW_ *NL3SF.R!X&
M/XSH#M#<PK&,DFP3=.B)=08(1[L^]WIY_:Z]O*YK7<<C:IXQJ<=($4>&(=U%
M@$J1(>]OT9/9P<1YL;,Z3SC&/*!YZZQJ'>T$Q_2TY^^7!-=G\GO:1#5M1CK(
M4H[)T.9JD;2&-8C:6LSZ-VO$A_&F,Y",!NQD$<D!Q#^I.G>GO:1';V?3QN?E
ML[6L$L/CMQMA%+Q&[4X%94!, /2=!W[H#B)GS:W:PIY?+'#SU$2'D'=UG7Z-
M_P"8/"$'YCR%>W9*#58LX]RJ9HDN[*5E6$N]N@M=TA$:_5XA2_-^.:QC"Z"%
M8>6M:N-1Z:P"-[6R83KM]/9V<" 9S-T7LG0#R%!LKD8*9(H":*)(@[>W3;'/
ME/$P/FQTR9;0_P ,?.V=S.7N<]L!/T].?7Q57/F6[1>M/6MQDJ# 6SO3.HK9
M65TPGIS'?UY3'UIXV1YIKW(+OMKXS#F=KH:[BE&Q;3&?#LC0YB>?/A )S^6J
M',01!>H-(FA.R!VA%1!C,E.V9[-9]G"5AYKL,)LQ*ECBK$DR)D-!@17N[W4&
M?[<>CAG0\TNHQ57,,5F*1$76W2/Q()%<8'5D<M-_=]43P/\ \I/F*H7J]6'Q
M!^) ^8=26+0_HIEZRY$/LX5,%99!_7NA*[)Q$S^W EID3_LQQK'9^#V<;9[(
MTC[D=L<:^B(DOI]7W^-)^U/J_P W$Z^F?O1QH7;]6?ZIX$?5'W^WB.)GB9]4
M?AY?8^F?P?\ I^P,>H?P\_Z_Z&!TV1/A,C[VTN?4I:3$2):1SY_1]N,&X.=V
MXB_-X!-D)=4Q]4O"6&DN3=1(XHEOD>EJM<2!;9D./-KJS@KXGS(G,>7Z[WUJ
MP%?R&31N%:C'X5!"FB+2$=DSO$>_VC2QM\DK8>%M8@K?A<98JXBS7*QO3:H2
MLYFTB&1#PE8R?.9W^G*4<7D69SYR&,+H34HQ<1=E,JL6E7'5USX8R".E7W?
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MU>J+&R1:PP>D>A4\,W(82PYXG&.S>/18Q5C(GM10MU"*+UZC:*G4[OPV <2
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M6A0*Q?+4U*AP0OC7GU&>N>+@T\I3KQD?%U?#0^5OJT'^""92">G8LFNM4<N
MDQA)'N$HTGB L9NF96#-=BN61;5\25?%JQE5M3<#O#V+$\["MK%[I&>]SW6^
MI81XLZ=2K44)1TE"FVQS1EYU6&J3KELG8/1*?]G Z1Q6R).6M:C 3I P>2!Q
MS*VL/34KP7[R6^4[146N[D0\^,%ME1RREEEF+(GX8-.@LHW:QIOB=8TY]SA'
M2JKR. O[HLU7 43#FTDU+U!S4VC$2CPR2 YIR$[MT1,P4<,N8E\IQ3@NBK(V
M[*&X^Q5KNZ;:]\,<60J7-M=(,G:LC'=!=-6L<3;*MG/,EM-?I^+9CJ5?&(H
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M7S-IV0< 6%A.>14M6FMJV7;2BKIH72F"TU+D4PG.U#'&Y&1=Y@M6GXN&>%;
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M:Q$[ 7NF3V:3WX]/KCB-WEJC;Z00(MJVF5D'J):C ]1,S^TD=2'EK/HX7/\
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M;/Y5I0BBFV)C7ZQ^'\2X"F83$GSGF/%8']4K;&TLCD'V'18=U;:ZQ+QPO$F
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MY!!SI'",RZ;?@[!YU:ME;<W=Y=3E'Y'<O?&D=/#NV?E\O7PK%Q#CN/Q=O+J
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M_H^7ADH">A?[)"&SJZC,%SF)Z:]D_;F>*]BM?35S*%Q76Z24$WB6+!JM&XD
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M.06*/;20"Q&N/N/8RQJOJ:RLXTQ]=%L?$Y"QCDYM?R"?_D7;M>8JV.;BOB1
MVC/'-=(R_>4%7ZW[)D#P=U]^S2R=+-IK6LC4I=%QX_&>>%XZQ=*G &*PM8BO
MU7;8V2$EIW)XWUFMR*L@[S4\(M8Z8G 5JO\ ,*KCXO\ BY!S+"APN5:Z(<)
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M[3/[FOF /+_E6MEFXZWC;7F"T>172NW,JW&5BKHQ*G5;"K=ZEA93S:ZJJ-T
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M/)V0LK\\M71M6UY$\YMA:<C?\MFNR?05 /\ E<7U[9,HFJ+2^!\.>/,)P/G
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MPU;R=D?X@N9"[DK:Q),9:]D,<],V&)6SK.42M.D>^:]F.I&1&I0?+9SEP_\
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MZN(\)7ALY)FY??\ AEKN@XB.%5+RUY+,9NV0XZN5E57#U(;FO.*!#Q-?"1D
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M4UC:)UAI,KG.UFJRJ#"IY1JJ-FNWEQ7HS3H%1IE3*K5LH6U=<\<:VT#4N=8
MZ;$B2Y[0D8TX=?;Y?QKK=F6E9MLJHF6L>.RP9;@@M;(:=3E\3ZVO%5KL-BWM
MI,)M2? (UKL*Y.0(UDP?>\>4NU]#9WQWN?"+>1Q6-OV:NGA;%NN-UZ1Z@O&
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M9.^8[.E'=Z:?:R8G7UQQ$#RV]FG+33CER/[Q?1ZBX(PY>EH:3IJ/,6#'H,.
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MI7;%E=--5WF%P/'(6BMM%?1HJLGOG:6R>%)LY#-5:T9C(X?(C@<1C_+M;&>
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MNMQDP[^'PIK(.K [1 QG\KCISNUCFSLTV^C3MY'/'(9T+D.I>Y/MTCW/P<1
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M5G@TP:P'(4T6,7 B##$QF",!&(B9YQ$?8O=W?^YV>YX6;V_X)]WP0R)7-?\
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MIS(XG7US,<XDY]'IX%ASS]V9] P7H'^UQKV0/>T]):=NOJB1]'&P?\P^J?\
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M'U0F(5'NRV.'$*B2KYME-@E$Q.FZEIU(*(8#/1I.[LY3,:3P'Z,?@X/]*/\
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MQKQS7Y?_ +3,F,_=\)$<<E8"?HNY3_ZDX_NN ^W<R<_AI<?LO+X__3.3G_\
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MOY *]=-K)-6),10I1,N=(QNV!,1SF./-?F+ Y2?YAYM13F_--K'2(V\G?BJ
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M(I=N .1]G^L,I_<#]L/DO]L_]S\+4_J-^^%\-ZI^9X31#XN_MS_L@
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MU:']]>N0FA7"B/J)@^;?^>6/P-'[9%POL5^-<TZO5?V;9\A#WP(7T5L^Q?\
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M63.?8*[3TW![U]L \*90OQ0OIBB6WP.SX)^09XNS^82Q]<%?F.?]S"*/ZG]
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M%:;P9 #*2?Z'S45>HU ;5VH@2Q-0@N.$R1V$7Y 9B$,)R QZ>M*0(<EO#_\
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MLX-M??H>Z]F0;$KR!.L\#S[XM'8Q0W4AHKCA?&(2I"]Z#0^5SYP(;%)VMO\
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MA-*;6DX[&]]N3U$&=>[AMI0S^+*7CP@G)$-FCOZ,\08VLB*XK#Z^,5@!UV=
M]Q, FR+-6Y 7+DTC:VPTJGP^F>I[@7XPI]NI?C/S@EH>C]Y'Z14Z(_<#9[B,
M<HN[)6QY)Q84Q+*U]VROU"&"7/%N.-3$V4$*.3YW4@LTHK#@!.=D<Y2;^.4X
MUQBAX3<(5AP9E>@=C7(3\6XJ8 51,_5I-]#!<V WL:7: UV U.[Y:+NY&2H0
MY'2DV#U@6/<;YP@HPW>23/A.JS9()5ZH%VO"QL.%5CL>B=?_ %A6U6 #?(?F
MB.O?!>08$%%!I5]@\N><U>.R=4)VZQ5$=VI(8;1Y/.?M OR+TQ,ON ^Y4R_
M6>%?HE^F(+Z+.-'Z#L_ZQUC1#D,#QI3BX=6; <T5/-WVUUB$!J#AZMUV>ZQM
MH\^1_P E]CUQ'.:_Y7EGT9%$;8+ 4[](SF1\N+13'1P^IK-,0/TZT,N"(1&\
M21.0 WTH3?MVK61)1UBB0'*2X%O'JZ=4$=<VC6&DHW^%9#T9B0,8@:2M97%#
M00'(61%  KK#JH)P&#J]'D@;X/(<,%TS6M2$:^V$YG90P\OG)Z)FK^ERNV5-
M5LYS=6V!L+'@8#T!^E^[/AZ]NX;PE#=E5@@^AX5U)\)2:^$((!AL Y.BP03&
M_3/W0QM$/A$S^6,K&0$+@8=!QX.@$ &C]4*"2+<$BIXG7P3-AM26,GCIHJF0
M!Z'-$6TQ,3#%X^@UHH"[#AH%P9K'5CGZ?P(L8_@?[!2G.DH@,T_Z\RR4_CPD
M;[*R9%!.:B&<P0-/H!<(/UFXF&:D9S&";SG D*H"NT[Z[L @=,Z):JI8HTC\
M!7FS;S3ZQ/=QYR '9+ZJ7Y7ZN?.$ ?.B\.RCEC;YP(@JQOT$Y\O289WC>^8>
MMOWRR\^%HWU2>^;\-.=3[K6>]Z5#ZO\ #C*3X&?JGY'!BCLM+ZCM]%SO(\?R
M'@G!*MON=D^#TRMFQ.>$@[(/. $7G"A]G\!AANXY1,;#P![$Q?< +17+8;?=
M@W:A@ZR+OY/X81A^ YI[$UX>C!(A %H:0$]#Z/&#CKBX!-J'\ELP\@@24> 0
M=\*^F2#CDX)R ]/YGG!,9!P[KR$5RG[P?Q'+_9S3[M_& ;^GWV.:C]_/W!^>
M=H/,'[V/D</R;S\OAI]GAP77VF[H#1MM]LUK8?\ 0]$8U#TFZI9"02CEHDS;
M$/TC6DG ]Q+;5^T4^:$C9=,+#^;6&]^EPD +^%BEGE@*>R8<N,HSR2HU@H,7
M-X;VI0<1'S1FF%_F LV(2 FDY<=&E-) ,KCW5S45[OY.AS@^X^<.ZU%::&CI
M=^CUSN<:%DYARX'G#&:LC!X#/1/;]<TJ<TYK0)=O<3(U4[;;&+1'^>)JB&XT
MLG+KV#.*)8:1"G4IK.I^S7L;/W,6#[(8/MJ<^;%]*_4<_BS7RWC%8'P)'(&)
M]30GK1[8TEHH\M3^D>QCJ>CZ9^'H\9A1Y5NPJFYW'OX,.U".T\@)N+A[=]81
M++10=) J"%$HS.+SKS-."9RP])LM/W*P=6(P/9E+9IG47)G@*J..<?1N7 #L
MF:(E20F@*XMX GR9X#JY*BY&M-8X)[&,1%)V2LAB>BE2FLB*2H0>5&,:W7%.
M&Q'3(YKK+!1%0,=(YP>.FD:H#DI:S+0,T_JE.NYMMW^EV^$J:BJ*B](S@0T9
M!C)T#E]3?Z0HO$%-6B)!8, Y". !5-?1^"3X<)M,R)"!;Y,P)\VA/3EG<^:M
M^$^)=CI7Z!%S*KT]0ONA.L87MPEZ0/5,B[0?'KU=1@7@_0KC>/3!"0$%UI7P
MAD@F]5! 1D+-&$;CB)6R=0TG9Q!"B343?C#1DL@[4$L[)?@V,;TT[[ JJHX@
M3L*JZ,U!R((A$*"2)= 7S&*>"4D C:X''19:0KFDSV[H!B<W&U%F":THSC+@
ML0WU T$49\ ;T*BGH6W&F"L#PON)G@+YR;]W1OW/^4TS@E0>G?Y6Y>#R8-&&
MG+-%#U5?7AH"XFR((>*0:IDS9.!KT UC58'9%#TLA[S/ ^V]X4GTF%3U2M^Z
MT9R!9M\;FIG\Y(MY5?'AT%<<G*<%H-;&A ^[RN(1%AI.EO1GB951LO!776E\
MP.*!1BH4V(/(;T;SES3O1XBA$'[.\[;D8A!OV_8.\W:TI319?[77/>-6A4K2
M@L2V>M^F0&IBIX6:J^XN+O@5CX@4[7MS@+T?O(?QG&#Y#]HOSG<]R?L_NSK?
MLWXLM'+[+\&4%\I)/W'Z8#=EJ,B]FB?C))?=.Y/6E?:9M@;VO]:YO9AZ]:38
M]Z_8XJFZ ;\DXS:#\I_RY.1/2/[OXS^4,?;7X8:Z/H#_  _?BOWRP?Z10,9X
M&G&^L-I4GC9=!JM"79C2X-@9N/0:/LYN0"""GP%-YN7H.L02+H@-^RSA+WQ7
M,SF!\)CD^CSE6' .IK*V-O8W@7)-J$\285V_8<IT LU*0HUP/3QB#,V:B> W
M>GD/3&UHDE ()K18WQG=Z)_NWZ7*X/D37W1G2>D+?X/IA/#S]]MZ?1WB0*'&
M"3'Q&>( )S7FC-\Z&GD@7V</), >WJ$K ?*I[G-<>MN"/LM0ZVXYP0TK7$/(
MZ>;X,AO*(W:IZ0$FC'[7_*8(/A/ 1A,B"J'D%-IZ-YC^B2,1>\ +SA4'8:T:
MU6S:8T#.1J D'4"[X9-,T@^P*AL\X<L&;*:H9'L[M./;'Q? @.CHBV#H,655
M4P$] H/-6)OH"8GO?D=;BXOCAKW2FKM&#RQ, +)&XM$;0\NOTH5=%!7Z)U_!
MG0^M2B#>$ZJ6?I'G0+(J"$6SBX"9PP @&@<'P:1J&00</!R-(+,LH\&LS3\0
M.:>!\?+_ !!G"_6!%I)7LQV,!4\8+*ZM]"4U4X1J8S8Z0W3N8C=_H2B%@$5<
MBMGU\&<0%6NQM3#KM%XF#;F0P#2FR*,%]W]\ORY?ESWY[\]^>_+\Y[\]^![0
MP=OR-0)YD?3R@@ZV07.P^48RQU[P#0=]7W,;5(7V14.&U'>_.2:C@+(1/MM>
M36;?$3UZC8UL!;F G<%UZ^O/MFA5/JOFKG;GE/Y/V?=GC1X./T98: CD"]PI
M.-I@(GR=0 $"0JSU.M/AC_$P!QR;[S<F\5&@[P:;Z>.6MY$(#KVP.7$><85D
MW4'59)1U6XU2YYZ$A2PCV-Y7$_.KSUT=5-0ZM>-.D6CI&.-)QW1BXGPZ$=\B
M&[8\N<<W RU<-H+>!WG-NZU1R$9$C;IQ9'B/#D.P2)@!C=[:8F1"4?&<H2*<
MU;!+8RYS4.? 00=Q1CK6<:E[>X"!!3=SRN,I(Q1Z#<XC.Y,V;+P$5;?R )NJ
M-.</T(-.%Y9&I4N!\7U/\/H(HB\Y$TQY8S+>C'K*$E^;4Q#V@IY-5W.G$&H6
MRF<!*JZ,6'=(2AFF'=PXCYG#>XJ>1Z).<UBV^VKHEJ%7"P(6LIOZ%X'HO6#B
M.FDO37@*^A3>,PM=CC7\H?SAN!^!>[=UC[O.:4CK9<['N/V!<O;^R)8U Q!.
M&N!2JL"\^N-CQ@=[-L:6PD W1>MZRJ ZF4">^(XC):>Z:B B)(;B3QE4Z-B1
M>5J$TF6A%.^'\#\F)-)E6'F]$\F([<\K?H)HS11#Q^2JH[X<[1"G=Q8#)#[]
M&+D]V#OM/5[\]N-(PHYI[]I0]/&#0<"N^57MX3]F,1&E&=@_2>>#$FM9Y J"
M0/*CMP%&E,8(DF#^4D..T@^6"C3E<7#WE5AM&0EPI+:#!4F$H XJT;(#W&XP
M= BB&7$F[[M]1G3Y=FIJO:,\#E@A#: Y30303HC>L0,1,,,5=2,\]1Q)F"A(
M$6W<.86#G.2]M"W/I6 -ZN56NF9:3;RUR\>[C9)!0#&5:\JOZ! *"?=]@:=F
MW^'9U?91 4>F;P[N>A7E\2Q?0)7Z8]%>PYE1#CB^7VT"T*%T9@E;"V(1RLC/
M@2H\NO 52XN/!S1_BN3IM9+4$$$PTB1Z?T<D?3,);K<*177PI8 1]D 6F."]
MOVU!K?#I'2 :X%>[DY.3DY.3DY.3G. -4X=STNCS@O"Z#1?I0%Y,8")UGD"=
M6SA]'G'4DPJ[ KU^&].,H'8R]12O?HX[U<A@8O$@4VF-/)35Q]'OO8>4'$MB
M,20>]^Y.#T-8VP@<N@]7*9<*;CS:@^ZY=,JKNU??45Q;RQ62GOM@-HT_=.(H
MB)W)?=.ILOG"G<HNO.&UUY>YB2:J0A<AH%V?LQ9[<'&8O,C9@ZR%E@^W8%51
M[M3*5;#K;Z'#?+Z><6_(:I;HIH\L$[OT\7DZ"5V^VL 0<DBGA ;C>!,[%4\@
MZ\ZX/> 5(0P,"9IH2X!R'?@:JI1Z[>,X(T.,JT00^E@_6,%@WO!L DZ.0+/&
MEK4E^N;I;S8QWXT4Q'9$B.&'#018W#$29PV<3A+=>5R9']<0D%T!+Y!BC6#H
MLJNYHE.U82<>( 0[F$!PX38@D09"L8T(&"R1M $[Z18P-9P:;S**2DV@>,E%
M'ZB0[M8C-HRMN< ;*PA*5AB5M0&Z$75I8(*VZ?=!)=OKE42AJ=MFB3MIX3/,
M6TPA4;"H48T20:,!D]M3[7'AK>(3N:';Z>,*D/0N27L![;Z86$#VY4GW]&G>
M%@ZWN016KO?'MBA1SD2I/4<=I^<NH;$$5 [-BBZY.\8FQ!I7N'HSVDNFYU!Y
MWR1TYXB'L)^1R\T?B9Z&D_\ 1BHBH@YTO=)$<,XT45Z[0@=E.3QQE[8-4= W
M]@:#\\!T^<^LQU]^M8&JDH=@%)VG!^Q@"V3]Q7H?T/?(R+%T0,'=1)LP0SJ=
M8%+,<*J8.%4+DM>W2VW:PN7Y3069 _66R 2F",&HE<"E& H @9($4'_G#.6C
M>[E4M+AR).!QP9*2!,(<./;"$ ZCUL@"Z,MMBHB3E60JF\6@&*#'2*-IZB%!
M0S>P7;<U2-T%!@ 7I#_A=H=3WG]+J;!%#ELHU'G/!($"3[!@[3_ R5$\"#V>
MJ)4<?C"9$<H.:D&L;((<9@E#0&"!-&]&_DJOHLWE-/RW.HI)+[RT0K,V&%"B
MJ:+A$!%NB7;[M?@<6W @29M%:?' ^)HM=';E:GS0.6(!YC;.I@[!M.-2@KRZ
MVN!9';>;'N_OGT9]&?1GT9]&?1GT9]&?1DU=I;(IU<(YTWK-]W&';<OP<=8&
MA$G6G0D^V'AQM1 -B4=E)S^["+DCI$A7LE4=_P 8J;J./G7<-#]CE(U64(4I
M]0]<89*/R!&;.*ZY[3%JG"%[]>US2X*0G,(<+?:3CG-AP-;CAUFUI3TV9SR!
M!.:@A@UJ[R^H<1LDU5!R?=D50#J5S?QD]\7@B--&Z_1VP]'%SC17,[>I <&-
MYM<;XF2V22&'/#H+((! DL%CV1)RN7=8UF#1!%BM/"<C-HQ#R(]^(QDYL::W
MK&]@,>I.(Z;B2)OTR8&#\R#@_!&0[>U8 @3,I"/V?3L=<*  EX/"W\04$7$6
M:31(O*+,R23O.M]T//$:83Z#WQ.Y]<NT8QP\\-MY!3^B\8WN6;J07$MI"LNH
M-"F6:')^>T83AJ[)9/T2*-=9<L4H#;-AVF6@8&?AE=<Z%W>!G#>]N[VU QOV
M-!FF^Q'P+!&\;L;>YBP-/D&A13<5@$[)4+MC6'+I W\GSY!B^9J%?EQZ,'((
ML1M+)@+J:F,%EF[HMH\DT&[G%=F8:VU_44(;QD:=1.-)_)X<*\W$>R".F7TQ
M\7.((%M:Z#3CP[]\*"1II;*VJU]ABACNNT50&;/Y.:N0&BNFMX*FKR8BFJ2E
MVMQ.ALL';2-U$FC+4XZ9;;*AL ]%??#O@XDAKQ$##57V7QFU"#42VSOLGG3C
M-4ZCZ\]9O$7]L2CX8^ $\G+\Y,+D%4ORW^QY>LD M.SP@9-X^QBH3$:ALU$:
M4C5TG2H.[=H_W8;7)0/(UX0J)5VW''&H!4B"*[?*#K,,I>(>*=K4IVYX^BC;
MJ;A$2HO/A_K2@[]& F33'+2WH\=%"GH:3"] @12]2<]=YL?J*12ZOKMV9!C5
M \\QIK(-J& +#*[:=^(A2&EJ EQ&ADA4B6[_ $@%,"P$Z?S"O.*R=26@]L=4
MY_P"AO LQS&L/ID5)/!=YQ3<N$D ==?VN:Y1,H)C;#$Y!.DW6#R#)\-X9H)B
MT]*(/X%(= L?#7&I_8_.$BS$<*GQ7@S8=S7(+1$;=9NP:6(@+)=$;I2S/BDA
MM8PP\!X@R[\ $3W6<"!<TO.>,3-Z(&P*H93>0+8KN&!?&TKQ$N(0B0(YPH"4
M$^%!(8OP+Q3&6'!135AO/H6+DKDN*.XP"7D'(X)&R!Q//THYH<D1SSF.E,1
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MB\&, ,ROGB4$-6ISP;E@U7;7/G0\E[_3L4,*H4)[=0)QB);M0*/07KJJSO\
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MK;9 <)0#5Y)-]PFDW4Q0J67#;S!.GO!ZWA-8+3N",$*"A'$PX%QK@%$U^4A
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M04"DZ5,'I#:!=M7:KA<V-\[*/KR$0XP1).0(7W\-)(&<"1U,GF@9: 9UJ..
M)Y5*Q&LTO&0RQM()'PWE?UZ-"O/]HSF ;'_FQ7)8VFE%P@HB5<3X$4@F #0C
M;?R4.3[4#^AW(YZ5OWJHMJ'#9X6_]:>IYH68*FH[];LP[%:.%Q7\(T2>F[N@
MQW1YKJ%]S@$%I,;<;$>3P$@&D-4J5M@A.Y>&)0$-0(&<UEFJ<2Z:8G32;V"3
M6G$_V)4@%&H)51S&O@NEHPPAXQXH:6$<J7I!O*7IHR1$,_5MDT8G=A.6FN4S
M(VMB]#: 0S;*'85L5J,4V'7E*2'GD<7_ &YG#OM.3N@ &^QTY,6 ,'-F5)W/
M*"HB!+C^AR'@^@]_1PHQY&9L?^5:?4P <P.G6 \S?/ZIT_1PTOS#Z%ZP=D<I
MUQ'U=_7!)Y+^+J?8?OE:]^'K^B90O%SYIY^W :_VGAZN:!/ \'_.L4C_  M=
M^SQDP E8A0=+3@II*,V;ZL'UU%C+3:,?$@]!Z$,#!8J>)7_8'H$\Z,!LQ]T+
M[RR"!K+!7(_>F9T.%S@D$72O25,;/"0;BS+>O""1+/=V2)#/ F\((P 8#ZU"
MWO)?H0_/YS?%7'*B3@6%MYUI81P M(K(6QYLM( 21)5X0VB:4:P$OG4$[ZV4
M)[*J\Y##$;.%IW3=U4M;5HR5V\%^I2=,;+')"Y,O@"GN^9@H+ <)),%?!%=%
ME"P67!J06WWV$T@T4!A9:C6*=%'2#$@L=J;*T0HQ1'!OND4",3BC,3,02;\&
MR\;HT R_6/#(LP U<Y*S?'X7'&LE-<+>OZSX(<P V;+"9 =MM<;KMNUKE^47
M@])0@@TXN3NP',+6-$?+RS(7Z@,%((+KL<"$ $] ]'OZ,H .=O:>GLP>_P"_
M4YOVS;#G\/!>KD0));0%6UMM#E./1$6L;L:V%<<.4%!Q;:XIU#NLF9?TLMV7
M(*8E!4ZR6:TBBS:VH;AR"D2+$<C6G:9KQRU.%6_6JID#AM*;/-FX=^/O2W<4
M&%B\_P!'Z'KZ4IY4(TDAP'+-Y.TD"06= 1,HD<)R5@\#4P'+=B<;ZQ5@M8.4
M-/6F:<B 8>H<'(X/:8W<)&=@1TRRMF_ XH:!VW5S"-9R#7#V1P0?NC0X_P!E
M2.%XV)$ !H;B;QZ "<;9] 0E;TQPX(J,G,<=L#<Q+V2!J!BKH=NP'?RG@LE$
MF'0,(Q7C_2%BC=4R&_9D,]TOHB.RNMD-4GU0XCNF$),M1(V1$D ZU"O A9J<
M0 T@8_ITQS/L?(8&FY-O@'><0Y:#T.SWS5>(1^1[X6ZV['R=3.XG[ ]VO&(W
MUS?1]8%Q]'?IE!VNO?\ YG UMT?)[9H^#/:\!ZW#6\\>DZGI,&>@>[5LY; 0
M7#:#Z5ZMU-7$#HLEKJ*+01"F@<_+G/PE:FP&.:$6=.D:01.:X"* ,#Y;,$F.
MZMO0BF4&+#6ON.^64BL,:?'J#3T"  S3-RDX'W%O"G@L8J-G;UV2?>L-DRTZ
M,\]:XT IP<',FIYA)$-#)R"Y))U@8+8%\&T7$$A.<@KOUH(MQCTN%Y;>*74=
M),PM6MUG: !N5L#EB8[Q#9[Y3$"VXHZ[%J\9W1=Z4CER956Y:>(["(CD(3RU
M'I@]Q<:WB=P+B@9-O[J'@!"NB]7BJBZ64=&I^#@(QO;LG?WO>!]0&E43\E/&
M]4&MSQ[$5X8DJ0<\9X! /F !\A!C@A]7*U.N*0":CATTJ"IMJND\S 2-#!4S
MJ@Z@.^0B%K?^U.3)/I@K'[?0I$F[IYDSZ#%O&WY7\98NWGS>_KA=/WF>?J>,
M!IYI,U:1OAV_Y<8&=R<OIW?29OIX/1,/H@)Y>OMSC$<]CY'=^N:W3\#OVZY0
MQ\[S0_\ 0X/H_4CQ&M)&05!H%+Y1A!'!UVM\7A;[]HT@"2"1X#:5A>2TIQFQ
M0^.U4^ ?(TW"L-YC.=TPJR7K!T4Z3D3HN2-FN2]@;75[:[ &=FU!U>Q2Q1-U
MX_V"R[TFBMBR< Z>&;"L!XY@/R(SJ19R>4#4'>=9B\)HTVNH*NGB8LWN'G:U
M(1()/"/TZ4<8%KWDZ8ZCB\QFN=J7N2 G(-JNS>S<SR9O@]I"'2M[V E.FDI[
M@NI0CSK0?TT;Y:'H_P!9JGEB?)T_G.Q['QT^CBFO'Y=G" 7O>>KW.LNW@-#P
M'!A*.M)]UXGG!G<W?KYOODH_R.WZO&4;X_$<L>H]SSW^AUD_</4\?6XKVGCH
M/'M,AOD3_CVSN][7@?V8\6AI]'?NN0(YX'EQ^7&:?8?8:91'CB\''X#-!TU?
M=_/& 5V?D_E, [.AUMW^[GO"E\NG\?XWZ(?J?^L*\K?F_3'S>CX\+[LA/5]_
M;ZG*O8V_A]'[9)'@'N.WZN0^KA/#^[^,['N>/#V<Y6FAZ#AC!/I#[G'NN-'T
M\)]<X/<]7]0XP\GJOGN>YUBGHXGI./MF@TVU.CM[/'KG*;.!Y.[DP7S?(]\7
M)QP].S.+KK[X-%:YC]S_ $RRZ\'@.##==HWZN[_.+>>7]5?(TW:49QM*I!,2
MF,E3L$T5&"':U. ID1.&4"-]JW\FE/<1$N'*>2]#8\EKA<74=C/HC,Y! 9J3
M8B>+,5>4Y>]OF=QA,PXQG-3N:]EZM9KC4FO]EP"+BG62Q;2"TNIG7NNG>/0A
M!?&;^B#7(J0-J!,T5.?9/>4 9EWDV[UO2/\ :@AQV:DW;T#K;!]1 [1VWL=T
M,;5D1:I0"=>4\,0VZZY'[RRVQXT.X*20G$(]]#8(8_I!M\1]>AG!.M?).?Y#
M#=VT]GR&>RH>OQ_;%0&M/H85+@N/N'\Y(<@5Z/W+D5>)O]CZX-W8J\NCZ# I
MVVO3X/3.STWST/N8J>8?=?XAD+&GL^'?N,+.H?U37T362WM>P[?=<W'&L]$+
M]QDMXJ'K'\N\J2<WZ T'US8/$OVTS"7Y&G!MV5[_ .0UA'E3W%WD!Y,?C_&5
M'?U1(_.:?OON']G.8^[^T?9E8[&GT-!]<B'T>QV_0,R(X_L\OK@V&C[H_D9&
M'$E\\@?7-X=*OK?R9*<)#V<OIW@;?)8_3UG[!ZO3W1Q=&@V'?\6-!-6;Z.'T
MR=.$:>#D]PYNX"T?4/<[P83>R?)SA[93\CW/&/T >HX7\8L\&GN_P93V''CH
M]/.: XWW.E_67>3E>1X?U53%D&VU.V;LE&U,V"4@>.4$,(+N<@*Z!(0@/)$V
ME@Q.IGP)80P%)*$VY7@>H[#<276QG'ULRXC?UJG+C@@UQ8J3=:,8FQZ#B8X*
M=<52ID<!P2'^P8!^:6V0@RS96\V2VC.ICKAPQ>CCX$WHBTVGHN;4_P K"M:'
M:WL8K-MW\X6@#IB$BIVL/18"^2!>)@^+-"U %F%ZL2D=5'QP=Z&'BVS1[VS/
M@@^ :(@IJG@2H!PA_0;S@/\ 8^?MQE,--M\3OZ8R?:)]![/./9<&_6Z/JS5V
MIJ?W'U,8JF:IT=_3AT/_ +ZGHYJ$\/H7;YYPJ.#?'$Y7VSFCWN)E))NR;!>5
M;$3?P'R.TZX,5L> Q".D!5$P?!G.8'2'T3IDRW@<Q7.LKG>1L(LWT?A-$;VS
MCX,U88MKBT$X%YA-T/YB:EH:.2:\;D;N!%CYR"-]#, H]VF:XWG@P=D685]K
M&08XHM_R#(*N +%JC)I>E90V,I H@BF9-3F4+0R]NH6N% X'+@!6V*?'6>:O
ME@'7YL,N2#[,\TH-"ULIEYP)W9:[N8A7@"Y&HYT^K;!&I@2G!>BB/&MY..\"
M;A#0>S4@NLK#M1'@GR0:2N%1;Z3SH.1M[4XE;:O26HEHP"91(9VK(#TEQI)$
M7$MMHT!<'L'!FL:8B@89<V,S%0K("@NE&RI@RKW?N!"A/P;X'FBU67P&Y!N9
MOAJ3>86<V720B41HB<J&:-!X23I4:4'EV:P)\2SJ./*,+LF%\VRF7T<!ISE3
M@#,X[W";-TQH&Y%=H;ZP5/>^@<K[8_2:>_3W8>U#93\!ZKBT''XIS]&>X-#\
MGV_=FC/J/D=C]<[%Z?=Q<]_7.8]0]_#ZOTW%_P!&KJR:.0D9C#GRAYM+A-"V
MSO'^4<3.[I 8+JTX/-I"\9(DJ*9,,&FH;8@"BIO\98*/,<23@AM''JQ\Y0!@
M<UZCNG@\*% 5:F(]3RTB=.:?[)7<59F0G+DW6<OAO$@(IU*"&D>B$TS<?-02
M+<H@Y=*!"RD=KSD/SX#['80W2+DAD0LLM4>ILD"XF"4K:X(H#63F8&C6#19+
M-$)0\%91']2I:T4D+ $6^;:BA17K>7>/Z-R^M+WQ_+'?KGNB1[/Y. <[7#R?
MV=89'=W?5_!FZN.#\B><ZY#4]#O]V:P2NU=^%[\,:2VW?OCN7<GJ#I/PY=J6
M6\S_ "W.0X+"(NAF1A5EL,<43#@M"@):Y*%<$<1=Q6FR'FF/BNT5'@HGV<P
MRJBR$ >SL78TU*P((UDFHD*!- 4:5U3Q%XK*-8X1T,:S$P+@U)<RH6_47B73
M6:]M6%NN["21F:AJV>QL)DQ0)\H'3=1$DX BL+-\C>&H+C"UE(#_ (QZ*W(.
MYPG@J"1.B3C8-ZQM%W:.$<%UJI8J/])QL&=A?VC=3&+MX X:[3G,HAL)W7K_
M 'B&T<3<*&/(9LL&V17=LMZH=#FBS/E@-A8C@[?S7>:=I$G3!49SH'CO<=I
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M#!.60YK#Y(X/\=758 A<&NPF>TO6S)1UFRP9!Q=T0?G)HW$A.FM3D)? 3;+
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M&!.T!7D9% F%%SGJ0BXSQ>"!:6B17H^>[^@D1?UW]5/U.8,G2F))06QV#"X
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MEA6X *Y\1EIWRY+QJ<IR^\3S[D&/:'S\'#14V0!&Y,(;XQF*+-\#3D,4:!B
M>8K8$#<M))-16"0(,N0O!YKZ@?!>FXI#_P 3%)Z")PC X'A#I;:<6UPPWM)^
MD(0XPZ8GN5[ZF!96 B@/B"L&2%L5=QI #7;@LA$Q-5-(Z?X\]!F2-+4J!4SZ
MJIQ'R<J905>&3#+E<>/XZ(H)1>VA_P!A*R? HZZSKV:&FQ+RDJ4,+EO"&CM.
M4*7E**S]2(27?7K%W\-9@66G(HVJA@^"3M#'O5."(27:?O\ 7-"1_ 2"J:^1
M[$P),YZ75MMAQH+(92R?[ZP?/2_J+KW[8!80S+X@!DY]I6W,SF49"F;2#,;&
MT)IZ@)U^YIN(FBJHAHZE.F+R$YI9UGMY J(<"JF@>!#Z'O?"38(* )BR)PJ)
MQ9OC45@<-LS?8D30RJZI%M#BB=B,#*76(V8!G(X_2E%]P8$RLB+J^XC-K\N"
M&DMA)F&B(F8:O(ZY@%Z0;(6K\*B\G*[ZY9K-G&'RBHB$DBN AU4=_P!ZNJR#
MB%]G(UR/&HXJQ?8 EH$"4A[Y3SL$&):&YJSSXJ$J#R"&593D+$D'_P#IO9C3
M!VWH9CHD,;C]-N1HA[BH6AIJ+G)BHKB9IFX<,V6LNLM7GEB&B%NK$=[V\-YA
M/=>I.-;3-D,')\]? TF/FCI97("K,)7)[?(NL9%<"#2QKE$AGAC':&"4QW$&
MS8)<2CY^1><Q.@W)2X4+E + >;!HZ(8"QIB>)G6KB7B:#[MO550*)X]4L$=-
M*$8&1WJ._!\4D68PTQF]R(= G3?.6T#1(&#!2Y9I*!O=/5,VI;YB%R&XIYFT
M%MF<9Y3)<'$EBU6<V0I<!>V(M,FM2&4Y8'F_!^<!BMP0%'(@U)2W2(%\ZI<6
MY39>?&R3-X<7K2[B2"1&AS?B3X>)I/G5-X8=CE;P($A*%.9AZ$$W!\CJ\&P!
M'J"J$&F'@7$T-*97K2E=V3]#5@"\,2ZC:M<O67Z60(VR,6RCPU3C#!R"3,>@
M,5<H6Z3(A%)ELL&?*G8P*6N41PL0R(58N:M*:37&IBSW]$YMH!(R//> "5$
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M5XJ'+B78_H6XTZ4CCH4A/]$P66FLQ28)9J,UA1PWL^[$9*Y)VWB>>F'[@K4
M^_-3+A1:$B&X"9!FXU-#R+'!E$MC:F-&6:8$4)':"<-#/"G1+039_O)0YGV;
MR:A?(XW1#O #<L5TE4>= '8<*#=7];]X7Z!Q)W/ !?0?M 80'(9M\5(&@!BF
M3NNDJ\FT( D8KYEP&M22NB/0AA\?D<J <!MM!T,#OTLM(F>]1CM%/=&)*,6P
ML:S'_P .UI6NF.N+2SI1-F,.,1AB'LIU%]?^QD@8[LC-:M+=5(0P>\ZZ.DXU
M+D4P<3X-82IP1/;02@8EL=JM(BJ#EMDO([.;?L71>)G'4[-!I>]6"$[=PV@?
M1,NCV9;P3R/7A>QI"EWB!$7+A ^>60="LI4NVDJC05+R+_ZL\0)L>^^(RRFK
MKID9I86 P:QO2!R$(6)K"_L_K?FY)4;*21=YILFR"2.;<I*HQ/*T-R!T.  Q
M3J]^%K%NL8D)BD48$'&9&&= ,0;-87 0R/8!9!C[85%(N:KU34H&C!N!PL2:
M1 EU@>T,?!WU+:$#!&1 U46DE4(A!'7)%BZ.8"-&O84QK6"BY%0Q*[194>PH
MR1HN^S( KR6%9X[SEF[@:S%DT44^L&58+^R A>N1E2^$QL7N+5MGW#'AO"V8
M-806+#AAFFV^>AT^SG#6%%:CP1ME6AX5."1@#4[#'AI!L<+C\^$70>-.,)>Z
MMNT=V4]/@AF:A%B7)HK=C$A/KXM"P&6Z)=2BI^E':MH1, /7TW%M7D>M($2T
MY)E(>'.S@"&Y" -T3 @<"8IOL/C%Y!?GPY8QW@7444Z:99#\D,%0L1'J+G#I
MPX[0<,AD"R% E-</MGE^^OXUO-@%HTJ;U<!FO0]%_+ NMM&3OR!]3$ZO:7\#
M+WF*+UQ=_I^TL("WCB+Q%;>]QD%X>R)SRH2 ME#%^H'+Q$AS;9X4RZA!$XMU
M\#@A*"O2"H"UT(<U649CY3LJ8#G015\B>\"UB,.M>U]]I3)G)O$M0)$7]L\\
ME>;,IH"9V3,=&!%]?U <>_HSIF.<,E=\%L:-T[ <G,9G?_W6ISTX,818&+,Y
M@%XJ1@#1YSA^S:3'.-SKU=ZL+$70QO5U<N5I4@<)<T$@AC2@.PMET!48!\,A
M,#FEK%^KTJQ:![9I%J\_H8$5AKD9,C)-4N\+.@2+JO$**%=.RW)N@%_2"0PF
M#TI_/*&0#V0YD1>2O4G3)VCY)Q[,L8[VPZ\H\Q2YY%BS$!QQ0R1=7V"GT=5B
MT(NA(*L'4OA Q0@HJ;P2(G 8A &C;X"/W _)]3$%D^%>9Y=<\%^F&<NXM?LT
M/59@2M4=0Z6& Q-X_<^U^\#\L\R/8U010]/.6':^0:90C49,M,=!-7C*L2-Z
M1[ BG?.2!.VR['">@>N,ET&@"0KL]V&+7A.HI59^SP8HJ."SF'L#K>C&DH/T
MR3B^S )+G4$:#I<SEO._A*R/HF-_7TR4BX/LM1;AH?7(#K#?D?6^E7!HNT9V
MNW@OTZQ%MACH/+.%/7OFT[%X_.3O$2#=WE'M<8;?J+B6'/T;%-N\=*((O@UR
M!TTC9A2MK<VZQT[ZL:8+9'#=/I1Y?73ZY*]V+/'#@G]QHQRTM/M@G;^A7QH&
M(MWFG9Z@BO:YM\1?X,O!Y9E(,)!RNC6GK-9 X[]>B>'1Z;<0SQD$]]M^XRBL
M3U%/&ZP[_&_NG*;YU@O+_P"A(7TRAJFPBO?;7M<>'U4/=3;ZX*7W""_1_&(?
M-@N5(:@4.)@KHGN<E0:E]#UQ28%'P%FL"_9!BG('IA@!X*F@.\5"<#6!=>86
ML!9DU[EAW7SY[QW6KXQJ+FZIM<V8R6#353I\]N+I#V$#OI(>KBV*;->0H(Y[
M:9P:-3>CT'M]9EZ1NY(W)H<#XQ:K4?C'7TL5(;"]EN$+SF^<9U%)6<(&GKE[
MXUI:]8;[9 >(>F(<IJ(/EKZH*X+I!V->FBX]#!Y]E\^N@;TO&6MOM5_6"90*
M.XPYXL*(?3+,1 0NYS*UZN2"AR<:"A/Z8T>Z"_8+?5AVS>)!V&H^OME<1W#@
M?6AZFO;$7L(0C"%4>*I-Q@1%Y!\#HQOK?O090SJE2+G)/*P$&8.NJ!C)]C9P
M_@0R&&"\:!HW#NC.*T@<UVR_$(E)1T.YVO32^\E3' F*$@])VYB1XVSSR_I,
M &F6(:DR_/;71 F$.7Q"^,NE1K>[ZAVB*%PTCN!ER!?24W(+*F/J$%PO*=D?
MN]383.$;[[-5W@4F.Q$;K8XG,)U># 2$KY7^0VO']V63',T+P\OAK;C-Q*&2
M%4T!QCYHO;7RCE",*TFH=UY_?!D,B8YF,HO4,B$+@&G3K52<V'+D0H.9#1%.
M/^+K/H-"<K_?&NX*C\A&LEHS:T!C*!M0O1U4@BHTK/P4UJAW[%^1RE)B!6J?
MH+FC'!;J1M:%O5O#FR@645K:M:\W E]+NRK<Z==4SMM-(;D1PZ+-CL#8()=5
MI,CH:F8O@;;Y?.E3$X9_'\44,/+G*HB!!6RC3N@!C7.6?![#W-8#,2F9VZ!P
M[O)BAO76G%?@Q1[\>@?RA1\RB<.*'-(UMC/>IUA!>TGD<X>U3E*Z)ODG#TZH
M7@D^17R6C+F(Y]U1QCPB*\O^%Q(/V(R%6THL^#0R<-%D3ZQH;#^Q)=^W"S$V
M5', :6Q-4PC!T7L+<O@+B$NA8]^C91D5W>%2D[*Y ED%8^,JKQD")LC]M#L@
M,0T/TSPV#?*0#-J/!:SQ2P4S8]5DM0:J,X 0;8.U%925!Q)?"U 73;3$:N5W
M"@@26P![B!2]V:CQ;<-,.(C29]H/\D36\#17NI ;0;/)BC'%/D5P]:8SAC36
MBV1+TV-(F6RZC#BQWM%(H9OJIR507=I\I7N+>VF\,.$2I_(F$O.C0\=>$1Y
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M!,"MIN787-I?*U.U<0*>MDS*^M?HNHL"X1@"5^]E6-B"!9S>&<R3=]->W.)
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MK678@&C8F3K1D)R!+!,=V'D2>-1W&1>14+?*P9;AHC.G2\=_;>.A#0ZR%3D
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M /\ O8?^]_A.!QQQQYXP4=PB47'OG2C*MZ%)G9RMU)FA28G\#F[;!<>73X+
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M?/GSYQM^CA*V.&G\^'_MX?\ MX?^WA_[>$/[\%^6][_=R_R?WS_D(9]6^_\
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M&@Z/J'/K!I?@8\182?R_H<L3B\)J?%_8^"J[95M]';!:GQXT:7K7[G60EB@
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MZ%4FZ0!B>?&%<#L3JH4%.W.R8X ?OD]%4F@.]@F^&]3VU>-TH<O2\[ZR.2?
MZCZ^HC,-5$?V,B_7WR1-&R<;VU_\WDU@'15]_/[X-(FI^-SKS>YSF]:GRG$#
MTOISBN6WHAT<5MUZYI#*\$T\W@\S7/&*MT26_P!S4UB112@^G"P7P2+W_9A
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M"\3#K_C][O(\AY4=:#??'+FM574)#:$"):+UCQJD7F'GVXIS,X,CX)>.^_\
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M=^W#G=1XE2Q\C@MZR[HA>":Z<ZYPS C@[-[\=)YP-,.<9P)Z5Q87!.)*$VG
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M,$[6J>9QRG.O$[7]=^W?Z%&AP7/6VO#UG/+X;YZZ_LPWRLZ/I[Y,Q]>8D\[
MT:V\89W8CK:C==I=\;SLF:32J>_H?^8CVHG?-RZ;4)K;<A V1:T0W6;J^J%P
MZ/\ 4 !]]G]:P"_0Y^'?P".\F&._7#-\_#AO6??-GMG.<:QTUATPG9GJST9>
MN&0ZR].,ZRN3-=Y,]N<]^?AKX7X5A.\K[,C;*]8$,4Z,"'KGX9QHS?P!OP]\
M<.)\4^WP.W'#CX?MCZ9WB_AQKN35ZF@_0=?;(XX).7COE.G?>\4P=OL++V[7
MAI.S*T: C@\&'E.V*&A'>% D77AWZS&L<A-G >0U2Z_+-V;]X#?&C?6*8=#\
M?;]50$F-UUUY=-/0V6KLV!CN/YAZFF\6V#V+OI$GGGBF[C-9%^F^?"]'7CMW
M =&[?N;Z:TU><D*\FY/D+RGNC4:#VOD;T.9V?<0/<'9MT_@WHA#_ "0WI>G4
MY.M^._;\"\SRP]L,5C:BT_8@,,%KO0V?-?H>V)*TM&SHG#';67%%%4%\#7OU
M?IG@/A #M0:FU?/.+0P-\(['B;1]-X7I$)%_@+V_?)!\G^'CXU],%X,(RKSG
M'/1\+-LM]LXYXRN=97%RC3QA;K'X%9MFSX-Y>/ZO;+><LX_69=ZR7G--9OOX
M5=]99K*ZRY3[9Z,%+C7I\+YQ8N?OCXS88[8?#TSC'C66_:D.UH&:4RUT*)X)
MY;(XJR(2?>M\N3ZX\\3-3F=BU?47"[.K&[</)=Z%&=X!4I7M=O5>1RV"4/L+
MRCT+KO-S86ODG%K0J>E\8 RUHU[?J9P0CN/RC[:ZF:!H;S^X+D^EN\G/B(GW
M]\8TAPY?RG^LTT//:[NA4/F9"-Z;'KN(.0X/?D[NE"?M@A$A.W\JOP1<BRHA
M<_PD"3LNHE]%=/@)2ZIMDY>#D,#P]5:41D%\&$-6$9WM!73-7SG2WZ7WV))L
MVN78W-GE\56SG?43>%?0PS'0]BI1O(@D%G#2^(,#-[YS5$VKMJ-5N@#8\F>D
M3]O]+RSG;CSZ9S[?!^V*Y$]V.L?..O;.<D,ZWDG&4?@=9*<9'-?#7PXYP^)Q
MZ/@]\YXR><]OA[9,,ESK-IO(RS$O.+\-'.;?0SCTP,TXSRZQ]<,/?#URS?62
M<<_I6.N)@/"U)6C90\-]=8*0O!BZWZ-W9>,7C&E3-[:*N$OO@6A!2)CNFIZB
MPW(8@I[ZL[YTBKHSCG/"NM3&G0V$=^V)W)0>W\O\YOS2V._ _8?YQ0AIT]X)
M&B/;U461P]/\+0(;+CJ3TN_I^"(M\_/73G(! 80>#E<66EW3:R32;D=^S<3+
MAY\F'0$?28WG/+I7@O3S/?."(':..J<0]]>,)T$W]!>.]?\ 2YN@DT\!ZX3[
M:R5H\L)Y]7]\.?A-YZ'PF/?G#;'7KG#><Y^&"/.29SB>,NO+.L\L'>_@GAS?
MG.N<AD^"3/I\!FV<:S[,DYSGTR93QDSTYP-[R!C[Y7S\#S@NLWB'#G=/5[^_
M,R;2 ;* RG%^W3F_)JPZY)]U^&#2K-/T_>_; 5"HA'G8CQ);ZD[T\[ING/\
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M04$V.><V/#L/7_4O"N7OEU-(Z*EP%%,G3 E;9FE3DJ8X=%FW>^$6E )3' "
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MG'#WYR"$F4")+-&KS/%[\]Y)<.<*GB/@=;SE":!KM534/3K'HJ,-D>T[+U@
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MRBUM:J'8P5I!/<G3 (1K?#K+ 65J;R[A\;YIAI2 NH+8V"&X%YQ?BA"4)G0
M>17W,1D9 76M^R:FFP.7 :[<T(;E5\JHYS<F[T&W8Q&8!(,$FL('4KT4H:69
MX2=Z&Y@'*K5,5H;KC+#D+E?<DH1R/#=Z;>R;HS&H*4!AP-05[ K.AX1,T)6%
M !M]4 ^[DV0K@5LNNTL#Y/W!FS77PNDV!D@EP>D//?'D-M3,=(?8*4'ZBU(5
MJ[,T"H@1#"6"ILJLE2OEV_I2("ELG4 !HV")5".E8KU*D\Y$:--H2 P@^  &
MJE9>ZC[W Q %FW7A4?D4K@J=R(B:8^0M@[9(.HS)M"9:"0DOD@:6%E73D[#D
M4<8 @5%>[J-ZM5'!,# ;D:?4OLYYNN "/B9A^@U]<&;C.@(A*([/H#PG6H65
MLN35/,*18R9(Q8NA(';$'5$A0HUE^MAJU&"*T>@M#U<Y&&$^38%3&A9&E(#1
M(PTBW@/%EM=2<AS.]ET"T%=&X-Z,'*M0\FAHBGN*A&3SY!';QH7&MO.80&TH
M$M2Z.NO3!CN_K/-"4KEK*!QVD8,B*7BS41$X@N\<;%$A G53>T[;R)<^I6DZ
M%SU8T?"+[,S6!.CR:!+=<&+_ -B)L7@4/SHPAI= \0]:O._3%&C*\KQY=G?W
MDQHR3@=FA3A/7Z94DMI9'H).EK]#$M]J/+>3Y>,C5S_=_LC0HMVQOX+.FZJ<
M_#B#?/C1.<3>_3-$!?6:VLWXOK@1U?</HYY\[S2CKI[8X>'QTXZ'T\8644V]
MV0Z69#]S+^>\^2?'^D]Q</4\ G)]UTP4=FMSEE(TM7E=0=O-6JP0(@=*[&V:
MF(VHF2M4S9/!>*TJ;LHPFD"5<L-VFH:K(W$(YRN!I[4^TD+!F^\AY"P!23$:
M*K0*3CMH<2!@U--F.0U+: M&TD:3;1E C:9:4>6P$VSMD/P*B.B56XX$;!D(
M'S]4'=$U=ZP0NV^R 13VBL6L< E75ID@:N$'P9KL')#P*#IOMC=R&#)@]+@J
ML/?"8P5AIAHLE%\C,9[O9-39Y0\T!B?B\@?.RI.833<U])D 8+<Z*(Q=%TBJ
M]0HH1%.?D91"9K*%P%78)9O*1P4NAV_:<*5!3XF;KQHDA-FD8&LU,]CBH$FK
M@!L,NOP*PA]UC?&"4@O*]C,;"-3TQE( )@LF@T4)IXT=,O00,3L-(U,VD"Z@
MNUGM+.-3L]BC_P!$^;>?B546[#8J;X$&TH);G<[0(Z613YE.0&X,F2PNQ &J
MUL>:PEO82. BP*!VUJN,%:ZL'9AIX&2:86Q#_>FDA*07((3T91W0@BQ31FN'
M8T,U.QH#7JU@\H'HF@Q$/W+%-G^ 182V.0HZ=.,00:4=!0D>0- -E6;@\;SE
M;LA*&HD?CW*29],@H#Y&GS^<)JWU=[AX\N;K-RWX3CZ3-"5\#SC:KH&ZGIOC
MSK#H!Z%&)]^?V9(/ A]>\$^:Y_V18.->$M>[KZ/@YK' N+/X0BIK>^.,ML6W
M7.F""_\ <BRP[1+:@TSR;S3;@S90^W&CKQYP-L*S@/+\O.A?IFR]J7I77FZ=
M?3!JPNKCE$W._3!3Q_C_ -+JR>#*]=)-;>N@9V+X%:A.TV!0%''&)E;C:/<V
M.1&&2/ZM<E&M':DW&\B67=A< (DW6.\IK'U)J/9BV&QN/FKITI]"JK"B+XK%
M'287@@(+7Q$\>V<9'@X(M(G";@,ETIE8:S7) 8;4EOEI!#)I1:#-A]K9=#9T
M.NW6DF^Y H&#0D\F'O(4SBX=PJG;08@T@7,)@@MA&'8 5]_&? K%3-MO+947
M5@FAUAX(7025?(MM1BPOC !-N/\ IT'#X,OKVIJ!V5D38--+!  XSZXGD-0M
M(&Q8)@_]Y86BKB@MB6A[)P1BM'8D<$:. P-BI><PJCB3CVJ>&Y(Y6! 4[ ;.
M03!Y= WF<4=,EDF"@\@'C)<MW-.$DVW4>(2'AKH<0 (N#V[6';[E J;97M<G
MF\>YL>!K"Q.][?1YVYKVR$'>KAJ>G8\\=[K5_1 #'(?7;NHKYO0PA\".Q91R
MX.B+M15)(9&W:\E]UDPI2#(2ACC'H2(%&2&CHXJM/$6>A>2Y6\I:U7T@D\.S
M%8#0FA^/&]=M0)SD#U#7T*B0PT97(B?*.@4AJ]AZ_2*ED7Z$P?:0+4-NA*T]
MIB8:VUL3G:PXZ-Y:40&G UJG"1_&#>OQT\OOY_;+VM+#M\G3QUPP:^DYK:Z2
M%(RWJX-W!'K?Y=SUR]C3R>_77^RI$2#K;V]G5]+O%IW_ -F5(I.-5W[XDQ)#
MUHCR#PO6'CJT^_)O6$8L=6OI'ZM8GT*>0<J'/KXS38/:Z!USY+UE,1['I1MY
MU*>=97+G^G_2W$)VZ<MHR*1V9J^4*/>[6-6F_4VG%D:R =F[Z)&R<'B!WNF&
MC2E#L3@G P]?L ELO8+PU'F*5(K7EV4(TW/.RYXE0(V45Q6<H5*/"(/!+B\F
M@<F*RO)"68&DL@#BCJH]%,D0&IE7)&^[RFL#!$/M';6G;?L<F<XH[M;!LLV+
MZ0.(.[<;UK0NCFT5&":2U'A@: ^5!%LPD=;9IV<>C^%S6(_9,=/H4B -$VT<
M+$PCUHT3HZV/8RTW6[<WRC=]!TN#:.\[;;[G;YN*2&=[O03R40:VS"H'P >#
M"(L://.EQ.32(*^@3ID4Z#IDP)U"&P)Z.GQ#JXD(:)K0-@IS&QP$\*HE:0$:
M1#ETR.AEHI*-9Y-$HH]O@;B,N*BRWH@5[&+ZU&5L-.SR!YFA3DFJ59).W5+$
M":/\+E].H!3UCT 'K@\/64G. &EE/-$L<DV-8>X-GM]?%_TB>V"SSQKZ\9>P
MFZ;KD:[-SS-XXR9T=G;?D.,%P#>@W0\GM#C!)ND5X6[4?,YPT&ICMN]>#UUF
MNP0/&DKBZHZWFRUT_6?8?FMS<%O]G^R9BRYFG6[=E/4FLK[AP%"_<.F]3G*.
M-JND>7P[WPF/J@R[W%?15OTSV9L)&U->)WE*EWWO@3[OOCQ*V%1'CW?PUQCX
M^>#6@_2?_"*!IQ/X96Q7'J#0>B_)B3ZE%V!SX/MK>.L5 @3OEYUO/&<^"\@G
MTO>.AI3=G _AYQDIOJH8_N1[N)!5L^YX^F<SY-_[+E WB*W+K9WJFVKKX,L<
MTNKOK!%-I-[_ .&4D#+'-4.:'#_>0V[#N=0[</1,6[ G>KYYZ\Y'K$+5^ /3
MM\F376 ]CAQRVM\V&+?08>[;]^WS@T?+3_X,/FC6$W[SCIH./0[YRXHB'Q)_
MX<3#,(444+]O!UA I YZZU_'T<&).=B1/Y&2$ZND7?OV)WQK#!-$>T/XQ9"$
M]!_LGF,LGE9&[B\TYR[QE>?[\<H,5TSL^T/QB>ND;V_X' )2(R6].2=_;%[E
M\OS#^?\ N;AT"GDU_ F=K')/E/.:(\Q]"\WL]O.6 W^C_IQR9,F3)DR?"?XS
M)DR9,CD^$R9/A/\ 0X35SS)K+.\-YUK7H)"@)D65]#XOX;R"/1J+UXP8@.#T
M#DF[YZQ$T-#D^GN=Y6X7AHAI].=?MC$T#S+;'V\>YD\F_P#9G"E6P*;^&FB]
MDY?@P^=[QN6)^JY'VNO1GGL<V<0[%Z#R\..OH.]A.QTA0S[M+^)Z/_O!GT:
M)SR\]!3URC$.A-C6KQML^N!$%:^70>TS8/?]7^>Y?A<N7+ERX,RY<N7+ERY<
MOPN7+E^%^%RY<N7>7+ERY?\ 0_"_AC%6I?1PWF[^NL-N5LZK1H?4_+@AI\%!
MK_GU\X""<CD3I?5_Z[SQQZ6G"@<"]_G+\O<3NZ(<CS/&W*,T3HZ/[S@^9_V2
M%$Q'$6C3EKD<<O@I+3P^N';A\N('[MT'>&D@/ +-\<QIQ]S!!O-O-[]T W;A
MK&DKMIZ/O?I^WOQ(]4J]4W,,:E;Q&Q@U<GGZ8H5O3KD\F<M7^KV_^#%7+]G1
MG,DUY%-;]#_N(/RG0'<C-O-]C*D/::OGGB^?MA>&HWGP(;TY>+Q\YT\^?-N=
MSG#'D 9QOGQXR,,7U&>R'^?]E*ND'2UM[3B^GWD6<\/W[S<*[MFAZ;ZXC-Y>
MWCR5A-O&LJ!F_P S.0<;],4K.W2<;^SV[Y\X'P=B#T&UZ"XKM[3GSY0Z3VTX
MA&AKR;!=WKIZ^<9/SAA\#X=X?"&3(9K-8YJ8AAD,AD,AFN,A@9#(9##^<A\.
MLAFLAD,X^,S6:^*9#.\AG>3X]9WFL[SWS63(?'OX'Z$X+-W%UK-9:*&$)N:Y
MO7&(+1F ;?;Q7\S'+7\S^++.)1PKI%%.'3IQXZ#K+)S[K>P"!O'YR]=@AIY)
MM/49Z8C3)5W'/R^A<X+F?T#]3/!CM0U3!6ZQF:=S(FLFR5HZ,0D<$TI:/-1!
M40@G.&^IS=7[0\O8 _R3! -A6P(Z\,#(9D6SJ,ZJBX*0>D7]02SLBP=!.;K)
M>!T!F [)3%6(Q\.:A.B<-(0F EB9(("(XQ):3F$-=U*9 JKD<*K<AM,R!%6B
M"7R8*3T%W%"OR5.VB+YE9%*U8 %FSCUX$B74\J('Z&4Z9K(@AB4WLK=5E7P4
M(DI#>\@TJ.23NFQ\^PGQ;Z!^@VW2V.[K3;)?!9\']V_OG#4/F\&_.E.\:,$)
MU9OU[_Q@'AJOW4[4T]-Y$+$34)YG_,8T2><[+ZIY/7*WYP=P.;-Z\?SBGDY'
MCJ.X_E,7@/@K\-YO(_"8Y,F3(X&3),F3X3)D^$^$R9,CF\WF_COX1R9,F3)F
M\F3X3)DR9,F3)D^^3)\(_"9U\+ERXZ>]'W,&%E:> N=>?J#D'<QW<.?SG\XF
M7>(+Y'T7U><=M@XJ6<-ZOUS52E!XYJ^HTP^7>3?-UQ#$W;0O\#6W'T=?T!0+
M-^C)#F[!L;Q;/Z M0,E(!9""L'0"V[@KIE'V#HSJ( .@24% '136SAMMMS8[
M(ZW9O;)HBP 5W"5EMEX=53F-P:W!06L*W58;0"!%>$<P.FRH&PAL+#T>S:0B
M"&EZD%&TE;/KT-U3PA&H+@:RS<FEB4ZHD>ZDEISBGLM+1NDUT"UW7$\K Q&!
M[Z:I#5=P$%%>2?&"*RZ[3:J(A&I)!6@L,[J<7$>FTSV08KR!?WD3XDD-B?H<
MX>]Y*72\W,YY=9R7_O<;:93[QH>N2B6.^>4)/60\>F+<-P5(1R]?;UP\SN^W
M#X^GRSG#):).K[.,4WR;?]!XGISBT.PK'=&WZ_W,5^(#EP<OPN7+ERY<N7+E
MRY<N7%RW+E^%RY<N5ERY<N7+ERY<MRY<N7+W\%RY67X7X7%P<OP7>+E_2OE/
M&/8*T\&&WO\ +UBOXB*)Q]SXG>128IR'U./3-S-Y3H\>>U<8YSPJ6U^\>-S&
M$YC)Q:_9]3C<SNPT>:W^<^GA^@"8> :WT>LGEQPRW/52 (!@&$T#4&GB/?)8
ML*IHL?"FE2U21U$C8 3O).()L$*B5$@JDKD:X9=*13;9I=O%$J^<V6<5JW#$
M]4[SHRM8*M#*>"HHJ(EK24OBS!!$H#($IP$&#@[)YWDTP4YR#!Z^/@T0XH+P
MD<3:-#@X]N!BANW2AF0:]114N]NJBWN4Q<V>[9B>)PVFSI"@%J:3(Y[=Z^4E
M/T&G06;R,AN]O).4N\)=>3_]=8/<4 ]+W&]76=+8+HUM>VD>O?$;J1X\EZ&X
MYK-@' 'BV?:8U0DPWN;;PK8>,9 C$[^!WT?;-)H7E473T(N&$Z_J^%Q9K(S6
M:S5S6:S6:S6:S7PUFLUAFLUFLUFL,U\=9WFL$F:QXS7PU\=8\? S6&:S6:S6
M:S6=YK+\ F:S6:P^ ^%PQ=F>GO<.9(H^;0?M7VP,7(;;8V_EK^<J>Z2ST?V(
MZPA01;D0\N2^F5.6*3TMG@:##4P#R]4\")WQA$)MHV:P_/>&'W^B4!+Y)<HF
M(A"$=,H^T&\0((=\C0APZ+DKVM0&5&J.]#XLP%1>!.M.IA%3T[!9GR"BRX*O
M8_ M(;MS.;B.;&$%-RXZM%%<"SO0.FHO7H6C>X0H$J@Y.L@(6RC+$FE**]$@
M4'?9:#T[.HJ*'<ZCXA3&T<6J[6KSJ$P\2&;#D,((P:&!994RC0WTI/E@<?U'
M4\<*HZ*[B@\Y.5M"ULY1;%W-?T;62M@6]-IM?0Y?"+Y&9N>3)73;KOC?%[<@
MD$Y.G%#;S(F'=W2( X'E)W,V(5O9M\W2^+OG*1=<R@]USW_&#9!UG07[IHYF
M";UU@*OUK4[\^<FIQ_.?$+B8&.)KX$^"9,F3!9,F3(_"?!,F&3')\)DQ/@F!
MDF3)GIWDR9,GPF3)B;R:R?!/A,F\F=9,K)@;Q,XQ^-F;KG7&\G#P>FE%V=WI
MSM)Y.=MJ-(O3],Y<'K1[FK3EK6 HPGH/9K?1U,%-Q[)Y+R'H<?'WD!Y;6R<:
M,8M0,! WXZQ$ C]SG]',@Y<Z;:/P#=TTQ*@(]XBI:I24T6KS=7KN@&B_,\+S
MO^%;QBDHT[3+U9$2J0IHLW*)A3B$((A+ [+M^MA>QC31^%#],2K9]WNKFW@$
MH[ELM <9""(T4'(Z 8SV-[O->BFPX@Q3+!\(>@UGPNGQ EQ4U*-HX-W40846
M.D7#0DQ44Y3$OF1B]EYE.1HW2."UV)<>!;#VS2X3*@6!"'?4%_0Y;&)XEHTZ
M#D>KUCH&<K-(5>$>9\ZRUCJU[;V>A*8CM[Z0^CU\.<] 'B :X9-_\P,(O.V]
MS7B[0F"&,K'D+;6ZG)A=!0NOJ_RX-'+_ $_$O6;P7%\8.5RX8KA<K<LP<J9<
MWC<WC?AN_#?ZMYO*YOX<YOX5RX.5P^-RY?A>LN7+E<KA7&F;Q7.L.<7#>//Q
MZ]!7XR (AV&)_P \C<-O5V>3<1)Z,PTCXVNSU[7VR&$#X>. 3C&"%%I^P^^;
M-2>"3@\ ?2WNXQ T]^N*!X_N_02JD5IH9T18XDT"X;PK2(AE$>B@,,'3L "T
M;V@V+ EH#MQ04IB$8$Y%.X8\\DH@=E/J1#LUG*$L[X'W,HE&$0[%0&#LE>H+
MMM:LPNHO8JK3A^5O!<):E*XR\(MNB/3%)CS)K52R.J[\-A_,M5%4)R?T'Q=0
M)F>AR12X2PD)4 9%)UP+#EX6#?DT_0E9E:E![/AJ=4R 1CG(@!PI'Q"H%$]#
M3OVG!]'O#Y;R0ZQ]2^@71RZWB)8F-T\HT:66>SF@(F@Z/2W5\CG"R7L@]?#_
M ,\9H4]T*SAKZCV^V")7T='IPO.M?7(%"TG)PA/8@9!+Y)\3QFIE,BY?@4P3
M-=X.LN\4R[Q<I,N4PIRY3.<[^!,[^%,N7*9KX7*93X&/&$,N7+D7*8.\UE,U
M\!,4^"F&G+E)\.L,<,>?C7F?\XE0'LJ<:0][WFXDME*US*2?WDLSCL'U@>=_
MSB48::<>?IX^^&^84"+-._X?1Q4N(#XO1Q>#'\X% ['M>GUP[._[/T0P^KD9
MV$>3D$M*#7EL*&&:%M.IA(L.4XD4:3^X#D'+M082"SP;$#6$+NH3L30X!-#(
MINNYY*[7[RACX& AN@C:+1"@N'2T40VFW [6 Y%17.&  MW&VUC:8*H.ZM^-
ME(&(\1"B0T6_0EOEH;?#ZY?QW*;D@=$8-9)E546I.03N[PP/)QL-F@>1;3;\
M$L[_ !)?Z2<RMAOZ&T2K8[O3;9'T.7PZ@]]A+6GS[B<<;-GIIWG+=)$Y]9X#
M<[P&#MX'@G1ZAUK&QN,IGU>>?? B)M[^KX/1[R(8>B*NQ/5D.<@O@[6W9'FW
MK6\LGE_3C\#SB:P#!@:Q,E^"8;,GP#)DGP<Y,GG)@9,GPF3X3)DR9,F3)\9D
MR9#)D9,F3#C)B:P,3X=XX8_"_!?@>?@<X&YB)]YOZ8H2*S7H/.N'L<Y/QW9Y
M+T7C4J<YUEU=]5'_ $UA7U,/05I/#SCD9.F@. ^G9O#9]@WX>9[-)?3'0,:!
MLZ/?/7MOG$0.?[/T&-ZV8@FEOEG,0YS$(HDQ2SM#\[7-QDVXK^0%$<"<5Q-W
M4Y\&>V-J&!QIEH3ZC.25$3%2JZZU)N@T'4%0IC;J7#2R4/MA@0O3RA3QW*DL
M$9.15.2K1 L-!HYSYLH]MHF97>&Z6ZWLX41[!-S('QTKN. (=0#4/Z,#K:Y$
MJV42# +_ * IB=F=T*GDY'A>LW-OM^<:;7?]&_??IO*3;$;:1'._4=QNLTX@
M>C:OL$A[X32:H6O!-^^&/!S[LX$UQUA1ME$BOEW#^+RX5YEB]>KWY?K3!-N?
MZ/B.<7%CEUF\K\-YO+K!Q=:PQ6Y=?"X8N'&5X_3,N5R_HO?POP;,%Q7#C+\'
MC!?B7%U@N+AQG>/'Q#C.\?@?T-X1^Y@+[T90K_O,\&0+11X.V_;G?5S:0-MH
M;@)PZGUPV5[I*ZH:?3DPQJD0:O"X<';QG/G3M V"2!W],U-0(?9.-<96_CT/
M7]0Y"BG, 25*",#/$9HD-2M;(?5-<'7M6.['5^46-E0WIK&CEAL7%"02$5.M
M3J1"Z'!@;LG0"%EH3B>G1!$D.5-59?L^!G!!P%'M#"]N&[8'_BH\EJ9CA/ZY
M;=I;&R(=[((/$)^B7.;>:D%\G!\AWA6N9XBP_8W\F.2A?- ;XNSM\'.+#K'K
M*CK22]<ZPX,F>D'VRMXDDS?P-E];HN]ZQ3<W;6EY>O4YX<V]8G.C3]\0_)S]
M,R8YUASC,,><ID?A/C3!QWQAB?ZM^!KG'?&:,<4PYQW^HX)\'C](<X>A?R&;
MCNAZ'+[G!;O4$[-<#V:ZPK=T/,WTX!T['ISOO*]@V[Z-]85)0;TV>3MRUZ8R
ML$'LK4W(0/?& 40,?5KW]\(AS_9^I;%.DG0&FG2V8/M+;GGJ^"ML;N,I4'0#
M]1X*@5DP/CDD+5J%/0!J8*?7R 'E2#N,B5*GE!6$[&@,&0AP<D(CN+,#P'UX
MR0,:=P2(=SB"./\ (VC1;#=Z;3:^AR^#->-?$(*21W_)JW!4KO5- NI]3WR(
MQL3T]-Y&],MFT-:$\[W[:R,![&TG G=G7CC&%\@#SX,\W@QF#=%UZ+PMZ_;*
MOY.?&,AB' ,0N'PG$R&3(S6<LVQ(8#X(P)A\)D^$R8<9,,F3(9,-Y,F3)D^+
M@R9.&;;R'P1\#L& 9,C$\8%QR9SG&/Q.<B8$I\!&YL U>@[>$?8ZQB=$][P_
M9]LJFIRT#B](;GV8T(DX.FURGUF(C@SP!Q['C**!-#;.5ZC9Y.<H%0=W =KZ
MFO>9Q7/]GZAJ=U%B-5]<.XD@_..& !]&IY  UB6D82@<DTYJE@!;&HE3ND04
MU4[FPSJ5<FCUJ$2J*%P+4U7=7>"Y3@2 ).98'GXX/@;-*A(<5E?8%:N8"  /
M@F(X!RKH#U<(>+4>!>A+HI"T_P *5)!/8UIZ3D>KUD4[/&[OOK-T3[P")'5V
MGEQ_M.EX9MTV>'C.-GS?4/,)/!DBM+3X/L)>/>G&,8[RJ/E.VN1UEAI6;ZS3
MPVEG'&"5/$X@NX3E728U'+_%^@SG$F!^@%QUDU\#?P<YX?I"[_UDF#CO+-9+
MOX6ZSC'?Q28%^*X8M_09X$']L0-@;X+).+$GC[YO%.C1O4=ZFG(','>\!P')
M#.-18G*FHX]CWW7 W%_2].- >^/.:\^30M,.2!(_SB!YA+[OVS3B &@\]]_7
M_.SB<#PNP1[$::CQE_SH("(KH>Q>MV/\ DDXCB&G;L.#Z/>!;?1^^$<(2#3Y
M>#+(&-(Z2\F[KV]S"JGBX?>OW.$QV#T'IX-?; 31&A>?,?L[QVFNX:MSGK?J
M_3C%8M[WM/LYT*.)^GH?"9/BX<9#XER7GXF<\X^GPAG##?/P0_U8?A-_!YR_
MBZ"<UJK3@6=F4%[:_O&C0J/07.V[A$V\]"^J.%P^X5FT?A05O)&.?*4([HE6
M 'MDL\7Z>4*%AGP$Y1?;Z/K%@]4%UQSG&/QA\)DR?",JZB(;UZ.;BG-T]?&
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MQ%23M?#CLEVY.YO%TA$!Y,)LI;+!0<G31_05#AA3!J8@J!>[@<5:\&GVS?\
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M P$  A$#$0  $           !P
M                   ! !>X]WD$KG <%@>1\R8P
M              !Q VH D)PD QJL,UMQF'P
M         !@*5GB4                                #7YNN
M    !P<N?EZ=\$?;;;;;;;;;;;;;;;;;;;;;;;;S*I[EYDQZ           !
MQ>-'M8#(EW-)/OVRI)))))))))),V_\ _MAJ<@DS!J]+        #@  $=L-
M ]/=C ,TUXDG7KY_;<ZK&JX,XWYPFZ@7%+P-752@ 5!+1XP#(H 0,QZ19D;X
M:5O'G4JKBM%[.X^A(,198G2Z:.5A@#^%[S@ &CBSQ0!9L 8!":YP0=SE &!P
M6@3LYV;.$PZMQ30+0"U_ UV: P /%  +Y $DT IH 8;"0NG413HA[0VP,DN1
MD-%4J0!X?G(CM/\ Y20HNI6'>P  @ !') K4 '%'1EKZY]IWECT9=J;M0]IX
MYO5FZO)H6Y)B(I^X]!BP( !0 !+A 45 '#P#C1  !=DMI2=^OR&AX+K+:#F&
M9%W:5M>IY0$6D O@ %P &D' E* #$'.E!ILH]E*4Z>7&5*4A-JD D9+7T-SR
MM0]HC,I?TJP $0 ! M +  $ ^)#O9DD+>2]R=81[ZRBRAPR<K+FD8J72,<4S
M17 ,*8 "  %P! B,  &4 85D%AIH?\AZ^,V.[,&4+Y!AO@_8G5#=IQ@,@#X4
M0 %0 '0$ U& &%L)   FS>2GT7D(2PVM5;NUYQD'NE$5@2/::1D;X:5( "
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M*Y            (%LK<B?G=S)&=,F'X&@L,>2FQLM?QQ@6K0@X'C9XB&#@
M         87!BI/?Y]"1<)$2"ZB35'8(I_!GR6D/W6T^1:,_!V;3
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MF':D  )XBJG>   !QM.--^>_GOM2&G]'7=I'D2L =^>IR"N<"I*G8EYF"C(
M    !+R   !QELOT6(E*RV_-Z7F>F2B7R2OMG<RTFKD1SQ DJMTC!R     !
MB:!!0 0$H8=^O9*46^Q3NOGB\MZ=5ZOIU^FMIRLC<Q;<#X%?"  )&>AAL''@
M!!*0<6)V_1B:2<J2^@LC>V/O#S8HL+;]L2:*;[:&-HZZ  /R$@5N(SP ANEE
MD)S_ $F,T*8?]:;:GZ$@?2U9>)T]4.HJ.FMZ%,>F      580<D 83OIY01
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M;;;;;8))))))(<Q:3            (
M       #8=000
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M;K=?0[0"XTC@*0-#WP95PG1-CTS-#+<+)J<Y@2"&IPH'5G7*"\_\$(E,3Y4
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M?6"<ROO'=WIC##XHPC0&<I*AOJ)GOCJ.[.>BEOE? @R-FJ*JI2<"T8QIJY(
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M7[-PR78.)1DX[I"#U,^6*.$/'P.:JHL'0XF5"1EY1R153D<F:T]Q,$VJ='C
MU LV !0&U)V^@QJ$-_3?0@B*NCEA1>YJ/2NUD\M'&2NF"=]U(M&+K6&'2'0P
M1#!5ZE(CCQ:6A!7 "$FN'QJO,+3RB5BIM7X-"9DJXP$45'#C6-X2.1UU1/:)
MQ5Q+%ID)IT"\X[V&O^MD42!H6!19REX?,- @-)$%RJ6A$WDZ6HC6,"!K,% F
MSZP*KP.6N_657*KC7%&8!)7@/4^>5(,HD2P10X<7\N,(]$:QY!RV+ +&]VE]
MJ[5N*3DR(/&U2$GD8"&5:.5 D;P! % ;51VC:-KVX)FED['R)0\H8:IT>)8)
M+';@ 5 %55A*KM7MSE1=AH%X%@TX_$"^XG\N;_+0H^FCH/0.LD::-E-"MU-O
M'+'<VDN>=)=*7H (.*9T@6GRKMQ\#Z"1W[<]#Z,#(O0LE@*M85U@=;VJL7D"
M/KB\X3I<LD4L;N&N_LW15[:5 /#XX(0 (FEJ68BV*WL%D3>V0LA1^(("M+%(
MRR>\9\Q4NBBM#V>>+?+]\+ ('37T 0P%#HV:F40*/>K2H0&TN\9GTJJ 5"(T
M:83"*DKH&[M'"@T=-:$M '3:<XF4!HZ7""HXHZA ((/0805XB@#.@W_3L+CG
MREB86X8CNU3F@    !    :"''P-ZLE%-$2CVM<D!G+98$P&P!7 157(3A4(
MX"*DW!9TMP@\DB \7!*5[\O&(=QAB 1Y!I'2 ZQ?D7<D8NR[T)P%&JJ.X=#:
M8=$#)*?(POS0H^B:<'KD*,-  >QTX6X,H@H8D!"D.M:P5)F=44N0<VY'($K1
M: L!?$<$1 /\#;LU/E,$&KUJNENJ9=@J7N\N H707$XQ%IM\_EV96JY$#WDW
MQCA.T %(BM]SR\!2CL#WZE9M=D&'6 #!F">-3TI(HI_0RCQ5))&(\F*<#)BH
M JHEK!$,4W^D_2,9X2TE#"M%XQ8WRWSRE,Z#2!&9#12:IU4L)S9FV;H]Y"R7
MJ E(\?T$1^)H*%*/M;0T*9$8H,6M@Z'X%2368 M2$Y0#!&T7;QA>Y##-18,@
MV3V_0%L:P"D?>L@*_@T&MUMEN_A <!IH9)M=4!1E+ ?K]KU<OT^V-F+@S*_,
M41X!DR(,_P!E'A>-DPRB9*N^W+S2%-AZYU"IO'TXE^5^-/8_(LD>@,7!O1;H
MQ,7Z?;+]/MB5%1"V  [##@585P H-]%6'2UN,FG*':@1%,@0U-=*<DNE) IP
M3K ->]#8:<44=S\LE_:33D&P7,@1JTG CCA)E'3('@$UXAGI?D_O/2_)_>>E
M^3^\("I>QV/(J<BCA<H,>U08DTE\7=;&(DE)B@.I+BO--@8[QFLV [I34BR.
M1LK42HPV:.51NP/B  *@V!=B9Z^*%:NU@0@&7@J>0.OL2(YON\FS=<.$';5:
M40-;F0$9/Z$%"L6&9++_ +--U/K)$R4>I>D7S,2.U@2ARDWT<!3^SBP2I5"9
M@ZU"-E_!Y_DZ43.%3X2QQ33H3SBFI"N1&F](D5"[*9R+%UBCTT3PU=+J6V)O
M6DR)08E8U6U$!66AY7'-@R$)DH=AQ-K)[&]J& _,ZU.A9=8'P9 5=$=5XA@,
M9K]R"3E5C($I]&8VMI1<QGXG2&O<8D<[QJETYO>W<:6?7 E7H;)6%S%T$9DZ
MO.)(!$-$@O,9J$-2AYL\.707^;N JHI#3:(7)HUM\75.B5 %-+AFVUMF<XF\
MU( UCP((-%M+\-BH5WD#8MU0"A8)\V'8!BB6@ST"6*AT,WB:!+I8-%&0<&]I
MCL1!(!K* " "X$&C/2_)_>>E^3^\]+\G]XHD)L)H*WNSTMT#2T-34"5KJ-(C
M2F-I*#(+]QPYI+N(G@5*6B ,D3F($VNT0B!10T@9V9X#ZP33RS*X&CK0@@BB
MLB""6B'XR_3[9?I]L'^_/+S4)9P?#%<^7Q1@_#4 ,F>,WV4(])XIFEV+[-A9
M0.D[4&I/=O"*B+]/ME^GVPI\@J\I&NLA-(7615:?!0.,EI;)6/Y*.JH?TY@\
MV,PLG **O>#2.J-%0   !/TM=+NY/*?%MV"0Q2;Q :F]B*4?:1QJS9$;"[7*
MB]0;!JU9; J'$++F9#O4'_%O[X;Z8IZH&"(<SX&@1\Z<W6 $6GE9\:4W6A;V
M?S<,-_:\:T?H9UZP22:7*75\'G7C,:(*4R!RWW,>";E4H?I)O+.3KGB9ZG[Y
M6[3:Q$-R2!T(*^T4I59K5G\(7RR@TA'J&*FB!1\+X\% 6!YF&R)V?OX*:4*V
M/N&K(69ZG[XPY_?.(CTJ<FLG)V2Z&"VZ-55!:*W,PEY##NX_&?8Q""= VP8H
M/C%)1T^[W]BS!H42M0="EE07++1E%",4 @CX(3'.W%G2^Q<:%SA'V N2WT04
M/3\L,$TH9AD$0T9WBJ F0>C(FW8^"8S5P9W#V>070*;8D Z2WMT -A\%YA9%
M14%I8B^0'($R^\&"'A-O)!&L384D"-+1<GDICH(/%(X(3B  U:?<6!#"S 1,
M IRL9P5,22X:"E8%VL(5&MJT'04 ]\>9&H**-#4;-3QD."-ZP0[8XPO!:%)U
MGUKA[#BOQ$IO8#7%9_?17I/KBRZ::3L?'N8-Z3W)\9S<)P]Q$@V #.VJFM-Z
M=I^ G-C:R(DSB\KAUM(9#5)S:(8.6Q,]Y</<T*Q^G7XG!>S#"I'DX9O<RG;=
M%A*<C^C.UJ$PAR!FO9YB(>W,*3 [:0K\ T&G%[?MJZ@Q$I,!N\%,]%"\;>62
MX?* C*4,XB$&;VX_+3DBA#8 -IAJ&1KKU(&4!BBZB<JRQF7'(;"W .:O@E#"
M.A#Z.$BGD 7.,F=RP)0&T!T,+\)3*RO*N*QH<D6_GFCT2N>\,M5O[PN%.F.;
M=/,X^#@I+F(* \BFF&:+I5NL\T%X#J[94<)>4UZ0?+).S&VAUG2 948YY+D8
M,@$$G=@.46CQ%-@="[2BQ;"Z X;$OJKA+U$\5LMUS+<@79.*P7#T,>P/]!AK
ML6XT#'RGM6?P*YE>AONIF^#:+0#S5-]4+(,HO R\(TA-9<<-AP*4S,6:W4$@
M#<UL=DF?XL\1=F$IZ_<'&(2&Q\,/A!>XGX3EUZ<IA5Q%ZGL9N(7"IXU-V6O
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M4: !/_5L1FE7VT(KF\B8CYAJ *@SZF#Y3T+E0&45>"(L&UJLG8=K-'I0C('
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MC-0XHLT0"]N?7! 0AM,X=Y>6/%R($C>YO$.WL)YQ(!VU)YVR)ZI,:9VBCT8
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MQ!D4G"*G5O3O  <4D&@#A"-R@?=2U 52=#" *B6(7@<R@ 3%JUETD*><0/1
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MU@)6MN-L6R/A8#B G;4)3O'F/K^;TGF<GW966(\$&L3AJ[=N2J(K^<M<!8J
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M &DGX0(,UE&!=,Z2$Q414N 1!)9NK:$B RF,)$D$P!L@W;@N\%LFE3)HP (
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M)Z3AMEKV1:1S;9.0[D:LXF8,<_I-GKI4OAV3XZ3./*H\-FI(S,V^_@^!:I^
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M_FZ)$>BOYL(#A"(273#F(>P9)15D@E9V+6?X&.5X,') -7"5"R\I@UFV.,,
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M)7E45RB&\@CXCL;7V-Y"*@A%(HL'+S@EA0*)W#B\=N76<8@@+/(K09P,*NJ
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M2/7IX%/ X%=N.KJ1:38#@!3MP7BV4*KC]5ZS7*J3YGX: -N, ?H.P>A+Q"[
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MH0U!0C, ^U04B"#U4M0'&[.EE7X*[K&5<J"F&P(%B'5PD8>56&')"K)A;@O
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MJ\B'W/-8;86J\CD O0=8E>5'*V&OI/LQ !4 -JK  W;E;0A( (<>:/L]<*@
MEY@(ZNU1]<WUU 2$SQTC[W%LF0B*K9H[R>)-/ U!\PU]<G:5&O( E=A[3K>*
M(1(&[IWK-,Y$GX ]G\K^G7?A_;$$4;M(C0A>'A;7.S[-7!^57C$):?5X+EXN
M!F$@(,!QD3@@X!@!B?JZ!QAV6VTS90"]XX<*)3F/:D_\M(^8*^T,;\2\$P1^
M9W[-0]&LT%Z(?[(#%TZD8ZM9(5_! S5LS#9(VPB,22MUI))- 52X+3<B>2^)
M;,29TFB+VT7F\8,DV4 D&7B(19<L"7#9E)(C.@\4F%RNT];U;B"C8XM2'#D&
M-C8/5)VFN)1  )2RY?3]):%KYDA^O(]<(K; R?\ ':]?;.7B9YNY[FGT<H-3
MMZ5E^.R'H8I,2C9VVO3_ )9# @/(VCV/SBD*F\7:4U2-\-GKG3DJ:ET >BQP
M4"BT(G8>J?9A->A'E_&;I\CF@()AIU5U39@B:)%A4R@=ZZ'H^F<<!T!9-!/#
M3VPW(2H[>)'RN$50]<D]N-3],9**!^&JK\;#A28 @$&V73:X=.$3B2@5*#]S
M9ZN00ZV.V !ZP]L,RCXA I^MF<J "-A*'P PK:(B-4(V%;&6M5L.!EOMPX_Q
M(J)#>5-A*7=_3#LM9G"$"=!%],%5D$#:XE=77 9M8+>Q9W-*?7$IF @/-U$"
MM86 !KXWG?\ ^<P@%&(V/ ?9#U9IL\O(KV.$ON>N,FA@\?02/;ZN63C4^E(#
MJ:X\7TS?+6$[7Q<<B^RXH'5TXL122Z&"A8[1M>\^MGW>F3YNZ% P$] &+#ZL
M&QH^M-^IB,A04.EV:LOX<.T$4M/>DM['F8.EMVYF,/3<?3%0\BC>Z,/%T>AA
M"IL #$Q:77(\TRL"- .@3Z!^<9*@ ."/7:?P,=KR%7M5JOW_ $A69!5-8:A!
M51M ".IY=66Y]>Q/(B#6HUH:$1RLXQI"X)"7H.O!2M[++T% ,9 #L#]9^><*
MY& WW^:5.Z++(& 1DIW@H<MS*C!OM>7Y!$"[5+0_V!OMA9YT  U.CX$IFBS9
M]Q#-+A\ N B2+J?!U@PIZ")!=0JO$:UX:<Z%(?J!:&]FVV$_00P"O<*=OS2Y
MJ,38W\K/P\3*M>D[5@*P9,X0Y8;)B3U\0@42$6<OI^DA#= ]VS\[*^A@KC?K
MI>+1OV,]Z?6AT'8IIZXO,$)IZ";M->KWQV*K]B<O8#;Y7)3W@'UO7'3T<3$K
M%PI]$>QXAA02I7$IQ]34Z;XRF<>A$0\(@/1!RGB(+D')TZGKC"Y 1\$,Y>%]
M)C,IL):D$]NB3E<3]0:."6YW,+S1P(0#J&DGA"O>X)C2\NF5HV#AZ&,!L0AI
M\#T?FRDP=5EHW1P9[L0< WPWJ-;L5],I!S$\4Z>%"^P><H0\0[4UC;)"O>.$
MJ4Y@5*S@_9FFXK/ZGW<"3E5.^0MY%>&P]C_$1P2]Y5RFJ1]LYZT)R<\"<E5]
M,$U\(=X?#7C'WR!HV[BRV;0JIQ)CWCL/8D6D9"=XG9#(]R->]2AZX"B)!T6
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M:>2P<3#YV8?EBAZ&)%=8O)S"[#W,*Z (M#<G#9'3A*+J804"I%5/LR()K#M
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M-C<UK9Q9/S(])[U(?S;%\]D;I4IZQS<N8 3MY+5M,!@>G/GE*%8KE^;*W$$
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MT6K8A?5B^#L_RC?,,[H:IE3"O]K2G397_*P#W$U$PN%?BLQW;7LM'JAQ /\
M4C;J;AKK,PTTA^294=+A\"E9^?&+.A2:F6Y\,P&^FS<MG1S.MFFL08F>UC>U
M4[S^!'2#53@UD%ZG>,3 %$)UQMC*!XYS-$QEH;:JAB4[AWXS<FR1I.SFF64J
M)R@L1_0KL/W_ %2(""N_0"=)7H(4D#KR?A@ 76F2X"W$"1B?V*RAKM&\+-PF
M:& SP5M .1CF48,V9A(;;;97,E('%I")5,K*!M%N@]H%QBE-2FX(#LOG;<X,
MXSQ4&,I@KEH(TMZ@@,BF %2'=-?V<;.MZY/1N2Q"U=[[ !W=!--!*(2IRX8H
MZ^]H!V$+;S9<7T)@TAQ@'>9(('Y"83<50.=B('T]H4"?V-]X;5V%KC>PF()9
M_%W.Z]R0,UQ:^".(-^G>2)W]&'!2;1H"#A_W'1%U1&LE"Q7""!]&9AT5EE<,
MH*QPU0Y!GU#,RR)AUJAG["5:$1@'X(L\27AIE@K%T49Q)H#97PK-R<5);,VP
M69"V=JB[ (X3.7DRZ(OB QUC8* (UBJ6,"2 1P]671ZQ+RX4259,<X!%,1-W
MS*C!'$N+Q4NTD Q4&T#_  64B&Q(RC\0!8W"-T<7<<8S0R)B]A:,FZ F.1GR
MZ_AQ[/7.3V1W=J_7:4&4&6CD&X*%XP0#Y_XY] 99@:,BP)'EA=;OOC"EL)2E
MD=02E= 47NZE ?>#F$+)UTR+-<5R!6*V3<))45G<-;I,*32$3AR9598]GJE.
MD*P,L98N@(%#1! VZ'*%:*"355N";70:U332P5"8H4 ^=>>FDZ9=N]THVFO&
M23A8'.774CWIK-)P!F"L!+6[4D4^,;SXF.=M!G)'8[A+ / W8!K^]%K3!Z!Y
M=$N("X&$8R@M2 &BA[E46C&"75Z>)#L"$U A%* .48!DEX##2BZ3D(XKX/F%
MQ\ (%Z5;PIHZQ+$H!6"\A6QO5RX64%0$HV NPYQ4&FA1"N!/O#:I>4B]=*]F
ML1+A5:B(,!S-Y2C90!&N%.WELQ"H'E[\]@KL\]8FZ@Z>%',]7I]&;.(@!.M)
M' Q4L!=>&US04\9S"X.MOM@ B?P1C@20J=;\V*^[D9ERP\@V$KMJ+LKG.'0G
M 9!;O:$6+]D/ >6T/<VF%K"= /=36LM?:['#T0%APJAG;!S":!OV2O7#N#2N
MS^E ]2PE#KB])PZ!QWE6#TS<S ^1_P"'6.9GARS)8_>46M):Y H+13@I@,>(
M6!WG-('E_M4T1CPN;+W7TT/F4%9VF=]T=SA]A+L[+OV+PDP#^L2# 1I!-JOD
M6JOQ66)*\+4I'7E\,=[F8*!Z*P59A_\ 6\HJ@Y"'1AM_GJNJMK-ITM7%)=/U
MXA8\ IYH]Y8CGLEQA#T[WG_!*)P9&3%'F;@$M%&#&& 0D=[!68K($*,*R4"0
M68P DHC)!=,*SHC]#"QBJ<X"&8:J#MP4 "I);(Q<;]6F+&R""Z3!Z67>;&/V
M*%:EL>VCC#9BA7I*DNCA'*'$7>@MV8!.36"2EHEM05\:><N"!\!!@1%(&A?>
M@WC%GEBQOZ36A+SY'F%)!7%5)6R@<8]+A#700Q$07R2T]=P F"$TK;A<<9>,
MAL6MD)&ZX#6\VVN 1+)7H;2*7"*!;3P=UJ.!<&8I+(ZQ(0$Q9&LH6"FW-*%(
M>!PISG.#$$IIZJP;V#@&#0 G.Z"73D&F!BU@38"-)9!&C%!06-$3ZN0FM@E'
M3FD#_H-LLC')(#U8J*<"-&J=D*%%Q$,VP3--$*! E0<LS,3HRG )Q4.<).K4
M<X"^!/%^^6SXQ1\,=N-]NS$R$EY8Y(WU1G61RLN6;N<YJ4]1R*02I%'ZH[9Z
MXB^BR.H!L3D2N<4CT5\R-:3M>QDST:YG1)D.6X-&!M@U4D:1!)IA]3$-0BI=
M=%&Z<_>9(X-JB$8X<M/LRJ(P?I6-J..:^,*!@D$=TZ&N]'UPX(.HD@WE+:)]
M\@) +)Y\+W TJWG!+(N=71TG+N[RQ>J3:&AI@L(;V4TG"=0R4&H[B9DZ)&7@
M*0$ ASX#%2(":+$%48B7M707# *=BW$2@@02*G ;+!T0G10JD%@CZ12CA2HJ
M*KG<,IAWPBIH@3;$YN%V)N2(+7CH0*W7+<Z"PB^$V2>=[Q.FL05568;5#XP<
M!6+KJ4PK ]S'(\6+XX%C6JM.40 8CDU$#?4 &%:VD#9N]:JD&EWAU8BE'R*\
M! "!.<@5AM&9 "[PD6<8W "+1Q]"_=ANBVR:0\_#TR[O,\(T,)7#S?&%(4%T
M +M(+Y,X?HFQ$T@1NP,><$"*7<+D"^$:#D8C1/H:4AJT>;'L& O#I7/#RRI#
M'](#I>4?JCN,L\YX5C9K3.;!@WQ?-D,3*B/UF9RCTH;_ .W:3XM\0R]>&E0L
MQM$[-YZM].!^YBRO*0 VCF;I<NHV:]NG"Z6E(GZHV#M[D-1.-"[.W7 6:BK.
M+<#M!,;SX7N#D<>5KK<TY=@'TK &0ET*?!.^DQ"AIM"@;J+@)RW04UF$07B=
M8XW!B[_)K)$V2F@(N?=8;<1QPHW8 !!X.3.-&5H0I8R(U D,YZB$"UJ"XM8.
MS9?@^ (^V^)FI==#-"^G64BM;X8 _& HKUKE)2$=SDG9[ F(4?'4.7F5ECJV
M"F*(5I[QQC,>-1MA3!2;KD'8W@:A?':!:'C7HKK3/,$\[.K !,&G-)3N)Z<^
M%ID8:TUO,XY@0#N_A&.52_\ *U /8HOW*(&NVC"M2./\:+=VR8;$JD[G0YE<
M0*[*<BOR)LFP=,\785);0AB[JG*D_%_0G>-M8$XSY_$P2/8Y.,2A/U>Z[#Q&
ML5]T$W3)#0A9 KAM-&=WI\MADT76=PWDV8F/,Y@UA!82.)QG[K(N;K#18 P;
M:Y0+^*+BQQ F8&H=$. 3XV26EX7QRA IS:#F;E8%@#88'(O_ ,%Y^EXLPYMW
M>R8-",\$L&C&I<DKB\.-8D4)HH2<;[KSX= =,N$GA%,,^4;:'V_6$DQ4"4CZ
M4%B&LLRA@(KZ GV4LGVC>6OMHU$"-C[9R$J\YTHR2_%G=VN/9YZ7P&6."OS-
MAF 2)!S-J6;J#NRI_H;8VZ^&/1>%$7POWP:X^>G+6?\ +$87)!L]Z'W?(4T.
M*R%4U#'<RA74@_CK^09$-X'!L'MGVH\=L$-[!E:S[JBX9&,9=(*\V )W._C[
M]7:EQJP!44%NN9,Q?PYCX5 $P<RG_(N@[5/RXP] ,[G%$.T7F>EQ^L/^R71-
M^('F)W=C.7$M?@F1O2A[CF5J:L!\,*?D>E)^J*T47>'MKD&-YO\ "/?.^MIB
MB$802O)V:5>L)TVP&(M=$(4;Y0:UA^G2"@ RP,[=G84$Q&19MNSQ(24PA[E]
M( Z'S &PV8M(CI,*($H"DFE[@S8,]DL#34-4Y?2D>0/9G<?A),$#!BU*$*!L
M#/#3'AL4 *-:-R@#<&D*;DTH<I\"D18Y&A/><37913E!FAEGO;OK4F^&TA2=
M*!DR3[7*O7ZI?&X3T.O]*91K=4%;, 6<7+;V/90OE"Q(P"YZ27.':38U(1;I
MJR"*[^EM"4,5$#N2W.B93GX53#)?[>61SX#*;X5.,_6N84OI4R)60=*:/<TK
M&0]C='ZSH0FUL*>3Q0X0G"-#1MK'4%X7N$;-3(K2QJMH6&T> T!<C^]D3Z92
ML#_# 0E3P*57893U^ \2PPHU@\FKD6P $/<8.JS(Q7RW)_N[?I8:11Z"$#?K
M69 P/;EO+35D9N&K(+4DN!WW'_\ !ZN3UC(P=AHB"3)#]2O*2*.P$[8"B*\+
M4$5I,6Y+@N)?= !@IL[X"$^T'I&'/V*HL ;*"%!,%MP^&[%>=MKH,5+V!NM"
MU0R#1P).<87!8+Z HN-T=L@D**:I=P5A=C9?H*HA+H@6:J!6>2="OU0* FI]
MKR,R,!58I!!@<G 082!4*@SI4)*R\;'%SB,DI3#5(W-WP42K%TF .$FSI( (
MB7=GB> *-DMXY,$D5*F7)!0!F$.!@9K<Q<<P8 Q> :!:H*J=-9I9H+!'9PR\
M@W-X:?*KPCRA",F""-CPB!D:< :N*CZ5*VPP-L(NAKGZ2@K[">Z]UD=1/W8!
M HN)@J,@J9_<V%<.Z=X'9PA/5B\9./"-W!CF4T0 2 XWDE(J51L0$4IBH\L
M_0T,F0=B$9^PA29=B@UJUR%1ZGH]0#2CA<(:Y5*<5ZBZ!#67AZ%P5MM80HI,
MI6Z0(7(*F0-.R84[%Q>5YW3#3C%BTN_/N$#$,N4L_(GETT",7F4M1W01!DC5
M#O+N?W#%)^L 8BXN7=?_  B'6LMRJ6OV5R=0X!W4)AJSR*,D-NS31K 1&_,Z
M2GA#HFV1" H$8L(00"+CYW90'!,3PK0A(E[Z$)1?V(V,\4H C%NF&(@E0\8:
M^+%RU=^5#Q[\D':P:-,2O8, &IKD$V\L&<546WLMJY 9+W( BM0_N&(VPPX0
M3W<0CK,8  +=$]9[6"E*X!4L10R&M'*7EP+NB19(?((80-8DQBT#*J4 !?&#
M;K<*UJ&26QP8*';5-+$!6;T!TE&R.7&H2N9/1(VXTO?4$C*$U(VH6I"BU!J>
MI&JK77 Q(*>$[8HP@:>T<,_76P@GI[!+O-,9[%8;ZD/1\L:$-DU*J^KZ@Y1*
MVA1E&0J(1Q2AD'GG1;#-->8)DFPMI,4PYCK3#3' %E,0@,*K-UXFY8&;\[=K
M<1/)%-9H@B=3,:1E-F'/762"B+FGI3&G!"N),DRP!S_.5A4K'' .S@C$?X5G
M#+YGDA/,-$FW G2;9MW(^ MBF.$6B)@\N2G5NW45D>I0Y3-:B\P;8$&W,"8O
M+02[=BB P1PHC3082(H+$%"&&2Q+:P#I4U6?,+GU#U-?JDLKEOO(\8;\S.$H
MCA>^XWY7 R%DX] ?.GEZ8PE&F^NM\<W"84L-: $ E5'(N-@D M0!-&P1;QPZ
M LC>U.F%2R<\.6!C0T]B==2:D$52Z&*/LQ (HEV5TGUK-H'"%0KSIH"W'XDI
MP 1!(&G1X+07&:RTBL %" P>()B33[\XQM:^JF]D&U0Z;UC9$;$B%1M@4HT9
M1-VC)"/%NTJ;PJ8)$VN,W*;!1;PP!RTM()\6KV6Y0;]%2TD%1&A7@=YJ$??J
M*TE(JMQNSD!Z@T(+I)>77 +A^OV/)L+<AX&&S@)#0:<A\H<Z8X3OX('\4TG9
M0J3"T!$8B;2EHFX!K!4B27 $>!4#2784 T$II.ID,B '(:G27@]LA?0Z G80
M?)#YQ194(><5,J/1PYQ[;60QNB3O+8/>5I.EIKT G,E]8 QG3@A8.EX0O@8F
M36R$:$C=3D(ZZQ@1+!H.R5ZSZXPDL'2J=1!X^MA //W'L('NRMPB"U(]\.JB
M9$G(/ NHBCT)\9J3"A5[!>DZ0'!K=[.RNT<'L><-'%=8&D6/VOTQ2%#A]DID
MJC=&)+,>@9 0"X 9Q9UOAY'1%!(<8 1IC$,",F9R:7LLT^5>2B/,W6>)^@[+
M&<AS2]W(Z29$0< ?4W&/&V7Y>GCG$%R).>3"F"*^?D\U]/Y'AZ9*"2B<)E!<
M%7-(PQAOZ&+$?C#.LX'0]O\ !50ZJ3>X2^DN1:-T5)L:9B(OD4RZ'EU1-;WK
MWA7&E?N$AUH*1'%I:NA.F0<>8[$-,*] VH!=-ULITH%SD.802=PIIO/1FC/F
MZF9$]QY>"",3A"1MR\25T<J<1%!6-P-((WC;Q@Z $H%2""+(CL>2F1*@7YB*
M#9NB:]3#4I!4XY-SLP%B0"Q(Y.$R2%3>G?V2>\SQA(1$%$%7."D0' [,^S<H
MP@YZF<K"F2OF;K'@Q;0%^+!7U)J<1NUIE/1;9G!B4U'<3?7[<4D1K:ZA ..G
M80MO^0;'>YZ%K,,05RO3$?/EEY/S9@8:BCA+M$J?XCTJK#6WY&ZG^Y&OQ#3Y
M?!/L[R'$@& IAJ4Z!TJ6:X,K$KF(IJ'5@ L9DZB&=$;T.]LN/$$B^^#B\F^0
MH_\ )T]9D2D'+PQHQ*TU%H@<54*NE3ES"J#/D)'M2!N-,D)A@AU00HA:'-A@
MD8+$WNT8\0KH[0MNR!2MP)94%3EQ"^M)0T-PS-; #B3\BY *2P)ER;HT,R>*
M+<*E(T06#2 [ZH#K-!O1.@-$4A7=\QJ$ZB&PPJ0<GQ&K"CA,9#C FT,"0&AR
M#W7#T X 26V:](#>G>%(X+AY1HGVQH,!I"DIH_1? R).9@)$A*+N,,B2APUJ
M)V8H6;L0,"N011K*#[%-UMLCAE=1XB.V T!@\;&,@*<&5 .>M,2)C(40+H1B
M@P,BIRBP:[E8HAA.F<13]"I1I-64R?)&:# $Y :6P(,S,KY<L(*ZVN9A,AE!
M>XZ^-;Y,H=IE^./@+FG U%?NO5 ^F$B7.J,<F5];B,#B5B[5 Y=)@%/2EE-B
M#F]Q@9=@G,M;XBU>-N'L&RHF *NB^D%0+=JTTM?,X/&GG.DJ?C.!:Z(R-9$S
M);L=,M[E!A@)Q%2$JMVV$H45I@58D)2SEAJR23K ))LO#=(D/73UP4L)+::#
MA/EQBI@-@:!0/1O%HGY'^@I^S",*:6T"5;H P?+$W!:^J@!+5&TP'(S0&N;C
M+@SH(3M[E8BWHLHQ18FJJK$*\I!FO[_)]_W*R5&9^<$B&DP#*Z*!P/;5!]R%
M10JT8X/C%J:J&ZLLMYFQV4G8$*@S0 51]2/"JN1#C:6"A0D<:+*&$_;OZL&1
M23'Q8E>15^%AF6(<!( @H(N(]H=<NWK)XN$"&9J>Y:7K#$GP95%TI1>\'')!
M0: HK8H71;++&+HQT(*08/<9I,)_"XI U /3R5,02;)<.D"X=<AQ+@!FZ;Z@
MF' 7C%79E2 5%&-QT" D>10SY0[-X(4IB$*9=KUY;\&!I]&WL2(+MSP4=] )
MH@@F9Y&FMA7E;W2V#%@&B,J<YWUH8R1GN1TN./P*!(5A1^A#*VU88<DE]OJ[
M6S3(#A/A(VA-+]3F*<I175#5%6Q7Z3L .)%;A.2*;N:R/'7AG(YRU4VG:WEV
MP",(#%?]#24@U;@C6OH1793HYQJ%)<OMS33=6,0UA_\ _2 =8#",*E@QFR+%
M>A%@A7&GB"=)0T8K( N0J<B[PD@U_BU?ZXE5U(&0'^:ZR8K(.G _"T5F3[J
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M9?I^?[R_3\_W@U"&V?.\%,E+4"$ KRVQE:\8"J%"4@^[O$)K:*2!48]A[.R
M=LU5R]0=+#D6F"6M6]L0:2HDT-!A+B&*24.P"U&_M@=S89T%J8 WO# -F2:M
M127G0ATWFQL0-2#J@(G>BX"H.9-W%0DI*<J<6;%RX[E<-UIR;&ADV0>Y%#B;
M[>/I?WCM">&9# 5H*.L[/C/;#(U"DK4$$Y 4<*Z5/TV1@L YD#.(\2=H<!*Y
MAKT @&H>Q8EN*8RFSZN/U#2QMHTH0J-E>'& [HD,1, ,H1IQ P$0%'A'2?!
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MT<L(ESH-(6/E-IR!R %)BL@4"<%AN&!01"($F& FAG8%WFJJ-%X14V\D<K6
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M4-D2V1YK;02R-/*9 FD@9-T1]]2NDX [QB;=UJKPX.N!ETSD*%Y8QY..8PB
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M!"W48!]6N"1!4LBDH@"/%553KV%CJ6[@%IL:Y6\BN<4Z=6LDX!3)I!>F,DZ
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M2,*\"U4 RY526@[E.D[K\22\$7GI#=V2R 1,4W_W+;N!4QSN4!<]2*JXL4%
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M:JX.M*3L!#I2B.!3A:U=&)AD"I]@K!@VFCCX!GC9E(+3ITD2^ =[QQC&JE;
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M&A$AII\3) 0P-C8:C:VNDU<4  "@ DMZPR2@=8\6P:AL1)T&V_IW@$& " >
M!?=!?&!Z++PET]\= 5=&\T?!W(6$=(91X'1\#P":\8,-]X:?6%^5V8LHUXXO
M5*^C7#3E<H/H@_H>N$^5,6G1R&]+U@\P@)NZ8H_;#'[=V% &- =@#L-1U5Q]
M:$ZUYN1>UB2<P*0=0X3DIU,*)R3KCDPRA-BC=OTSZ] 05 0$A%Q;B)>8F,$$
MP#(*<;Q&%HPGY@:@\C(QA[/TK]_3V,=$\_)AYZ,VOJXI/_1E&G/]O7*LZ/H?
MMKTQ0)M3?O\ /OD6@,\?SB-J^V'YO\8-N@Z3^/Y_.): OTUZ:=Q]V8S.B]%^
M8_?$C4GK?XQ-5/J!_.13^S^/_,2M/W_O(&M7UN>H?9RGAOOC!TCZ?UB@WOY?
M4PWN[X[^GG!+1#G$I7+D\<X6_HQ5=CDNLXUR?%R/+G._?X:1P9!>\X_;(_\
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M7;NYW[OJ[Q5K:KSYH?KL\Z.L%")%&^D4/<] T:P,  TWU2QXI4\*IEY[4[0
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MO8MUD&&GK:B%.3?.&6L@,H2%&0Z#"X?]91 3JP/RD=,!AO.Y?H]1+Z]F(K&
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M,TFPJ4=[Q]@ K)!T:$<*;IHR@DIQHBJ0%1N.Q#C?VH"WCL2! 4%)QADW/@A
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MJ@,6V,( /&2'JXPG:4!:H1$;2QE6&5C\-V"  W5\X )M$OC "PFBM& !H[(
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MX:/J[N+==X#,+<1.</&4'PPD],,:PQ&W$*>LU3> /%B"%PQOG/<SW,6)O.1
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MCC,XQ$H@O:U5.UG0 :B7?E#36!V_0-(VI:>9RDJ;HXG0=. $Z:DY<Q==1A
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M #T;M6<%O-*LK(4H.0%7L)L,"< E(Q^ 4'2M(><((N( M&EMXHBT!<-IEM@
M0. )RNU:W&^_&^CV(SP::#B ' 06GE5!V^E1"WK%5@=AX0]]U)=:B71NO:WI
MYWYW?RYYO">WZ V\\=]N\OZ)^A+:Z&]MM*>1V1UD(L;"I6[.$X0>FGC(6B&^
MU[V^4Y1,$, 4LA"3@Z]B A<#&!4TX5:>BP\2\JX Q0!M[@\VG7AQ;JP3@>H<
MP7I[)(&AD-]5T2:5NNNV:2(ESIKA5AL>QX?I"P(S?0/[UO6KQFC25 %AT,Z
MA;:5%#H5G9$47WX*TB%P)/0C+14 4'#!DK.1,"+1Z)!8%I@=H8M2(9A';1E"
M .012!:]A(<BE#M+.A]<@P  9TX 7G8';J^9+X>K_LBX;*%X2BMB@1L-)A&C
M;HFR.-3S?_>62!! F$$J]L!2#>%)DJX])5=K5'#'EM!0F1"U='CNJ:!/PU",
MV4*JVT_5"U.!;5A1L/L8I^))%7U$R'7G2J\A"8 0TV@MAC7#T#@Z8<#1QZLU
M:]X?H<-8X8X:QC@S/VRG>#V\YMQA,H0-I$=ZXL=:V.[-48A.Q<399JTVZFQQ
MI+E@AL[GA8.X=Y5-O4!G&F)#L1T)R0ZG+*ZO%FTV[XU'F"0[1&8IM8JF^9YX
MP<*SA*EZ57''*%>16P"Q5 O*P0XXO?J (A@&F7FSHET=/@I.##C):ZTNW?=F
ML+$2!P?1VTZOJSTXLH@P MW@+OT1OE <&5[@V+K0O1S:FTR-J.$2""!L'RBA
MS<)F].-3V]/'LU[Y8+8F3X@KJ )J;:'$ !"GN$BSHZV'7!E\C0%7?(/M(FN\
MNJ[YT>;?S]V_:N-D2U.P$YVK'==LP8#U#9X@4BKJCGG2X1$9J0+Z&FGBFM/6
M<X<&M3<)^/L@=7&#Q$/PV 0&S2=$S?(BDZ2-"D";Z9'297:-$+3R:&Q1[=G#
MBAAM0HN]%BM>7MZVY>D7G/+'F&JCNSLF;]BMIJO )(OPN4;EL-4]8^!@]'>"
M2+D@.P-*)/-I"<DW$=*YJ;'V^OZ9BDPQ;[X.L?.76'/ZF6 @<[ KZ72P'6F6
M"(<L/K():"*TBKR!3<+HV U]($JR(&20\V8JF :Q&(#;$0!NS8"G0C(5$@W
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M:#>6XY8N],3PAZ9-V1Q>B.(I YL5L>V' VRC["<]8BT,_$S?!I[<0 _0_O\
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M ![17J;SAHM2B&*IT>0<'X0M(%8*9JZ>$=,<V]A'1!L0( G.Z4KEX*32KO*
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MV#Z^7M_K >@OGYYP+0B?S[_W_.1H!S[9X@^=8D0=CUU\_P YKT?+CJ!/D_O
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M8E2T_? Y%3SBNPBI^_PVU]?X^/.>A^V<?7G*^CG<Q)9S<0#ARG]?U@TOHO\
M?]YHSF'V_P"?)@B;*PTS9?/R8<#@NGZ_MY,WL>GW/GYN& =\_/X?^_HW?H>Q
M_;^,8*O$T?W\[]L>3:C7WY_K)RYWCW_; NN@?F8,)?VXDC:Z]#Y>\"O_ $<'
M@.O;YY<DV<O+^\QUE-@]\..Y1]PQ.3% "581-ABG=IE$=QH 1.PZ+20,RZ84
MG) D4:!0!$:-BZU< V9AK#H.F85IC21*D2H*8<HJ9O<Y$(02@0#4H%3%F+OP
M:D\OW0 ZPN+EH';2;G)N-OZE-*PP 0M<GG+WW\%7E7!'"_"PY)T($?0Y^YK"
MV2S%-;+%L5<1 1P?H "H+=5%!ZB/AN7"#CK0 )0H2[0_ 2$40@4T,2@NM.3>
M7159IV* 1+8Q70H:(@%.9J0WY;)N7"FGN>S14WOVTFQ>?]"2<"B>I"-P,E>'
MPYAR0E%(H9^,2.WD #M+P5'*:!4,9@PKF2-0^;94Q?O0<Y-(:6+D':C@=BG3
M5M\=4 XY>6$J\.E.DW20=(W0X868R*A;0N/@KP7L1:0IE!=/ !5)'&&C9X&@
M\29U>,0)R7G^_.0KT_9^?O@&N1U_6".<_/\ ?S<H6[3\_7$?5G'SSBB@U![8
MNU_@?/SQB#9].GV]_P!\GV?F>C\) '>CSZOIC3>#\^WI<._L>_S[X:NV./[_
M *P>I\?3\&10Z'7_ #*=XOY^N2\$/?'CZN<%],-!CMOKG0]/^X0KR_/[_"76
M.,>?Z_Y,$3(+AD!0WO$#, LP=G1^^(%</:;X_E_?X&='R?\ ,Y]K^_\ YF[/
M(YWG-G ?3^<'Q&\_WA=\<^9Y,I [OY^N&U-WOY\YR4W?'S^^<O/Y%^?9]\25
M1Y]D[]GO$W.7']>_P#T+1_+X,A4=&GH]O7O#2?N_?YYPT=Z_O@_G""=L TZD
M^88U@U\\X>[^'_<*I-/SK-#P3[8<_1^?XP_H N@$0^-H\F*P(<T\,VBAP)5;
MFD8&B\WZB=F(CIFL# AS8 !I: X5F6$G@(L* 4T+%.S%*(1>R0P1)<%$< 2(
M1K2.A*OF08">*#0&\!Y*$'DP+J4 -"WLM?::_P J!*S*G(>4#CD1.D<';&B:
M6RBA^_>,6IYG8:\/?)2" 4P2@1EW2 ",H+N600K%TLL#;P5Q(%A',:, DYVD
M.7!2UM(+0@*W(@MA&.%B1DM8N9Z/5&N*_"[>W@#F;:-GZ#D\C J9!&+T(-/@
MN@J)DG)I!WWUY,H2_(P3=0=$5\QB 5P(L3 )MLK0VN:"2 SM</W#2$<KH5NJ
M K$Z&0&V>+D.E1A"CA0A):0 *PD\N0@EC0D&;,.D2'C5(@*Z1L=EO!,/5FY6
MZB7U]$$3&^LXJ#YY<H/T]L0ZTSYW_>;&'^\05T^>3$434?37[8BT;._G3@:4
M0^?F81ASX?VO_F#(]L>_K_>4=$?'S\^V.]GLZ/?R_C(\;O;_ %[9N<C=O]?-
M<B.7L_U_>29ROG[Y/PA\^,GH./J#@NC@QCR//\?WB ]N#*L>,"KVX.!T?^Y6
M5GRGYWQFBD_?*.S]\(N]>K/IQ#9F!IT\L)(<9MIOV?<^?^8@F5E9%CL^7!*/
M"8"7LS;3AQAY</\ #@GR?-P2CPX*S8/G6*[+^=F3P'L^?/\ S([FCU\_G ?0
M/S\_;#:FCUTX$:>UZ_L_)@%"O/1\_7Z970V]O!C('],)PNCH^9@0-/D^^0(%
M3^WIG(NY^^!(0^7.38;?QAH>8?ME3[O\8>1XG]8ZX_?NXC<#:. JF.M%79!E
M3AD,E[$:=56Z*1T"!$V!=Y0W&1+"(!%0:(AAU/2E)QT!E@$E$<KGWTB%)","
M:*K4E@/C]H7LDC19'@EHS.FAE2&E4# TQ1HH-<M0\C<_RG04  55T &U7@Q&
MI!=JT @O#9QWB05YCLG07N%.8XJ>ZC6>6HH0T2.BU5V3TX2D16VS5G7KEK@!
MU26*H3N0W6,P0M1E.=7P *[:Y.#01N U3:[$02B1!$D))WE\"Y!_0<HW.L-K
MK.#=&,#N9#6O=$-:<T7T-XN,&A7E8P AP0&+M"IVF4\X@ "&K&P FZ!4,* !
MU=#1TQXW!AP,"=E5JZ@XC01 @2BP=4Y#0_)KM$%MK5H*..('&B&P%$6 ,(4F
MG"+W5U^E?2YR/G&AR5SIE'YYQ_ XI]/IB<(-!-ZOOQER!-7TNOZQR%4%[U@"
MW!#MM\ZGWQ ]0NX?:_?$)"8!WNE\?/C":B@>=!XH?G( #:^T%OKX\8 <@=R?
M4_\ <-F--"G'[Y9@ '6N7AU^3*- 76OY'YQ HO)>_7TS8ZO'#WK*T EA[?/.
M;(!I?S)QU^<E0#/RU?M<:+_*OW/SFU3C\!BB='[Y\WC_ +^V:RF4QB1XQ5^?
MGO3XG_>91[?SA1"8A4\>+EX!A'G1\_/]821W?GB?/C)-<OXRF4RF6-.<02_5
MZ?\ ,HZ?E\_U@SP?MF]B3)?5X_KSBFCK&PFQ\_,<&<CZZ^?HYIW$]&SZ_/WQ
M-Z7U*?/MGJV?G(Y%/4OY<LRE\=_P8%S]GG[</[XWF_8X^W)B@@AZ.\"<;Y/&
M(Y7]_/X]<77I\OOBZ&V\]8J%?3^?ZPVSK%K<TGAG(^=84E#2Z$2.MDNL-=ZI
M9'A(.$<BXEAR*+JW 0/5N*83J((< '-FJ4\N. UP[0(4U T&[Q1<> RW#VK*
M-#I0PN$,-2BP! /9E=G3E>F<( (B4( $ED,1L%R('+<G,XKXGZ [9=2&M4W#
MK2]=8.CE  "Q-BF0'(WC$%"1 PJ3!2G@AN1T)J!'G#70AMX5UD#!2@@[A&FP
MV<(< ($!9"J'9ORAO/5MW+%02%6!#28FM1D'2H'D (QH*?+=&!E46\GIO+5/
MI184-)=Y2Q&(XDE+L Z+.*S0D&I4& HFW;A-UX,W<0X R@%%!RFUK"-@RO/(
M.BNRDAV[90XQ<X,8 B[U%&LQ52R>DV!44$3@\AP>- $-IJ):Y:3A</L>+W6Y
M =HKE?HMM"@L+5+4@ANT\,<&[UML[T/QDOV%M NPFS(T*'8*?V@14V\'D60)
M3"7BP@1N&F:$2D?1&Y1(VPEAV+%9,)R6R2L0FJ 0G9BK2\(N>LM8@*%!CE W
M:A(J #98!!3B_P#H>/4X1VYZ_K&! IY]><;2[O\ [G"@+WU_SZ8=75OU]\XH
M1_[?WQ;06[WWE79Z?(QT87U9].[[7%J2%]C7&MNOI@>Q05WHW^_WSJW]N//[
M^V3'5"!Z>._YP%L<N'>^=/\ S%"5Q/IAI!/H_P!XQ1"+XPAMGH?S@*IN^<!)
MH'F;XR"&CV_?/EOY?XS:;U\OOE#^7]>/WR&0R&0R&0QEL_/AZ_KC-2<IXO[5
M^?7$^"WS_P \Y<@/LOMUXRC?&N?3T]\XGG(9#(9#(8:V<YKEI_'_ #+VW\N'
M^,"<_G]G 79'Y^><VZ4'KDFXGMEO/Y,^C[8,X_;^\^B/IHP=@3S;\_4P;H?9
M(_/WS@D,(X3[=?1RO(0\N_S_ ,RG)7TW_7[9> ^JXJZI/KFGJY';3WQ3AQ^^
M1L\^/[P*]<=(<&-"X.A=R+$]?K)XR*>[)>U.U%TZ+"(3'8HK9GH*",CA2(+$
M"T7]T$-.,N(TC(+#-G3T#C+<Z^X(4O6WG =]( Y>32AE#15 C2.JF5$[C784
MI,V_4H(^K5OTA_EJ^=12 6@*DY(ZZ>,,==:SN4,;3F@Y@>,%\ =GU]D\DRE:
M49(5EK$ K"]6#H-PB0%*(1+)-IU@]5B"0+>B2-$>&QPB8T7DB((E510$0TVP
M:L-G"4U\3@\X7M?/\FD.APH]!/T1<UDB\+42@ JV2%Q@\-6@DWZN^T^N7EH8
M!R8"T"=FE\8PX&9*/>>32J:PY$JXXA!A^TU.B3VO?8+U6DL>57=:\C) C6@*
M!*:$1IDRK$9R72NP$#1P_P!!<AP"["%; U^<+.HN/6V>G\-R%\/'?_<MU_U@
M)M;^SC_X:_YA#13-N]^V;ZOVQ7O\N#J'X/YRGTHA";TZ:TW,%P8L*K&MH @E
M0SRP<H$C-@$T-Y!E';(W(@.,X2C)!U!N4$(*,?'K8_MWD]'Z.;,;QOF83T^[
MFSP^?KBCRKE\:SG;S_J)28@;UWE7D/S@CL#ZYL</\?UDY3?O_P"YIQ?N_P!9
M[^LM2?=EW^3^/?!;#Y/KBP'?MK[_ /F<)I]W]O\ W*(';VU^<:-5\C_;@J"R
M^NG\9PU^'+WU],Z*7-V\X=!'Y[<@<OME=!KYYR!SM\8ZJ\K !LO1=7M3MB1R
MA+"\E,F'=.G .;&6UB\BAO4"<9.DBG+'2L4 VEA2X+H(9(TG0%06:$:& )3#
MWP(;H=BIN77*:<%:NI!I8E< X$8A>B2FTY9<94.NY4E=?RS_ &6J@WF%BTE>
M4V<NL#4<(? 44M]Q.9BH#3Y%1:2QZ%T5$* UC8=BM1H<I!"8 "P2A:B$D!8$
M/&$>2#7@ +8$4M0"Q" "DTH;@"""0;,  ZEP5A7K(G0G./.5C=L[!1V"A= 0
M$BUO&ON5NS56JX#5&%[_ +SUD??\F\]8C\^F4Z4^??/<^W_<OA7S[YMR+[N:
M/#\_WBG*OX,9EW8 -9M=0!V#E'.@JM5:\NTA8D "U$D5&C2LA5)&F30J."6
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MO-^=9KDHG/G$?2X+O)>-9[&;88O9I2Q%]*[:"GQB(12C(*^D$0PFSA8YM5%
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ML 5  T#?CCL$D-56JKM5VOZ;2P(SNH)DR"$DB898#:HDE(P2+&+;*A( 556
M!X .,I@>2@T/8H%0* )3\PA"PU!P99^*V"T1[8*/,0W3D+PZ?T>2(?7-[;,&
M@FN 8<,Q)P:"@PH =N]OZ&L:$SG5#22P3*?@W.)5!#<;3\<.0"#KV%=Z:-V8
MF:[YR& 1XN*&O7_S$O.:OOO$O.0R&0SBL=^V.>V3KK.7XW+,2D<,U?3.YG<>
M,9FCVS4N:=F&R8X?G.=Y,O\ @]?A^V7-_!\YU,OWS1K6(5Q+?9D';AADUOG
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M@Q@@6C1YTD8T7A)!QFRB1&H,0>1@KS;:0):1@%2++V82ZU&OAE!2'V##AX@
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M XX@1,.ZP=P,TFWC:TP*L<K\WJZ&"E/+-(T7-*[%"=N-="0007@QN7F(A8(
MJH!$<RUGE64@@BM4L%-Q&&Q7C3%%AD1G/6FEN9J7Y!I%*1L1NA(8PA*4Q6 N
MG)5(80JFDAZ [)FI6@$'\DUD*AMJ"J[%[&,%J7V" ($(<@48%!"/()^=Y5H
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M<R"L"U3:QEG@4RI2)0%S<)FA%RR5@AYK#&(Q$?@PGN #R$(@#+'O>G6(1X6
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ME".$LJ-HPYS>F  U15"(G:5DU7'L%0 "$(WI;J9P8VX,!D*B550"G28K##9
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M%D IQ9?+50T4HMO8!Y*ZJDI8D0ZAR%+%]0MF7!H (VYT>B6FA=%RD@BJ!["
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MF<Y)D7(Y'(Y4W8Z&[AL9;/.#[J"@-HIN@^K(-8*Z4VO(DM)H33>%PQ/"9P%
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M\3D=M<AG%1 .F\H,T"HAH'S'U*D7"+7F(5IK,FPJ"-Y<B$!Q"T,%M=7=F$D
MY7>WY=?HULD$$F"'(&[E -D^9"^$.Q+6"*9EOR]4N9C,4=.8 @O#V!:9X8I+
M3/U@EW*4)@[\!AT;;D628R,@J,^O K3EA%=1>X[V\KS  4)&I]"I]ZB%0S)[
M$,&H^Q\6!QP5^3H -KO0 04R9E2 IK25B=A$(8?0E97'$")P1B";XU-$3P@;
M2\ X:X]428C&@X2_U!"(%5$)!:-(1J.%BZFI;4<4>,#0K E.'XF:5 %BA4*
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MQY[$(!*D6X/*DDH;)$JJ;T6N!3MC1B4[ (E0673C<*Q4+*9) JZ>=R$'C^&
M "5#2J5=;F;&EEBY% 8R8ZHH.%N$ZPW0A.7=UQG5'+0=?HLJWD0RK FKHTY)
M$H;@]R1 *8 ,)RP![7D4ZG+*#PHV6 ($J&=@P^OR@L(F@(:C@$W!5KCC"Z8$
M*6:+@4Z"J$\5&<"6E&")SAL+%U+36*VFP67 4H(+)LIUJQ)J(ME(&",]I4NK
M2S<(('Q)<:%@B5EULWVD2D&)^TBUUB?D%:.-XA*$;\!Q\$L *ODZ47]$#9W.
M'\)N(Z6_X!M::1[5IX.-TRZE (+1NDD]5=.+DTH& TDQ& N&BM  ]$D:6"('
MACJ3#5906:E4[1L*.T&]D"A1\0-  /IJ;,FG3<$HE8QJ-C("M-K@U0.Q 3:
M$IWAVSMO6]?GVQY^#.6KBCEK]\/H8@!_\U@)KC_F12<O/S\\X S<G_NLH/E\
MS!V^><1"\G]YV.)_.0Z>, ]Y,.!ZXGZ_/TQPHZZR+3ZX,90!W<H5UBB?/WQ
M]?\ N*;8HD[_ /<(>N(X?G6(*GSO"CXQKVRG7[8 LSY/KGDX\?7%&SO%/?(?
M4_MB P"<_C$WY\9,-_,S@>?Z,>S_ ,S83*CU_P"?/[XA\]81L^=8P:\8B^V4
M'F92:X;B+[Y /6 D>-_MC1/.+6YVSEG'./USF^!S@>]0OMOST%?H8*-!SBY2
M%$-RNE <;@;X"0@B 00/")DH>NT;I\R.U$)RN+W)13OPZ&=ITQ%&89;NB!P!
M4TK!)NE< _2LCQEBD"\Z9<=F,DY2*"4")L+-<X1K50B1G=YUXU^@<%6D$ :6
M#M0VQ0N* Z;LCK44X$/U?U*@F5B\!\3N:[8#)[E3FBEX8#]#&UX2C&YGMWHF
M:7E\I!C3ZNP?^2A%=CBZ^U3C.U_I_G.>_L",;=!0&%, 2RD@0;X <C"YFZ$G
MGJ:]! 0+^-5F^:)+KN@$TQ"4V:$TAI:/"!&9>4+0S[G&.-B_!A:*"EIQ_(4V
M_P 2>DB! (G0D';6C(51I-'LT.OGHR>)NN5.-$*IL$I)CQ-R0:-(P>: 3Q,"
M\=L21WWA2<GLNE\A@]1(; @ FSV20H'1%(+2 %(-E*X<X=)'K! .YW.+<U/L
MJ*2=[*9NE)D,2*+37$;AH^VYP*!ACKX$VNL!71A+'> QZ/\ G]YR=_+D5;\V
M8P^?.&JN)4'YWA8'G-VY*[>3^+E-F0\M?^7.J_MUD<O. P/C)-C+/SA7*_\
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M(W,N5'378QF0T)%/1Q]ATR)B(@X4=T1CK1E3#E275@ VH@!RXZZ-D,@%0=8
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MK*^<%N6-Q7=UB:/3+E[^F"N<,>HH3($1$F@U$#00>+ !0+ ,A6!!6<XJ,")
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MVP=S]"U],],]N,[UG##G.-N-3%NC#17-_!@=44TZB^>2R/HXK[P:A)X% TK
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@)28O<!N*(=?[332VR#6*FB:[3_XX7K&]\YOO]&_C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g790774page016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g790774page016.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P@ 1" -P A8# 1$
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M\)&AL<'Q8-%PH.& D,#_V@ , P$  A$#$0   ?[^
M
M
M
M
M
M
M
M
M
M
M
M
M                              %1];YX>YEZEQ98#-CLQ9:_A[F7V7'E
M@,V.S%EK^&29#'<?IEQV8<M8R8Y_+/%Q^F7'9ARUC)CG\L\7'ZN7'/#EK&7'
M/S<?%GJ7W,\66L9<<_%Q\V>I?<RQ98#-CLQ98?$]S+U+BRP&;'9BRU_#W,OL
MN/+ 9L=FIMY[GXWTH                                 '@]@
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ME,/"ZYE(0MR8EAB7(PDB$+2E=6Z)3UWST8C:0L<2Z0:[9Y-M-999.G@
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M>$M@        !73EBVU+D11\-8DS3,Y\/AG-<TR7,)D+"  0I-  @R<
M           -<B3X<?70.C):C4./K%G2TIZYRRI7EAS;-TWB#/),FT=%3C*Z
M1U]+61I-  @R<.7G)E@"WDH4%;,F@>B8) ^E6+65TFRG%L-8B2\$09XA*]'H
MERN'ZB3V  "./)G-P        $.>"4,Y"DT "JFV>32,A\/1B,QY/AZ,I$FZ
M93&? 9S 0I83R>CR8C,#$;A]               /)80
M  83&>#:- RGLSFL9#7-DQ'T\'T^GT]F0Q&(]&8Q'TR&8
M    'Y.7B\L95G*>7PKQN1CK7B6K8-,U#[%>JQQ[J#+ <^EMUDL:1$Q'5^GT
M_3: #\ZK-G."RF,A#?+<=30     #G1SA8Q>C)4(GJI9:R,-DT#"7(AS?-D_
M0"            ?G9?T2@    & T0     #?,QC,@!Y/!E   /S LZ
M      0!^H4                                   _/:U,WB(+8>"%-
M$M!520,IH& LQ#&<CBS$*2ID*N70BB+-(ZN75                !8"1 !Y
M/0     !\/H   /A] /)Z                   *R:P
M             !/D@                                   50U0
M                         "QDD
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MG)I/JQ9$&D=42@R^:F20-%(!9\A@?I]CC-D]E[.4KV=
M !Q1:(09%EUBM$W6L9#:BK6Y"=39(4FB#/2V%.5RY*LTFY7LSE?74.^)A.SH
M                  .*+$$(;1(&B:9+%=+":1)D0:T76JB;Q*FL7=.<+;"O
M%W3IX .,+V= !^=%^F(R'Z#38              .*+VM             .,+
MV= !"$"2)N$88P             6,Y(O:T             XPO9T
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M[.@                  XHO:T             XPO9T
M  'Y/7H8            !#'Z&0
M
M
M
M
M
M
M
M
M
M             "!V^G$;.[2RZ=W'FS37\7ZF"[?22.')'9]>288[GKW;+Z^#
M3SZ,LP\KAN>]ASZN6[3SZ)K5YVGET6#3Y>]CS                    "A=
M?TW&_1_0+-I\?#=E&ZOH['I\G'<]2[[)I\B2PY*!U_46?1XT5L[<-VS.KSN<
M]OUO4^#XJ,V=GAE?>3YCEW?]I?N3Y>*S[J[N]7O'E?F=HT>,
M        *7T_0\J[_MI/#CLNCQX#=ZFQCJ@-WJ6G1XL+L]#6RW;^'+L35%9]
MT/M[MO'3,:O/E<.+#=D%M]*?T^97MWJ>DD<.3Z0FST?T7X_Y.!R"7X=?L^@
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M,)&+/V4Y8:K'C++5=W^SS#N^RV\=$3L[]B:=_#FU\MNQCJA]G?9M'CPVWO\
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MQ[&.F(V=^GGOM'/XT'N]*5U<.EGTYIKZ1Q?(]+XOD /SI,OR',OZ>Y:]H
M            @JTY<466S9./^C]YR/T/NYK5Y]%Z_I)'#EDL..M;O8E]?!CN
M6AGU7SC^9IG5]!BNRR:?(PLX#=ZEDT^1;.?PXC9W[^'+XN7Q<-V6/3Y/=O*_
M- !QJ7EJ_K5CZH               ("A7-WK4+K^GD]?'XM])@NS-,-7+=(X
M<F28Z]V5+H]Z:U^=NX<VMEOW,>?0RZ>K\'Q&>:P   !28NM?0
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M>BXTEQ0XZE)"#1BQ!7<T./K&XX%DGMQ\2RREOMV..F6DYL492^U&Y=CCJWV
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M36:+;XHM:+E#K3[A ^)]QK6"EC',&?W!_1OG']"2\]&-3#EDAB74R]3VX23
M>$U*UI_!YBK2(3<G!2SWGZS%'^2@:Z6B6IR6AIBLD8_)U;40-(1:PW;1#BC%
M&0<:E<I6'4G[B15M+:E2VIN/<T/8PFR8^:9#*CW1G12Y<)$)*24=J/(D'V!W
M'8=AJG/LO"&?W!_1OG']"2+5UW(Z8^DK:*%ON\?9N:0R$?07BF(Z^)3&BW-!
M@XWT7:A57]G937T+;AX%Y4<X/?EXIKZ9SFM6WOV1_H(SJ&?H2B'(ZS-"&-77
M>@M329$-N_"X&Q9]@M-W\9V.;L+<M^ S^X/X)FZD0TNCZ1&JP#Z1'GGM?28M
MY;2]N-?G?G']"?FS/[@_@7&QSA,;6X6)1X2%Z>XR-WBH4;>_",9X1C/",9X1
MC/",9X1C/",9X1C/",9X1C/",9X1C/",9X1C/",9X1C/",9X1C/",9X1C/",
M9X1C/",9X1C/",9X1C/",9X1C!ATBM?./Z$_-F?W!_1OG']"?FS/[@_@<GHA
MD[JMYW8NWNHWQ_[_ )[YQ_0GYLS^X/X)BD^7D8KYL[R _-/'N-_,0FM[(D@M
M:D)93:3)I:3)LR.0U(2Q#:S9EM/=3F=Y-<>ZG,[R:X[/E]+0;,N)[J<SO9G:
MNZG,[J<S1DUO.ZG,[R:X]U.9W4YG=3F=U.8DZ8<S<E*)4L^7;SNIS.ZG,[J<
MP99"VOG']"?FS/[@_P BQUY%A0CYS.=J31+"Z/(0JI")D/GTHXY8ZQ+RY\53
MK(\^)1+$*2Q0YUK<S3Y$Z:GJ0Y+S,!6)B)EF*'9T853;:*/Z$=MQBB3*2XNG
M&!1#5,G@T5RG2<0;JDS_ $GZ%(Z('I%J0KT2:4G5-D/6U?.CRR9&DOR;%=JD
MQ$2S]$G^BY\_E4C1(CP$9\X_H3\V9_<'^7< [*:)7@I\?2*]]"(9]4O0S]?C
MYP%]T+Z$H\:#O77L]=DIF7K,=<!9(FM7,>4AHNX,SMBKUBFC+57Y&9-K$7<P
MI.8B+R0]+TRU2.]P-S&;B:_] !,L@4[*Q+D?845IZ%^@[$9C;F,58Q[63,[J
M]W* U%WUC0E<O#18ZW'&/G']"?FS/[@_R[5[5H=</] >-6[]):PQJ]C5UL+Z
M.*>:+]*<P0?Z+SG^^=D<U>&F71/I#>GSOH(:Q!OI+[0S7U![4;[0S Q2+?K0
MB?I&F-/W J#:%^DQXI1GT&-($3]#]<;%^D-XV/\ 4F\(U]-ZL.D]N._C\X_H
M3\V9_<']&^<?T)^;,_N#^C?./Z$_-F?W!_1OG']"?FS/[@_HU3FI6!K?N)>>
MXEY[B7GN)>>XEY[B7GN)>>XEY[B7GN)>>XEY[B7GN)>>XEY[B7GN)>>XEY[B
M7GN)>>XEY[B7GN)>>XEY[B7GN)>>XEY[B7@)4A,W+_HF9*0;C!6K##N879HL
M(X6?C2Q4S\(K%S\,WMV>B6A=V.$TVNPP[1GEXSE]B@N*9Z(<=38H5>.V:$:9
M9F8HC>K!";TW.Q#SZ)R-5O<_&<'IF*'>U/PNTN66&993+QBM>>AL&)9,'_2K
M":.$$5,5)TEPZN%(8-AP@=NU;;4>[5Y'7DJXWBI&IDNOF5D\19=>:CTGU@-"
MWZM"&OFU!Y3DG5=NH-K\3%".P&UR)E=KA1!]6>"$E:XL8J.C#Y1&XL<P+M37
MQT18Y>S:>O(9YAZ/_2IUXM@-9UE&SO[ DCNI=V6>-F>:+.F^Y1*V?8T@5)#/
MNR-B;T3(6?>Y$^4%-D7I]$F\Y,=MN?G'G5R%DQ@ZP+R8.D4OCDS+Q:9*2>3(
M'SZ6V9B7[C4O:7-A&3TB1'$2ZQGYBX.-_P ;C=X"C@Z^A4+>_P!%F&I)X4H*
M8T*R%;G-=E964GQ4P\5H*U^+=C[4-GC[<A]0D\N6?$M#Q$;'V(4M8ULXBM68
M:6[.V>.T)=7=KA;&Z02+8E,L"V-3[PEG:R,&LRW9&/MI&UM6+;:8JX[<B1YO
M3_X+9-UV(RU6#Y_34<=<O\22VA=>3'WFY05+;<@PZTB086O;R$N:F E;W*,)
MUY,7E1(LKV3)C"8W)"ND?D5'LI(_C8V(PD%V.JFW^PKFC"(^*? 7'51L@X.#
M*Q+=8W'-P<'L)Y$ 8V2#6VRDQ=<<&?AZ\/N6172Y.4U"2!Q#$1$+;AX!Q147
M7$+?A(!LM<E7W8N69@VEQ/@T/B#U=+Y0L 5H>5AX$ *4CY+?\;\'':<FZU5X
M:O\ +_X?Q*%;+0F*'1GB!>+ (XZ$BM)6IE"G-PP>]KCQG,3$#IS0+.M/QS#Z
MFXD1IW^<0]V[38TAM))KG B2#8T+(Z>5_"UK0B.8=@>Z0B&,,(DQ!Y3KP"XY
M@^".Q>AA1_\ 39S:H(0;NX-]3<I :=F%Z8(9FJTWJ'*K<D7YV),4/-UD1;;L
M(^ 5/UXE@]V AR3I"N/B=W /NMR-8=Q38JC$3M==W#"1S(G\;77)F1DRJE?2
MQ>BGH?Q(T[R\QO)S$<G$OMV=G.;TH_:.I*\>:23C:RN8GO>?FD-Z&43U"U$Z
MS6R=L[7(*PG;Z6NH7O;'?.9_KI$;[[;2U&Z6PHQS#%&HQ'=<[JSM/,[7MH@5
M@I.F^R>4A*TECB,9V;BCU2"QEH6EQ,JN30.J0NG4659T1:R;DO39=Q0TDFU+
MD'?;--]Q;7D[+N/,(59W"7#;;N17(V_;$@78&B6"+4ZEV1N"=Q94ZLUQAEW.
M&LX:WG#6<,X:Q2$K2AIIM'X+JU?"&(VK?1H6X?Y\/XE)(5KIGJQ396W%-2G#
MIR&,\_3=;/XZ[E3SK3^EJ[G%H-V^PTXD=MLE*W6SN9#)O(TTZG$MR.U],K6+
M:DTIZ4C@W7TC\4E_]GC[S3"&2HME;(QA4@VTAE%LDI>*C#[3(1;L5:BY$J*N
M<T867<)85U5GGFQE?1))H9ZRR^AR[6>.R_=)_ME7B7<V?:Y4+(JUV8@TBW60
M0TRU2K$9N]')5"V:4ECX2SRDN5&W2;**/M\J$\Y9K"D)FZ2CKJ[@>B'!N,@0
M;^"V S<I.:EIS52_U>C^>._\6D+0XE;;;J6X80=$>E6A<LOL'C" +R^60)?^
MIRW0V.,<NZ4[_<=;4ZW<U'O[^@(UM/T-QQ<;<]!H&N:XF.9OH+ZQ;[L@%5V9
M(8_=!X=35_96XU>@HEG]SEM+"NSQ$>/>ER$3N]#$',_0-R  _P!';*?$O*)2
MMJLNF?XW:<EPY02\V8. YU='\^Y'#.;_ /R;>WP"7&6NITLNB=NQBXR+ZIL0
M(J-/C(O;#$9 ,NQ$?&1FQHZOF#]K#EUMN.BF%G0L$ ZU$1Z88V'B'D-0X//V
M%>4PT-"E1!-9A62@VHCP[=$=95^W3_#]OUI=W1C&84JAE[::^?$Y!U)^%E_P
M6"R)A[ Y:X@Z1_\ E^B2<4#,#ZH=5TM=0@7(]%.K[;I-/@3-.4NN.[9IU>'(
MW2*WS/U2$(0358,M2:A H"_;N"VH^CU\X3TV Z;-'K;#A-/@2RFZ+6FMMHTT
MW_*E:Y!3A/\ @7__V@ ( 0(  04"_P"H%VV%G3"X],/.F)PZ87'IA9R"<.F'
MG3"X],/.F)PZ87'IAYR"<.F'G3"X],3.F)G3"X],/.03ATP\Z87'IB<.F'G3
M"SIAYR"<.F'G3"X],3ATP\Z87'IAYR"<.F%G3"X\@G#IAYTPN/3#SD$X=,+C
MTPLY!.'3#SIA<>F'G3$X=,/CTP\Y!.'3#SIA<>F'G3$X=,+CTPLY!.'3#SIA
M<>F'G3$X=,+CTP\Y!.&FP>/_ *."0GGWMES6)96I.VEZWTG,Z3F::<WOHN9T
M7-IZ:\Z+N=)SAT7,TR[O>VUZSI.YTG-:Z2\Z2\TVO>NDYFF7-[Z:\Z3F;UM.
M_P!*93M2DMD<-)>3FTN*5P?Q>GT9R/9R$:UI+R5<KVU\KZLX/N)TDC6<C_#E
M=<6K3N(2\]K27]*4V]QTM:4?^>TJYDZWS[3RD8YK>E_I36D[5RL[SE:X<K>F
M]);Q:6N'(QQ1I&]:0SFD,8A*%)1IKDUT^/2:UKD9S:6L;2CAO3>D\B-8A+6;
M;;X=-C%):1I>F^.FQ_TMO:-;2IOFVH?.9G>)<;UKF8Y^9C><X_#F:Z>E,:TM
M;*D\1\5MG;?,/S\PVLZC.M:VSQVIGAI3&\7MC@A8^LXLYSC8YMKA^EL[7I6E
MO\.9[ETM>E<[_!*G=9_K\_5=YM=5.:4]PYWN.G'MXWUM(1U$)UMQS.H[K-+>
MS3KO+R.Z6WMW>.=7@K;_  TIU.;0XZI2%H_E\<X_@X_FV/\ Z]]7E_U$ITA6
MT<'>?:74Y_FK?_?/]56^5W6<CO!O_/6VWL<T\C72<3FVGE9P=TK33VMITZYI
M*'M*Y7=:Y']9_GR])[6.*7M7Z4WR<>0;.5CGX#9RC<>#')KM\X#ZSE&Q6F.'
M*/R<@_%"6MZWIC6:0/BTM<O'>OQ\=_I@Z&W%I80O2V$HTX,VE*1V]ZZ#7'LT
M;WIEOBEA.]Z&:X]JWB6&U8MAG2=#LJ2EA&U]JG'&$-I<80VE8S>DI'0K6F&>
M;8R-:[=/44.C2?TMGI<^E"Z3I0F?^V2M/:Y_[/&NVY==IG_L\YQN;B-U%[$5
MKB)P5VV];['6^(F\XBJ<WV/'F&UI6Q>1SM=Z3L3E5L/ETH7D>Z/']*&_R7I:
M^"7-\Z5KX[6[O'%+7FUNIWS.)>YE[Q+CJM;<5U$N.:S;BLYGN.]N:<T\YO2M
MN=396MYWFL[O_+ND[<26GCLO6.D:<;_2T.*;WW3^=P[S=R[PT0ZG.Y>S9#V]
M=R]FGW=9I]U.=P[S=X[B2G4J[EW-E/;S1#J==T]O/^_^$?_:  @! P !!0+_
M *@73TGPZTGPV](YU9'CIZ3X;>D^'5D.;3TEG6D^&WI'CU9'CUI/AMZ3X=60
MYM/27#K2?#;LCQT](\>M)\-O27#JR'-IZ3X=:3X=61XZ>D>/6D^&WI+.K(<V
MGI+AMZ3X=61XZ>D<ZTGPV])9U9#FT])\-O2?#JR/'3TEG6D^&WI+.K(<VGI+
MAMZ2X=60XZ>DLZTEPV])9U9'CIZ2X;>D^'5D.;3TEG6D^&WI'.K(\=/2?#;T
MGPZLAS:>DLZTEPV](YU9'CIZ3X;>DN'5D.;;\KR_^C@A!5&/+BCT8Q#FD#/1
M9;#VXN1UB8N07I$8<M[43([6F*/6QV)G'Q,EFXP]*-Q4CK$0\BMQP UK/%R.
M+C3FVMQIFLU%F8B/-=;\7(\40\@MS8)FM^,D,>:6P[^E10[I!# $ZAE TLRI
MP<\@GDFN<I$R)G:2RLT)-M(:'F!GTL2JRMC3+ZDMS4B.V//-Z2'-<BAY0XU]
M$GI(K$K+,M#339#X4LEYDLP8)6C71R.N.T[LQUC0\\G#VW&ROTJ-;8<(2-$.
MYVL7MKH@(!;'C^!@T=T5!0W5%9$>;0)$JVR+#:P04-X<1$8H-" .MXN-;0D6
M(QP:+3@ PFVG68]MC8@C>Q1HS:E@ ]+8,*G1 \8(T6T EUL" 0O]* 6(AYD@
M#;RR().^XB'-BF@-L]Q"=Z@J$>SNH)3>GXQ(+3\,VT65$O,)=@\>7#O ]>#[
MO;]=1I,A$H:9>BM../1.FT/PR\,>ATH%*@VM)7$Z7LV Y3G8[I_I<2Z8R0@N
M;Z?=2VV&BC6R4ES:FAB))G-KF>[7)26B&U2C"FB9=;.S)9+S1\J[H'<JP&'N
M1%&:=..2H^41IDV65IN1DUL)$E$& N22TG>14V^[,[:9?E&=NA'R9) 10FOT
MJ$2I1;B)/HJ5(,#M!ONA=.426X-)C8G;KSO_ )+S6I-]WH23>E!2G( GJM.1
M\NK9[,L(QXTYC3L=,/I4B1;)9C)5EP9$F>R,++-O]"4;0H291FE/:85&RR,D
M'RW'_P!*!2&IW0M>Y$LPRC$LU].U,0"E[9A$BH\'M?2@V]Z8@.#[,,EE(\%H
M5(L#IP5B+6RXU"(V@2 WAK,:D=+CB,X[SCO^/'>:5M.U+6I7Z7!A@FF#0HIJ
M#81@5DVOQ[##$ "\C4-&+=U5!%O-Q /58A!G7&J]&=75<!3@L($1AL)#M#M0
M40^.Q"A.&>M#;U(0X8(TC#!@LEUZ.99%@0B&T0\5LA=>"0A,",H\F %:'_2X
M?Q?>-%5MMAI^K\O&O#ECHKN]_P#ZDE<:NOZ&;U5E9QJJ4)+K^WU/5Y)Q;E8)
M;2]6--$ZKKC3GIJ'=+J[B4KK1!SGIR5I(KK;13M:2*=JM/-#KJ^A27:DIEM^
MMJ#E]1&W/TJO;T@Q)AO(.>_HL8PWJN&2;B#RC#-.ERC#O7/8EEE&N)&D)(I"
MSRMR YYR%+/)Y>YE=.+>D&3V9B16R^L[OUV5#FO;&\]I2I&K(PN19LS'.NTM
M9)3K<B#^EAG$@.[LTUM*9Z324J?E%H9GI-C$V&61IR?E76O8Y;@U-R+2F9N2
M8UN=DU$>UR7 :R2@S_L$ISKL<NXEJ>DV&56677I:N=7^$/_:  @! @(&/P+_
M (@4I=?EX._QY;=4>J]%\F6GCV;8]1^?@[O'GLUQZCU3R9Z./;LCU7HODRT\
M>R)W7HI\'=X\]D>HY:?)GHXMNR)77Y>#O\>6W5'JO1?)EIX]FV/4?@?!W>//
M9KCU'JGDSS\>V/5>B^3+3Q[-L3NOS\'=X\]FN/4<M/DST<6W9$KK\O!W^/+;
MJCU7HODRT\>S;'J/P/@SR\?^(]1ZH/!GGX_\QZKT7R9:>/9MB=U^?@[O'GLU
MQZCEI\F>CBV[(E=?EX._QY;=4>J]%\F6GCV;8]1ZH?!GEX]L>H_ >#O\>6W5
M'JO1?)EIX]FV)W7Y^#N\>>S7'J.6GR9Z.+;LB5UZ*/!W^/+;'JO1?)EIX]D>
MH]4\F>0X]NR/4?EX._QY;=4>J]%\F6GCV;8G=?GX.[QY[-<>H]:?)GHXMNR)
M77HH\'?X\ML>J]%\F7_GV1ZCU3R9Z.+;LCU7Y>#O\>6W5'JO1?)EIX]FV)W7
MY^#N\>>S7'J.6GR9Z.+;LCU7HH\&6?CB=UZ+Y,LO''J.6GR9Z.+;LB5U^7@[
M_'EMU1ZKT7R9:>/9MB=U^?@[O'GLUQZCU3R9Z.+;LCU7HODRS\>R)W7HI\&6
M7C_Q'J.6GR9Z.+;LB5U^7@[_ !Y;=4>J]%\F6GCV;8]1^?@[O'GLUQZCU3R9
MZ./;LCU7HODRT\>R)W7HI\'=X\]D>HY:?)GHXMNR/5?EX._QY;=4>J]%\F6G
MCV;8]1^!\'=X\]D>H]4\F>8X]L>J]%\F6GCV;8G=?GX.[QY[-<>HY:?)GHXM
MNR"MUZ?]/_W_ /)P=(C"45C"*<XP,8&*4G")%0$H,L(X3"D2$80B1,&,#"D2
M_P#"<H4 I&!@A)B!(SC Q2<?HO=D4A%D>WU0&+).WUQ2#,#Z^V,%2*O\142)
M0'**LHI412#A]L%"%_ PM07M]T%3+LL*TCM\H0.$(O#/[8D1\=4&>,5L(J/^
M8!<02/PBH'MV,*J?+Y]T$@KAEJAKJMXQDO8:/\1O8_1>\4CC014'E4BI=Y(4
MOF?NA6NG"5PKG3^/;M*..%J[=N^ :D<GWP%*.7[X+*MV)ND86K;J^^.*#6Y"
M(W25)$$5[V';[X(+M/;MH@&N7;LD<79()85=&ZZ2Z8FY?HO?P@[LDA*>W?%%
M)E!#FY_=&&XD*6QPS2$3?2,)]M<2&]"-!7MK@D!'=OL@2W4C!8I27;7!J$NV
MN$ WX0M-2?9!"$&-X3[:X6D]OG&$(T;WT8K,8X85!V[8QS@,?KA V?;LL$ -
M7'OBNG&$I"B"ZG>)[?7'#V[8Z8X8DW"*:1"4]L4[:8K8!+[907.9).W;* C)
M0#3V[?=%=,X-P!23V^Z.'!.Q^V.'**$$AV_&"[.-X)]%XI*"ZJ6J*P<OK$-
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M>'(^GCJVQ.Q;6D^[GD/3STY:#!2Q;5![N>8]/+3GH$>C;IK_ '/#I]/'\NV
MMBWG[O=[>>>C7'H6UI_=S7#T\$FOR2)6+>7N]_MY9:=4>C;IJ/NY9'T\3HRT
MF)V+:TGW<\AZ>>G+1!2Q;5![N>8]/+3GJCT;=-?[GAT^GC^7; 6Q;S]WN]O/
M/1KCT+:T_NYKAZ>"9_)(E8MHH]W+/V\MNJ)V;:5'W<LCZ>>C+28G8MK3^[GD
M/3V[(*6+:H/=SS]O+;JCT;=-?[GA\WIX_EVP$Z>U5G^L?_RG_P G!\AA:UR>
M(H)0O+<YE%2B8I0%>X_&/Y5NGE(N.BKNX#BD#ITJNEM2-G(8_5C@DP2(*V;D
MM7;YZ,X!9:>5U?'[H'3\LBZYM2&4M,X+.4Y6X]RX_"&]2RV76G8)/-,,<1#V
M\MZV^*6&?U3^$X)Y-Q!JA]RY;<UC&J5E+"/2=AE/('ZC'+-MS?\ 5("2_5V6
M%N6GM"@3&9P$>C<Q3#Y]CA!O7+3FVVA2LLPWZR(DVHYALR)5;P$Q+3H.B +C
M:'.X0Z1<LMW3^(CFV[3S;G--&/;XZ(IY-Q53"+EIK/U+?%,9@N&P&& VWK<X
M98]OQCTGX$X:(=8NRN,<0?B/HL\A]%UK%!0G$AJ2!\V*2B@7&"T]HEGPM;Y<
M0Q)Z)Z3%OHFW6\KE5"2A'$M(.ZKIO((0HNJ7(MW6ULM-'"@6\)@4MUS?(9J)
M0\7+UE]]S9;M7CM5GADJBI<9R2<&^^];KMM,DQ&:(U$1#--46[_-8>I#1RQ3
MB'!Q=X>()G\IP>G%ZS30J)BU&IX,]B3UCI;-QC766*T@><Z:5QDID,R(N\I[
M#=:X52DO+N?EP#0]NA4QQ@7?Y%OF!R-W98@^62.9F)R2+KKCV<MI+7*V<B*R
M-U<::J=XZ(KLW&*49PS0H!BS0[>T>+>AS+5^TA/SF3^76LO@)RAS.:'&S3<J
M+4F6UX4_&3L=$$VKMDM7U'!'4-$VTH=V<],\U,/WY7'-&\V3L9JF3F@?./Y?
M1O9SWH'(IF&B[-6_E"I)33@3%I_47+3[EH5-!7A8&$N.[X12LU1IE#>HLW%5
MSFEM. ;O*O\ ]CO@N.CG<PVZF$AO*:*0X&Y\K3J?B2CB-Z+MRS=K+C:!_3 4
M&U4#JDH/>8Z;J7WUOO<C06A-Y6FHYB0;\(W'6N9)I :/$>6!P(:4IDM :D.Y
MSFNO.1Q3!7"K0-,TE]%EO47#:;09JD_NVP3_ "G6[>"5:-$N$Y#+..>SJGB]
MR20KA(IPZ=+42>(1ICG\YW\DV^$$3)("$(H#=?'DD-NW>J=S'I@[#<!WL^-6
MI(X&.;8O_J%S0A<LB-XZ<=. TP&?RW\.-0DE(1?FXC"3:<3 N7[[A=<J[X&:
M4S_+OJ9'@&]!>[K'U$#N*A"N*),:' Y&!<_D.WA-I<!WG\NA-_%L6W\YUN_0
M2Y'+PEY*C%NZ&@9.<YNN&"[>?:ON?,AW"E94L^3-:X'*+G1NZI_\4(6FK,C>
M"C=G($X:8#[G4O%JX9&H"I$*IDA*3JTB#=/4[Y")7Q&C$J%XYZ,I06CJ7%IP
MWI82<1D%44G>S6</_F=0;3[;D #OA4GQTC1.&GI[KW/?<8J.WJ354VG,C<WL
M'' "<7+7\O\ [C>822$)S;.8:4XU0C=A]NYU#FBNX 00A8*$Q\RDXSH3$PQ_
M\LBT0<7 [L\&XS(;^GB(<1U))F.(>21DM2'X+PB</N])>YE]B4;S9&IN7B45
M%<!@0L-=8ZA]#KWG!1KB:CDA$E)XZORF*KW45XY]TPAT3X2J##Z+7K&U6T^,
MU&2M\*C&1(.47 SIUMFT QJ$FILRN\LRJD99"&L_CN7!Z@C!<-_%4J^!C^*>
MFN&@R%*&;M[ JO#CD$E#V7[(+GW?+@TED@:E" %-9AKQ:<.CY:$9KEXL0/D3
MEG#KE[IW[K1PC)  3O2-6.F-ZP6W2QV"R<<$WN[0(HY2];0BSD5F>*<N&6Z1
MFL-JM.==*58RW0')OXU NPDJ1^E:(ZBIN22S7>STHJQ18M777%*2G.J7&9 (
M/EW7;EE@M]3D-Y>,(F\4 MK4JJ=$HMN%MW\86R'2Q=-#Q:-O?%!M.>:6S"C*
M8XN*KQ89)!L&T2QS@J-IEH&^2!\YP\WF5,+PB-.&:;^[.>)E*4&U:LN'5N:1
MPYEN(!<4GPZ >\6[UAYZD6J4#4W@P#SXAP)62C7%VR+-QEY%:HP)#4\6'QFG
M<6NO6W&X&CP^(":FN>_/A&[+5#+O(N5<0%&( FN^A0[RHB22*6V7S193/%G5
M+&>E(-FQ:++\IH1/.1<4:<A]&%_1-JNANP%I/U)\#"?QJDQ(Q*MIF1.K,YIB
M$CG.ML>XNIDXEQJ\015<U &W%W%EJ/\ <6K)_5>6G>57N=4->6>*&!999'-P
MJ!"\*%RKCI>J>&+UNW9L.>4NSFG,0@-G_P"G&<.ZP6:>8&-QD0H*2XJJ4/<8
MY7\:V+ED-D<A4N)/B4-29W0,5BY?_C_K7KC2!4$W6I/)]58I_,"440T\BIQ7
MQ%=VF>/"[%[1QE28=_V[#O+Q"2"964LJIM EH,%EKIFCEDM*&E#@F*D85!34
M2"8;8_C,#&M\3J:E#CIEKPRX5AMD6)MK+G.-,A^HUB@KDXT\3FO(2F<#J^DM
MVVNMA[9.0ESVM9(++*D:>Z'W^HZ1&<M= TS&8 !0<5L1;%GH_P!)):VHF/SF
M5G(2AEQMEI%=/$CE:@_U-T5+AN0[JV].ZMI)<-<U_P 1<ZZW9YEVZ]E.KB!.
M*A0"Q=<I@0IZ=AH-LEP-7"'.#7Z7;YK/B,$#IZ@ZV<'$NFRE'9G$[FD:&P.D
MY;'.MV6N2K *P2*I,IS ,0JQ>OTM%T)4"X>59*<"&J,L)PT]2QS*L%[:QWCZ
M+-%PVWBV4(3%0 )JF..J+G4CJ10P&3&^)K5EM5XGI@=6RZUQY:A@'"'L0N%(
M E4998Q8LVNIIM;KD(P?B$0+*HS)Q7"!TS+X#PRK@&-="!!PU;QR$W(HCGOO
M#GW+C+>&4T?4FENZ['08MV?Y3ZWM5W"H'-1$HEC5Q&>(A_6V[MQVZX5(TL:+
M30X!RL:A<9,W6H42J'M=U8!9<+6JW6R<@C2KVSQ&]\W\_K$W1PL43#FZ,-U
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MR)M^ @B[TEESS;I4IH GNX$@N.:G$)'\Z]8-+>G-MK5:9\PO$RQ )EO 9=\
M7^EM\A;<@&H&M194SS<W>".,RX0>7TEI:E#C27<-(+MQ"X8A$&(0XQ0^W_W[
MGM5R#@9;:U ?S/;7ANX*0?HSG=*4>B8 R4' KF!#V<[<>5(I;^0:-%MNWS.6
M[U@>/Y%YM+C2W!$T2EWYP^V]X+7U+NM\==22D3S'A1D4T1;-M[?TAN[K?+3H
MF:0 NJ' 7 CFH=UOE#='E:(Y+[BVT<,&X.!!&&ASO@I@M-P%I<YQ!:T@UJ7
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MXC>Z"GS4YVK$8Z!Q'EL;B:7*8Y;/CGC[*I;N@13'FQZ=QOF!3KY9^KE?/?\
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M*AKC.4ZHU$4J=:#58I%.]]C6>F4G!\#2=C,JF_V7IGS3LO1.5IV]U1B3N#E
MR.4:/JZKW$?.DUI6UJ]Y#KKIPG%6L>W'/WY6U45VV2K5V8U>1Z:K"Z>3=;LX
M4'R^)718V22'R=!C2/4F1H5<S8>?IVUB&8>7M&<C7R.>];E%G&B;8 ,QAXMU
M; 3$Q+*QROVRO:]N2P&?N^H?ZSW+-;-UHMA15Z>/JE1_I(6C3\NK8N10>/\
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M5VRZ=:CB.LD34-B"854;$5R6EB\77(S 1D=R]D3/(N.A7]/86M5LI@\9F 0
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M+XQJ6M7*;==38B2*!Y:2 <8-)>F*+<MEK+[-?&VCJJ52M=H=V^ZS>"K:$7"
M;2E8')LF/S=2A:V^GJA-QBU-&Y?B76ZK^BFT:D;,<ZE(UK<P.O=1,F'4$?9/
M$A<],45HP;<77IY.J<6K:%^H[KZ:9JT4XSN%:DHR:(%,_%NUG3RW'^GJX5^J
M)G9<FP@OF>=SO;.&L&'8M9JOX]ED8L-KD#':QXM>+E*/3=:NFI(W'WZ: !G=
M>3Y/(+E8=F%6)Z ,2$=R+-[O"&A3/ 8OU+Z6QM1>/?BIKXH'8ZQ0KX^\O(L.
MY4,TU%K+'TL7<EJ1")+9L#?#(URN/H8%4G7M6U[:UCH2YU*UCL,JU;CR\4)J
MO)RE@P&/*(@1D8^#,7[N#4JSB;5_$WL>OM;$.M95E)[4(M2"5LKY@[J#81B'
M,O>1J,\1AT^E<?C\]:)T9)M=YE7Z33Q31-5JGB&%8FUYC!%UEUH@USJ7."FU
MBP](XRQBU5*6=S#%Q4K]%;+EBBIR*G;3W3J@),M-Z] \(:S.G&P?2=+W"6[!
M$4=V*ZV(1ESE*XQW:C30O$5A+W\&/27.R8 >*B*WI6BZPW$78[.;$U4*]/5O
M+UOJ S*8>ANZ[+0 *-@UY@-2:,:</Q@>CL1UHLGZ5H1%VMTK*+V,CU);KO/R
MOYIC#QP=1@QUM[HV[2^7PFDOT_/>^8$)CW'6O)RC5WZV4FC!5II$JF&,9##[
ME.J(DH'3E.0O5/2V*QF4KJ[)E/:M+]C::B"I=@\?5N49(-%'N1MF \$L#2>&
MW;/HK&L'&86;F0B;5)\U?3M6Y>0E57JX]<6F0W&6C&O[M8B$>/<<1P+E^D\;
MDC\DRN8O6?FM5H8O'E7"T"P96.+CVKR93"S)8SSB2Y\9K.?U+Q&0'%V;UDF6
M]Z+-SL['EC;1LL8&:AN:G%*T&'.G8 "6FV-/4DW?16),\=(,RTZN;W5YJL9E
M)*&Q@NT9$6L@$R<LZ\D,ET]=.#C^K0K0K&9"U3[4EECK5GTG=_HW'XQ3Z]20
ML.MF[HE*5;7H.)^2,\/"QZ84N+1T[Q6351-%K,+OP5%+6;/M'=#'US+VDHM)
MWZ:VF8O 4<%5DE3 U <LWZ2Y2^M!XN@B>D"_#TF/"-=-?C_<9$LEC3=;J-54
M:,C7ZCZU.I_6"C9 F. .TF[,*7,S'SN8'\O&):K$&=W*JP]]3JUY2+C3S5ZV
MN BDBZ#<F6/L8]AVHB#%0 4\X@N+I1ACR%HO3.)]1/0;**FNJ4MF;53@F68^
M?X1>25:CV#[^) M=="PE;TA==?K;;QXQ>36/95Z]"FZ7T;IY$5(]QG 1"TD'
M4WR,^[B9XN.K^FGV&=&S5"FJH(S>Q_\ 5\V1>HTA=TY4^@DZ<M$8>'3E9:#I
MKB?5$X59F&13C*DSE:]E:['>690Y^0.ZVLY-:Q)FJ6ZL01\A M8XLVKWIDVX
MFMYM59<$J35^:VD^?9.HD>N+=MFY7T[F-![H8F-(T/C.Y(O3R&X[%L74N!UJ
M=^O?/NJM^"#)R]B;)U\A8$FF9=13PG7F/%V[C\)V]IUC"USBK8KV%-+U!?-=
M,*EB'E734[ILFP0V!$E,Z3/%J\WTF6.:",_F(CJU+?\ HADT1<BMTK)JJ;LJ
M[>L V 9#OGGQ;2[&,LKIO%DKFWCRZ+Z/J*EC*K<@'<;L7!9(A:@F\C%13'.-
M.*F4N8%5FO<MV2V*LH[>HV\YURS=L94&!7J+L/K1/6W1'7((UC76,GC3Q#&X
MO&-HRQ;\Q6FQW#[F);6=OF^UZE(N9)9=?J[1V:C.FG&.<OTT&[<":I3:IKH-
MB+N<)=F;W=36R*HM8U[DO+J3U6[AF#DIXJ8R/3R:UQ.)37J63*C$=CY=UX13
M1+19>QBDW33U5"P89O&8B.<P"?3LJ>O&LMKNBU*@D%47 2L6F[9 ;%D*F,%;
MNA[T0(-8D9G1B%>EV9?-OI!9-6^L@'U'X[IOLLFS974FRJG8&MOF.K/5@(+I
M[I&/2CJQL.X[(XJSC'",2@,97ZS>XV,G:$B,0.TIF"TX/M_3H3.)N%"3BU08
M5>T_U)5QG6R=@K)MQ[[60I@X)?J30KSI^KTX+)CZ98%9#:2,ID*EU,TJ]O,L
M[RK7.JFV 9-)MS0FPH60!W/P^/;C%5,! >:JP.:1UWUJX**S4RMO'0VU;L'L
M+'JPQB 1J ;H@.6O&<-7I.2O8ZN68:!6J"G-&E8I9>Q:H5;-H)77.WM>+DCT
MK#5:G,%MU]-6\EZ?BC;SURVZ&B:CKT;*XL9H;&4E#XKOAEV=ZIVLV6G;HTF9
M+BA?L8&V[(>3+S0+9%7NP14O&R*;ZB[FMN]CTJ9>6J1/:(S*_>3I.+R-3',#
M%6[)4<2OJ5J2F4E5+MRO>";#(%=2W5HR2(GQG!ARC7E:QE7#)!/96D.)[J<-
M95S*:67O)*BMK'=&VS(#U)]DGKQW53&WJ!7?ZV/O03?=4A]/V&V;;GH*Z==/
MF\^^K],?>07/3GP5M?I<SIWJF,NYBW#:N[$,R><NU.C"1N2:GTL[C&'9FG[&
MCU(WESX9<I>EJ3(IH#M*I6:#K#.ZKY,"!S(8<5K)IRMGJ2PI(I>>LS.L\4KO
M]5GIJXZFOU)8F&X]GDM+U#-V1OPL;$]>S83-AC@7J0+F?;)0,I"/2BQK82CD
M<]5R=<Z$=BB$5\=D3KJ8T;2S-5@%2,1H01_%C@O3V/H1=I6]N)(&7$5L65;'
MUL0$5ZJ;+8W#"\P 2 A&_9.OP<9=5KTT&0K$&,K>I\ATZLI6.0.L%$'5VLAM
MSI0A)LD!U6$!,;IC2*-[%X!-6QZC?:4EDY7'[H\5>]90PSLL&FYMC("<UP^4
M>L_!Q:MT_3MNP./O-M92_$T@.G?37MX<'])ED663\MKZ%(?(0P?;.Z!;ZLJ8
M::4)BHM**%\+!666:]6G21->O:&@-HXL*3'4^3RU+2->*WIZ_P"F$JR=BUE!
ML5;5K'K!3+Y8RQ9:FYUOGC,EYT#(@/'O ODD \,QMCTU,8S&T6W2R'<56A%7
M,V(HWFFMKYO-98L.F'26I%&LZSPG%IPZKA,>NH%Z;:*'*@44%]FSKKMLZ89!
M@;1TU&9&>4\7<1<]- 56G2LY?V4:J[$H]/V*[/+J[G(FTJ,/6FHR5:[-=I#L
MU*&5D>G)R3<M#LAD:E2YCG@RI0['']RRP3U(?9G8M:U1.LPKG(\M;=>[B&6P
MQ]S0)&]3 ZEF,Y'IM;;3TV@?@V6&N.5[IB6H%L? 0\3T?3PT,>>%\[9:IW<9
M-::U"O6QZ$K '!O=.B:ZM(@9Y<^7%$5X?O;F51Z=N*&+&.B\VR=G(QCT*K%:
MWV686W5?+R"9"O$&>LB,\7?5E;"WD=D\%=08;3?=RK+KBL8_M(M*4ZU5S61-
M#)='3BR3(W:#,\5Z.1]-"/J1Y=*TN]=I37$152178O=8*KD6MIYC0-%]2(@Q
MY<M;5<_2T14JX^;C\KUZMB.PNMJXYL2NR\[D@) *]FF@J'P\N7%7T]4P=:W6
MBU;0AI6*]-,2;:2+14R-PVFDQCAU$=)W+B?; \9;#*]/F[T_C%M_K#9'MCK(
MFW2\SL38KV'=YD=:K1-QQ!E[R/E>+;C*CO3=K#9#).2A;F,JVV!1S2[#EWLA
M>BVYFT[.#!#8(C)9]+VKYQ3R.0P;MR$*9W5QU0;->JK(96:]AF*&YUK=.H[%
MG8(]AQ7@MW*8+2JIOI\U5;U"UF>D::LJ5DL;+L/8Q+FJLFL,QTD/4.A;&K48
MP4^PLL%G W I^EU76Y?O2L.[)ZE:V\2)E;:RXNQCZJWDH9*LU!I*==\<'3S_
M *<["W==6R+%7,CC:8P"\=;[/)>:+N"NM:6C#G7T$Q8,CIK(3NG!]/TC!8_,
M]B[8Z*5,\<=#'6<JGOJMAG4%M*C4;NV[IW:A.NZ>'5<9Z>L8MMO&*SE!#GH8
M>4Q^@HK>_P"YL34-$2L.@<[4BP=O+72K9SGIV,="<=F+^.K-.L[NJ^.O*[FG
M\T?*7=Q?/="6ZJDHW3Q;8[!JMMPOF%9 OO5R:Z5WCKNJOJJ=H%>W8QHSM?J$
MZ1K'!]SZ7L5ISPY,G43RE-W?QYR-*XJEC^_)%J]<RC2VI2,&R?REIQE6OQEE
MS5YZIB<HX#ZE8MU>PF<U8J!=Z78X]V"<AK"7U0[22TV1!<';?Z8@X;4L^H9L
MM\O4=E]!%YY,I+=8"+KAC'3U"3)$)F,E&DD45,;'IK'R.653NS'?8QJ#73RI
M]D2IAD]U9J7ZLL@1Y@41\/%PL'CF40BMCK3-M\;]01R OLJJ>ZM6$4;Z!\3:
M^@R L"?9,?N;49>C-C)4<&FZU_2-JF5*>17=K8T0%VVQ>[P0<*9#Q1I/LXZ+
MO3SJ5B]E9$ZI9'"U>C>Q#O.UL"V?J%6/JFJWE"*%I;#-Y&,AIKQ<IU/3MEK\
M58SU5]1:EJO;,?CSQF0,;-O((E^/?BS,$^]D#A4B,0:](5DG8JU19?6+RB;K
M:E[HLJ5Z?2<_%9 QZ%BC55!JAD@4".Z-T<0K+>GCPH4,M<PE>_>L4*E:O>R>
M(')60K6:68-E53\?65(SX(%FS;H<<JF*Q=)YBNRK.*L7,C3.P=VQ1'(!?8-C
M,NSE\SKVHCJ]-B^>FN@\J]?+XY[[&=ZID 7!"F3+7;>GV68QSLI5%^2:K("K
M?60VUT]>,JZQB<@%+*+?EQ?,#T?41X%E2MU*"E7Y:-QAK1"H8""LCMGQ1'+%
M6&4[;[]Q'IVW78%M2UL[^Q;##,?A_-5.R;\:^&R1C5?-3F6L;9D453P^1HQV
M#<S359L%5*[BO4EAC[A]3%9-T.IW[$?.*SB]NW<O3;PVO8PV0[3&W[-(\M2:
MRM7JY;(/K^HV4P;6R-?([W9"$F)"'179D1@AGV4["5Y'LU.ZU)YY\K&1 V(G
M<?FN)S=ZV!2FX2R6;]T#.V1TTX6H</FJ%:W>4&/25M_E5ZQB\YC<+%FIC:^9
M?505'(+K%[Q*F2'BB"\7 Y)6,OI8^W0>I];-4L?(6,PC.9)<^95?4J*6,:0]
MV3JYN4S<_FN>I$\%:HX'/W6(F5]XK)]6J.6##KA@C)Y[H^9ECRBN5_3893(=
M>=>89JYZ<S;!\MIY?(=1B)JU,016@Q^4RN.KYDZ5R1A;R"(6^PL%E.V- UO(
M#&98NP;9([*LS)W(BK=3Z7:NSDU^H"O8G'^*!@;K*R)K@1:> M*V=K8XJ]:D
MJ]F*RAD28B75FC:E,)M-ILER-8'89*F)U&=.? /'&928J>G\?ZA3%+NZUZ%9
MK,Q9IXU;*N00^<SYTL9Z,E[HSY%$'.M.NJKD[61J]GE :5_)FIE5"%VL1G;Q
MGD25DZUD;'2KM?#6$0DO3W);*>%.CDPMEY0^LZIF[*K59=MV0PF.K49+.5\P
MRI5%CXFM4 U)4<ELY\-?3PV2R%G('<Q**7F].ZRP5Y%J<H05"]1/3AV6*V-(
M[#7=LUG\9DS'&M_'6;%?'SC*<H<D@96;EKPT1K$(V1][5NTMCN?AE?*2^%Q(
MPKA*M-O/$X"I%<%L>FO-[#)3&5+*5ZYXBU*M3 *>\NGK&X=:$*K/KTL8V%XZ
M*F97#JTUJAT1E61].Y>QR[6P:Y'K[M)G='!?,,EZ75YF>$^?Y92<)-ZKB(?(
MQ33GK6.7ICZ81!RH9(M-.>[@*U'!Q+')QF0EEBU0#>)8M.6I;\>68+(V515R
M(P7S<TE,S$S,1PUL8*]9<JN.>RB\8YPT*M.G;:]-^]C3R-6C:Z=WJM6H%.9)
MB9B&[V^6X]>:V]$04AMJY?0$(S,X!5*G%_)/"L?5GJ" ;8FKH?LB(XPE@,=<
M);*.)JUJIVE8E85E1E;-+%YH<EF,=1>6-/#.]S9)FA%&S=!S/!X2QCWMO&JU
MAV$3Z)Q"NUJ9FRIB*>3;=55* 7I8E4))D0(GXAW3:\MS%K+34M9:ZS"7[5-R
M\=7C'UWV+<!E<>%E9112((CJ&SI3M#Y7%RPBFQS<>U2W/\PK#7N%C;AS1.WB
M:>5-[P38@F5BN5H^,?@XQGIU-<UW\7A6>6EXYK5J3)0H\>+2=,E:)-,&;"B9
MZ0;M>+@V:1I\OQ<YR],/O#1.I%O)6.M:KJL]*Z^M8E[ ZBSE>[P?!H[%7L-G
MU5[*Z*_+,SD0L?,+E>YV3AO93/NI8Y6F-,!";"6C8@1@=Y#,V*U/!96O<K4H
MM.R^0LJLS8KYJ4P'5<_+6\H]MCR,1T:O<H40/AC2)LKNXNW<[=>)J97)*V=K
MC@MWPL8Q5G6XFP>EN!:4I6SI!,2>@\6+6.JY.K?%09![TY5B0>#W[(7>#"YE
MZ@=OJQ/;6A$MOYNF[C)^;X;*N6ALT;MT;!^5,R#/3O=+'LE98"\P+#V>BNS-
M<9@B@(9'AXQEJQ0S%E5QURI68?J5-UK$M31L6Z-G)!ZH>IZK0RO3'$\V.()V
MHG29X97O^G,E1C&Y/RI5N,GCL4ON[A?UK#IY /4=0E*DJT60EI!TSG8.DE(\
M4G%ALOD*:TX9#KUXYL129D[M/(XJCD3O9,K5LSN]LPBB'J"#7)'TYUXZ];#/
M@;^7K;YEM/%!7SN/[W-'5EV4RV/KT;V*?U.NM9#$-;*_%[R(?Z</#W54,AD,
MQ1ZE@:QX^[E)Z^8RE=9HO6+2FE)N:)2"PF0+IER'C'I#'769/+"]8WBM=P]P
MN?CTM%MO+Y(+&2L;DH]TOKN!*^0P$<'UO3&8=D6OL89=0CQ<6+(X:Q%Z[(&K
M-=HJM0M $[V,"3,Q@=VO%GU#2Q>?)* ;:R.8Q]JW20#PQR<NVE?K)RU5SB77
M2L2@TD@&STY*)DN"S]>J5M!MA2[<N;&-S'9B: N=DNSV>176(S4MKE3/A\&H
MP!<7&V?3F4LX>6>6+R5NV+:UO9=GTU%--W(YL6X^E7;D6"J'S73MWL5\<EB(
MPK9//#BF6:RKF)L#;\QR%]]%8J1FVE=K]WU2;-<6UP6<]2>G!;<@_*>E+=2O
M?9<[BL^<:M=AF#SF+QU@Q[?,S1H]#--474DTQ,@3-?AFY4JX6[?MYDHLW,;7
MG%V^_6[%)AUCN/-#Q+:\8U"@+:[:4D(QK,SQ?6&%R=V[B\-&7M+L&=JSY>5&
M4VJ'4S>2'>>+Q=X994(MJUVAVQ)'/&-]-QBK*+.(57;61=OXDF4>KB'@J.CY
MV_(7OZ,L$!$ /#Q\YY3,-OUZ=C<?88Q"EN?=LG#;45L;B<?%ZR2ZE:;5O0%"
M2D!NUG2(U@L7;PMZN_L;V*NX\VTALHJW[B)MTA5.8AF2.X5I;ABGW#"6<;><
M[>(ML99I5;U\*L]?)W6XZO8R5ICI9T+UXJ5%9V3F9E8C\K3AAKQ;[=5G4Q>]
M;*R4&JYD,K>DU7K>4K5%]6_B6-2?5%A-E?2\4\J66G$ OM.WKH( /N/Z6L+I
M1W<$T9MD3+T[Y?O*-YS[9G6W@&8EB:N!Q>EE,90 QZJ2<.]XF&&G-#>O-KXU
MQ+!P5&&&ND%X?#YOEJ.;QENL_'X9JPR!K;T'=:\'?)PN99494H5^L^P+]34H
M3U'3Y3[&*J35FK$>G6?+'<K -=50O9U3%@U]Q0#)]Y(3S_<Y1>7QKFW5VGLO
MY"%R32?_ %7FP=,7*L1D.VG ^P8&*\'\,,Y\5[4QZGK6GG<R+<HO(RVY"!''
M8Y]B[:JY%_50(M2.P=[/#KMUUF0O]AD)M]OD:2&;MK;53U3?L,OQ+)OB@0;<
M091%@EFK=.R(W3Q9K;,F*\?BU9&P,@-D:58,6%I2/#980B5-/)D:UI;.WJ]2
M=..K85;JW2.SZK &QU8:VK3CTZYRF5+%JFQHTITZ$'KM$F;?#,P3$)]28@ R
M]3!%5LLL3CW9$J2ZP&=<;-D.E6I+7+'%HL(VS,Z\"W,4_4%*:KWX5O4Z]6M8
M$3JW[:+8TK1PZG7A:VL(O# ?DW<#BRI9"^<6V]*JYY'BJ>W,?.QJ5+EQ2RJ%
MF*/O%J!D:HVP.V(&6V\/CK-=(6Z=NNTNH@5$BU<R50L8:7F%-,-ON@ZXR! #
M)4U8C.SBS7I8KU*5Y+:WIU"KF^[:8-*G.11C,;-B^Q:J=/'MZ\SJL-I1J4GI
M'%3,0C*7ISKFN3B:9V@BS?JTSJVKMC&M?6K5[N.K(V,-NS8P!_ZV X.BB+59
M6*Q86.DVG867;UZ6*?%<(:,,9=!&6K1*Y]Y)'I[=>+UBE2S%D:%A]E(6[Q-A
M+AS,Y)Z,95\Q85/N,K0@B$A5OV",^&-.%6C#*^G!J46V:I'9;C+#E>D4LQ#&
MIA=LXLW4IR)U]9U:X>4ZP :6[M+S4/+66666VL@44&WJ0LPUK(NI1>,IN2JN
M0DQJA@M-_P KQ<8\5XKU+"VU*>,QU!(W:_\ 6/$ NU>JK,9M+1>H)2#6$-@P
M,!.1.(AT"=AB"R=-U1V*J,=3\SHW9?ZLS'>4HU42V/.KEB9O@]>T]Z,Q 2<2
MO#K7D*U"T-2N"K"FDVQ7]2LOZ9!CE.>:TO-3V.8<@28U(H&-.&GVC"&ME\HO
M(*L*N,JU;6+R56G<L9*O9*4QCZUJ\IX&42D5Z.C01UBEEJH6*M&_-/!42Z=I
M@S27?R3Z1*24ET<4B+;G"S2 "II/R!CA=/+I?YA:1@RBX!2 U!KY/(LP[ 8#
MPL*8%^';C4$Z!^MF%\4:;W>I\<FW;I3@SM6,G7FL&4#(*JY#%O6XF8^A86QB
M62<A*Q8,,$8(>,?4KIS_ &ZFT<;%FPV]Y;:OC#LIBTY0R?)VL@HKDF#7#,DT
MAWF3-O%W#'@\VMM0NP@DPV&WRR^+#!KH4[(7>K87>QE2"VG(J'H=8]I!!<!<
M*UEW(9=N52'(S8MY&O>IHM,MTG"<D:Y1&.9RUD9GY,S!1,T[M&KD\DZRUOJ1
M78UK#C$K>)FO:M,0QBYB54M5FG23!G+9OXM7\>W-*QN.\OKO)5IEC%L]SBL%
M4=V'=LML$:[4:ME4#M#?,_#-RID'Y +=)&;QUR:WF%1.1JX>I1R>5Q+FUY!5
MY71OZB$\SD7"$\F1-DDXN_:NU[UKU%8*LLY)=NM3RGIEK559MKL6(BOB7Z*0
MHQWQ#-N^8GCSW&]\H!N8+$(RN)MW5]Z]"9P&-*JX'=.TL0S,UF.CD4CXIGIQ
MI>]11C<O1/!W,D^Q;NBR+MFT%?R[)H&%67G?%DTA&53J!O "&)*!GB.[??78
M7B<<\IK%?H-MX7U+:76&HPD$J;2)LP$6%_+KR0Z[=W/)6:5.[C*U&FSU'9K6
MZAK?./R,6\B-VN$&V&5GRET (EX)#9H/*.+F3LX3)JRM',5#\T8A*F-R%O'C
M1J5D7V70 :;\67);#77TGG[R=)Q.6LT/4%CSFNK%17IBU:;"+,,<JAF<>Y]<
M=#BPSD8\O%$\7W]3U-';44V.Y[W)6,D_&+L/Q5?'U91;LO97EUP@&JV(,R;O
MVR?BBXBD9K=2JX7%M!2;;5^7(P]O,X@ZG(XL51H-;&]>Z9/P3STXQEN:>7*S
MF"60U@<"*>1##OQ[*EFX Y$<=D@JNR:I#IDTYG4"B=D@-/(8RADDC:J)Q5;:
MRM\]JU:]G)(-X'D^GU:R!9M)^U^C)'X=(QF4N'D&CZP=7*FCK9&*9V+N'7CT
M9!U 2%=)G82M$-,8V-8$<F%$\2NU/JRQBPB*]6PZ[=BOEZ-^W3PQTU.9;4MF
M.L/Z?TCI;A]XN=NI<.!E2R61"SA\F5!BY;+GY*@S 8^4B+VT+2^T/I,@#):Y
M8$GI)#/&((<;ZCKB^QT*V.<=GIW)]-VT(38LTN_9YCY/9( 6,=1\BJ/ 8*B1
MFC8;E*=NBC-^L(9C77EM'K1;/);'I+0[%L#<05_:0@4C'AX7E*(9[*N:JQF@
MA/?7:U0+%"J=_*A2<X078*K;$6;0ET$9A ZR<<8_S0LD];J",C\QLN''V,9%
MU!5F7:PV51> +1"8P ,;IK\$S$L*M5S8O#-W9I-QK^EDK.5NG<7D%TI1?ZZ5
M-52<;(?TE0M>_EMB86CL\VE=FO7KE@TG>KI,K.+NT(8ZDRVI-C(AC:#%^TVN
MD1D(8>TN,I65B\S5WY&IUXE +I-O9%<*KG4A]P%5^]76ZA<EQ)1)'XRG67R[
M-)"SC\EZE0E=G)J5CO+,E.3OE26#>VJ9"QD,:UHB.O5A#97[O=JEC*^9LY/O
MZ(0UK"L9,7XA,9"NU=M=P@?,5<I(DI!L<]9DN5G&Z.,?C<D)@TUYK*(F2M]N
MD2R5?U'D3M.$NFGKW*'56)_*%#('E!1Q<SUVMZ@Q#!;C&=VL;]"\:KJ"HUVT
MXIM(QKG2@B>OPL4L.HP!D1+BW3=5-=U=;U";K'3M]S9KU,8BAE:7F.[JVAC%
MV@Z2).=13O"-5:QF\O2CU4,UVQC[Y8PF36-J1=A L]J5GI"ZJ:8'1@@WY![)
M'Q<8G#98;BV9S:50)AJ[-:Q0A5U3G6ZI_,+2+0KA9[X^<2(C.L\*ND=PT92G
M7L/S%XL@%BNQ]JW8K.OW&D-C'Y5=_#2M<^$UM6I8Z:K'C$#:H96X]D+SM:C5
MIN.]552Z6MRW6$@,8KG:$95XF&<Z"!3$Z6<N99.I2L7WU'LHV<DJRYGF>2IW
M5$A3-[*?5M63;$CM%,=3ELB8R?IZT=VO6PF*L7VC57;42:OII]/E1LJGJ,M5
MW=+I ,[S^#7GQ4EU?U/D%>I*G2? V'6J&07&+:#(RJ6V@W.'%)F2\/. _A<.
MR%F2S@,J8DK#;SK&<+M\\-NG2ZPFRQHVC3JV",BCJUZ_4,ITF9XS-+'U_4*.
MR=TK<92PQU#N6@FSOJ=6W8F765/%LE\,'SYZQ^YS(7WFG*^;XS&Y%R5O"[%K
MU5AZN!HX];QK$3:&1H$&X8DD@P9,MI!J*+[+\Y)]",M2HMO44SL=3NX\+E?'
MJK8NJMM^; H)/3&7/ ]R]X<X'&DS(8RQ2K4G.=4J&Q##HIR5^DR\P\?:H6<B
M-0;6DG$F03I.L[-'9[-7,^K%U4!2,[]=E:5%>J+PHW:Z(QPV4@Q-Z((50-/=
MXR5K$SPW$9#)7+=GSFCZ=WR/;,1EZT#Z@JH0S'4*=96@W=IMB-A=;H&4R6SB
MVS()R5KN79&$I;C\G\YLY.Q0PMNWA@FK'<-0^FI<-5KT-^O*#UG&-R)75SG,
ME:555<&R+K-[-XHL987:1TMR!=47IXX !84<]2B.%OK6\U77Z?QCJIWYJ-;3
MOUL);>[(E.3MXVQ-JZ-QK>LQ# :TR*1F9C6*/:YVZ5KU%&.-?>A)3DUV:.39
MAT6']DG1T+J6)@W3W3&Q -,BV#Q<M5+&<BPJROU!YEBJ%]K*UEV#H5S!!31L
M(U/",43$&!>$I+3</AP+(7ZAKT]Y)QEJKC;UC(R66*:K1O(LTK?5#-LM^*+*
MB%Q'!>W28Q4+;=D$9)-VA63%Y]H[F$+&>ENV976J72N+7;P:BB!-HP?L'EE(
M#)Y%,5IQ3+E'(4>FVF7J7(N#&1$+QB+KRLVVD/B-LKCY6GMX+#WAM,V4\ABG
MNFO9L5,?'JRVNU*K-^$'6I7;=C;T=2@AW#_#'6U<Q&4;<QV0QYYEJK*T#671
MR]W(N8TV%0K7(GN:]@26YA$K28*(XP[*69]369*O6LX:S6&[:L8+&!W&,7!H
M\N8%*K/68ADVU$XY#QS/1U ;"PS)2EBPIL%&69&8>3::09CCFO(YATV,;NWC
M)Z=1K==AR7 5YKA-+$U%8]J#J.KM0[-6O(5MNKBLIWG0V:!HEA^]3J>NF[7A
M&5KLRV2#(8!^,.U4KY2ZZUC?5V5L1$WTJK3,7#RJ'*"3"&),B"=-=.,?1SU>
MU914Q39BN5.ZZOC*&16-'S'*=%,CCRA:#4#62.P>K\$','DY\^O*Q->I1=NI
M/D,K&#OW#5L-E'N[K1O=3J=N8];V%N&>$W7VLI937IXX::LXNT$AA<GYAAL?
M515?42VQ0MS:8.I0;3VC)G.T>%7L?8S\8C%C1OK7E9M*Q[CH8^*M3*2=RNNS
M>--2O!;B80[H@YC=I/%W,+O6PWX_&>IBO(BPBS1KX^,@JI<2IU>9587"+"VI
M,"*?$!ASTX3Z;L>:.D9/.6;0KM,\>8'+5FY#*9 $]NGN-]B>>T5P/*!&(C@\
MG39ZJQS\I97 =A2RB&9&+V*:$MHI=CV:5[U+%FUAIV%U!DYD3/4GXA1Y92K=
MU"YQ]C'DC%]^FM1S88P;YXP&RX*=8#FN5F?#!1IRY%7.,K<1DQNX%2JY9"UE
M+%FCVU>Z^M"0FYWU9OIWJE8_A"1:^/G>R-(W-.:9W[62.E<L5Z2"\U]0FON>
MT^8M).2><KG;.G@^5&WBFJ!R*,7C\AC!J5F5+B\@R_4R-6_CJZ:W0A]N;%J%
MZ;!D3&?;IKHS%6"R!T[.45E,DEE'(=.O=N^H&[*N7UK?-%,S=>0E1Z1I'/P3
MK+\?:C)5XQN2KY"&"K)10Q]Q%>QF%8VM<2CM@4VI;.>VW3!Q(A$;H".&4G,]
M261]08PL)$WZ5\\EY'CJ?2F*Z4TE$FA15E=>I"]V]LS.Z8Y9&K_^\]:W9RE6
MJ^*V*R&]MZCAY8-9:+%!].ZF<,'4,#!JB&8+Y6WC#2J^0X;#6J44'EW40+ZF
M#G,HZQ&K>0>4LZDZQ$:^'Y7AXQ@3B<Z,-LIQY4#PN5%>1NTQL9#'EF:_9##W
MUEVF/2TM/AUF9#0<;%=F4Z>/M$VID4^:@C'GD<4.#K8M^24L!K =%:HKI,H(
M#!)1H4KU+U-6O3D85B_/69.^L9TI97HB%R4!2K*5<B?36R=JQL08%U-3+BCB
M;*LUD^D5BM7P61PK"L5U^71585FHG%5GDHJ&0':YTE//D6Z"X&GZ@LV[%G#>
ME;5Q+7S;LVZ>+H-2VQE4.2DM<OUJ2S@HU><HW",[9X(SRUWW=54XP@T<JM7B
MUA_4**.(86/;&0ZAV*IIJG-F=A[5#$;HA"LB[)NR.&92]1'<%%B8I=G3LA6[
MP\;35436LUJ1:JVPMA*'EOV<*Q#K.99%>7O9C,<FW>9:1DVSF7L;5"G:+8F3
MW0]4 ]&_8+(D])EQL-N5RMNY7"RLG*N#V&+=C;M%12N)KTNP<W4)\)$TICG/
M&1OU['J.E-ZY96YN+KY"*N5;D#Q^%R%;&,[%RS!UNHOJ=M(3U9)L3XB+A 6J
MF379J5,?B:'3Q>1!F,L1"\SBD4F15*:F8'H@:M)UY",_%PF4W_4B^\M=_B '
M%L3D%V+%BVJ;%%<88+%E;XO.5,6.LLE$43&G!XY+L\O>!ULA5IT[3VQ6K;WW
M2R6/\M?616!F=U(NB/2,O<[-DZ6P>N]D)HY;!4;M6O1OY-2[]1$5L0ARXKOA
MR73=Z6[Q 3XD9G>!1%NC7J9<BJ2VD%]Z[R)I5J$6L.>$Q]]Z1'LJJK-BOT?%
MX#/G/MXM5P[NE3NM-MO'TF)5CVRY":]G2D==M=)V1K@4L6(-%D28$)&<D5Z_
M5*Q:F*"UN-A;ZZ,>39"K7GVKKV(LM%P_]:+CB?;Q+[P6LM,BA<ADVK>MB:M6
MU2IKL""4]Y-2M=:(,=U':%S.=(T=0<-YRGJ!9,9=;-D96=0UN6^-& \)I!&[
MX1W1.L%/&1<UM^P>26"&$^S!&FL%WOPKK<*A>T L1&V7DXP"-HS \N.^OI8R
MX*:B:MD6R#<?V5R;ZG4"CZ.\K.V3+\_IC$\HXMPM#QB]4P%2T/<'(-'TVWJX
MYVPM0&SX1AIQ$2T0'7V<)LS:R%&RE%BGW&-L]JYM*V23L5&'L.86PT!,$&UJ
MYC4#'6>(1>FYDL>%R]>1BL@U3\?7L9#O.X(%P@&MC2^V!ZILVP? "R+[I"0G
MJ-O,)A[$N1M:?+JB0MU*)^40C,^SC&@<-TQ0L"IHR8F(;CW8PNI/Y_S:P7_.
MY\5^OCQ>BMCZV.BHR8[1JZE>[40ZPD1&'6PK9%X=2>>C)X:-8K!R_L^LRRZ7
MM9-+'U<:HR,N<G-:F&Z?SBUGX?W-C)LL9%%RR:VR=9Z@$'H#&A4L !UV#UJ4
M8[W4SKM[AO\ "C;5FH%E:JES&9%-<[$V$Q?Q5&UC4V_G(N8+FTK, >THUA(:
M::3J[*VGVP:^N%<Q0&/&8A=:Y4&5W#HLR*1E5T]ZQ="F?G#,;HEF!<PGT&V:
MU@P&GBJ&[M7U7PHE8S'TJY@XJD0<R&\AF8U]FGC?EWG" !+VW]'(N#V13EA-
M*E=3)L?C4-DF;PZBX\/P<"BSDLE9&NTV8\;"\0Y6/AV55E["UUCQ<U[(V+2
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MB5'OCG[)XNP.$=9I);DPVHQ5QC%"I5J,&2'KLD.5C+-A1-E8#%37:?\ "B;
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M0&3M@3HU0($L6[M-=>@3AZFFO3W1NTUX5<I."Q5>.Y+@UV,&)D=PZQ'+6/\
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M5Q"(Y?F#45I_],?BXC2E6Y::>Y#EM%8#\'P"H8_YL<?0:OLT_4A[-A+T]G\
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M\N5D*;;TA99VB["F/@*9UU6I)8%)#T&6EP43SC=^ZK?Y'=_[['_N7_Y=>_\
MNF?W"VK9*BU'QP(E,1!1)1H<2/C&-/[_ !&N1:7R?\7JQKI-:2]BOSX4<?\
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MO=E2/'J.T?GUCHN"OMUA7NF%SV!/.;F8#T'ZB05N*B3KEE?1[$MIHK]-U6Q
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MDW/O7*_SWCY-S[URO\]XB8&YK$Q,?TIE)YQS]DW-)_LP *6 #&@@("(Q'/E
MQ&D1SXZ715TN4=/IAT]!YC&S3;X9]G!D("),F),H&(DYB-L2<QS*8&-/W,NZ
M*NJ0@!-Z8=0@66]8R>FZ1 ^<?%/$LZ2^H4")'L'>4#.X8DM-9@9]G#%"A(J=
M+"<N%!"VDW];+ TVG+?SM?;QN"N@2V*7N%0"731.J0U@==B9^3'YOP<<E+C3
M;^8/YNW;\'YNR-/WN",4)$RZ<$<*""*$Q,*@BB-9Z43X?BX61(21)@A3,K"9
M4)CL,5S,>""#E.GMC@Q[2MM;TNH/05HSM](1OC;H?1@8V:_)TY<3[L/%&A>
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M(E $("P^H8@,&S; =0XB((]D<AW3ST^#^Z]#,U:'HU-;)5@MH4_(9N7K4WF
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MGQ>:V;:ET)"&,948(.AL"2F5C^0U1B8SNUB-"CB_5&VP 5VC6$W&!=47--J
M95;([TZ$.K()4#K! V.1<8^S?RDVL,[NK#+%ZGWF2?=QFV;"+,MJ:II""=Y#
M)E)GX]G*3XWU/4EIMAC&5JN0\I79JD^E/<M2MP^Y;8%%>"/9M$U:3SG6>,9.
M+O6CL'CZ]BH=BBU-6TY>4R&27W#E1"P=9"H^#$ED1"J"UY:3E,94RUAM8L/+
M(?VT5IQZAOVKG4V,EHEVQR!!$]2.11.D3"XM6[WJC(KB; V,@-C%,G2VWS(T
M M37/LU:A5FM]P+-T3,3!!/AXHBW.V(KX:U>18@L8MLY&Q3FU9MG8) 'UP*L
M>PH.#*1 --NOC+=D\J"8$H2T,=*ZY[*7<BRNU+ZZ[*.D)2V(B2:K: Z;=>+-
M^O<L&JKB9LEW&)6)%6JU^\M]/(@;3M-1&1"1'>4J2<+C7G/#KRLYD^VQ555Z
MSU*K!A&/!;MJP%'2DB<UMAE;:1^^(Y&"TTXN7OZPV&5\182FTNIBT5MK7%Y+
M6CETEMFUL$C86Z&EHV)$2G5/7R5MPW/,K*TEBU-:/48>+N/L.E<Q-''.V2L)
MY [QCNDXTR5Q'J')5ZM196+]950MS+:J5;!!9DR-8,08O1N0V)U)<%$A&LRE
MEW-7'6LA6DE%.)K$A-K.KL(J&8^^KPZ'L8Q$:20;9W',;9X'&>>69LVKD5BL
M!0 70>1#$VDKW,U?TT*&(7XS)4L/^"7%^S0RM^^R]C0HL6C&O8RM&5+'H[E2
M+A6$]E#Y5 K,3A9R<')<XBGAPSMU5NSV[H0.'BJ(JKG?R-+LP8TGT:)5W$:@
MW&D=>>DD(QB_*;^BPN]C:KKP@Q8.RACI3T/<I&K;8P)@'\RV?(UB9F*@ K)!
MW@@2S=CWK6'4FC"Q<4Q[LC\R1,?D9'Y=-VE\.;-L,H6!(TH 66;81MG6K74>
MXR^+\O$YL+1,H0<+W@EL'U)KC9D.FP0(26HO%NTVS[>$ZY>I!OFI )D]'1-W
MH=OO5/C7O[@?;_\ BG@;-1Z["#DQ%JBW 4K,E'H4>W:P)CCT]_[1]6_^K^CO
M[C^E/_):?_0XRU+)>GN\5^K98JGU7M#I4#V-473B'N[4>FN"@RE80,%NB>*E
M)WI?)7$U)Z5""LE8-O=+H=/9UK.R_P!-]HH9J9]MT]?@G:Z"]%77$&3IE7GH
M!9A[QI,)!K:]_1Z=3>2.F)2"QG;IRD8'*U<$G?1OS1/'VGDKM]K1IE+%I-BK
M'N:@]"/%\'3\7*3FKZ8S>AW'*:*I?728;'CUD?.UK3!=C/(.F8]*(_@Q.066
M$MG6]/ILWQ2R1);>L^=Z!"M8)>Y9P'NV_JBB.6H:\,D?2]Q1NQU_+S-MIU#.
M "+@,2JL\R&Q<+P.,=IB.BSUB8'BO-'!7K=IG234.DZ;-7YXLV1T(=;[>LD6
M73")VAM SV^'=Q,UO3N0"K;QN/WO7-M@.;;D(*A8389-1KJ=!JI^41P$[(T$
M>%V1]*VIB)!I#:CK"4S(@4M2ZRV+5I(L+I[A(AK>,?=<",>C+&X!H]DOIJEV
M@&NU7+WK0Z3%L&):43,P$!OF8((XQ;P]-WY5<NV,55H5H*LY?3 J6QO2M*3V
MK%R(S&Z0@9Y_)XR%ROANV%SUX-[,S>NE';/QP,?WDC-UM4G= *T::L872U_-
MCAM)'I&].O:=:M=@-EE:X/)U]2-MAMMW5;OT*)GQ$1?)+AE1?IN2&S4Q[W)Q
MS2"UV=4)RU2QU!)$]&G=L/%9">N^-!^*)A_I?), &KZC6&9K!U^SN8B=]V7B
MHSW->C;I/+<,D4<4^W]*,=&0QB[TM1>R2A5UNI9[4B1K'2%U26#$:#!Z'$04
M\5U9CTV+&J!Z$WT6KLH0JI_6!5?J,;*+<WX\LDE-VE*XL3,,@I\13_4>M7$,
M;6)JB:T+UB&-J'?57]TNP\Z%OJ[3B#(H7$ZA!<,)/HS'TC[HMI$SI:+*$7Y$
M@Z:82VP_$5B%>D:D/A$]"X1M](=.Z,2V%(>P\DIJ)N5N<62CMZZZK-H"3.GT
MRVA,Z0'&4R_]3550Q3%=F8.LK.Z^K?8\5L&%BRPI5FV;HU @@OCF(TKO_J@_
MK/.W2=1%EQ!4NQ104$G=0C>I996I22#HTCIQ#8GEI.,>KTFYYW"O#T.G=45
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MA$*>YLLQ>Q&/?Y/TKS=N0F8B8SJ-R_UH^+6.4:U:P4;*J[V-KLM.=5'I6)/
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MT2.YG4=I/+=)P@/4$@8M6;+06LFNQ?B*UE*>XB6OKUO*3<,HZ2]6=(=Q#/.
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M0E5ZYCK+"* *8[J>4^*)H4K%D[CZM1"'6F$1F]BEB)L(S\9R4Q[9YSQZ4_\
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MIHJDLD"=Q=;K*\);-W+BD^WENNKN$7,F"[\NBT^*>,"]&QU=80BS%9BEK@=
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M_K'D5*UC(J \:%DA@JM@&BSJ77BKF!#TPUG2="X:P:W<%T;T,KB6#%/=LKY
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M(7>KU1DH#N#9$QS]B>U2]%5,LJUQL$)LE51A5H/6&N+9,K\.Z=VGM_N6!TZ
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MK$!7422![P[8"J"A1;KM8HD:S"B.W&0$=>$?TW97';DO:=9A&SN':H4:XZA
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MLW?G3'BUY3P,E+V0+(=L:V6#+O#N:4%$R1,V\]>7#P5!0%B2DXW<HW1,:!_
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M\,]O$BPF2PMVLRR9*/BVEKX>%ZRV=)#<1,@@Z?1\8S&NZ6]?X?BXG262,0P
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M4\*ZP!<K@^FXCVSKU3"1\.^.+3L<5%E7J9IE9MMJ+!:&MIT:,2:ILU$S;KI
MH I&!(ITU&.')]3#7.V)0:[-+9%0D\TBN!Y-A\]'JGKRB&P,>S]QZ6]/XO*4
M/3O]979!)>H,C1G(@JS4"K-/$4*QOK5"RV6*P4JZQ;=B#VB9:<6?4=C_ &HX
M2_EZ=JXG_P#E]E,'AJV4L6JM]E1?I\AQKJV85FKD+B D$D$,./"0>*>ITBW]
M/?T=8W[MN[I:Z[=VO+^X!%[U1'.XNWL/1J7\.14P1DORZ<^ KP2FB7^/2'-8
MB.NUU?J#O,YCY4%I^3AT=X;F,$AE9P*ZY 0Z;( (F5%'M@N<Z^W6.%];3J[
MZNWY/4VQOV^SEN_L4ZX7SQC;.6I(&\#FIZ"BATW]>D);NIC(<$;MHB106L2,
M<.NI_P!H*:Z;+'V-A6Q()J,L&9RS?E!W6J\7%(!T0(@H &0DN?'I>$>ITUL>
MNW8D\HVT_K9*W<*.BRK/=B$W.X&=LF9 N?S)]G%&,9ZU6USV8[$I"+-E\W;K
M+ZQM;RK7S/M;GF@,>&WF4+GJ /+BS%WURQZJ[45[M2U8?6B!P=RJNY5D3NP7
MEXO1TQ^5LZA1)GK/&2Q,^KJ<*+$5?36+37R'O:UY]2:EN_%/K?-[;YHJVK%A
M;32PHD>I(Q+Z/K<J=:+J+9ILL8+=*^7R"ZNT7Y$;"1<=U: G\\!#EXHX"C>]
M88Z;:,@>9*S-[S055XZ^+QM9918H/;VE1B0Z@[98\=^GCYU[+_7-N(MJK^I5
M>:=P,SC[A].K:(IN(2.1 V[%'IH(QH2BTUXJXW*>M+ /;76Q'.XJJM-JK;$+
MG4\P-8][..8QA$R8)VLQM@XCCU4DO6165V;0=[D#M$18IJK$ME;97>B.H<ET
MITZ<$ B,Q.G!*M_[0*3(JE68$6964*>RHOWQPK*HUDQ7+%[.GTX+X8]KV7?7
MJ%/*<FB:TY*;-?;5RK[[@M,BU0ZX'6*!NKVCX]=IQIQV8>IZ9NNYJEZB6^MM
M)J#QV,[9S2UOF0!_0[B YG5;(TF#VSPO U_6Z^Y#,4;2K:S8(RY]6.VIU5.O
MG#Q?^M(9:T>X*?#$S P%-GK%*NC:*H%$$3(IN3D'^J0BYT[^V&K"J4ZELTTU
MC37;PO U?70E<7D4N#(M89]9F2J6$*JB)WAAQ.&29, W2+'.1CY/"3'/W&2%
MA=EP61LN588M^29#2",@N1L+5> %SKL'H#J)>R-@^I;JU#0J4%K2@D[!J8WR
M];/=W!'?&XCB8B)C737X>%'7]1Y2LE=R;?06=C37N+# Z9%<F0:FNT$@7,86
M',9UY>4U<L$G8S:<E<M&JVF"2&,5CV!TE7R?8:R:XMG<\8EDS/*(B.#*IZAO
M]YTLE/6>RSU'6;?7Z!]<+6VOX#!+IA1[U!&V GGP$O\ 4E^1Z'1;63W2ZP0=
MP[3DU=<@35UG">TH(C*9B"B1TV\0U=R?)T5KDHI QPBR_>R5RS%AE>2-8]G1
ML]#7=/5^5M&1_<^F,99&B&-RR?4-N_>O'"HH#@J=:VIPL80H6&YWB(_DZ<#E
M/2O^SW*^K;T[0#U+6PV-Q-,@^3)(]0>H&8YUQ(1^=7AP3'LF>/9ST]G_ .+7
M^XL5;ZB:D6=48!SD$+.DU.X6(-;(F%N+X>*S?*X)M-1)KM*S;DP V7VESZ_B
MF69-L\_AV_P TH8LJK>RQKRLU51<MQM<;"<4G(NB61U3UB)Y#\&D<5G+J,6R
MJ5,E[+EP8+R^,=V0/&'[;"ZY8I!0)ZQN7K[9G6]#ZSBC(GU+41=N!NULG;,1
MV/CIK.RTBD8TB9*>$D5(]4.!ZYBW;&88%I]V)Y._\39,O[^GLX[I-#:[?5;N
M[BS,=:F]%A+=LMF-_4JKU_A0$1/ F-)BF+KTJRF)N7%,4./!"ZK%,!\&NPM-
M8 WQ.X@'2>*:R0\(H448ZI*+UVN::U73MX%BGB?44.HP>N[:91KXIX23:DZ5
M\?Y6E:[%E2AI16N4P5TEM$-5UL@X!+Y40R>+V/74)=3(V LVEKLV0F6+=W 0
M!PW>M4.UG9$[?%/+2>!G?D-H6C<L!O6 A55F.\M;CTR)P2:[T"/5D=&-V1N*
M8X.GV[*X37N5PE%AXB'=OM6X.4RR4O*I<NL:GJ"4*.>7#5S5<4O(F/<5Z[-A
MSC5DTF]ECN.K+B#,6-2UU\?Y(TK,729!5'+>C6W;(18LH/61)TB4&0C)1["Z
M8_%Q;NMK/[F\<'88J]=3)3%6S3G3HO#9NK6V#.GP%Q7(*3-:S0>K6Y<F(8!L
M9NF)?I/4-GB_A;1_@QP"XDRA8"$$PR:R8&(&)-AR1L.=.<S.LS_P>,MY?%U,
MB_#M<_&E;7UAJN> K:P5%[HB(0CY43I,:QS_ /@;_]H " $! P$_(?\ V!7&
M)I\-T'8R7PXVIH&=(;M*==< K?&J4A]&G &WAB14GD&A&H(".[2G8 3*\;>@
M4C54SFA7?DY72T.76X-+<ZO4>'0^./*T "\ITY)PM\,;42&S2:WBDS0T7  ,
M/D)= $5P;IBD4!%C>PK%P)=\%*@/F*&ID 6M*IG%D.]W;@GH[=>T)]^N%'Q9
M>KH@;[5$!"#9$RJ0'II(M3&%#18 1%ZQWJ9!9ENF*"8'6-[F06)+M@ID!\Q
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M5@'-BTSG"6--5%3P-+.8IUWSJG"J"1NMUT!Y#9%=:%C12WZ8TM$5@/#]KSX
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M805.M9\#=J"4* ^'PZBM0$.X 4BT+ZC78=4P0Y!O5B?FB3"@PT\L<HB,:V$
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M@9>YE)K64=^!,L84*9"+:AU05B,9(L3+41]F<S:*P)B"69F;<C)0T.#O(/\
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MIO)D%1(V6\XA47!@HO8T?\&6R$ANSR/C+=S9S^6ENV9U+3;B1'& .K+@3O8
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M.D0J$QHBA>5^N,;GP9B#8P"\X31>;36,<%KX843_ # I21A0#9=F"Y;+U92
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MS2:#Q(HQJA?8(5'75:IMX,D#J!CR9RQ]%+;2W\.H+[!01F'7L .<:/\ @O\
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M!%YZH?U>'9;D[ 9=^W7S/C)EJ_"L]%?17HJ^EF5?R4OT%5$O^P8-3CH=A?\
M;_.*0*])P04D-5R;?5X^1(75\Y$=PX? 0XNWKEY,^% .MROMI_KAS2&^.-/'
MWYS=*T[TA(ET<O@1\Y D6!3W-\:VGQO.@==&MB>/::YN/6'0?+QR\\7WP;\B
M??;B>9XDQ=FG^%]O'??&/1HL_G5XYFO,]L@@5K7R\>>#LWA6QR/[UQX=N(/+
M)>(4?/ 7[><FB#?VWNZ[FO.6O;W/>_RV^V,C<GM[''O]F]Y&#6;I\AR;&:_G
M'D#W3X]N?'?.66A#@25YUAX#7)\71KDB0Z]L86&G^/\ 'XVO37XQG?X@?/\
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M$0  $
M
M
M
M
M
M
M
M
M
M
M
M                                                       !D$L*
MIE@T2B,M$1E@H-JTIE?N=A$$D*IE@
M   !                                 );8"0PZ
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M"2 !           !       !0 "":;()))     "3338    !*)      *
M10 (*9*;     ! 3)+"#+9*';8*#( )0 ""9*0!*1+         )") # 0 !
M#0  *  0+0):;32:        "223;3"* "9"#)0 "*3!"2:")##8 *:*38:(
M28(1>":)!  :  0  +<!31:2         +""2;2:;3  !0 "
M     +!112(9! ! 8**  02; ;;(8013 C2+   !(         (!0 *33:;;
M3;3:::22322222222222222222                   !)!! ())!)()!
M                   *R+#[Q!/=:,9/2  1:;9;;;;;;28/*;:88
M            "222223  !(   #))))))))))))*
M                ;::::3;32;3";+;;;;;;;;;;;;;;;:8        !
M(                      2222222222222222222222222222228
M                             +;;;;;;;;;;;;;;;;;;;;;;;;;;;;;:
M8
M      30  2#S";3R+0[ZP32+[6+##VR2222222!   !( !)0)+!!))  !)!
M1 )#1       !:8  23"3308;(9;3*:!+2+ ;;2222222:+ 0  +(++8)!)9
MY:!++0+):: 988                          !))  )1 ;#)*))(  #92
M222222222:2222!;#(" (5 *0+:2(                   ":^37):28-'2
M1)                   !+0+"* Y;+1)0 (   8
M        !  (39;;;;;;;;;;;;;;              (
M               !  +)                             (  *222:::2
M:23223228             !    *&;*:(#*092:"0:0             (
M  !.#Z Y)+++:930             !     !;::1*"1#+01:
M   (                                !
M          (                                !
M   *             "
M
M
M
M
M
M
M
M
M
M      !UFVT%TF!+L"D                    !5):=XY1XZV:N0
M             %IIA&-%1S'G:4 -@                 !=6ATCR$@8S1:
M!D0 [?/10J        & '\R&X4FD_I'[D #& 'G?4?W0      '&N #G>0["
M1A?9W)@ R@ YT43"UMH3]$+WP,/):H)-KU39VIYP 'R "Q W$&UP]+N    -
M8EB#[NJO"L]^N  A0              .)Z,&Y0=LWL'KAQ& $B
M     *-18J"E2^ R;/6   @@               $@&%S8;.CP/     '
M                              /_V@ ( 0$# 3\0_P#8%4RA<,G;8;@P
M\C:0U02KE!J$D,B1)OF\F$E#G*D+A!MUC/F)36P]SVZAE6A&+G5/P@"#7&R8
M(Z^$DHM2>Q4$#;OT;0F"9*WAJ!8)%'/2O5<);9!D@=CP7!\2U@UXA)Q]H$@1
MRXC(/&H<KC:/W8+,8DKA6)C9*2NEC^L4;7QRDV_#%M%Y(]*\Q6#8#O.V)=^3
M.6' 0'_?MXACBU9ABJ^]:Y+',HR%;E9 K_9G !P'P+2<O0]JD60UN<'&T\JG
M.GA18'2,S.04L:V#K4F5=M<[,%F*,7[!( ]7%8![.YNC8OK IQ#WVI!622V4
M9,"40S12M/!)#*@D95BQT""JZ<^S3GPP 3#'[.$-/!S/[,6$*$Y.?">! ?O&
M=,6M; DR;YO-T0@QUBVL.@(%@RQ2L%,#P$A:4J*!+>V%$;':AF0AT\W+K?WA
M@/U]MVT,\8O_ )6^XQW0QIU'5$H8W, :Z&%@Z4\7)N:"!#2"=C5L!0-S"]+G
M&0+H'(C@KT!W:LN=  UV**80$U@;\;!)]V1&0-G(WIR 0[M , [.3LLTD68
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M0# 92LTW!''I<TB*I8#;H(0=_P"=XNJ Y4 V64X]K^6:4OI,EADE$[*42,_
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M*?I ^BK&(2(-K)G]4!1N@WX9V1K8+S];0B 8BJFR%T0:F[;PP>F&7=L2Y!K
M,"[1Q?>2H,D67#,P>.(8 @&@S]L_YS]L_P"<_;/^<_;/^<_;/^<_;/\ G/VS
M_G/VS_G/VS_G/VS_ )S]L_YS]L_YS]L_YS]L_P"<_;/^<_;/^<_;/^<_;/\
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MGSY\^?/GSY\^?/GSY\XO9;@Z:+!K0;YYE6BZ4R)N@?@L^?/GSY\^=_W0KT!
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M6:'#N0FG'"5Q4'+3@NP114;IX1S,@*(TD.R!(^)B@HFD_/?O/C^@A7/O1B
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MO>W3#<=) )(>T4YGK^=>//8\;)3$U"/CZUO#4+KC>7P<_'RP<5N!'JFP/&A
M'B51<W.#36%;@Q5M:86.IB0"S/'\6?@SI!1C8C<8I-&#& ZE&?O/C^D!0+CQ
MM&1 4 M<1>:,%WGC[M3LK  1T$&[I.>ED);YZ-'T [<QPU0N_47$?.?=V+<B
M,2;[PD*2C6@UPV75 RT'KNE5,(@0R-!.)1&_0.](!&:56Z)3,%++$GI"!S?O
ME$)GDS]K!?88$*0NS%0T2GR3YC9<P([XM%V<G>0 S9\#B;SR#8\NIJ [ZPYY
M?S;$@WN+<_,N!FNAFG+45N4+)%MIC&AS<;Y_0[2<V2&HK_*</!^I+K@Z .&[
MJ'&6V-W>J'>+*12\5K;\"'R9ST>=/38TJ17T/]Y\?^!A?WGQ_P"!A?WGQ_X&
M%_>?'_@86'*KN5Z=^XK4?F^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?N!DG<;\
MYUPR/_2:47OSD"]<!039%2Z/L>]V,.A!@[<,3=3UT* :&'9 1"%"$P],"0R%
MX"F^*%"$F]L% A2 @ 3([TY&L!0,W8C($87:9=AP@;F(1Y*H!$D",,4@+[6M
MJ&&DUJF4#&L--BW0;F[71CF#"7ZV0K#C0DL0QXW_ #D2O!>'D50)8Y6&0#\^
MLQT<-Q)UE.I<("90#"Z#8E)E.AJN8PNFL,6JN]"<",%M@VL<H9E#F'/LG/0[
M<]NIB<($*8QBKHWU1M:H+H3A5%-HP)DK  :Q@VT++_F()$4/O8.L8SI3.&9(
M6QF'BRW0")^EG0^('$( F79XW?D+.U=%D+)9=Z0N&M4:GCL::Y:[X5@H:XMB
MRQ&-AMO ;DS)3;?&'DK[HAL#!*:#QYKU"[.>XB.\*08IKV4LX@E8/M\[]K&X
MH(%1JTXW8!!#W6,4;P"R)D-<JE%L 5$T!CK+*.<Y#F"'<KVWV(\+VZA@*UZW
MW*XL."O&GY; %#%--9!2.HW9':IQR:1S?10F"MA62\VW@\\)*@XMQHFHR9P=
MV,8X]A$JD*.2&EG<@(ETN:]1R0T&LTZC*-*^6#@/">R*"'M@7FYR)3(QCP&
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M02$Q9W$3@^9GQ8(J\**")?Q:P3!(^DH0 !T"UUX:CHW:I/XK^0RUB!Y:/-T
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M#%Q=,/*%L L"L944F9J9I*]J5H7D*L1VZ$B>"UJ!:+8=U.9!$LM-LIP\ITW
M1O/D*Y:5CK8K"2:'40G@3Z&'"/AP$/V@"X86A[2Z7D;V%E[V/P_#^4]OH3'
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MF#A0)K/J #&Z1#<-P,.H'*PF$)BA0$9E@V6EK5X2G@DQ2 A-*([N"V !<0&
MZ8R!A*K@44UEF@)X&!"0%PEBZW251J':MI@%RF#Q!$0$ HD##MMK<;*PDAJ
M##%9B:"FB1Y*ZQ)+DL5IB-8<@DTAYQI-#4]9H,IC<<(2HX5L)"#V*Z(A$@'V
MR!0;2X)HH[ZEQN40'E5Y#U6 MJ-UU!<&%(F!1B%\,Q5QU'*_9*P*H@=JI)0@
M*W&2\TD.E9S8-)P+F"0';Q$%O5L-F4N@WP<9(HV4@*I5(((H)PKHF7PSOAX3
MPW!*?W*3YP$RTL. #.%%I8IF1_08C%Q<23L8.&Y @CF Z!A'G99^$HH0'D
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M(L+UJ#!A3QA?'(6\T00'&ANP.:TU5$9#@+FR+X<<68N2OX1YTKU6G) P0J
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MX2"=4[MR1S<JX#LE,0S0"1B3%*,"B%:!1P4)"EHU!C!6IKJ)#P!DK"Q<0%(
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MOXZS#C?.&'%WB1GJX&W$!50%1FT5E)KSDR 5T0XRAMV#5#9-8# 6&+  "-'
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MR+[8FYD=9&?=D??(>^1B3(WD'C(]\\>\#>\B8!+D7(L_?]LC3(/G(](7G(R
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MP%[WC5+E<#C3=WF_.5Q=9RYW@)NS&C[Y[G>)#)>'<P(;<#1N;YN\5RY7G?\
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MR BGRO0()A4V2*/9<.YL8)4'?>3A*B1"U+ 8 C4<-(&AL3*6K086D.(D%54
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M1**-8$@69L#R[58B%A%B0PF5SJEJ(L^,$P3&'$\-G<L42K,I^V#D*%"U%B%
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M<@OUI*8TPH]I3*0BZEFC4Z.2X8%+0\OVUBE64"-S4! E1GOX#W8@8>DBPG0
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L)3"P4R]J#$$NU>Q$IO8U%+248 !I,;8-=7PI2"(**L&@  /PQ3C_ (-__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
